
<html lang="en"     class="pb-page"  data-request-id="b392d09e-2d1e-495f-a885-d9930c5bc8f6"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-2;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.0c01777"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors: Optimization of Whole-Cell Anticryptococcal Activity and Insights into the Structural Origins of Cryptococcal Selectivity" /></meta><meta name="dc.Creator" content="Paul T.  Marcyk" /></meta><meta name="dc.Creator" content="Emmanuelle V.  LeBlanc" /></meta><meta name="dc.Creator" content="Douglas A.  Kuntz" /></meta><meta name="dc.Creator" content="Alice  Xue" /></meta><meta name="dc.Creator" content="Francisco  Ortiz" /></meta><meta name="dc.Creator" content="Richard  Trilles" /></meta><meta name="dc.Creator" content="Stephen  Bengtson" /></meta><meta name="dc.Creator" content="Tristan M. G.  Kenney" /></meta><meta name="dc.Creator" content="David S.  Huang" /></meta><meta name="dc.Creator" content="Nicole  Robbins" /></meta><meta name="dc.Creator" content="Noelle S.  Williams" /></meta><meta name="dc.Creator" content="Damian J.  Krysan" /></meta><meta name="dc.Creator" content="Gilbert G.  Privé" /></meta><meta name="dc.Creator" content="Luke  Whitesell" /></meta><meta name="dc.Creator" content="Leah E.  Cowen" /></meta><meta name="dc.Creator" content="Lauren E.  Brown" /></meta><meta name="dc.Description" content="The essential eukaryotic chaperone Hsp90 regulates the form and function of diverse client proteins, many of which govern thermotolerance, virulence, and drug resistance in fungal species. However,..." /></meta><meta name="Description" content="The essential eukaryotic chaperone Hsp90 regulates the form and function of diverse client proteins, many of which govern thermotolerance, virulence, and drug resistance in fungal species. However,..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 14, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01777" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01777" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01777" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01777" /></link>
        
    
    

<title>Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors: Optimization of Whole-Cell Anticryptococcal Activity and Insights into the Structural Origins of Cryptococcal Selectivity | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01777" /></meta><meta property="og:title" content="Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors: Optimization of Whole-Cell Anticryptococcal Activity and Insights into the Structural Origins of Cryptococcal Selectivity" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0022.jpeg" /></meta><meta property="og:description" content="The essential eukaryotic chaperone Hsp90 regulates the form and function of diverse client proteins, many of which govern thermotolerance, virulence, and drug resistance in fungal species. However, use of Hsp90 inhibitors as antifungal therapeutics has been precluded by human host toxicities and suppression of immune responses. We recently described resorcylate aminopyrazoles (RAPs) as the first class of Hsp90 inhibitors capable of discriminating between fungal (Cryptococcus neoformans, Candida albicans) and human isoforms of Hsp90 in biochemical assays. Here, we report an iterative structure–property optimization toward RAPs capable of inhibiting C. neoformans growth in culture. In addition, we report the first X-ray crystal structures of C. neoformans Hsp90 nucleotide binding domain (NBD), as the apoprotein and in complexes with the non-species-selective Hsp90 inhibitor NVP-AUY922 and three RAPs revealing unique ligand-induced conformational rearrangements, which reaffirm the hypothesis that intrinsic differences in protein flexibility can confer selective inhibition of fungal versus human Hsp90 isoforms." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01777"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01777">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01777&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01777&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01777&amp;href=/doi/10.1021/acs.jmedchem.0c01777" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 2</span><span class="cit-fg-pageRange">, 1139-1169</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/2" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01783" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01912" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors: Optimization of Whole-Cell Anticryptococcal Activity and Insights into the Structural Origins of Cryptococcal Selectivity</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Paul T. Marcyk</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul T. Marcyk</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry and Center for Molecular Discovery (BU-CMD), Boston University, Boston, Massachusetts 02215, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul+T.++Marcyk">Paul T. Marcyk</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5414-0293" title="Orcid link">http://orcid.org/0000-0001-5414-0293</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Emmanuelle V. LeBlanc</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Emmanuelle V. LeBlanc</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1M1, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Emmanuelle+V.++LeBlanc">Emmanuelle V. LeBlanc</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4278-0984" title="Orcid link">http://orcid.org/0000-0003-4278-0984</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Douglas A. Kuntz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Douglas A. Kuntz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Princess Margaret Cancer Centre, Toronto, Ontario M5G 1L7, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Douglas+A.++Kuntz">Douglas A. Kuntz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alice Xue</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alice Xue</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1M1, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alice++Xue">Alice Xue</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Francisco Ortiz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Francisco Ortiz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry, UT Southwestern Medical Center, Dallas, Texas 75390-9038, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Francisco++Ortiz">Francisco Ortiz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Richard Trilles</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard Trilles</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry and Center for Molecular Discovery (BU-CMD), Boston University, Boston, Massachusetts 02215, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Trilles">Richard Trilles</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stephen Bengtson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stephen Bengtson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry and Center for Molecular Discovery (BU-CMD), Boston University, Boston, Massachusetts 02215, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stephen++Bengtson">Stephen Bengtson</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9383-5159" title="Orcid link">http://orcid.org/0000-0002-9383-5159</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tristan M. G. Kenney</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tristan M. G. Kenney</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G 1L7, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tristan+M.+G.++Kenney">Tristan M. G. Kenney</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8242-4349" title="Orcid link">http://orcid.org/0000-0001-8242-4349</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David S. Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David S. Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry and Center for Molecular Discovery (BU-CMD), Boston University, Boston, Massachusetts 02215, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+S.++Huang">David S. Huang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0256-5307" title="Orcid link">http://orcid.org/0000-0003-0256-5307</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nicole Robbins</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nicole Robbins</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1M1, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nicole++Robbins">Nicole Robbins</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Noelle S. Williams</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Noelle S. Williams</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry, UT Southwestern Medical Center, Dallas, Texas 75390-9038, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Noelle+S.++Williams">Noelle S. Williams</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Damian J. Krysan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Damian J. Krysan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departments of Pediatrics and Microbiology/Immunology, Carver College of Medicine, University of Iowa, Iowa City, Iowa 52242, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Damian+J.++Krysan">Damian J. Krysan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gilbert G. Privé</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gilbert G. Privé</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Princess Margaret Cancer Centre, Toronto, Ontario M5G 1L7, Canada</div><div class="loa-info-affiliations-info">Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G 1L7, Canada</div><div class="loa-info-affiliations-info">Department of Biochemistry, University of Toronto, Toronto, Ontario M5S 1A8, Canada</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#682f010446381a011e0d281d00061a0d1b0d091a0b00460b09"><span class="__cf_email__" data-cfemail="df98b6b3f18fadb6a9ba9faab7b1adbaacbabeadbcb7f1bcbe">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gilbert+G.++Priv%C3%A9">Gilbert G. Privé</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Luke Whitesell</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Luke Whitesell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1M1, Canada</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#2b475e404e055c43425f4e584e47476b5e5f445944455f4405484a"><span class="__cf_email__" data-cfemail="6d01180608431a050419081e0801012d1819021f02031902430e0c">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Luke++Whitesell">Luke Whitesell</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Leah E. Cowen</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Leah E. Cowen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1M1, Canada</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#610d0400094f020e16040f2114150e130e0f150e4f0200"><span class="__cf_email__" data-cfemail="177b72767f397478607279576263786578796378397476">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Leah+E.++Cowen">Leah E. Cowen</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5797-0110" title="Orcid link">http://orcid.org/0000-0001-5797-0110</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Lauren E. Brown</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lauren E. Brown</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry and Center for Molecular Discovery (BU-CMD), Boston University, Boston, Massachusetts 02215, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#0260706d756c6e674260772c676677"><span class="__cf_email__" data-cfemail="84e6f6ebf3eae8e1c4e6f1aae1e0f1">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lauren+E.++Brown">Lauren E. Brown</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9489-484X" title="Orcid link">http://orcid.org/0000-0001-9489-484X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01777&amp;href=/doi/10.1021%2Facs.jmedchem.0c01777" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 2</span><span class="cit-pageRange">, 1139–1169</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 14, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>20 October 2020</li><li><span class="item_label"><b>Published</b> online</span>14 January 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 January 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01777" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01777</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1139%26pageCount%3D31%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DPaul%2BT.%2BMarcyk%252C%2BEmmanuelle%2BV.%2BLeBlanc%252C%2BDouglas%2BA.%2BKuntz%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D2%26contentID%3Dacs.jmedchem.0c01777%26title%3DFungal-Selective%2BResorcylate%2BAminopyrazole%2BHsp90%2BInhibitors%253A%2BOptimization%2Bof%2BWhole-Cell%2BAnticryptococcal%2BActivity%2Band%2BInsights%2Binto%2Bthe%2BStructural%2BOrigins%2Bof%2BCryptococcal%2BSelectivity%26numPages%3D31%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1169%26publicationDate%3DJanuary%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01777"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1017</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">3</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01777" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors: Optimization of Whole-Cell Anticryptococcal Activity and Insights into the Structural Origins of Cryptococcal Selectivity&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;T. Marcyk&quot;},{&quot;first_name&quot;:&quot;Emmanuelle&quot;,&quot;last_name&quot;:&quot;V. LeBlanc&quot;},{&quot;first_name&quot;:&quot;Douglas&quot;,&quot;last_name&quot;:&quot;A. Kuntz&quot;},{&quot;first_name&quot;:&quot;Alice&quot;,&quot;last_name&quot;:&quot;Xue&quot;},{&quot;first_name&quot;:&quot;Francisco&quot;,&quot;last_name&quot;:&quot;Ortiz&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Trilles&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;Bengtson&quot;},{&quot;first_name&quot;:&quot;Tristan&quot;,&quot;last_name&quot;:&quot;M. G. Kenney&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;S. Huang&quot;},{&quot;first_name&quot;:&quot;Nicole&quot;,&quot;last_name&quot;:&quot;Robbins&quot;},{&quot;first_name&quot;:&quot;Noelle&quot;,&quot;last_name&quot;:&quot;S. Williams&quot;},{&quot;first_name&quot;:&quot;Damian&quot;,&quot;last_name&quot;:&quot;J. Krysan&quot;},{&quot;first_name&quot;:&quot;Gilbert&quot;,&quot;last_name&quot;:&quot;G. Privé&quot;},{&quot;first_name&quot;:&quot;Luke&quot;,&quot;last_name&quot;:&quot;Whitesell&quot;},{&quot;first_name&quot;:&quot;Leah&quot;,&quot;last_name&quot;:&quot;E. Cowen&quot;},{&quot;first_name&quot;:&quot;Lauren&quot;,&quot;last_name&quot;:&quot;E. Brown&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;14&quot;,&quot;issue&quot;:&quot;2&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;1139-1169&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01777&quot;},&quot;abstract&quot;:&quot;The essential eukaryotic chaperone Hsp90 regulates the form and function of diverse client proteins, many of which govern thermotolerance, virulence, and drug resistance in fungal species. However, use of Hsp90 inhibitors as antifungal therapeutics has been precluded by human host toxicities and suppression of immune responses. We recently described resorcylate aminopyrazoles (RAPs) as the first class of Hsp90 inhibitors capable of discriminating between fungal (Cryptococcus neoformans, Candida albicans) and human isoforms of Hsp90 in biochemical assays. Here, we report an iterative structure–property optimization toward RAPs capable of inhibiting C. neoformans growth in culture. In addition, we report the first X-ray crystal structures of C. neoformans Hsp90 nucleotide binding domain (NBD), as the apoprotein and in complexes with the non-species-selective Hsp90 inhibitor NVP-AUY922 and three RAPs revealing unique ligand-induced conformational rearrangements, which reaffirm the hypothesis that intrinsic diffe&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01777&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01777" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01777&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01777" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01777&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01777" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01777&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01777&amp;href=/doi/10.1021/acs.jmedchem.0c01777" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01777" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01777" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01777%26sid%3Dliteratum%253Aachs%26pmid%3D33444025%26genre%3Darticle%26aulast%3DMarcyk%26date%3D2021%26atitle%3DFungal-Selective%2BResorcylate%2BAminopyrazole%2BHsp90%2BInhibitors%253A%2BOptimization%2Bof%2BWhole-Cell%2BAnticryptococcal%2BActivity%2Band%2BInsights%2Binto%2Bthe%2BStructural%2BOrigins%2Bof%2BCryptococcal%2BSelectivity%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D2%26spage%3D1139%26epage%3D1169%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (9)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=290676" title="Substituents">Substituents</a>,</li><li><a href="/action/doSearch?ConceptID=291445" title="Chemical structure">Chemical structure</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/2" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/jmcmar.2021.64.issue-2/20210128/jmcmar.2021.64.issue-2.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01777&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The essential eukaryotic chaperone Hsp90 regulates the form and function of diverse client proteins, many of which govern thermotolerance, virulence, and drug resistance in fungal species. However, use of Hsp90 inhibitors as antifungal therapeutics has been precluded by human host toxicities and suppression of immune responses. We recently described resorcylate aminopyrazoles (RAPs) as the first class of Hsp90 inhibitors capable of discriminating between fungal (<i>Cryptococcus neoformans</i>, <i>Candida albicans</i>) and human isoforms of Hsp90 in biochemical assays. Here, we report an iterative structure–property optimization toward RAPs capable of inhibiting <i>C. neoformans</i> growth in culture. In addition, we report the first X-ray crystal structures of <i>C. neoformans</i> Hsp90 nucleotide binding domain (NBD), as the apoprotein and in complexes with the non-species-selective Hsp90 inhibitor NVP-AUY922 and three RAPs revealing unique ligand-induced conformational rearrangements, which reaffirm the hypothesis that intrinsic differences in protein flexibility can confer selective inhibition of fungal versus human Hsp90 isoforms.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14075" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14075" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Invasive fungal diseases impose a major economic and public health burden worldwide, killing over 1.5 million each year.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> Approximately 90% of deaths due to fungal infection are caused by <i>Candida</i>, <i>Aspergillus</i>, and <i>Cryptococcus</i> species.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Of these, <i>Cryptococcus</i> is now recognized as one of the most significant fungal threats to human health, with incidence increasing in both immunocompromised and immunocompetent hosts.<a onclick="showRef(event, 'ref1 ref5'); return false;" href="javascript:void(0);" class="ref ref1 ref5">(1,5)</a> Recent data from the WHO place the annual global burden of cryptococcal meningitis, the major clinical manifestation of the disease, in excess of 223 000 cases annually, causing more than 150 000 attributable mortalities and approximately 30% of all AIDS-associated deaths.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> Cryptococcal meningitis has a 100% mortality rate if left untreated, and mortality rates remain high at 30% in resource-rich and 70% in resource-poor contexts.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Of the meager four drug classes approved for treatment of systemic fungal infections, only three are effective against <i>Cryptococcus</i>. Azoles and polyenes, which can each be used as single agents, both act <i>via</i> distinct mechanisms to deplete ergosterol, the major component of fungal membranes.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> Resistance to each class has emerged, particularly for the azoles, with fungal infections becoming increasingly difficult to cure. A third class, antimetabolite pyrimidines, are only used in combination with other antifungals due to rapid emergence of resistance.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> The fourth antifungal class, the cell wall-targeting echinocandins, have limited activity against <i>Cryptococcus</i> and no CNS penetration.<a onclick="showRef(event, 'ref12 ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15">(12−15)</a> Given the limited array of antifungal drug classes and targets and the dramatically increasing incidence of resistance to current agents, the discovery of new chemotypes that act in ways that are mechanistically distinct from the available armamentarium is desperately needed.</div><div class="NLM_p">Targeting core hubs of stress response circuitry is a powerful, yet unexploited strategy to cripple fungal pathogens. A prime example is the eukaryotic molecular chaperone Hsp90.<a onclick="showRef(event, 'ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19">(16−19)</a> Hsp90 is essential in all fungi, and in addition to enabling survival, Hsp90 client proteins are also critical to virulence and drug resistance mechanisms.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Although profound compromise of Hsp90 expression or function is lethal to fungi, more modest compromise <i>via</i> chemical inhibitors or genetic reduction prevents and reverses resistance to antifungals in culture.<a onclick="showRef(event, 'ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23">(21−23)</a> In <i>Cryptococcus neoformans</i>, recent studies have implicated Hsp90 in its thermotolerance, capsule assembly, and sensitivity to antifungals, strongly influencing its virulence in a nematode model.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> Beyond an intrinsic potential for broad-spectrum single-agent antifungal activity, the unique effects on fungal biology inherent to Hsp90 inhibitors also render them strong candidates for the development of combination treatment regimens that would actively impede mechanisms of drug resistance.</div><div class="NLM_p">Due in large part to its prominent role in supporting the function of numerous oncoproteins, Hsp90 has been studied extensively as an anticancer target.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Unfortunately, all Hsp90 inhibitors currently being developed as anticancer drugs exert mammalian host toxicities, especially suppression of innate and acquired immune mechanisms, that preclude their use as antifungals.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> In fact, although numerous drug candidates have progressed into clinical trials over the past decade, none have been approved due to limited anticancer efficacy at their maximally tolerated doses.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> One approach to reducing toxicity and improving therapeutic index for cancer and other indications has been the pursuit of paralog-selective inhibitors across the four Hsp90 family members in humans: Hsp90α, Hsp90β, Trap1, and Grp94.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a> The resorcylate scaffold, one of several privileged Hsp90-inhibitory chemotypes, has been modified to confer human paralog selectivity with applications in oncology and glaucoma.<a onclick="showRef(event, 'ref31 ref32 ref33 ref34 ref35 ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33 ref34 ref35 ref36 ref37 ref38">(31−38)</a> In addition, selective purine mimetics, such as TAS-116<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> and modified analogues of BIIB021 selectively targeting Trap1,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> have been described. Paralog selectivity has also been reported for modified benzamides resembling SNX-2112.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40,41)</a></div><div class="NLM_p">We previously described efforts to develop Hsp90 inhibitors that are selective for fungal isoforms, initially templated from the resorcylic acid macrolactone natural products radicicol and monocillin.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Building on successes in achieving <i>Candida albicans</i> selectivity with semisynthetic radicicol and monocillin oximes, as well as the strong preclinical track record of nonmacrocyclic resorcylate drug candidates such as AT13387 (onalespib),<a onclick="showRef(event, 'ref43 ref44 ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref43 ref44 ref45 ref46">(43−46)</a> NVP-AUY922 (luminespib),<a onclick="showRef(event, 'ref47 ref48 ref49 ref50 ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref47 ref48 ref49 ref50 ref51 ref52">(47−52)</a> and STA-9090 (ganetespib),<a onclick="showRef(event, 'ref53 ref54 ref55 ref56 ref57 ref58 ref59 ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref53 ref54 ref55 ref56 ref57 ref58 ref59 ref60 ref61">(53−61)</a> we more recently disclosed the design, synthesis, and characterization of resorcylate aminopyrazoles (RAPs). RAPs are the first class of inhibitors capable of selectively inhibiting fungal isoforms of Hsp90 (specifically, <i>C. neoformans</i> and <i>C. albicans</i>) over their human orthologues Hsp90α/β, TRAP1, and Grp94.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Our development of increasingly potent and fungal-selective RAPs, as well as structure–activity relationships (SARs) for 112 early members of the series against <i>C. neoformans</i> and <i>C. albicans</i> culminated in our first generation of fungal-selective lead RAPs (<b>1</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), which were all <i>N</i>-methylated at R<sup>1</sup> and <i>C</i>-arylated at R<sup>2</sup>. Interestingly, species-specific divergences in potency and fungal selectivity (FS) occurred with ortho/para positioning of R<sup>2</sup> aryl-ring substituents, while activity and selectivity generally converged with meta-substituents. However, despite this interesting biochemical activity profile, whole-cell permeance of RAPs was an unsolved problem; of the 94 compounds from this study that showed potent cryptococcal Hsp90 binding (EC<sub>50</sub> ≤ 1 μM in fungal lysate), only six had whole-cell minimal inhibitory concentrations (MICs) ≤ 25 μM and only one of these six fit the desired profile of high biochemical potency and high fungal selectivity.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Generic structure of resorcylate aminopyrazoles (RAPs, left) and summary of activity and selectivity profile for previously reported first-generation cryptococcal-selective RAP series of type <b>1</b>, which are <i>N</i>-methylated at R<sup>1</sup> and bear a monosubstituted phenyl ring at R<sup>2</sup> to increase fungal selectivity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01777&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In fungi, the cell wall presents an inherent impediment to passive small-molecule permeability that is not present in mammalian cells and other microorganisms, which lack this strong protective barrier.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> As a key virulence factor, <i>C. neoformans</i> also elaborates a dense polysaccharide capsule, which in addition to the plasma membrane and semipermeable fibrillary network of the cell wall contributes to limiting the accumulation of passively permeable compounds within this organism.<a onclick="showRef(event, 'ref64 ref65 ref66'); return false;" href="javascript:void(0);" class="ref ref64 ref65 ref66">(64−66)</a> In <i>C. neoformans</i> as in other fungi, a network of efflux pumps also prevents accumulation of many xenobiotics.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> In this report, we thus designate “permeant” molecules as having the combined features of active or passive cell penetration and evasion of efflux in <i>C. neoformans</i> so as to accumulate within the fungus and engage the target.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a></div><div class="NLM_p last">Among the six cryptococcal-permeant analogues in our first-generation RAP library, we identified unique structural features that appeared to distinguish these compounds from nonpermeant near-neighbors. Here, we now report significant achievements toward improving whole-cell anticryptococcal activity <i>via</i> a rational structure–property approach. In addition, we describe the first X-ray structures of the <i>C. neoformans</i> Hsp90 nucleotide binding domain (NBD), crystallized as the apoprotein and in co-complexes with three fungal-selective RAPs. Together, these new developments define the binding mode of this novel Hsp90 inhibitor class, providing insights into the most plausible chemostructural origins of their observed fungal selectivity. Equally important from the therapeutic perspective, they advance our understanding of the structure–activity and structure–property relationships critical to conferring selective, whole-cell anticryptococcal activity.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62156" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62156" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Rational Optimization of RAPs toward the Combined Features of Potent, Fungal-Selective Hsp90 Inhibition and Improved Whole-Cell Activity</h3><div class="NLM_p">To arrive at rationally designed, second-generation RAPs with the combined qualities of fungal accumulation and fungal selectivity, we sought to merge the structural features found to confer biochemical selectivity for fungal Hsp90 with nascent features, which appeared to track with permeance. To enable efficient elaboration of new second-generation analogues, the RAP scaffold (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) was synthesized in a convergent manner using an alternate protecting group strategy from our published first-generation set,<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> allowing for modular variation of the aminopyrazole and amide portion of the molecule. By synthesizing bespoke 5-aminopyrazoles, various <i>N</i>-alkyl groups at R<sup>1</sup> as well as differential substitution patterns on the R<sup>2</sup> aromatic ring could be incorporated (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Starting from commercially available mono- and disubstituted methyl benzoate derivatives (<b>2a</b>–<b>ab</b>), acylation of deprotonated acetonitrile afforded α-cyanoketone products <b>3a</b>–<b>ab</b>. Condensation of <b>3a–ab</b> with a variety of <i>N</i>-alkyl-hydrazines incorporated the R<sup>1</sup> alkyl group of the 5-aminopyrazole building blocks (<b>4a</b>–<b>bb</b>).</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0013.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Building Block Aminopyrazoles <b>4</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01777&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions: (a) MeCN, <i>n-</i>BuLi, tetrahydrofuran (THF), −78 °C to room temperature (rt); (b) R<sup>1</sup>NH-NH<sub>2</sub>, MeOH, 120 °C, microwave or R<sup>1</sup>NH-NH<sub>2</sub>·HCl, NEt<sub>3</sub>, MeOH, 120 °C, microwave.</p></p></figure><div class="NLM_p">The resorcinol core was prepared by the formylation of 3,5-dimethoxybromobenzene (<b>5</b>) and subsequent demethylation with BBr<sub>3</sub> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Bis-benzyl protection of <b>6</b> gave stable common intermediate (<b>7</b>), which could be elaborated with various amide groups. Pinnick oxidation of the aldehyde (<b>7</b>), followed by hexafluorophosphate azabenzotriazole tetramethyl uronium (HATU)-mediated amide coupling with isoindoline hydrochloride or substituted fluoroisoindoline derivatives, gave resorcylate amide bromides (<b>8a</b>–<b>c</b>). The synthesis was completed by the Buchwald–Hartwig cross-coupling of aryl bromides <b>8a</b>–<b>c</b> with 5-aminopyrazole (<b>4a</b>–<b>bb</b>) followed by global deprotection with palladium on carbon to give the targeted RAP compounds (<b>9a</b>–<b>bi</b>).</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0014.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Convergent Synthesis of RAPs <b>9a</b>–<b>bi</b> from Resorcylate Amides <b>8a</b>–<b>c</b> and Aminopyrazoles <b>4a</b>–<b>bb</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01777&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions: (a) POCl<sub>3</sub>, DMF, 0 °C to 100 °C; (b) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt; (c) BnBr, K<sub>2</sub>CO<sub>3</sub>, MeCN, reflux; (d) NaOCl<sub>2</sub>, NaH<sub>2</sub>PO<sub>4</sub>·H<sub>2</sub>O, 2-methyl-2-butene, THF/<i>t-</i>BuOH/H<sub>2</sub>O; (e) isoindoline·HCl (for <b>8a</b>), 4-fluoroisoindoline·HCl (for <b>8b</b>), or 5-fluoroisoindoline·HCl (for <b>8c</b>), HATU, Et<sub>3</sub>N, THF/CH<sub>2</sub>Cl<sub>2</sub>; (f) Pd(OAc)<sub>2</sub> (10 mol %), Xantphos (20 mol %), Cs<sub>2</sub>CO<sub>3</sub>, toluene, 130 °C or Pd<sub>2</sub>(dba)<sub>3</sub> (4 mol %), Xantphos (10 mol %), NaOPh, dioxane, 170 °C, microwave; (g) Pd/C (cat.), H<sub>2</sub>, MeOH or Pd(OH)<sub>2</sub>/C (cat.), H<sub>2</sub>, EtOAc.</p></p></figure><div class="NLM_p">To determine target binding affinity, we used a fluorescence polarization (FP)-based competitive binding assay.<a onclick="showRef(event, 'ref42 ref62'); return false;" href="javascript:void(0);" class="ref ref42 ref62">(42,62)</a> Use of whole-cell lysates enables assessment of binding to Hsp90 while complexed with relevant cochaperones and, in the case of human lysate, to the entire repertoire of Hsp90 family members expressed in human cells. Given these factors, FP in lysate is highly relevant to selectivity in the whole-cell context but can only provide relative quantification of binding affinity because the absolute concentration of the protein targets is unknown. In comparison, FP using purified NBD proteins allows for measurement of assay-independent ligand dissociation constants.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> In our published first-generation set, the most potent and selective inhibitors were <i>meta</i>-methoxy-substituted RAPs <b>10</b>–<b>12</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A), which disappointingly all failed to inhibit cryptococcal growth at concentrations of up to 25 μM. In addition to five nonselective whole-cell-active RAPs (<b>13</b>–<b>17</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B), the only RAP exhibiting the combined features of >5-fold cryptococcal selectivity plus a cryptococcal MIC ≤ 25 μM was the R<sup>2</sup><i>ortho</i>-tolyl-substituted compound <b>18</b>. This compound was one of only three examples of an RAP bearing an ortho-substituted R<sup>2</sup> aryl ring and was the single instance among these three with an isoindoline amide. Notably, despite a roughly equal proportion of isoindoline, pyridopyrrolidine, and pyrazolopyrrolidine amides within the early SAR set (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), whole-cell activity was limited solely to isoindoline or fluoroisoindolines at this site.</div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) RAPs with meta-substituted R<sup>2</sup> aryl rings exhibiting high fungal selectivity (FS) for cryptococcal Hsp90 over human isoforms. (B) Among 94 RAPs with fungal target affinity (H99 EC<sub>50</sub>) ≤ 1 μM, only six demonstrate whole-cell antifungal activity (MIC ≤ 25 μM). Values for compounds with either fold-selectivity >5 <b>or</b> MIC<sub>80</sub> ≤ 12.5 μM are highlighted in <b>blue</b>. Values for compounds with both fold-selectivity >5 <b>and</b> MIC<sub>80</sub> ≤ 12.5 μM are highlighted in <b>red</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01777&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Based on these observations, we postulated that lipophilicity at the amide may be a key driver for permeance, and opted to explore other ortho-substituents in combination with isoindoline (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, entries 1–3) to discern whether compound <b>18</b> represented an outlier or was suggestive of a potential structural trend. Gratifyingly, improved whole-cell activity was also observed in the biochemically potent <i>ortho</i>-fluorinated (<b>9a</b>), <i>ortho</i>-chlorinated (<b>9b</b>), and <i>ortho</i>-trifluoromethylated (<b>9c</b>) analogues. However, this improvement was offset by a disappointing drop in fungal selectivity for all three compounds.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Early Exploration of the Impact of (1) Ortho-Substituents at the R<sup>2</sup> Aryl Ring and (2) Increased Aliphatic Bulk at R<sup>1</sup> on Biochemical Potency and Selectivity in Binding Cryptococcal Hsp90, and in Growth Inhibition of <i>C. neoformans</i> in Culture<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0015.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0016.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">EC<sub>50</sub> values were determined by fluorescence polarization (FP)-based equilibrium competition assay performed in 384-well format using whole-cell lysates prepared from <i>C. neoformans</i> and serial compound dilutions. All determinations were performed in duplicate.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">To calculate fold-selectivity, the EC<sub>50</sub> values determined by FP using human HepG2 cell lysate were divided by the EC<sub>50</sub> value determined using <i>C. neoformans</i> lysate. The resulting ratio was then normalized by the ratio of values determined for the Hsp90 inhibitor geldanamycin using lysate of each cell type. Results for key selective compounds were confirmed by repeat assay in lysates, as well as by measuring ligand dissociation constants (<i>K<sub>i</sub></i>) using purified NBDs in FP assays (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_001.pdf" class="ext-link">Supporting Tables 1 and 2; Figures S1–S3</a>).</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Concentration of compound resulting in >80% inhibition of fungal cell growth compared to vehicle control. Values for compounds with either fold-selectivity >5 <b>or</b> MIC<sub>80</sub> ≤ 12.5 μM are highlighted in <b>blue</b>. Values for compounds with both fold-selectivity >5 <b>and</b> MIC<sub>80</sub> ≤ 12.5 μM are highlighted in <b>red</b>.</p></div></div><div></div></div><div class="NLM_p">Given the comparatively higher selectivity observed with the <i>ortho</i>-methylated parent compound, we next designed analogues in which this substituent was retained, and instead paired with other potentially permeance-enhancing features. Revisiting the cohort of permeant compounds in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B, another structural commonality that we deemed unique to these compounds compared to the larger set was the presence of relatively large, lipophilic groups at both R<sup>1</sup> and R<sup>2</sup>, again in the presence of an isoindoline or fluoroisoindoline amide. Analogues <b>9d</b> and <b>9e</b> were prepared as examples of such features in combination with the <i>ortho</i>-tolyl group at R<sup>2</sup>. The introduction of an <i>N</i>-<i>tert</i>-butyl group (<b>9d</b>) at R<sup>1</sup> was sufficient to retain both fungal selectivity (11.1-fold) and whole-cell activity (MIC 12.5 μM) that was comparable to the <i>N</i>-Me parent <b>18</b> (14.1-fold and MIC 10 μM, respectively). Isoindoline fluorination of <b>18</b>, however, was detrimental to both whole-cell activity and selectivity (compound <b>9e</b>).</div><div class="NLM_p">In our prior study,<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> similar biochemical potencies and fungal selectivities were observed among compounds bearing a <i>meta</i>-tolyl or <i>meta</i>-methoxyphenyl group at R<sup>2</sup>. In contrast, at the ortho site, we found that new compound <b>9f</b>, the methoxy analogue of <b>18</b>, showed a precipitous loss of selectivity and no measurable whole-cell activity, despite high binding affinity for Hsp90. Compounds <b>9g</b>–<b>9l</b> were next prepared to again test the strategy of increased bulk and lipophilicity at R<sup>1</sup> to improve permeance; for these analogues, whole-cell activities were again improved, but gains in fungal selectivity were only modest. Interestingly, converting the methoxy to trifluoromethoxy delivered mixed results, with the <i>N</i>-methylated compound <b>9n</b> exhibiting no selectivity and submicromolar whole-cell activity, while the <i>N</i>-<i>tert</i>-butyl compound <b>9o</b> showed modest 6.8-fold selectivity in combination with an impressive MIC of 1.8 μM.</div><div class="NLM_p">With initial confirmation that the whole-cell activity of R<sup>2</sup>-arylated RAPs could be improved <i>via</i> increased bulk and lipophilicity at R<sup>1</sup>, we next sought to deploy this strategy on R<sup>2</sup> meta-substituted scaffolds, which had trended toward the highest cryptococcal Hsp90 selectivity in our previous study. Compounds <b>9p</b>, <b>9q</b>, and <b>9r</b> were each prepared as <i>N</i>-<i>tert</i>-butyl analogues of earlier <i>N</i>-methylated inhibitors, which had exhibited fungal selectivities ranging from low (e.g., <i>meta</i>-trifluoromethyl) to the highest observed in the study at 12- or 33-fold (<i>meta</i>-methyl or <i>meta</i>-methoxy). Unfortunately, although this modification was again successful in achieving sufficient permeance for whole-cell activity, biochemical potencies dropped to the low micromolar range and a concomitant drop in selectivity was also observed. Similar trends were also observed with <i>meta</i>-trifluoromethoxylated compounds <b>9s</b> and <b>9t</b>. In contrast, improved selectivity and potency were observed with <i>meta</i>-fluorination at R<sup>2</sup> (compounds <b>9u</b> and <b>9v</b>) with measurable, albeit high MIC values against whole cells. Replacement of the fluorine with chlorine in these analogues (<b>9w</b> and <b>9x</b>), plus an <i>N</i>-cyclohexyl variant (<b>9y</b>) reduced biochemical potencies from nanomolar to low micromolar range. Again, with these chlorinated analogues, there was an apparent trade-off between fungal selectivity >5-fold and whole-cell activity <25 μM, with no compounds espousing both features.</div><div class="NLM_p">In sum, this initial cohort of second-generation RAPs confirmed our prior observations: while selectivity and permeance were most often orthogonal qualities, the combination of key structural features could in some cases (e.g., compounds <b>9d</b>, <b>9u</b>, <b>9v</b>) provide an inroad to optimized inhibitors.</div><div class="NLM_p">Although the trend was not consistent across all analogues, we did note that in several instances, conversion of the R<sup>1</sup><i>N</i>-methyl to <i>N</i>-<i>tert</i>-butyl dampened fungal selectivity in addition to improving whole-cell activity. In response, we next pursued an alternative method of pairing the apparent permeance-inducing ortho-substituent with a selectivity-inducing meta-substituent, on scaffolds that retained the R<sup>1</sup><i>N</i>-methylation  (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Here, we observed improved fungal selectivities with the 2,3-dimethyl series <b>9z</b>–<b>9ab</b>, but this R<sup>2</sup> group generally did not render the inhibitors permeant. Interestingly, this set also exhibited an extreme sensitivity to positioning of the isoindoline fluorine substituent with respect to biochemical potency. In contrast, we had significant success with R<sup>2</sup>-fluorinated analogues. Compounds <b>9ac</b>–<b>9ae</b>, with an R<sup>2</sup> 2,5-substitution pattern embodying one of two possible hybrids of monosubstituted compounds <b>18</b> and <b>9u</b>, showed dramatically improved potencies and selectivities, in concert with good whole-cell MICs ranging from 6.25 to 14.1 μM. Similarly, improved activity profiles were observed among 2-fluoro-3-methyl analogues <b>9af</b>–<b>9ah</b>. Inspired by these promising results, we next examined an array of disubstituted aryl rings at R<sup>2</sup>, paired with isoindoline amide A (compounds <b>9ai</b>–<b>9au</b>). While selectivity and permeance sometimes diverged, we identified a number of ortho/meta pairings (again in both 2,3- and 2,5-relationships), which conferred high selectivity, and in select cases (<b>9ak</b>, <b>9am</b>, <b>9an</b>, and <b>9ar</b>) good concomitant whole-cell activity (MIC values 12.5 μM or lower). Of note, the <i>meta</i>-chlorination present in analogues <b>9ak</b> and <b>9ao</b> again appeared to dampen biochemical potency, as was observed in <b>9w</b>–<b>9y</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). This reduced cryptococcal potency in turn lowered fungal selectivity in comparison to other near-neighbor analogues. In contrast, <i>meta</i>-fluorination appeared to consistently yield biochemical potencies below 100 nM, fungal selectivities greater than 15-fold, and whole-cell activity at or below MIC 12.5 μM when paired with either a suitable ortho-substituent (<b>9ac–9ae</b>, <b>9am</b>, <b>9an</b>) or a bulky aliphatic group at R<sup>1</sup> (<b>9v</b>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Compound <b>9as</b>, bearing two <i>ortho</i>-fluorine substituents in a 2,6 arrangement, exhibited moderate potency and whole-cell activity, but a complete loss of selectivity. Finally, ortho substitution (<b>9at</b>, <b>9au</b>) was also sufficient to achieve permeance in combination with additional para-substituents, but consistent with our previously published SAR, these para-substituted analogues were not found to confer any cryptococcal selectivity.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Efforts to Improve Whole-Cell Anticryptococcal Activities and Selectivities for Inhibitors <i>N</i>-Methylated at R<sup>1</sup>, <i>via</i> a Paring of Ortho/Meta-Substituents on the R<sup>2</sup> Aryl Ring<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0017.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0018.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">EC<sub>50</sub> values were determined by FP-based equilibrium competition assay performed in a 384-well format using whole-cell lysates prepared from <i>C. neoformans</i> and serial compound dilutions. All determinations were performed in duplicate.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">To calculate fold-selectivity, the EC<sub>50</sub> value determined in human HepG2 cell lysate was divided by the EC<sub>50</sub> value determined in <i>C. neoformans</i> lysate. The resulting ratio was then normalized by the ratio of values determined for the Hsp90 inhibitor geldanamycin using lysate of each cell type. Results for key selective compounds were confirmed by repeat assay in lysates, as well as by measuring ligand dissociation constants (<i>K<sub>i</sub></i>) using purified NBDs in FP assays (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_001.pdf" class="ext-link">Supporting Tables 1 and 2</a>).</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Concentration of compound resulting in >80% inhibition of fungal cell growth compared to vehicle control. Values for compounds with either fold-selectivity >5 <b>or</b> MIC<sub>80</sub> ≤ 12.5 μM are highlighted in <b>blue</b>. Values for compounds with both fold-selectivity >5 <b>and</b> MIC<sub>80</sub> ≤ 12.5 μM are highlighted in <b>red</b>.</p></div></div><div></div></div><div class="NLM_p">With two successful permeance-enhancing strategies identified, we next examined the combination of both approaches (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Gratifyingly, merging our optimal disubstitution patterns at R<sup>2</sup> with a variety of bulky aliphatic moieties at R<sup>1</sup> (<i>tert</i>-butyl, isopropyl, cyclopentyl, and cyclohexyl) afforded inhibitors <b>9av</b>–<b>9bi</b> with almost universally improved activity profiles. Notably, all compounds in this series had measurable MICs at or below 25 μM, with several compounds achieving the best cryptococcal whole-cell growth inhibition observed for fungal-selective RAPs to date at 3.13 μM (<b>9bb</b>, <b>9bd</b>, <b>9bf</b>, and <b>9bi</b>). Among this series, the strongest whole-cell potencies appeared to track to the <i>N</i>-<i>tert</i>-butyl and <i>N</i>-cyclohexyl substitutions at R<sup>1</sup>, with the corresponding <i>N</i>-isopropyl (<b>9ba</b>, <b>9be</b>) and <i>N</i>-cyclopentyl (<b>9bc</b>, <b>9bh</b>) congeners espousing slightly higher MICs at 6.25 μM. Interestingly, while substitution of the isoindoline amide of <b>9bf</b> for 4-fluoroisoindoline (compound <b>9bg</b>) depressed potency to increase the lysate EC<sub>50</sub> to the low micromolar range, this compound still exhibited selectivity and whole-cell activity comparable to near-neighbor analogues with lysate EC<sub>50</sub>’s in the 100–400 nM range.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Strategic Merging of Bulky Aliphatic Moieties at R<sup>1</sup> and Optimal Disubstituted Aromatics at R<sup>2</sup> Result in Advanced Leads with Significantly Improved Activity Profiles<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0019.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0020.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">EC<sub>50</sub> values were determined by FP-based equilibrium competition assay performed in 384-well format using whole-cell lysates prepared from <i>C. neoformans</i> and serial compound dilutions. All determinations were performed in duplicate.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">To calculate fold-selectivity, the EC<sub>50</sub> value determined in human HepG2 cell lysate was divided by the EC<sub>50</sub> value determined in <i>C. neoformans</i> lysate. The resulting ratio was then normalized to the ratio of values determined for the nonselective inhibitor geldanamycin using lysate of each cell type. Results for key selective compounds were confirmed by repeat assay in lysates, as well as by measuring ligand dissociation constants (<i>K<sub>i</sub></i>) using purified NBDs in FP assays (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_001.pdf" class="ext-link">Supporting Tables 1 and 2</a>).</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Concentration of compound resulting in >80% inhibition of fungal cell growth compared to vehicle control. Values for compounds with either fold-selectivity >5 <b>or</b> MIC<sub>80</sub> ≤ 12.5 μM are highlighted in <b>blue</b>. Values for compounds with both fold-selectivity >5 <b>and</b> MIC<sub>80</sub> ≤ 12.5 μM are highlighted in <b>red</b>.</p></div></div><div></div></div><div class="NLM_p">With a larger cohort of whole-cell-active, fungal-selective compounds in hand, we next sought to further evaluate these compounds for potential use in animals. In our prior study, poor metabolic stability was identified as a significant liability among several of our most promising first-generation RAPs, with many compounds showing very high microsomal metabolism (<i>T</i><sub>1/2</sub> < 10 min), and only one RAP with intermediate (CL<sub>int</sub> ∼ 20–70, <i>T</i><sub>1/2</sub> 20–60 min) metabolic stability. In this study, we examined a wider array of RAPs from our second-generation set, including all of the most promising compounds summarized in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, to better understand the metabolic liabilities present and attempt rational modifications to minimize them. Starting from first-generation RAP <b>18</b> (<i>T</i><sub>1/2</sub> = 6 min), we found that a number of structural modifications conferred a net stabilizing effect, with microsomal half-lives for nearly half of the compounds (11 of 24) extended to >20 min. Such modifications include conversion of the R<sup>1</sup> methyl to <i>tert</i>-butyl (<b>9ax</b>) and cyclohexyl (<b>9az</b>), fluorination of the isoindoline at the 4- (<b>9ad</b>) and 5-position (<b>9ae</b>), and conversion of the R<sup>2</sup><i>ortho</i>-methyl substituent to fluorine (<b>9am</b>) and chlorine (<b>9an</b>). However, matched-pair analysis for other members of the cohort (not shown) showed that these same types of single structural modifications impart divergent effects on microsomal stability, depending on the structure of the parent RAP. While it is difficult to discern clear structure–property relationships or pinpoint exact sites of metabolism from these data, we postulate that the observed trends are consistent with either metabolism that is largely occurring at the isoindoline with extreme sensitivity to CYP450 binding effects imparted by the entire aminopyrazole subunit, or more likely that several potential metabolic soft spots exist on the RAP scaffold, and that access to these potential hot spots by CYP450 enzymes is strongly governed by each site’s positioning relative to other substituents exerting distal effects on CYP450 binding. While the extension of half-lives from the low to intermediate range represents a key advancement, there is clearly room for further optimization of metabolic stability.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Mammalian Cytotoxicity and Microsomal Stability Assessments for 24 Select RAPs, Including 22 RAPs with Biochemical FS >5 and <i>C. neoformans</i> MIC ≤ 12.5 μM<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0021.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">All whole-cell testing results are representative of two independent experiments, each performed with technical triplicates. Compounds with NIH 3T3 therapeutic index >2 are highlighted in <b>green</b>. Compounds with intermediate microsomal stability (CL<sub>int</sub> ∼ 20–70 μL/min/mg)<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> are highlighted in <b>orange</b>.</p></div></div><div></div></div><div class="NLM_p">Next, we examined the downstream translatability of potency and selectivity in lysates to the context of whole cells. Strikingly, a plot of biochemical vs whole-cell potency (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A) clearly shows that these values are noncorrelative. The lack of correlation suggests that although barriers to cryptococcal permeance have been lowered with this series, as-yet-undefined mechanisms still reduce compound accumulation in <i>Cryptococcus</i> and, as a result, dampen whole-cell potency to levels well below what would be expected based on biochemical target engagement. This point is perhaps best exemplified by direct comparison of compounds <b>9bg</b> and <b>9ac</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A); despite a >30-fold difference in biochemical potency in cryptococcal H99 lysate (1.15 μM vs 34 nM, respectively), both compounds were equally effective in H99 whole cells (MIC 6.25 μM).</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Scatter plots of the top 22 most fungal-selective, whole-cell-active RAPs showing that (A) biochemical potency (H99 lysate pEC50, <i>x</i>-axis) and whole-cell antifungal activity (<i>C. neoformans</i> MIC, μM, <i>y</i>-axis) are poorly correlated. Similarly, no correlation is seen between fungal selectivity and therapeutic index (TI, mammalian IC<sub>50</sub> ÷ <i>C. neoformans</i> MIC) in (B) NIH 3T3 cells or (C) HepG2 cells. In (A–C), scatter points are colored based on relative H99 selectivity in cellular lysates. (D) Structures of key highlighted compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01777&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">To investigate whether permeance limitations in <i>Cryptococcus</i> extended to mammalian cells, we proceeded to evaluate the cytotoxicity of our most promising compounds, again mainly focused on those with FS >5 and MIC ≤ 12.5 μM, in mammalian systems (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). These RAPs were tested in nine-point dose response for cytotoxic activity against human liver cancer (HepG2) and mouse fibroblast (NIH 3T3) cell lines (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_001.pdf" class="ext-link">Supporting Tables 3 and 4; Figures S4 and S5</a>). The disparity in these cell lines between whole-cell activity and biochemical potency for our RAPs was not as great as in <i>Cryptococcus</i>. As a result, we found that high fungal target selectivity in lysates did not translate to a useful therapeutic index (TI = mammalian IC<sub>50</sub> ÷ <i>C. neoformans</i> MIC<sub>80</sub>) in most cases. Using the noncancerous cell line NIH 3T3, known to be less sensitive to Hsp90 inhibition than cancer cells such as HepG2,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> only a handful of compounds showed a modest therapeutic window (TI 1.5–3.1). Somewhat surprisingly, we observed a near-inverse relationship between cellular TI and lysate fold-selectivity; the most selective compound in mouse fibroblasts (<b>9o</b>) was among the least selective in lysates, whereas the RAP exhibiting the highest lysate selectivity (<b>9ad</b>) was among the least selective in NIH 3T3 cells (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B,D). In HepG2 cells, which due to their oncogenic nature are known to be hypersensitive to Hsp90 inhibition, none of the compounds exhibited cytotoxicity less than the minimum concentration required to suppress <i>C. neoformans</i> growth (all TIs < 1, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C,D). From these data, we conclude that although progress has been made, achieving adequate fungal permeance remains a challenge, a well-recognized hurdle for many small-molecule xenobiotics.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Structural Insights into Fungal Selectivity of RAPs</h3><div class="NLM_p">In addition to pursuing a property-driven optimization of our RAP series, we performed structural studies to better understand the binding mode of these inhibitors and the basis of their selectivity. We determined the crystal structures (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_001.pdf" class="ext-link">Supporting Tables 5 and 6</a>) of the <i>C. neoformans</i> NBD domain in the apo state, in complex with the nonselective Hsp90 inhibitor NVP-AUY922 (luminespib)<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> and in complex with the fungal-selective RAPs <b>10</b>, <b>18</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), and <b>19</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> These structures provide the first insights into the mode of RAP binding and also reveal a plausible structural rationale for their fungal selectivity.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structures of ligands including RAP <b>19</b>;<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> previously reported <i>C. albicans</i>-selective inhibitor CMLD013075;<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> clinical inhibitors NVP-AUY922,<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> AT13387, and SNX-2112; and purine inhibitor PU3.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01777&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Multiple copies of the protein were present in the asymmetric units of the crystals in all cases (three in apo, six in complex with AUY922, and two with each of <b>10</b>, <b>18</b>, and <b>19</b>), providing independent views of the protein in different states (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_001.pdf" class="ext-link">Supporting Figure S6</a>). Excluding the flexible lid domain that spans residues 86–124 and includes helices α4−α6, the core backbone structure of the <i>C. neoformans</i> NBD in the apo state and in complex with AUY922 aligns well with the previously determined human and <i>C. albicans</i> structures (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). The conservation of this core, which includes the entire β sheet and α1, across three distantly related species in both apo and ligand-bound states demonstrates that this core is rigid and not easily deformed. In the more flexible lid domain, two of the three <i>C. neoformans</i> apo chains resemble the “closed” (catalytically active) state of the human structure (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YER">1YER</a><a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a>), as defined by the inward positioning of the catalytic loop between helices α4 and α5, while the third chain adopts the “open” state, similar to that seen in the human structure (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YES">1YES</a><a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a>). In the apo and AUY922 structures, the lid adopts a range of conformational states and the catalytic loop between helices α4 and α5 ranges in length from two to eight residues. The lid regions in the six RAP structures, however, are similar to each other but differ from the previously described structures. Notably, helices α4 and α5 are fused into a single continuous helix from residues 86–110 that curves around the nucleotide binding site (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_001.pdf" class="ext-link">Supporting Figure S6</a>). The structure of this lid region is similar in all six RAP complex structures; however, there are minor differences in the conformation of the fused helix, including a bulge<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> at residue L93 in three of six cases. In addition, and in contrast to the <i>C. neoformans</i> apo and AUY922 structures, the six RAP structures show consistent changes in the conserved core of the domain. Notably, strand β1 could not be modeled due to disorder, while α1 and the following loop connecting to α2 are shifted relative to the canonical structure (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). Similar N-terminal changes involving β1 and α1 have been observed in structures of <i>C. albicans</i> with AUY922 and the <i>C. albicans</i>-selective Hsp90 inhibitor CMLD013075 (<b>20</b>, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), although the specific details differ (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Overlay of human, <i>C. albicans</i>, and <i>C. neoformans</i> Hsp90 NBD structures, viewed from the “back” side of the domain. In this view, the ligand-binding pocket and lid helices α4−α6 are behind the protein, away from the viewer, and are deemphasized to accentuate the changes in the β-sheet and α1. (A) Superposition of Cα traces from 21 structures that share a similar core. Traces are colored black, with β-strands in blue with blue labels. The lid is in light gray behind strands β5-β4-β7. Bound ligands in the nucleotide binding pocket are shown in pale orange behind strands β4−β7. The structures include the human protein in the apo state (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YER">1YER</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YES">1YES</a>, 2 chains) and in complex with radicicol (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EGK">4EGK</a>, 1 chain), SNX-2112 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NH7">4NH7</a>, 2 chains), AUY922 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VCI">2VCI</a>, 1 chain), AT13387 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XJX">2XJX</a>, 1 chain), and PU3 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UY6">1UY6</a>, 1 chain); <i>C. albicans</i> apo (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJI">6CJI</a>, 1 chain) and in complex with ADP (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJJ">6CJJ</a>, 1 chain), radicicol (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJL">6CJL</a>, 2 chains), and SNX-2112 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJR">6CJR</a>, 1 chain); and <i>C. neoformans</i> apo (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9R">7K9R</a>, 3 chains) and in complex with AUY922 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9S">7K9S</a>, 6 chains). (B) Same as (A), but with the addition of structures from <i>C. neoformans</i> with compounds <b>10</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9W">7K9W</a>, 2 chains), <b>18</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9V">7K9V</a>, 2 chains), and <b>19</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9U">7K9U</a>, 2 chains), shown in red. This set shows consistent changes in β5, β6, and α1 and a disordering of strand β1 (not modeled in the crystal structures). (C) Same as (A), but with the addition of chains from <i>C. albicans</i> in complex with AUY922 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJS">6CJS</a>, 1 chain) and CMLD013075 (<b>20</b>) (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJP">6CJP</a>, 2 chain), shown in magenta. Changes in the core structure are seen in β6, β1, and α1. (D) Individual structures from the box in (B) showing <i>C. neoformans</i> in complex with AUY922 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9S">7K9S</a>, left) and <b>18</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9V">7K9V</a>, right).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01777&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Overall, five regions of the NBDs make contact with the ligands: residues from α2; the loop that precedes α4; the α4−α5 segment of the lid; helix α7; and residues on the inward-facing strands of β4, β5, and β7 of the main sheet (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_001.pdf" class="ext-link">Supporting Figure S7</a>). With the exception of the lid, there is little structural variability in the backbone of these elements, and most of the side chains adopt similar rotamers irrespective of the species or bound ligand. As previously described, the vast majority of the Hsp90 residues in direct contact with ligands are identical between the three species, with the exception of positions S38/A41/S52 on α2 and M173/L176/V186 on β7 (<i>C. neoformans</i>/<i>C. albicans</i>/human residue numbering). These side chains occupy similar volumes in all structures and are roughly isosteric, but they do make contributions to the surface of the pocket that accepts the resorcinol ring, among others. These positions may modulate ligand-binding affinity and thus may contribute to species specificity.</div><div class="NLM_p">A comparison of the <i>C. neoformans</i> complex with <b>10</b> and the human complex with AT13387 shows excellent overlap between the common resorcinol and isoindoline rings (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). In comparison to other liganded Hsp90 structures in the PDB, the RAP aminopyrazole ring is positioned in an induced pocket that is similar to, but slightly deeper than, the pocket induced by the indazole ring of nonselective inhibitor SNX-2112.<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41,42)</a> While originally designed to mimic the CMLD013075 oxime, the aminopyrazole instead sits in an orthogonal position, with a π-stacking interaction between the R<sup>2</sup> aryl ring and Hsp90 F124.</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0007.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Comparison with previously reported complexes. (A) Overlay of the human Hsp90/AT13387 complex (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XJX">2XJX</a>, cyan carbon atoms) with the <i>C. neoformans</i>/<b>10</b> complex (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9W">7K9W</a>, orange carbon atoms). The surface of the fungal protein is shown, and the AT13387 piperazine ring is omitted for clarity. (B) Staggered view of aligned ligands from four complexes: the two chains from the <i>C. neoformans</i>/<b>10</b> crystal structure (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9W">7K9W</a>), human/SNX-2112 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NH7">4NH7</a>), and human/PU3 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UY6">1UY6</a>). The gray oval represents the deep hydrophobic pocket of Hsp90, indicated in the left part of (A).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01777&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The R<sup>2</sup> aryl rings in the RAP series introduce an important feature that distinguishes these compounds from previously reported inhibitors.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> A comparison of the structures of the human and two fungal NBDs in complex with AUY922 reveal highly similar structures, with the exception of moderate shifts in the α4-α5 lid region (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A). However, in all six RAP structures, the lid is displaced outward in response to the R<sup>2</sup> rings (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B). Hydrophobic residues L93, F124, and W148 are in close contact in all of the apo and AUY922 complexes (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>C,D) but are displaced in the RAP structures to accommodate the aryl rings (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>E,F). The aromatic residues F124 and W148 in the NBD are on the relatively well-fixed α7 and β5 strand elements, while L93 is on the more malleable lid and is more easily displaced to accept the aryl ring. The disruption of this packing and outward displacement of L93 promotes the adoption of an α-helical conformation in the loop between α4 and α5, resulting in the formation of a continuous helix that spans the N-terminus of α4 to the C-terminus of α5 (residues 86–110) (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_001.pdf" class="ext-link">Supporting Figure S6</a>). Equivalent L93/F124/W148 packing is observed in the majority of apo and complex NBD structures from human and <i>C. albicans</i>, and similar disruptions of this core have been observed by the indazole ring of the nonselective inhibitor SNX-2112 in human<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> and <i>C. albicans</i>,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> and the methoxy-substituted aryl ring of PU3 in human (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B).<a onclick="showRef(event, 'ref72 ref75'); return false;" href="javascript:void(0);" class="ref ref72 ref75">(72,75)</a> Notably, the RAP R<sup>2</sup> aryl ring penetrates more deeply into this site and engages F124 in π–π stacking interaction (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> and <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>), potentially offsetting the energetic cost of repacking the hydrophobic core.</div><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0008.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Ligand-driven reorganization of the <i>C. neoformans</i> binding pocket. (A) Overlay of the human (light blue, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VCI">2VCI</a>), <i>C. albicans</i> (red, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJS">6CJS</a>), and <i>C. neoformans</i> (orange, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9S">7K9S</a>) complexes with AUY922. (B) Overlay of the <i>C. neoformans</i> NBD in complex with AUY422 (orange, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9S">7K9S</a>) and RAP compounds <b>10</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9W">7K9W</a>), <b>18</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9V">7K9V</a>), and <b>19</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9U">7K9U</a>) (dark blue). (C–F) Residues L93, F125, and W128 from helices α4, α7, and strand β5, respectively, are in packing contact in the apo (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJI">6CJI</a>, C) and AUY922 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9S">7K9S</a>, D) complexes, but are disrupted by the R<sup>2</sup> aryl ring of the RAPs (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9W">7K9W</a>, E/F). The two chains in the co-crystals of the <i>C. neoformans</i> NBD with <b>10</b> reveal different rotamers of the <i>meta</i>-methoxy aryl ring, shown in (E) and (F).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01777&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The <i>C. neoformans</i> structures reveal two packing arrangements of the RAP R<sup>2</sup> aryl groups (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_001.pdf" class="ext-link">Supporting Figure S6</a>). In four of the complexes (chain A of <b>10</b>, chains A and B of <b>18</b>, and chain A of <b>19</b>), the aryl ring is in the position shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>E, while in the other two (chain B of <b>10</b> and <b>19</b>), the conformer is as in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>F. Thus, the pocket can adjust to two rotamers of the ligand aryl ring relative to the aminopyrazole ring. These structures, in combination with the SNX-2112 and AT13387 structures, demonstrate the plasticity of this induced binding pocket in both fungal and human Hsp90s. While we expect that the RAPs can induce similar rearrangements in the human protein, the weaker <i>K</i><sub>d</sub>’s strongly suggest that the energetics of repacking differs between the two species. Although there is no obvious trend to show how the aryl ring substituents may favor different binding states, these structures clearly show that ring substitution is a viable strategy to modulate the binding affinity within this series of inhibitors.</div><div class="NLM_p">The insertion of RAP aryl rings not only displaces and remodels the α4-α5 lid but also has smaller but significant effects on β5 due to backbone shifts at residue W148 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>E,F and <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>). This has a domino effect that affects neighboring strand β6 by displacing F156, ultimately resulting in the loss of the N-terminal β1 strand of the sheet (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). In turn, the disruption of strand β1 results in the shift in α1 since the N-terminus of this helix is no longer anchored to the protein (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> and <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>).</div><figure id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0009.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. RAP binding disrupts the β-sheet. (A) Overlay of the <i>C. neoformans</i> and human structures from <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> were divided into two sets. Set A includes all of the eight human structures [<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YER">1YER</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YES">1YES</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EGK">4EGK</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NH7">4NH7</a> (two chains), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VCI">2VCI</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XJX">2XJX</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UY6">1UY6</a>] and the nine <i>C. neoformans</i> apo and AUY922 structures [<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9R">7K9R</a> (three chains) and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9S">7K9S</a> (six chains)] and is shown in black Cα trace. Set B includes the six fungal RAP complexes [<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9U">7K9U</a> (two chains), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9V">7K9V</a> (two chains), and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9W">7K9W</a> (two chains)] and is shown in red Cα trace. Selected side chains from set A are shown in stick representation with van der Waals surface and fungal/human numbering. (B) The same backbone traces are represented, but with the side chains from set B as well as the RAP inhibitor <b>10</b> in space filling representation. Note that strand β1 is present only in the structures from set A.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01777&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Each of the three major ligand-induced conformational changes seen in the <i>C. neoformans</i> RAP complexes (disruption of the L93/F125/W128 core, fusion of the lid helices, and disruption of the N-terminus) have been observed in other NBD complexes, but not in the same structures (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_001.pdf" class="ext-link">Supporting Table 7</a>). Given the current data, it is challenging to propose a single unifying model to explain how these changes are correlated to each other and to ligand binding. We propose, however, that the fusion of the lid helices is not directly correlated with the other observed changes and is most likely driven by direct interactions with the ligands. Support for this model can be found in the structures with AUY922, which are known for all three species under consideration. The binding of AUY922 to the <i>C. albicans</i> NBD results in a fused lid helix and disrupted N-terminus, but does not disrupt the core, while none of these changes are present in the human AUY922 complex. In addition, a fused lid helix is seen in two of the six AUY922 complexes with the <i>C. neoformans</i> NBDs, but all have an intact L93/F125/W128 core and an ordered N-terminus. The second pattern that emerges from the set of complexes is that the disruption of the N-terminal region co-occurs with the disruption of the W148/F156 stack between strands β5 and β6. This stack is disrupted in some, but not all, of the ligand complexes that disrupt the L93/F125/W128 core. These include the six <i>C. neoformans</i>/RAP structures presented here and the <i>C. albicans</i> complexes with AUY922 and CMLD013075.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Complexes with SNX-2112 (human, <i>C. albicans</i>) and PU3 (human) are able to disrupt the core packing, but do not reach deeply enough into the induced pocket to affect the position of W148, and consequently, these ligands do not disrupt the β1/α1 N-terminus. It is notable that N-terminal remodeling has been observed in approximately half of the available <i>C. neoformans</i> and <i>C. albicans</i> structures, but never in a human structure. This may simply reflect the selection of structures that are currently available, or it may be because the fungal NBDs are more prone to structural rearrangements in regions outside of the lid. Overall, these results reflect the complex interplay between the ligands and the proteins and support the idea that Hsp90 inhibitors can be designed with species-specific properties.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Summary of Structure–Activity Relationships and Insights from Modeling</h3><div class="NLM_p">With X-ray crystallographic structures providing an improved understanding of the binding modes of R<sup>1</sup>-methylated, R<sup>2</sup> monosubstituted RAPs, we next attempted to further rationalize the observed structure–activity and structure–property relationships across different RAP structural subtypes. <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a> shows a scatter plot summarizing the cryptococcal fold-selectivity (y-axis), biochemical potency (color), and whole-cell activity (symbol) of the cohort of inhibitors from <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, binned on the x-axis based on their patterns of substitution at R<sup>1</sup> (methyl vs bulky aliphatic substituents) as well as at the R<sup>2</sup> phenyl ring (2-substituted, 3-substituted, 2,3-disubstituted, and 2,5-disubstituted). From this plot, we can glean generalized SAR trends through head-to-head comparisons of different cohorts. For example, in comparing groups A–B and E–F, it is clear that <i>ortho</i>-monosubstituted compounds in group A generally have very good (low nM) biochemical potencies but are limited in their fungal selectivity. In contrast, <i>meta</i>-monosubstitutions (groups B and F) generally lead to suppression of biochemical potency, in some cases to the micromolar range. Interestingly, for the <i>meta</i>-monosubstituted subset B, selectivity does not appear to track as cleanly with biochemical activity compared to the <i>ortho</i>-monosubstituted subset A. Also apparent is the general overall improvement in biochemical potency and selectivity that is achieved when incorporating a second substituent at R<sup>2</sup> (groups C/D/G/H as compared to groups A/B/E/F). It is also notable that group to group, these improvements in selectivity do sometimes come at a cost: for example, the most potent and selective <i>N</i>-methylated, 2,3-disubstituted inhibitors (group D) tend to have poor whole-cell activity, and highly selective inhibitors bearing bulky R<sup>1</sup> substituents are generally less potent than their <i>N</i>-methylated counterparts (<i>cf.</i> groups G/H and groups C/D).</div><figure id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0010.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Scatter plots of cryptococcal selectivity, biochemical potency, and whole-cell activity for <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> RAPs, binned by the aminopyrazole substructure class as defined by the R<sup>1</sup> and R<sup>2</sup> substitution patterns. The y-axis depicts cryptococcal fold-selectivity on a logarithmic scale. Points are colored by H99 lysate EC<sub>50</sub> on a logarithmic scale, on a gradient ranging from cyan (10 μM) to red (1 nM). Point symbols indicate whole-cell activity class, with circles corresponding to compounds with little to no whole-cell activity (H99 MIC ≥ 25 μM) and stars indicating whole-cell-active compounds with an H99 MIC < 25 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01777&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In judging these structural subclasses by their full complement of relevant parameters, two clear “optimal” themes emerge (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A): first, for compounds that are <i>N</i>-methylated at R<sup>1</sup>, overall whole-cell activity is best among R<sup>2</sup>-disubstituted compounds where the substituents have a 2,5 relationship (group C); in contrast, compounds bearing bulky aliphatic groups at R<sup>1</sup> generally exhibit improved potency and selectivity when R<sup>2</sup> is 2,3-disubstituted (group H). Interestingly, these two orthogonal subsets also diverge somewhat in the nature of their “optimal” properties; while group C is exemplary in biochemical potency and selectivity, group H is stronger in terms of whole-cell anticryptococcal activity; this feature is even more pronounced when considering the relative whole-cell potencies, which for simplicity are not represented here. In <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>B, we provide representative leading members of each of these two classes, as starting points for future optimizations of potency; selectivity; whole-cell activity; and additional absorption, distribution, metabolism, and excretion (ADME) parameters including metabolic stability.</div><figure id="fig10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0011.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A) Two predominant structural classes among RAPs with optimal combined biochemical potency/fungal selectivity/whole-cell activity profile, each with slightly divergent activity profiles. (B) Representative structures and activities of top inhibitors <b>9ac</b>, <b>9ad</b>, <b>9ba</b>, and <b>9bb</b> from these subclasses.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01777&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We next attempted to model these various structural subclasses into our existing X-ray structures to rationalize structure–activity trends observed among the R<sup>2</sup>-disubstituted inhibitors. In doing so, it is important to consider that due to the inherent plasticity of the Hsp90 NBD and the number and scope of remodeling events which have so far been documented across different species and in co-complex with different ligand structural subclasses, any effort to model other RAP structural subclasses into these rigid, RAP-induced receptors is of only limited and speculative utility. Nonetheless, in each RAP-liganded X-ray structure, the R<sup>1</sup>-methyl substituent is projected outward and solvent-exposed; we posit that expansion of this group to a larger lipophilic moiety is likely to create entropic penalties due to bulk water disruption, which may in part explain the general overall trend of lowered biochemical EC<sub>50</sub>’s as the size and lipophilicity of this substituent increases. Given the proximity of this solvent-exposed group to a polar region of the binding pocket periphery, it is also possible that incompatible sterics and polarities also compound this issue. In addition, since the overall structural disruptions of the NBD appear to be induced by the R<sup>2</sup> aryl ring, we postulate that the added steric demands imposed by a second substituent on this ring may be the source of further improvements to selectivity. While we are reluctant to definitively propose binding modes for the R<sup>2</sup>-disubstituted RAPs, we have performed computational (Glide) docking<a onclick="showRef(event, 'ref76 ref77'); return false;" href="javascript:void(0);" class="ref ref76 ref77">(76,77)</a> of the 24 RAPs from <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> to explore whether the pockets induced by compounds <b>10</b>, <b>18</b>, and <b>19</b> are large enough to accommodate larger R<sup>1</sup> and R<sup>2</sup> substituents in similar binding poses without any further protein structure remodeling (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_001.pdf" class="ext-link">Supporting Table 8</a>). Glide docking with positioning restricted to the reference RAP ligand core produced excellently scored poses (−14.3 to −15.5 kcal/mol), for 20 out of the 24 compounds into at least one of the six independent chains with a core atom root-mean-square deviation (RMSD) to the native ligand of <0.1 Å. Notably, each compound also produced at least one high-scored docking pose for each of the two types of R<sup>2</sup> rotamers that were observed for compound <b>10</b> in the independent chains of the <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9W">7K9W</a> structure, underscoring the flexibility of this pocket to accommodate disubstituted R<sup>2</sup> aryl rings in multiple orientations. Select docking poses of compounds <b>9an</b>, <b>9ba</b>, and <b>9bc</b>, which illustrate this phenomenon, are depicted in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>B–G.</div><figure id="fig11" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0012.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Results of computational modeling using RAP-liganded X-ray crystal structures. (A) X-ray crystal structure (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9V">7K9V</a>) with compound <b>18</b> bound at Chain A. (B, C) Comparative views of two rotamers of compound <b>9an</b> docked into structure 7K9V Chain A. Docking scores are −15.3 and −14.5 kcal/mol, respectively. (D, E) Comparative views of two rotamers of compound <b>9ba</b> docked into structure 7K9V Chain A. Docking scores are −14.7 and −14.5 kcal/mol, respectively. (F, G) Comparative views of two rotamers of compound <b>9bc</b> docked into structure <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9V">7K9V</a> Chain A. Docking scores are −14.2 and −14.4 kcal/mol, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01777&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Out of the set of RAPs docked, only the R<sup>1</sup>-cyclohexyl-substituted compounds (<b>9j</b>, <b>9az</b>, <b>9bd</b>, and <b>9bi)</b> failed to produce any poses in any of the six chains under the applied constraints, which we ascribe to the entropic and steric factors described above. For the remaining 20 compounds, very high docking scores were obtained across compounds with widely varying biochemical potencies and selectivities; as such, it is difficult to fully rationalize the divergent activities on the basis of this structural modeling. However, this limited computational study does confirm an overall compatibility of the R<sup>2</sup>-disubstituted RAPs with the RAP-induced binding pocket. In addition, the accommodation of multiple R<sup>2</sup> substituents and in multiple orientations suggests that the potency gains observed for disubstituted compounds may in part arise due to additional beneficial van der Waals interactions and an improved occupancy of the deep hydrophobic cavity in the R<sup>2</sup>-induced pocket.<a onclick="showRef(event, 'ref78 ref79'); return false;" href="javascript:void(0);" class="ref ref78 ref79">(78,79)</a> What is not clear from this modeling, however, is whether these added R<sup>1</sup>/R<sup>2</sup> substituents may induce further changes to the protein structure, nor do they explain what role the size and nature of the R<sup>1</sup>/R<sup>2</sup> groups play in other important improvements such as whole-cell permeance and reduced mammalian cytotoxicity. Given the number of unexpected ligand-induced conformations that have been observed in fungal Hsp90 structures to date, further crystallographic work is needed to fully understand the binding modes of the optimized R<sup>2</sup>-disubstituted compounds described herein.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56345" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56345" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Continuing in our pursuit of fungal-selective, resorcylate inhibitors of the protein-folding chaperone Hsp90, and building on early leads from our prior study of resorcylate aminopyrazoles (RAPs), we have used a rational structure–property approach to improve the whole-cell fungal permeance of a lead series which exhibits high selectivity for cryptococcal Hsp90. Toward this goal, we have achieved synthesis of 22 new fungal-selective RAPs that effectively inhibit growth of <i>C. neoformans</i> whole cells at low-to-sub-micromolar concentrations. Further pharmacological and biological characterization of these RAPs showed that despite moderate improvements in both microsomal stability and whole-cell anticryptococcal activity, further optimization of fungal permeance is still needed to achieve an adequate therapeutic window for use in infection-relevant contexts. We have also solved the first X-ray crystal structures of <i>C. neoformans</i> Hsp90 in various states, including structures in complex with three fungal-selective RAPs. Conformational rearrangements induced by RAPs, while unique within the direct binding site, create downstream conformational reorganizations that are consistent with other changes induced by a resorcylate compound that selectively binds <i>C. albicans</i> Hsp90. Further studies to parlay these foundational findings into improved fungal-selective Hsp90 inhibitors for use as chemical biological probes and eventually therapeutics are ongoing.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06435" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06435" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Fungal Strains and Culture Conditions</h3><div class="NLM_p last">The strain used in this study was <i>C. neoformans</i> H99.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Archive of this strain was maintained at −80 °C in 25% glycerol. Active cultures were maintained on solid (2% agar) yeast extract peptone (YPD, 1% yeast extract, 2% bacopeptone, and 2% glucose) at 4 °C for no more than 1 month.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Antifungal Sensitivity Testing</h3><div class="NLM_p last">Minimum inhibitory concentrations (MICs) were determined in flat-bottom, 96-well-plate format using RPMI medium (Gibco SKU no. 318000-089, 3.5% MOPS, 2% glucose, pH 7.0). A modified broth microdilution protocol was used as previously described,<a onclick="showRef(event, 'ref23 ref81'); return false;" href="javascript:void(0);" class="ref ref23 ref81">(23,81)</a> except that a relative viable cell number was monitored by standard dye-reduction assay after a 3 h incubation with resazurin at 37 °C. All compounds were formulated in dimethyl sulfoxide (DMSO, Sigma-Aldrich Co.). Each compound was tested in duplicate in at least two independent experiments.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Mammalian Cell Culture and Cytotoxicity Testing</h3><div class="NLM_p last">The cell lines NIH 3T3 (CRL-1658) and HepG2 (HB-8065) were purchased from the American Type Culture Collection (ATCC). The cells were maintained in RPMI medium supplemented with 10% fetal bovine serum at 37 °C under 5% CO<sub>2</sub>. Experiments were performed using cells within 10 passages post recovery from low-passage stocks maintained in liquid nitrogen and confirmed negative for mycoplasma contamination by PCR-based assay. The cells were plated in a 384-well format at a density of 2000 per well (HepG2) or 2500 per well (NIH 3T3) in RPMI supplemented with 10% fetal bovine serum (FBS). Following overnight adherence, twofold dilutions of test inhibitors were added to wells and plates were incubated for 72 h. Subsequent determination of relative viable cell number was performed using standard resazurin dye-reduction assay with incubation at 37 °C for 3 h and measurement in a Tecan Spark microplate reader using SparkControl software (version 2.2). Nonlinear four-parameter curve fitting of raw dose–response data was performed in GraphPad Prism 7 to determine IC<sub>50</sub> values. Results reported are representative of two independent experiments, each performed with technical triplicate.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> FP Assays</h3><div class="NLM_p last">FP assays performed with whole-cell lysates and purified <i>C. neoformans</i> Hsp90 NBD were performed as previously described.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> In calculating fold-selectivity for compounds, a normalization factor of 0.84 was applied based on the EC<sub>50</sub> values determined in human and fungal cell lysate for geldanamycin, the same Hsp90 inhibitor used to generate the FP probe itself.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> NBD Expression and Purification</h3><div class="NLM_p last">Recombinant Hsp90 NBDs were expressed and purified as previously described.<a onclick="showRef(event, 'ref42 ref62'); return false;" href="javascript:void(0);" class="ref ref42 ref62">(42,62)</a></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Analytical LC-MS/MS Conditions</h3><div class="NLM_p last">Compound levels for <i>in vitro</i> metabolic stability assays were monitored by LC-MS/MS using an AB Sciex (Framingham, MA) 4000 QTRAP mass spectrometer coupled to a Shimadzu (Columbia, MD) Prominence LC. The parent ion and the two most prominent daughter ions were followed to confirm compound identity, although only the most abundant daughter was used for quantitation. Analytes were detected with the mass spectrometer in negative multiple reaction monitoring (MRM) mode for the following compounds: <b>9i</b> 541.3-404.0; <b>9j</b> 541.2-404.0; <b>9n</b> 477.1-358.0; <b>9o</b> 551.3-432.0; <b>9ac</b> 457.1-337.9; <b>9ad</b> 475.2-338.1; <b>9ae</b> 475.1-337.9; <b>9ah</b> 475.2-338.0; <b>9ak</b> 477.1-357.9. The following compounds were detected in positive MRM mode: <b>9d</b> 483.2-308.0; <b>9v</b> 487.2-312.0; <b>9af</b> 459.2-340.1; <b>9am</b> 463.1-344.1; <b>9ar</b> 529.1-410.1; <b>9av</b> 497.2-322.0; <b>9ax</b> 501.2-326.0; <b>9az</b> 527.2-326.0; <b>9ba</b> 487.2-326.1; <b>9bb</b> 501.2-326.0; <b>9bc</b> 513.2-326.0; <b>9bd</b> 527.2-326.1; <b>9be</b> 491.2-330.1; <b>9bf</b> 505.2-330.0; <b>9bg</b> 523.2-330.1; <b>9bi</b> 531.2-330.1. An Agilent (Santa Clara, CA) C18 XDB column (5 μm, 50 mm × 4.6 mm) was used for chromatography for compounds detected in negative mode under the following conditions: Buffer A: dH<sub>2</sub>O + 0.1% formic acid, Buffer B: methanol + 0.1% formic acid, 0–1.0 min 5% B, 1.0–2 min gradient to 100% B, 2–3.5 min 100% B, 3.5–3.6 min gradient to 5% B, 3.6–4.5 5% B. Tolbutamide (transition 269.1-169.9) from Sigma (St. Louis, MO) was used as an internal standard (IS). Conditions for compounds evaluated in positive mode were nearly identical, except the gradient conditions: 0–1.0 min 5% B, 1.0–1.5 min gradient to 100% B, 1.5–3.0 min 100% B, 3.0–3.2 min gradient to 5% B, 3.2–4.5 5% B, and <i>N</i>-benzylbenzamide (Sigma) was used as the internal standard (transition 212.1–91.1). Solvents (methanol and water) and formic acid were all of LC-MS/MS grade (“Optima”) and purchased from Fisher Scientific (Waltham, MA).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Mouse Liver Microsome Stability</h3><div class="NLM_p last">Female ICR/CD-1 mouse microsome fractions were purchased from BioIVT (Westbury, NY), and the protocol provided with the microsomes for assessment of compound stability was followed as detailed herein. All chemical reagents aside from the aforementioned solvents were purchased from Sigma (St. Louis, MO). Microsome protein (0.5 mg/mL) was added to a glass screw cap tube; then, 50 mM Tris, pH 7.5 solution, containing the compound of interest in DMSO (final DMSO concentration, 0.1%) was added on ice. The final concentration of compound after addition of all reagents was 2 μM. A nicotinamide adenine dinucleotide phosphate (NADPH)-regenerating system (1.7 mg/mL NADP, 7.8 mg/mL glucose-6-phosphate, 6 U/mL glucose-6-phosphate dehydrogenase in 2% w/v NaHCO<sub>3</sub>/10 mm MgCl<sub>2</sub>) was added for analysis of Phase I metabolism after both the microsome/compound mixture and regenerating system were warmed to 37 °C for 5 min. The tube was then placed in a 37 °C shaking water bath. At varying time points after addition of the NADPH regenerating system, the reaction was stopped by the addition of 0.5 mL of methanol containing an internal standard (IS) and formic acid such that the final concentration of tolbutamide IS was 50 ng/mL and that of <i>N</i>-benzylbenzamide IS was 100 ng/mL, and acid was 0.1%. Time 0 samples were quenched with methanol prior to addition of compound. The samples were incubated 10 min at room temperature and then spun at 16 100<i>g</i> for 5 min in a microcentrifuge at 4 °C. The supernatant was analyzed by LC-MS/MS. The method described in McNaney et al.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> was used with modification for determination of metabolic stability half-life by substrate depletion. A “% remaining” value was used to assess the metabolic stability of a compound over time. The LC-MS/MS peak area of the incubated sample at each time point was divided by the LC-MS/MS peak area of the time 0 (T0) sample and multiplied by 100. The natural log (LN) of the % remaining of compound was then plotted versus time (in minutes) and a linear regression curve plotted going through <i>y</i>-intercept at LN(100). The metabolism of some compounds failed to show linear kinetics at a later time point, so those time points were excluded. The half-life (<i>T</i><sub>1/2</sub>) was calculated as <i>T</i><sub>1/2</sub> = −0.693/slope. To determine intrinsic clearance,<a onclick="showRef(event, 'ref82 ref83 ref84 ref85'); return false;" href="javascript:void(0);" class="ref ref82 ref83 ref84 ref85">(82−85)</a> which allows for comparison of data obtained using different volumes and protein concentrations, the following calculations were employed:<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_m001.gif" alt="" id="_i22" /></img></span><span class="NLM_disp-formula" id="ueq2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_m002.gif" alt="" id="_i23" /></img></span></div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Statistical Methods</h3><div class="NLM_p last">For FP experiments in support of SAR studies, GraphPad Prism 5.0 was used to perform curve fitting and calculate the concentrations of compounds resulting in 50% reduction in maximal polarization signal (EC<sub>50</sub>). All curve fits demonstrated a correlation coefficient (R<sup>2</sup>) > 0.95. The number of independent experiments performed and the number of technical replicates in each experiment are provided in the legends of figures and tables characterizing the biochemical and biological activities of compounds. In calculating the error of selectivity determinations, the fractional error of measurements in each species was summed to yield a composite error for the derived ratio.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Protein Crystallization and Structure Determination</h3><div class="NLM_p">Aliquots of purified <i>C. neoformans</i> NBD (residues 1–211 or 1–215) were crystallized either alone (apo) or in the presence of AUY922 or RAPs <b>10</b>, <b>18</b>, and <b>19</b>. Crystals were obtained by mixing one part of protein solution at 10–15 mg/mL (20 mM Hepes, pH 7.5, 500 mM NaCl, 8% glycerol, 10% DMSO with or without 2 mM ligand) with one part of reservoir solution. Crystals were obtained by sitting-drop vapor diffusion at 21 °C. The best diffracting crystals were produced with a reservoir containing 20–25% PEG6K, 0.1 M Hepes, pH 7, and 1 M LiCl<sub>2</sub>.</div><div class="NLM_p last">Crystals were cryo-protected by passage through paratone before flash-cooling in liquid nitrogen. Diffraction data were collected at the APS or NSLS II synchrotrons, as indicated in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_001.pdf" class="ext-link">Supplementary Tables 5 and 6</a>. Data were processed and integrated with XDS<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> and Aimless,<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> and structures were determined by molecular replacement using <i>C. albicans</i> Hsp90 NBD (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJI">6CJI</a>) as a search model for the apo structure. The apo structure was then used to solve the RAP complexes by molecular replacement. Model building was done with Coot,<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> and the structures were refined with Phenix.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Software used in this project was curated by SBGrid.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a></div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Computational Docking</h3><div class="NLM_p last">Molecular docking of the 24 compounds listed in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> was performed using six separate docking grids (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9U">7K9U</a> Chain A, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9U">7K9U</a> Chain B, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9V">7K9V</a> Chain A, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9V">7K9V</a> Chain B, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9W">7K9W</a> Chain A, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9W">7K9W</a> Chain B) using the Glide docking program (Schrödinger Maestro Version 12.4.079). Proteins were treated using Schrödinger’s Protein Preparation Wizard with retention of waters, optimization of hydrogen bonds, and restrained minimization converging heavy atoms to RMSD 0.3 Å. Protein structures were kept rigid during docking experiments. Docking grids were prepared using a receptor-based box centered at the native ligand for each chain. Ligands were prepared using Schrodinger’s LigPrep and kept at a neutral ionization state. Docking was run at Standard precision with flexible ligands, with the docking restricted to a reference position (identified using Maximum Common Substructure) defined by the 5-((1<i>H</i>-pyrazol-5-yl)amino)benzene-1,3-diol core substructure from the native ligand of each chain. The output was set to report up to five poses per ligand, and Epik state penalties were included in the calculation of docking score. All of the output docking poses fell into one of the two possible R<sup>2</sup> aryl-ring rotamers as originally observed for compound <b>10</b> in the <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9W">7K9W</a> X-ray structure. Where two R<sup>2</sup> aryl-ring rotamers were present, the highest-scored poses for each of the two rotamers were kept for analysis; otherwise, only the highest-scored pose for each compound into each chain was kept. Tabular results for docking each compound into each chain are reported in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_001.pdf" class="ext-link">Supporting Table 8</a>.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Chemistry Methods</h3><div id="sec4_11_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> General Methods</h4><div class="NLM_p last"><sup>1</sup>H NMR spectra were recorded at 400 or 500 MHz at ambient temperature. <sup>13</sup>C NMR spectra were recorded at 101 or 126 MHz at ambient temperature. <sup>19</sup>F NMR spectra were recorded at 470 MHz at ambient temperature. Chemical shifts are reported in parts per million. Data for <sup>1</sup>H NMR are reported as follows: chemical shift, multiplicity (app = apparent, br = broad, s = singlet, d = doublet, t = triplet, q = quartet, sxt = sextet, hept = heptet, m = multiplet,), coupling constants, and integration. All <sup>13</sup>C NMR spectra were recorded with complete proton decoupling. Analytical thin-layer chromatography was performed using 0.25 mm silica gel 60-F plates. Silica flash chromatography was performed using prepacked columns (SI-HC, puriFlash or Premium Universal, Yamazen) on either an Interchim puriFlash450 or Yamazen Smart Flash EPCLC W-Prep2XY system. All mass-guided preparative high-performance liquid chromatography (HPLC) experiments were performed using an acetonitrile/water gradient (mobile phase modified with 0.01% formic acid) on a Waters FractionLynx system equipped with a 600 HPLC pump, a micromass ZQ quadrupole, Waters 996 diode array, and Sedere Sedex 75 ELS detectors, using an XBridge Prep C18 5 μM OBD 19 mm diameter column of either 100 or 250 mm length. Isolated yields refer to chromatographically and spectroscopically pure compounds, unless otherwise stated. All reactions were carried out in oven-dried glassware under a nitrogen atmosphere unless otherwise noted. Analytical UPLC–MS experiments were performed using a Waters Acquity (ultraperformance liquid chromatography) with a binary solvent manager, an SQ mass spectrometer, a Waters 2996 photodiode array (PDA) detector, and an evaporative light-scattering detector (ELSD). All microwave experiments were performed on a CEM Discover microwave reactor, using a sealed 10 or 35 mL vessel with temperatures monitored by an external sensor. All compounds tested in biological assays were determined to be >95% pure by UPLC–MS-ELSD analysis.</div></div><div id="sec4_11_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> α-Cyanoketone Synthesis</h4><div class="NLM_p last">α-Cyanoketones <b>3a</b>, <b>3c</b>, <b>3e</b>, <b>3g</b>, <b>3h</b>, <b>3i</b>, <b>3k</b>, and <b>3l</b> were obtained from commercial sources.</div></div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> General Procedure A</h3><div class="NLM_p">To a flame-dried nitrogen-flushed round-bottom flask equipped with a magnetic stir bar were added anhydrous THF (4 mL) and <i>n</i>BuLi solution (3 mmol, 1.2 equiv). The solution was cooled to −78 °C in a dry ice/acetone bath. To the reaction flask was added a solution of MeCN (0.26 mL, 5 mmol, 2 equiv, 2 M in THF) dropwise over 2 min. The mixture was stirred for 1 h at −78 °C. A solution of methyl ester <b>2</b> (2.5 mmol, 2 M in THF) was prepared and added to the reaction flask dropwise over 2 min. The reaction was stirred at −78 °C for 30 min and then at room temperature for 2 h. The reaction was quenched with 1 M HCl (30 mL), extracted with EtOAc (3 × 50 mL), washed with brine, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. Purification by silica flash chromatography (2–40% EtOAc in hexanes) afforded the desired α-cyanoketone product <b>3</b>.</div><div id="sec4_12_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 3-Oxo-3-(2-(trifluoromethyl)phenyl)propanenitrile (<b>3b</b>)</h4><div class="NLM_p last"><b>3b</b> was prepared from methyl 3-(trifluoromethyl)benzoate (0.78 mL, 5 mmol) according to General Procedure A. <b>3b</b> (799 mg, 3.75 mmol, 74% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.82–7.75 (m, 1H), 7.73–7.64 (m, 2H), 7.54–7.48 (m, 1H), 3.95 (s, 2H).</div></div><div id="sec4_12_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 3-Oxo-3-(2-(trifluoromethoxy)phenyl)propanenitrile (<b>3e</b>)</h4><div class="NLM_p last"><b>3e</b> was prepared from methyl 2-(trifluoromethoxy)benzoate (1.10 g, 5 mmol) according to General Procedure A. <b>3e</b> (1.08 g, 4.73 mmol, 94% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.88 (dd, <i>J</i> = 7.9, 1.8 Hz, 1H), 7.70–7.63 (m, 1H), 7.49–7.41 (m, 1H), 7.41–7.33 (m, 1H), 4.05 (s, 2H).</div></div><div id="sec4_12_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 3-Oxo-3-(3-(trifluoromethoxy)phenyl)propanenitrile (<b>3i</b>)</h4><div class="NLM_p last"><b>3i</b> was prepared from methyl 3-(trifluoromethoxy)benzoate (1.10 g, 5 mmol) according to General Procedure A. <b>3i</b> (979 mg, 4.27 mmol, 85% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.86–7.81 (m, 1H), 7.79–7.75 (m, 1H), 7.62–7.55 (m, 1H), 7.53–7.48 (m, 1H), 4.13 (s, 2H).</div></div><div id="sec4_12_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 3-(2,3-Dimethylphenyl)-3-oxopropanenitrile (<b>3l</b>)</h4><div class="NLM_p last"><b>3l</b> was prepared from methyl 2,3-dimethylbenzoate (985 mg, 6 mmol) according to General Procedure A. <b>3l</b> (647 mg, 3.74 mmol, 62% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.37 (d, <i>J</i> = 7.7 Hz, 2H), 7.21 (t, <i>J</i> = 7.7 Hz, 1H), 3.99 (s, 2H), 2.40 (s, 3H), 2.34 (s, 3H).</div></div><div id="sec4_12_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 3-(5-Fluoro-2-methylphenyl)-3-oxopropanenitrile (<b>3m</b>)</h4><div class="NLM_p last"><b>3m</b> was prepared from methyl 5-fluoro-2-methyl-benzoate (1.01 g, 5 mmol) according to General Procedure A. <b>3m</b> (706 mg, 3.98 mmol, 66% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.34–7.27 (m, 2H), 7.20 (td, <i>J</i> = 8.1, 2.6 Hz, 1H), 4.02 (s, 2H), 2.52 (s, 3H).</div></div><div id="sec4_12_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 3-(2-Fluoro-3-methylphenyl)-3-oxopropanenitrile (<b>3n</b>)</h4><div class="NLM_p last"><b>3n</b> was prepared from methyl 2-fluoro-3-methyl-benzoate (1.01 g, 6 mmol) according to General Procedure A. <b>3n</b> (1020 mg, 5.76 mmol, 95% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.76 (t, <i>J</i> = 7.3 Hz, 1H), 7.51–7.43 (m, 1H), 7.22–7.13 (m, 1H), 4.12–4.05 (m, 2H), 2.34 (s, 3H).</div></div><div id="sec4_12_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 3-(2,3-Difluorophenyl)-3-oxopropanenitrile (<b>3o</b>)</h4><div class="NLM_p last"><b>3o</b> was prepared from methyl 2,3-difluorobenzoate (1.03 g, 6 mmol) according to General Procedure A. <b>3o</b> (694 mg, 3.83 mmol, 63% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.76–7.68 (m, 1H), 7.53–7.43 (m, 1H), 7.30–7.21 (m, 1H), 4.11 (d, <i>J</i> = 2.4 Hz, 2H).</div></div><div id="sec4_12_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 3-(2-Methyl-3-(trifluoromethyl)phenyl)-3-oxopropanenitrile (<b>3p</b>)</h4><div class="NLM_p last"><b>3p</b> was prepared from methyl 2-methyl-3-(trifluoromethyl)benzoate (501 mg, 2.3 mmol) according to General Procedure A. <b>3p</b> (449 mg, 1.98 mmol, 85% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.84 (d, <i>J</i> = 7.9 Hz, 1H), 7.67 (d, <i>J</i> = 7.8 Hz, 1H), 7.44 (t, <i>J</i> = 7.9 Hz, 1H), 4.00 (s, 2H), 2.57 (s, 3H).</div></div><div id="sec4_12_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 3-(3-Chloro-2-fluorophenyl)-3-oxopropanenitrile (<b>3q</b>)</h4><div class="NLM_p last"><b>3q</b> was prepared from methyl 3-chloro-2-fluoro-benzoate (471 mg, 2.5 mmol) according to General Procedure A. <b>3q</b> (443 mg, 2.24 mmol, 89% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.89–7.81 (m, 1H), 7.73–7.64 (m, 1H), 7.30–7.19 (m, 1H), 4.11 (s, 2H).</div></div><div id="sec4_12_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 3-(2-Fluoro-3-(trifluoromethoxy)phenyl)-3-oxopropanenitrile (<b>3r</b>)</h4><div class="NLM_p last">To a 20 mL scintillation vial were added 2-fluoro-3-(trifluoromethoxy)benzoic acid (504 mg, 2.25 mmol), concentrated sulfuric acid (0.2 mL), and methanol (6 mL, 0.38 M). The vial was sealed, and the reaction was heated at 75 °C for 18 h. The reaction was cooled to room temperature, diluted with ethyl acetate (50 mL), washed with saturated sodium bicarbonate solution (3 × 50 mL), washed with brine (50 mL), dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude methyl ester was carried on without further purification and treated according to General Procedure A. <b>3r</b> (445 mg, 1.80 mmol, 80% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.96–7.88 (m, 1H), 7.66–7.58 (m, 1H), 7.39–7.31 (m, 1H), 4.12 (d, <i>J</i> = 2.7 Hz, 2H).</div></div><div id="sec4_12_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 3-(2,5-Difluorophenyl)-3-oxopropanenitrile (<b>3s</b>)</h4><div class="NLM_p last"><b>3s</b> was prepared from methyl 2,5-difluorobenzoate (516 mg, 3 mmol) according to General Procedure A. <b>3s</b> (248 mg, 1.37 mmol, 45% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.72–7.60 (m, 1H), 7.40–7.28 (m, 1H), 7.25–7.14 (m, 1H), 4.10 (d, <i>J</i> = 2.7 Hz, 2H).</div></div><div id="sec4_12_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 3-(2-Chloro-5-fluorophenyl)-3-oxopropanenitrile (<b>3t</b>)</h4><div class="NLM_p last"><b>3t</b> was prepared from methyl 2-chloro-5-fluoro-benzoate (471 mg, 2.5 mmol) according to General Procedure A. <b>3t</b> (441 mg, 2.23 mmol, 89% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.53–7.45 (m, 1H), 7.42–7.36 (m, 1H), 7.31–7.22 (m, 1H), 4.19 (s, 2H).</div></div><div id="sec4_12_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 3-(5-Chloro-2-fluorophenyl)-3-oxopropanenitrile (<b>3u</b>)</h4><div class="NLM_p last"><b>3u</b> was prepared from methyl 5-chloro-2-fluoro-benzoate (471 mg, 2.5 mmol) according to General Procedure A. <b>3u</b> (445 mg, 2.25 mmol, 90% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.94 (m, 1H), 7.59 (m, 1H), 7.18 (m, 1H), 4.08 (d, <i>J</i> = 2.6 Hz, 2H).</div></div><div id="sec4_12_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 3-(2-Fluoro-5-methylphenyl)-3-oxopropanenitrile (<b>3v</b>)</h4><div class="NLM_p last"><b>3v</b> was prepared from methyl 2-fluoro-5-methyl-benzoate (505 mg, 3 mmol) according to General Procedure A. <b>3v</b> (323 mg, 1.82 mmol, 60% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.74 (dd, <i>J</i> = 7.1, 2.4 Hz, 1H), 7.45–7.34 (m, 1H), 7.08 (dd, <i>J</i> = 11.3, 8.4 Hz, 1H), 4.08 (dd, <i>J</i> = 2.5, 0.6 Hz, 2H), 2.38 (s, 3H).</div></div><div id="sec4_12_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 3-(2-Fluoro-5-(trifluoromethyl)phenyl)-3-oxopropanenitrile (<b>3w</b>)</h4><div class="NLM_p last"><b>3w</b> was prepared from methyl 2-fluoro-5-(trifluoromethyl)benzoate (511 mg, 2.3 mmol) according to General Procedure A. <b>3w</b> (489 mg, 2.11 mmol, 91% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.29–8.21 (m, 1H), 7.94–7.86 (m, 1H), 7.42–7.33 (m, 1H), 4.14–4.10 (m, 2H).</div></div><div id="sec4_12_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 3-(2-Fluoro-5-(trifluoromethoxy)phenyl)-3-oxopropanenitrile (<b>3x</b>)</h4><div class="NLM_p last">To a 20 mL scintillation vial were added 2-fluoro-5-(trifluoromethoxy)benzoic acid (504 mg, 2.25 mmol), concentrated sulfuric acid (0.2 mL), and methanol (6 mL, 0.38 M). The vial was sealed, and the reaction was heated at 75 °C for 18 h. The reaction was cooled to room temperature, diluted with ethyl acetate (50 mL), washed with saturated sodium bicarbonate solution (3 × 50 mL), washed with brine (50 mL), dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude methyl ester was carried on without further purification and treated according to General Procedure A. <b>3x</b> (414 mg, 1.68 mmol, 74% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.83 (dd, <i>J</i> = 5.9, 2.9 Hz, 1H), 7.53–7.46 (m, 1H), 7.31–7.25 (m, 1H), 4.13–4.09 (m, 2H).</div></div><div id="sec4_12_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 3-(2,6-Difluorophenyl)-3-oxopropanenitrile (<b>3y</b>)</h4><div class="NLM_p last"><b>3y</b> was prepared from methyl 2,6-difluorobenzoate (258 mg, 1.5 mmol) according to General Procedure A. <b>3y</b> (169 mg, 0.93 mmol, 62% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.60–7.50 (m, 1H), 7.09–6.99 (m, 2H), 4.02–3.94 (m, 2H).</div></div><div id="sec4_12_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 3-(4-Chloro-2-fluorophenyl)-3-oxopropanenitrile (<b>3z</b>)</h4><div class="NLM_p last"><b>3z</b> was prepared from methyl 4-chloro-2-fluoro-benzoate (1.13 g, 6 mmol) according to General Procedure A. <b>3z</b> (1.08 g, 5.46 mmol, 91% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.00–7.87 (m, 1H), 7.34–7.28 (m, 1H), 7.28–7.20 (m, 1H), 4.10–4.03 (m, 2H).</div></div><div id="sec4_12_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 3-(2-Chloro-4-fluorophenyl)-3-oxopropanenitrile (<b>3aa</b>)</h4><div class="NLM_p last"><b>3aa</b> was prepared from methyl 2-chloro-4-fluoro-benzoate (1.13 g, 6 mmol) according to General Procedure A. <b>3aa</b> (1.11 g, 5.62 mmol, 93% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.79–7.70 (m, 1H), 7.25–7.19 (m, 1H), 7.16–7.06 (m, 1H), 4.15 (s, 2H).</div></div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 5-Aminopyrazole Synthesis</h3><div class="NLM_p last">5-Aminopyrazoles <b>4a</b>, <b>4f</b>, and <b>4s</b> were obtained from commercial sources.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> General Procedure B</h3><div class="NLM_p last">To a microwave vial equipped with a magnetic stir bar were added α-cyanoketone <b>3</b> (1 equiv), methyl hydrazine (1.1 equiv), and anhydrous methanol (1 M). The vial was capped and heated in a microwave reactor maintaining 120 °C for 90 min. The vial was cooled to room temperature and the reaction was concentrated under reduced pressure. The crude residue was purified by silica flash chromatography (5-60% EtOAc in CH<sub>2</sub>Cl<sub>2</sub>) to afford the desired 5-aminopyrazole.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> General Procedure C</h3><div class="NLM_p">To a microwave vial equipped with a magnetic stir bar were added α-cyanoketone <b>3</b> (1 equiv), <i>N</i>-alkyl-hydrazine hydrochloride (1.1 equiv), triethylamine (1.5 equiv), and anhydrous methanol (1 M). The vial was capped and heated in a microwave reactor maintaining 120 °C for 90 min. The vial was cooled to room temperature and the reaction was concentrated under reduced pressure. The crude residue was purified by silica flash chromatography (5–50% EtOAc in hexanes) to afford the desired 5-aminopyrazole.</div><div id="sec4_15_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 3-(2-Chlorophenyl)-1-methyl-1<i>H</i>-pyrazol-5-amine (<b>4b</b>)</h4><div class="NLM_p last"><b>4b</b> was prepared from 2-chlorobenzoylacetonitrile <b>3a</b> (898 mg, 5 mmol, 1 equiv) according to General Procedure B. <b>4b</b> (508 mg, 2.45 mmol, 48% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.76 (dd, <i>J</i> = 7.8, 1.8 Hz, 1H), 7.41 (dd, <i>J</i> = 7.8, 1.5 Hz, 1H), 7.32–7.18 (m, 2H), 6.11 (s, 1H), 3.75 (s, 3H), 3.56 (s, 2H).</div></div><div id="sec4_15_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 1-Methyl-3-(2-(trifluoromethyl)phenyl)-1<i>H</i>-pyrazol-5-amine (<b>4c</b>)</h4><div class="NLM_p last"><b>4c</b> was prepared from <b>3b</b> (710 mg, 3.33 mmol, 1 equiv) according to General Procedure B. <b>4c</b> (501 mg, 2.1 mmol, 62% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.74–7.60 (m, 2H), 7.54 (t, <i>J</i> = 7.6 Hz, 1H), 7.42 (t, <i>J</i> = 7.7 Hz, 1H), 5.85–5.77 (m, 1H), 3.77–3.72 (m, 3H), 3.69–3.51 (m, 2H).</div></div><div id="sec4_15_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 1-(<i>tert</i>-Butyl)-3-(<i>o</i>-tolyl)-1<i>H</i>-pyrazol-5-amine (<b>4d</b>)</h4><div class="NLM_p last"><b>4d</b> was prepared from <i>o</i>-toluoylacetonitrile <b>3c</b> (239 mg, 1.5 mmol, 1 equiv) and <i>tert</i>-butylhydrazine hydrochloride (206 mg, 1.65 mmol, 1.1 equiv) according to General Procedure C. <b>4d</b> (221 mg, 0.96 mmol, 64% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.56–7.51 (m, 1H), 7.37–7.30 (m, 1H), 7.23–7.12 (m, 2H), 5.77 (s, 1H), 3.56 (s, 2H), 2.51 (s, 3H), 1.69 (s, 9H).</div></div><div id="sec4_15_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 1-Methyl-3-(<i>o</i>-tolyl)-1<i>H</i>-pyrazol-5-amine (<b>4e</b>)</h4><div class="NLM_p last"><b>4e</b> was prepared from <i>o</i>-toluoylacetonitrile <b>3c</b> (239 mg, 1.5 mmol, 1 equiv) according to General Procedure B. <b>4e</b> (135 mg, 0.72 mmol, 47% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.55–7.46 (m, 1H), 7.23–7.17 (m, 3H), 5.73 (s, 1H), 3.74 (s, 3H), 3.51 (s, 2H), 2.46 (s, 3H).</div></div><div id="sec4_15_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 1-Isopropyl-3-(2-methoxyphenyl)-1<i>H</i>-pyrazol-5-amine (<b>4g</b>)</h4><div class="NLM_p last"><b>4g</b> was prepared from 2-methoxybenzoylacetonitrile <b>3d</b> (175 mg, 1 mmol, 1 equiv) and isopropylhydrazine hydrochloride (122 mg, 1.1 mmol, 1.1 equiv) according to General Procedure C. <b>4g</b> (191 mg, 0.83 mmol, 82% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.00–7.86 (m, 1H), 7.26–7.24 (m, 1H), 7.08–6.87 (m, 2H), 6.13 (s, 1H), 4.50–4.32 (m, 1H), 3.88 (s, 3H), 3.45 (s, 2H), 1.52 (d, <i>J</i> = 6.7 Hz, 6H).</div></div><div id="sec4_15_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 1-Cyclohexyl-3-(2-methoxyphenyl)-1<i>H</i>-pyrazol-5-amine (<b>4h</b>)</h4><div class="NLM_p last"><b>4h</b> was prepared from 2-methoxybenzoylacetonitrile <b>3d</b> (175 mg, 1 mmol, 1 equiv) and cyclohexylhydrazine hydrochloride (166 mg, 1.1 mmol, 1.1 equiv) according to General Procedure C. <b>4h</b> (231 mg, 0.85 mmol, 84% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.99–7.84 (m, 1H), 7.26–7.18 (m, 1H), 7.08–6.89 (m, 2H), 6.12 (s, 1H), 4.06–3.91 (m, 1H), 3.88 (s, 3H), 3.45 (s, 2H), 2.12–1.86 (m, 6H), 1.79–1.67 (m, 1H), 1.49–1.20 (m, 3H).</div></div><div id="sec4_15_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 1-Cyclopentyl-3-(2-methoxyphenyl)-1<i>H</i>-pyrazol-5-amine (<b>4i</b>)</h4><div class="NLM_p last"><b>4i</b> was prepared from 2-methoxybenzoylacetonitrile <b>3d</b> (175 mg, 1.1 mmol, 1 equiv) and cyclopentylhydrazine hydrochloride (150 mg, 1.1 mmol, 1.1 equiv) according to General Procedure C. <b>4i</b> (204 mg, 0.79 mmol, 79% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.01–7.80 (m, 1H), 7.27–7.20 (m, 2H), 7.05–6.84 (m, 2H), 6.13 (s, 1H), 4.64–4.30 (m, 1H), 3.88 (s, 3H), 3.47 (s, 2H), 2.24–2.11 (m, 2H), 2.11–1.89 (m, 4H), 1.74–1.61 (m, 2H).</div></div><div id="sec4_15_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 1-Isobutyl-3-(2-methoxyphenyl)-1<i>H</i>-pyrazol-5-amine (<b>4j</b>)</h4><div class="NLM_p last"><b>4j</b> was prepared from 2-methoxybenzoylacetonitrile <b>3d</b> (175 mg, 1 mmol, 1 equiv) and isobutylhydrazine hydrochloride (137 mg, 1.1 mmol, 1.1 equiv) according to General Procedure C. <b>4j</b> (206 mg, 0.84 mmol, 84% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.93–7.85 (m, 1H), 7.30–7.22 (m, 1H), 7.05–6.90 (m, 2H), 6.12 (s, 1H), 3.88 (s, 3H), 3.80 (d, <i>J</i> = 7.4 Hz, 2H), 3.44 (s, 2H), 2.36–2.19 (m, 1H), 0.97 (d, <i>J</i> = 6.6 Hz, 6H).</div></div><div id="sec4_15_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 1-(<i>tert</i>-Butyl)-3-(2-methoxyphenyl)-1<i>H</i>-pyrazol-5-amine (<b>4k</b>)</h4><div class="NLM_p last"><b>4k</b> was prepared from 2-methoxybenzoylacetonitrile <b>3d</b> (168 mg, 0.96 mmol, 1 equiv) and <i>tert</i>-butylhydrazine hydrochloride (131 mg, 1.05 mmol, 1.1 equiv) according to General Procedure C. <b>4k</b> (193 mg, 0.79 mmol, 81% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.01–7.92 (m, 1H), 7.25–7.19 (m, 1H), 7.05–6.95 (m, 1H), 6.92 (d, <i>J</i> = 8.3 Hz, 1H), 6.18 (s, 1H), 3.88 (s, 3H), 3.56 (s, 2H), 1.69 (s, 9H).</div></div><div id="sec4_15_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 1-Methyl-3-(2-(trifluoromethoxy)phenyl)-1<i>H</i>-pyrazol-5-amine (<b>4l</b>)</h4><div class="NLM_p last"><b>4l</b> was prepared from <b>3e</b> (458 mg, 2 mmol, 1 equiv) according to General Procedure B. <b>4l</b> (348 mg, 1.35 mmol, 67% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.03–7.96 (m, 1H), 7.33–7.27 (m, 3H), 6.03 (s, 1H), 3.74 (s, 3H), 3.54 (s, 2H).</div></div><div id="sec4_15_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 1-(<i>tert</i>-Butyl)-3-(2-(trifluoromethoxy)phenyl)-1<i>H</i>-pyrazol-5-amine (<b>4m</b>)</h4><div class="NLM_p last"><b>4m</b> was prepared from <b>3e</b> (343 mg, 1.5 mmol, 1 equiv) and <i>tert</i>-butylhydrazine hydrochloride (206 mg, 1.65 mmol, 1.1 equiv) according to General Procedure C. <b>4m</b> (303 mg, 1.01 mmol, 67% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.10–8.00 (m, 1H), 7.37–7.22 (m, 4H), 6.06 (s, 1H), 3.56 (s, 2H), 1.74–1.65 (m, 9H).</div></div><div id="sec4_15_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 1-(<i>tert</i>-Butyl)-3-(3-methoxyphenyl)-1<i>H</i>-pyrazol-5-amine (<b>4n</b>)</h4><div class="NLM_p last"><b>4n</b> was prepared from 3-methoxybenzoylacetonitrile <b>3f</b> (219 mg, 1.25 mmol, 1 equiv) and <i>tert</i>-butylhydrazine hydrochloride (171 mg, 1.38 mmol, 1.1 equiv) according to General Procedure C. <b>4n</b> (288 mg, 1.17 mmol, 93% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.35–7.29 (m, 2H), 7.28–7.21 (m, 1H), 6.84–6.76 (m, 1H), 5.89 (s, 1H), 3.85 (s, 3H), 3.59 (s, 2H), 1.75–1.59 (m, 9H).</div></div><div id="sec4_15_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 1-(<i>tert</i>-Butyl)-3-(<i>m</i>-tolyl)-1<i>H</i>-pyrazol-5-amine (<b>4o</b>)</h4><div class="NLM_p last"><b>4o</b> was prepared from <i>m</i>-toluoylacetonitrile <b>3g</b> (199 mg, 1.25 mmol, 1 equiv) and <i>tert</i>-butylhydrazine hydrochloride (171 mg, 1.38 mmol, 1.1 equiv) according to General Procedure C. <b>4o</b> (276 mg, 1.20 mmol, 96% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.62–7.57 (m, 1H), 7.56–7.48 (m, 1H), 7.23 (t, <i>J</i> = 7.6 Hz, 1H), 7.10–7.01 (m, 1H), 5.89 (s, 1H), 3.58 (s, 2H), 2.37 (s, 3H), 1.69 (s, 9H).</div></div><div id="sec4_15_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 1-(<i>tert</i>-Butyl)-3-(3-(trifluoromethyl)phenyl)-1<i>H</i>-pyrazol-5-amine (<b>4p</b>)</h4><div class="NLM_p last"><b>4p</b> was prepared from 3-(trifluoromethyl)benzoylacetonitrile <b>3h</b> (266 mg, 1.25 mmol, 1 equiv) and <i>tert</i>-butylhydrazine hydrochloride (171 mg, 1.38 mmol, 1.1 equiv) according to General Procedure C. <b>4p</b> (255 mg, 0.90 mmol, 71% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.04–7.95 (m, 1H), 7.93–7.85 (m, 1H), 7.52–7.39 (m, 2H), 5.93 (s, 1H), 3.63 (s, 2H), 1.70 (s, 9H).</div></div><div id="sec4_15_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 1-Methyl-3-(3-(trifluoromethoxy)phenyl)-1<i>H</i>-pyrazol-5-amine (<b>4q</b>)</h4><div class="NLM_p last"><b>4q</b> was prepared from <b>3i</b> (344 mg, 1.5 mmol, 1 equiv) according to General Procedure B. <b>4q</b> (246 mg, 0.96 mmol, 63% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.70–7.60 (m, 1H), 7.60–7.55 (m, 1H), 7.37 (t, <i>J</i> = 8.0 Hz, 1H), 7.15–7.06 (m, 1H), 5.86 (s, 1H), 3.72 (s, 3H), 3.57 (s, 2H).</div></div><div id="sec4_15_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 1-(<i>tert</i>-Butyl)-3-(3-(trifluoromethoxy)phenyl)-1<i>H</i>-pyrazol-5-amine (<b>4r</b>)</h4><div class="NLM_p last"><b>4r</b> was prepared from <b>3i</b> (344 mg, 1.65 mmol, 1 equiv) and <i>tert</i>-butylhydrazine hydrochloride (206 mg, 1.65 mmol, 1.1 equiv) according to General Procedure C. <b>4r</b> (248 mg, 0.83 mmol, 55% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.74–7.63 (m, 1H), 7.62–7.57 (m, 1H), 7.35 (t, <i>J</i> = 8.0 Hz, 1H), 7.12–7.04 (m, 1H), 5.89 (s, 1H), 3.60 (s, 2H), 1.69 (s, 9H).</div></div><div id="sec4_15_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 1-(<i>tert</i>-Butyl)-3-(3-fluorophenyl)-1<i>H</i>-pyrazol-5-amine (<b>4t</b>)</h4><div class="NLM_p last"><b>4t</b> was prepared from 3-fluorobenzoylacetonitrile <b>3j</b> (245 mg, 1.5 mmol, 1 equiv) and <i>tert</i>-butylhydrazine hydrochloride (206 mg, 1.65 mmol, 1.1 equiv) according to General Procedure C. <b>4t</b> (222 mg, 0.95 mmol, 63% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.54–7.40 (m, 2H), 7.35–7.25 (m, 1H), 6.98–6.88 (m, 1H), 5.89 (s, 1H), 3.61 (s, 2H), 1.69 (s, 9H).</div></div><div id="sec4_15_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 3-(3-Chlorophenyl)-1-methyl-1<i>H</i>-pyrazol-5-amine (<b>4u</b>)</h4><div class="NLM_p last"><b>4u</b> was prepared from 3-chlorobenzoylacetonitrile <b>3k</b> (898 mg, 5 mmol, 1 equiv) according to General Procedure B. <b>4u</b> (614 mg, 2.96 mmol, 59% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.72 (s, 1H), 7.61 (d, <i>J</i> = 7.6 Hz, 1H), 7.33–7.21 (m, 2H), 5.86 (s, 1H), 3.75 (s, 3H), 3.60 (s, 2H).</div></div><div id="sec4_15_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 1-(<i>tert</i>-Butyl)-3-(3-chlorophenyl)-1<i>H</i>-pyrazol-5-amine (<b>4v</b>)</h4><div class="NLM_p last"><b>4v</b> was prepared from 3-chorobenzoylacetonitrile <b>3k</b> (224 mg, 1.25 mmol, 1 equiv) and <i>tert</i>-butylhydrazine hydrochloride (171 mg, 1.38 mmol, 1.1 equiv) according to General Procedure C. <b>4v</b> (232 mg, 0.93 mmol, 74% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.77–7.73 (m, 1H), 7.64–7.58 (m, 1H), 7.31–7.24 (m, 1H), 7.24–7.17 (m, 1H), 5.88 (s, 1H), 3.61 (s, 2H), 1.69 (s, 9H).</div></div><div id="sec4_15_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 3-(3-Chlorophenyl)-1-cyclohexyl-1<i>H</i>-pyrazol-5-amine (<b>4w</b>)</h4><div class="NLM_p last"><b>4w</b> was prepared from 3-chlorobenzoylacetonitrile <b>3k</b> (269 mg, 1.5 mmol, 1 equiv) and cyclohexylhydrazine hydrochloride (226 mg, 1.5 mmol, 1 equiv) according to General Procedure C. <b>4w</b> (328 mg, 1.19 mmol, 79% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.72 (t, <i>J</i> = 2.0 Hz, 1H), 7.61–7.54 (m, 1H), 7.26–7.20 (m, 1H), 7.20–7.15 (m, 1H), 5.81 (s, 1H), 3.95–3.81 (m, 1H), 3.52 (s, 2H), 2.00–1.82 (m, 6H), 1.70 (d, <i>J</i> = 12.0 Hz, 1H), 1.50–1.24 (m, 3H).</div></div><div id="sec4_15_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 3-(2,3-Dimethylphenyl)-1-methyl-1<i>H</i>-pyrazol-5-amine (<b>4x</b>)</h4><div class="NLM_p last"><b>4x</b> was prepared from <b>3l</b> (350 mg, 2 mmol, 1 equiv) according to General Procedure B. <b>4x</b> (197 mg, 0.98 mmol, 48% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.32–7.26 (m, 2H), 7.13–7.08 (m, 2H), 5.66 (s, 1H), 3.73 (s, 3H), 3.51 (s, 2H), 2.33 (s, 3H), 2.31 (s, 3H).</div></div><div id="sec4_15_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 3-(5-Fluoro-2-methylphenyl)-1-methyl-1<i>H</i>-pyrazol-5-amine (<b>4y</b>)</h4><div class="NLM_p last"><b>4y</b> was prepared from <b>3m</b> (298 mg, 1.68 mmol, 1 equiv) according to General Procedure B. <b>4y</b> (194 mg, 0.95 mmol, 56% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.32–7.22 (m, 1H), 7.18–7.10 (m, 1H), 6.93–6.84 (m, 1H), 5.72 (s, 1H), 3.72 (s, 3H), 3.54 (s, 2H), 2.41 (s, 3H).</div></div><div id="sec4_15_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 3-(2-Fluoro-3-methylphenyl)-1-methyl-1<i>H</i>-pyrazol-5-amine (<b>4z</b>)</h4><div class="NLM_p last"><b>4z</b> was prepared from <b>3n</b> (461 mg, 2.6 mmol, 1 equiv) according to General Procedure B. <b>4z</b> (299 mg, 1.46 mmol, 55% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.77–7.68 (m, 1H), 7.13–6.97 (m, 2H), 6.07–5.93 (m, 1H), 3.74 (s, 3H), 3.56 (s, 2H), 2.33–2.28 (m, 3H).</div></div><div id="sec4_15_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 3-(2,3-Difluorophenyl)-1-methyl-1<i>H</i>-pyrazol-5-amine (<b>4aa</b>)</h4><div class="NLM_p last"><b>4aa</b> was prepared from <b>3o</b> (221 mg, 1.22 mmol, 1 equiv) according to General Procedure B. <b>4aa</b> (142 mg, 0.68 mmol, 55% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.74–7.62 (m, 1H), 7.11–6.99 (m, 2H), 6.05 (d, <i>J</i> = 4.0 Hz, 1H), 3.75 (s, 3H), 3.55 (s, 2H).</div></div><div id="sec4_15_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 1-Methyl-3-(2-methyl-3-(trifluoromethyl)phenyl)-1<i>H</i>-pyrazol-5-amine (<b>4ab</b>)</h4><div class="NLM_p last"><b>4ab</b> was prepared from <b>3p</b> (284 mg, 1.25 mmol, 1 equiv) according to General Procedure B. <b>4ab</b> (138 mg, 0.54 mmol, 43% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.65–7.57 (m, 2H), 7.32–7.27 (m, 1H), 5.68 (s, 1H), 3.79–3.75 (m, 3H), 3.66 (s, 2H), 2.51 (d, <i>J</i> = 1.8 Hz, 3H).</div></div><div id="sec4_15_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> 3-(3-Chloro-2-fluorophenyl)-1-methyl-1<i>H</i>-pyrazol-5-amine (<b>4ac</b>)</h4><div class="NLM_p last"><b>4ac</b> was prepared from <b>3q</b> (247 mg, 1.25 mmol, 1 equiv) according to General Procedure B. <b>4ac</b> (180 mg, 0.80 mmol, 63% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.86 (t, <i>J</i> = 7.4 Hz, 1H), 7.30 (t, <i>J</i> = 7.3 Hz, 1H), 7.08 (m, 1H), 6.05 (d, <i>J</i> = 4.2 Hz, 1H), 3.76 (s, 3H), 3.71–3.49 (m, 2H).</div></div><div id="sec4_15_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 3-(2-Fluoro-3-(trifluoromethoxy)phenyl)-1-methyl-1<i>H</i>-pyrazol-5-amine (<b>4ad</b>)</h4><div class="NLM_p last"><b>4ad</b> was prepared from <b>3r</b> (247 mg, 1 mmol, 1 equiv) according to General Procedure B. <b>4ad</b> (202 mg, 0.73 mmol, 73% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.92–7.85 (m, 1H), 7.25–7.09 (m, 2H), 6.09–5.99 (m, 1H), 3.74 (s, 3H), 3.60 (s, 2H).</div></div><div id="sec4_15_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> 3-(2,5-Difluorophenyl)-1-methyl-1<i>H</i>-pyrazol-5-amine (<b>4ae</b>)</h4><div class="NLM_p last"><b>4ae</b> was prepared from <b>3s</b> (248 mg, 1.37 mmol, 1 equiv) according to General Procedure B. <b>4ae</b> (193 mg, 0.92 mmol, 67% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.68–7.59 (m, 1H), 7.12–6.98 (m, 1H), 6.98–6.82 (m, 1H), 6.04 (d, <i>J</i> = 4.1 Hz, 1H), 3.74 (s, 3H), 3.54 (s, 2H).</div></div><div id="sec4_15_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> 3-(2-Chloro-5-fluorophenyl)-1-methyl-1<i>H</i>-pyrazol-5-amine (<b>4af</b>)</h4><div class="NLM_p last"><b>4af</b> was prepared from <b>3t</b> (247 mg, 1.25 mmol, 1 equiv) according to General Procedure B. <b>4af</b> (159 mg, 0.71 mmol, 56% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.57–7.49 (m, 1H), 7.41–7.31 (m, 1H), 6.98–6.85 (m, 1H), 6.15 (s, 1H), 3.74 (s, 3H), 3.69–3.43 (m, 2H).</div></div><div id="sec4_15_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> 3-(5-Chloro-2-fluorophenyl)-1-methyl-1<i>H</i>-pyrazol-5-amine (<b>4ag</b>)</h4><div class="NLM_p last"><b>4ag</b> was prepared from <b>3u</b> (247 mg, 1.25 mmol, 1 equiv) according to General Procedure B. <b>4ag</b> (183 mg, 0.81 mmol, 64% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.98–7.88 (m, 1H), 7.20–7.13 (m, 1H), 7.08–6.93 (m, 1H), 6.03 (d, <i>J</i> = 4.1 Hz, 1H), 3.74 (s, 3H), 3.53 (s, 2H).</div></div><div id="sec4_15_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> 3-(2-Fluoro-5-methylphenyl)-1-methyl-1<i>H</i>-pyrazol-5-amine (<b>4ah</b>)</h4><div class="NLM_p last"><b>4ah</b> was prepared from <b>3v</b> (323 mg, 1.82 mmol, 1 equiv) according to General Procedure B. <b>4ah</b> (271 mg, 1.32 mmol, 72% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.81–7.64 (m, 1H), 7.14–6.80 (m, 2H), 6.13–5.91 (m, 1H), 3.81–3.66 (m, 3H), 3.66–3.46 (m, 2H), 2.33 (s, 3H).</div></div><div id="sec4_15_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> 3-(2-Fluoro-5-(trifluoromethyl)phenyl)-1-methyl-1<i>H</i>-pyrazol-5-amine (<b>4ai</b>)</h4><div class="NLM_p last"><b>4ai</b> was prepared from <b>3w</b> (289 mg, 1.25 mmol, 1 equiv) according to General Procedure B. <b>4ai</b> (109 mg, 0.42 mmol, 33% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.33–8.24 (m, 1H), 7.54–7.43 (m, 1H), 7.23–7.13 (m, 1H), 6.10–6.00 (m, 1H), 3.78 (s, 3H), 3.69 (s, 2H).</div></div><div id="sec4_15_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> 3-(2-Fluoro-5-(trifluoromethoxy)phenyl)-1-methyl-1<i>H</i>-pyrazol-5-amine (<b>4aj</b>)</h4><div class="NLM_p last"><b>4aj</b> was prepared from <b>3x</b> (247 mg, 1 mmol, 1 equiv) according to General Procedure B. <b>4aj</b> (163 mg, 0.59 mmol, 59% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.86–7.81 (m, 1H), 7.11–7.05 (m, 2H), 6.04 (dd, <i>J</i> = 4.1, 0.7 Hz, 1H), 3.75 (s, 3H), 3.59 (s, 2H).</div></div><div id="sec4_15_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> 3-(2,6-Difluorophenyl)-1-methyl-1<i>H</i>-pyrazol-5-amine (<b>4ak</b>)</h4><div class="NLM_p last"><b>4ak</b> was prepared from <b>3y</b> (169 mg, 0.93 mmol, 1 equiv) according to General Procedure B. <b>4ak</b> (48 mg, 0.23 mmol, 24% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.26–7.15 (m, 1H), 6.94 (t, <i>J</i> = 8.3 Hz, 2H), 5.90 (d, <i>J</i> = 1.9 Hz, 1H), 3.77 (s, 3H), 3.53 (s, 2H).</div></div><div id="sec4_15_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> 3-(4-Chloro-2-fluorophenyl)-1-methyl-1<i>H</i>-pyrazol-5-amine (<b>4al</b>)</h4><div class="NLM_p last"><b>4al</b> was prepared from <b>3z</b> (296 mg, 1.5 mmol, 1 equiv) according to General Procedure B. <b>4al</b> (172 mg, 0.76 mmol, 50% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.90 (t, <i>J</i> = 8.3 Hz, 1H), 7.17–7.08 (m, 2H), 6.01 (d, <i>J</i> = 4.1 Hz, 1H), 3.75 (s, 3H), 3.70–3.51 (m, 2H).</div></div><div id="sec4_15_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> 3-(2-Chloro-4-fluorophenyl)-1-methyl-1<i>H</i>-pyrazol-5-amine (<b>4am</b>)</h4><div class="NLM_p last"><b>4am</b> was prepared from <b>3aa</b> (296 mg, 1.5 mmol, 1 equiv) according to General Procedure B. <b>4am</b> (135 mg, 0.60 mmol, 39% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.80–7.69 (m, 1H), 7.21–7.09 (m, 1H), 7.09–6.95 (m, 1H), 6.06 (s, 1H), 3.74 (s, 3H), 3.60 (s, 2H).</div></div><div id="sec4_15_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> 1-(<i>tert</i>-Butyl)-3-(2,3-dimethylphenyl)-1<i>H</i>-pyrazol-5-amine (<b>4ao</b>)</h4><div class="NLM_p last"><b>4ao</b> was prepared from <b>3l</b> (260 mg, 1.5 mmol, 1 equiv) and <i>tert</i>-butylhydrazine hydrochloride (206 mg, 1.65 mmol, 1.1 equiv) according to General Procedure C. <b>4ao</b> (122 mg, 0.50 mmol, 33% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.33–7.27 (m, 1H), 7.12–7.03 (m, 2H), 5.69 (s, 1H), 3.60 (s, 2H), 2.37 (s, 3H), 2.30 (s, 3H), 1.69 (s, 9H).</div></div><div id="sec4_15_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> 3-(5-Fluoro-2-methylphenyl)-1-isopropyl-1<i>H</i>-pyrazol-5-amine (<b>4ap</b>)</h4><div class="NLM_p last"><b>4ap</b> was prepared from <b>3m</b> (177 mg, 1 mmol, 1 equiv) and isopropylhydrazine hydrochloride (82 mg, 1.1 mmol, 1.1 equiv) according to General Procedure C. <b>4ap</b> (93 mg, 0.40 mmol, 40% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.30–7.23 (m, 1H), 7.23–7.08 (m, 1H), 6.92–6.83 (m, 1H), 5.72 (s, 1H), 4.51–4.32 (m, 1H), 3.65 (s, 2H), 2.43 (s, 3H), 1.51 (d, <i>J</i> = 6.6 Hz, 6H).</div></div><div id="sec4_15_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> 1-(<i>tert</i>-Butyl)-3-(5-fluoro-2-methylphenyl)-1<i>H</i>-pyrazol-5-amine (<b>4aq</b>)</h4><div class="NLM_p last"><b>4aq</b> was prepared from <b>3m</b> (266 mg, 1.5 mmol, 1 equiv) and <i>tert</i>-butylhydrazine hydrochloride (206 mg, 1.65 mmol, 1.1 equiv) according to General Procedure C. <b>4aq</b> (118 mg, 0.48 mmol, 31% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.32–7.27 (m, 1H), 7.17–7.10 (m, 1H), 6.89–6.79 (m, 1H), 5.78 (s, 1H), 3.58 (s, 2H), 2.46 (s, 3H), 1.68 (s, 9H).</div></div><div id="sec4_15_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> 1-Cyclopentyl-3-(5-fluoro-2-methylphenyl)-1<i>H</i>-pyrazol-5-amine (<b>4ar</b>)</h4><div class="NLM_p last"><b>4ar</b> was prepared from <b>3m</b> (177 mg, 1 mmol, 1 equiv) and cyclopentylhydrazine hydrochloride (150 mg, 1.1 mmol, 1.1 equiv) according to General Procedure C. <b>4ar</b> (202 mg, 0.78 mmol, 78% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.34–7.24 (m, 1H), 7.18–7.10 (m, 1H), 6.88 (m, 1H), 5.75 (s, 1H), 4.67–4.53 (m, 1H), 2.43 (s, 3H), 2.23–1.87 (m, 6H), 1.67 (m, 2H).</div></div><div id="sec4_15_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> 1-Cyclohexyl-3-(5-fluoro-2-methylphenyl)-1<i>H</i>-pyrazol-5-amine (<b>4as</b>)</h4><div class="NLM_p last"><b>4as</b> was prepared from <b>3m</b> (177 mg, 1 mmol, 1 equiv) and cyclohexylhydrazine hydrochloride (166 mg, 1.1 mmol, 1.1 equiv) according to General Procedure C. <b>4as</b> (185 mg, 0.68 mmol, 68% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.29–7.21 (m, 1H), 7.18–7.08 (m, 1H), 6.93–6.83 (m, 1H), 5.75–5.70 (m, 1H), 4.08–3.92 (m, 1H), 3.77 (s, 2H), 2.42 (s, 3H), 2.04–1.85 (m, 7H), 1.71 (d, <i>J</i> = 12.6 Hz, 1H), 1.50–1.29 (m, 2H).</div></div><div id="sec4_15_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> 3-(2-Fluoro-3-methylphenyl)-1-isopropyl-1<i>H</i>-pyrazol-5-amine (<b>4at</b>)</h4><div class="NLM_p last"><b>4at</b> was prepared from <b>3n</b> (177 mg, 1 mmol, 1 equiv) and isopropylhydrazine hydrochloride (82 mg, 1.1 mmol, 1.1 equiv) according to General Procedure C. <b>4at</b> (149 mg, 0.64 mmol, 64% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.83 (td, <i>J</i> = 7.4, 2.0 Hz, 1H), 7.13–6.99 (m, 2H), 6.03 (d, <i>J</i> = 4.1 Hz, 1H), 4.46 (hept, <i>J</i> = 6.6 Hz, 1H), 3.73 (s, 1H), 2.30 (d, <i>J</i> = 2.3 Hz, 3H), 1.52 (d, <i>J</i> = 6.6 Hz, 6H).</div></div><div id="sec4_15_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> 1-(<i>tert</i>-Butyl)-3-(2-fluoro-3-methylphenyl)-1<i>H</i>-pyrazol-5-amine (<b>4au</b>)</h4><div class="NLM_p last"><b>4au</b> was prepared from <b>3n</b> (266 mg, 1.5 mmol, 1 equiv) and <i>tert</i>-butylhydrazine hydrochloride (206 mg, 1.65 mmol, 1.1 equiv) according to General Procedure C. <b>4au</b> (238 mg, 0.96 mmol, 64% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.86–7.78 (m, 1H), 7.11–6.94 (m, 2H), 6.10–5.97 (m, 1H), 3.55 (s, 2H), 2.33–2.25 (m, 3H), 1.69 (s, 9H).</div></div><div id="sec4_15_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> 1-Cyclopentyl-3-(2-fluoro-3-methylphenyl)-1<i>H</i>-pyrazol-5-amine (<b>4av</b>)</h4><div class="NLM_p last"><b>4av</b> was prepared from <b>3n</b> (177 mg, 1 mmol, 1 equiv) and cyclopentylhydrazine hydrochloride (150 mg, 1.1 mmol, 1.1 equiv) according to General Procedure C. <b>4av</b> (208 mg, 0.80 mmol, 80% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.91–7.79 (m, 1H), 7.20–6.99 (m, 2H), 6.09–6.02 (m, 1H), 4.74–4.49 (m, 1H), 2.37–2.23 (m, 3H), 2.24–1.88 (m, 6H), 1.80–1.56 (m, 2H).</div></div><div id="sec4_15_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> 1-Cyclohexyl-3-(2-fluoro-3-methylphenyl)-1<i>H</i>-pyrazol-5-amine (<b>4aw</b>)</h4><div class="NLM_p last"><b>4aw</b> was prepared from <b>3n</b> (266 mg, 1.5 mmol, 1 equiv) and cyclohexylhydrazine hydrochloride (226 mg, 1 mmol, 1 equiv) according to General Procedure C. <b>4aw</b> (322 mg, 1.18 mmol, 78% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.82–7.72 (m, 1H), 7.10–6.97 (m, 2H), 6.02 (d, <i>J</i> = 4.2 Hz, 1H), 4.02–3.86 (m, 1H), 3.47 (s, 2H), 2.30 (d, <i>J</i> = 2.4 Hz, 3H), 2.07–1.83 (m, 6H), 1.78–1.68 (m, 1H), 1.49–1.22 (m, 3H).</div></div><div id="sec4_15_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> 3-(2,3-Difluorophenyl)-1-isopropyl-1<i>H</i>-pyrazol-5-amine (<b>4ax</b>)</h4><div class="NLM_p last"><b>4ax</b> was prepared from <b>3o</b> (181 mg, 1 mmol, 1 equiv) and isopropylhydrazine hydrochloride (82 mg, 1.1 mmol, 1.1 equiv) according to General Procedure C. <b>4ax</b> (128 mg, 0.54 mmol, 54% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.84–7.74 (m, 1H), 7.14–6.99 (m, 2H), 6.08–6.02 (m, 1H), 4.52–4.37 (m, 1H), 3.76–3.55 (m, 2H), 1.52 (d, <i>J</i> = 6.4 Hz, 6H).</div></div><div id="sec4_15_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> 1-(<i>tert</i>-Butyl)-3-(2,3-difluorophenyl)-1<i>H</i>-pyrazol-5-amine (<b>4ay</b>)</h4><div class="NLM_p last"><b>4ay</b> was prepared from <b>3o</b> (272 mg, 1.5 mmol, 1 equiv) and <i>tert</i>-butylhydrazine hydrochloride (206 mg, 1.65 mmol, 1.1 equiv) according to General Procedure C. <b>4ay</b> (244 mg, 0.97 mmol, 64% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.83–7.71 (m, 1H), 7.13–6.96 (m, 2H), 6.12–6.04 (m, 1H), 3.78–3.51 (m, 2H), 1.69 (s, 9H).</div></div><div id="sec4_15_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> 1-Cyclopentyl-3-(2,3-difluorophenyl)-1<i>H</i>-pyrazol-5-amine (<b>4az</b>)</h4><div class="NLM_p last"><b>4az</b> was prepared from <b>3o</b> (181 mg, 1 mmol, 1 equiv) and cyclopentylhydrazine hydrochloride (150 mg, 1.1 mmol, 1.1 equiv) according to General Procedure C. <b>4az</b> (193 mg, 0.73 mmol, 73% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.82–7.73 (m, 1H), 7.11–6.98 (m, 2H), 6.05 (d, <i>J</i> = 4.1 Hz, 1H), 4.55 (p, <i>J</i> = 7.4 Hz, 1H), 3.85–3.53 (m, 2H), 2.27–1.91 (m, 6H), 1.78–1.59 (m, 2H).</div></div><div id="sec4_15_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> 1-Cyclohexyl-3-(2,3-difluorophenyl)-1<i>H</i>-pyrazol-5-amine (<b>4bb</b>)</h4><div class="NLM_p last"><b>4bb</b> was prepared from <b>3o</b> (181 mg, 1.5 mmol, 1 equiv) and cyclohexylhydrazine hydrochloride (166 mg, 1.1 mmol, 1.1 equiv) according to General Procedure C. <b>4bb</b> (237 mg, 0.85 mmol, 85% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.92–7.83 (m, 1H), 7.10 (t, <i>J</i> = 6.1 Hz, 2H), 6.10 (d, <i>J</i> = 3.8 Hz, 1H), 4.24–4.04 (m, 1H), 2.22–2.05 (m, 1H), 2.03–1.86 (m, 5H), 1.74–1.66 (m, 1H), 1.51–1.26 (m, 3H).</div></div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> Recorcylate Amide Bromide Synthesis</h3><div id="sec4_16_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> 2-Bromo-4,6-dimethoxybenzaldehyde (<b>S1</b>)</h4><div class="NLM_p last">To a 250 mL round-bottom flask equipped with a magnetic stir bar were added 3,5-dimethoxybromobenzene (10.0 g, 46.1 mmol) and DMF (23 mL, 2 M). The mixture was cooled to 0 °C, and POCl<sub>3</sub> (12.8 mL, 138 mmol, 3 equiv) was added dropwise over 5 min. The reaction was warmed to room temperature and then heated to 90 °C for 6 h. The reaction was cooled to room temperature and poured into ice water (200 mL). The reaction was quenched with a slow addition of KOH (55 g) to reach pH 14. The slurry was warmed to room temperature and stirred for 16 h. The aqueous phase was extracted with Et<sub>2</sub>O (3 × 200 mL), and the combined organic extracts were washed with water (3 × 100 mL) and brine (150 mL), dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. No further purification was required affording aldehyde <b>S1</b> as a brown solid (10.4 g, 92% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.31 (s, 1H), 6.78 (d, <i>J</i> = 2.2 Hz, 1H), 6.44 (d, <i>J</i> = 2.2 Hz, 1H), 3.95–3.80 (m, 6H). UPLC/MS [M + H] = 245.359, <i>t</i><sub>R</sub> = 1.41 min.</div></div><div id="sec4_16_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> 2-Bromo-4,6-dihydroxybenzaldehyde (<b>6</b>)</h4><div class="NLM_p last">To a flamed-dried 250 mL round-bottom flask equipped with a magnetic stir bar was added 2-bromo-4,6-dimethoxybenzaldehyde <b>S1</b> (10 g, 40.8 mmol). The flask was fitted with a rubber septum, evacuated, and backfilled with N<sub>2</sub>. Anhydrous CH<sub>2</sub>Cl<sub>2</sub> (150 mL, 0.27 M) was added, and the mixture was cooled to 0 °C. In a separate round-bottom flask, a solution of BBr<sub>3</sub> (11.6 mL, 122 mmol, 3 equiv) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (30 mL, 4 M) was prepared. The BBr<sub>3</sub> solution was added dropwise via a cannula over 15 min. The reaction was slowly warmed to room temperature as the ice bath melted and stirred for 18 h. The reaction was poured into ice water (300 mL), extracted with EtOAc (3 × 200 mL), washed with brine (300 mL), dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude product was purified by silica flash chromatography (5–50% acetone in hexanes) affording aldehyde <b>6</b> (6.61 g, 75% yield) as a light purple solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.19 (s, 1H), 9.97 (s, 1H), 6.71 (d, <i>J</i> = 2.1 Hz, 1H), 6.30 (d, <i>J</i> = 2.0 Hz, 1H). UPLC/MS [M + H] = 216.956, <i>t</i><sub>R</sub> = 1.29 min.</div></div><div id="sec4_16_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> 2,4-Bis(benzyloxy)-6-bromobenzaldehyde (<b>7</b>)</h4><div class="NLM_p last">To a 200 mL round-bottom flask equipped with a magnetic stir bar were added 2-bromo-4,6-dihydroxybenzaldehyde <b>6</b> (3.33 g, 15.3 mmol), K<sub>2</sub>CO<sub>3</sub> (5.3 g, 38.3 mmol, 2.5 equiv), benzyl bromide (4.6 mL, 38.3 mmol, 2.5 equiv), and MeCN (45 mL, 0.33 M). The flask was fitted with a reflux condenser, and the reaction was heated at reflux in a 90 °C oil bath for 16 h. The reaction was cooled to room temperature, and the salts were removed by vacuum filtration and washed with EtOAc (100 mL). The filtrate was concentrated under reduced pressure and purified by silica flash chromatography (2–40% EtOAc in hexanes) affording aldehyde <b>7</b> (5.0 g, 82% yield) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.39 (s, 1H), 7.49–7.29 (m, 10H), 6.89 (d, <i>J</i> = 2.1 Hz, 1H), 6.57 (d, <i>J</i> = 2.2 Hz, 1H), 5.13 (s, 2H), 5.07 (s, 2H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 188.86, 163.47, 162.92, 135.66, 135.43, 128.94, 128.87, 128.71, 128.40, 127.76, 127.18, 126.64, 117.63, 113.07, 100.33, 70.96, 70.76. UPLC/MS [M + H] = 397.337, <i>t</i><sub>R</sub> = 2.30 min.</div></div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> General Procedure D</h3><div class="NLM_p">To a 100 mL round-bottom flask equipped with a magnetic stir bar were added 2,4-bis(benzyloxy)-6-bromobenzaldehyde <b>7</b> (1.59 g, 4 mmol), <i>t-</i>BuOH (12 mL), and THF (10 mL). In a separate flask, sodium chlorite (1.09 g, 12 mmol, 3 equiv) and sodium monobasic phosphate monohydrate (4.14 g, 30 mmol, 7.5 equiv) were dissolved in H<sub>2</sub>O (10 mL). The aqueous solution was added to the reaction portion-wise over 2 min, turning the reaction bright yellow. 2-Methyl-2-butene (5.1 mL, 48 mmol, 12 equiv) was added, and the reaction was stirred for 30 min until the yellow color dissipated and the reaction turned colorless again. The reaction was quenched with 3 M HCl (30 mL) and extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with saturated NH<sub>4</sub>Cl solution (2 × 50 mL), washed with brine (50 mL), dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The resulting benzoic acid was immediately used without purification.</div><div class="NLM_p">In a 100 mL round-bottom flask equipped with a magnetic stir bar, the crude benzoic acid was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (12 mL) and THF (12 mL). Amine (4.40 mmol, 1.1 equiv), <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA, 1.74 mL, 10 mmol, 2.5 equiv), and HATU (1.83 g, 4.80 mmol, 1.2 equiv) were added. The reaction was stirred at room temperature for 3 h. The reaction was quenched with saturated NaHCO<sub>3</sub> solution (30 mL), extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 50 mL), washed with brine (75 mL), dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude product was purified by silica flash chromatography (5–60% EtOAc in hexane) to afford the desired amide <b>8</b>.</div><div id="sec4_17_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> (2,4-Bis(benzyloxy)-6-bromophenyl)(isoindolin-2-yl)methanone (<b>8a</b>)</h4><div class="NLM_p last"><b>8a</b> was prepared according to General Procedure D from isoindoline hydrochloride (685 mg, 4.40 mmol, 1.1 equiv). <b>8a</b> (1.67 g, 3.24 mmol) was obtained in 81% yield as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.48–7.22 (m, 13H), 7.15 (d, <i>J</i> = 7.3 Hz, 1H), 6.85 (d, <i>J</i> = 2.1 Hz, 1H), 6.59 (d, <i>J</i> = 2.1 Hz, 1H), 5.16–5.05 (m, 2H), 5.02 (d, <i>J</i> = 7.1 Hz, 4H), 4.68–4.45 (m, 2H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 165.90, 160.46, 156.51, 136.54, 136.47, 136.16, 136.03, 128.86, 128.70, 128.48, 128.12, 127.86, 127.71, 127.62, 127.04, 123.27, 122.74, 122.19, 120.39, 110.63, 100.80, 70.75, 70.63, 53.32, 51.89. UPLC/MS [M + H] = 514.231, <i>t</i><sub>R</sub> = 2.10 min.</div></div><div id="sec4_17_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> (2,4-Bis(benzyloxy)-6-bromophenyl)(4-fluoroisoindolin-2-yl)methanone (<b>8b</b>)</h4><div class="NLM_p last"><b>8b</b> was prepared according to General Procedure D from 4-fluoroisoindoline (290 mg, 2.11 mmol). <b>8b</b> (585 mg, 1.10 mmol) was obtained in 57% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.47–7.21 (m, 11H), 7.15–6.87 (m, 2H), 6.86–6.80 (m, 1H), 6.68–6.54 (m, 1H), 5.09–4.99 (m, 6H), 4.67–4.40 (m, 2H). UPLC/MS [M + H] = 532.195, <i>t</i><sub>R</sub> = 2.09 min.</div></div><div id="sec4_17_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> (2,4-Bis(benzyloxy)-6-bromophenyl)(5-fluoroisoindolin-2-yl)methanone (<b>8c</b>)</h4><div class="NLM_p"><b>8c</b> was prepared according to General Procedure D from 5-fluoroisoindoline hydrochloride (382 mg, 2.2 mmol). <b>8c</b> (917 mg, 1.72 mmol) was obtained in 86% yield.</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.55–7.32 (m, 5H), 7.33–7.19 (m, 6H), 7.13–6.92 (m, 2H), 6.87–6.78 (m, 1H), 6.58 (dd, <i>J</i> = 2.2, 1.2 Hz, 1H), 5.09–4.90 (m, 6H), 4.60–4.38 (m, 2H). UPLC/MS [M + H] = 532.438, <i>t</i><sub>R</sub> = 2.08 min.</div></div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> RAP Synthesis</h3><div id="sec4_18_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> General Procedure E</h4><div class="NLM_p"><b>E1a</b>: To a flame-dried 2D vial equipped with a magnetic stir bar was added resorcylate amide bromide <b>8a</b>–<b>c</b> (0.15 mmol, 1 equiv), aminopyrazole <b>4a</b>–<b>bb</b> (0.165 mmol, 1.1 equiv), Pd(OAc)<sub>2</sub> (15 μmol, 0.1 equiv), xantphos (30 μmol, 0.2 equiv), and Cs<sub>2</sub>CO<sub>3</sub> (0.3 mmol, 2 equiv). The vial was fitted with a rubber septum, evacuated, backfilled with N<sub>2</sub>, and anhydrous toluene (0.6 mL, 0.25 M) was added. The septum was replaced with a cap, and the vial was sealed with PTFE tape. The reaction was heated at 130 °C for 16 h in a heating block. The reaction was cooled to room temperature and filtered through silica plug eluting with EtOAc (12 mL). The filtrate was concentrated and used without further purification.</div><div class="NLM_p"><b>E1b</b>: To a flame-dried microwave vial equipped with a magnetic stir bar were added resorcylate amide bromide <b>8a</b>–<b>c</b> (0.15 mmol, 1 equiv), aminopyrazole <b>4a</b>–<b>bb</b> (0.165 mmol, 1.1 equiv), Pd<sub>2</sub>(dba)<sub>3</sub> (6 μmol, 0.04 equiv), xanthphos (15 μmol, 0.1 equiv), and sodium phenoxide (0.225 mmol, 1.5 equiv). The vial was fitted with a rubber septum, evacuated, backfilled with N<sub>2</sub>, and anhydrous 1,4-dioxane (0.1 M reaction concentration) was added. The septum was replaced with a microwave cap, and the reaction was heated in a microwave holding at 170 °C for 2 h. The reaction was cooled to room temperature and filtered through a silica plug eluting with EtOAc (8× reaction volume). The filtrate was concentrated and used without further purification.</div><div class="NLM_p"><b>E2a</b>: In a 2D vial equipped with a magnetic stir bar were added benzyl-protected RAP (1 equiv), MeOH (2 mL), and Pd/C (20% wt). The vial was fitted with a rubber septum and a hydrogen balloon. Hydrogen was bubbled through the solution for 10 min; then, the reaction was stirred under hydrogen atmosphere for 16 h or until full conversion was observed by UPLC/MS. The reaction was filtered through celite plug eluting with MeOH (6 mL) and EtOAc (6 mL) and concentrated. The crude material was purified by mass-guided preparative HPLC.</div><div class="NLM_p last"><b>E2b</b>: In a 2D vial equipped with a magnetic stir bar was added benzyl-protected RAP (1 equiv), EtOAc (2 mL), and Pd(OH)<sub>2</sub>/C (20% wt). The vial was fitted with a rubber septum and a hydrogen balloon. Hydrogen was bubbled through the solution for 10 min; then, the reaction was stirred under hydrogen atmosphere for 16 h or until full conversion was observed by UPLC/MS. The reaction was filtered through celite plug eluting with MeOH (6 mL) and EtOAc (6 mL) and concentrated. The crude material was purified by mass-guided preparative HPLC.</div></div><div id="sec4_18_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> (2-((3-(2-Fluorophenyl)-1-methyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9a</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (45 mg, 0.087 mmol, 1 equiv) was coupled to 5-amino-3-(2-fluorophenyl)-1-methylpyrazole <b>4a</b> (18.4 mg, 0.096 mmol, 1.1 equiv) according to General Procedure <b>E1a</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9a</b> (16.7 mg, 0.037 mmol) was obtained in a 43% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.64 (s, 1H), 9.31 (s, 1H), 7.89 (dt, <i>J</i> = 1.90, 7.8 Hz, 1H), 7.29–7.35 (m, 3H), 7.24–7.29 (m, 2H), 7.22–7.24 (m, 1H), 7.21 (s, 2H), 7.20 (s, 1H), 6.36 (d, <i>J</i> = 3.9 Hz, 1H), 5.89 (d, <i>J</i> = 2.0 Hz, 1H), 5.62 (d, <i>J</i> = 2.0 Hz, 1H), 4.63–4.86 (m, 4H), 3.63 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.5, 160.3, 159.4, 158.3, 155.7, 143.9, 142.8, 141.6, 141.6, 129.2, 129.1, 127.6, 127.4, 124.6, 123.0, 121.3, 121.2, 116.3, 116.1, 104.5, 99.8, 99.7, 94.6, 93.0, 40.6, 35.2.</div></div><div id="sec4_18_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> (2-((3-(2-Chlorophenyl)-1-methyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9b</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (51 mg, 0.1 mmol, 1 equiv) was coupled to <b>4b</b> (23 mg, 0.11 mmol, 1.1 equiv) according to General Procedure <b>E1a</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9b</b> (3.4 mg, 0.007 mmol) was obtained in 7% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.64 (s, 1H), 9.32 (s, 1H), 7.78–7.72 (m, 1H), 7.50–7.45 (m, 1H), 7.38–7.29 (m, 4H), 7.29–7.25 (m, 2H), 7.21 (s, 1H), 6.48 (s, 1H), 5.90 (d, <i>J</i> = 2.1 Hz, 1H), 5.65 (d, <i>J</i> = 2.1 Hz, 1H), 4.82–4.69 (m, 4H), 3.62 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.34, 159.23, 155.52, 145.71, 143.74, 140.82, 132.16, 130.72, 130.20, 129.88, 128.88, 127.23, 127.14, 122.86, 104.28, 100.19, 94.50, 92.87, 35.04. UPLC/MS [M + H] = 461.337, <i>t</i><sub>R</sub> = 2.36 min.</div></div><div id="sec4_18_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> (2,4-Dihydroxy-6-((1-methyl-3-(2-(trifluoromethyl)phenyl)-1<i>H</i>-pyrazol-5-yl)amino)phenyl)(isoindolin-2-yl)methanone (<b>9c</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (77 mg, 0.15 mmol, 1 equiv) was coupled to <b>4c</b> (40 mg, 0.165 mmol, 1.1 equiv) according to General Procedure <b>E1a</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9c</b> (13 mg, 0.026 mmol) was obtained in 17% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.63–9.59 (m, 1H), 9.32 (s, 1H), 7.78 (dd, <i>J</i> = 8.0, 1.3 Hz, 1H), 7.68–7.63 (m, 1H), 7.63–7.60 (m, 1H), 7.58–7.53 (m, 1H), 7.41–7.25 (m, 4H), 7.23 (s, 1H), 6.18 (s, 1H), 5.91 (d, <i>J</i> = 2.1 Hz, 1H), 5.64 (d, <i>J</i> = 2.1 Hz, 1H), 4.75 (s, 4H), 3.61 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.32, 159.22, 155.48, 146.45, 143.68, 140.85, 137.21, 133.27, 132.20, 131.56, 128.06, 127.25, 126.09, 125.26, 122.88, 104.34, 99.67, 94.51, 92.87, 35.02. UPLC/MS [M + H] = 495.601, <i>t</i><sub>R</sub> = 1.49 min.</div></div><div id="sec4_18_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> (2-((1-(<i>tert</i>-Butyl)-3-(<i>o</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9d</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (62 mg, 0.120 mmol, 1 equiv) was coupled to <b>4d</b> (30 mg, 0.132 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9d</b> (18.5 mg, 0.038 mmol) was obtained in 32% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.69 (s, 1H), 9.29 (s, 1H), 7.58–7.51 (m, 1H), 7.38–7.32 (m, 2H), 7.32–7.26 (m, 2H), 7.24–7.16 (m, 3H), 6.98 (s, 1H), 6.37 (s, 1H), 5.85 (d, <i>J</i> = 2.1 Hz, 1H), 5.70 (d, <i>J</i> = 2.1 Hz, 1H), 4.81 (s, 4H), 2.48 (s, 3H), 1.55 (s, 9H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.36, 159.88, 156.00, 147.57, 145.54, 139.92, 137.13, 135.37, 133.63, 131.35, 128.69, 127.73, 127.45, 126.14, 123.31, 103.48, 103.20, 94.24, 92.56, 59.70, 29.89, 21.90 UPLC/MS [M + H] = 483.575, <i>t</i><sub>R</sub> = 1.81 min.</div></div><div id="sec4_18_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> (2,4-Dihydroxy-6-((1-methyl-3-(<i>o</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)amino)phenyl)(5-fluoroisoindolin-2-yl)methanone (<b>9e</b>)</h4><div class="NLM_p last">Compound <b>9e</b> was obtained according to the route and procedures described in ref <a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a>. (2-Bromo-4,6-bis(methoxymethoxy)phenyl)(5-fluoroisoindolin-2-yl)methanone (78 mg, 0.177 mmol, 1 equiv), 2-methyl-5-(<i>o</i>-tolyl)pyrazol-3-amine (<b>4e</b>) (22 mg, 0.195 mmol, 1.1 equiv), Pd<sub>2</sub>(dba)<sub>3</sub> (8.1 mg, 5 mol %), xantphos (10.3 mg, 10 mol %), sodium phenoxide (31 mg, 0.266 mmol, 1.5 equiv), and anhydrous dioxane (2 mL) were heated to 120 °C in a 2 dram vial under an atmosphere of nitrogen. The reaction was cooled to room temperature, diluted with ethyl acetate, and passed through a prewetted 3 mL hydromatrix cartridge eluting with ethyl acetate. The eluents were dried with sodium sulfate, filtered, and condensed by rotary evaporation. Purification on a short silica column with a gradient of 25% to 40% acetone in hexanes afforded a yellow gum, which was then dissolved in methanol (5 mL) and 2 M aqueous HCl (0.53 mL). The reaction was heated to 50 °C overnight, cooled to room temperature, and the solvent was removed by rotary evaporation. The crude residue was purified by mass-guided preparative HPLC to afford <b>9e</b> (24.2 mg, 28% yield over two steps). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.41 (d, <i>J</i> = 7.34 Hz, 1H), 7.06–7.17 (m, 4H), 6.92 (dt, <i>J</i> = 1.96, 8.56 Hz, 1H), 6.86 (br d, <i>J</i> = 8.31 Hz, 1H), 6.81 (s, 1H), 6.10 (s, 1H), 5.97 (d, <i>J</i> = 0.98 Hz, 1H), 5.78 (d, <i>J</i> = 1.47 Hz, 1H), 4.91 (br s, 2H), 4.72–4.86 (m, 2H), 3.64 (s, 3H), 2.33 (s, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 168.8, 161.8, 160.5, 156.4, 150.4, 144.8, 140.6, 136.0, 132.9, 132.0, 130.9, 129.1, 128.0, 126.0, 124.2, 124.1, 115.1, 114.9, 110.2, 110.0, 100.0, 95.9, 94.0, 52.9, 52.4, 40.9, 21.2. UPLC/MS [M + H] = 459.393, <i>t</i><sub>R</sub> = 1.70 min.</div></div><div id="sec4_18_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117"> (2,4-Dihydroxy-6-((3-(2-methoxyphenyl)-1-methyl-1<i>H</i>-pyrazol-5-yl)amino)phenyl)(isoindolin-2-yl)methanone (<b>9f</b>)</h4><div class="NLM_p last">Compound <b>9f</b> was obtained from (2-bromo-4,6-bis(methoxymethoxy)phenyl)(isoindolin-2-yl)methanone<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> and 5-(2-methoxyphenyl)-2-methyl-pyrazol-3-amine (<b>4f</b>) according to the same procedures described above for <b>9e</b>. <b>9f</b> (17.8 mg) was obtained in 35% yield over two steps. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.76 (dd, <i>J</i> = 1.47, 7.83 Hz, 1H), 7.21–7.25 (m, 3H), 7.17–7.21 (m, 3H), 6.90 (br t, <i>J</i> = 7.50 Hz, 1H), 6.85 (d, <i>J</i> = 8.31 Hz, 1H), 6.72 (s, 1H), 6.49 (s, 1H), 5.97 (d, <i>J</i> = 0.98 Hz, 1H), 5.76 (d, <i>J</i> = 1.96 Hz, 1H), 4.94–5.09 (m, 2H), 4.81–4.93 (m, 2H), 3.75 (s, 3H), 3.66 (s, 3H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 168.8, 160.5, 156.8, 156.4, 147.1, 145.3, 140.3, 136.7, 129.0, 128.3, 127.7, 122.9, 122.3, 120.9, 111.4, 103.1, 101.6, 95.6, 93.8, 77.5, 55.5, 53.0, 40.9, 35.1. UPLC/MS [M + H] = 457.409, <i>t</i><sub>R</sub> = 1.56 min.</div></div><div id="sec4_18_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i118" class="anchor-spacer"></div><h4 class="article-section__title" id="_i118"> (2,4-Dihydroxy-6-((1-isopropyl-3-(2-methoxyphenyl)-1<i>H</i>-pyrazol-5-yl)amino)phenyl)(isoindolin-2-yl)methanone (<b>9g</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (77 mg, 0.150 mmol, 1 equiv) was coupled to <b>4g</b> (38 mg, 0.165 mmol, 1.1 equiv) according to General Procedure <b>E1a</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9g</b> (22 mg, 0.046 mmol) was obtained in 37% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.58 (s, 1H), 9.25 (s, 1H), 7.91 (m, 1H), 7.42–7.21 (m, 5H), 7.12–6.94 (m, 3H), 6.46 (s, 1H), 5.84 (d, <i>J</i> = 2.1 Hz, 1H), 5.54 (d, <i>J</i> = 2.1 Hz, 1H), 4.77 (m, 4H), 4.50–4.37 (p, <i>J</i> = 6.6 Hz, 1H), 3.85–3.78 (m, 3H), 1.35 (d, <i>J</i> = 6.6 Hz, 6H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.62, 159.35, 156.32, 155.64, 145.20, 145.08, 139.03, 136.90, 128.51, 127.40, 127.25, 123.03, 122.49, 120.49, 111.89, 103.84, 102.14, 94.11, 92.40, 55.49, 47.87, 22.45. UPLC/MS [M + H] = 485.231, <i>t</i><sub>R</sub> = 1.52 min.</div></div><div id="sec4_18_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119"> (2-((1-Cyclohexyl-3-(2-methoxyphenyl)-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9h</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (77 mg, 0.150 mmol, 1 equiv) was coupled to <b>4h</b> (45 mg, 0.165 mmol, 1.1 equiv) according to General Procedure <b>E1a</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9h</b> (20 mg, 0.039 mmol) was obtained in 26% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.66 (s, 1H), 9.33 (s, 1H), 8.01–7.96 (m, 1H), 7.43 (t, <i>J</i> = 4.4 Hz, 2H), 7.40–7.31 (m, 3H), 7.17–7.09 (m, 2H), 7.09–7.02 (m, 1H), 6.56 (s, 1H), 5.94 (d, <i>J</i> = 2.1 Hz, 1H), 5.65 (d, <i>J</i> = 2.1 Hz, 1H), 4.86 (s, 4H), 4.15–4.05 (m, 1H), 3.89 (s, 3H), 1.99–1.81 (m, 6H), 1.69–1.65 (m, 1H), 1.36–1.19 (m, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.49, 159.16, 156.15, 155.46, 144.91, 144.86, 138.97, 136.70, 128.33, 127.25, 127.07, 122.84, 122.30, 120.32, 111.72, 103.76, 102.07, 94.01, 92.29, 55.32, 55.25, 32.34, 25.12, 24.91. UPLC/MS [M + H] = 526.363, <i>t</i><sub>R</sub> = 3.06 min.</div></div><div id="sec4_18_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120"> (2-((1-Cyclohexyl-3-(2-methoxyphenyl)-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(4-fluoroisoindolin-2-yl)methanone (<b>9i</b>)</h4><div class="NLM_p last">Amide bromide <b>8b</b> (48 mg, 0.090 mmol, 1 equiv) was coupled to <b>4h</b> (27 mg, 0.099 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9i</b> (19 mg, 0.035 mmol) was obtained in 39% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.59 (s, 1H), 9.26 (s, 1H), 7.93–7.85 (m, 1H), 7.37–7.30 (m, 1H), 7.28–7.22 (m, 1H), 7.19 (d, <i>J</i> = 7.6 Hz, 1H), 7.10 (t, <i>J</i> = 8.8 Hz, 1H), 7.07–7.00 (m, 2H), 7.00–6.93 (m, 1H), 6.46 (s, 1H), 5.85 (d, <i>J</i> = 2.1 Hz, 1H), 5.57 (d, <i>J</i> = 2.1 Hz, 1H), 4.92–4.68 (m, 4H), 4.07–3.97 (m, 1H), 3.79 (s, 3H), 1.91–1.70 (m, 7H), 1.61–1.57 (m, 1H), 1.28–1.14 (m, 3H), <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.43, 159.25, 156.11, 155.52, 144.96, 144.87, 138.97, 128.29, 127.01, 122.24, 120.29, 113.63 (d, <i>J</i> = 19.4 Hz), 111.67, 103.45, 102.04, 93.99, 92.49, 79.16, 55.27, 32.34, 25.11, 24.91. UPLC/MS [M + H] = 543.598, <i>t</i><sub>R</sub> = 1.79 min.</div></div><div id="sec4_18_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i121" class="anchor-spacer"></div><h4 class="article-section__title" id="_i121"> (2-((1-Cyclohexyl-3-(2-methoxyphenyl)-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(5-fluoroisoindolin-2-yl)methanone (<b>9j</b>)</h4><div class="NLM_p last">Amide bromide <b>8c</b> (48 mg, 0.90 mmol, 1 equiv) was coupled to <b>4h</b> (27 mg, 0.099 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9j</b> (19 mg, 0.034 mmol) was obtained in 38% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.57 (s, 1H), 9.24 (s, 1H), 7.91–7.86 (m, 1H), 7.43–7.32 (m, 1H), 7.27–7.22 (m, 1H), 7.22–7.18 (m, 1H), 7.11–7.06 (m, 1H), 7.04–7.01 (m, 2H), 6.45 (s, 1H), 5.84 (d, <i>J</i> = 2.1 Hz, 1H), 5.57 (d, <i>J</i> = 2.1 Hz, 1H), 4.73 (s, 6H), 3.80 (s, 3H), 1.93–1.71 (m, 6H), 1.66–1.55 (m, 1H), 1.31–1.13 (m, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.44, 159.20, 156.12, 155.48, 144.91, 144.88, 139.00, 128.30, 127.05, 124.54, 122.27, 120.30, 114.22, 111.68, 110.06, 103.62, 102.01, 94.00, 92.44, 79.17, 55.30, 48.58, 32.35, 25.12. UPLC/MS [M + H] = 543.322, <i>t</i><sub>R</sub> = 1.79 min.</div></div><div id="sec4_18_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122"> (2-((1-Cyclopentyl-3-(2-methoxyphenyl)-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9k</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (77 mg, 0.150 mmol, 1 equiv) was coupled to <b>4i</b> (42 mg, 0.165 mmol, 1.1 equiv) according to General Procedure <b>E1a</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9k</b> (30.5 mg, 0.060 mmol) was obtained in 40% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.59 (s, 1H), 7.92–7.87 (m, 1H), 7.39–7.32 (m, 2H), 7.30–7.22 (m, 3H), 7.10–7.01 (m, 2H), 7.01–6.93 (m, 1H), 6.47 (s, 1H), 5.86 (d, <i>J</i> = 2.1 Hz, 1H), 5.55 (d, <i>J</i> = 2.1 Hz, 1H), 4.77 (s, 4H), 4.58 (p, <i>J</i> = 7.3 Hz, 1H), 3.81 (s, 3H), 2.04–1.78 (m, 6H), 1.67–1.47 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.52, 159.21, 156.18, 155.48, 145.00, 144.83, 139.60, 136.76, 128.38, 127.26, 127.10, 122.86, 122.30, 120.37, 111.75, 103.72, 101.94, 94.04, 92.39, 56.91, 55.34, 32.25, 24.16. UPLC/MS [M + H] = 511.295, <i>t</i><sub>R</sub> = 1.74 min.</div></div><div id="sec4_18_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i123" class="anchor-spacer"></div><h4 class="article-section__title" id="_i123"> (2,4-Dihydroxy-6-((1-isobutyl-3-(2-methoxyphenyl)-1<i>H</i>-pyrazol-5-yl)amino)phenyl)(isoindolin-2-yl)methanone (<b>9l</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (77 mg, 0.150 mmol, 1 equiv) was coupled to <b>4j</b> (40 mg, 0.165 mmol, 1.1 equiv) according to General Procedure <b>E1a</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9l</b> (20.7 mg, 0.0415 mmol) was obtained in 28% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.63 (s, 1H), 9.29 (s, 1H), 7.90–7.84 (m, 1H), 7.34 (s, 2H), 7.31–7.24 (m, 3H), 7.08 (s, 1H), 7.07–7.04 (m, 1H), 6.98–6.94 (m, 1H), 6.50 (s, 1H), 5.87 (d, <i>J</i> = 2.1 Hz, 1H), 5.67 (d, <i>J</i> = 2.1 Hz, 1H), 4.77 (s, 4H), 3.82 (s, 3H), 3.72 (d, <i>J</i> = 7.3 Hz, 2H), 2.14–2.03 (m, 1H), 0.78 (d, <i>J</i> = 6.7 Hz, 6H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.03, 159.72, 156.66, 155.95, 145.55, 144.68, 140.56, 137.11, 128.92, 127.72, 127.56, 123.31, 122.57, 120.83, 112.24, 104.24, 101.43, 94.67, 92.89, 55.82, 55.00, 29.14, 20.25. UPLC/MS [M + H] = 499.343, <i>t</i><sub>R</sub> = 1.74 min.</div></div><div id="sec4_18_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i124" class="anchor-spacer"></div><h4 class="article-section__title" id="_i124"> (2-((1-(<i>tert</i>-Butyl)-3-(2-methoxyphenyl)-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9m</b>)</h4><div class="NLM_p">Amide bromide <b>8a</b> (77 mg, 0.150 mmol, 1 equiv) was coupled to <b>4k</b> (40 mg, 0.165 mmol, 1.1 equiv) according to General Procedure <b>E1a</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9m</b> (12.4 mg, 0.025 mmol) was obtained in 12.5% yield over two steps.</div><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.67 (s, 1H), 9.26 (s, 1H), 7.94–7.89 (m, 1H), 7.41–7.33 (m, 2H), 7.31–7.24 (m, 3H), 7.08–7.02 (m, 1H), 6.97 (s, 1H), 6.94–6.91 (m, 1H), 6.54 (d, <i>J</i> = 0.7 Hz, 1H), 5.84 (d, <i>J</i> = 2.1 Hz, 1H), 5.62 (d, <i>J</i> = 2.1 Hz, 1H), 4.81 (s, 4H), 3.81 (s, 3H), 1.55 (s, 9H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.35, 159.83, 156.68, 155.97, 145.81, 143.75, 139.66, 137.12, 128.81, 127.73, 127.46, 123.31, 122.73, 120.82, 112.21, 105.28, 103.41, 94.12, 92.51, 59.69, 55.81, 29.91. UPLC/MS [M + H] = 499.343, <i>t</i><sub>R</sub> = 1.62 min.</div></div><div id="sec4_18_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125"> (2,4-Dihydroxy-6-((1-methyl-3-(2-(trifluoromethoxy)phenyl)-1<i>H</i>-pyrazol-5-yl)amino)phenyl)(isoindolin-2-yl)methanone (<b>9n</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (77 mg, 0.15 mmol, 1 equiv) was coupled to <b>4l</b> (42 mg, 0.165 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9n</b> (36 mg, 0.70 mmol) was obtained in 47% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.63 (s, 1H), 9.29 (s, 1H), 8.00–7.92 (m, 1H), 7.44–7.36 (m, 3H), 7.32 (s, 2H), 7.28–7.23 (m, 3H), 6.35 (s, 1H), 5.92 (d, <i>J</i> = 2.1 Hz, 1H), 5.62 (d, <i>J</i> = 2.1 Hz, 1H), 4.75 (s, 4H), 3.63 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.34, 159.27, 155.52, 145.02, 143.73, 143.28, 141.43, 136.73, 128.92, 128.62, 127.64, 127.25, 126.95, 122.85, 121.53, 121.22, 119.18, 104.39, 99.57, 94.56, 92.88, 35.17. UPLC/MS [M + H] = 511.162, <i>t</i><sub>R</sub> = 1.49 min.</div></div><div id="sec4_18_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i126" class="anchor-spacer"></div><h4 class="article-section__title" id="_i126"> (2-((1-(<i>tert</i>-Butyl)-3-(2-(trifluoromethoxy)phenyl)-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9o</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (64 mg, 0.125 mmol, 1 equiv) was coupled to <b>4m</b> (41 mg, 0.138 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9o</b> (14.7 mg, 0.027 mmol) was obtained in 22% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.69 (s, 1H), 9.26 (s, 1H), 8.02–7.97 (m, 1H), 7.45–7.37 (m, 3H), 7.37–7.31 (m, 2H), 7.32–7.26 (m, 2H), 7.02 (s, 1H), 6.44 (s, 1H), 5.86 (d, <i>J</i> = 2.1 Hz, 1H), 5.62 (d, <i>J</i> = 2.1 Hz, 1H), 4.80 (s, 4H), 1.56 (s, 9H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.78, 159.40, 155.50, 144.95, 141.74, 140.21, 136.60, 128.80, 128.69, 127.62, 127.27, 127.04, 122.83, 121.57, 121.28, 119.24, 103.26, 103.19, 93.90, 92.08, 59.77, 29.32.UPLC/MS [M + H] = 553.609, <i>t</i><sub>R</sub> = 1.87 min.</div></div><div id="sec4_18_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i127" class="anchor-spacer"></div><h4 class="article-section__title" id="_i127"> (2-((1-(<i>tert</i>-Butyl)-3-(3-methoxyphenyl)-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9p</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (77 mg, 0.150 mmol, 1 equiv) was coupled to <b>4n</b> (40 mg, 0.165 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9p</b> (32.3 mg, 0.065 mmol) was obtained in 43% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.70 (s, 1H), 9.28 (s, 1H), 7.38–7.32 (m, 3H), 7.32–7.25 (m, 4H), 6.97 (s, 1H), 6.86–6.80 (m, 1H), 6.58 (d, <i>J</i> = 0.6 Hz, 1H), 5.86 (d, <i>J</i> = 2.1 Hz, 1H), 5.67 (d, <i>J</i> = 2.1 Hz, 1H), 4.99–4.66 (m, 4H), 3.78 (s, 3H), 1.56 (s, 9H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.90, 159.49, 159.42, 155.54, 146.34, 145.08, 140.43, 136.66, 135.22, 129.55, 127.28, 122.86, 117.14, 112.72, 110.05, 103.03, 100.57, 93.82, 92.24, 59.36, 55.02, 29.41 UPLC/MS [M + H] = 499.255, <i>t</i><sub>R</sub> = 1.66 min.</div></div><div id="sec4_18_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i128" class="anchor-spacer"></div><h4 class="article-section__title" id="_i128"> (2-((1-(<i>tert</i>-butyl)-3-(<i>m</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9q</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (77 mg, 0.150 mmol, 1 equiv) was coupled to <b>4o</b> (38 mg, 0.165 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9q</b> (34.7 mg, 0.072 mmol) was obtained in 48% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.70 (s, 1H), 9.28 (s, 1H), 7.61–7.57 (m, 1H), 7.57–7.52 (m, 1H), 7.40–7.32 (m, 2H), 7.32–7.21 (m, 3H), 7.11–7.04 (m, 1H), 7.00–6.96 (m, 1H), 6.53 (s, 1H), 5.86 (d, <i>J</i> = 2.1 Hz, 1H), 5.69 (d, <i>J</i> = 2.1 Hz, 1H), 5.06–4.62 (m, 4H), 2.32 (s, 3H), 1.56 (s, 9H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.92, 159.43, 155.55, 146.55, 145.06, 140.42, 137.50, 136.67, 133.72, 128.37, 127.82, 127.29, 125.19, 122.86, 121.91, 103.06, 100.22, 93.84, 92.26, 59.31, 29.44, 21.10. UPLC/MS [M + H] = 483.247, <i>t</i><sub>R</sub> = 1.85 min.</div></div><div id="sec4_18_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i129" class="anchor-spacer"></div><h4 class="article-section__title" id="_i129"> (2-((1-(<i>tert</i>-Butyl)-3-(3-(trifluoromethyl)phenyl)-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9r</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (77 mg, 0.150 mmol, 1 equiv) was coupled to <b>4p</b> (46.7 mg, 0.165 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9r</b> (49.8 mg, 0.093 mmol) was obtained in 62% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.72 (s, 1H), 9.29 (s, 1H), 8.10–8.02 (m, 2H), 7.64–7.57 (m, 2H), 7.41–7.31 (m, 2H), 7.31–7.24 (m, 2H), 7.03 (s, 1H), 6.75 (s, 1H), 5.88 (d, <i>J</i> = 2.1 Hz, 1H), 5.70 (d, <i>J</i> = 2.1 Hz, 1H), 5.04–4.59 (m, 4H), 1.58 (s, 9H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.33, 159.89, 156.01, 145.47, 145.35, 141.49, 137.11, 130.13, 129.91 (q, <i>J</i> = 30.8 Hz), 128.95, 127.73, 125.82, 124.14–123.94 (m), 123.65, 123.30, 121.23–121.03 (m), 103.64, 101.20, 94.43, 92.85, 60.13, 29.80. UPLC/MS [M + H] = 537.270, <i>t</i><sub>R</sub> = 1.94 min.</div></div><div id="sec4_18_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i130" class="anchor-spacer"></div><h4 class="article-section__title" id="_i130"> (2,4-Dihydroxy-6-((1-methyl-3-(3-(trifluoromethoxy)phenyl)-1<i>H</i>-pyrazol-5-yl)amino)phenyl)(isoindolin-2-yl)methanone (<b>9s</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (77 mg, 0.15 mmol, 1 equiv) was coupled to <b>4q</b> (42 mg, 0.165 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9s</b> (43 mg, 0.084 mmol) was obtained in 56% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.64 (s, 1H), 9.30 (s, 1H), 7.76–7.70 (m, 1H), 7.69–7.64 (m, 1H), 7.47 (t, <i>J</i> = 8.0 Hz, 1H), 7.34–7.29 (m, 2H), 7.29–7.23 (m, 3H), 7.22 (s, 1H), 6.58 (s, 1H), 5.91 (d, <i>J</i> = 2.1 Hz, 1H), 5.66 (d, <i>J</i> = 2.1 Hz, 1H), 4.92–4.51 (m, 4H), 3.63 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.40, 159.27, 155.55, 148.90–148.76 (m), 146.67, 142.02, 136.68, 135.92, 130.55, 127.24, 123.63, 122.84, 121.15, 119.45, 119.11, 116.59, 104.27, 97.13, 94.52, 93.09, 35.10. UPLC/MS [M + H] = 511.162, <i>t</i><sub>R</sub> = 1.62 min.</div></div><div id="sec4_18_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i131" class="anchor-spacer"></div><h4 class="article-section__title" id="_i131"> (2-((1-(<i>tert</i>-Butyl)-3-(3-(trifluoromethoxy)phenyl)-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9t</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (77 mg, 0.150 mmol, 1 equiv) was coupled to <b>4r</b> (49 mg, 0.165 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9t</b> (39.4 mg, 0.071 mmol) was obtained in 47% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.71 (s, 1H), 9.28 (s, 1H), 7.82–7.77 (m, 1H), 7.73–7.68 (m, 1H), 7.50 (t, <i>J</i> = 8.0 Hz, 1H), 7.40–7.32 (m, 2H), 7.32–7.21 (m, 3H), 7.02 (s, 1H), 6.69 (s, 1H), 5.87 (d, <i>J</i> = 2.1 Hz, 1H), 5.68 (d, <i>J</i> = 2.1 Hz, 1H), 5.05–4.58 (m, 4H), 1.57 (s, 9H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.33, 159.89, 156.01, 149.38–149.25 (m), 145.44, 145.40, 141.38, 137.11, 136.64, 131.01, 127.73, 124.08, 121.61, 119.79, 119.57, 117.16, 103.60, 101.30, 94.40, 92.80, 60.10, 29.79. UPLC/MS [M + H] = 553.278, <i>t</i><sub>R</sub> = 544.246 min.</div></div><div id="sec4_18_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i132" class="anchor-spacer"></div><h4 class="article-section__title" id="_i132"> (2-((3-(3-Fluorophenyl)-1-methyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9u</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (45 mg, 0.087 mmol, 1 equiv) was coupled to 2-methyl-5-(3-fluorophenyl)pyrazol-3-amine <b>4s</b> (18 mg, 0.096 mmol, 1.1 equiv) according to General Procedure <b>E1a</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9u</b> (24.7 mg, 0.056 mmol) was obtained in 64% yield over two steps. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.45–7.39 (m, 1H), 7.38–7.26 (m, 2H), 7.26–7.21 (m, 4H), 7.01–6.89 (m, 1H), 6.38 (s, 1H), 5.96 (d, <i>J</i> = 2.1 Hz, 1H), 5.79 (d, <i>J</i> = 2.1 Hz, 1H), 4.95–4.72 (m, 4H), 3.71 (s, 3H); (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.63 (s, 1H), 9.29 (s, 1H), 7.59–7.53 (m, 1H), 7.50–7.46 (m, 1H), 7.41–7.35 (m, 1H), 7.35–7.29 (m, 2H), 7.30–7.25 (m, 2H), 7.19 (s, 1H), 7.10–7.03 (m, 1H), 6.54 (s, 1H), 5.89 (d, <i>J</i> = 2.1 Hz, 1H), 5.64 (d, <i>J</i> = 2.1 Hz, 1H), 4.84–4.68 (m, 4H), 3.61 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.83, 162.99 (d, <i>J</i> = 242.2 Hz), 159.70, 155.99, 147.48 (d, <i>J</i> = 2.4 Hz), 144.29, 142.26, 136.54 (d, <i>J</i> = 8.2 Hz), 130.93 (d, <i>J</i> = 8.5 Hz), 127.69, 123.30, 121.06, 114.28 (d, <i>J</i> = 21.7 Hz), 111.51 (d, <i>J</i> = 22.4 Hz), 104.64, 97.54, 94.90, 93.42, 35.51. UPLC/MS [M + H] = 445.408, <i>t</i><sub>R</sub> = 2.31 min.</div></div><div id="sec4_18_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i133" class="anchor-spacer"></div><h4 class="article-section__title" id="_i133"> (2-((1-(<i>tert</i>-Butyl)-3-(3-fluorophenyl)-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9v</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (77 mg, 0.150 mmol, 1 equiv) was coupled to <b>4t</b> (38.5 mg, 0.165 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9v</b> (32.8 mg, 0.067 mmol) was obtained in 45% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.71 (s, 1H), 9.28 (s, 1H), 7.64–7.59 (m, 1H), 7.59–7.51 (m, 1H), 7.44–7.38 (m, 1H), 7.37–7.32 (m, 2H), 7.32–7.25 (m, 2H), 7.11–7.04 (m, 1H), 7.00 (s, 1H), 6.65 (s, 1H), 5.87 (d, <i>J</i> = 2.1 Hz, 1H), 5.67 (d, <i>J</i> = 2.1 Hz, 1H), 4.97–4.71 (m, 4H), 1.56 (s, 9H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.88, 162.58 (d, <i>J</i> = 242.3 Hz), 159.43, 155.56, 145.35 (d, <i>J</i> = 2.6 Hz), 144.99, 140.75, 136.67, 136.31 (d, <i>J</i> = 8.1 Hz), 130.50 (d, <i>J</i> = 8.6 Hz), 127.29, 122.86, 120.65 (d, <i>J</i> = 2.7 Hz), 113.75 (d, <i>J</i> = 21.0 Hz), 111.06 (d, <i>J</i> = 22.4 Hz), 103.11, 100.80, 93.91, 92.30, 59.58, 29.37. UPLC/MS [M + H] = 487.501, <i>t</i><sub>R</sub> = 1.82 min.</div></div><div id="sec4_18_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i134" class="anchor-spacer"></div><h4 class="article-section__title" id="_i134"> (2-((3-(3-Chlorophenyl)-1-methyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9w</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (129 mg, 0.25 mmol, 1 equiv) was coupled to <b>4u</b> (57 mg, 0.275 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2b</b>. <b>9w</b> (20.4 mg, 0.044 mmol) was obtained in 18% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.43 (s, 1H), 9.07 (s, 1H), 7.49 (t, <i>J</i> = 1.9 Hz, 1H), 7.45–7.39 (m, 1H), 7.11 (t, <i>J</i> = 7.9 Hz, 1H), 7.09–7.00 (m, 5H), 6.95 (s, 1H), 6.30 (s, 1H), 5.65 (d, <i>J</i> = 2.1 Hz, 1H), 5.40 (d, <i>J</i> = 2.1 Hz, 1H), 4.65–4.33 (m, 4H), 3.36 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.38, 159.25, 155.56, 146.72, 143.76, 141.87, 136.95, 135.67, 133.40, 130.40, 127.23, 126.92, 124.13, 123.14, 122.83, 104.20, 96.93, 94.49, 93.01, 35.06. UPLC/MS [M + H] = 461.175, <i>t</i><sub>R</sub> = 1.54 min.</div></div><div id="sec4_18_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i135" class="anchor-spacer"></div><h4 class="article-section__title" id="_i135"> (2-((1-(<i>tert</i>-Butyl)-3-(3-chlorophenyl)-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9x</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (77 mg, 0.150 mmol, 1 equiv) was coupled to <b>4v</b> (41 mg, 0.165 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2b</b>. <b>9x</b> (6.4 mg, 0.013 mmol) was obtained in 9% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.70 (s, 1H), 9.27 (s, 1H), 7.79 (t, <i>J</i> = 1.9 Hz, 1H), 7.77–7.69 (m, 1H), 7.39 (t, <i>J</i> = 7.9 Hz, 1H), 7.37–7.33 (m, 2H), 7.33–7.27 (m, 3H), 7.00 (s, 1H), 6.66 (s, 1H), 5.85 (d, <i>J</i> = 2.1 Hz, 1H), 5.67 (d, <i>J</i> = 2.1 Hz, 1H), 4.93–4.69 (m, 4H), 1.56 (s, 9H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.84, 159.40, 155.53, 145.03, 144.90, 140.81, 136.31, 135.90, 133.40, 130.43, 127.27, 126.88, 124.08, 123.20, 122.85, 103.11, 100.71, 93.90, 92.29, 59.59, 29.35. UPLC/MS [M + H] = 503.236, <i>t</i><sub>R</sub> = 1.86 min.</div></div><div id="sec4_18_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i136" class="anchor-spacer"></div><h4 class="article-section__title" id="_i136"> (2-((3-(3-Chlorophenyl)-1-cyclohexyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9y</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (77 mg, 0.150 mmol, 1 equiv) was coupled to <b>4w</b> (46 mg, 0.165 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2b</b>. <b>9y</b> (85 mg, 0.016 mmol) was obtained in 11% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.59 (s, 1H), 9.25 (s, 1H), 7.76 (t, <i>J</i> = 1.9 Hz, 1H), 7.71–7.65 (m, 1H), 7.36 (t, <i>J</i> = 7.9 Hz, 1H), 7.34–7.25 (m, 5H), 7.10 (s, 1H), 6.55 (s, 1H), 5.86 (d, <i>J</i> = 2.1 Hz, 1H), 5.61 (d, <i>J</i> = 2.1 Hz, 1H), 4.75 (s, 4H), 4.07–3.98 (m, 1H), 1.90–1.70 (m, 6H), 1.61–1.55 (m, 1H), 1.26–1.13 (m, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.42, 159.16, 155.49, 146.69, 144.42, 140.58, 136.65, 135.92, 133.37, 130.38, 127.24, 126.83, 124.07, 123.18, 122.82, 104.02, 97.97, 94.27, 92.75, 55.44, 40.43, 32.24, 24.85. UPLC/MS [M + H] = 529.319, <i>t</i><sub>R</sub> = 1.90 min.</div></div><div id="sec4_18_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i137" class="anchor-spacer"></div><h4 class="article-section__title" id="_i137"> (2-((3-(2,3-Dimethylphenyl)-1-methyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9z</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (77 mg, 0.15 mmol, 1 equiv) was coupled to <b>4x</b> (33.2 mg, 0.165 mmol, 1.1 equiv) according to General Procedure <b>E1a</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9z</b> (5.5 mg, 0.012 mmol) was obtained in 8% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): 9.60 (s, 1H), 9.30 (s, 1H), 7.34 (s, 2H), 7.31–7.26 (m, 2H), 7.24–7.18 (m, 1H), 7.17 (s, 1H), 7.13–7.09 (m, 1H), 7.06 (t, <i>J</i> = 7.5 Hz, 1H), 6.13 (s, 1H), 5.88 (d, <i>J</i> = 2.1 Hz, 1H), 5.66 (d, <i>J</i> = 2.1 Hz, 1H), 4.82–4.70 (m, 4H), 3.60 (s, 3H), 2.30 (s, 3H), 2.26 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.40, 159.24, 155.50, 149.40, 143.88, 140.45, 136.76, 133.87, 133.85, 128.76, 127.25, 126.92, 125.06, 122.87, 104.09, 99.74, 94.34, 92.74, 34.85, 20.36, 16.59. UPLC/MS [M + H] = 455.303, <i>t</i><sub>R</sub> = 1.52 min.</div></div><div id="sec4_18_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i138" class="anchor-spacer"></div><h4 class="article-section__title" id="_i138"> (2-((3-(2,3-Dimethylphenyl)-1-methyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(4-fluoroisoindolin-2-yl)methanone (<b>9aa</b>)</h4><div class="NLM_p last">Amide bromide <b>8b</b> (66.6 mg, 0.125 mmol, 1 equiv) was coupled to <b>4x</b> (27.7 mg, 0.138 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9aa</b> (17.5 mg, 0.037 mmol) was obtained in 30% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.66 (s, 1H), 9.34 (s, 1H), 7.40–7.30 (m, 1H), 7.25–7.14 (m, 3H), 7.15–7.08 (m, 2H), 7.05 (t, <i>J</i> = 7.5 Hz, 1H), 6.14 (s, 1H), 5.89 (d, <i>J</i> = 2.1 Hz, 1H), 5.68 (d, <i>J</i> = 2.1 Hz, 1H), 4.83–4.70 (m, 4H), 3.17 (s, 3H), 2.30 (s, 3H), 2.26 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.42, 159.39, 157.13 (d, <i>J</i> = 241.2 Hz), 155.58, 149.41, 144.01, 140.43, 136.76, 133.84 (d, <i>J</i> = 4.3 Hz), 129.93, 128.77, 126.89, 125.06, 123.23, 119.19, 113.69 (d, <i>J</i> = 19.2 Hz), 103.74, 99.74, 94.34, 92.89, 34.86, 20.37, 16.59. UPLC/MS [M + H] = 473.751, <i>t</i><sub>R</sub> = 1.54min.</div></div><div id="sec4_18_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i139" class="anchor-spacer"></div><h4 class="article-section__title" id="_i139"> (2-((3-(2,3-Dimethylphenyl)-1-methyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(5-fluoroisoindolin-2-yl)methanone (<b>9ab</b>)</h4><div class="NLM_p last">Amide bromide <b>8c</b> (53.2 mg, 0.1 mmol, 1 equiv) was coupled to <b>4x</b> (22.1 mg, 0.11 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9ab</b> (8.2 mg, 0.017 mmol) was obtained in 17% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.60 (s, 1H), 9.30 (s, 1H), 7.38–7.34 (m, 1H), 7.24–7.18 (m, 2H), 7.17 (s, 1H), 7.13–7.03 (m, 3H), 6.12 (s, 1H), 5.88 (d, <i>J</i> = 2.1 Hz, 1H), 5.66 (d, <i>J</i> = 2.0 Hz, 1H), 5.05–4.42 (m, 4H), 3.60 (s, 3H), 2.29 (s, 3H), 2.26 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.35, 159.28, 155.51, 149.38, 143.93, 140.44, 138.77, 136.74, 133.83 (d, <i>J</i> = 2.8 Hz), 128.75, 126.89, 125.04, 110.01 (d, <i>J</i> = 24.7 Hz), 103.93, 99.74, 94.32, 92.81, 34.85, 20.35, 16.58. UPLC/MS [M + H] = 473.670, <i>t</i><sub>R</sub> = 1.53 min.</div></div><div id="sec4_18_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i140" class="anchor-spacer"></div><h4 class="article-section__title" id="_i140"> (2-((3-(5-Fluoro-2-methylphenyl)-1-methyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9ac</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (77 mg, 0.15 mmol, 1 equiv) was coupled to <b>4y</b> (34 mg, 0.165 mmol, 1.1 equiv) according to General Procedure <b>E1a</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9ac</b> (9 mg, 0.020 mmol) was obtained in 13% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.60 (s, 1H), 9.29 (s, 1H), 7.36–7.22 (m, 6H), 7.20 (s, 1H), 7.01 (td, <i>J</i> = 8.4, 2.9 Hz, 1H), 6.34 (s, 1H), 5.89 (d, <i>J</i> = 2.0 Hz, 1H), 5.66 (d, <i>J</i> = 2.0 Hz, 1H), 4.78–4.70 (m, 4H), 3.61 (s, 3H), 2.41 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 160.37, 154.39 (d, <i>J</i> = 240.2 Hz), 153.23, 149.51, 141.62, 137.82, 134.93, 130.69, 128.85 (d, <i>J</i> = 7.4 Hz), 126.51 (d, <i>J</i> = 7.8 Hz), 124.91 (d, <i>J</i> = 2.8 Hz), 121.23, 116.84, 108.17 (d, <i>J</i> = 21.8 Hz), 107.62 (d, <i>J</i> = 21.1 Hz), 98.17, 93.52, 88.41, 86.87, 29.00, 14.55. UPLC/MS [M + H] = 459.452, <i>t</i><sub>R</sub> = 1.43 min.</div></div><div id="sec4_18_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i141" class="anchor-spacer"></div><h4 class="article-section__title" id="_i141"> (2-((3-(5-Fluoro-2-methylphenyl)-1-methyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(4-fluoroisoindolin-2-yl)methanone (<b>9ad</b>)</h4><div class="NLM_p last">Amide bromide <b>8b</b> (66.6 mg, 0.125 mmol, 1 equiv) was coupled to <b>4y</b> (28.2 mg, 0.138 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9ad</b> (27 mg, 0.056 mmol) was obtained in 45% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.66 (s, 1H), 9.34 (s, 1H), 7.36–7.30 (m, 1H), 7.30–7.26 (m, 1H), 7.26–7.21 (m, 2H), 7.20–7.15 (m, 1H), 7.08 (t, <i>J</i> = 8.8 Hz, 1H), 7.00 (td, <i>J</i> = 8.4, 2.9 Hz, 1H), 6.34 (s, 1H), 5.90 (d, <i>J</i> = 2.1 Hz, 1H), 5.68 (d, <i>J</i> = 2.1 Hz, 1H), 4.87–4.71 (m, 4H), 3.62 (s, 3H), 2.40 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.39, 160.39 (d, <i>J</i> = 240.5 Hz), 159.37, 147.62 (d, <i>J</i> = 2.3 Hz), 143.98, 140.95, 134.80 (d, <i>J</i> = 7.9 Hz), 132.51 (d, <i>J</i> = 8.0 Hz), 130.88 (d, <i>J</i> = 2.9 Hz), 129.85, 119.14, 114.12 (d, <i>J</i> = 22.1 Hz), 113.71 (d, <i>J</i> = 7.1 Hz), 113.55 (d, <i>J</i> = 8.8 Hz), 103.85, 99.51, 94.43, 93.12, 89.17 (d, <i>J</i> = 104.5 Hz), 35.02, 20.57. UPLC/MS [M + H] = 477.489, <i>t</i><sub>R</sub> = 1.53 min.</div></div><div id="sec4_18_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i142" class="anchor-spacer"></div><h4 class="article-section__title" id="_i142"> (2-((3-(5-Fluoro-2-methylphenyl)-1-methyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(5-fluoroisoindolin-2-yl)methanone (<b>9ae</b>)</h4><div class="NLM_p last">Amide bromide <b>8c</b> (66.6 mg, 0.125 mmol, 1 equiv) was coupled to <b>4y</b> (28.2 mg, 0.138 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9ae</b> (19 mg, 0.40 mmol) was obtained in 32% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.61 (s, 1H), 9.30 (s, 1H), 7.37–7.31 (m, 1H), 7.29–7.25 (m, 1H), 7.25–7.22 (m, 1H), 7.22–7.16 (m, 2H), 7.12–7.04 (m, 1H), 7.04–6.98 (m, 1H), 6.32 (s, 1H), 5.89 (d, <i>J</i> = 2.1 Hz, 1H), 5.66 (d, <i>J</i> = 2.1 Hz, 1H), 4.80–4.65 (m, 4H), 3.62 (s, 3H), 2.40 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.32, 160.35 (d, <i>J</i> = 240.5 Hz), 159.26, 155.54, 147.60 (d, <i>J</i> = 2.4 Hz), 143.90, 140.96, 134.80 (d, <i>J</i> = 7.7 Hz), 132.49 (d, <i>J</i> = 8.1 Hz), 130.87 (d, <i>J</i> = 2.9 Hz), 124.50 (d, <i>J</i> = 8.8 Hz), 114.22, 114.05, 113.67, 113.51, 109.96 (d, <i>J</i> = 23.2 Hz), 104.03, 99.51, 94.41, 93.04, 35.01, 20.56. UPLC/MS [M + H] = 477.489, <i>t</i><sub>R</sub> = 1.52 min.</div></div><div id="sec4_18_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i143" class="anchor-spacer"></div><h4 class="article-section__title" id="_i143"> (2-((3-(2-Fluoro-3-methylphenyl)-1-methyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9af</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (77 mg, 0.150 mmol, 1 equiv) was coupled to <b>4z</b> (33.8 mg, 0.165 mmol, equiv) according to General Procedure <b>E1a</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9af</b> (13.7 mg, 0.030 mmol) was obtained in 20% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.61 (s, 1H), 9.29 (s, 1H), 7.74–7.67 (m, 1H), 7.35–7.29 (m, 2H), 7.29–7.23 (m, 2H), 7.21 (s, 1H), 7.20–7.15 (m, 1H), 7.08 (t, <i>J</i> = 7.6 Hz, 1H), 6.35 (d, <i>J</i> = 4.1 Hz, 1H), 5.89 (d, <i>J</i> = 2.1 Hz, 1H), 5.64 (d, <i>J</i> = 2.0 Hz, 1H), 4.81–4.67 (m, 4H), 3.62 (s, 3H), 2.24 (d, <i>J</i> = 2.1 Hz, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.33, 159.21, 157.64 (d, <i>J</i> = 246.4 Hz), 155.51, 143.78, 142.88, 141.33, 130.20, 127.19, 125.07–124.96 (m), 124.79 (d, <i>J</i> = 17.8 Hz), 123.88, 122.81, 120.73, 104.26, 99.46, 94.47, 35.04, 14.29 (d, <i>J</i> = 5.0 Hz). UPLC/MS [M + H] = 459.496, <i>t</i><sub>R</sub> = 1.49 min.</div></div><div id="sec4_18_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i144" class="anchor-spacer"></div><h4 class="article-section__title" id="_i144"> (2-((3-(2-Fluoro-3-methylphenyl)-1-methyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(4-fluoroisoindolin-2-yl)methanone (<b>9ag</b>)</h4><div class="NLM_p last">Amide bromide <b>8b</b> (66.6 mg, 0.125 mmol, 1 equiv) was coupled to <b>4z</b> (28.2 mg, 0.138 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9ag</b> (39 mg, 0.082 mmol) was obtained in 66% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.68–9.64 (m, 1H), 9.34 (s, 1H), 7.73–7.66 (m, 1H), 7.35–7.27 (m, 1H), 7.25 (s, 1H), 7.20–7.13 (m, 2H), 7.10–7.03 (m, 2H), 6.33 (d, <i>J</i> = 4.1 Hz, 1H), 5.91 (d, <i>J</i> = 2.1 Hz, 1H), 5.68 (d, <i>J</i> = 2.0 Hz, 1H), 4.87–4.67 (m, 4H), 3.63 (s, 3H), 2.23 (d, <i>J</i> = 2.1 Hz, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.36, 159.34, 157.65 (d, <i>J</i> = 247.1 Hz), 155.61, 144.25, 142.85, 141.38, 130.21, 124.92 (d, <i>J</i> = 4.1 Hz), 124.76, 123.87 (d, <i>J</i> = 3.6 Hz), 120.73 (d, <i>J</i> = 12.5 Hz), 119.08, 113.59 (d, <i>J</i> = 19.1 Hz), 103.95, 99.49 (d, <i>J</i> = 10.2 Hz), 94.50, 93.29, 79.16, 35.05, 14.28 (d, <i>J</i> = 4.8 Hz). UPLC/MS [M + H] = 477.489, <i>t</i><sub>R</sub> = 1.44 min.</div></div><div id="sec4_18_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i145" class="anchor-spacer"></div><h4 class="article-section__title" id="_i145"> (2-((3-(2-Fluoro-3-methylphenyl)-1-methyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(5-fluoroisoindolin-2-yl)methanone (<b>9ah</b>)</h4><div class="NLM_p last">Amide bromide <b>8c</b> (53.2 mg, 0.1 mmol, 1 equiv) was coupled to <b>4z</b> (22.6 mg, 0.11 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9ah</b> (18 mg, 0.038 mmol) was obtained in 38% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.62 (s, 1H), 9.26 (s, 0H), 7.73–7.66 (m, 1H), 7.35–7.29 (m, 1H), 7.22 (s, 1H), 7.20–7.12 (m, 2H), 7.11–7.02 (m, 2H), 6.32 (d, <i>J</i> = 4.1 Hz, 1H), 5.89 (d, <i>J</i> = 2.1 Hz, 1H), 5.66 (d, <i>J</i> = 2.1 Hz, 1H), 4.84–4.56 (m, 4H), 3.63 (s, 3H), 2.24 (d, <i>J</i> = 2.1 Hz, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.30, 160.78, 159.24, 156.66 (d, <i>J</i> = 244.7 Hz), 155.55, 143.88, 142.11 (d, <i>J</i> = 181.7 Hz), 130.16, 125.03–124.87 (m), 124.75 (d, <i>J</i> = 7.8 Hz), 124.41, 123.85 (d, <i>J</i> = 4.3 Hz), 120.74 (d, <i>J</i> = 12.4 Hz), 114.34 (d, <i>J</i> = 24.9 Hz), 109.81 (d, <i>J</i> = 25.6 Hz), 104.12, 99.50 (d, <i>J</i> = 10.4 Hz), 94.48, 93.18, 35.05, 14.26 (d, <i>J</i> = 4.8 Hz). UPLC/MS [M + H] = 477.445, <i>t</i><sub>R</sub> = 1.51 min.</div></div><div id="sec4_18_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i146" class="anchor-spacer"></div><h4 class="article-section__title" id="_i146"> (2-((3-(2,3-Difluorophenyl)-1-methyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9ai</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (77 mg, 0.150 mmol, 1 equiv) was coupled to <b>4aa</b> (34.5 mg, 0.165 mmol, 1.1 equiv) according to General Procedure <b>E1a</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9ai</b> (5.7 mg, 0.012 mmol) was obtained in 8% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.61 (s, 1H), 9.30 (s, 1H), 7.70–7.63 (m, 1H), 7.35–7.28 (m, 3H), 7.27–7.22 (m, 3H), 7.22–7.16 (m, 1H), 6.37 (d, <i>J</i> = 3.7 Hz, 1H), 5.90 (d, <i>J</i> = 2.0 Hz, 1H), 5.65 (d, <i>J</i> = 2.1 Hz, 1H), 4.79–4.66 (m, 4H), 3.64 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.28, 159.19, 155.53, 143.71, 141.77, 136.38, 132.64, 127.16, 124.43, 122.90, 122.78, 104.41, 94.60, 93.20, 35.16. UPLC/MS [M + H] = 463.241, <i>t</i><sub>R</sub> = 1.45 min.</div></div><div id="sec4_18_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i147" class="anchor-spacer"></div><h4 class="article-section__title" id="_i147"> (2,4-Dihydroxy-6-((1-methyl-3-(2-methyl-3-(trifluoromethyl)phenyl)-1<i>H</i>-pyrazol-5-yl)amino)phenyl)(isoindolin-2-yl)methanone (<b>9aj</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (64 mg, 0.125 mmol, 1 equiv) was coupled to <b>4ab</b> (35 mg, 0.138 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9aj</b> (3.4 mg, 0.007 mmol) was obtained in 6% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.60 (s, 1H), 9.30 (s, 1H), 7.66 (t, <i>J</i> = 7.8 Hz, 2H), 7.38 (t, <i>J</i> = 7.8 Hz, 1H), 7.34–7.31 (m, 3H), 7.31–7.25 (m, 2H), 7.23 (s, 1H), 6.27 (s, 1H), 5.89 (d, <i>J</i> = 2.1 Hz, 1H), 5.68 (d, <i>J</i> = 2.0 Hz, 1H), 4.83–4.69 (m, 4H), 3.62 (s, 3H), 2.49 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.34, 159.22, 155.52, 147.64, 143.75, 140.96, 136.17, 133.85, 133.27, 127.23, 125.93, 122.84, 104.25, 100.08, 94.47, 93.01, 34.99, 16.38; <sup>19</sup>F NMR (470 MHz, DMSO-<i>d</i><sub>6</sub>): δ −59.28. UPLC/MS [M + H] = 509.514, <i>t</i><sub>R</sub> = 1.56 min.</div></div><div id="sec4_18_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i148" class="anchor-spacer"></div><h4 class="article-section__title" id="_i148"> (2-((3-(3-Chloro-2-fluorophenyl)-1-methyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9ak</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (64 mg, 0.125 mmol, 1 equiv) was coupled to <b>4ac</b> (31 mg, 0.138 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2b</b>. <b>9ak</b> (18 mg, 0.037 mmol) was obtained in 30% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.62 (s, 1H), 9.31 (s, 1H), 7.87–7.80 (m, 1H), 7.51–7.44 (m, 1H), 7.33–7.27 (m, 2H), 7.27–7.19 (m, 4H), 6.38 (d, <i>J</i> = 4.0 Hz, 1H), 5.90 (d, <i>J</i> = 2.1 Hz, 1H), 5.66 (d, <i>J</i> = 2.1 Hz, 1H), 4.87–4.60 (m, 4H), 3.64 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.29, 159.20, 155.55, 154.13 (d, <i>J</i> = 250.7 Hz), 143.69, 141.84–141.68 (m), 136.63, 129.05, 127.16, 126.21 (d, <i>J</i> = 3.6 Hz), 125.29 (d, <i>J</i> = 4.3 Hz), 122.86, 122.77, 120.45 (d, <i>J</i> = 18.0 Hz), 104.41, 99.55 (d, <i>J</i> = 9.8 Hz), 94.61, 93.22, 35.18; <sup>19</sup>F NMR (470 MHz, DMSO-<i>d</i><sub>6</sub>) δ −116.80 to −124.29 (m). UPLC/MS [M + H] = 479.219, <i>t</i><sub>R</sub> = 1.46 min.</div></div><div id="sec4_18_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i149" class="anchor-spacer"></div><h4 class="article-section__title" id="_i149"> (2-((3-(2-Fluoro-3-(trifluoromethoxy)phenyl)-1-methyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9al</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (64 mg, 0.125 mmol, 1 equiv) was coupled to <b>4ad</b> (38 mg, 0.138 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9al</b> (29 mg, 0.056 mmol) was obtained in 45% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.63 (s, 1H), 9.32 (s, 1H), 7.93–7.86 (m, 1H), 7.49–7.41 (m, 1H), 7.34–7.20 (m, 6H), 6.40 (d, <i>J</i> = 3.7 Hz, 1H), 5.91 (d, <i>J</i> = 2.1 Hz, 1H), 5.67 (d, <i>J</i> = 2.1 Hz, 1H), 4.81–4.64 (m, 4H), 3.65 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.32, 159.23, 155.57, 150.83 (d, <i>J</i> = 254.4 Hz), 143.69, 141.93 (d, <i>J</i> = 1.9 Hz), 141.50, 136.65, 136.23–136.00 (m), 127.18, 126.41 (d, <i>J</i> = 3.3 Hz), 125.00 (d, <i>J</i> = 4.5 Hz), 123.32 (d, <i>J</i> = 9.5 Hz), 122.79, 122.19, 121.12, 119.07, 104.49, 99.50 (d, <i>J</i> = 9.2 Hz), 94.68, 93.28, 35.22; <sup>19</sup>F NMR (470 MHz, DMSO-<i>d</i><sub>6</sub>) δ −57.82 (d, <i>J</i> = 4.9 Hz), −134.22 to −134.33 (m). UPLC/MS [M + H] = 529.562, <i>t</i><sub>R</sub> = 1.54 min.</div></div><div id="sec4_18_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i150" class="anchor-spacer"></div><h4 class="article-section__title" id="_i150"> (2-((3-(2,5-Difluorophenyl)-1-methyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9am</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (77 mg, 0.150 mmol, 1 equiv) was coupled to <b>4ae</b> (34.5 mg, 0.165 mmol, 1.1 equiv) according to General Procedure <b>E1a</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9am</b> (14.6 mg, 0.032 mmol) was obtained in 21% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.62 (s, 1H), 9.30 (s, 1H), 7.62–7.56 (m, 1H), 7.34–7.23 (m, 6H), 7.19–7.11 (m, 1H), 6.38 (d, <i>J</i> = 4.0 Hz, 1H), 5.90 (d, <i>J</i> = 2.1 Hz, 1H), 5.63 (d, <i>J</i> = 2.1 Hz, 1H), 4.84–4.60 (m, 4H), 3.64 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.28, 159.19, 157.26, 155.53, 154.23 (d, <i>J</i> = 243.9 Hz), 143.70, 141.85 (d, <i>J</i> = 2.4 Hz), 141.70, 127.19, 122.80, 118.04–117.56 (m), 115.52–114.98 (m), 113.10–112.60 (m), 104.44, 99.60 (d, <i>J</i> = 10.1 Hz), 94.61, 93.15, 35.17 (d, <i>J</i> = 241.7 Hz); <sup>19</sup>F NMR (470 MHz, DMSO-<i>d</i><sub>6</sub>) δ −118.66 to −118.78 (m), −121.71 to −121.84 (m) UPLC/MS [M + H] = 463.241, <i>t</i><sub>R</sub> = 1.46 min.</div></div><div id="sec4_18_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i151" class="anchor-spacer"></div><h4 class="article-section__title" id="_i151"> (2-((3-(2-Chloro-5-fluorophenyl)-1-methyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9an</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (64 mg, 0.125 mmol, 1 equiv) was coupled to <b>4af</b> (31 mg, 0.138 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2b</b>. <b>9an</b> (18 mg, 0.038 mmol) was obtained in 30% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.62 (s, 1H), 9.32 (s, 1H), 7.56–7.48 (m, 2H), 7.33–7.29 (m, 2H), 7.28–7.22 (m, 3H), 7.22–7.15 (m, 1H), 6.56 (s, 1H), 5.91 (d, <i>J</i> = 2.1 Hz, 1H), 5.66 (d, <i>J</i> = 2.0 Hz, 1H), 4.80–4.69 (m, 4H), 3.64 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.30, 160.66 (d, <i>J</i> = 243.7 Hz), 159.21, 155.54, 144.63 (d, <i>J</i> = 1.9 Hz), 143.70, 141.25, 136.60, 133.85 (d, <i>J</i> = 8.5 Hz), 132.11 (d, <i>J</i> = 8.7 Hz), 127.21, 125.85 (d, <i>J</i> = 3.0 Hz), 122.82, 115.74 (d, <i>J</i> = 22.7 Hz), 115.64 (d, <i>J</i> = 22.1 Hz), 104.43, 100.19, 94.61, 93.12, 35.15; <sup>19</sup>F NMR (470 MHz, DMSO-<i>d</i><sub>6</sub>) δ −115.27 to −115.40 (m). UPLC/MS [M + H] = 479.259, <i>t</i><sub>R</sub> = 1.53 min.</div></div><div id="sec4_18_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i152" class="anchor-spacer"></div><h4 class="article-section__title" id="_i152"> (2-((3-(5-Chloro-2-fluorophenyl)-1-methyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9ao</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (64 mg, 0.125 mmol, 1 equiv) was coupled to <b>4ag</b> (31 mg, 0.138 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2b</b>. <b>9ao</b> (18 mg, 0.037 mmol) was obtained in 30% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.63 (s, 1H), 9.32 (s, 1H), 7.89–7.82 (m, 1H), 7.39–7.33 (m, 1H), 7.33–7.21 (m, 6H), 6.38 (d, <i>J</i> = 4.0 Hz, 1H), 5.91 (d, <i>J</i> = 2.1 Hz, 1H), 5.65 (d, <i>J</i> = 2.1 Hz, 1H), 4.96–4.53 (m, 4H), 3.64 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.30, 159.21, 157.66 (d, <i>J</i> = 248.4 Hz), 155.55, 143.69, 141.92 (d, <i>J</i> = 2.3 Hz), 141.36 (d, <i>J</i> = 2.1 Hz), 136.61, 128.57–128.40 (m), 127.19, 126.41 (d, <i>J</i> = 4.3 Hz), 122.87 (d, <i>J</i> = 13.3 Hz), 122.79, 118.19 (d, <i>J</i> = 24.2 Hz), 104.49, 99.62 (d, <i>J</i> = 9.9 Hz), 94.67, 93.25, 35.20; <sup>19</sup>F NMR (470 MHz, DMSO-<i>d</i><sub>6</sub>) δ −118.55 to −118.64 (m). UPLC/MS [M + H] = 479.219, <i>t</i><sub>R</sub> = 1.57 min.</div></div><div id="sec4_18_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i153" class="anchor-spacer"></div><h4 class="article-section__title" id="_i153"> (2-((3-(2-Fluoro-5-methylphenyl)-1-methyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9ap</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (77 mg, 0.150 mmol, 1 equiv) was coupled to <b>4ah</b> (33.9 mg, 0.165 mmol, 1.1 equiv) according to General Procedure <b>E1a</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9ap</b> (12.5 mg, 0.027 mmol) was obtained in 18% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.60 (s, 1H), 9.29 (s, 1H), 7.72–7.66 (m, 1H), 7.37–7.30 (m, 2H), 7.30–7.23 (m, 2H), 7.19 (s, 1H), 7.14–7.05 (m, 2H), 6.33 (d, <i>J</i> = 3.9 Hz, 1H), 5.89 (d, <i>J</i> = 2.1 Hz, 1H), 5.63 (d, <i>J</i> = 2.1 Hz, 1H), 4.82–4.67 (m, 4H), 3.62 (s, 3H), 2.30 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.32, 159.20, 156.44 (d, <i>J</i> = 244.4 Hz), 155.49, 143.78, 142.78, 141.37 (d, <i>J</i> = 2.1 Hz), 133.37 (d, <i>J</i> = 3.2 Hz), 129.35, 127.55 (d, <i>J</i> = 4.1 Hz), 127.21, 120.56 (d, <i>J</i> = 11.9 Hz), 115.75 (d, <i>J</i> = 22.3 Hz), 104.31, 99.55, 94.48, 92.90, 35.03, 20.22. UPLC/MS [M + H] = 459.256, <i>t</i><sub>R</sub> = 1.52 min.</div></div><div id="sec4_18_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i154" class="anchor-spacer"></div><h4 class="article-section__title" id="_i154"> (2-((3-(2-Fluoro-5-(trifluoromethyl)phenyl)-1-methyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9aq</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (64 mg, 0.125 mmol, 1 equiv) was coupled to <b>4ai</b> (36 mg, 0.138 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9aq</b> (36 mg, 0.071 mmol) was obtained in 57% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.66 (s, 1H), 9.34 (s, 1H), 8.21–8.15 (m, 1H), 7.72–7.65 (m, 1H), 7.49–7.41 (m, 1H), 7.28 (q, <i>J</i> = 3.2 Hz, 3H), 7.25–7.17 (m, 2H), 6.42 (d, <i>J</i> = 4.1 Hz, 1H), 5.93 (d, <i>J</i> = 2.1 Hz, 1H), 5.68 (s, 1H), 4.72 (s, 4H), 3.67 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.78, 161.24 (d, <i>J</i> = 254.5 Hz), 159.68, 156.06, 144.19, 142.61 (d, <i>J</i> = 2.3 Hz), 141.56, 137.13, 127.62, 126.55–125.77 (m), 125.39, 124.86–124.44 (m), 123.21 (d, <i>J</i> = 3.0 Hz), 122.48 (d, <i>J</i> = 13.2 Hz), 118.08 (d, <i>J</i> = 23.5 Hz), 105.03, 100.17 (d, <i>J</i> = 10.3 Hz), 95.20, 93.91, 49.04, 35.69. UPLC/MS [M + H] = 513.212, <i>t</i><sub>R</sub> = 1.63 min.</div></div><div id="sec4_18_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i155" class="anchor-spacer"></div><h4 class="article-section__title" id="_i155"> (2-((3-(2-Fluoro-5-(trifluoromethoxy)phenyl)-1-methyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9ar</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (64 mg, 0.125 mmol, 1 equiv) was coupled to <b>4aj</b> (38 mg, 0.138 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9ar</b> (33 mg, 0.063 mmol) was obtained in 50% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.64 (d, <i>J</i> = 1.3 Hz, 1H), 9.32 (s, 1H), 7.82–7.76 (m, 1H), 7.40–7.19 (m, 7H), 6.40 (d, <i>J</i> = 4.1 Hz, 1H), 5.91 (d, <i>J</i> = 2.1 Hz, 1H), 5.65 (d, <i>J</i> = 2.0 Hz, 1H), 4.84–4.62 (m, 4H), 3.65 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.31, 159.22, 157.27 (d, <i>J</i> = 248.5 Hz), 155.58, 144.54–144.35 (m), 143.74, 142.08 (d, <i>J</i> = 2.3 Hz), 141.25 (d, <i>J</i> = 2.2 Hz), 136.71, 127.18, 122.78, 122.65, 121.59 (d, <i>J</i> = 8.6 Hz), 121.09, 119.21 (d, <i>J</i> = 5.1 Hz), 119.05, 118.12 (d, <i>J</i> = 24.9 Hz), 104.53, 99.71 (d, <i>J</i> = 10.5 Hz), 94.70, 93.34, 35.23; <sup>19</sup>F NMR (470 MHz, DMSO-<i>d</i><sub>6</sub>) δ −57.20, −117.44 to −117.53 (m). UPLC/MS [M + H] = 529.529, <i>t</i><sub>R</sub> = 1.66 min.</div></div><div id="sec4_18_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i156" class="anchor-spacer"></div><h4 class="article-section__title" id="_i156"> (2-((3-(2,6-Difluorophenyl)-1-methyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9as</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (45 mg, 0.087 mmol, 1 equiv) was coupled to <b>4ak</b> (20 mg, 0.096 mmol, 1.1 equiv) according to General Procedure <b>E1a</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9as</b> (20.6 mg, 0.045 mmol) was obtained in 52% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.63 (s, 1H), 9.33 (s, 1H), 7.44–7.36 (m, 1H), 7.32 (s, 2H), 7.30–7.24 (m, 2H), 7.24–7.17 (m, 1H), 7.14 (t, <i>J</i> = 8.3 Hz, 2H), 6.27–6.23 (m, 1H), 5.89 (d, <i>J</i> = 2.1 Hz, 1H), 5.61 (d, <i>J</i> = 2.1 Hz, 1H), 4.87–4.56 (m, 4H), 3.62 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.35, 159.73 (dd, <i>J</i> = 249.7, 7.3 Hz), 159.25, 155.53, 143.72, 140.91, 137.83, 129.40, 127.26, 112.02 (d, <i>J</i> = 25.9 Hz), 112.02 (d, <i>J</i> = 15.0 Hz), 111.43, 104.32, 101.85–100.61 (m), 94.52, 92.84, 35.13; <sup>19</sup>F NMR (470 MHz, DMSO-<i>d</i><sub>6</sub>) δ −112.05 to −112.16 (m). UPLC/MS [M + H] = 463.225, <i>t</i><sub>R</sub> = 1.36 min.</div></div><div id="sec4_18_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i157" class="anchor-spacer"></div><h4 class="article-section__title" id="_i157"> (2-((3-(4-Chloro-2-fluorophenyl)-1-methyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9at</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (64 mg, 0.125 mmol, 1 equiv) was coupled to <b>4al</b> (31 mg, 0.138 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2b</b>. <b>9at</b> (7 mg, 0.014 mmol) was obtained in 11% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.61 (s, 1H), 9.30 (s, 1H), 7.89 (t, <i>J</i> = 8.5 Hz, 1H), 7.46–7.40 (m, 1H), 7.32–7.21 (m, 6H), 6.34 (d, <i>J</i> = 4.0 Hz, 1H), 5.89 (d, <i>J</i> = 2.1 Hz, 1H), 5.63 (d, <i>J</i> = 2.1 Hz, 1H), 4.87–4.52 (m, 4H), 3.63 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.29, 159.20, 157.79 (d, <i>J</i> = 250.8 Hz), 155.53, 143.72, 141.72 (t, <i>J</i> = 2.5 Hz), 136.72, 132.15 (d, <i>J</i> = 10.5 Hz), 128.50 (d, <i>J</i> = 4.6 Hz), 127.18, 124.84 (d, <i>J</i> = 3.2 Hz), 122.80, 120.19 (d, <i>J</i> = 11.8 Hz), 116.65 (d, <i>J</i> = 26.1 Hz), 104.39, 99.42 (d, <i>J</i> = 9.7 Hz), 94.58, 93.11, 35.14; <sup>19</sup>F NMR (470 MHz, DMSO-<i>d</i><sub>6</sub>) δ −113.56 to −113.67 (m). UPLC/MS [M + H] = 479.259, <i>t</i><sub>R</sub> = 1.58 min.</div></div><div id="sec4_18_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i158" class="anchor-spacer"></div><h4 class="article-section__title" id="_i158"> (2-((3-(2-Chloro-4-fluorophenyl)-1-methyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9au</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (64 mg, 0.125 mmol, 1 equiv) was coupled to <b>4am</b> (31 mg, 0.138 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2b</b>. <b>9au</b> (18 mg, 0.037 mmol) was obtained in 30% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.62 (s, 1H), 9.31 (s, 1H), 7.80–7.74 (m, 1H), 7.45 (dd, <i>J</i> = 8.9, 2.7 Hz, 1H), 7.32 (s, 2H), 7.29–7.20 (m, 4H), 6.45 (s, 1H), 5.90 (d, <i>J</i> = 2.1 Hz, 1H), 5.66 (d, <i>J</i> = 2.0 Hz, 1H), 4.85–4.64 (m, 4H), 3.62 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.33, 160.98 (d, <i>J</i> = 247.9 Hz), 159.22, 155.53, 144.92, 143.74, 140.96, 136.58, 131.46 (d, <i>J</i> = 10.5 Hz), 131.29 (d, <i>J</i> = 8.7 Hz), 128.94 (d, <i>J</i> = 3.4 Hz), 127.22, 122.84, 117.17 (d, <i>J</i> = 24.9 Hz), 114.56 (d, <i>J</i> = 21.1 Hz), 104.33, 99.96, 94.54, 93.00, 35.04; <sup>19</sup>F NMR (470 MHz, DMSO-<i>d</i><sub>6</sub>) δ −113.06 to −113.20 (m). UPLC/MS [M + H] = 479.219, <i>t</i><sub>R</sub> = 1.52 min.</div></div><div id="sec4_18_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i159" class="anchor-spacer"></div><h4 class="article-section__title" id="_i159"> (2-((1-(<i>tert</i>-Butyl)-3-(2,3-dimethylphenyl)-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9av</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (64 mg, 0.125 mmol, 1 equiv) was coupled to <b>4ao</b> (33 mg, 0.138 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9av</b> (31 mg, 0.063 mmol) was obtained in 50% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.68 (s, 1H), 9.30 (s, 1H), 7.37–7.32 (m, 2H), 7.32–7.25 (m, 3H), 7.16–7.05 (m, 2H), 6.99 (s, 1H), 6.24 (s, 1H), 5.86 (d, <i>J</i> = 2.1 Hz, 1H), 5.72 (d, <i>J</i> = 2.1 Hz, 1H), 4.89–4.75 (m, 4H), 2.34 (s, 3H), 2.27 (s, 3H), 1.55 (s, 9H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.92, 159.44, 147.76, 145.08, 139.31, 136.86, 136.70, 133.91, 133.87, 128.68, 127.27, 126.89, 125.09, 122.85, 103.17, 103.03, 93.79, 92.11, 79.17, 59.17, 29.48, 20.43, 16.60. UPLC/MS [M + H] = 497.600, <i>t</i><sub>R</sub> = 1.80 min.</div></div><div id="sec4_18_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i160" class="anchor-spacer"></div><h4 class="article-section__title" id="_i160"> (2-((3-(5-Fluoro-2-methylphenyl)-1-isopropyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9aw</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (64 mg, 0.125 mmol, 1 equiv) was coupled to <b>4ap</b> (32 mg, 0.138 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9aw</b> (40 mg, 0.083 mmol) was obtained in 66% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.63 (s, 1H), 9.30 (s, 1H), 7.38–7.29 (m, 3H), 7.30–7.22 (m, 3H), 7.13 (s, 1H), 7.05–6.97 (m, 1H), 6.35 (s, 1H), 5.88 (d, <i>J</i> = 2.1 Hz, 1H), 5.63 (d, <i>J</i> = 2.1 Hz, 1H), 4.87–4.69 (m, 4H), 4.51–4.40 (m, <i>J</i> = 6.9 Hz, 1H), 2.44 (s, 3H), 1.35 (d, <i>J</i> = 6.5 Hz, 6H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.48, 160.43 (d, <i>J</i> = 240.5 Hz), 159.26, 155.56, 147.71 (d, <i>J</i> = 2.4 Hz), 144.58, 139.50, 136.72, 135.06 (d, <i>J</i> = 7.9 Hz), 132.59 (d, <i>J</i> = 8.0 Hz), 130.93 (d, <i>J</i> = 2.9 Hz), 127.25, 122.85, 114.15 (d, <i>J</i> = 22.0 Hz), 113.51 (d, <i>J</i> = 20.7 Hz), 103.90, 100.20, 94.21, 92.57, 47.90, 22.20, 20.66; <sup>19</sup>F NMR (470 MHz, DMSO-<i>d</i><sub>6</sub>) δ −117.99 to −118.09 (m). UPLC/MS [M + H] = 487.545, <i>t</i><sub>R</sub> = 1.70 min.</div></div><div id="sec4_18_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i161" class="anchor-spacer"></div><h4 class="article-section__title" id="_i161"> (2-((1-(<i>tert</i>-Butyl)-3-(5-fluoro-2-methylphenyl)-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9ax</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (64 mg, 0.125 mmol, 1 equiv) was coupled to <b>4aq</b> (34 mg, 0.138 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9ax</b> (35.5 mg, 0.067 mmol) was obtained in 54% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.70 (s, 1H), 9.29 (s, 1H), 7.40–7.32 (m, 3H), 7.32–7.22 (m, 3H), 7.05–6.97 (m, 2H), 6.47 (s, 1H), 5.86 (d, <i>J</i> = 2.1 Hz, 1H), 5.70 (d, <i>J</i> = 2.1 Hz, 1H), 4.95–4.62 (m, 4H), 3.35 (s, 3H), 2.46 (s, 3H), 1.56 (s, 9H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.90, 160.47 (d, <i>J</i> = 240.3 Hz), 159.45, 155.56, 146.05 (d, <i>J</i> = 2.4 Hz), 145.01, 139.78, 136.68, 134.88 (d, <i>J</i> = 7.7 Hz), 132.67 (d, <i>J</i> = 7.9 Hz), 130.90 (d, <i>J</i> = 2.9 Hz), 127.28, 122.85, 114.10 (d, <i>J</i> = 22.0 Hz), 113.48 (d, <i>J</i> = 20.8 Hz), 103.08, 102.94, 93.86, 92.18, 59.47, 29.38, 20.82; <sup>19</sup>F NMR (470 MHz, DMSO-<i>d</i><sub>6</sub>) δ −117.90 to −118.08 (m). UPLC/MS [M + H] = 501.569, <i>t</i><sub>R</sub> = 1.87 min.</div></div><div id="sec4_18_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i162" class="anchor-spacer"></div><h4 class="article-section__title" id="_i162"> (2-((1-Cyclopentyl-3-(5-fluoro-2-methylphenyl)-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9ay</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (64 mg, 0.125 mmol, 1 equiv) was coupled to <b>4ar</b> (36 mg, 0.138 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9ay</b> (31 mg, 0.060 mmol) was obtained in 50% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.64 (s, 1H), 9.31 (s, 1H), 7.39–7.30 (m, 3H), 7.30–7.22 (m, 3H), 7.15 (s, 1H), 7.04–6.97 (m, 1H), 6.36 (s, 1H), 5.88 (d, <i>J</i> = 2.1 Hz, 1H), 5.63 (d, <i>J</i> = 2.1 Hz, 1H), 4.87–4.69 (m, 4H), 4.61 (p, <i>J</i> = 7.1 Hz, 1H), 2.44 (s, 3H), 1.92 (s, 4H), 1.87–1.76 (m, 2H), 1.59–1.50 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.50, 160.44 (d, <i>J</i> = 240.3 Hz), 159.25, 155.56, 147.70 (d, <i>J</i> = 2.3 Hz), 144.43, 140.18, 136.71, 134.96 (d, <i>J</i> = 7.7 Hz), 132.62 (d, <i>J</i> = 8.0 Hz), 130.92 (d, <i>J</i> = 2.8 Hz), 127.26, 122.84, 114.17 (d, <i>J</i> = 21.9 Hz), 113.51 (d, <i>J</i> = 20.7 Hz), 103.93, 100.05, 94.28, 92.72, 57.03, 32.28, 24.18, 20.72; <sup>19</sup>F NMR (470 MHz, DMSO-<i>d</i><sub>6</sub>) δ −117.94 to −118.06 (m). UPLC/MS [M + H] = 513.564, <i>t</i><sub>R</sub> = 1.83 min.</div></div><div id="sec4_18_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i163" class="anchor-spacer"></div><h4 class="article-section__title" id="_i163"> (2-((1-Cyclohexyl-3-(5-fluoro-2-methylphenyl)-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9az</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (64 mg, 0.125 mmol, 1 equiv) was coupled to <b>4as</b> (38 mg, 0.138 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9az</b> (35 mg, 0.066 mmol) was obtained in 53% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.60 (s, 1H), 9.28 (s, 1H), 7.36–7.29 (m, 3H), 7.30–7.21 (m, 3H), 7.11 (s, 1H), 7.00 (td, <i>J</i> = 8.4, 2.9 Hz, 1H), 6.36 (s, 1H), 5.87 (d, <i>J</i> = 2.1 Hz, 1H), 5.64 (d, <i>J</i> = 2.1 Hz, 1H), 4.87–4.70 (m, 4H), 4.07–4.00 (m, 1H), 2.43 (s, 3H), 1.90–1.70 (m, 6H), 1.64–1.55 (m, 1H), 1.25–1.12 (m, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.47, 160.42 (d, <i>J</i> = 240.3 Hz), 159.20, 155.52, 147.59 (d, <i>J</i> = 2.1 Hz), 144.50, 139.62, 136.65, 135.02 (d, <i>J</i> = 7.7 Hz), 132.57 (d, <i>J</i> = 7.9 Hz), 130.91 (d, <i>J</i> = 2.9 Hz), 127.25, 122.82, 114.13 (d, <i>J</i> = 22.0 Hz), 113.47 (d, <i>J</i> = 20.6 Hz), 103.99, 100.25, 94.25, 92.65, 55.33, 32.27, 25.05, 24.89, 20.69; <sup>19</sup>F NMR (470 MHz, DMSO-<i>d</i><sub>6</sub>) δ −118.01 to −118.16 (m). UPLC/MS [M + H] = 527.578, <i>t</i><sub>R</sub> = 1.90 min.</div></div><div id="sec4_18_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i164" class="anchor-spacer"></div><h4 class="article-section__title" id="_i164"> (2-((3-(2-Fluoro-3-methylphenyl)-1-isopropyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9ba</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (64 mg, 0.125 mmol, 1 equiv) was coupled to <b>4at</b> (32 mg, 0.138 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9ba</b> (38 mg, 0.078 mmol) was obtained in 65% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.62 (s, 1H), 9.29 (s, 1H), 7.79–7.71 (m, 1H), 7.36–7.30 (m, 2H), 7.30–7.23 (m, 2H), 7.21–7.15 (m, 1H), 7.14 (s, 1H), 7.09 (t, <i>J</i> = 7.6 Hz, 1H), 6.34 (d, <i>J</i> = 4.1 Hz, 1H), 5.87 (d, <i>J</i> = 2.1 Hz, 1H), 5.61 (d, <i>J</i> = 2.1 Hz, 1H), 4.85–4.68 (m, 4H), 4.52–4.40 (m, 1H), 2.25 (d, <i>J</i> = 2.1 Hz, 3H), 1.36 (d, <i>J</i> = 6.2 Hz, 6H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.46, 159.25, 157.71 (d, <i>J</i> = 247.1 Hz), 155.56, 144.57, 142.99, 139.93 (d, <i>J</i> = 2.2 Hz), 136.72, 130.21 (d, <i>J</i> = 5.1 Hz), 127.26, 125.17 (d, <i>J</i> = 3.8 Hz), 124.86 (d, <i>J</i> = 17.6 Hz), 123.91 (d, <i>J</i> = 3.8 Hz), 122.87, 121.09 (d, <i>J</i> = 12.4 Hz), 104.00, 100.52 (d, <i>J</i> = 10.1 Hz), 94.26, 92.62, 48.02, 22.23, 14.35 (d, <i>J</i> = 4.8 Hz); <sup>19</sup>F NMR (470 MHz, DMSO-<i>d</i><sub>6</sub>) δ −120.64 to −121.59 (m). UPLC/MS [M + H] = 487.545, <i>t</i><sub>R</sub> = 1.70 min.</div></div><div id="sec4_18_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i165" class="anchor-spacer"></div><h4 class="article-section__title" id="_i165"> (2-((1-(<i>tert</i>-Butyl)-3-(2-fluoro-3-methylphenyl)-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9bb</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (77 mg, 0.150 mmol, 1 equiv) was coupled to <b>4au</b> (41 mg, 0.165 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9bb</b> (41.8 mg, 0.084 mmol) was obtained in 56% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.70 (s, 1H), 9.29 (s, 1H), 7.80–7.73 (m, 1H), 7.38–7.32 (m, 2H), 7.31–7.25 (m, 2H), 7.22–7.15 (m, 1H), 7.10 (t, <i>J</i> = 7.6 Hz, 1H), 7.02 (s, 1H), 6.43 (d, <i>J</i> = 4.2 Hz, 1H), 5.87 (d, <i>J</i> = 2.1 Hz, 1H), 5.68 (d, <i>J</i> = 2.1 Hz, 1H), 4.86–4.71 (m, 4H), 2.26 (d, <i>J</i> = 2.1 Hz, 3H), 1.57 (s, 9H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.87, 159.42, 157.76 (d, <i>J</i> = 246.9 Hz), 155.56, 144.96, 141.26, 140.21 (d, <i>J</i> = 2.3 Hz), 136.68, 130.19 (d, <i>J</i> = 4.8 Hz), 127.27, 125.09 (d, <i>J</i> = 3.8 Hz), 124.84 (d, <i>J</i> = 17.5 Hz), 123.93 (d, <i>J</i> = 3.8 Hz), 122.85, 121.03 (d, <i>J</i> = 12.6 Hz), 103.29 (d, <i>J</i> = 10.1 Hz), 103.18, 93.94, 92.22, 59.59, 29.37, 14.32 (d, <i>J</i> = 4.7 Hz); <sup>19</sup>F NMR (470 MHz, DMSO-<i>d</i><sub>6</sub>) δ −121.11 to −121.25 (m). UPLC/MS [M + H] = 501.437, <i>t</i><sub>R</sub> = 1.88 min.</div></div><div id="sec4_18_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i166" class="anchor-spacer"></div><h4 class="article-section__title" id="_i166"> (2-((1-Cyclopentyl-3-(2-fluoro-3-methylphenyl)-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9bc</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (64 mg, 0.125 mmol, 1 equiv) was coupled to <b>4av</b> (36 mg, 0.138 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9bc</b> (43 mg, 0.085 mmol) was obtained in 68% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.63 (s, 1H), 9.30 (s, 1H), 7.77–7.70 (m, 1H), 7.36–7.30 (m, 2H), 7.26 (dd, <i>J</i> = 5.6, 3.2 Hz, 2H), 7.21–7.15 (m, 2H), 7.09 (t, <i>J</i> = 7.6 Hz, 1H), 6.35 (d, <i>J</i> = 4.1 Hz, 1H), 5.88 (d, <i>J</i> = 2.1 Hz, 1H), 5.62 (d, <i>J</i> = 2.1 Hz, 1H), 4.76 (s, 4H), 4.61 (p, <i>J</i> = 7.3 Hz, 1H), 2.25 (d, <i>J</i> = 2.1 Hz, 3H), 1.95–1.89 (m, 4H), 1.87–1.76 (m, 2H), 1.58–1.52 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.50, 159.25, 157.72 (d, <i>J</i> = 247.0 Hz), 155.56, 144.44, 142.94, 140.62 (d, <i>J</i> = 2.3 Hz), 136.72, 130.23 (d, <i>J</i> = 5.0 Hz), 127.27, 125.17 (d, <i>J</i> = 3.9 Hz), 124.87 (d, <i>J</i> = 17.5 Hz), 123.94 (d, <i>J</i> = 3.8 Hz), 122.86, 121.06 (d, <i>J</i> = 12.4 Hz), 104.03, 100.43 (d, <i>J</i> = 10.0 Hz), 94.34, 92.75, 57.15, 32.22, 24.15, 14.35 (d, <i>J</i> = 4.7 Hz); <sup>19</sup>F NMR (470 MHz, DMSO-<i>d</i><sub>6</sub>) δ −119.76 to −122.97 (m). UPLC/MS [M + H] = 513.564, <i>t</i><sub>R</sub> = 1.80 min.</div></div><div id="sec4_18_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i167" class="anchor-spacer"></div><h4 class="article-section__title" id="_i167"> (2-((1-Cyclohexyl-3-(2-fluoro-3-methylphenyl)-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9bd</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (77 mg, 0.150 mmol, 1 equiv) was coupled to <b>4aw</b> (45 mg, 0.165 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9bd</b> (50.7 mg, 0.096 mmol) was obtained in 64% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.60 (s, 1H), 9.28 (s, 1H), 7.77–7.70 (m, 1H), 7.35–7.30 (m, 2H), 7.29–7.22 (m, 2H), 7.20–7.13 (m, 1H), 7.13–7.05 (m, 2H), 6.35 (d, <i>J</i> = 4.1 Hz, 1H), 5.87 (d, <i>J</i> = 2.1 Hz, 1H), 5.62 (d, <i>J</i> = 2.0 Hz, 1H), 4.84–4.64 (m, 4H), 4.10–4.00 (m, 1H), 2.24 (d, <i>J</i> = 2.0 Hz, 3H), 1.79 (d, <i>J</i> = 28.9 Hz, 6H), 1.61–1.57 (m, 1H), 1.26–1.11 (m, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.50, 159.23, 157.71 (d, <i>J</i> = 247.1 Hz), 155.55, 144.52, 142.90, 140.04 (d, <i>J</i> = 2.1 Hz), 136.68, 130.19 (d, <i>J</i> = 4.8 Hz), 127.27, 125.15 (d, <i>J</i> = 3.8 Hz), 124.86 (d, <i>J</i> = 17.5 Hz), 123.90 (d, <i>J</i> = 3.8 Hz), 122.85, 121.09 (d, <i>J</i> = 12.4 Hz), 104.08, 100.60 (d, <i>J</i> = 10.1 Hz), 94.32, 92.70, 55.49, 32.30, 25.12, 24.93, 14.35 (d, <i>J</i> = 4.7 Hz); <sup>19</sup>F NMR (470 MHz, DMSO-<i>d</i><sub>6</sub>) δ −120.94 to −121.05 (m). UPLC/MS [M + H] = 527.589, <i>t</i><sub>R</sub> =1.90 min.</div></div><div id="sec4_18_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i168" class="anchor-spacer"></div><h4 class="article-section__title" id="_i168"> (2-((3-(2,3-Difluorophenyl)-1-isopropyl-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9be</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (64 mg, 0.125 mmol, 1 equiv) was coupled to <b>4ax</b> (33 mg, 0.138 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9be</b> (33 mg, 0.067 mmol) was obtained in 56% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.65 (s, 1H), 9.31 (s, 1H), 7.75–7.68 (m, 1H), 7.41–7.09 (m, 7H), 6.37 (d, <i>J</i> = 3.7 Hz, 1H), 5.89 (d, <i>J</i> = 2.1 Hz, 1H), 5.61 (d, <i>J</i> = 2.0 Hz, 1H), 4.76–4.71 (m, 4H), 4.53–4.43 (m, 1H), 1.38–1.33 (m, 6H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.40, 159.22, 155.62, 150.30 (d, <i>J</i> = 244.6 Hz), 147.06 (d, <i>J</i> = 248.9 Hz), 144.44, 140.40, 127.20, 124.63, 123.59, 122.80, 122.50, 115.63 (d, <i>J</i> = 16.6 Hz), 104.14, 100.40 (d, <i>J</i> = 8.7 Hz), 94.41, 92.85, 48.16, 22.16. UPLC/MS [M + H] = 491.531, <i>t</i><sub>R</sub> = 1.59 min.</div></div><div id="sec4_18_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i169" class="anchor-spacer"></div><h4 class="article-section__title" id="_i169"> (2-((1-(<i>tert</i>-Butyl)-3-(2,3-difluorophenyl)-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9bf</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (64 mg, 0.125 mmol, 1 equiv) was coupled to <b>4ay</b> (34.6 mg, 0.138 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9bf</b> (33.4 mg, 0.066 mmol) was obtained in 53% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.74 (s, 1H), 9.32 (s, 1H), 7.77–7.70 (m, 1H), 7.37–7.18 (m, 6H), 7.05 (s, 1H), 6.48 (d, <i>J</i> = 3.8 Hz, 1H), 5.88 (d, <i>J</i> = 2.1 Hz, 1H), 5.67 (d, <i>J</i> = 2.1 Hz, 1H), 4.82–4.79 (m, 4H), 1.57 (s, 9H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.86, 159.44, 155.62, 150.40 (dd, <i>J</i> = 244.2, 12.7 Hz), 147.11 (dd, <i>J</i> = 249.6, 13.8 Hz), 144.89, 140.68 (d, <i>J</i> = 1.9 Hz), 140.21 (d, <i>J</i> = 3.4 Hz), 136.68, 127.30, 124.87–124.61 (m), 123.55 (d, <i>J</i> = 8.3 Hz), 122.87, 122.52 (t, <i>J</i> = 3.0 Hz), 115.71 (d, <i>J</i> = 17.1 Hz), 103.35, 103.29 (d, <i>J</i> = 1.9 Hz), 94.06, 92.34, 59.91, 29.34; <sup>19</sup>F NMR (470 MHz, DMSO-<i>d</i><sub>6</sub>) δ −138.74 to −139.72 (m), −142.92 to −143.90 (m). UPLC/MS [M + H] = 505.538, <i>t</i><sub>R</sub> = 1.83 min.</div></div><div id="sec4_18_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i170" class="anchor-spacer"></div><h4 class="article-section__title" id="_i170"> (2-((1-(<i>tert</i>-Butyl)-3-(2,3-difluorophenyl)-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(4-fluoroisoindolin-2-yl)methanone (<b>9bg</b>)</h4><div class="NLM_p last">Amide bromide <b>8b</b> (67 mg, 0.125 mmol, 1 equiv) was coupled to <b>4ay</b> (35 mg, 0.138 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9bg</b> (34 mg, 0.066 mmol) was obtained in 53% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.77 (s, 1H), 9.33 (s, 1H), 7.77–7.70 (m, 1H), 7.38–7.27 (m, 2H), 7.26–7.17 (m, 2H), 7.14–7.04 (m, 2H), 6.47 (d, <i>J</i> = 3.7 Hz, 1H), 5.88 (d, <i>J</i> = 2.1 Hz, 1H), 5.67 (d, <i>J</i> = 2.1 Hz, 1H), 4.82 (m, 4H), 1.58 (s, 9H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.80, 159.53, 155.66, 149.70 (d, <i>J</i> = 423.9 Hz), 144.98, 140.66, 140.18, 129.92, 124.69, 123.51 (d, <i>J</i> = 8.5 Hz), 122.46, 119.14, 115.66 (d, <i>J</i> = 17.2 Hz), 114.03, 113.68 (d, <i>J</i> = 19.1 Hz), 103.38, 102.94, 94.01, 92.45, 59.92, 29.32. UPLC/MS [M + H] = 523.576, <i>t</i><sub>R</sub> = 1.86 min.</div></div><div id="sec4_18_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i171" class="anchor-spacer"></div><h4 class="article-section__title" id="_i171"> (2-((1-Cyclopentyl-3-(2,3-difluorophenyl)-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9bh</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (64 mg, 0.125 mmol, 1 equiv) was coupled to <b>4az</b> (36 mg, 0.138 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9bh</b> (44 mg, 0.085 mmol) was obtained in 68% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.74 (s, 1H), 9.40 (s, 1H), 7.81 (t, <i>J</i> = 7.2 Hz, 1H), 7.46–7.25 (m, 7H), 6.48 (d, <i>J</i> = 3.7 Hz, 1H), 6.00 (d, <i>J</i> = 2.1 Hz, 1H), 5.72 (d, <i>J</i> = 2.0 Hz, 1H), 4.87–4.83 (m, 4H), 4.73 (p, <i>J</i> = 7.3 Hz, 1H), 2.04 (s, 4H), 1.96–1.88 (m, 2H), 1.70–1.61 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.45, 159.24, 155.58, 150.22 (d, <i>J</i> = 248.2 Hz), 147.18 (d, <i>J</i> = 248.2 Hz), 144.33, 141.78, 141.07, 136.74, 127.22, 124.68, 123.55 (d, <i>J</i> = 8.6 Hz), 122.81, 122.52, 115.65 (d, <i>J</i> = 16.8 Hz), 104.18, 100.35 (d, <i>J</i> = 8.9 Hz), 94.49, 92.99, 57.27, 32.23, 24.14. UPLC/MS [M + H] = 517.533, <i>t</i><sub>R</sub> = 1.75 min.</div></div><div id="sec4_18_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i172" class="anchor-spacer"></div><h4 class="article-section__title" id="_i172"> (2-((1-Cyclohexyl-3-(2,3-difluorophenyl)-1<i>H</i>-pyrazol-5-yl)amino)-4,6-dihydroxyphenyl)(isoindolin-2-yl)methanone (<b>9bi</b>)</h4><div class="NLM_p last">Amide bromide <b>8a</b> (64 mg, 0.125 mmol, 1 equiv) was coupled to <b>4bb</b> (38 mg, 0.138 mmol, 1.1 equiv) according to General Procedure <b>E1b</b>. The resulting product was deprotected according to General Procedure <b>E2a</b>. <b>9bi</b> (46 mg, 0.087 mmol) was obtained in 73% yield over two steps. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.64 (s, 1H), 9.30 (s, 1H), 7.74–7.66 (m, 1H), 7.34–7.09 (m, 7H), 6.37 (d, <i>J</i> = 3.8 Hz, 1H), 5.89 (d, <i>J</i> = 2.1 Hz, 1H), 5.63 (d, <i>J</i> = 2.1 Hz, 1H), 4.76–4.72 (m, 4H), 4.13–4.03 (m, 1H), 1.91–1.70 (m, 6H), 1.62–1.58 (m, 1H), 1.21–1.15 (m, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.87, 159.64, 156.03, 151.83, 146.30, 142.17, 140.97, 137.05, 127.65, 125.04, 123.99 (d, <i>J</i> = 8.6 Hz), 123.22, 122.93, 116.04 (d, <i>J</i> = 16.8 Hz), 104.68, 100.90 (d, <i>J</i> = 9.4 Hz), 94.92, 93.43, 56.01, 40.87, 25.51, 25.33. UPLC/MS [M + H] = 531.547, T<sub>R</sub> = 1.85 min.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i173"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01777" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75117" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75117" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01777?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01777</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Supporting Tables 1–8, Supporting Figures S1–S7 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Confirmation of lysate EC<sub>50s</sub> (Table 1); confirmation of fungal selectivity using purified NBDs (Table 2); HepG2 cytotoxicity dose–response data and statistics (Table 3); NIH 3T3 cytotoxicity dose–response data and statistics (Table 4); crystallographic data for apoprotein and NVP-AUY922-liganded structures (Table 5); crystallographic data for RAP-liganded structures (Table 6); features of selected Hsp90 NBD structures (Table 7); summary of computational docking results for the compounds in Table 4 (Table 8); correlation between lysate and purified NBD potencies in <i>C. neoformans</i> (Figure S1); correlation between lysate and purified NBD potencies in human (Figure S2); correlation between fold-selectivities calculated using lysates and purified NBDs (Figure S3); HepG2 cytotoxicity dose–response curves (Figure S4); NIH 3T3 cytotoxicity dose–response curves (Figure S5); ligand variability in the <i>C. neoformans</i> RAP complexes (Figure S6); and contact sites between ligands and structural elements of HSP90 (Figure S7) (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_002.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and associated biological data (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_003.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Coordinate files used to generate <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>B (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_004.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Coordinate files used to generate <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>C (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_005.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Coordinate files used to generate <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>D (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_006.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Coordinate files used to generate <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>E (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_007.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Coordinate files used to generate <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>F (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_008.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Coordinate files used to generate <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>G (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_009.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_001.pdf">jm0c01777_si_001.pdf (1.61 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_002.pdf">jm0c01777_si_002.pdf (710.27 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_003.csv">jm0c01777_si_003.csv (9.13 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_004.pdb">jm0c01777_si_004.pdb (857.16 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_005.pdb">jm0c01777_si_005.pdb (857.16 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_006.pdb">jm0c01777_si_006.pdb (858.06 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_007.pdb">jm0c01777_si_007.pdb (858.06 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_008.pdb">jm0c01777_si_008.pdb (858.48 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_009.pdb">jm0c01777_si_009.pdb (858.48 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Coordinates have been deposited in the PDB with the following accession numbers: apo (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9R">7K9R</a>), NVP-AUY922 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9S">7K9S</a>), compound <b>19</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9U">7K9U</a>), compound <b>18</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9V">7K9V</a>), and compound <b>10</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9W">7K9W</a>). The authors will release coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.0c01777" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57020" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57020" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gilbert G. Privé</span> - <span class="hlFld-Affiliation affiliation">Princess
Margaret Cancer Centre, Toronto, Ontario M5G 1L7, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Medical Biophysics, University of Toronto, Toronto, Ontario M5G 1L7, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Biochemistry, University of Toronto, Toronto, Ontario M5S 1A8, Canada</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d394babffd83a1baa5b693a6bbbda1b6a0b6b2a1b0bbfdb0b2"><span class="__cf_email__" data-cfemail="6027090c4e30120916052015080e12051305011203084e0301">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luke Whitesell</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1M1, Canada</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#066a736d6328716e6f726375636a6a467372697469687269286567"><span class="__cf_email__" data-cfemail="69051c020c471e01001d0c1a0c0505291c1d061b06071d06470a08">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Leah E. Cowen</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1M1, Canada</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5797-0110" title="Orcid link">http://orcid.org/0000-0001-5797-0110</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d5b9b0b4bdfbb6baa2b0bb95a0a1baa7babba1bafbb6b4"><span class="__cf_email__" data-cfemail="771b12161f591418001219370203180518190318591416">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lauren E. Brown</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry and Center for Molecular Discovery (BU-CMD), Boston University, Boston, Massachusetts 02215, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9489-484X" title="Orcid link">http://orcid.org/0000-0001-9489-484X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b8dacad7cfd6d4ddf8dacd96dddccd"><span class="__cf_email__" data-cfemail="fb9989948c95979ebb998ed59e9f8e">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul T. Marcyk</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry and Center for Molecular Discovery (BU-CMD), Boston University, Boston, Massachusetts 02215, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5414-0293" title="Orcid link">http://orcid.org/0000-0001-5414-0293</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emmanuelle V. LeBlanc</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1M1, Canada</span>; 
    <span>Present Address:
                        E.V.L: Queen’s University, Kingston, ON, K7L 3N6, Canada</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4278-0984" title="Orcid link">http://orcid.org/0000-0003-4278-0984</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Douglas A. Kuntz</span> - <span class="hlFld-Affiliation affiliation">Princess
Margaret Cancer Centre, Toronto, Ontario M5G 1L7, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alice Xue</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1M1, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francisco Ortiz</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry, UT Southwestern Medical
Center, Dallas, Texas 75390-9038, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Trilles</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry and Center for Molecular Discovery (BU-CMD), Boston University, Boston, Massachusetts 02215, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen Bengtson</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry and Center for Molecular Discovery (BU-CMD), Boston University, Boston, Massachusetts 02215, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9383-5159" title="Orcid link">http://orcid.org/0000-0002-9383-5159</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tristan M. G. Kenney</span> - <span class="hlFld-Affiliation affiliation">Department
of Medical Biophysics, University of Toronto, Toronto, Ontario M5G 1L7, Canada</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8242-4349" title="Orcid link">http://orcid.org/0000-0001-8242-4349</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David S. Huang</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry and Center for Molecular Discovery (BU-CMD), Boston University, Boston, Massachusetts 02215, United States</span>; 
    <span>Present Address:
                        D.S.H.: Foghorn Therapeutics, 100 Binney Street, Cambridge, Massachusetts 02142, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0256-5307" title="Orcid link">http://orcid.org/0000-0003-0256-5307</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicole Robbins</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular Genetics, University of Toronto, Toronto, Ontario M5G 1M1, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Noelle S. Williams</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry, UT Southwestern Medical
Center, Dallas, Texas 75390-9038, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Damian J. Krysan</span> - <span class="hlFld-Affiliation affiliation">Departments
of Pediatrics and Microbiology/Immunology, Carver College of Medicine, University of Iowa, Iowa City, Iowa 52242, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li><span class="author-information-subsection-header">Funding</span><p>NIH R01AI120958</p></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): L.E.C. is a cofounder, Chief Scientific Officer, and shareholder of Bright Angel Therapeutics, a platform company for the development of novel antifungal therapeutics. L.E.C. is a consultant for Boragen, a small molecule development company focused on leveraging the unique chemical properties of boron chemistry for crop protection and animal health. L.W. is a co-founder and shareholder of Bright Angel Therapeutics. L.E.B., D.S.H., P.T.M., L.E.C. and L.W. are named as inventors on a patent application pertaining to findings reported here.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e10121-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i178">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12040" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12040" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by a grant from the National Institutes of Health (Grant R01AI120958 to L.E.C., L.E.B., and D.J.K.). L.E.C. holds a Canada Research Chair in Microbial Genomics & Infectious Disease and is Co-Director of the CIFAR Program, Fungal Kingdom: Threats & Opportunities. G.G.P. was supported by grants from NSERC and the Samuel Waxman Cancer Research Foundation.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">Hsp90</td><td class="NLM_def"><p class="first last">heat shock protein 90</p></td></tr><tr><td class="NLM_term">Trap1</td><td class="NLM_def"><p class="first last">TNF receptor-associated protein 1</p></td></tr><tr><td class="NLM_term">Grp94</td><td class="NLM_def"><p class="first last">94 kDa glucose-regulated protein</p></td></tr><tr><td class="NLM_term">NBD</td><td class="NLM_def"><p class="first last">nucleotide binding domain</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">Cl<sub>int</sub></td><td class="NLM_def"><p class="first last">intrinsic clearance</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">ELSD</td><td class="NLM_def"><p class="first last">evaporative light-scattering detector</p></td></tr><tr><td class="NLM_term">FBS</td><td class="NLM_def"><p class="first last">fetal bovine serum</p></td></tr><tr><td class="NLM_term">FP</td><td class="NLM_def"><p class="first last">fluorescence polarization</p></td></tr><tr><td class="NLM_term">FS</td><td class="NLM_def"><p class="first last">fungal selectivity</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">hexafluorophosphate azabenzotriazole tetramethyl uronium</p></td></tr><tr><td class="NLM_term">IS</td><td class="NLM_def"><p class="first last">internal standard</p></td></tr><tr><td class="NLM_term">MRM</td><td class="NLM_def"><p class="first last">multiple reaction monitoring</p></td></tr><tr><td class="NLM_term">TI</td><td class="NLM_def"><p class="first last">therapeutic index</p></td></tr><tr><td class="NLM_term">UPLC</td><td class="NLM_def"><p class="first last">ultraperformance liquid chromatography</p></td></tr><tr><td class="NLM_term">WHO</td><td class="NLM_def"><p class="first last">World Health Organization</p></td></tr><tr><td class="NLM_term">YPD</td><td class="NLM_def"><p class="first last">yeast extract peptone dextrose</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i180">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05530" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05530" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 90 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denning, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gow, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitz, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Netea, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, T. C.</span></span> <span> </span><span class="NLM_article-title">Hidden killers: human fungal infections</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">165rv113</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.3004404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1126%2Fscitranslmed.3004404" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&author=G.+D.+Brownauthor=D.+W.+Denningauthor=N.+A.+Gowauthor=S.+M.+Levitzauthor=M.+G.+Neteaauthor=T.+C.+White&title=Hidden+killers%3A+human+fungal+infections&doi=10.1126%2Fscitranslmed.3004404"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3004404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3004404%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DG.%2BD.%26aulast%3DDenning%26aufirst%3DD.%2BW.%26aulast%3DGow%26aufirst%3DN.%2BA.%26aulast%3DLevitz%26aufirst%3DS.%2BM.%26aulast%3DNetea%26aufirst%3DM.%2BG.%26aulast%3DWhite%26aufirst%3DT.%2BC.%26atitle%3DHidden%2520killers%253A%2520human%2520fungal%2520infections%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2012%26volume%3D4%26doi%3D10.1126%2Fscitranslmed.3004404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanglard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurr, S. J.</span></span> <span> </span><span class="NLM_article-title">Worldwide emergence of resistance to antifungal drugs challenges human health and food security</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">739</span>– <span class="NLM_lpage">742</span>, <span class="refDoi"> DOI: 10.1126/science.aap7999</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1126%2Fscience.aap7999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=29773744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsVCgsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2018&pages=739-742&author=M.+C.+Fisherauthor=N.+J.+Hawkinsauthor=D.+Sanglardauthor=S.+J.+Gurr&title=Worldwide+emergence+of+resistance+to+antifungal+drugs+challenges+human+health+and+food+security&doi=10.1126%2Fscience.aap7999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Worldwide emergence of resistance to antifungal drugs challenges human health and food security</span></div><div class="casAuthors">Fisher, Matthew C.; Hawkins, Nichola J.; Sanglard, Dominique; Gurr, Sarah J.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">6390</span>),
    <span class="NLM_cas:pages">739-742</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The recent rate of emergence of pathogenic fungi that are resistant to the limited no. of commonly used antifungal agents is unprecedented.  The azoles, for example, are used not only for human and animal health care and crop protection but also in antifouling coatings and timber preservation.  The ubiquity and multiple uses of azoles have hastened the independent evolution of resistance in many environments.  One consequence is an increasing risk in human health care from naturally occurring opportunistic fungal pathogens that have acquired resistance to this broad class of chems.  To avoid a global collapse in our ability to control fungal infections and to avoid crit. failures in medicine and food security, we must improve our stewardship of extant chems., promote new antifungal discovery, and leverage emerging technologies for alternative solns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolE2CwqdzBv7Vg90H21EOLACvtfcHk0ljsEtIyOjHwZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsVCgsbg%253D&md5=8add9de472138d5aca677fa3585ddd72</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.aap7999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aap7999%26sid%3Dliteratum%253Aachs%26aulast%3DFisher%26aufirst%3DM.%2BC.%26aulast%3DHawkins%26aufirst%3DN.%2BJ.%26aulast%3DSanglard%26aufirst%3DD.%26aulast%3DGurr%26aufirst%3DS.%2BJ.%26atitle%3DWorldwide%2520emergence%2520of%2520resistance%2520to%2520antifungal%2520drugs%2520challenges%2520human%2520health%2520and%2520food%2520security%26jtitle%3DScience%26date%3D2018%26volume%3D360%26spage%3D739%26epage%3D742%26doi%3D10.1126%2Fscience.aap7999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denning, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitz, S. M.</span></span> <span> </span><span class="NLM_article-title">Tackling human fungal infections</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>336</i></span>,  <span class="NLM_fpage">647</span>, <span class="refDoi"> DOI: 10.1126/science.1222236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1126%2Fscience.1222236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=22582229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvF2jtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=336&publication_year=2012&pages=647&author=G.+D.+Brownauthor=D.+W.+Denningauthor=S.+M.+Levitz&title=Tackling+human+fungal+infections&doi=10.1126%2Fscience.1222236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Tackling human fungal infections</span></div><div class="casAuthors">Brown, Gordon D.; Denning, David W.; Levitz, Stuart M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">336</span>
        (<span class="NLM_cas:issue">6082</span>),
    <span class="NLM_cas:pages">647</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEe-AdzM8oD7Vg90H21EOLACvtfcHk0ljQyPKaieHTBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvF2jtLc%253D&md5=ad0c19c925c3821e35a52717f1cb071e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.1222236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1222236%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DG.%2BD.%26aulast%3DDenning%26aufirst%3DD.%2BW.%26aulast%3DLevitz%26aufirst%3DS.%2BM.%26atitle%3DTackling%2520human%2520fungal%2520infections%26jtitle%3DScience%26date%3D2012%26volume%3D336%26spage%3D647%26doi%3D10.1126%2Fscience.1222236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pfaller, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diekema, D. J.</span></span> <span> </span><span class="NLM_article-title">Epidemiology of invasive mycoses in North America</span>. <i>Crit. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.3109/10408410903241444</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.3109%2F10408410903241444" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=20088682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252FksF2htQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2010&pages=1-53&author=M.+A.+Pfallerauthor=D.+J.+Diekema&title=Epidemiology+of+invasive+mycoses+in+North+America&doi=10.3109%2F10408410903241444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology of invasive mycoses in North America</span></div><div class="casAuthors">Pfaller Michael A; Diekema Daniel J</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in microbiology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-53</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The incidence of invasive mycoses is increasing, especially among patients who are immunocompromised or hospitalized with serious underlying diseases.  Such infections may be broken into two broad categories: opportunistic and endemic.  The most important agents of the opportunistic mycoses are Candida spp., Cryptococcus neoformans, Pneumocystis jirovecii, and Aspergillus spp. (although the list of potential pathogens is ever expanding); while the most commonly encountered endemic mycoses are due to Histoplasma capsulatum, Coccidioides immitis/posadasii, and Blastomyces dermatitidis.  This review discusses the epidemiologic profiles of these invasive mycoses in North America, as well as risk factors for infection, and the pathogens' antifungal susceptibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRHHNyyGVuQmuxsqfvU0ziafW6udTcc2eYQkqhelXoPBbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252FksF2htQ%253D%253D&md5=e68785c3d62889a68a0fcfbceee5fc53</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3109%2F10408410903241444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10408410903241444%26sid%3Dliteratum%253Aachs%26aulast%3DPfaller%26aufirst%3DM.%2BA.%26aulast%3DDiekema%26aufirst%3DD.%2BJ.%26atitle%3DEpidemiology%2520of%2520invasive%2520mycoses%2520in%2520North%2520America%26jtitle%3DCrit.%2520Rev.%2520Microbiol.%26date%3D2010%26volume%3D36%26spage%3D1%26epage%3D53%26doi%3D10.3109%2F10408410903241444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Köhler, J. R.</span>; <span class="NLM_string-name">Hube, B.</span>; <span class="NLM_string-name">Puccia, R.</span>; <span class="NLM_string-name">Casadevall, A.</span>; <span class="NLM_string-name">Perfect, J. R.</span></span> <span> </span><span class="NLM_article-title">Fungi that infect humans</span>.  <i>The Fungal Kingdom</i>; <span class="NLM_publisher-name">Wiley</span>, <span class="NLM_year">2017</span>; Vol.  <span class="NLM_volume">5</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1128%2F9781555819583.ch39" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=J.+R.+K%C3%B6hler&author=B.+Hube&author=R.+Puccia&author=A.+Casadevall&author=J.+R.+Perfect&title=The+Fungal+Kingdom"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1128%2F9781555819583.ch39&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1128%252F9781555819583.ch39%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25B6hler%26aufirst%3DJ.%2BR.%26atitle%3DFungi%2520that%2520infect%2520humans%26btitle%3DThe%2520Fungal%2520Kingdom%26pub%3DWiley%26date%3D2017%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wannemuehler, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marston, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govender, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappas, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiller, T. M.</span></span> <span> </span><span class="NLM_article-title">Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS</span>. <i>AIDS</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">530</span>, <span class="refDoi"> DOI: 10.1097/QAD.0b013e328322ffac</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1097%2FQAD.0b013e328322ffac" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=19182676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A280%3ADC%252BD1M7mvFSmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=525-530&author=B.+J.+Parkauthor=K.+A.+Wannemuehlerauthor=B.+J.+Marstonauthor=N.+Govenderauthor=P.+G.+Pappasauthor=T.+M.+Chiller&title=Estimation+of+the+current+global+burden+of+cryptococcal+meningitis+among+persons+living+with+HIV%2FAIDS&doi=10.1097%2FQAD.0b013e328322ffac"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS</span></div><div class="casAuthors">Park Benjamin J; Wannemuehler Kathleen A; Marston Barbara J; Govender Nelesh; Pappas Peter G; Chiller Tom M</div><div class="citationInfo"><span class="NLM_cas:title">AIDS (London, England)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">525-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Cryptococcal meningitis is one of the most important HIV-related opportunistic infections, especially in the developing world.  In order to help develop global strategies and priorities for prevention and treatment, it is important to estimate the burden of cryptococcal meningitis.  DESIGN:  Global burden of disease estimation using published studies.  METHODS:  We used the median incidence rate of available studies in a geographic region to estimate the region-specific cryptococcal meningitis incidence; this was multiplied by the 2007 United Nations Programme on HIV/AIDS HIV population estimate for each region to estimate cryptococcal meningitis cases.  To estimate deaths, we assumed a 9% 3-month case-fatality rate among high-income regions, a 55% rate among low-income and middle-income regions, and a 70% rate in sub-Saharan Africa, based on studies published in these areas and expert opinion.  RESULTS:  Published incidence ranged from 0.04 to 12% per year among persons with HIV.  Sub-Saharan Africa had the highest yearly burden estimate (median incidence 3.2%, 720 000 cases; range, 144 000-1.3 million).  Median incidence was lowest in Western and Central Europe and Oceania (</=0.1% each).  Globally, approximately 957 900 cases (range, 371 700-1 544 000) of cryptococcal meningitis occur each year, resulting in 624 700 deaths (range, 125 000-1 124 900) by 3 months after infection.  CONCLUSION:  This study, the first attempt to estimate the global burden of cryptococcal meningitis, finds the number of cases and deaths to be very high, with most occurring in sub-Saharan Africa.  Further work is needed to better define the scope of the problem and track the epidemiology of this infection, in order to prioritize prevention, diagnosis, and treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTs2E37kZj4yYkFb3mqPUYDfW6udTcc2eYQkqhelXoPBbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M7mvFSmuw%253D%253D&md5=22081153f2d332b6f4032023cbecbbeb</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1097%2FQAD.0b013e328322ffac&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FQAD.0b013e328322ffac%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DB.%2BJ.%26aulast%3DWannemuehler%26aufirst%3DK.%2BA.%26aulast%3DMarston%26aufirst%3DB.%2BJ.%26aulast%3DGovender%26aufirst%3DN.%26aulast%3DPappas%26aufirst%3DP.%2BG.%26aulast%3DChiller%26aufirst%3DT.%2BM.%26atitle%3DEstimation%2520of%2520the%2520current%2520global%2520burden%2520of%2520cryptococcal%2520meningitis%2520among%2520persons%2520living%2520with%2520HIV%252FAIDS%26jtitle%3DAIDS%26date%3D2009%26volume%3D23%26spage%3D525%26epage%3D530%26doi%3D10.1097%2FQAD.0b013e328322ffac" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajasingham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarvis, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govender, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiller, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denning, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loyse, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulware, D. R.</span></span> <span> </span><span class="NLM_article-title">Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">873</span>– <span class="NLM_lpage">881</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(17)30243-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1016%2FS1473-3099%2817%2930243-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=28483415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A280%3ADC%252BC1crlt1Sjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=873-881&author=R.+Rajasinghamauthor=R.+M.+Smithauthor=B.+J.+Parkauthor=J.+N.+Jarvisauthor=N.+P.+Govenderauthor=T.+M.+Chillerauthor=D.+W.+Denningauthor=A.+Loyseauthor=D.+R.+Boulware&title=Global+burden+of+disease+of+HIV-associated+cryptococcal+meningitis%3A+an+updated+analysis&doi=10.1016%2FS1473-3099%2817%2930243-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis</span></div><div class="casAuthors">Rajasingham Radha; Smith Rachel M; Park Benjamin J; Chiller Tom M; Jarvis Joseph N; Govender Nelesh P; Denning David W; Loyse Angela; Boulware David R</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Infectious diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">873-881</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Cryptococcus is the most common cause of meningitis in adults living with HIV in sub-Saharan Africa.  Global burden estimates are crucial to guide prevention strategies and to determine treatment needs, and we aimed to provide an updated estimate of global incidence of HIV-associated cryptococcal disease.  METHODS:  We used 2014 Joint UN Programme on HIV and AIDS estimates of adults (aged >15 years) with HIV and antiretroviral therapy (ART) coverage.  Estimates of CD4 less than 100 cells per μL, virological failure incidence, and loss to follow-up were from published multinational cohorts in low-income and middle-income countries.  We calculated those at risk for cryptococcal infection, specifically those with CD4 less than 100 cells/μL not on ART, and those with CD4 less than 100 cells per μL on ART but lost to follow-up or with virological failure.  Cryptococcal antigenaemia prevalence by country was derived from 46 studies globally.  Based on cryptococcal antigenaemia prevalence in each country and region, we estimated the annual numbers of people who are developing and dying from cryptococcal meningitis.  FINDINGS:  We estimated an average global cryptococcal antigenaemia prevalence of 6·0% (95% CI 5·8-6·2) among people with a CD4 cell count of less than 100 cells per μL, with 278 000 (95% CI 195 500-340 600) people positive for cryptococcal antigen globally and 223 100 (95% CI 150 600-282 400) incident cases of cryptococcal meningitis globally in 2014.  Sub-Saharan Africa accounted for 73% of the estimated cryptococcal meningitis cases in 2014 (162 500 cases [95% CI 113 600-193 900]).  Annual global deaths from cryptococcal meningitis were estimated at 181 100 (95% CI 119 400-234 300), with 135 900 (75%; [95% CI 93 900-163 900]) deaths in sub-Saharan Africa.  Globally, cryptococcal meningitis was responsible for 15% of AIDS-related deaths (95% CI 10-19).  INTERPRETATION:  Our analysis highlights the substantial ongoing burden of HIV-associated cryptococcal disease, primarily in sub-Saharan Africa.  Cryptococcal meningitis is a metric of HIV treatment programme failure; timely HIV testing and rapid linkage to care remain an urgent priority.  FUNDING:  None.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR6kthTNuMfLqNc3HjJRoFAfW6udTcc2eafBvtP4VQLubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crlt1Sjug%253D%253D&md5=85268904374cb498fc2d92ac35cd4aee</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2817%2930243-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252817%252930243-8%26sid%3Dliteratum%253Aachs%26aulast%3DRajasingham%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DR.%2BM.%26aulast%3DPark%26aufirst%3DB.%2BJ.%26aulast%3DJarvis%26aufirst%3DJ.%2BN.%26aulast%3DGovender%26aufirst%3DN.%2BP.%26aulast%3DChiller%26aufirst%3DT.%2BM.%26aulast%3DDenning%26aufirst%3DD.%2BW.%26aulast%3DLoyse%26aufirst%3DA.%26aulast%3DBoulware%26aufirst%3DD.%2BR.%26atitle%3DGlobal%2520burden%2520of%2520disease%2520of%2520HIV-associated%2520cryptococcal%2520meningitis%253A%2520an%2520updated%2520analysis%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2017%26volume%3D17%26spage%3D873%26epage%3D881%26doi%3D10.1016%2FS1473-3099%2817%2930243-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loyse, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koulla-Shiro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mghamba, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramadhani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyirenda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliyu, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oladele, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesikari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muzoora, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temfack, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mapoure, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimwela, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakhi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngoma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gondwe-Chunda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perfect, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shroufi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrieux-Meyer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosseinipour, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Horst, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klausner, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulware, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyderman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalloo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarvis, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denning, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lortholary, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dromer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stack, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molloy, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bicanic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Oosterhout, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mwaba, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanyama, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kouanfack, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mfinanga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govender, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, T. S.</span></span> <span> </span><span class="NLM_article-title">Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">e143</span>– <span class="NLM_lpage">e147</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(18)30493-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1016%2FS1473-3099%2818%2930493-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=30344084" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=e143-e147&author=A.+Loyseauthor=J.+Burryauthor=J.+Cohnauthor=N.+Fordauthor=T.+Chillerauthor=I.+Ribeiroauthor=S.+Koulla-Shiroauthor=J.+Mghambaauthor=A.+Ramadhaniauthor=R.+Nyirendaauthor=S.+H.+Aliyuauthor=D.+Wilsonauthor=T.+Leauthor=R.+Oladeleauthor=S.+Lesikariauthor=C.+Muzooraauthor=N.+Kalataauthor=E.+Temfackauthor=Y.+Mapoureauthor=V.+Siniauthor=D.+Chandaauthor=M.+Shimwelaauthor=S.+Lakhiauthor=J.+Ngomaauthor=L.+Gondwe-Chundaauthor=C.+Perfectauthor=A.+Shroufiauthor=I.+Andrieux-Meyerauthor=A.+Chanauthor=C.+Schutzauthor=M.+Hosseinipourauthor=C.+Van+der+Horstauthor=J.+D.+Klausnerauthor=D.+R.+Boulwareauthor=R.+Heydermanauthor=D.+Lallooauthor=J.+Dayauthor=J.+N.+Jarvisauthor=M.+Rodriguesauthor=S.+Jaffarauthor=D.+Denningauthor=C.+Migoneauthor=M.+Dohertyauthor=O.+Lortholaryauthor=F.+Dromerauthor=M.+Stackauthor=S.+F.+Molloyauthor=T.+Bicanicauthor=J.+van+Oosterhoutauthor=P.+Mwabaauthor=C.+Kanyamaauthor=C.+Kouanfackauthor=S.+Mfinangaauthor=N.+Govenderauthor=T.+S.+Harrison&title=Leave+no+one+behind%3A+response+to+new+evidence+and+guidelines+for+the+management+of+cryptococcal+meningitis+in+low-income+and+middle-income+countries&doi=10.1016%2FS1473-3099%2818%2930493-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2818%2930493-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252818%252930493-6%26sid%3Dliteratum%253Aachs%26aulast%3DLoyse%26aufirst%3DA.%26aulast%3DBurry%26aufirst%3DJ.%26aulast%3DCohn%26aufirst%3DJ.%26aulast%3DFord%26aufirst%3DN.%26aulast%3DChiller%26aufirst%3DT.%26aulast%3DRibeiro%26aufirst%3DI.%26aulast%3DKoulla-Shiro%26aufirst%3DS.%26aulast%3DMghamba%26aufirst%3DJ.%26aulast%3DRamadhani%26aufirst%3DA.%26aulast%3DNyirenda%26aufirst%3DR.%26aulast%3DAliyu%26aufirst%3DS.%2BH.%26aulast%3DWilson%26aufirst%3DD.%26aulast%3DLe%26aufirst%3DT.%26aulast%3DOladele%26aufirst%3DR.%26aulast%3DLesikari%26aufirst%3DS.%26aulast%3DMuzoora%26aufirst%3DC.%26aulast%3DKalata%26aufirst%3DN.%26aulast%3DTemfack%26aufirst%3DE.%26aulast%3DMapoure%26aufirst%3DY.%26aulast%3DSini%26aufirst%3DV.%26aulast%3DChanda%26aufirst%3DD.%26aulast%3DShimwela%26aufirst%3DM.%26aulast%3DLakhi%26aufirst%3DS.%26aulast%3DNgoma%26aufirst%3DJ.%26aulast%3DGondwe-Chunda%26aufirst%3DL.%26aulast%3DPerfect%26aufirst%3DC.%26aulast%3DShroufi%26aufirst%3DA.%26aulast%3DAndrieux-Meyer%26aufirst%3DI.%26aulast%3DChan%26aufirst%3DA.%26aulast%3DSchutz%26aufirst%3DC.%26aulast%3DHosseinipour%26aufirst%3DM.%26aulast%3DVan%2Bder%2BHorst%26aufirst%3DC.%26aulast%3DKlausner%26aufirst%3DJ.%2BD.%26aulast%3DBoulware%26aufirst%3DD.%2BR.%26aulast%3DHeyderman%26aufirst%3DR.%26aulast%3DLalloo%26aufirst%3DD.%26aulast%3DDay%26aufirst%3DJ.%26aulast%3DJarvis%26aufirst%3DJ.%2BN.%26aulast%3DRodrigues%26aufirst%3DM.%26aulast%3DJaffar%26aufirst%3DS.%26aulast%3DDenning%26aufirst%3DD.%26aulast%3DMigone%26aufirst%3DC.%26aulast%3DDoherty%26aufirst%3DM.%26aulast%3DLortholary%26aufirst%3DO.%26aulast%3DDromer%26aufirst%3DF.%26aulast%3DStack%26aufirst%3DM.%26aulast%3DMolloy%26aufirst%3DS.%2BF.%26aulast%3DBicanic%26aufirst%3DT.%26aulast%3Dvan%2BOosterhout%26aufirst%3DJ.%26aulast%3DMwaba%26aufirst%3DP.%26aulast%3DKanyama%26aufirst%3DC.%26aulast%3DKouanfack%26aufirst%3DC.%26aulast%3DMfinanga%26aufirst%3DS.%26aulast%3DGovender%26aufirst%3DN.%26aulast%3DHarrison%26aufirst%3DT.%2BS.%26atitle%3DLeave%2520no%2520one%2520behind%253A%2520response%2520to%2520new%2520evidence%2520and%2520guidelines%2520for%2520the%2520management%2520of%2520cryptococcal%2520meningitis%2520in%2520low-income%2520and%2520middle-income%2520countries%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2019%26volume%3D19%26spage%3De143%26epage%3De147%26doi%3D10.1016%2FS1473-3099%2818%2930493-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maertens, J. A.</span></span> <span> </span><span class="NLM_article-title">History of the development of azole derivatives</span>. <i>Clin. Microbiol. Infect.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1111/j.1470-9465.2004.00841.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1111%2Fj.1470-9465.2004.00841.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=14748798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtFymu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=1-10&author=J.+A.+Maertens&title=History+of+the+development+of+azole+derivatives&doi=10.1111%2Fj.1470-9465.2004.00841.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">History of the development of azole derivatives</span></div><div class="casAuthors">Maertens, J. A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology and Infection</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">CMINFM</span>;
        ISSN:<span class="NLM_cas:issn">1198-743X</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Until the 1940s, relatively few agents were available for the treatment of systemic fungal infections.  The development of the polyene antifungals represented a major advance in medical mycol.  Although amphotericin B quickly became the mainstay of therapy for serious infections, its use was assocd. with infusion-related side-effects and dose-limiting nephrotoxicity.  The continued search for new and, less toxic antifungals led to the discovery of the azoles several decades later.  Ketoconazole, the first available compd. for the oral treatment of systemic fungal infections, was released in the early 1980s.  For almost a decade, ketoconazole was regarded as the drug of choice in nonlife-threatening endemic mycoses.  The introduction of the first-generation triazoles represented a second major advance in the treatment of fungal infections.  Both fluconazole and itraconazole displayed a broader spectrum of antifungal activity than the imidazoles and had a markedly improved safety profile compared with amphotericin B and ketoconazole.  Despite widespread use, however, these agents became subject to a no. of clin. important limitations related to their suboptimal spectrum of activity, the development of resistance, the induction of hazardous drug-drug interactions, their less than optimal pharmacokinetic profile (itraconazole capsules), and toxicity.  To overcome these limitations, several analogs have been developed.  These so-called 'second-generation' triazoles, including voriconazole, posaconazole and ravuconazole, have greater potency and possess increased activity against resistant and emerging pathogens, in particular against Aspergillus spp.  If the toxicity profile of these agents is comparable to or better than that of the first-generation triazoles and drug interactions remain manageable, then these compds. represent a true expansion of our antifungal arsenal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmvC1qYnP897Vg90H21EOLACvtfcHk0lis2gXDhV41-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtFymu7Y%253D&md5=d57e2d90d93844d58562d357652fd1d7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1111%2Fj.1470-9465.2004.00841.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1470-9465.2004.00841.x%26sid%3Dliteratum%253Aachs%26aulast%3DMaertens%26aufirst%3DJ.%2BA.%26atitle%3DHistory%2520of%2520the%2520development%2520of%2520azole%2520derivatives%26jtitle%3DClin.%2520Microbiol.%2520Infect.%26date%3D2004%26volume%3D10%26spage%3D1%26epage%3D10%26doi%3D10.1111%2Fj.1470-9465.2004.00841.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clay, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cioffi, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hisao, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuttle, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieuwkoop, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comellas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maryum, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uno, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildeman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rienstra, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, M. D.</span></span> <span> </span><span class="NLM_article-title">Amphotericin forms an extramembranous and fungicidal sterol sponge</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">400</span>– <span class="NLM_lpage">406</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1496</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1038%2Fnchembio.1496" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=24681535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFOnu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=400-406&author=T.+M.+Andersonauthor=M.+C.+Clayauthor=A.+G.+Cioffiauthor=K.+A.+Diazauthor=G.+S.+Hisaoauthor=M.+D.+Tuttleauthor=A.+J.+Nieuwkoopauthor=G.+Comellasauthor=N.+Maryumauthor=S.+Wangauthor=B.+E.+Unoauthor=E.+L.+Wildemanauthor=T.+Gonenauthor=C.+M.+Rienstraauthor=M.+D.+Burke&title=Amphotericin+forms+an+extramembranous+and+fungicidal+sterol+sponge&doi=10.1038%2Fnchembio.1496"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Amphotericin forms an extramembranous and fungicidal sterol sponge</span></div><div class="casAuthors">Anderson, Thomas M.; Clay, Mary C.; Cioffi, Alexander G.; Diaz, Katrina A.; Hisao, Grant S.; Tuttle, Marcus D.; Nieuwkoop, Andrew J.; Comellas, Gemma; Maryum, Nashrah; Wang, Shu; Uno, Brice E.; Wildeman, Erin L.; Gonen, Tamir; Rienstra, Chad M.; Burke, Martin D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">400-406</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">For over 50 years, amphotericin has remained the powerful but highly toxic last line of defense in treating life-threatening fungal infections in humans with minimal development of microbial resistance.  Understanding how this small mol. kills yeast is thus crit. for guiding development of derivs. with an improved therapeutic index and other resistance-refractory antimicrobial agents.  In the widely accepted ion channel model for its mechanism of cytocidal action, amphotericin forms aggregates inside lipid bilayers that permeabilize and kill cells.  In contrast, the authors report that amphotericin exists primarily in the form of large, extramembranous aggregates that kill yeast by extg. ergosterol from lipid bilayers.  These findings reveal that extn. of a polyfunctional lipid underlies the resistance-refractory antimicrobial action of amphotericin and suggests a roadmap for sepg. its cytocidal and membrane-permeabilizing activities.  This new mechanistic understanding is also guiding development of what are to our knowledge the first derivs. of amphotericin that kill yeast but not human cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4oRh3dbpforVg90H21EOLACvtfcHk0lh1n9nkOuj4mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFOnu78%253D&md5=0c093fd6aecb24b98f31a9ee1c0bcecd</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1496%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DT.%2BM.%26aulast%3DClay%26aufirst%3DM.%2BC.%26aulast%3DCioffi%26aufirst%3DA.%2BG.%26aulast%3DDiaz%26aufirst%3DK.%2BA.%26aulast%3DHisao%26aufirst%3DG.%2BS.%26aulast%3DTuttle%26aufirst%3DM.%2BD.%26aulast%3DNieuwkoop%26aufirst%3DA.%2BJ.%26aulast%3DComellas%26aufirst%3DG.%26aulast%3DMaryum%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DUno%26aufirst%3DB.%2BE.%26aulast%3DWildeman%26aufirst%3DE.%2BL.%26aulast%3DGonen%26aufirst%3DT.%26aulast%3DRienstra%26aufirst%3DC.%2BM.%26aulast%3DBurke%26aufirst%3DM.%2BD.%26atitle%3DAmphotericin%2520forms%2520an%2520extramembranous%2520and%2520fungicidal%2520sterol%2520sponge%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26spage%3D400%26epage%3D406%26doi%3D10.1038%2Fnchembio.1496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbach, W. J.</span></span> <span> </span><span class="NLM_article-title">Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance</span>. <i>Eukaryotic Cell</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">747</span>– <span class="NLM_lpage">764</span>, <span class="refDoi"> DOI: 10.1128/EC.00041-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1128%2FEC.00041-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=18375617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmvVSrsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=747-764&author=L.+E.+Cowenauthor=W.+J.+Steinbach&title=Stress%2C+drugs%2C+and+evolution%3A+the+role+of+cellular+signaling+in+fungal+drug+resistance&doi=10.1128%2FEC.00041-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Stress, drugs, and evolution: The role of cellular signaling in fungal drug resistance</span></div><div class="casAuthors">Cowen, Leah E.; Steinbach, William J.</div><div class="citationInfo"><span class="NLM_cas:title">Eukaryotic Cell</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">747-764</span>CODEN:
                <span class="NLM_cas:coden">ECUEA2</span>;
        ISSN:<span class="NLM_cas:issn">1535-9786</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUWyPvwTDrFbVg90H21EOLACvtfcHk0ljLIXFJ_sHa8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmvVSrsro%253D&md5=a1be495a855797c0781cee6c9a6a0f21</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1128%2FEC.00041-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FEC.00041-08%26sid%3Dliteratum%253Aachs%26aulast%3DCowen%26aufirst%3DL.%2BE.%26aulast%3DSteinbach%26aufirst%3DW.%2BJ.%26atitle%3DStress%252C%2520drugs%252C%2520and%2520evolution%253A%2520the%2520role%2520of%2520cellular%2520signaling%2520in%2520fungal%2520drug%2520resistance%26jtitle%3DEukaryotic%2520Cell%26date%3D2008%26volume%3D7%26spage%3D747%26epage%3D764%26doi%3D10.1128%2FEC.00041-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span> <span> </span><span class="NLM_article-title">Regulatory circuitry governing fungal development, drug resistance, and disease</span>. <i>Microbiol. Mol. Biol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1128/MMBR.00045-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1128%2FMMBR.00045-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=21646428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpslOisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2011&pages=213-267&author=R.+S.+Shapiroauthor=N.+Robbinsauthor=L.+E.+Cowen&title=Regulatory+circuitry+governing+fungal+development%2C+drug+resistance%2C+and+disease&doi=10.1128%2FMMBR.00045-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Regulatory circuitry governing fungal development, drug resistance, and disease</span></div><div class="casAuthors">Shapiro, Rebecca S.; Robbins, Nicole; Cowen, Leah E.</div><div class="citationInfo"><span class="NLM_cas:title">Microbiology and Molecular Biology Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-267</span>CODEN:
                <span class="NLM_cas:coden">MMBRF7</span>;
        ISSN:<span class="NLM_cas:issn">1092-2172</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review.  Pathogenic fungi have become a leading cause of human mortality due to the increasing frequency of fungal infections in immunocompromised populations and the limited armamentarium of clin. useful antifungal drugs.  Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus are the leading causes of opportunistic fungal infections.  In these diverse pathogenic fungi, complex signal transduction cascades are crit. for sensing environmental changes and mediating appropriate cellular responses.  For C. albicans, several environmental cues regulate a morphogenetic switch from yeast to filamentous growth, a reversible transition important for virulence.  Many of the signaling cascades regulating morphogenesis are also required for cells to adapt and survive the cellular stresses imposed by antifungal drugs.  Many of these signaling networks are conserved in C. neoformans and A. fumigatus, which undergo distinct morphogenetic programs during specific phases of their life cycles.  Furthermore, the key mechanisms of fungal drug resistance, including alterations of the drug target, overexpression of drug efflux transporters, and alteration of cellular stress responses, are conserved between these species.  This review focuses on the circuitry regulating fungal morphogenesis and drug resistance and the impact of these pathways on virulence.  Although the three human-pathogenic fungi highlighted in this review are those most frequently encountered in the clinic, they represent a minute fraction of fungal diversity.  Exploration of the conservation and divergence of core signal transduction pathways across C. albicans, C. neoformans, and A. fumigatus provides a foundation for the study of a broader diversity of pathogenic fungi and a platform for the development of new therapeutic strategies for fungal disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDVkw0rexUfrVg90H21EOLACvtfcHk0ljLIXFJ_sHa8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpslOisbY%253D&md5=3b5e83c509ae56353be4148dd1fb2150</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1128%2FMMBR.00045-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMMBR.00045-10%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DR.%2BS.%26aulast%3DRobbins%26aufirst%3DN.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26atitle%3DRegulatory%2520circuitry%2520governing%2520fungal%2520development%252C%2520drug%2520resistance%252C%2520and%2520disease%26jtitle%3DMicrobiol.%2520Mol.%2520Biol.%2520Rev.%26date%3D2011%26volume%3D75%26spage%3D213%26epage%3D267%26doi%3D10.1128%2FMMBR.00045-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caplan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polvi, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckhalter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span> <span> </span><span class="NLM_article-title">Functional genomic screening reveals core modulators of echinocandin stress responses in <i>Candida albicans</i></span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2292</span>– <span class="NLM_lpage">2298</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2018.04.084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1016%2Fj.celrep.2018.04.084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=29791841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVSgtrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=2292-2298&author=T.+Caplanauthor=E.+J.+Polviauthor=J.+L.+Xieauthor=S.+Buckhalterauthor=M.+D.+Leachauthor=N.+Robbinsauthor=L.+E.+Cowen&title=Functional+genomic+screening+reveals+core+modulators+of+echinocandin+stress+responses+in+Candida+albicans&doi=10.1016%2Fj.celrep.2018.04.084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Functional Genomic Screening Reveals Core Modulators of Echinocandin Stress Responses in Candida albicans</span></div><div class="casAuthors">Caplan, Tavia; Polvi, Elizabeth J.; Xie, Jinglin L.; Buckhalter, Shoshana; Leach, Michelle D.; Robbins, Nicole; Cowen, Leah E.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2292-2298</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Candida albicans is a leading cause of death due to fungal infection.  Treatment of systemic candidiasis often relies on echinocandins, which disrupt cell wall synthesis.  Resistance is readily acquired via mutations in the drug target gene, FKS1.  Both basal tolerance and resistance to echinocandins require cellular stress responses.  We performed a systematic anal. of 3,030 C. albicans mutants to define circuitry governing cellular responses to echinocandins.  We identified 16 genes for which deletion or transcriptional repression enhanced echinocandin susceptibility, including components of the Pkc1-MAPK signaling cascade.  We discovered that the mol. chaperone Hsp90 is required for the stability of Pkc1 and Bck1, establishing key mechanisms through which Hsp90 mediates echinocandin resistance.  We also discovered that perturbation of the CCT chaperonin complex causes enhanced echinocandin sensitivity, altered cell wall architecture, and aberrant septin localization.  Thus, we provide insights into the mechanisms by which cellular chaperones enable crucial responses to echinocandin-induced stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9l_0NWj5xVLVg90H21EOLACvtfcHk0lhRt8mKK9tYug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVSgtrjO&md5=09d3c6dc6df400c435862cca5f5f7128</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2018.04.084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2018.04.084%26sid%3Dliteratum%253Aachs%26aulast%3DCaplan%26aufirst%3DT.%26aulast%3DPolvi%26aufirst%3DE.%2BJ.%26aulast%3DXie%26aufirst%3DJ.%2BL.%26aulast%3DBuckhalter%26aufirst%3DS.%26aulast%3DLeach%26aufirst%3DM.%2BD.%26aulast%3DRobbins%26aufirst%3DN.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26atitle%3DFunctional%2520genomic%2520screening%2520reveals%2520core%2520modulators%2520of%2520echinocandin%2520stress%2520responses%2520in%2520Candida%2520albicans%26jtitle%3DCell%2520Rep.%26date%3D2018%26volume%3D23%26spage%3D2292%26epage%3D2298%26doi%3D10.1016%2Fj.celrep.2018.04.084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caplan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span> <span> </span><span class="NLM_article-title">Molecular evolution of antifungal drug resistance</span>. <i>Annu. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">753</span>– <span class="NLM_lpage">775</span>, <span class="refDoi"> DOI: 10.1146/annurev-micro-030117-020345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1146%2Fannurev-micro-030117-020345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=28886681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKlurvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2017&pages=753-775&author=N.+Robbinsauthor=T.+Caplanauthor=L.+E.+Cowen&title=Molecular+evolution+of+antifungal+drug+resistance&doi=10.1146%2Fannurev-micro-030117-020345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Evolution of Antifungal Drug Resistance</span></div><div class="casAuthors">Robbins, Nicole; Caplan, Tavia; Cowen, Leah E.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Microbiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">753-775</span>CODEN:
                <span class="NLM_cas:coden">ARMIAZ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4227</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  The fungal pathogens Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus have transitioned from a rare curiosity to a leading cause of human mortality.  The management of infections caused by these organisms is intimately dependent on the efficacy of antifungal agents; however, fungi that are resistant to these treatments are regularly isolated in the clinic, impeding our ability to control infections.  Given the significant impact fungal pathogens have on human health, it is imperative to understand the mol. mechanisms that govern antifungal drug resistance.  This review describes our current knowledge of the mechanisms by which antifungal drug resistance evolves in exptl. populations and clin. settings.  We explore current antifungal treatment options and discuss promising strategies to impede the evolution of drug resistance.  By tackling antifungal drug resistance as an evolutionary problem, there is potential to improve the utility of current treatments and accelerate the development of novel therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf_rS6B3dA4bVg90H21EOLACvtfcHk0lhRt8mKK9tYug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKlurvE&md5=2eb2fbfc778bce94065a35e0bd9bea3b</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1146%2Fannurev-micro-030117-020345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-micro-030117-020345%26sid%3Dliteratum%253Aachs%26aulast%3DRobbins%26aufirst%3DN.%26aulast%3DCaplan%26aufirst%3DT.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26atitle%3DMolecular%2520evolution%2520of%2520antifungal%2520drug%2520resistance%26jtitle%3DAnnu.%2520Rev.%2520Microbiol.%26date%3D2017%26volume%3D71%26spage%3D753%26epage%3D775%26doi%3D10.1146%2Fannurev-micro-030117-020345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, N.</span>; <span class="NLM_string-name">Wright, G. D.</span>; <span class="NLM_string-name">Cowen, L. E.</span></span>, <span> </span><span class="NLM_article-title">Antifungal Drugs: the Current Armamentarium and Development of New Agents</span>. In  <i>The Fungal Kingdom</i>, <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, J.</span>; <span class="NLM_string-name">Howlett, B.</span>; <span class="NLM_string-name">Crous, P.</span>; <span class="NLM_string-name">Stukenbrock, E.</span>; <span class="NLM_string-name">James, T.</span>; <span class="NLM_string-name">Gow, N.</span></span>, Eds. <span class="NLM_publisher-name">ASM Press</span>: <span class="NLM_publisher-loc">Washington DC</span>., <span class="NLM_year">2017</span>; Vol.  <span class="NLM_volume">4</span>, pp  <span class="NLM_fpage">903</span>– <span class="NLM_lpage">922</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1128%2F9781555819583.ch44" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=903-922&author=N.+Robbins&author=G.+D.+Wright&author=L.+E.+Cowenauthor=J.+Heitman&author=B.+Howlett&author=P.+Crous&author=E.+Stukenbrock&author=T.+James&author=N.+Gow&title=The+Fungal+Kingdom"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1128%2F9781555819583.ch44&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1128%252F9781555819583.ch44%26sid%3Dliteratum%253Aachs%26aulast%3DRobbins%26aufirst%3DN.%26atitle%3DAntifungal%2520Drugs%253A%2520the%2520Current%2520Armamentarium%2520and%2520Development%2520of%2520New%2520Agents%26btitle%3DThe%2520Fungal%2520Kingdom%26aulast%3DHeitman%26aufirst%3DJ.%26pub%3DASM%2520Press%26date%3D2017%26volume%3D4%26spage%3D903%26epage%3D922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Meara, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veri, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polvi, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valaei, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diezmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span> <span> </span><span class="NLM_article-title">Mapping the Hsp90 genetic network reveals ergosterol biosynthesis and phosphatidylinositol-4-kinase signaling as core circuitry governing cellular stress</span>. <i>PLoS Genet.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e1006142</span> <span class="refDoi"> DOI: 10.1371/journal.pgen.1006142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1371%2Fjournal.pgen.1006142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=27341673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVyrs77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&author=T.+R.+O%E2%80%99Mearaauthor=A.+O.+Veriauthor=E.+J.+Polviauthor=X.+Liauthor=S.+F.+Valaeiauthor=S.+Diezmannauthor=L.+E.+Cowen&title=Mapping+the+Hsp90+genetic+network+reveals+ergosterol+biosynthesis+and+phosphatidylinositol-4-kinase+signaling+as+core+circuitry+governing+cellular+stress&doi=10.1371%2Fjournal.pgen.1006142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping the Hsp90 genetic network reveals ergosterol biosynthesis and phosphatidylinositol-4-kinase signaling as core circuitry governing cellular stress</span></div><div class="casAuthors">O'Meara, Teresa R.; Veri, Amanda O.; Polvi, Elizabeth J.; Li, Xinliu; Valaei, Seyedeh Fereshteh; Diezmann, Stephanie; Cowen, Leah E.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Genetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e1006142/1-e1006142/21</span>CODEN:
                <span class="NLM_cas:coden">PGLEB5</span>;
        ISSN:<span class="NLM_cas:issn">1553-7404</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Candida albicans is a leading human fungal pathogen that causes life-threatening systemic infections.  A key regulator of C. albicans stress response, drug resistance, morphogenesis, and virulence is the mol. chaperone Hsp90.  Targeting Hsp90 provides a powerful strategy to treat fungal infections; however, the therapeutic utility of current inhibitors is compromised by toxicity due to inhibition of host Hsp90.  To identify components of the Hsp90-dependent circuitry governing virulence and drug resistance that are sufficiently divergent for selective targeting in the pathogen, we pioneered chem. genomic profiling of the Hsp90 genetic network in C. albicans.  Here, we screen mutant collections covering ∼10% of the genome for hypersensitivity to Hsp90 inhibition in multiple environmental conditions.  We identify 158 HSP90 chem. genetic interactors, most of which are important for growth only in specific environments.  We discovered that the sterol C-22 desaturase gene ERG5 and the phosphatidylinositol-4-kinase (PI4K) gene STT4 are HSP90 genetic interactors under multiple conditions, suggesting a function upstream of Hsp90.  By systematic anal. of the ergosterol biosynthetic cascade, we demonstrate that defects in ergosterol biosynthesis induce cellular stress that overwhelms Hsp90's functional capacity.  By anal. of the phosphatidylinositol pathway, we demonstrate that there is a genetic interaction between the PI4K Stt4 and Hsp90.  We also establish that Stt4 is required for normal actin polarization through regulation of Wal1, and suggest a model in which defects in actin remodeling induces stress that creates a cellular demand for Hsp90 that exceeds its functional capacity.  Consistent with this model, actin inhibitors are synergistic with Hsp90 inhibitors.  We highlight new connections between Hsp90 and virulence traits, demonstrating that Erg5 and Stt4 enable activation of macrophage pyroptosis.  This work uncovers novel circuitry regulating Hsp90 functional capacity and new effectors governing drug resistance, morphogenesis, and virulence, revealing new targets for antifungal drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG2e3o6huNAbVg90H21EOLACvtfcHk0lgH2ZgaF6H-_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVyrs77I&md5=40afaeaeec33813cc052b32b0b7625ca</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pgen.1006142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pgen.1006142%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DT.%2BR.%26aulast%3DVeri%26aufirst%3DA.%2BO.%26aulast%3DPolvi%26aufirst%3DE.%2BJ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DValaei%26aufirst%3DS.%2BF.%26aulast%3DDiezmann%26aufirst%3DS.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26atitle%3DMapping%2520the%2520Hsp90%2520genetic%2520network%2520reveals%2520ergosterol%2520biosynthesis%2520and%2520phosphatidylinositol-4-kinase%2520signaling%2520as%2520core%2520circuitry%2520governing%2520cellular%2520stress%26jtitle%3DPLoS%2520Genet.%26date%3D2016%26volume%3D12%26doi%3D10.1371%2Fjournal.pgen.1006142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardeshi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuomo, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span> <span> </span><span class="NLM_article-title">Genetic analysis of <i>Candida auris</i> implicates Hsp90 in morphogenesis and azole tolerance and Cdr1 in azole resistance</span>. <i>mBio</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e02529</span>– <span class="NLM_lpage">02518</span>, <span class="refDoi"> DOI: 10.1128/mBio.02529-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1128%2FmBio.02529-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=30696744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht12ht73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=e02529-02518&author=S.+H.+Kimauthor=K.+R.+Iyerauthor=L.+Pardeshiauthor=J.+F.+Munozauthor=N.+Robbinsauthor=C.+A.+Cuomoauthor=K.+H.+Wongauthor=L.+E.+Cowen&title=Genetic+analysis+of+Candida+auris+implicates+Hsp90+in+morphogenesis+and+azole+tolerance+and+Cdr1+in+azole+resistance&doi=10.1128%2FmBio.02529-18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic analysis of Candida auris implicates Hsp90 in morphogenesis and azole tolerance and Cdr1 in azole resistance</span></div><div class="casAuthors">Kim, Sang Hu; Iyer, Kali R.; Pardeshi, Lakhansing; Munoz, Jose F.; Robbins, Nicole; Cuomo, Christina A.; Wong, Koon Ho; Cowen, Leah E.</div><div class="citationInfo"><span class="NLM_cas:title">mBio</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e02529</span>CODEN:
                <span class="NLM_cas:coden">MBIOCL</span>;
        ISSN:<span class="NLM_cas:issn">2150-7511</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Candida auris is an emerging fungal pathogen and a serious global health threat as the majority of clin. isolates display elevated resistance to currently available antifungal drugs.  Despite the increased prevalence of C. auris infections, the mechanisms governing drug resistance remain largely elusive.  However, role of Hsp90 in the pathobiol. of C. auris remains unknown.  In order to study regulatory functions of Hsp90 in C. auris, we placed HSP90 under the control of a doxycycline-repressible promoter to enable transcriptional repression.  We found that Hsp90 is essential for growth in C. auris and that it enables tolerance of clin. isolates with respect to azoles, which inhibit biosynthesis of the membrane sterol ergosterol.  High-level azole resistance was independent of Hsp90 but dependent on the ABC transporter CDR1, deletion of which resulted in abrogated resistance.  Strikingly, we discovered that C. auris undergoes a morphogenetic transition from yeast to filamentous growth in response to HSP90 depletion or cell cycle arrest but not in response to other cues that induce C. albicans filamentation.  Finally, we obsd. that this developmental transition is assocd. with global transcriptional changes, including the induction of cell wall-related genes.  Overall, this report provides a novel insight into mechanisms of drug tolerance and resistance in C. auris and describes a developmental transition in response to perturbation of a core regulator of protein homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL3IYAhv3SN7Vg90H21EOLACvtfcHk0lifaNbJO2XnWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht12ht73O&md5=673b28df89855de5ff4cd82eab83c550</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1128%2FmBio.02529-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FmBio.02529-18%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DIyer%26aufirst%3DK.%2BR.%26aulast%3DPardeshi%26aufirst%3DL.%26aulast%3DMunoz%26aufirst%3DJ.%2BF.%26aulast%3DRobbins%26aufirst%3DN.%26aulast%3DCuomo%26aufirst%3DC.%2BA.%26aulast%3DWong%26aufirst%3DK.%2BH.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26atitle%3DGenetic%2520analysis%2520of%2520Candida%2520auris%2520implicates%2520Hsp90%2520in%2520morphogenesis%2520and%2520azole%2520tolerance%2520and%2520Cdr1%2520in%2520azole%2520resistance%26jtitle%3DmBio%26date%3D2019%26volume%3D10%26spage%3De02529%26epage%3D02518%26doi%3D10.1128%2FmBio.02529-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veri, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebbji, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Meara, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colazo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyas, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteway, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span> <span> </span><span class="NLM_article-title">Tuning Hsf1 levels drives distinct fungal morphogenetic programs with depletion impairing Hsp90 function and overexpression expanding the target space</span>. <i>PLoS Genet.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>, <span class="NLM_elocation-id">e1007270</span> <span class="refDoi"> DOI: 10.1371/journal.pgen.1007270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1371%2Fjournal.pgen.1007270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=29590106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslCgtrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&author=A.+O.+Veriauthor=Z.+Miaoauthor=R.+S.+Shapiroauthor=F.+Tebbjiauthor=T.+R.+O%E2%80%99Mearaauthor=S.+H.+Kimauthor=J.+Colazoauthor=K.+Tanauthor=V.+K.+Vyasauthor=M.+Whitewayauthor=N.+Robbinsauthor=K.+H.+Wongauthor=L.+E.+Cowen&title=Tuning+Hsf1+levels+drives+distinct+fungal+morphogenetic+programs+with+depletion+impairing+Hsp90+function+and+overexpression+expanding+the+target+space&doi=10.1371%2Fjournal.pgen.1007270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Tuning Hsf1 levels drives distinct fungal morphogenetic programs with depletion impairing Hsp90 function and overexpression expanding the target space</span></div><div class="casAuthors">Veri, Amanda O.; Miao, Zhengqiang; Shapiro, Rebecca S.; Tebbji, Faiza; O'meara, Teresa R.; Kim, Sang Hu; Colazo, Juan; Tan, Kaeling; Vyas, Valmik K.; Whiteway, Malcolm; Robbins, Nicole; Wong, Koon Ho; Cowen, Leah E.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Genetics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e1007270/1-e1007270/39</span>CODEN:
                <span class="NLM_cas:coden">PGLEB5</span>;
        ISSN:<span class="NLM_cas:issn">1553-7404</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The capacity to respond to temp. fluctuations is crit. for microorganisms to survive within mammalian hosts, and temp. modulates virulence traits of diverse pathogens.  One key temp.-dependent virulence trait of the fungal pathogen Candida albicans is its ability to transition from yeast to filamentous growth, which is induced by environmental cues at host physiol. temp.  A key regulator of temp.-dependent morphogenesis is the mol. chaperone Hsp90, which has complex functional relationships with the transcription factor Hsf1.  Although Hsf1 controls global transcriptional remodeling in response to heat shock, its impact on morphogenesis remains unknown.  Here, we establish an intriguing paradigm whereby overexpression or depletion of C. albicansHSF1 induces morphogenesis in the absence of external cues.  HSF1 depletion compromises Hsp90 function, thereby driving filamentation.  HSF1 overexpression does not impact Hsp90 function, but rather induces a dose-dependent expansion of Hsf1 direct targets that drives overexpression of pos. regulators of filamentation, including Brg1 and Ume6, thereby bypassing the requirement for elevated temp. during morphogenesis.  This work provides new insight into Hsf1-mediated environmentally contingent transcriptional control, implicates Hsf1 in regulation of a key virulence trait, and highlights fascinating biol. whereby either overexpression or depletion of a single cellular regulator induces a profound developmental transition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMfGoaF-w23bVg90H21EOLACvtfcHk0lifaNbJO2XnWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslCgtrnJ&md5=305df6345b9b590c80a669ae63e4229e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pgen.1007270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pgen.1007270%26sid%3Dliteratum%253Aachs%26aulast%3DVeri%26aufirst%3DA.%2BO.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DShapiro%26aufirst%3DR.%2BS.%26aulast%3DTebbji%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DT.%2BR.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DColazo%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DK.%26aulast%3DVyas%26aufirst%3DV.%2BK.%26aulast%3DWhiteway%26aufirst%3DM.%26aulast%3DRobbins%26aufirst%3DN.%26aulast%3DWong%26aufirst%3DK.%2BH.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26atitle%3DTuning%2520Hsf1%2520levels%2520drives%2520distinct%2520fungal%2520morphogenetic%2520programs%2520with%2520depletion%2520impairing%2520Hsp90%2520function%2520and%2520overexpression%2520expanding%2520the%2520target%2520space%26jtitle%3DPLoS%2520Genet.%26date%3D2018%26volume%3D14%26doi%3D10.1371%2Fjournal.pgen.1007270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Meara, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span> <span> </span><span class="NLM_article-title">The Hsp90 chaperone network modulates <i>Candida</i> virulence traits</span>. <i>Trends Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">809</span>– <span class="NLM_lpage">819</span>, <span class="refDoi"> DOI: 10.1016/j.tim.2017.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1016%2Fj.tim.2017.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=28549824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A280%3ADC%252BC1cnhvVWgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=809-819&author=T.+R.+O%E2%80%99Mearaauthor=N.+Robbinsauthor=L.+E.+Cowen&title=The+Hsp90+chaperone+network+modulates+Candida+virulence+traits&doi=10.1016%2Fj.tim.2017.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The Hsp90 Chaperone Network Modulates Candida Virulence Traits</span></div><div class="casAuthors">O'Meara Teresa R; Robbins Nicole; Cowen Leah E</div><div class="citationInfo"><span class="NLM_cas:title">Trends in microbiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">809-819</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hsp90 is a conserved molecular chaperone that facilitates the folding and function of client proteins.  Hsp90 function is dynamically regulated by interactions with co-chaperones and by post-translational modifications.  In the fungal pathogen Candida albicans, Hsp90 enables drug resistance and virulence by stabilizing diverse signal transducers.  Here, we review studies that have unveiled regulators of Hsp90 function, as well as downstream effectors that govern the key virulence traits of morphogenesis and drug resistance.  We highlight recent work mapping the Hsp90 genetic network in C. albicans under diverse environmental conditions, and how these interactions provide insight into circuitry important for drug resistance, morphogenesis, and virulence.  Ultimately, elucidating the Hsp90 chaperone network will aid in the development of therapeutics to treat fungal disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQIfwZvIeSQw1QKX3ooHxWjfW6udTcc2eY4tP3zvABA6Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnhvVWgtQ%253D%253D&md5=e4d32d19bc2ed5f682a2048682cb6dd7</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.tim.2017.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tim.2017.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DT.%2BR.%26aulast%3DRobbins%26aufirst%3DN.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26atitle%3DThe%2520Hsp90%2520chaperone%2520network%2520modulates%2520Candida%2520virulence%2520traits%26jtitle%3DTrends%2520Microbiol.%26date%3D2017%26volume%3D25%26spage%3D809%26epage%3D819%26doi%3D10.1016%2Fj.tim.2017.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leach, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klipp, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. J.</span></span> <span> </span><span class="NLM_article-title">Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs</span>. <i>Nat. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">704</span>, <span class="refDoi"> DOI: 10.1038/nrmicro2875</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1038%2Fnrmicro2875" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=22976491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlertbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2012&pages=693-704&author=M.+D.+Leachauthor=E.+Klippauthor=L.+E.+Cowenauthor=A.+J.+Brown&title=Fungal+Hsp90%3A+a+biological+transistor+that+tunes+cellular+outputs+to+thermal+inputs&doi=10.1038%2Fnrmicro2875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs</span></div><div class="casAuthors">Leach, Michelle D.; Klipp, Edda; Cowen, Leah E.; Brown, Alistair J. P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Microbiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">693-704</span>CODEN:
                <span class="NLM_cas:coden">NRMACK</span>;
        ISSN:<span class="NLM_cas:issn">1740-1526</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Heat shock protein 90 (Hsp90) is an essential, abundant and ubiquitous eukaryotic chaperone that has crucial roles in protein folding and modulates the activities of key regulators.  The fungal Hsp90 interactome, which includes numerous client proteins such as receptors, protein kinases and transcription factors, displays a surprisingly high degree of plasticity that depends on environmental conditions.  Furthermore, although fungal Hsp90 levels increase following environmental challenges, Hsp90 activity is tightly controlled via post-translational regulation and an autoregulatory loop involving heat shock transcription factor 1 (Hsf1).  In this Review, we discuss the roles and regulation of fungal Hsp90.  We propose that Hsp90 acts as a biol. transistor that modulates the activity of fungal signaling networks in response to environmental cues via this Hsf1-Hsp90 autoregulatory loop.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxYlx4CLzINrVg90H21EOLACvtfcHk0lji_AwJwCVksg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlertbnM&md5=26880d38c60d1a9d83c84328240b0e35</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrmicro2875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrmicro2875%26sid%3Dliteratum%253Aachs%26aulast%3DLeach%26aufirst%3DM.%2BD.%26aulast%3DKlipp%26aufirst%3DE.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26aulast%3DBrown%26aufirst%3DA.%2BJ.%26atitle%3DFungal%2520Hsp90%253A%2520a%2520biological%2520transistor%2520that%2520tunes%2520cellular%2520outputs%2520to%2520thermal%2520inputs%26jtitle%3DNat.%2520Rev.%2520Microbiol.%26date%3D2012%26volume%3D10%26spage%3D693%26epage%3D704%26doi%3D10.1038%2Fnrmicro2875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindquist, S.</span></span> <span> </span><span class="NLM_article-title">Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>309</i></span>,  <span class="NLM_fpage">2185</span>– <span class="NLM_lpage">2189</span>, <span class="refDoi"> DOI: 10.1126/science.1118370</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1126%2Fscience.1118370" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=16195452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeksbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2005&pages=2185-2189&author=L.+E.+Cowenauthor=S.+Lindquist&title=Hsp90+potentiates+the+rapid+evolution+of+new+traits%3A+drug+resistance+in+diverse+fungi&doi=10.1126%2Fscience.1118370"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 potentiates the rapid evolution of new traits: Drug resistance in diverse fungi</span></div><div class="casAuthors">Cowen, Leah E.; Lindquist, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">309</span>
        (<span class="NLM_cas:issue">5744</span>),
    <span class="NLM_cas:pages">2185-2189</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Hsp90 is a mol. chaperone for many signal transducers and may influence evolution by releasing previously silent genetic variation in response to environmental change.  In fungi sepd. by ∼800 million years of evolution, Hsp90 potentiated the evolution of drug resistance in a different way, by enabling new mutations to have immediate phenotypic consequences.  Resistance was abrogated by Hsp90 inhibitors and by febrile temps., suggesting new therapeutic strategies and a clin. benefit of fever.  During selection in a human host, drug resistance that was initially Hsp90-dependent evolved toward independence.  Thus, Hsp90 can act in diverse ways to couple environmental contingency to the emergence and fixation of new traits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiYEERY_9yw7Vg90H21EOLACvtfcHk0ljg8JDKFviXpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeksbbI&md5=153bda853d501270402f5e18ab14b5d8</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1126%2Fscience.1118370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1118370%26sid%3Dliteratum%253Aachs%26aulast%3DCowen%26aufirst%3DL.%2BE.%26aulast%3DLindquist%26aufirst%3DS.%26atitle%3DHsp90%2520potentiates%2520the%2520rapid%2520evolution%2520of%2520new%2520traits%253A%2520drug%2520resistance%2520in%2520diverse%2520fungi%26jtitle%3DScience%26date%3D2005%26volume%3D309%26spage%3D2185%26epage%3D2189%26doi%3D10.1126%2Fscience.1118370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaas, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schell, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perfect, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span> <span> </span><span class="NLM_article-title">Hsp90 governs echinocandin resistance in the pathogenic yeast <i>Candida albicans</i> via calcineurin</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e1000532</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1000532</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1371%2Fjournal.ppat.1000532" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=19649312" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&author=S.+D.+Singhauthor=N.+Robbinsauthor=A.+K.+Zaasauthor=W.+A.+Schellauthor=J.+R.+Perfectauthor=L.+E.+Cowen&title=Hsp90+governs+echinocandin+resistance+in+the+pathogenic+yeast+Candida+albicans+via+calcineurin&doi=10.1371%2Fjournal.ppat.1000532"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1000532&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1000532%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DS.%2BD.%26aulast%3DRobbins%26aufirst%3DN.%26aulast%3DZaas%26aufirst%3DA.%2BK.%26aulast%3DSchell%26aufirst%3DW.%2BA.%26aulast%3DPerfect%26aufirst%3DJ.%2BR.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26atitle%3DHsp90%2520governs%2520echinocandin%2520resistance%2520in%2520the%2520pathogenic%2520yeast%2520Candida%2520albicans%2520via%2520calcineurin%26jtitle%3DPLoS%2520Pathog.%26date%3D2009%26volume%3D5%26doi%3D10.1371%2Fjournal.ppat.1000532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohler, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaas, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schell, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aziz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mylonakis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perfect, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindquist, S.</span></span> <span> </span><span class="NLM_article-title">Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">2818</span>– <span class="NLM_lpage">2823</span>, <span class="refDoi"> DOI: 10.1073/pnas.0813394106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1073%2Fpnas.0813394106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=19196973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD1MXislaht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=2818-2823&author=L.+E.+Cowenauthor=S.+D.+Singhauthor=J.+R.+Kohlerauthor=C.+Collinsauthor=A.+K.+Zaasauthor=W.+A.+Schellauthor=H.+Azizauthor=E.+Mylonakisauthor=J.+R.+Perfectauthor=L.+Whitesellauthor=S.+Lindquist&title=Harnessing+Hsp90+function+as+a+powerful%2C+broadly+effective+therapeutic+strategy+for+fungal+infectious+disease&doi=10.1073%2Fpnas.0813394106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease</span></div><div class="casAuthors">Cowen, Leah E.; Singh, Sheena D.; Kohler, Julia R.; Collins, Cathy; Zaas, Aimee; Schell, Wiley A.; Aziz, Hamza; Mylonakis, Eleftherios; Perfect, John R.; Whitesell, Luke; Lindquist, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2818-2823</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Invasive fungal infections are a leading cause of mortality among immunocompromised individuals.  Treatment is notoriously difficult with the limited armamentarium of antifungal drugs, whose efficacy is compromised by host toxicity, a limited activity spectrum, or the emergence of drug resistance.  We previously established that the mol. chaperone Hsp90 enables the emergence and maintenance of fungal drug resistance.  For the most prevalent fungal pathogen of humans, Candida albicans, Hsp90 mediates resistance to azoles, which inhibit ergosterol biosynthesis and are the most widely deployed antifungals in the clinic.  For the emerging opportunistic pathogen Aspergillus terreus, Hsp90 is required for basal resistance to echinocandins, which inhibit β(1, 3)-glucan synthesis and are the only new class of antifungals to reach the clinic in decades.  Here, we explore the therapeutic potential of Hsp90 inhibitors in fungal disease using a tractable host-model system, larvae of the greater wax moth Galleria mellonella, and a murine model of disseminated disease.  Combination therapy with Hsp90 inhibitors that are well tolerated in humans and an azole rescued larvae from lethal C. albicans infections.  Combination therapy with an Hsp90 inhibitor and an echinocandin rescued larvae from infections with the most lethal mold, Aspergillus fumigatus.  In a murine model of disseminated candidiasis, genetic compromise of C. albicans HSP90 expression enhanced the therapeutic efficacy of an azole.  Thus, harnessing Hsp90 provides a much-needed strategy for improving the treatment of fungal disease because it enhances the efficacy of existing antifungals, blocks the emergence of drug resistance, and exerts broad-spectrum activity against diverse fungal pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtMf02gFiLZLVg90H21EOLACvtfcHk0ljg8JDKFviXpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXislaht7s%253D&md5=a0bf89b9285831333d619bb9edc8f4ef</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0813394106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0813394106%26sid%3Dliteratum%253Aachs%26aulast%3DCowen%26aufirst%3DL.%2BE.%26aulast%3DSingh%26aufirst%3DS.%2BD.%26aulast%3DKohler%26aufirst%3DJ.%2BR.%26aulast%3DCollins%26aufirst%3DC.%26aulast%3DZaas%26aufirst%3DA.%2BK.%26aulast%3DSchell%26aufirst%3DW.%2BA.%26aulast%3DAziz%26aufirst%3DH.%26aulast%3DMylonakis%26aufirst%3DE.%26aulast%3DPerfect%26aufirst%3DJ.%2BR.%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DLindquist%26aufirst%3DS.%26atitle%3DHarnessing%2520Hsp90%2520function%2520as%2520a%2520powerful%252C%2520broadly%2520effective%2520therapeutic%2520strategy%2520for%2520fungal%2520infectious%2520disease%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D2818%26epage%3D2823%26doi%3D10.1073%2Fpnas.0813394106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatu, U.</span></span> <span> </span><span class="NLM_article-title">Heat shock protein 90 localizes to the surface and augments virulence factors of <i>Cryptococcus neoformans</i></span>. <i>PLoS Negl. Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">e0005836</span> <span class="refDoi"> DOI: 10.1371/journal.pntd.0005836</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1371%2Fjournal.pntd.0005836" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=28783748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVCltbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&author=S.+Chatterjeeauthor=U.+Tatu&title=Heat+shock+protein+90+localizes+to+the+surface+and+augments+virulence+factors+of+Cryptococcus+neoformans&doi=10.1371%2Fjournal.pntd.0005836"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Heat shock protein 90 localizes to the surface and augments virulence factors of Cryptococcus neoformans</span></div><div class="casAuthors">Chatterjee, Sharanya; Tatu, Utpal</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e0005836/1-e0005836/20</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background Thermotolerance is an essential attribute for pathogenesis of Cryptococcus as exemplified by the fact that only two species in the genus, which can grow at 37°C, are human pathogens.  Species which have other virulence factors including capsule formation and melanisation, but lack the ability to propagate at 37°C are not pathogenic.  In another related fungal pathogen, Candida albicans, heat shock protein 90 has been implicated to be a central player in commanding pathogenicity by governing yeast to hyphal transition and drug resistance.  Exploring Hsp90 biol. in Cryptococcus in context of thermotolerance may thus highlight important regulatory principles of virulence and open new therapeutic avenues.  Methodol./Principal findings Hsp90 is involved in regulating thermotolerance in Cryptococcus as indicated by growth hypersensitivity at 37°C upon mild compromise of Hsp90 function relative to 25°C.  Biochem. studies revealed a more potent inhibition of ATPase activity by pharmacol. inhibitor 17-AAG at 37°C as compared to 25°C.  Catalytic efficiency of the protein at 37°C was found to be 6.39 × 10-5μM-1.  Furthermore, indirect immunofluorescence anal. using a specific antibody revealed cell surface localization of Hsp90 via ER Golgi classical secretory pathway.  Hsp90 was found to be induced under capsule inducing conditions and Hsp90 inhibition led to decrease in capsular vol.  Finally compromising Hsp90 function improved anidulafungin tolerance in Cryptococcus.  Conclusions/Significance Our findings highlight that Hsp90 regulates pathogenicity of the fungus by myriad ways.  Firstly, it is involved in mediating thermotolerance which implies targeting Hsp90 can abrogate thermotolerance and hence growth of the fungus.  Secondly, this study provides the first report of biochem. properties of Hsp90 of a pathogenic fungus.  Finally, since Hsp90 is localised at the cell wall, targeting cell surface Hsp90 can represent a novel strategy to combat this lethal infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox--VK--z5SLVg90H21EOLACvtfcHk0liw3F-YPhTAqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVCltbjF&md5=d268755893a680cd9ef4f3e35e88690c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0005836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0005836%26sid%3Dliteratum%253Aachs%26aulast%3DChatterjee%26aufirst%3DS.%26aulast%3DTatu%26aufirst%3DU.%26atitle%3DHeat%2520shock%2520protein%252090%2520localizes%2520to%2520the%2520surface%2520and%2520augments%2520virulence%2520factors%2520of%2520Cryptococcus%2520neoformans%26jtitle%3DPLoS%2520Negl.%2520Trop.%2520Dis.%26date%3D2017%26volume%3D11%26doi%3D10.1371%2Fjournal.pntd.0005836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Aguiar Cordeiro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evangelista, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serpa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marques, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Melo, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Oliveira, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco Jda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Alencar, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandeira Tde, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brilhante, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidrim, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocha, M. F.</span></span> <span> </span><span class="NLM_article-title">, Inhibition of heat-shock protein 90 enhances the susceptibility to antifungals and reduces the virulence of <i>Cryptococcus neoformans</i>/<i>Cryptococcus gattii</i> species complex</span>. <i>Microbiology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1099/mic.0.000222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1099%2Fmic.0.000222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=26645478" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2016&pages=309-317&author=R.+de%0AAguiar+Cordeiroauthor=A.+J.+Evangelistaauthor=R.+Serpaauthor=F.+J.+Marquesauthor=C.+V.+de+Meloauthor=J.+S.+de+Oliveiraauthor=S.+Franco+Jdaauthor=L.+P.+de+Alencarauthor=J.+Bandeira+Tdeauthor=R.+S.+Brilhanteauthor=J.+J.+Sidrimauthor=M.+F.+Rocha&title=%2C+Inhibition+of+heat-shock+protein+90+enhances+the+susceptibility+to+antifungals+and+reduces+the+virulence+of+Cryptococcus+neoformans%2FCryptococcus+gattii+species+complex&doi=10.1099%2Fmic.0.000222"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1099%2Fmic.0.000222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fmic.0.000222%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BAguiar%2BCordeiro%26aufirst%3DR.%26aulast%3DEvangelista%26aufirst%3DA.%2BJ.%26aulast%3DSerpa%26aufirst%3DR.%26aulast%3DMarques%26aufirst%3DF.%2BJ.%26aulast%3Dde%2BMelo%26aufirst%3DC.%2BV.%26aulast%3Dde%2BOliveira%26aufirst%3DJ.%2BS.%26aulast%3DFranco%2BJda%26aufirst%3DS.%26aulast%3Dde%2BAlencar%26aufirst%3DL.%2BP.%26aulast%3DBandeira%2BTde%26aufirst%3DJ.%26aulast%3DBrilhante%26aufirst%3DR.%2BS.%26aulast%3DSidrim%26aufirst%3DJ.%2BJ.%26aulast%3DRocha%26aufirst%3DM.%2BF.%26atitle%3D%252C%2520Inhibition%2520of%2520heat-shock%2520protein%252090%2520enhances%2520the%2520susceptibility%2520to%2520antifungals%2520and%2520reduces%2520the%2520virulence%2520of%2520Cryptococcus%2520neoformans%252FCryptococcus%2520gattii%2520species%2520complex%26jtitle%3DMicrobiology%26date%3D2016%26volume%3D162%26spage%3D309%26epage%3D317%26doi%3D10.1099%2Fmic.0.000222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Q. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. L.</span></span> <span> </span><span class="NLM_article-title">Heat shock protein 90 inhibitors: An update on achievements, challenges, and future directions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1798</span>– <span class="NLM_lpage">1822</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00940</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00940" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVKkurvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1798-1822&author=L.+Liauthor=L.+Wangauthor=Q.+D.+Youauthor=X.+L.+Xu&title=Heat+shock+protein+90+inhibitors%3A+An+update+on+achievements%2C+challenges%2C+and+future+directions&doi=10.1021%2Facs.jmedchem.9b00940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions</span></div><div class="casAuthors">Li, Li; Wang, Lei; You, Qi-Dong; Xu, Xiao-Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1798-1822</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Hsp90 is one of the most important chaperones involved in regulating the maturation of more than 300 client proteins, many of which are closely assocd. with refractory diseases, including cancer, neurodegenerative diseases and viral infections.  Clin. Hsp90 inhibitors bind to the ATP pocket in the N-terminal domain of Hsp90 and subsequently suppress the ATPase activity of Hsp90.  Recently, with the increased understanding of the discrepancies in the isoforms of Hsp90 and the modes of Hsp90-cochaperone-client complex interactions, some new strategies for Hsp90 inhibition have emerged.  Novel Hsp90 inhibitors that offer selective suppression of Hsp90 isoforms or specific disruption of Hsp90-cochaperone protein-protein interactions are expected to breakthrough with satisfactory efficacy and safety profiles.  This review summarizes the recent progress in Hsp90 inhibitors.  Addnl., Hsp90 inhibitory strategies are emphasized in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkbKTcDYjrzrVg90H21EOLACvtfcHk0liAOH1gSMu96g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVKkurvO&md5=972a35d1b12f5e21a7fa27cbb6bfc0cd</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00940%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYou%26aufirst%3DQ.%2BD.%26aulast%3DXu%26aufirst%3DX.%2BL.%26atitle%3DHeat%2520shock%2520protein%252090%2520inhibitors%253A%2520An%2520update%2520on%2520achievements%252C%2520challenges%252C%2520and%2520future%2520directions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1798%26epage%3D1822%26doi%3D10.1021%2Facs.jmedchem.9b00940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jaeger, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stopfer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaglia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santagata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, N. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trepel, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacks, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindquist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, L.</span></span> <span> </span><span class="NLM_article-title">Rebalancing protein homeostasis enhances tumor antigen presentation</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">6392</span>– <span class="NLM_lpage">6405</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-19-0596</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1158%2F1078-0432.CCR-19-0596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=31213460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVSmsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=6392-6405&author=A.+M.+Jaegerauthor=L.+Stopferauthor=S.+Leeauthor=G.+Gagliaauthor=D.+Sandelauthor=S.+Santagataauthor=N.+U.+Linauthor=J.+B.+Trepelauthor=F.+Whiteauthor=T.+Jacksauthor=S.+Lindquistauthor=L.+Whitesell&title=Rebalancing+protein+homeostasis+enhances+tumor+antigen+presentation&doi=10.1158%2F1078-0432.CCR-19-0596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Rebalancing protein homeostasis enhances tumor antigen presentation</span></div><div class="casAuthors">Jaeger, Alex M.; Stopfer, Lauren; Lee, Sunmin; Gaglia, Giorgio; Sandel, Demi; Santagata, Sandro; Lin, Nancy U.; Trepel, Jane B.; White, Forest; Jacks, Tyler; Lindquis, Susan; Whitesell, Luke</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6392-6405</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Despite the accumulation of extensive genomic alterations, many cancers fail to be recognized as "foreign" and escape destruction by the host immune system.  Immunotherapies designed to address this problem by directly stimulating immune effector cells have led to some remarkable clin. outcomes, but unfortunately, most cancers fail to respond, prompting the need to identify addnl. immunomodulatory treatment options.  Exptl. Design: We elucidated the effect of a novel treatment paradigm using sustained, low-dose HSP90 inhibition in vitro and in syngeneic mouse models using genetic and pharmacol. tools.  Profiling of treatment-assocd. tumor cell antigens was performed using immunopptn. followed by peptide mass spectrometry.  Results: We show that sustained, low-level inhibition of HSP90 both amplifies and diversifies the antigenic repertoire presented by tumor cells on MHC-I mols. through an IFNγ-independent mechanism.  In stark contrast, we find that acute, high-dose exposure to HSP90 inhibitors, the only approach studied in the clinic to date, is broadly immunosuppressive in cell culture and in patients with cancer.  In mice, chronic non-heat shock-inducing HSP90 inhibition slowed progression of colon cancer implants, but only in syngeneic animals with intact immune function.  Addn. of a single dose of nonspecific immune adjuvant to the regimen dramatically increased efficacy, curing a subset of mice receiving combination therapy.  Conclusions: These highly translatable observations support reconsideration of the most effective strategy for targeting HSP90 to treat cancers and suggest a practical approach to repurposing current orally bioavailable HSP90 inhibitors as a new immunotherapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0-I8CkNNE0LVg90H21EOLACvtfcHk0lj6dSBCnkC6ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVSmsrvJ&md5=f35aa9e0e1ba541e3b79461ae2db4b4a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-19-0596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-19-0596%26sid%3Dliteratum%253Aachs%26aulast%3DJaeger%26aufirst%3DA.%2BM.%26aulast%3DStopfer%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DGaglia%26aufirst%3DG.%26aulast%3DSandel%26aufirst%3DD.%26aulast%3DSantagata%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DN.%2BU.%26aulast%3DTrepel%26aufirst%3DJ.%2BB.%26aulast%3DWhite%26aufirst%3DF.%26aulast%3DJacks%26aufirst%3DT.%26aulast%3DLindquist%26aufirst%3DS.%26aulast%3DWhitesell%26aufirst%3DL.%26atitle%3DRebalancing%2520protein%2520homeostasis%2520enhances%2520tumor%2520antigen%2520presentation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D25%26spage%3D6392%26epage%3D6405%26doi%3D10.1158%2F1078-0432.CCR-19-0596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jaeger, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, L.</span></span> <span> </span><span class="NLM_article-title">HSP90: Enabler of cancer adaptation</span>. <i>Annu. Rev. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">297</span>, <span class="refDoi"> DOI: 10.1146/annurev-cancerbio-030518-055533</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1146%2Fannurev-cancerbio-030518-055533" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2019&pages=275-297&author=A.+M.+Jaegerauthor=L.+Whitesell&title=HSP90%3A+Enabler+of+cancer+adaptation&doi=10.1146%2Fannurev-cancerbio-030518-055533"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1146%2Fannurev-cancerbio-030518-055533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-cancerbio-030518-055533%26sid%3Dliteratum%253Aachs%26aulast%3DJaeger%26aufirst%3DA.%2BM.%26aulast%3DWhitesell%26aufirst%3DL.%26atitle%3DHSP90%253A%2520Enabler%2520of%2520cancer%2520adaptation%26jtitle%3DAnnu.%2520Rev.%2520Cancer%2520Biol.%26date%3D2019%26volume%3D3%26spage%3D275%26epage%3D297%26doi%3D10.1146%2Fannurev-cancerbio-030518-055533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gewirth, D. T.</span></span> <span> </span><span class="NLM_article-title">Paralog specific Hsp90 inhibitors - a brief history and a bright future</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2779</span>– <span class="NLM_lpage">2791</span>, <span class="refDoi"> DOI: 10.2174/1568026616666160413141154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.2174%2F1568026616666160413141154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=27072700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOhsrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=2779-2791&author=D.+T.+Gewirth&title=Paralog+specific+Hsp90+inhibitors+-+a+brief+history+and+a+bright+future&doi=10.2174%2F1568026616666160413141154"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Paralog Specific Hsp90 Inhibitors - A Brief History and a Bright Future</span></div><div class="casAuthors">Gewirth, Daniel T.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2779-2791</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background. The high sequence and structural homol. among the hsp90 paralogs - Hsp90α, Hsp90β, Grp94, and Trap-1 - has made the development of paralog-specific inhibitors a challenging proposition.  Objective. This review surveys the state of developments in structural anal., compd. screening, and structure-based design that have been brought to bear on this problem.  Results. First generation compds. that selectively bind to Hsp90, Grp94, or Trap-1 have been identified.  Conclusion. With the proof of principle firmly established, the prospects for further progress are bright.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdyZyrXOyou7Vg90H21EOLACvtfcHk0lh5685hbWLFug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOhsrzN&md5=208025ff36aa6e2d92d3ee107b20ab5f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.2174%2F1568026616666160413141154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026616666160413141154%26sid%3Dliteratum%253Aachs%26aulast%3DGewirth%26aufirst%3DD.%2BT.%26atitle%3DParalog%2520specific%2520Hsp90%2520inhibitors%2520-%2520a%2520brief%2520history%2520and%2520a%2520bright%2520future%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2016%26volume%3D16%26spage%3D2779%26epage%3D2791%26doi%3D10.2174%2F1568026616666160413141154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheon, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, B. H.</span></span> <span> </span><span class="NLM_article-title">Development of a mitochondria-targeted Hsp90 inhibitor based on the crystal structures of human TRAP1</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">4358</span>– <span class="NLM_lpage">4367</span>, <span class="refDoi"> DOI: 10.1021/ja511893n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja511893n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksl2htrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=4358-4367&author=C.+Leeauthor=H.+K.+Parkauthor=H.+Jeongauthor=J.+Limauthor=A.+J.+Leeauthor=K.+Y.+Cheonauthor=C.+S.+Kimauthor=A.+P.+Thomasauthor=B.+Baeauthor=N.+D.+Kimauthor=S.+H.+Kimauthor=P.+G.+Suhauthor=J.+H.+Ryuauthor=B.+H.+Kang&title=Development+of+a+mitochondria-targeted+Hsp90+inhibitor+based+on+the+crystal+structures+of+human+TRAP1&doi=10.1021%2Fja511893n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Mitochondria-Targeted Hsp90 Inhibitor Based on the Crystal Structures of Human TRAP1</span></div><div class="casAuthors">Lee, Changwook; Park, Hye-Kyung; Jeong, Hanbin; Lim, Jaehwa; Lee, An-Jung; Cheon, Keun Young; Kim, Chul-Su; Thomas, Ajesh P.; Bae, Boram; Kim, Nam Doo; Kim, Seong Heon; Suh, Pann-Ghill; Ryu, Ja-Hyoung; Kang, Byoung Heon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4358-4367</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The mitochondrial pool of Hsp90 and its mitochondrial paralog, TRAP1, suppresses cell death and reprograms energy metab. in cancer cells; therefore, Hsp90 and TRAP1 have been suggested as target proteins for anticancer drug development.  Here, the authors report that the actual target protein in cancer cell mitochondria is TRAP1, and current Hsp90 inhibitors cannot effectively inactivate TRAP1 because of their insufficient accumulation in the mitochondria.  To develop mitochondrial TRAP1 inhibitors, the authors detd. the crystal structures of human TRAP1 complexed with Hsp90 inhibitors.  The iso-Pr amine of the Hsp90 inhibitor PU-H71 was replaced with the mitochondria-targeting moiety triphenylphosphonium to produce SMTIN-P01.  SMTIN-P01 showed a different mode of action from the nontargeted PU-H71, as well as much improved cytotoxicity to cancer cells.  In addn., the authors detd. the structure of a TRAP1-adenylyl-imidodiphosphate (AMP-PNP) complex.  On the basis of comparative anal. of TRAP1 structures, the authors propose a mol. mechanism of ATP hydrolysis that is crucial for chaperone function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN-VB5CkPi2LVg90H21EOLACvtfcHk0lh5685hbWLFug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksl2htrs%253D&md5=c1142149eaa5f4157377ce64662fcfc1</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fja511893n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja511893n%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DH.%2BK.%26aulast%3DJeong%26aufirst%3DH.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DA.%2BJ.%26aulast%3DCheon%26aufirst%3DK.%2BY.%26aulast%3DKim%26aufirst%3DC.%2BS.%26aulast%3DThomas%26aufirst%3DA.%2BP.%26aulast%3DBae%26aufirst%3DB.%26aulast%3DKim%26aufirst%3DN.%2BD.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DSuh%26aufirst%3DP.%2BG.%26aulast%3DRyu%26aufirst%3DJ.%2BH.%26aulast%3DKang%26aufirst%3DB.%2BH.%26atitle%3DDevelopment%2520of%2520a%2520mitochondria-targeted%2520Hsp90%2520inhibitor%2520based%2520on%2520the%2520crystal%2520structures%2520of%2520human%2520TRAP1%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D4358%26epage%3D4367%26doi%3D10.1021%2Fja511893n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandelwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stothert, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huard, D. J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duerfeldt, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kizziah, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieberman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickey, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S. J.</span></span> <span> </span><span class="NLM_article-title">Development of glucose regulated protein 94-selective inhibitors based on the BnIm and radamide scaffold</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3471</span>– <span class="NLM_lpage">3488</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00085</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00085" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC28XksFGrs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3471-3488&author=V.+M.+Crowleyauthor=A.+Khandelwalauthor=S.+Mishraauthor=A.+R.+Stothertauthor=D.+J.+E.+Huardauthor=J.+Zhaoauthor=A.+Muthauthor=A.+S.+Duerfeldtauthor=J.+L.+Kizziahauthor=R.+L.+Liebermanauthor=C.+A.+Dickeyauthor=B.+S.+J.+Blagg&title=Development+of+glucose+regulated+protein+94-selective+inhibitors+based+on+the+BnIm+and+radamide+scaffold&doi=10.1021%2Facs.jmedchem.6b00085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Glucose Regulated Protein 94-Selective Inhibitors Based on the BnIm and Radamide Scaffold</span></div><div class="casAuthors">Crowley, Vincent M.; Khandelwal, Anuj; Mishra, Sanket; Stothert, Andrew R.; Huard, Dustin J. E.; Zhao, Jinbo; Muth, Aaron; Duerfeldt, Adam S.; Kizziah, James L.; Lieberman, Raquel L.; Dickey, Chad A.; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3471-3488</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">(Arylmethyl)imidazolylethyl chlorodihydroxybenzoates I (R = Ph, 4-FC6H4, 4-ClC6H4, 4-BrC6H4, 4-IC6H4, 4-MeC6H4, 4-EtC6H4, 4-i-PrC6H4, 4-NCC6H4, 4-HC≡CC6H4, 4-F3CC6H4, 4-PhC6H4, 4-MeOC6H4, 3,4-Cl2C6H3, 1-naphthyl, 2-naphthyl, 5-quinolinyl, 3-FC6H4, 3-ClC6H4, 3-BrC6H4, 3-IC6H4, 3-MeOC6H4, 3-MeC6H4, 3-PhC6H4, 2-FC6H4, 2-ClC6H4, 2-BrC6H4, 2-MeC6H4, 2-H2NC6H4, 2-MeOC6H4, 2-EtC6H4, 2-EtOC6H4, 2-i-PrOC6H4, 2-n-PrOC6H4, 2-F3CC6H4, 2-MeO-4-MeC6H3, 3-furanyl, 2-furanyl, 5-Me-2-furanyl, 5-Cl-2-furanyl, 3,5-dimethyl-2-furanyl, 2-thienyl, 3-thienyl, 5-Me-2-thienyl, 5-Cl-2-thienyl, 4-Cl-2-thienyl, 3-Cl-2-thienyl, 5-isoxazolyl, 2-thiazolyl, 3-vinyl-2-thienyl, 3-vinyl-2-furanyl, 3-Et-2-thienyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 5-pyrimidinyl) were prepd. as selective inhibitors of glucose regulated protein 94 (Grp94), the endoplasmic reticulum-resident isoform of the heat shock protein 90 (Hsp90), for potential use in the treatment of glaucoma and cancer; the effect of the aryl substituents on Grp94 binding and selectivity was detd.  I were prepd. by the cyclocondensation of a bissilylated chloro(oxopropyl)dihydroxybenzoate with glyoxal and arylmethylamines RCH2NH2 (R = Ph, 4-FC6H4, 4-ClC6H4, 4-BrC6H4, 4-IC6H4, 4-MeC6H4, 4-EtC6H4, 4-i-PrC6H4, 4-NCC6H4, 4-HC≡CC6H4, 4-F3CC6H4, 4-PhC6H4, 4-MeOC6H4, 3,4-Cl2C6H3, 1-naphthyl, 2-naphthyl, 5-quinolinyl, 3-FC6H4, 3-ClC6H4, 3-BrC6H4, 3-IC6H4, 3-MeOC6H4, 3-MeC6H4, 3-PhC6H4, 2-FC6H4, 2-ClC6H4, 2-BrC6H4, 2-MeC6H4, 2-H2NC6H4, 2-MeOC6H4, 2-EtC6H4, 2-EtOC6H4, 2-i-PrOC6H4, 2-n-PrOC6H4, 2-F3CC6H4, 2-MeO-4-MeC6H3, 3-furanyl, 2-furanyl, 5-Me-2-furanyl, 5-Cl-2-furanyl, 3,5-dimethyl-2-furanyl, 2-thienyl, 3-thienyl, 5-Me-2-thienyl, 5-Cl-2-thienyl, 4-Cl-2-thienyl, 3-Cl-2-thienyl, 5-isoxazolyl, 2-thiazolyl, 3-vinyl-2-thienyl, 3-vinyl-2-furanyl, 3-Et-2-thienyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 5-pyrimidinyl) followed by desilylation.  I (R = 2-MeO-4-MeC6H3CH2, 5-chloro-2-furanylmethyl) were tested as inhibitors of cell migration in a cancer metastasis model and for their enhancement of the degrdn. of mutants of the protein myocilin in a glaucoma model.  The structures of the lead compd. radamide bound to Hsp82 and Grp94 and of I (R = 5-chloro-2-furanyl) bound to the N-terminal domain of Hsp94 lacking its acidic linker were detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3v_0NEYj1Z7Vg90H21EOLACvtfcHk0liar59SVe8deg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksFGrs7k%253D&md5=c73bbf30c243e281aae197689162c9e1</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00085%26sid%3Dliteratum%253Aachs%26aulast%3DCrowley%26aufirst%3DV.%2BM.%26aulast%3DKhandelwal%26aufirst%3DA.%26aulast%3DMishra%26aufirst%3DS.%26aulast%3DStothert%26aufirst%3DA.%2BR.%26aulast%3DHuard%26aufirst%3DD.%2BJ.%2BE.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DMuth%26aufirst%3DA.%26aulast%3DDuerfeldt%26aufirst%3DA.%2BS.%26aulast%3DKizziah%26aufirst%3DJ.%2BL.%26aulast%3DLieberman%26aufirst%3DR.%2BL.%26aulast%3DDickey%26aufirst%3DC.%2BA.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DDevelopment%2520of%2520glucose%2520regulated%2520protein%252094-selective%2520inhibitors%2520based%2520on%2520the%2520BnIm%2520and%2520radamide%2520scaffold%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3471%26epage%3D3488%26doi%3D10.1021%2Facs.jmedchem.6b00085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidler, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Que, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taldone, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finotti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephani, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gewirth, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiosis, G.</span></span> <span> </span><span class="NLM_article-title">Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">677</span>– <span class="NLM_lpage">684</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1038%2Fnchembio.1335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=23995768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlGltb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=677-684&author=P.+D.+Patelauthor=P.+Yanauthor=P.+M.+Seidlerauthor=H.+J.+Patelauthor=W.+Sunauthor=C.+Yangauthor=N.+S.+Queauthor=T.+Taldoneauthor=P.+Finottiauthor=R.+A.+Stephaniauthor=D.+T.+Gewirthauthor=G.+Chiosis&title=Paralog-selective+Hsp90+inhibitors+define+tumor-specific+regulation+of+HER2&doi=10.1038%2Fnchembio.1335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2</span></div><div class="casAuthors">Patel, Pallav D.; Yan, Pengrong; Seidler, Paul M.; Patel, Hardik J.; Sun, Weilin; Yang, Chenghua; Que, Nanette S.; Taldone, Tony; Finotti, Paola; Stephani, Ralph A.; Gewirth, Daniel T.; Chiosis, Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">677-684</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although the Hsp90 chaperone family, comprised in humans of four paralogs, Hsp90α, Hsp90β, Grp94 and Trap-1, has important roles in malignancy, the contribution of each paralog to the cancer phenotype is poorly understood.  This is in large part because reagents to study paralog-specific functions in cancer cells have been unavailable.  Here the authors combine compd. library screening with structural and computational analyses to identify purine-based chem. tools that are specific for Hsp90 paralogs.  The authors show that Grp94 selectivity is due to the insertion of these compds. into a new allosteric pocket.  The authors use these tools to demonstrate that cancer cells use individual Hsp90 paralogs to regulate a client protein in a tumor-specific manner and in response to proteome alterations.  Finally, the authors provide new mechanistic evidence explaining why selective Grp94 inhibition is particularly efficacious in certain breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAIwIoA9btZLVg90H21EOLACvtfcHk0liar59SVe8deg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlGltb7J&md5=8bdfb2c60b4171bbdd6046e455e413bb</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1335%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DP.%2BD.%26aulast%3DYan%26aufirst%3DP.%26aulast%3DSeidler%26aufirst%3DP.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BJ.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DQue%26aufirst%3DN.%2BS.%26aulast%3DTaldone%26aufirst%3DT.%26aulast%3DFinotti%26aufirst%3DP.%26aulast%3DStephani%26aufirst%3DR.%2BA.%26aulast%3DGewirth%26aufirst%3DD.%2BT.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DParalog-selective%2520Hsp90%2520inhibitors%2520define%2520tumor-specific%2520regulation%2520of%2520HER2%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D9%26spage%3D677%26epage%3D684%26doi%3D10.1038%2Fnchembio.1335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Que, N. L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duerfeldt, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gewirth, D. T.</span></span> <span> </span><span class="NLM_article-title">Structure based design of a Grp94-selective inhibitor: Exploiting a key residue in Grp94 to optimize paralog-selective binding</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2793</span>– <span class="NLM_lpage">2805</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01608</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01608" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlGhsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2793-2805&author=N.+L.+S.+Queauthor=V.+M.+Crowleyauthor=A.+S.+Duerfeldtauthor=J.+Zhaoauthor=C.+N.+Kentauthor=B.+S.+J.+Blaggauthor=D.+T.+Gewirth&title=Structure+based+design+of+a+Grp94-selective+inhibitor%3A+Exploiting+a+key+residue+in+Grp94+to+optimize+paralog-selective+binding&doi=10.1021%2Facs.jmedchem.7b01608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Design of a Grp94-Selective Inhibitor: Exploiting a Key Residue in Grp94 To Optimize Paralog-Selective Binding</span></div><div class="casAuthors">Que, Nanette L. S.; Crowley, Vincent M.; Duerfeldt, Adam S.; Zhao, Jinbo; Kent, Caitlin N.; Blagg, Brian S. J.; Gewirth, Daniel T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2793-2805</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Grp94 and Hsp90, the ER and cytoplasmic hsp90 paralogs, share a conserved ATP-binding pocket that has been targeted for therapeutics.  Paralog-selective inhibitors may lead to drugs with fewer side effects.  Here, the authors analyzed 1 (BnIm), a benzyl imidazole resorcinylic inhibitor, for its mode of binding.  The structures of 1 bound to Hsp90 and Grp94 reveal large conformational changes in Grp94 but not Hsp90 that expose site 2, a binding pocket adjacent to the central ATP cavity that is ordinarily blocked.  The Grp94:1 structure reveals a flipped pose of the resorcinylic scaffold that inserts into the exposed site 2.  The authors exploited this flipped binding pose to develop a Grp94-selective deriv. of 1.  The authors' structural anal. shows that the ability of the ligand to insert its benzyl imidazole substituent into site 1, a different side pocket off the ATP binding cavity, is the key to exposing site 2 in Grp94.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhACqcGHClIrVg90H21EOLACvtfcHk0lhZPUHvNT923A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlGhsLw%253D&md5=a44f6bf0bd3df65cf20ca570a1ef37b8</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01608%26sid%3Dliteratum%253Aachs%26aulast%3DQue%26aufirst%3DN.%2BL.%2BS.%26aulast%3DCrowley%26aufirst%3DV.%2BM.%26aulast%3DDuerfeldt%26aufirst%3DA.%2BS.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DKent%26aufirst%3DC.%2BN.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26aulast%3DGewirth%26aufirst%3DD.%2BT.%26atitle%3DStructure%2520based%2520design%2520of%2520a%2520Grp94-selective%2520inhibitor%253A%2520Exploiting%2520a%2520key%2520residue%2520in%2520Grp94%2520to%2520optimize%2520paralog-selective%2520binding%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2793%26epage%3D2805%26doi%3D10.1021%2Facs.jmedchem.7b01608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stothert, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suntharalingam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huard, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontaine, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieberman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickey, C. A.</span></span> <span> </span><span class="NLM_article-title">Exploiting the interaction between Grp94 and aggregated myocilin to treat glaucoma</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6470</span>, <span class="refDoi"> DOI: 10.1093/hmg/ddu367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1093%2Fhmg%2Fddu367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=25027323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitl2ntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=6470&author=A.+R.+Stothertauthor=A.+Suntharalingamauthor=D.+J.+Huardauthor=S.+N.+Fontaineauthor=V.+M.+Crowleyauthor=S.+Mishraauthor=B.+S.+Blaggauthor=R.+L.+Liebermanauthor=C.+A.+Dickey&title=Exploiting+the+interaction+between+Grp94+and+aggregated+myocilin+to+treat+glaucoma&doi=10.1093%2Fhmg%2Fddu367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting the interaction between Grp94 and aggregated myocilin to treat glaucoma</span></div><div class="casAuthors">Stothert, Andrew R.; Suntharalingam, Amirthaa; Huard, Dustin J. E.; Fontaine, Sarah N.; Crowley, Vincent M.; Mishra, Sanket; Blagg, Brian S. J.; Lieberman, Raquel L.; Dickey, Chad A.</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6470-6480</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Gain-of-function mutations in the olfactomedin domain of the MYOC gene facilitate the toxic accumulation of amyloid-contg. myocilin aggregates, hastening the onset of the prevalent ocular disorder primary open-angle glaucoma.  Aggregation of wild-type myocilin has been reported in other glaucoma subtypes, suggesting broader relevance of misfolded myocilin across the disease spectrum, but the absence of myocilin does not cause disease.  Thus, strategies aimed at eliminating myocilin could be therapeutically relevant for glaucoma.  Here, a novel and selective Grp94 inhibitor reduced the levels of several mutant myocilin proteins as well as wild-type myocilin when forced to misfold in cells.  This inhibitor rescued mutant myocilin toxicity in primary human trabecular meshwork cells.  Mechanistically, in vitro kinetics studies demonstrate that Grp94 recognizes on-pathway aggregates of the myocilin olfactomedin domain (myoc-OLF), accelerates rates of aggregation and co-ppts. with myoc-OLF.  These results indicate that aberrant myocilin quaternary structure drives Grp94 recognition, rather than peptide motifs exposed by unfolded protein.  Inhibition of Grp94 ameliorates the effects of Grp94-accelerated myoc-OLF aggregation, and Grp94 remains in soln.  In cells, when wild-type myocilin is driven to misfold and aggregate, it becomes a client of Grp94 and sensitive to Grp94 inhibition.  Taken together, the interaction of Grp94 with myocilin aggregates can be manipulated by cellular environment and genetics; this process can be exploited with Grp94 inhibitors to promote the clearance of toxic forms of myocilin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeQYeK777kKLVg90H21EOLACvtfcHk0lhZPUHvNT923A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitl2ntb8%253D&md5=cbabbce383403838a4cbc3ffe24bdce8</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fddu367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fddu367%26sid%3Dliteratum%253Aachs%26aulast%3DStothert%26aufirst%3DA.%2BR.%26aulast%3DSuntharalingam%26aufirst%3DA.%26aulast%3DHuard%26aufirst%3DD.%2BJ.%26aulast%3DFontaine%26aufirst%3DS.%2BN.%26aulast%3DCrowley%26aufirst%3DV.%2BM.%26aulast%3DMishra%26aufirst%3DS.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%26aulast%3DLieberman%26aufirst%3DR.%2BL.%26aulast%3DDickey%26aufirst%3DC.%2BA.%26atitle%3DExploiting%2520the%2520interaction%2520between%2520Grp94%2520and%2520aggregated%2520myocilin%2520to%2520treat%2520glaucoma%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2014%26volume%3D23%26spage%3D6470%26doi%3D10.1093%2Fhmg%2Fddu367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stothert, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suntharalingam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordhues, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huard, D. J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passaglia, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieberman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickey, C. A.</span></span> <span> </span><span class="NLM_article-title">Isoform-selective Hsp90 inhibition rescues model of hereditary open-angle glaucoma</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">17951</span> <span class="refDoi"> DOI: 10.1038/s41598-017-18344-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1038%2Fs41598-017-18344-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=29263415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A280%3ADC%252BC1MzjslWisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&author=A.+R.+Stothertauthor=A.+Suntharalingamauthor=X.+Tangauthor=V.+M.+Crowleyauthor=S.+J.+Mishraauthor=J.+M.+Websterauthor=B.+A.+Nordhuesauthor=D.+J.+E.+Huardauthor=C.+L.+Passagliaauthor=R.+L.+Liebermanauthor=B.+S.+J.+Blaggauthor=L.+J.+Blairauthor=J.+Korenauthor=C.+A.+Dickey&title=Isoform-selective+Hsp90+inhibition+rescues+model+of+hereditary+open-angle+glaucoma&doi=10.1038%2Fs41598-017-18344-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Isoform-selective Hsp90 inhibition rescues model of hereditary open-angle glaucoma</span></div><div class="casAuthors">Stothert Andrew R; Suntharalingam Amirthaa; Tang Xiaolan; Webster Jack M; Nordhues Bryce A; Blair Laura J; Koren John 3rd; Dickey Chad A; Tang Xiaolan; Passaglia Christopher L; Crowley Vincent M; Mishra Sanket J; Blagg Brian S J; Huard Dustin J E; Lieberman Raquel L</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17951</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The heat shock protein 90 (Hsp90) family of molecular chaperones regulates protein homeostasis, folding, and degradation.  The ER-resident Hsp90 isoform, glucose-regulated protein 94 (Grp94), promotes the aggregation of mutant forms of myocilin, a protein associated with primary open-angle glaucoma.  While inhibition of Grp94 promotes the degradation of mutant myocilin in vitro, to date no Grp94-selective inhibitors have been investigated in vivo.  Here, a Grp94-selective inhibitor facilitated mutant myocilin degradation and rescued phenotypes in a transgenic mouse model of hereditary primary open-angle glaucoma.  Ocular toxicities previously associated with pan-Hsp90 inhibitors were not evident with our Grp94-selective inhibitor, 4-Br-BnIm.  Our study suggests that selective inhibition of a distinct Hsp90 family member holds translational promise for ocular and other diseases associated with cell stress and protein misfolding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREMjSSm_naSNhSDZx9hyjKfW6udTcc2ebjdYDQNvsjtLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MzjslWisQ%253D%253D&md5=2d2b50528853d6b6d6a5704655da3c56</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-18344-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-18344-4%26sid%3Dliteratum%253Aachs%26aulast%3DStothert%26aufirst%3DA.%2BR.%26aulast%3DSuntharalingam%26aufirst%3DA.%26aulast%3DTang%26aufirst%3DX.%26aulast%3DCrowley%26aufirst%3DV.%2BM.%26aulast%3DMishra%26aufirst%3DS.%2BJ.%26aulast%3DWebster%26aufirst%3DJ.%2BM.%26aulast%3DNordhues%26aufirst%3DB.%2BA.%26aulast%3DHuard%26aufirst%3DD.%2BJ.%2BE.%26aulast%3DPassaglia%26aufirst%3DC.%2BL.%26aulast%3DLieberman%26aufirst%3DR.%2BL.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26aulast%3DBlair%26aufirst%3DL.%2BJ.%26aulast%3DKoren%26aufirst%3DJ.%26aulast%3DDickey%26aufirst%3DC.%2BA.%26atitle%3DIsoform-selective%2520Hsp90%2520inhibition%2520rescues%2520model%2520of%2520hereditary%2520open-angle%2520glaucoma%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26doi%3D10.1038%2Fs41598-017-18344-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandelwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S. J.</span></span> <span> </span><span class="NLM_article-title">Development of radamide analogs as Grp94 inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4083</span>– <span class="NLM_lpage">4098</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.05.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1016%2Fj.bmc.2014.05.075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=25027801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFGru7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=4083-4098&author=A.+Muthauthor=V.+Crowleyauthor=A.+Khandelwalauthor=S.+Mishraauthor=J.+Zhaoauthor=J.+Hallauthor=B.+S.+J.+Blagg&title=Development+of+radamide+analogs+as+Grp94+inhibitors&doi=10.1016%2Fj.bmc.2014.05.075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Development of radamide analogs as Grp94 inhibitors</span></div><div class="casAuthors">Muth, Aaron; Crowley, Vincent; Khandelwal, Anuj; Mishra, Sanket; Zhao, Jinbo; Hall, Jessica; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4083-4098</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Hsp90 isoform-selective inhibition is highly desired as it can potentially avoid the toxic side-effects of pan-inhibition.  The current study developed selective inhibitors of one such isoform, Grp94, predicated on the chimeric and pan-Hsp90 inhibitor, radamide (RDA).  Replacement of the quinone moiety of RDA with a Ph ring (2) was found to be better suited for Grp94 inhibition as it can fully interact with a unique hydrophobic pocket present in Grp94.  An extensive SAR for this scaffold showed that substitutions at the 2- and 4-positions (8 and 27, resp.) manifested excellent Grp94 affinity and selectivity.  Introduction of heteroatoms into the ring also proved beneficial, with a 2-pyridine deriv. (38) exhibiting the highest Grp94 affinity (Kd = 820 nM).  Subsequent cell-based assays showed that these Grp94 inhibitors inhibit migration of the metastatic breast cancer cell line, MDA-MB-231, as well as exhibit an anti-proliferative affect against the multiple myeloma cell line, RPMI 8226.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxdbHibsHh3rVg90H21EOLACvtfcHk0lhBihZjyiTo8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFGru7bK&md5=6025c533f1c107eb5c54a559c679c8d2</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.05.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.05.075%26sid%3Dliteratum%253Aachs%26aulast%3DMuth%26aufirst%3DA.%26aulast%3DCrowley%26aufirst%3DV.%26aulast%3DKhandelwal%26aufirst%3DA.%26aulast%3DMishra%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DHall%26aufirst%3DJ.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DDevelopment%2520of%2520radamide%2520analogs%2520as%2520Grp94%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D4083%26epage%3D4098%26doi%3D10.1016%2Fj.bmc.2014.05.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khandelwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S. J.</span></span> <span> </span><span class="NLM_article-title">Resorcinol-based Grp94-selective inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1013</span>– <span class="NLM_lpage">1018</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00193</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00193" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVejs73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1013-1018&author=A.+Khandelwalauthor=V.+M.+Crowleyauthor=B.+S.+J.+Blagg&title=Resorcinol-based+Grp94-selective+inhibitors&doi=10.1021%2Facsmedchemlett.7b00193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Resorcinol-Based Grp94-Selective Inhibitors</span></div><div class="casAuthors">Khandelwal, Anuj; Crowley, Vincent M.; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1013-1018</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glucose regulated protein 94 (Grp94) is the endoplasmic reticulum resident of the 90 kDa heat shock protein (Hsp90) family and represents a promising therapeutic target for the treatment of several diseases.  Grp94 is the most unique member of the 90 kDa heat shock protein family due to a five amino acid insertion into its primary sequence, which creates hydrophobic subpockets exclusive to Grp94 that can be utilized for selective inhibition.  The first resorcinol-based Grp94-selective inhibitor I to take advantage of the hydrophobic S2 subpocket has been developed and shown to manifest low nanomolar affinity and ∼10-fold selectivity for Grp94.  Furthermore, these Grp94-selective inhibitors manifest low micromolar GI50 values against multiple myeloma cells, supporting Grp94 as an emerging target for the treatment of this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok_wSMzlEsHLVg90H21EOLACvtfcHk0lhBihZjyiTo8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVejs73K&md5=a398cf6e5adaacc4892aed8b2340b901</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00193%26sid%3Dliteratum%253Aachs%26aulast%3DKhandelwal%26aufirst%3DA.%26aulast%3DCrowley%26aufirst%3DV.%2BM.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DResorcinol-based%2520Grp94-selective%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D1013%26epage%3D1018%26doi%3D10.1021%2Facsmedchemlett.7b00193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khandelwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzbeierlein, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matts, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S. J.</span></span> <span> </span><span class="NLM_article-title">Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">425</span> <span class="refDoi"> DOI: 10.1038/s41467-017-02013-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1038%2Fs41467-017-02013-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=29382832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A280%3ADC%252BC1MvlsFyksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&author=A.+Khandelwalauthor=C.+N.+Kentauthor=M.+Balchauthor=S.+Pengauthor=S.+J.+Mishraauthor=J.+Dengauthor=V.+W.+Dayauthor=W.+Liuauthor=C.+Subramanianauthor=M.+Cohenauthor=J.+M.+Holzbeierleinauthor=R.+Mattsauthor=B.+S.+J.+Blagg&title=Structure-guided+design+of+an+Hsp90%CE%B2+N-terminal+isoform-selective+inhibitor&doi=10.1038%2Fs41467-017-02013-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor</span></div><div class="casAuthors">Khandelwal Anuj; Mishra Sanket J; Kent Caitlin N; Blagg Brian S J; Balch Maurie; Peng Shuxia; Deng Junpeng; Matts Robert; Day Victor W; Liu Weiya; Holzbeierlein Jeffery M; Subramanian Chitra; Cohen Mark</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">425</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The 90 kDa heat shock protein (Hsp90) is a molecular chaperone responsible for folding proteins that are directly associated with cancer progression.  Consequently, inhibition of the Hsp90 protein folding machinery results in a combinatorial attack on numerous oncogenic pathways.  Seventeen small-molecule inhibitors of Hsp90 have entered clinical trials, all of which bind the Hsp90 N-terminus and exhibit pan-inhibitory activity against all four Hsp90 isoforms. pan-Inhibition of Hsp90 appears to be detrimental as toxicities have been reported alongside induction of the pro-survival heat shock response.  The development of Hsp90 isoform-selective inhibitors represents an alternative approach towards the treatment of cancer that may limit some of the detriments.  Described herein is a structure-based approach to design isoform-selective inhibitors of Hsp90β, which induces the degradation of select Hsp90 clients without concomitant induction of Hsp90 levels.  Together, these initial studies support the development of Hsp90β-selective inhibitors as a method to overcome the detriments associated with pan-inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmyRre9-yoQBpyrDyM_m9cfW6udTcc2eZVmkQKwlOfCLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvlsFyksA%253D%253D&md5=cfa47e314c9bdbc1c38802108330cba7</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-02013-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-02013-1%26sid%3Dliteratum%253Aachs%26aulast%3DKhandelwal%26aufirst%3DA.%26aulast%3DKent%26aufirst%3DC.%2BN.%26aulast%3DBalch%26aufirst%3DM.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DMishra%26aufirst%3DS.%2BJ.%26aulast%3DDeng%26aufirst%3DJ.%26aulast%3DDay%26aufirst%3DV.%2BW.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DSubramanian%26aufirst%3DC.%26aulast%3DCohen%26aufirst%3DM.%26aulast%3DHolzbeierlein%26aufirst%3DJ.%2BM.%26aulast%3DMatts%26aufirst%3DR.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DStructure-guided%2520design%2520of%2520an%2520Hsp90%25CE%25B2%2520N-terminal%2520isoform-selective%2520inhibitor%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26doi%3D10.1038%2Fs41467-017-02013-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohkubo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muraoka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitotsumachi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitade, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanoh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonekura, K.</span></span> <span> </span><span class="NLM_article-title">TAS-116, a highly selective inhibitor of heat shock protein 90α and β, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1158%2F1535-7163.MCT-14-0219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=25416789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslWgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=14-22&author=S.+Ohkuboauthor=Y.+Kodamaauthor=H.+Muraokaauthor=H.+Hitotsumachiauthor=C.+Yoshimuraauthor=M.+Kitadeauthor=A.+Hashimotoauthor=K.+Itoauthor=A.+Gomoriauthor=K.+Takahashiauthor=Y.+Shibataauthor=A.+Kanohauthor=K.+Yonekura&title=TAS-116%2C+a+highly+selective+inhibitor+of+heat+shock+protein+90%CE%B1+and+%CE%B2%2C+demonstrates+potent+antitumor+activity+and+minimal+ocular+toxicity+in+preclinical+models&doi=10.1158%2F1535-7163.MCT-14-0219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models</span></div><div class="casAuthors">Ohkubo, Shuichi; Kodama, Yasuo; Muraoka, Hiromi; Hitotsumachi, Hiroko; Yoshimura, Chihoko; Kitade, Makoto; Hashimoto, Akihiro; Ito, Kenjiro; Gomori, Akira; Takahashi, Koichi; Shibata, Yoshihiro; Kanoh, Akira; Yonekura, Kazuhiko</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-22</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The mol. chaperone HSP90 plays a crucial role in cancer cell growth and survival by stabilizing cancer-related proteins.  A no. of HSP90 inhibitors have been developed clin. for cancer therapy; however, potential off-target and/or HSP90-related toxicities have proved problematic.  The 4-(1H-pyrazolo[3,4-b]pyridine-1-yl)benzamide TAS-116 is a selective inhibitor of cytosolic HSP90α and β that does not inhibit HSP90 paralogs such as endoplasmic reticulum GRP94 or mitochondrial TRAP1.  Oral administration of TAS-116 led to tumor shrinkage in human tumor xenograft mouse models accompanied by depletion of multiple HSP90 clients, demonstrating that the inhibition of HSP90α and β alone was sufficient to exert antitumor activity in certain tumor models.  One of the most notable HSP90-related adverse events universally obsd. to differing degrees in the clin. setting is visual disturbance.  A two-week administration of the isoxazole resorcinol NVP-AUY922, an HSP90 inhibitor, caused marked degeneration and disarrangement of the outer nuclear layer of the retina and induced photoreceptor cell death in rats.  In contrast, TAS-116 did not produce detectable photoreceptor injury in rats, probably due to its lower distribution in retinal tissue.  Importantly, in a rat model, the antitumor activity of TAS-116 was accompanied by a higher distribution of the compd. in s.c. xenografted NCI-H1975 non-small cell lung carcinoma tumors than in retina.  Moreover, TAS-116 showed activity against orthotopically transplanted NCI-H1975 lung tumors.  Together, these data suggest that TAS-116 has a potential to maximize antitumor activity while minimizing adverse effects such as visual disturbances that are obsd. with other compds. of this class.  Mol Cancer Ther; 14(1); 14-22. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB25Txc_IcKbVg90H21EOLACvtfcHk0lgNx7Rbfunv1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslWgug%253D%253D&md5=3ffdc26a7f0178d4e44413e22c003f77</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0219%26sid%3Dliteratum%253Aachs%26aulast%3DOhkubo%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DY.%26aulast%3DMuraoka%26aufirst%3DH.%26aulast%3DHitotsumachi%26aufirst%3DH.%26aulast%3DYoshimura%26aufirst%3DC.%26aulast%3DKitade%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DA.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DGomori%26aufirst%3DA.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DShibata%26aufirst%3DY.%26aulast%3DKanoh%26aufirst%3DA.%26aulast%3DYonekura%26aufirst%3DK.%26atitle%3DTAS-116%252C%2520a%2520highly%2520selective%2520inhibitor%2520of%2520heat%2520shock%2520protein%252090%25CE%25B1%2520and%2520%25CE%25B2%252C%2520demonstrates%2520potent%2520antitumor%2520activity%2520and%2520minimal%2520ocular%2520toxicity%2520in%2520preclinical%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D14%26epage%3D22%26doi%3D10.1158%2F1535-7163.MCT-14-0219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccola, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turnbull, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kargo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woody, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcacio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nezami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamos, D.</span></span> <span> </span><span class="NLM_article-title">Identification of novel HSP90α/β isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington’s Disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3382</span>– <span class="NLM_lpage">3400</span>, <span class="refDoi"> DOI: 10.1021/jm500042s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500042s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFGlsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3382-3400&author=J.+T.+Ernstauthor=T.+Neubertauthor=M.+Liuauthor=S.+Sperryauthor=H.+Zuccolaauthor=A.+Turnbullauthor=B.+Fleckauthor=W.+Kargoauthor=L.+Woodyauthor=P.+Chiangauthor=D.+Tranauthor=W.+Chenauthor=P.+Snyderauthor=T.+Alcacioauthor=A.+Nezamiauthor=J.+Reynoldsauthor=K.+Alviauthor=L.+Gouletauthor=D.+Stamos&title=Identification+of+novel+HSP90%CE%B1%2F%CE%B2+isoform+selective+inhibitors+using+structure-based+drug+design.+Demonstration+of+potential+utility+in+treating+CNS+disorders+such+as+Huntington%E2%80%99s+Disease&doi=10.1021%2Fjm500042s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel HSP90α/β isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease</span></div><div class="casAuthors">Ernst, Justin T.; Neubert, Timothy; Liu, Michael; Sperry, Samuel; Zuccola, Harmon; Turnbull, Amy; Fleck, Beth; Kargo, William; Woody, Lisa; Chiang, Peggy; Tran, Dao; Chen, Weichao; Snyder, Phillip; Alcacio, Timothy; Nezami, Azin; Reynolds, James; Alvi, Khisal; Goulet, Lance; Stamos, Dean</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3382-3400</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A structure-based drug design strategy was used to optimize a novel benzolactam series of HSP90α/β inhibitors to achieve >1000-fold selectivity vs. the HSP90 endoplasmic reticulum and mitochondrial isoforms (GRP94 and TRAP1, resp.).  Selective HSP90α/β inhibitors were found to be equipotent to pan-HSP90 inhibitors in promoting the clearance of mutant huntington protein (mHtt) in vitro, however with less cellular toxicity.  Improved tolerability profiles may enable the use of HSP90α/β selective inhibitors in treating chronic neurodegenerative indications such as Huntington's disease (HD).  A potent, selective, orally available HSP90α/β inhibitor, 8-Cyclopentyl-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)-3,4-dihydroisoquinolin-1(2H)-one, was identified that crosses the blood-brain barrier and demonstrated proof of concept by successfully reducing brain Htt levels following oral dosing in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKpHcuphxPXbVg90H21EOLACvtfcHk0lgNx7Rbfunv1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFGlsLY%253D&md5=0d55fb738fc0f0615b5336b8dc17056a</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm500042s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500042s%26sid%3Dliteratum%253Aachs%26aulast%3DErnst%26aufirst%3DJ.%2BT.%26aulast%3DNeubert%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DSperry%26aufirst%3DS.%26aulast%3DZuccola%26aufirst%3DH.%26aulast%3DTurnbull%26aufirst%3DA.%26aulast%3DFleck%26aufirst%3DB.%26aulast%3DKargo%26aufirst%3DW.%26aulast%3DWoody%26aufirst%3DL.%26aulast%3DChiang%26aufirst%3DP.%26aulast%3DTran%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DSnyder%26aufirst%3DP.%26aulast%3DAlcacio%26aufirst%3DT.%26aulast%3DNezami%26aufirst%3DA.%26aulast%3DReynolds%26aufirst%3DJ.%26aulast%3DAlvi%26aufirst%3DK.%26aulast%3DGoulet%26aufirst%3DL.%26aulast%3DStamos%26aufirst%3DD.%26atitle%3DIdentification%2520of%2520novel%2520HSP90%25CE%25B1%252F%25CE%25B2%2520isoform%2520selective%2520inhibitors%2520using%2520structure-based%2520drug%2520design.%2520Demonstration%2520of%2520potential%2520utility%2520in%2520treating%2520CNS%2520disorders%2520such%2520as%2520Huntington%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3382%26epage%3D3400%26doi%3D10.1021%2Fjm500042s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccola, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turnbull, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vought, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamos, D.</span></span> <span> </span><span class="NLM_article-title">Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity—Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">204</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.11.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1016%2Fj.bmcl.2013.11.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=24332488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOlt7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=204-208&author=J.+T.+Ernstauthor=M.+Liuauthor=H.+Zuccolaauthor=T.+Neubertauthor=K.+Beaumontauthor=A.+Turnbullauthor=A.+Kallelauthor=B.+Voughtauthor=D.+Stamos&title=Correlation+between+chemotype-dependent+binding+conformations+of+HSP90%CE%B1%2F%CE%B2+and+isoform+selectivity%E2%80%94Implications+for+the+structure-based+design+of+HSP90%CE%B1%2F%CE%B2+selective+inhibitors+for+treating+neurodegenerative+diseases&doi=10.1016%2Fj.bmcl.2013.11.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases</span></div><div class="casAuthors">Ernst, Justin T.; Liu, Michael; Zuccola, Harmon; Neubert, Timothy; Beaumont, Kevin; Turnbull, Amy; Kallel, Adam; Vought, Bryan; Stamos, Dean</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">204-208</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">HSP90 continues to be a target of interest for neurodegeneration indications.  Selective knockdown of the HSP90 cytosolic isoforms α and β is sufficient to reduce mutant huntingtin protein levels in vitro.  Chemotype-dependent binding conformations of HSP90α/β appear to strongly influence isoform selectivity.  The rational design of HSP90α/β inhibitors selective vs. the mitochondrial (TRAP1) and endoplasmic reticulum (GRP94) isoforms offers a potential mitigating strategy for mechanism-based toxicities.  Better tolerated HSP90 inhibitors would be attractive for targeting chronic neurodegenerative diseases such as Huntington's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq64ZOr5JsRerVg90H21EOLACvtfcHk0ljHcpBvuoerZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOlt7jO&md5=6799a46090ee297d70700f7c42b79f80</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.11.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.11.036%26sid%3Dliteratum%253Aachs%26aulast%3DErnst%26aufirst%3DJ.%2BT.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DZuccola%26aufirst%3DH.%26aulast%3DNeubert%26aufirst%3DT.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DTurnbull%26aufirst%3DA.%26aulast%3DKallel%26aufirst%3DA.%26aulast%3DVought%26aufirst%3DB.%26aulast%3DStamos%26aufirst%3DD.%26atitle%3DCorrelation%2520between%2520chemotype-dependent%2520binding%2520conformations%2520of%2520HSP90%25CE%25B1%252F%25CE%25B2%2520and%2520isoform%2520selectivity%25E2%2580%2594Implications%2520for%2520the%2520structure-based%2520design%2520of%2520HSP90%25CE%25B1%252F%25CE%25B2%2520selective%2520inhibitors%2520for%2520treating%2520neurodegenerative%2520diseases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D204%26epage%3D208%26doi%3D10.1016%2Fj.bmcl.2013.11.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shekhar-Guturja, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeBlanc, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nation, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trilles, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krysan, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindquist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatu, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizarro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span> <span> </span><span class="NLM_article-title">Structural basis for species-selective targeting of Hsp90 in a pathogenic fungus</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">402</span> <span class="refDoi"> DOI: 10.1038/s41467-018-08248-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1038%2Fs41467-018-08248-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=30679438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntFersrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&author=L.+Whitesellauthor=N.+Robbinsauthor=D.+S.+Huangauthor=C.+A.+McLellanauthor=T.+Shekhar-Guturjaauthor=E.+V.+LeBlancauthor=C.+S.+Nationauthor=R.+Huiauthor=A.+Hutchinsonauthor=C.+Collinsauthor=S.+Chatterjeeauthor=R.+Trillesauthor=J.+L.+Xieauthor=D.+J.+Krysanauthor=S.+Lindquistauthor=J.+A.+Porcoauthor=U.+Tatuauthor=L.+E.+Brownauthor=J.+Pizarroauthor=L.+E.+Cowen&title=Structural+basis+for+species-selective+targeting+of+Hsp90+in+a+pathogenic+fungus&doi=10.1038%2Fs41467-018-08248-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for species-selective targeting of Hsp90 in a pathogenic fungus</span></div><div class="casAuthors">Whitesell, Luke; Robbins, Nicole; Huang, David S.; McLellan, Catherine A.; Shekhar-Guturja, Tanvi; LeBlanc, Emmanuelle V.; Nation, Catherine S.; Hui, Raymond; Hutchinson, Ashley; Collins, Cathy; Chatterjee, Sharanya; Trilles, Richard; Xie, Jinglin L.; Krysan, Damian J.; Lindquist, Susan; Porco, John A., Jr.; Tatu, Utpal; Brown, Lauren E.; Pizarro, Juan; Cowen, Leah E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">402</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">New strategies are needed to counter the escalating threat posed by drug-resistant fungi.  The mol. chaperone Hsp90 affords a promising target because it supports survival, virulence and drug-resistance across diverse pathogens.  Inhibitors of human Hsp90 under development as anticancer therapeutics, however, exert host toxicities that preclude their use as antifungals.  Seeking a route to species-selectivity, we investigate the nucleotide-binding domain (NBD) of Hsp90 from the most common human fungal pathogen, Candida albicans.  Here we report structures for this NBD alone, in complex with ADP or in complex with known Hsp90 inhibitors.  Encouraged by the conformational flexibility revealed by these structures, we synthesize an inhibitor with >25-fold binding-selectivity for fungal Hsp90 NBD.  Comparing co-crystals occupied by this probe vs. anticancer Hsp90 inhibitors revealed major, previously unreported conformational rearrangements.  These insights and our probe's species-selectivity in culture support the feasibility of targeting Hsp90 as a promising antifungal strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc0j6rgX3IDrVg90H21EOLACvtfcHk0ljHcpBvuoerZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntFersrg%253D&md5=ee973dc62c7912479f26d2ad26f024bc</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-08248-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-08248-w%26sid%3Dliteratum%253Aachs%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DRobbins%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DD.%2BS.%26aulast%3DMcLellan%26aufirst%3DC.%2BA.%26aulast%3DShekhar-Guturja%26aufirst%3DT.%26aulast%3DLeBlanc%26aufirst%3DE.%2BV.%26aulast%3DNation%26aufirst%3DC.%2BS.%26aulast%3DHui%26aufirst%3DR.%26aulast%3DHutchinson%26aufirst%3DA.%26aulast%3DCollins%26aufirst%3DC.%26aulast%3DChatterjee%26aufirst%3DS.%26aulast%3DTrilles%26aufirst%3DR.%26aulast%3DXie%26aufirst%3DJ.%2BL.%26aulast%3DKrysan%26aufirst%3DD.%2BJ.%26aulast%3DLindquist%26aufirst%3DS.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26aulast%3DTatu%26aufirst%3DU.%26aulast%3DBrown%26aufirst%3DL.%2BE.%26aulast%3DPizarro%26aufirst%3DJ.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26atitle%3DStructural%2520basis%2520for%2520species-selective%2520targeting%2520of%2520Hsp90%2520in%2520a%2520pathogenic%2520fungus%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26doi%3D10.1038%2Fs41467-018-08248-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woodhead, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angove, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chessari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyle, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosme, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazal, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueroa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederickson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMenamin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parra, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trewartha, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinkovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolford, A. J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of (2,4-Dihydroxy-5-isopropylphenyl)- 5-(4-methylpiperazin-1-ylmethyl)-1,3- dihydroisoindol-2-yl methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">5956</span>– <span class="NLM_lpage">5969</span>, <span class="refDoi"> DOI: 10.1021/jm100060b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100060b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCitrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5956-5969&author=A.+J.+Woodheadauthor=H.+Angoveauthor=M.+G.+Carrauthor=G.+Chessariauthor=M.+Congreveauthor=J.+E.+Coyleauthor=J.+Cosmeauthor=B.+Grahamauthor=P.+J.+Dayauthor=R.+Downhamauthor=L.+Fazalauthor=R.+Feltellauthor=E.+Figueroaauthor=M.+Fredericksonauthor=J.+Lewisauthor=R.+McMenaminauthor=C.+W.+Murrayauthor=M.+A.+O%E2%80%99Brienauthor=L.+Parraauthor=S.+Patelauthor=T.+Phillipsauthor=D.+C.+Reesauthor=S.+Richauthor=D.+M.+Smithauthor=G.+Trewarthaauthor=M.+Vinkovicauthor=B.+Williamsauthor=A.+J.+A.+Woolford&title=Discovery+of+%282%2C4-Dihydroxy-5-isopropylphenyl%29-+5-%284-methylpiperazin-1-ylmethyl%29-1%2C3-+dihydroisoindol-2-yl+methanone+%28AT13387%29%2C+a+novel+inhibitor+of+the+molecular+chaperone+Hsp90+by+fragment+based+drug+design&doi=10.1021%2Fjm100060b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design</span></div><div class="casAuthors">Woodhead, Andrew J.; Angove, Hayley; Carr, Maria G.; Chessari, Gianni; Congreve, Miles; Coyle, Joseph E.; Cosme, Jose; Graham, Brent; Day, Philip J.; Downham, Robert; Fazal, Lynsey; Feltell, Ruth; Figueroa, Eva; Frederickson, Martyn; Lewis, Jonathan; McMenamin, Rachel; Murray, Christopher W.; O'Brien, M. Alistair; Parra, Lina; Patel, Sahil; Phillips, Theresa; Rees, David C.; Rich, Sharna; Smith, Donna-Michelle; Trewartha, Gary; Vinkovic, Mladen; Williams, Brian; Woolford, Alison J.-A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5956-5969</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of the mol. chaperone heat shock protein 90 (Hsp90) are currently generating significant interest in clin. development as potential treatments for cancer.  In a preceding publication (DOI: 10.1021/jm100059d) we describe Astex's approach to screening fragments against Hsp90 and the subsequent optimization of two hits into leads with inhibitory activities in the low nanomolar range.  This paper describes the structure guided optimization of the 2,4-dihydroxybenzamide lead mol. 1 and details some of the drug discovery strategies employed in the identification of AT13387 (35), which has progressed through preclin. development and is currently being tested in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEEtcgAmkVk7Vg90H21EOLACvtfcHk0ljs4w8nymqQNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCitrg%253D&md5=a2d2ac6dd9e9ba4cb89f83c32727a1d8</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm100060b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100060b%26sid%3Dliteratum%253Aachs%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26aulast%3DAngove%26aufirst%3DH.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DChessari%26aufirst%3DG.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DCoyle%26aufirst%3DJ.%2BE.%26aulast%3DCosme%26aufirst%3DJ.%26aulast%3DGraham%26aufirst%3DB.%26aulast%3DDay%26aufirst%3DP.%2BJ.%26aulast%3DDownham%26aufirst%3DR.%26aulast%3DFazal%26aufirst%3DL.%26aulast%3DFeltell%26aufirst%3DR.%26aulast%3DFigueroa%26aufirst%3DE.%26aulast%3DFrederickson%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DJ.%26aulast%3DMcMenamin%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%2BA.%26aulast%3DParra%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DT.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DRich%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DD.%2BM.%26aulast%3DTrewartha%26aufirst%3DG.%26aulast%3DVinkovic%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DB.%26aulast%3DWoolford%26aufirst%3DA.%2BJ.%2BA.%26atitle%3DDiscovery%2520of%2520%25282%252C4-Dihydroxy-5-isopropylphenyl%2529-%25205-%25284-methylpiperazin-1-ylmethyl%2529-1%252C3-%2520dihydroisoindol-2-yl%2520methanone%2520%2528AT13387%2529%252C%2520a%2520novel%2520inhibitor%2520of%2520the%2520molecular%2520chaperone%2520Hsp90%2520by%2520fragment%2520based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5956%26epage%3D5969%26doi%3D10.1021%2Fjm100060b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Do, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speranza, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polley, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trepel, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinders, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antony, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doroshow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummar, S.</span></span> <span> </span><span class="NLM_article-title">Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors</span>. <i>Invest. New Drug.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">921</span>– <span class="NLM_lpage">930</span>, <span class="refDoi"> DOI: 10.1007/s10637-015-0255-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1007%2Fs10637-015-0255-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=26082332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVektLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=921-930&author=K.+Doauthor=G.+Speranzaauthor=L.-C.+Changauthor=E.+C.+Polleyauthor=R.+Bishopauthor=W.+Zhuauthor=J.+B.+Trepelauthor=S.+Leeauthor=M.-J.+Leeauthor=R.+J.+Kindersauthor=L.+Phillipsauthor=J.+Collinsauthor=J.+Lyonsauthor=W.+Jeongauthor=R.+Antonyauthor=A.+P.+Chenauthor=L.+Neckersauthor=J.+H.+Doroshowauthor=S.+Kummar&title=Phase+I+study+of+the+heat+shock+protein+90+%28Hsp90%29+inhibitor+onalespib+%28AT13387%29+administered+on+a+daily+for+2+consecutive+days+per+week+dosing+schedule+in+patients+with+advanced+solid+tumors&doi=10.1007%2Fs10637-015-0255-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors</span></div><div class="casAuthors">Do, Khanh; Speranza, Giovanna; Chang, Lun-Ching; Polley, Eric C.; Bishop, Rachel; Zhu, Weimin; Trepel, Jane B.; Lee, Sunmin; Lee, Min-Jung; Kinders, Robert J.; Phillips, Larry; Collins, Jerry; Lyons, John; Jeong, Woondong; Antony, Ramya; Chen, Alice P.; Neckers, Len; Doroshow, James H.; Kummar, Shivaani</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">921-930</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Inhibition of heat shock 90 (Hsp90) mol. chaperones allows targeting of multiple proteins involved in tumorigenesis.  We investigated the safety, recommended phase 2 dose (RP2D), and pharmacokinetic and pharmacodynamic profile of onalespib (AT13387), a potent synthetic Hsp90 inhibitor, administered on days 1, 2, 8, 9, 15, and 16 of 28 day cycles (QDx2/wk) in a phase I trial.  This study followed an accelerated titrn. design with a starting dose of 20 mg/m2/dose and a std. 3 + 3 dose escalation design for dose level 4 (120 mg/m2/dose) and above.  Addnl. patients were enrolled at the RP2D with mandatory paired tumor biopsies to assess modulation of 210 client proteins using reverse phase protein array anal.  Thirty-one patients were treated; RP2D was established at 160 mg/m2/dose on the QDx2/wk schedule.  Common toxicities were gastrointestinal, hepatic, and hematol.  Pharmacokinetic profile was linear and plasma levels increased proportionally with dose (T1/2 ∼8 h).  No responses were obsd.; eight patients had stable disease for > 2 cycles with one patient remaining on study for 6 cycles.  Target engagement was demonstrated by transcriptional upregulation of Hsp70 and Hsp27 in PBMCs.  Statistically significant modulation of client proteins was not achieved in the 9 paired tumor biopsies evaluated; however, hierarchical clustering revealed two subgroups of patients with differential patterns of protein expression.  Further combination studies are needed in order to target prospective driver oncoproteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCXt8s5_XMBLVg90H21EOLACvtfcHk0lieHENl_cubIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVektLfJ&md5=624adbaad8dad65d69ea9318a96e984e</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs10637-015-0255-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-015-0255-1%26sid%3Dliteratum%253Aachs%26aulast%3DDo%26aufirst%3DK.%26aulast%3DSperanza%26aufirst%3DG.%26aulast%3DChang%26aufirst%3DL.-C.%26aulast%3DPolley%26aufirst%3DE.%2BC.%26aulast%3DBishop%26aufirst%3DR.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DTrepel%26aufirst%3DJ.%2BB.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DM.-J.%26aulast%3DKinders%26aufirst%3DR.%2BJ.%26aulast%3DPhillips%26aufirst%3DL.%26aulast%3DCollins%26aufirst%3DJ.%26aulast%3DLyons%26aufirst%3DJ.%26aulast%3DJeong%26aufirst%3DW.%26aulast%3DAntony%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DA.%2BP.%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DKummar%26aufirst%3DS.%26atitle%3DPhase%2520I%2520study%2520of%2520the%2520heat%2520shock%2520protein%252090%2520%2528Hsp90%2529%2520inhibitor%2520onalespib%2520%2528AT13387%2529%2520administered%2520on%2520a%2520daily%2520for%25202%2520consecutive%2520days%2520per%2520week%2520dosing%2520schedule%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drug.%26date%3D2015%26volume%3D33%26spage%3D921%26epage%3D930%26doi%3D10.1007%2Fs10637-015-0255-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agulnik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahadevan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedel, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Mehren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trent, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yule, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oganesian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keer, H.</span></span> <span> </span><span class="NLM_article-title">Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2016.03.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1016%2Fj.ejca.2016.03.076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=27156227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslKqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2016&pages=94-101&author=A.+J.+Wagnerauthor=M.+Agulnikauthor=M.+C.+Heinrichauthor=D.+Mahadevanauthor=R.+F.+Riedelauthor=M.+von+Mehrenauthor=J.+Trentauthor=G.+D.+Demetriauthor=C.+L.+Corlessauthor=M.+Yuleauthor=J.+F.+Lyonsauthor=A.+Oganesianauthor=H.+Keer&title=Dose-escalation+study+of+a+second-generation+non-ansamycin+HSP90+inhibitor%2C+onalespib+%28AT13387%29%2C+in+combination+with+imatinib+in+patients+with+metastatic+gastrointestinal+stromal+tumour&doi=10.1016%2Fj.ejca.2016.03.076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour</span></div><div class="casAuthors">Wagner, Andrew J.; Agulnik, Mark; Heinrich, Michael C.; Mahadevan, Daruka; Riedel, Richard F.; von Mehren, Margaret; Trent, Jonathan; Demetri, George D.; Corless, Christopher L.; Yule, Murray; Lyons, John F.; Oganesian, Aram; Keer, Harold</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">94-101</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Gastrointestinal stromal tumors (GIST) treated with the tyrosine kinase inhibitor (TKI) imatinib can become resistant when addnl. mutations in the receptor tyrosine kinases KIT or PDGFRA block imatinib activity.  Mutated KIT requires the mol. chaperone heat-shock protein 90 (HSP90) to maintain stability and activity.  Onalespib (AT13387) is a potent non-ansamycin HSP90 inhibitor.  We hypothesised that the combination of onalespib and imatinib may be safe and effective in managing TKI-resistant GIST.In this dose-escalation study, we evaluated the safety and efficacy of combination once-weekly i.v. onalespib for 3 wk and daily oral imatinib in 28-d cycles.  Twenty-six patients with TKI-resistant GIST were enrolled into four sequential dose cohorts of onalespib (dose range, 150-220 mg/m2) and imatinib 400 mg.  The relationship between tumor mutational status (KIT/PDGFRA) and efficacy of treatment was explored.Common onalespib-related adverse events were diarrhea (58%), nausea (50%), injection site events (46%), vomiting (39%), fatigue (27%), and muscle spasms (23%).  Overall, 81% of patients reported more than one onalespib-related gastrointestinal disorder.  Nine patients (35%) had a best response of stable disease, including two patients who had KIT mutations known to be assocd. with resistance to imatinib and sunitinib.  Disease control at 4 mo was achieved in five patients (19%), and median progression-free survival was 112 d (95% confidence interval 43-165).  One patient with PDGFRA-mutant GIST had a partial response for more than 376 d.The combination of onalespib plus imatinib was well tolerated but exhibited limited antitumor activity as dosed in this TKI-resistant GIST patient population.Trial registration ID: clinicaltrials.gov: NCT01294202.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0EPUydR0h8bVg90H21EOLACvtfcHk0lgB0ZxkrjSi3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslKqs7s%253D&md5=53b38c85eb3a83c174f28347d985ecf9</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2016.03.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2016.03.076%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26aulast%3DAgulnik%26aufirst%3DM.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DMahadevan%26aufirst%3DD.%26aulast%3DRiedel%26aufirst%3DR.%2BF.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DTrent%26aufirst%3DJ.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DYule%26aufirst%3DM.%26aulast%3DLyons%26aufirst%3DJ.%2BF.%26aulast%3DOganesian%26aufirst%3DA.%26aulast%3DKeer%26aufirst%3DH.%26atitle%3DDose-escalation%2520study%2520of%2520a%2520second-generation%2520non-ansamycin%2520HSP90%2520inhibitor%252C%2520onalespib%2520%2528AT13387%2529%252C%2520in%2520combination%2520with%2520imatinib%2520in%2520patients%2520with%2520metastatic%2520gastrointestinal%2520stromal%2520tumour%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2016%26volume%3D61%26spage%3D94%26epage%3D101%26doi%3D10.1016%2Fj.ejca.2016.03.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Canella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welker, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abas, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesanakurti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarajan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beattie, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulman, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gumin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurcan, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puduvalli, V. K.</span></span> <span> </span><span class="NLM_article-title">Efficacy of onalespib, a long-acting second-generation HSP90 inhibitor, as a single agent and in combination with temozolomide against malignant gliomas</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6215</span>– <span class="NLM_lpage">6226</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-3151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1158%2F1078-0432.CCR-16-3151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=28679777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1CgtrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=6215-6226&author=A.+Canellaauthor=A.+M.+Welkerauthor=J.+Y.+Yooauthor=J.+Xuauthor=F.+S.+Abasauthor=D.+Kesanakurtiauthor=P.+Nagarajanauthor=C.+E.+Beattieauthor=E.+P.+Sulmanauthor=J.+Liuauthor=J.+Guminauthor=F.+F.+Langauthor=M.+N.+Gurcanauthor=B.+Kaurauthor=D.+Sampathauthor=V.+K.+Puduvalli&title=Efficacy+of+onalespib%2C+a+long-acting+second-generation+HSP90+inhibitor%2C+as+a+single+agent+and+in+combination+with+temozolomide+against+malignant+gliomas&doi=10.1158%2F1078-0432.CCR-16-3151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas</span></div><div class="casAuthors">Canella, Alessandro; Welker, Alessandra M.; Yoo, Ji Young; Xu, Jihong; Abas, Fazly S.; Kesanakurti, Divya; Nagarajan, Prabakaran; Beattie, Christine E.; Sulman, Erik P.; Liu, Joseph; Gumin, Joy; Lang, Frederick F.; Gurcan, Metin N.; Kaur, Balveen; Sampath, Deepa; Puduvalli, Vinay K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6215-6226</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: HSP90, a highly conserved mol. chaperone that regulates the function of several oncogenic client proteins, is altered in glioblastoma.  However, HSP90 inhibitors currently in clin. trials are short-acting, have unacceptable toxicities, or are unable to cross the blood-brain barrier (BBB).  We examd. the efficacy of onalespib, a potent, long-acting novel HSP90 inhibitor as a single agent and in combination with temozolomide (TMZ) against gliomas in vitro and in vivo.  Exptl. Design: The effect of onalespib on HSP90, its client proteins, and on the biol. of glioma cell lines and patient-derived glioma-initiating cells (GSC) was detd.  Brain and plasma pharmacokinetics of onalespib and its ability to inhibit HSP90 in vivo were assessed in non-tumor-bearing mice.  Its efficacy as a single agent or in combination with TMZ was assessed in vitro and in vivo using zebrafish and patient-derived GSC xenograft mouse glioma models.  Results: Onalespib-mediated HSP90 inhibition depleted several survival-promoting client proteins such as EGFR, EGFRvIII, and AKT, disrupted their downstream signaling, and decreased the proliferation, migration, angiogenesis, and survival of glioma cell lines and GSCs.  Onalespib effectively crossed the BBB to inhibit HSP90 in vivo and extended survival as a single agent in zebrafish xenografts and in combination with TMZ in both zebrafish and GSC mouse xenografts.  Conclusions: Our results demonstrate the long-acting effects of onalespib against gliomas in vitro and in vivo, which combined with its ability to cross the BBB support its development as a potential therapeutic agent in combination with TMZ against gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqiyFYlY0U3bVg90H21EOLACvtfcHk0liJsT56e_WYPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1CgtrfO&md5=ad3c936d44737c257889bbd4602c4dc3</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-3151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-3151%26sid%3Dliteratum%253Aachs%26aulast%3DCanella%26aufirst%3DA.%26aulast%3DWelker%26aufirst%3DA.%2BM.%26aulast%3DYoo%26aufirst%3DJ.%2BY.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DAbas%26aufirst%3DF.%2BS.%26aulast%3DKesanakurti%26aufirst%3DD.%26aulast%3DNagarajan%26aufirst%3DP.%26aulast%3DBeattie%26aufirst%3DC.%2BE.%26aulast%3DSulman%26aufirst%3DE.%2BP.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGumin%26aufirst%3DJ.%26aulast%3DLang%26aufirst%3DF.%2BF.%26aulast%3DGurcan%26aufirst%3DM.%2BN.%26aulast%3DKaur%26aufirst%3DB.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DPuduvalli%26aufirst%3DV.%2BK.%26atitle%3DEfficacy%2520of%2520onalespib%252C%2520a%2520long-acting%2520second-generation%2520HSP90%2520inhibitor%252C%2520as%2520a%2520single%2520agent%2520and%2520in%2520combination%2520with%2520temozolomide%2520against%2520malignant%2520gliomas%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D6215%26epage%3D6226%26doi%3D10.1158%2F1078-0432.CCR-16-3151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stühmer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zöllinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegmund, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grella, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knop, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortüm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unzicker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quadt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chène, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoepfer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Echeverría, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einsele, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wajant, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargou, R. C.</span></span> <span> </span><span class="NLM_article-title">Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1604</span>– <span class="NLM_lpage">1612</span>, <span class="refDoi"> DOI: 10.1038/leu.2008.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1038%2Fleu.2008.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=18480838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpslSntL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=1604-1612&author=T.+St%C3%BChmerauthor=A.+Z%C3%B6llingerauthor=D.+Siegmundauthor=M.+Chatterjeeauthor=E.+Grellaauthor=S.+Knopauthor=M.+Kort%C3%BCmauthor=C.+Unzickerauthor=M.+R.+Jensenauthor=C.+Quadtauthor=P.+Ch%C3%A8neauthor=J.+Schoepferauthor=C.+Garc%C3%ADa-Echeverr%C3%ADaauthor=H.+Einseleauthor=H.+Wajantauthor=R.+C.+Bargou&title=Signalling+profile+and+antitumour+activity+of+the+novel+Hsp90+inhibitor+NVP-AUY922+in+multiple+myeloma&doi=10.1038%2Fleu.2008.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma</span></div><div class="casAuthors">Stuehmer, T.; Zoellinger, A.; Siegmund, D.; Chatterjee, M.; Grella, E.; Knop, S.; Kortuem, M.; Unzicker, C.; Jensen, M. R.; Quadt, C.; Chene, P.; Schoepfer, J.; Garcia-Echeverria, C.; Einsele, H.; Wajant, H.; Bargou, R. C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1604-1612</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We as well as others have recently shown that Hsp90 is overexpressed in multiple myeloma (MM) and critically contributes to tumor cell survival.  Pharmacol. blockade of Hsp90 has consistently been found to induce MM cell death.  However, most data have been obtained with MM cell lines whereas knowledge about the mol. effects of pharmacol. Hsp90 blockade in primary tumor cells is limited.  Furthermore, these investigations have so far focused on geldanamycin derivs.  We analyzed the biochem. effects of a novel diarylisoxazole-based Hsp90 inhibitor (NVP-AUY922) on signalling pathways and cell death in a large set of primary MM tumor samples and in MM cell lines.  Treated cells displayed the mol. signature and pharmacodynamic properties for abrogation of Hsp90 function, such as downregulation of multiple survival pathways and strong upregulation of Hsp70.  NVP-AUY922 treatment efficiently induced MM cell apoptosis and revealed both sensitive and resistant subgroups.  Sensitivity was not correlated with TP53 mutation or Hsp70 induction levels and stromal cells from the bone marrow microenvironment were unable to abrogate NVP-AUY922-induced apoptosis of MM cells.  Thus, NVP-AUY922 may be a promising drug for treatment of MM and clin. studies are warranted.  Leukemia (2008) 22, 1604-1612; doi:10.1038/leu.2008.111; published online 15 May 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY5_BOjQZtgLVg90H21EOLACvtfcHk0liJsT56e_WYPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpslSntL8%253D&md5=5a83e6c4e8d05b3ad9fddd3b0d55a63f</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fleu.2008.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2008.111%26sid%3Dliteratum%253Aachs%26aulast%3DSt%25C3%25BChmer%26aufirst%3DT.%26aulast%3DZ%25C3%25B6llinger%26aufirst%3DA.%26aulast%3DSiegmund%26aufirst%3DD.%26aulast%3DChatterjee%26aufirst%3DM.%26aulast%3DGrella%26aufirst%3DE.%26aulast%3DKnop%26aufirst%3DS.%26aulast%3DKort%25C3%25BCm%26aufirst%3DM.%26aulast%3DUnzicker%26aufirst%3DC.%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DQuadt%26aufirst%3DC.%26aulast%3DCh%25C3%25A8ne%26aufirst%3DP.%26aulast%3DSchoepfer%26aufirst%3DJ.%26aulast%3DGarc%25C3%25ADa-Echeverr%25C3%25ADa%26aufirst%3DC.%26aulast%3DEinsele%26aufirst%3DH.%26aulast%3DWajant%26aufirst%3DH.%26aulast%3DBargou%26aufirst%3DR.%2BC.%26atitle%3DSignalling%2520profile%2520and%2520antitumour%2520activity%2520of%2520the%2520novel%2520Hsp90%2520inhibitor%2520NVP-AUY922%2520in%2520multiple%2520myeloma%26jtitle%3DLeukemia%26date%3D2008%26volume%3D22%26spage%3D1604%26epage%3D1612%26doi%3D10.1038%2Fleu.2008.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoepfer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radimerski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guy, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brueggen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quadt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drysdale, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Echeverria, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chène, P.</span></span> <span> </span><span class="NLM_article-title">NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">R33</span> <span class="refDoi"> DOI: 10.1186/bcr1996</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1186%2Fbcr1996" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=18430202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A280%3ADC%252BD1czktlKhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&author=M.+R.+Jensenauthor=J.+Schoepferauthor=T.+Radimerskiauthor=A.+Masseyauthor=C.+T.+Guyauthor=J.+Brueggenauthor=C.+Quadtauthor=A.+Bucklerauthor=R.+Cozensauthor=M.+J.+Drysdaleauthor=C.+Garcia-Echeverriaauthor=P.+Ch%C3%A8ne&title=NVP-AUY922%3A+a+small+molecule+HSP90+inhibitor+with+potent+antitumor+activity+in+preclinical+breast+cancer+models&doi=10.1186%2Fbcr1996"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models</span></div><div class="casAuthors">Jensen Michael Rugaard; Schoepfer Joseph; Radimerski Thomas; Massey Andrew; Guy Chantale T; Brueggen Josef; Quadt Cornelia; Buckler Alan; Cozens Robert; Drysdale Martin J; Garcia-Echeverria Carlos; Chene Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer research : BCR</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">R33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Heat shock protein 90 (HSP90) is a key component of a multichaperone complex involved in the post-translational folding of a large number of client proteins, many of which play essential roles in tumorigenesis.  HSP90 has emerged in recent years as a promising new target for anticancer therapies.  METHODS:  The concentrations of the HSP90 inhibitor NVP-AUY922 required to reduce cell numbers by 50% (GI50 values) were established in a panel of breast cancer cell lines and patient-derived human breast tumors.  To investigate the properties of the compound in vivo, the pharmacokinetic profile, antitumor effect, and dose regimen were established in a BT-474 breast cancer xenograft model.  The effect on HSP90-p23 complexes, client protein degradation, and heat shock response was investigated in cell culture and breast cancer xenografts by immunohistochemistry, Western blot analysis, and immunoprecipitation.  RESULTS:  We show that the novel small molecule HSP90 inhibitor NVP-AUY922 potently inhibits the proliferation of human breast cancer cell lines with GI50 values in the range of 3 to 126 nM.  NVP-AUY922 induced proliferative inhibition concurrent with HSP70 upregulation and client protein depletion--hallmarks of HSP90 inhibition.  Intravenous acute administration of NVP-AUY922 to athymic mice (30 mg/kg) bearing subcutaneous BT-474 breast tumors resulted in drug levels in excess of 1,000 times the cellular GI50 value for about 2 days.  Significant growth inhibition and good tolerability were observed when the compound was administered once per week.  Therapeutic effects were concordant with changes in pharmacodynamic markers, including HSP90-p23 dissociation, decreases in ERBB2 and P-AKT, and increased HSP70 protein levels.  CONCLUSION:  NVP-AUY922 is a potent small molecule HSP90 inhibitor showing significant activity against breast cancer cells in cellular and in vivo settings.  On the basis of its mechanism of action, preclinical activity profile, tolerability, and pharmaceutical properties, the compound recently has entered clinical phase I breast cancer trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQRY3cZ5prrYd1QT_1O5WBYfW6udTcc2ebBNkLasoOCJbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czktlKhuw%253D%253D&md5=2779e042ee1da49407fc813cca82305e</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1186%2Fbcr1996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fbcr1996%26sid%3Dliteratum%253Aachs%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DSchoepfer%26aufirst%3DJ.%26aulast%3DRadimerski%26aufirst%3DT.%26aulast%3DMassey%26aufirst%3DA.%26aulast%3DGuy%26aufirst%3DC.%2BT.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DQuadt%26aufirst%3DC.%26aulast%3DBuckler%26aufirst%3DA.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DDrysdale%26aufirst%3DM.%2BJ.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DCh%25C3%25A8ne%26aufirst%3DP.%26atitle%3DNVP-AUY922%253A%2520a%2520small%2520molecule%2520HSP90%2520inhibitor%2520with%2520potent%2520antitumor%2520activity%2520in%2520preclinical%2520breast%2520cancer%2520models%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2008%26volume%3D10%26doi%3D10.1186%2Fbcr1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onozawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuse, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akimov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boku, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtsu, A.</span></span> <span> </span><span class="NLM_article-title">Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">629</span>– <span class="NLM_lpage">636</span>, <span class="refDoi"> DOI: 10.1007/s00280-014-2521-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1007%2Fs00280-014-2521-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=25059319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1egu7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=629-636&author=T.+Doiauthor=Y.+Onozawaauthor=N.+Fuseauthor=T.+Yoshinoauthor=K.+Yamazakiauthor=J.+Watanabeauthor=M.+Akimovauthor=M.+Robsonauthor=N.+Bokuauthor=A.+Ohtsu&title=Phase+I+dose-escalation+study+of+the+HSP90+inhibitor+AUY922+in+Japanese+patients+with+advanced+solid+tumors&doi=10.1007%2Fs00280-014-2521-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors</span></div><div class="casAuthors">Doi, Toshihiko; Onozawa, Yusuke; Fuse, Nozomu; Yoshino, Takayuki; Yamazaki, Kentaro; Watanabe, Junichiro; Akimov, Mikhail; Robson, Matthew; Boku, Narikazu; Ohtsu, Atsushi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">629-636</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: AUY922 is a potent non-geldanamycin inhibitor of heat-shock protein 90.  This study was carried out in Japanese patients to det. the max. tolerated dose (MTD), and to characterize safety, tolerability and pharmacokinetics of single-agent AUY922.  Methods: Japanese patients with advanced solid tumors whose disease had progressed on at least one line of std. therapy, or for whom no std. therapy existed, were treated with AUY922 (i.v., once-weekly, 28-day cycle, starting dose 8 mg/m2).  Results: Thirty-one patients were treated.  Two DLTs were reported in one patient of the 54 mg/m2 cohort; fatigue and decreased appetite (both Grade 3, resolving to Grade 1 within 8 days).  No MTD was detd., and the dose recommended for Phase II studies was detd. to be 70 mg/m2 once-weekly.  Most common drug-related toxicities were diarrhea, night blindness and nausea.  Grade 1 and 2 visual toxicities at high AUY922 doses ≥22 mg/m2 were obsd.  Ten patients (32 %) achieved a best overall response of stable disease, and one patient (3 %) achieved a confirmed partial response.  Conclusion: Overall, AUY922 exhibited acceptable toxicities and demonstrated potential clin. activity in Japanese patients, with similar safety and pharmacokinetic profiles to those reported in a preceding global Phase I study in Western patients (CAUY922A2101).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHpBWf7yeQ6rVg90H21EOLACvtfcHk0ljdXL1ZvaBMtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1egu7bI&md5=b45329cadb86c932a68ced6951b796db</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1007%2Fs00280-014-2521-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-014-2521-x%26sid%3Dliteratum%253Aachs%26aulast%3DDoi%26aufirst%3DT.%26aulast%3DOnozawa%26aufirst%3DY.%26aulast%3DFuse%26aufirst%3DN.%26aulast%3DYoshino%26aufirst%3DT.%26aulast%3DYamazaki%26aufirst%3DK.%26aulast%3DWatanabe%26aufirst%3DJ.%26aulast%3DAkimov%26aufirst%3DM.%26aulast%3DRobson%26aufirst%3DM.%26aulast%3DBoku%26aufirst%3DN.%26aulast%3DOhtsu%26aufirst%3DA.%26atitle%3DPhase%2520I%2520dose-escalation%2520study%2520of%2520the%2520HSP90%2520inhibitor%2520AUY922%2520in%2520Japanese%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2014%26volume%3D74%26spage%3D629%26epage%3D636%26doi%3D10.1007%2Fs00280-014-2521-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seggewiss-Bernhardt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargou, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alegre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bladé, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottmann, O. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Ibarra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akimov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, S. P.</span></span> <span> </span><span class="NLM_article-title">Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">2185</span>– <span class="NLM_lpage">2192</span>, <span class="refDoi"> DOI: 10.1002/cncr.29339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1002%2Fcncr.29339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=25809731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVKntL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2015&pages=2185-2192&author=R.+Seggewiss-Bernhardtauthor=R.+C.+Bargouauthor=Y.+T.+Gohauthor=A.+K.+Stewartauthor=A.+Spencerauthor=A.+Alegreauthor=J.+Blad%C3%A9author=O.+G.+Ottmannauthor=C.+Fernandez-Ibarraauthor=H.+Luauthor=S.+Painauthor=M.+Akimovauthor=S.+P.+Iyer&title=Phase+1%2F1B+trial+of+the+heat+shock+protein+90+inhibitor+NVP-AUY922+as+monotherapy+or+in+combination+with+bortezomib+in+patients+with+relapsed+or+refractory+multiple+myeloma&doi=10.1002%2Fcncr.29339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma</span></div><div class="casAuthors">Seggewiss-Bernhardt, Ruth; Bargou, Ralf C.; Goh, Yeow Tee; Stewart, A. Keith; Spencer, Andrew; Alegre, Adrian; Blade, Joan; Ottmann, Oliver G.; Fernandez-Ibarra, Cristina; Lu, Hong; Pain, Scott; Akimov, Mikhail; Iyer, Swaminathan Padmanabhan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2185-2192</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BACKGROUND : NVP-AUY922 (AUY; Luminespib) with or without bortezomib showed preclin. activity against multiple myeloma (MM) cells.  This phase 1/1B study assessed NVP-AUY922 alone and with bortezomib in patients with relapsed or refractory MM.  METHODS : Dose escalation was guided by an adaptive Bayesian logistic regression model.  In phase 1, patients who progressed after 2 to 4 prior therapies received NVP-AUY922 i.v. once weekly.  In phase 1B, patients who progressed after 2 or fewer prior therapies received NVP-AUY922 plus bortezomib.  The primary objective was to det. the max. tolerated dose (MTD) of NVP-AUY922.  RESULTS : Twenty-four patients received NVP-AUY922 monotherapy at doses of 8 to 70 mg/m2.  One dose-limiting toxicity (DLT) was obsd. (grade 3 blurred vision at 70 mg/m2); no MTD was reached.  The recommended phase 2 dose was 70 mg/m2.  The most frequent drug-related adverse events (AEs) were diarrhea, nausea, and ocular toxicities.  Grade 3/4 AEs were uncommon (<10%).  Eight patients discontinued treatment because of AEs; 5 had ocular toxicities (≥45 mg/m2).  The best response was stable disease in 66.7% of the patients.  There were no partial or complete responses.  Five patients received NVP-AUY922 (which was started at 50 mg/m2) plus bortezomib (1.3 mg/m2).  Three of these patients experienced DLT.  No further dose escalation was performed; the MTD for NVP-AUY922 plus bortezomib was not established.  CONCLUSIONS : This study showed disease stabilization with NVP-AUY922 in patients with relapsed or refractory MM.  The MTD for NVP-AUY922 was not reached, but reversible ocular toxicity has been reported at high dose levels.  Bortezomib at the std. recommended dose plus NVP-AUY922 was not tolerated.  Cancer 2015;121:2185-2192. © 2015 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV8J1qkTHQbbVg90H21EOLACvtfcHk0lhSRGTKaN2fvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVKntL3L&md5=5ecc6c0563033e7449a8bda4490354ce</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1002%2Fcncr.29339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.29339%26sid%3Dliteratum%253Aachs%26aulast%3DSeggewiss-Bernhardt%26aufirst%3DR.%26aulast%3DBargou%26aufirst%3DR.%2BC.%26aulast%3DGoh%26aufirst%3DY.%2BT.%26aulast%3DStewart%26aufirst%3DA.%2BK.%26aulast%3DSpencer%26aufirst%3DA.%26aulast%3DAlegre%26aufirst%3DA.%26aulast%3DBlad%25C3%25A9%26aufirst%3DJ.%26aulast%3DOttmann%26aufirst%3DO.%2BG.%26aulast%3DFernandez-Ibarra%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DPain%26aufirst%3DS.%26aulast%3DAkimov%26aufirst%3DM.%26aulast%3DIyer%26aufirst%3DS.%2BP.%26atitle%3DPhase%25201%252F1B%2520trial%2520of%2520the%2520heat%2520shock%2520protein%252090%2520inhibitor%2520NVP-AUY922%2520as%2520monotherapy%2520or%2520in%2520combination%2520with%2520bortezomib%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520multiple%2520myeloma%26jtitle%3DCancer%26date%3D2015%26volume%3D121%26spage%3D2185%26epage%3D2192%26doi%3D10.1002%2Fcncr.29339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renouf, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krzyzanowska, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmuck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, M. J.</span></span> <span> </span><span class="NLM_article-title">A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">541</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.1007/s00280-016-3102-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1007%2Fs00280-016-3102-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=27422303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ejtLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2016&pages=541-545&author=D.+J.+Renoufauthor=D.+Hedleyauthor=M.+K.+Krzyzanowskaauthor=M.+Schmuckauthor=L.+Wangauthor=M.+J.+Moore&title=A+phase+II+study+of+the+HSP90+inhibitor+AUY922+in+chemotherapy+refractory+advanced+pancreatic+cancer&doi=10.1007%2Fs00280-016-3102-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer</span></div><div class="casAuthors">Renouf, D. J.; Hedley, D.; Krzyzanowska, M. K.; Schmuck, M.; Wang, L.; Moore, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">541-545</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Objectives: AUY922 is a novel heat shock protein inhibitor with preclin. activity in pancreatic cancer.  This phase II study evaluated the efficacy of AUY922 in patients with advanced pancreatic cancer previously treated with chemotherapy.  Methods: In this single-arm, Simon two-stage phase II trial, patients with metastatic or locally advanced pancreatic ductal adenocarcinoma who had progressed on at least one line of chemotherapy and were of good performances status (ECOG 0 or 1) were treated with AUY922 at a dose of 70 mg/m2 IV weekly.  The primary endpoint was disease control rate (objective response and stable disease ≥16 wk).  Results: Twelve patients were accrued, all of whom received treatment.  At least possibly related ≥grade 3 adverse events included fatigue (8 %) and AST elevation (8 %).  Ten patients were evaluable for response with 1 (10 %) having stable disease and 9 (90 %) progressive disease.  The median progression-free survival was 1.6 mo, and the median overall survival was 2.9 mo.  Conclusions: AUY922 was not assocd. with significant efficacy in previously treated patients with advanced pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCYdfJvebVGLVg90H21EOLACvtfcHk0lhIFnQgHYsFdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ejtLrJ&md5=e34132dfb40cc97ab41c169c59612e8a</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1007%2Fs00280-016-3102-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-016-3102-y%26sid%3Dliteratum%253Aachs%26aulast%3DRenouf%26aufirst%3DD.%2BJ.%26aulast%3DHedley%26aufirst%3DD.%26aulast%3DKrzyzanowska%26aufirst%3DM.%2BK.%26aulast%3DSchmuck%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMoore%26aufirst%3DM.%2BJ.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520the%2520HSP90%2520inhibitor%2520AUY922%2520in%2520chemotherapy%2520refractory%2520advanced%2520pancreatic%2520cancer%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2016%26volume%3D78%26spage%3D541%26epage%3D545%26doi%3D10.1007%2Fs00280-016-3102-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bendell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penley, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigel, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earwood, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span> <span> </span><span class="NLM_article-title">A phase 2 study of the Hsp90 inhibitor AUY922 as treatment for patients with refractory gastrointestinal stromal tumors</span>. <i>Cancer Invest.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">270</span>, <span class="refDoi"> DOI: 10.1080/07357907.2016.1193746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1080%2F07357907.2016.1193746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=27379708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFCrsr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=265-270&author=J.+C.+Bendellauthor=T.+M.+Bauerauthor=R.+Lamarauthor=M.+Josephauthor=W.+Penleyauthor=D.+S.+Thompsonauthor=D.+R.+Spigelauthor=R.+Oweraauthor=C.+M.+Laneauthor=C.+Earwoodauthor=H.+A.+Burris&title=A+phase+2+study+of+the+Hsp90+inhibitor+AUY922+as+treatment+for+patients+with+refractory+gastrointestinal+stromal+tumors&doi=10.1080%2F07357907.2016.1193746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors</span></div><div class="casAuthors">Bendell, Johanna C.; Bauer, Todd M.; Lamar, Ruth; Joseph, Mathew; Penley, William; Thompson, Dana S.; Spigel, David R.; Owera, Rami; Lane, Cassie M.; Earwood, Chris; Burris, Howard A., III</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Investigation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">265-270</span>CODEN:
                <span class="NLM_cas:coden">CINVD7</span>;
        ISSN:<span class="NLM_cas:issn">0735-7907</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Background: AUY922 is an inhibitor of heat shock protein 90 (Hsp90).  Hsp90 inhibitors induce kit degrdn. in preclin. gastrointestinal stromal tumor (GIST) models.  This trial was designed to det. the progression-free survival (PFS) of patients with GIST refractory to or intolerant of imatinib and sunitinib.  Methods: Eligible patients received AUY922 70 mg/mg2 by i.v. (IV) infusion on days 1, 8, and 15 of 21-day cycles.  Treatment continued until progression or unacceptable toxicity.  Results: Between Dec. 2011 and Jan. 2015, 25 patients were enrolled (median age, 63 years; 56% male) and received a median of 2 cycles (range: 1-12) of AUY922 treatment.  Thirty-four patients were planned, but enrollment was stopped early due to slow accrual.  Median PFS was 3.9 mo (95% CI: 2.5, 5.3) and median OS was 8.5 mo (95% CI: 5.2, 16.7).  Radiog. response was evaluated in 21 patients; one patient achieved PR (4%) with another 15 having best response of stable disease (60%).  The most common treatment-related adverse event was diarrhea (60% all grades).  Reversible ocular toxicities that resulted in drug hold (24%) or redn. (8%) were also obsd.  Conclusion: AUY922 produced a median PFS which compares favorably to historical controls of placebo (6 wk) for patients refractory to treatment with imatinib.  While diarrhea and ocular toxicities were common, the majority of patients received treatment until disease progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmYmW82WPEprVg90H21EOLACvtfcHk0lhIFnQgHYsFdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFCrsr%252FE&md5=5dfc57d92a51bc78c5765387cac0393c</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1080%2F07357907.2016.1193746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07357907.2016.1193746%26sid%3Dliteratum%253Aachs%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DLamar%26aufirst%3DR.%26aulast%3DJoseph%26aufirst%3DM.%26aulast%3DPenley%26aufirst%3DW.%26aulast%3DThompson%26aufirst%3DD.%2BS.%26aulast%3DSpigel%26aufirst%3DD.%2BR.%26aulast%3DOwera%26aufirst%3DR.%26aulast%3DLane%26aufirst%3DC.%2BM.%26aulast%3DEarwood%26aufirst%3DC.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26atitle%3DA%2520phase%25202%2520study%2520of%2520the%2520Hsp90%2520inhibitor%2520AUY922%2520as%2520treatment%2520for%2520patients%2520with%2520refractory%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DCancer%2520Invest.%26date%3D2016%26volume%3D34%26spage%3D265%26epage%3D270%26doi%3D10.1080%2F07357907.2016.1193746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bear, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ying, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsoum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">London, C.</span></span> <span> </span><span class="NLM_article-title">The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors</span>. <i>Exp. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1266</span>– <span class="NLM_lpage">1277</span>, <span class="refDoi"> DOI: 10.1016/j.exphem.2008.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1016%2Fj.exphem.2008.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=18657349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFylsLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=1266-1277&author=T.-Y.+Linauthor=M.+Bearauthor=Z.+Duauthor=K.+P.+Foleyauthor=W.+Yingauthor=J.+Barsoumauthor=C.+London&title=The+novel+HSP90+inhibitor+STA-9090+exhibits+activity+against+Kit-dependent+and+-independent+malignant+mast+cell+tumors&doi=10.1016%2Fj.exphem.2008.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors</span></div><div class="casAuthors">Lin, Tzu-Yin; Bear, Misty; Du, Zhenjian; Foley, Kevin P.; Ying, Weiwen; Barsoum, James; London, Cheryl</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Hematology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1266-1277</span>CODEN:
                <span class="NLM_cas:coden">EXHMA6</span>;
        ISSN:<span class="NLM_cas:issn">0301-472X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Mutations of the receptor tyrosine kinase Kit occur in several human and canine cancers.  While Kit inhibitors have activity in the clin. setting, they possess variable efficacy against particular forms of mutant Kit and drug resistance often develops over time.  Inhibitors of heat shock protein 90 (HSP90), a chaperone for which Kit is a client protein, have demonstrated activity against human cancers and evidence suggests they downregulate several mutated and imatinib-resistant forms of Kit.  The purpose of this study was to evaluate a novel HSP90 inhibitor, STA-9090, against wild-type (WT) and mutant Kit in canine bone marrow-derived cultured mast cells (BMCMCs), malignant mast cell lines, and fresh malignant mast cells.  BMCMCs, cell lines, and fresh malignant mast cells were treated with STA-9090, 17-AAG, and SU11654 and evaluated for loss in cell viability, cell death, alterations in HSP90 and Kit expression/signaling, and Kit mutation.  STA-9090 activity was tested in a canine mastocytoma xenograft model.  Treatment of BMCMCs, cell lines, and fresh malignant cells with STA-9090 induced growth inhibition, apoptosis that was caspase-3/7-dependent, and downregulation of phospho/total Kit and Akt, but not extracellular signal-regulated kinase (ERK) or phosphoinositide-3 kinase (PI-3K).  Loss of Kit cell-surface expression was also obsd.  Furthermore, STA-9090 exhibited superior activity to 17-AAG and SU11654, and was effective against malignant mast cells expressing either WT or mutant Kit.  Lastly, STA-9090 inhibited tumor growth in a canine mastocytoma mouse xenograft model.  STA-9090 exhibits broad activity against mast cells expressing WT or mutant Kit, suggesting it may be an effective agent in the clin. setting against mast cell malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzWCSaAah6lrVg90H21EOLACvtfcHk0liG3qf9aVQpdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFylsLvK&md5=0ded2a0f878a699b895088651fc47913</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.exphem.2008.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exphem.2008.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DT.-Y.%26aulast%3DBear%26aufirst%3DM.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DFoley%26aufirst%3DK.%2BP.%26aulast%3DYing%26aufirst%3DW.%26aulast%3DBarsoum%26aufirst%3DJ.%26aulast%3DLondon%26aufirst%3DC.%26atitle%3DThe%2520novel%2520HSP90%2520inhibitor%2520STA-9090%2520exhibits%2520activity%2520against%2520Kit-dependent%2520and%2520-independent%2520malignant%2520mast%2520cell%2520tumors%26jtitle%3DExp.%2520Hematol.%26date%3D2008%26volume%3D36%26spage%3D1266%26epage%3D1277%26doi%3D10.1016%2Fj.exphem.2008.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ying, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proia, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackman, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatsuta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acquaviva, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsoum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koya, K.</span></span> <span> </span><span class="NLM_article-title">Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">484</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0755</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1158%2F1535-7163.MCT-11-0755" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=22144665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=475-484&author=W.+W.+Yingauthor=Z.+J.+Duauthor=L.+J.+Sunauthor=K.+P.+Foleyauthor=D.+A.+Proiaauthor=R.+K.+Blackmanauthor=D.+Zhouauthor=T.+Inoueauthor=N.+Tatsutaauthor=J.+Sangauthor=S.+X.+Yeauthor=J.+Acquavivaauthor=L.+S.+Ogawaauthor=Y.+Wadaauthor=J.+Barsoumauthor=K.+Koya&title=Ganetespib%2C+a+unique+triazolone-containing+Hsp90+inhibitor%2C+exhibits+potent+antitumor+activity+and+a+superior+safety+profile+for+cancer+therapy&doi=10.1158%2F1535-7163.MCT-11-0755"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy</span></div><div class="casAuthors">Ying, Weiwen; Du, Zhenjian; Sun, Lijun; Foley, Kevin P.; Proia, David A.; Blackman, Ronald K.; Zhou, Dan; Inoue, Takayo; Tatsuta, Noriaki; Sang, Jim; Ye, Shuxia; Acquaviva, Jamie; Ogawa, Luisa Shin; Wada, Yumiko; Barsoum, James; Koya, Keizo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">475-484</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Targeted inhibition of the mol. chaperone Hsp90 results in the simultaneous blockade of multiple oncogenic signaling pathways and has, thus, emerged as an attractive strategy for the development of novel cancer therapeutics.  Ganetespib (formerly known as STA-9090) is a unique resorcinolic triazolone inhibitor of Hsp90 that is currently in clin. trials for a no. of human cancers.  In the present study, we showed that ganetespib exhibits potent in vitro cytotoxicity in a range of solid and hematol. tumor cell lines, including those that express mutated kinases that confer resistance to small-mol. tyrosine kinase inhibitors.  Ganetespib treatment rapidly induced the degrdn. of known Hsp90 client proteins, displayed superior potency to the ansamycin inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG), and exhibited sustained activity even with short exposure times.  In vivo, ganetespib showed potent antitumor efficacy in solid and hematol. xenograft models of oncogene addiction, as evidenced by significant growth inhibition and/or regressions.  Notably, evaluation of the microregional activity of ganetespib in tumor xenografts showed that ganetespib was efficiently distributed throughout tumor tissue, including hypoxic regions >150 μm from the microvasculature, to inhibit proliferation and induce apoptosis.  Importantly, ganetespib showed no evidence of cardiac or liver toxicity.  Taken together, this preclin. activity profile indicates that ganetespib may have broad application for a variety of human malignancies, and with select mechanistic and safety advantages over other first- and second-generation Hsp90 inhibitors.  Mol Cancer Ther; 11(2); 475-84.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFhzG1TPr4lbVg90H21EOLACvtfcHk0liG3qf9aVQpdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWksrY%253D&md5=269d41b30e5add9b9503cb43a98b0157</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0755%26sid%3Dliteratum%253Aachs%26aulast%3DYing%26aufirst%3DW.%2BW.%26aulast%3DDu%26aufirst%3DZ.%2BJ.%26aulast%3DSun%26aufirst%3DL.%2BJ.%26aulast%3DFoley%26aufirst%3DK.%2BP.%26aulast%3DProia%26aufirst%3DD.%2BA.%26aulast%3DBlackman%26aufirst%3DR.%2BK.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DTatsuta%26aufirst%3DN.%26aulast%3DSang%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DS.%2BX.%26aulast%3DAcquaviva%26aufirst%3DJ.%26aulast%3DOgawa%26aufirst%3DL.%2BS.%26aulast%3DWada%26aufirst%3DY.%26aulast%3DBarsoum%26aufirst%3DJ.%26aulast%3DKoya%26aufirst%3DK.%26atitle%3DGanetespib%252C%2520a%2520unique%2520triazolone-containing%2520Hsp90%2520inhibitor%252C%2520exhibits%2520potent%2520antitumor%2520activity%2520and%2520a%2520superior%2520safety%2520profile%2520for%2520cancer%2520therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D475%26epage%3D484%26doi%3D10.1158%2F1535-7163.MCT-11-0755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lock, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carol, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorlick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keir, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billups, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurmasheva, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houghton, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. A.</span></span> <span> </span><span class="NLM_article-title">Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program</span>. <i>Pediatr. Blood Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">E42</span>– <span class="NLM_lpage">E45</span>, <span class="refDoi"> DOI: 10.1002/pbc.24451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1002%2Fpbc.24451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=23303741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslWhu7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2013&pages=E42-E45&author=R.+B.+Lockauthor=H.+Carolauthor=J.+M.+Marisauthor=M.+H.+Kangauthor=C.+P.+Reynoldsauthor=E.+A.+Kolbauthor=R.+Gorlickauthor=S.+T.+Keirauthor=C.+A.+Billupsauthor=R.+T.+Kurmashevaauthor=P.+J.+Houghtonauthor=M.+A.+Smith&title=Initial+testing+%28stage+1%29+of+ganetespib%2C+an+Hsp90+inhibitor%2C+by+the+pediatric+preclinical+testing+program&doi=10.1002%2Fpbc.24451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program</span></div><div class="casAuthors">Lock, Richard B.; Carol, Hernan; Maris, John M.; Kang, Min H.; Reynolds, C. Patrick; Kolb, E. Anders; Gorlick, Richard; Keir, Stephen T.; Billups, Catherine A.; Kurmasheva, Raushan T.; Houghton, Peter J.; Smith, Malcolm A.</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric Blood & Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">E42-E45, 4</span>CODEN:
                <span class="NLM_cas:coden">PBCEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1545-5017</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Ganetespib, an Hsp90 inhibitor, was tested against the PPTP in vitro cell line panel and selected xenografts in vivo, including JAK2- and BRAF-mutated models.  Ganetespib demonstrated potent in vitro cytotoxic activity (median rIC50 8.8 nM, range 4.4- 27.1 nM).  In vivo, ganetespib induced significant differences in EFS distribution for 4 of 11 xenografts.  Intermediate activity (EFS T/C > 2) was noted only for the MV4;11 xenograft, and there were no objective responses.  Administered as single agents, Hsp90 inhibitors examd. by the PPTP have shown limited evidence for a therapeutic window against both solid tumor and leukemia pediatric preclin. models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxyDM0rHGFS7Vg90H21EOLACvtfcHk0lhUdfAbHlKchQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslWhu7bJ&md5=20c807fb3c0f989ef4825d486764032f</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1002%2Fpbc.24451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpbc.24451%26sid%3Dliteratum%253Aachs%26aulast%3DLock%26aufirst%3DR.%2BB.%26aulast%3DCarol%26aufirst%3DH.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26aulast%3DKang%26aufirst%3DM.%2BH.%26aulast%3DReynolds%26aufirst%3DC.%2BP.%26aulast%3DKolb%26aufirst%3DE.%2BA.%26aulast%3DGorlick%26aufirst%3DR.%26aulast%3DKeir%26aufirst%3DS.%2BT.%26aulast%3DBillups%26aufirst%3DC.%2BA.%26aulast%3DKurmasheva%26aufirst%3DR.%2BT.%26aulast%3DHoughton%26aufirst%3DP.%2BJ.%26aulast%3DSmith%26aufirst%3DM.%2BA.%26atitle%3DInitial%2520testing%2520%2528stage%25201%2529%2520of%2520ganetespib%252C%2520an%2520Hsp90%2520inhibitor%252C%2520by%2520the%2520pediatric%2520preclinical%2520testing%2520program%26jtitle%3DPediatr.%2520Blood%2520Cancer%26date%3D2013%26volume%3D60%26spage%3DE42%26epage%3DE45%26doi%3D10.1002%2Fpbc.24451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jhaveri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lake, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilewski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldfarb, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drullinsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugarman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasserheit-Leiblich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moynahan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddington, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haque, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vukovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Hariry, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, S.</span></span> <span> </span><span class="NLM_article-title">A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer</span>. <i>Clin. Breast Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">160</span>, <span class="refDoi"> DOI: 10.1016/j.clbc.2013.12.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1016%2Fj.clbc.2013.12.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=24512858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFegsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=154-160&author=K.+Jhaveriauthor=S.+Chandarlapatyauthor=D.+Lakeauthor=T.+Gilewskiauthor=M.+Robsonauthor=S.+Goldfarbauthor=P.+Drullinskyauthor=S.+Sugarmanauthor=C.+Wasserheit-Leiblichauthor=J.+Fasanoauthor=M.+E.+Moynahanauthor=G.+D%E2%80%99Andreaauthor=K.+Limauthor=L.+Reddingtonauthor=S.+Haqueauthor=S.+Patilauthor=L.+Baumanauthor=V.+Vukovicauthor=I.+El-Hariryauthor=C.+Hudisauthor=S.+Modi&title=A+phase+II+open-label+study+of+ganetespib%2C+a+novel+heat+shock+protein+90+inhibitor+for+patients+with+metastatic+breast+cancer&doi=10.1016%2Fj.clbc.2013.12.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer</span></div><div class="casAuthors">Jhaveri, Komal; Chandarlapaty, Sarat; Lake, Diana; Gilewski, Teresa; Robson, Mark; Goldfarb, Shari; Drullinsky, Pamela; Sugarman, Steven; Wasserheit-Leiblich, Carolyn; Fasano, Julie; Moynahan, Mary Ellen; D'Andrea, Gabriella; Lim, Kristina; Reddington, Laura; Haque, Sofia; Patil, Sujata; Bauman, Lynne; Vukovic, Vojo; El-Hariry, Iman; Hudis, Clifford; Modi, Shanu</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Breast Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">154-160</span>CODEN:
                <span class="NLM_cas:coden">CBCLB7</span>;
        ISSN:<span class="NLM_cas:issn">1526-8209</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background:Ganetespib is a small mol., nongeldanamycin HSP90 inhibitor with potent inhibitory effects on HSP90-dependent oncoproteins of relevance to breast cancer pathogenesis.  We therefore tested ganetespib in an unselected cohort of patients with MBC.  Patients and Methods: Patients were treated with single agent ganetespib at 200 mg/m2 once weekly for 3 wk, on a 28-day cycle.  Therapy was continued until disease progression.  The primary end point was ORR using Reponse Evaluation Criteria in Solid Tumors version 1.1.  Results: Twenty-two patients were enrolled with a median age of 51(range, 38-70) years and a median Eastern Cooperative Oncol. Group performance status of 0 (range, 0-1).  Most patients had at least 2 previous lines of chemotherapy in the metastatic setting.  Most common toxicities, largely grade 1/2, were diarrhea, fatigue, nausea, and hypersensitivity reaction.  The ORR in this unselected population was 9%, with all responses coming from the subset of patients with HER2-pos. MBC (2/13; 15%).  One patient with TNBC had objective tumor regression in the lung metastases.  The clin. benefit rate (complete response + partial response + stable disease > 6 mo) was 9%, median progression-free survival was 7 wk (95% confidence interval [CI], 7-19), and median overall survival was 46 wk (95% CI, 27-not applicable).  Conclusion: The study did not meet the prespecified criteria for ORR in the first stage of the Simon 2-stage model in this heavily pretreated unselected population of MBC.  However, activity was obsd. in trastuzumab-refractory HER2-pos. and TNBC.  Ganetespib was well tolerated and responses in more targeted populations harboring specific HSP90-dependent oncoproteins justifies its further study, particularly as part of rational combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKRWFzPxBRzbVg90H21EOLACvtfcHk0lji1A1gzo9rkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFegsLc%253D&md5=15edad6cf71a9559eb42997563c57f53</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.clbc.2013.12.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clbc.2013.12.012%26sid%3Dliteratum%253Aachs%26aulast%3DJhaveri%26aufirst%3DK.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DLake%26aufirst%3DD.%26aulast%3DGilewski%26aufirst%3DT.%26aulast%3DRobson%26aufirst%3DM.%26aulast%3DGoldfarb%26aufirst%3DS.%26aulast%3DDrullinsky%26aufirst%3DP.%26aulast%3DSugarman%26aufirst%3DS.%26aulast%3DWasserheit-Leiblich%26aufirst%3DC.%26aulast%3DFasano%26aufirst%3DJ.%26aulast%3DMoynahan%26aufirst%3DM.%2BE.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DG.%26aulast%3DLim%26aufirst%3DK.%26aulast%3DReddington%26aufirst%3DL.%26aulast%3DHaque%26aufirst%3DS.%26aulast%3DPatil%26aufirst%3DS.%26aulast%3DBauman%26aufirst%3DL.%26aulast%3DVukovic%26aufirst%3DV.%26aulast%3DEl-Hariry%26aufirst%3DI.%26aulast%3DHudis%26aufirst%3DC.%26aulast%3DModi%26aufirst%3DS.%26atitle%3DA%2520phase%2520II%2520open-label%2520study%2520of%2520ganetespib%252C%2520a%2520novel%2520heat%2520shock%2520protein%252090%2520inhibitor%2520for%2520patients%2520with%2520metastatic%2520breast%2520cancer%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D154%26epage%3D160%26doi%3D10.1016%2Fj.clbc.2013.12.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jhaveri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teplinsky, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadoo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haque, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteva, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, S.</span></span> <span> </span><span class="NLM_article-title">A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>, <span class="NLM_elocation-id">89</span> <span class="refDoi"> DOI: 10.1186/s13058-017-0879-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1186%2Fs13058-017-0879-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=28764748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVGju7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&author=K.+Jhaveriauthor=R.+Wangauthor=E.+Teplinskyauthor=S.+Chandarlapatyauthor=D.+Solitauthor=K.+Cadooauthor=J.+Speyerauthor=G.+D%E2%80%99Andreaauthor=S.+Adamsauthor=S.+Patilauthor=S.+Haqueauthor=T.+O%E2%80%99Neillauthor=K.+Friedmanauthor=F.+J.+Estevaauthor=C.+Hudisauthor=S.+Modi&title=A+phase+I+trial+of+ganetespib+in+combination+with+paclitaxel+and+trastuzumab+in+patients+with+human+epidermal+growth+factor+receptor-2+%28HER2%29-positive+metastatic+breast+cancer&doi=10.1186%2Fs13058-017-0879-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer</span></div><div class="casAuthors">Jhaveri, Komal; Wang, Rui; Teplinsky, Eleonora; Chandarlapaty, Sarat; Solit, David; Cadoo, Karen; Speyer, James; D'Andrea, Gabriella; Adams, Sylvia; Patil, Sujata; Haque, Sofia; O'Neill, Tara; Friedman, Kent; Esteva, Francisco J.; Hudis, Clifford; Modi, Shanu</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89/1-89/8</span>CODEN:
                <span class="NLM_cas:coden">BRCRFS</span>;
        ISSN:<span class="NLM_cas:issn">1465-542X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Targeted therapies in HER2-pos. metastatic breast cancer significantly improve outcomes but efficacy is limited by therapeutic resistance.  HER2 is an acutely sensitive Heat Shock Protein 90 (HSP90) client and HSP90 inhibition can overcome trastuzumab resistance.  Preclin. data suggest that HSP90 inhibition is synergistic with taxanes with the potential for significant clin. activity.  We therefore tested ganetespib, a HSP90 inhibitor, in combination with paclitaxel and trastuzumab in patients with trastuzumab-refractory HER2-pos. metastatic breast cancer.  Methods: In this phase I dose-escalation study, patients with trastuzumab-resistant HER2-pos. metastatic breast cancer received weekly trastuzumab (2 mg/kg) and paclitaxel (80 mg/m2) on days 1, 8, 15, and 22 of a 28-day cycle with escalating doses of ganetespib (100 mg/m2, 150 mg/m2, and a third cohort of 125 mg/m2 if needed) on days 1, 8, and 15.  Therapy was continued until disease progression or toxicity.  The primary objective was to establish the safety and max. tolerated dose and/or recommended phase II dose (RP2D) of this therapy.  The secondary objectives included evaluation of the effects of ganetespib on the pharmacokinetics of paclitaxel, and to make a preliminary assessment of the efficacy of the combination therapy.  Results: Dose escalation was completed for the two main cohorts without any obsd. dose-limiting toxicities.  Nine patients received treatment.  The median prior lines of anti-HER2 therapy numbered three (range 2-4), including prior pertuzumab in 9/9 patients and ado-trastuzumab emtansine (T-DM1) in 8/9 patients.  The most common grade 1/2 adverse events (AEs) were diarrhea, fatigue, anemia, and rash.  There were no grade 4 AEs related to ganetespib.  The overall response rate was 22% (2/9 patients had partial response) and stable disease was seen in 56% (5/9 patients).  The clin. benefit rate was 44% (4/9 patients).  The median progression-free survival was 20 wk (range 8-55).  Conclusion: The RP2D of ganetespib is 150 mg/m2 in combination with weekly paclitaxel plus trastuzumab.  The combination was safe and well tolerated.  Despite prior taxanes, pertuzumab, and T-DM1, clin. activity of this triplet regimen in this heavily pretreated cohort is promising and warrants further study in HER2-pos. metastatic breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUSvrm6d3_trVg90H21EOLACvtfcHk0lji1A1gzo9rkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVGju7zO&md5=7e725dae322c9d5b8cf3967665da5c82</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1186%2Fs13058-017-0879-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-017-0879-5%26sid%3Dliteratum%253Aachs%26aulast%3DJhaveri%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DTeplinsky%26aufirst%3DE.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DSolit%26aufirst%3DD.%26aulast%3DCadoo%26aufirst%3DK.%26aulast%3DSpeyer%26aufirst%3DJ.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DG.%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DPatil%26aufirst%3DS.%26aulast%3DHaque%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DT.%26aulast%3DFriedman%26aufirst%3DK.%26aulast%3DEsteva%26aufirst%3DF.%2BJ.%26aulast%3DHudis%26aufirst%3DC.%26aulast%3DModi%26aufirst%3DS.%26atitle%3DA%2520phase%2520I%2520trial%2520of%2520ganetespib%2520in%2520combination%2520with%2520paclitaxel%2520and%2520trastuzumab%2520in%2520patients%2520with%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520%2528HER2%2529-positive%2520metastatic%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2017%26volume%3D19%26doi%3D10.1186%2Fs13058-017-0879-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heilbrun, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonarakis, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaishampayan, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzinic, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heath, E. I.</span></span> <span> </span><span class="NLM_article-title">A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study</span>. <i>Invest. New Drug.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1007/s10637-015-0307-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1007%2Fs10637-015-0307-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=26581400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWlsLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=112-118&author=M.+K.+Thakurauthor=L.+K.+Heilbrunauthor=S.+Shengauthor=M.+Steinauthor=G.+Liuauthor=E.+S.+Antonarakisauthor=U.+Vaishampayanauthor=S.+H.+Dzinicauthor=X.+Liauthor=S.+Freemanauthor=D.+Smithauthor=E.+I.+Heath&title=A+phase+II+trial+of+ganetespib%2C+a+heat+shock+protein+90+Hsp90%29+inhibitor%2C+in+patients+with+docetaxel-pretreated+metastatic+castrate-resistant+prostate+cancer+%28CRPC%29-a+prostate+cancer+clinical+trials+consortium+%28PCCTC%29+study&doi=10.1007%2Fs10637-015-0307-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study</span></div><div class="casAuthors">Thakur, Manish K.; Heilbrun, Lance K.; Sheng, Shijie; Stein, Mark; Liu, Glenn; Antonarakis, Emmanuel S.; Vaishampayan, Ulka; Dzinic, Sijana H.; Li, Xiaohua; Freeman, Stacy; Smith, Daryn; Heath, Elisabeth I.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">112-118</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Introduction Heat shock protein 90 (Hsp90) has been studied as a therapeutic target in many cancers.  In preclin. trials, the Hsp90 ATPase inhibitor ganetespib demonstrated potent inhibition of solid tumor growth, with superior potency than prior Hsp90 inhibitors.  Given the promising preclin. outcome and favorable pharmacol. properties of ganetespib, we conducted a phase II trial of single-agent ganetespib in patients with metastatic, castrate-resistant prostate cancer (mCRPC).  The primary objective of the study was to det. the 6-mo progression-free survival (PFS) rate.  Methods Patients with mCRPC who had been previously treated with docetaxel were enrolled after meeting eligibility criteria.  All patients received ganetespib at 200 mg/m2 on days 1, 8, and 15 of every 28 days (one cycle).  Subjects who tolerated therapy were continued on ganetespib until disease progression.  Considering that Hsp90 acetylation may confer insensitivity to Hsp90 inhibitors and maspin inhibits protein deacetylation, maspin-assocd. mol. markers were evaluated.  Results Eighteen patients were recruited into the trial; most were Caucasian, had performance status 1, had received prior docetaxel, and were heavily pretreated.  Of the 17 patients who were treated, none attained 6-mo PFS.  Only 2 patients achieved PFS > 4 mo.  The median PFS was 1.9 mo.  As per the study design, the trial was terminated after the interim anal.  The most frequent types of Grade 3 toxicity were dehydration, diarrhea, and fatigue.  Mol. markers provided little addnl. insight regarding drug activity.  Conclusions Ganetespib demonstrated minimal clin. activity in men with mCRPC.  The true 6-mo PFS rate was, at most, 0.20.  Possible reasons for this include selection of a heavily pretreated patient population and lack of agent potency in patients with mCRPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEc_FjjTbGprVg90H21EOLACvtfcHk0lhjv48_zjla4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWlsLjN&md5=08f9e46b0d9880d2caa2395be001ce8e</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1007%2Fs10637-015-0307-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-015-0307-6%26sid%3Dliteratum%253Aachs%26aulast%3DThakur%26aufirst%3DM.%2BK.%26aulast%3DHeilbrun%26aufirst%3DL.%2BK.%26aulast%3DSheng%26aufirst%3DS.%26aulast%3DStein%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DAntonarakis%26aufirst%3DE.%2BS.%26aulast%3DVaishampayan%26aufirst%3DU.%26aulast%3DDzinic%26aufirst%3DS.%2BH.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DFreeman%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DHeath%26aufirst%3DE.%2BI.%26atitle%3DA%2520phase%2520II%2520trial%2520of%2520ganetespib%252C%2520a%2520heat%2520shock%2520protein%252090%2520Hsp90%2529%2520inhibitor%252C%2520in%2520patients%2520with%2520docetaxel-pretreated%2520metastatic%2520castrate-resistant%2520prostate%2520cancer%2520%2528CRPC%2529-a%2520prostate%2520cancer%2520clinical%2520trials%2520consortium%2520%2528PCCTC%2529%2520study%26jtitle%3DInvest.%2520New%2520Drug.%26date%3D2016%26volume%3D34%26spage%3D112%26epage%3D118%26doi%3D10.1007%2Fs10637-015-0307-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadlow, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaszkowsky, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolpin, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCleary, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheehan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundaram, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karol, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, A. X.</span></span> <span> </span><span class="NLM_article-title">A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma</span>. <i>Invest. New Drug.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">128</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1007/s10637-014-0164-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1007%2Fs10637-014-0164-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=25248753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVSru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=128-137&author=L.+Goyalauthor=R.+C.+Wadlowauthor=L.+S.+Blaszkowskyauthor=B.+M.+Wolpinauthor=T.+A.+Abramsauthor=N.+J.+McClearyauthor=S.+Sheehanauthor=E.+Sundaramauthor=M.+D.+Karolauthor=J.+Chenauthor=A.+X.+Zhu&title=A+phase+I+and+pharmacokinetic+study+of+ganetespib+%28STA-9090%29+in+advanced+hepatocellular+carcinoma&doi=10.1007%2Fs10637-014-0164-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma</span></div><div class="casAuthors">Goyal, Lipika; Wadlow, Raymond C.; Blaszkowsky, Lawrence S.; Wolpin, Brian M.; Abrams, Thomas A.; McCleary, Nadine Jackson; Sheehan, Susan; Sundaram, Eamala; Karol, Michael D.; Chen, John; Zhu, Andrew X.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">128-137</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Background: Ganetespib (STA-9090) is an Hsp90 inhibitor that downregulates VEGFR, c-MET, HER2, IGF-IR, EGFR, and other Hsp90 client proteins involved in hepatocarcinogenesis, thereby making it an attractive therapy for HCC.  This Phase I study was performed to establish the safety, tolerability, recommended Phase 2 dose (RP2D), and preliminary clin. activity of ganetespib in previously treated patients with advanced HCC.  Methods: Patients with advanced HCC, Child-Pugh A cirrhosis, progression on or intolerance to sorafenib, and ECOG PS ≤ 1 were enrolled in a std. 3x3 dose escalation study at doses of 100 mg/m2, 150 mg/m2, and 200 mg/m2 IV given on days 1, 8, and 15 of each 28-day cycle.  Objective response by RECIST version 1.1 criteria was evaluated by CT/MRI every 8 wk.  Results: Fourteen patients were enrolled in this trial and received at least one dose of the study drug.  Of the 14 patients: median age, 57 years old; male 71 %; Asian 36 %; HCC etiol. (HBV 36 %, HCV 43 %, Hemachromatosis 7 %, unknown 21 %); Child Pugh Class (A 93 %, B 7 %); median no. of prior treatments 2; median baseline AFP 70.1 ng/mL.  The RP2D was detd. to be 200 mg/m2.  The most commonly seen AEs were diarrhea (93 %), fatigue (71 %), AST elevation (64 %), and hyperglycemia (64 %).  The most common Gr 3/4 AEs were hyperglycemia (21 %) and lipasemia (21 %).  One (7 %) patient had a fatal AE, septic shock, within 30 days of receiving the study drug.  One dose-limiting toxicity, grade 3 lipasemia, was obsd. at the 100 mg/m2 dose.  Pharmacokinetics studies showed a t1/2, CL, Tmax, and Vss of 6.45 h, 48.28 L/h (25.56 L/h/m2), 0.76 h, and 191 L (100.4 L/m2), resp.  No objective responses were seen; one patient (7 %) had stable disease at 16 wk.  Median time to progression was 1.8 mo, and median overall survival was 7.2 mo.  Conclusion: Ganetespib had a manageable safety profile in patients with advanced HCC who had progressed on at least one line of systemic therapy.  The pharmacokinetic profile showed that ganetespib exposure in patients with mild hepatic dysfunction is similar to that seen in patients with normal liver function.  Ganetespib showed limited clin. benefit in patients with advanced HCC in this phase I trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr57teDffjuSrVg90H21EOLACvtfcHk0lhjv48_zjla4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVSru7c%253D&md5=c55ec15b28353dea4e1aca73525f7e9b</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1007%2Fs10637-014-0164-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-014-0164-8%26sid%3Dliteratum%253Aachs%26aulast%3DGoyal%26aufirst%3DL.%26aulast%3DWadlow%26aufirst%3DR.%2BC.%26aulast%3DBlaszkowsky%26aufirst%3DL.%2BS.%26aulast%3DWolpin%26aufirst%3DB.%2BM.%26aulast%3DAbrams%26aufirst%3DT.%2BA.%26aulast%3DMcCleary%26aufirst%3DN.%2BJ.%26aulast%3DSheehan%26aufirst%3DS.%26aulast%3DSundaram%26aufirst%3DE.%26aulast%3DKarol%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DA.%2BX.%26atitle%3DA%2520phase%2520I%2520and%2520pharmacokinetic%2520study%2520of%2520ganetespib%2520%2528STA-9090%2529%2520in%2520advanced%2520hepatocellular%2520carcinoma%26jtitle%3DInvest.%2520New%2520Drug.%26date%3D2015%26volume%3D33%26spage%3D128%26epage%3D137%26doi%3D10.1007%2Fs10637-014-0164-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Socinski, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Hariry, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koczywas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vukovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paschold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonomi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahmer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belani, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huberman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teofilovici, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span> <span> </span><span class="NLM_article-title">A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non–small cell lung cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">3068</span>– <span class="NLM_lpage">3077</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-3381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1158%2F1078-0432.CCR-12-3381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=23553849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC3sXos12isLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=3068-3077&author=M.+A.+Socinskiauthor=J.+Goldmanauthor=I.+El-Hariryauthor=M.+Koczywasauthor=V.+Vukovicauthor=L.+Hornauthor=E.+Pascholdauthor=R.+Salgiaauthor=H.+Westauthor=L.+V.+Sequistauthor=P.+Bonomiauthor=J.+Brahmerauthor=L.-C.+Chenauthor=A.+Sandlerauthor=C.+P.+Belaniauthor=T.+Webbauthor=H.+Harperauthor=M.+Hubermanauthor=S.+Ramalingamauthor=K.-K.+Wongauthor=F.+Teofiloviciauthor=W.+Guoauthor=G.+I.+Shapiro&title=A+multicenter+phase+II+study+of+ganetespib+monotherapy+in+patients+with+genotypically+defined+advanced+non%E2%80%93small+cell+lung+cancer&doi=10.1158%2F1078-0432.CCR-12-3381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Socinski, Mark A.; Goldman, Jonathan; El-Hariry, Iman; Koczywas, Marianna; Vukovic, Vojo; Horn, Leora; Paschold, Eugene; Salgia, Ravi; West, Howard; Sequist, Lecia V.; Bonomi, Philip; Brahmer, Julie; Chen, Lin-Chi; Sandler, Alan; Belani, Chandra P.; Webb, Timothy; Harper, Harry; Huberman, Mark; Ramalingam, Suresh; Wong, Kwok-Kin; Teofilovici, Florentina; Guo, Wei; Shapiro, Geoffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3068-3077</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Ganetespib is a novel inhibitor of the heat shock protein 90 (Hsp90), a chaperone protein crit. to tumor growth and proliferation.  In this phase II study, we evaluated the activity and tolerability of ganetespib in previously treated patients with non-small cell lung cancer (NSCLC).  Exptl. Design: Patients were enrolled into cohort A (mutant EGFR), B (mutant KRAS), or C (no EGFR or KRAS mutations).  Patients were treated with 200 mg/m2 ganetespib by i.v. infusion once weekly for 3 wk followed by 1 wk of rest, until disease progression.  The primary endpoint was progression-free survival (PFS) at 16 wk.  Secondary endpoints included objective response (ORR), duration of treatment, tolerability, median PFS, overall survival (OS), and correlative studies.  Results: Ninety-nine patients with a median of 2 prior systemic therapies were enrolled; 98 were assigned to cohort A (n = 15), B (n = 17), or C (n = 66), with PFS rates at 16 wk of 13.3%, 5.9%, and 19.7%, resp.  Four patients (4%) achieved partial response (PR); all had disease that harbored anaplastic lymphoma kinase (ALK) gene rearrangement, retrospectively detected by FISH (n = 1) or PCR-based assays (n = 3), in crizotinib-naive patients enrolled to cohort C. Eight patients (8.1%) experienced treatment-related serious adverse events (AE); 2 of these (cardiac arrest and renal failure) resulted in death.  The most common AEs were diarrhea, fatigue, nausea, and anorexia.  Conclusions: Ganetespib monotherapy showed a manageable side effect profile as well as clin. activity in heavily pretreated patients with advanced NSCLCs, particularly in patients with tumors harboring ALK gene rearrangement.  Clin Cancer Res; 19(11); 3068-77. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFukeZlyNCmbVg90H21EOLACvtfcHk0lgmlu05vF83YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXos12isLw%253D&md5=7fe5177633a6f003a7412431e6fb492d</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-3381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-3381%26sid%3Dliteratum%253Aachs%26aulast%3DSocinski%26aufirst%3DM.%2BA.%26aulast%3DGoldman%26aufirst%3DJ.%26aulast%3DEl-Hariry%26aufirst%3DI.%26aulast%3DKoczywas%26aufirst%3DM.%26aulast%3DVukovic%26aufirst%3DV.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DPaschold%26aufirst%3DE.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DWest%26aufirst%3DH.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DBonomi%26aufirst%3DP.%26aulast%3DBrahmer%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DL.-C.%26aulast%3DSandler%26aufirst%3DA.%26aulast%3DBelani%26aufirst%3DC.%2BP.%26aulast%3DWebb%26aufirst%3DT.%26aulast%3DHarper%26aufirst%3DH.%26aulast%3DHuberman%26aufirst%3DM.%26aulast%3DRamalingam%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DTeofilovici%26aufirst%3DF.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DA%2520multicenter%2520phase%2520II%2520study%2520of%2520ganetespib%2520monotherapy%2520in%2520patients%2520with%2520genotypically%2520defined%2520advanced%2520non%25E2%2580%2593small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D3068%26epage%3D3077%26doi%3D10.1158%2F1078-0432.CCR-12-3381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raju, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Hariry, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teofilivici, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vukovic, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karol, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, L. S.</span></span> <span> </span><span class="NLM_article-title">A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">152</span> <span class="refDoi"> DOI: 10.1186/1471-2407-13-152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1186%2F1471-2407-13-152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=23530663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotVKisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&author=J.+W.+Goldmanauthor=R.+N.+Rajuauthor=G.+A.+Gordonauthor=I.+El-Hariryauthor=F.+Teofiliviciauthor=V.+M.+Vukovicauthor=R.+Bradleyauthor=M.+D.+Karolauthor=Y.+Chenauthor=W.+Guoauthor=T.+Inoueauthor=L.+S.+Rosen&title=A+first+in+human%2C+safety%2C+pharmacokinetics%2C+and+clinical+activity+phase+I+study+of+once+weekly+administration+of+the+Hsp90+inhibitor+ganetespib+%28STA-9090%29+in+patients+with+solid+malignancies&doi=10.1186%2F1471-2407-13-152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies</span></div><div class="casAuthors">Goldman, Jonathan W.; Raju, Robert N.; Gordon, Gregory A.; El-Hariry, Iman; Teofilivici, Florentina; Vukovic, Vojo M.; Bradley, Robert; Karol, Michael D.; Chen, Yu; Guo, Wei; Inoue, Takayo; Rosen, Lee S.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">152</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: This phase I study investigated the max. tolerated dose (MTD), safety, pharmacokinetics and antitumor activity of ganetespib in patients with solid malignancies.  Methods: Patients were enrolled in cohorts of escalating ganetespib doses, given as 1 h IV infusion, once weekly for 3 wk, followed by a 1-wk rest until disease progression or unacceptable toxicity.  Endpoints included safety, pharmacokinetic and pharmacodynamic parameters and preliminary clin. activity.  Results: Fifty-three patients were treated at doses escalating from 7 to 259 mg/m2.  The most common adverse events were Grade 1 and 2 diarrhea, fatigue, nausea or vomiting.  Dose-limiting toxicities (DLT) obsd. were: one Grade 3 amylase elevation (150 mg/m2), one Grade 3 diarrhea and one Grade 3 and one Grade 4 asthenia (259 mg/m2).  The MTD was 216 mg/m2 and the recommended phase 2 dose was established at 200 mg/m2 given IV at Days 1, 8, and 15 every 4 wk.  There was a linear relationship between dose and exposure.  Plasma HSP70 protein levels remained elevated for over a week post treatment.  Disease control rate (objective response and stable disease at ≥16 wk) was 24.4%.  Conclusions: Ganetespib is well tolerated as a weekly infusion for 3 of every 4 wk cycle.  The recommended phase II dose is 200 mg/m2, and is assocd. with an acceptable tolerability profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_c-SmyNHbmbVg90H21EOLACvtfcHk0li3kJFTPFZgJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotVKisbc%253D&md5=55823d1bccdb38864b2528a787e3d16b</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-13-152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-13-152%26sid%3Dliteratum%253Aachs%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DRaju%26aufirst%3DR.%2BN.%26aulast%3DGordon%26aufirst%3DG.%2BA.%26aulast%3DEl-Hariry%26aufirst%3DI.%26aulast%3DTeofilivici%26aufirst%3DF.%26aulast%3DVukovic%26aufirst%3DV.%2BM.%26aulast%3DBradley%26aufirst%3DR.%26aulast%3DKarol%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DRosen%26aufirst%3DL.%2BS.%26atitle%3DA%2520first%2520in%2520human%252C%2520safety%252C%2520pharmacokinetics%252C%2520and%2520clinical%2520activity%2520phase%2520I%2520study%2520of%2520once%2520weekly%2520administration%2520of%2520the%2520Hsp90%2520inhibitor%2520ganetespib%2520%2528STA-9090%2529%2520in%2520patients%2520with%2520solid%2520malignancies%26jtitle%3DBMC%2520Cancer%26date%3D2013%26volume%3D13%26doi%3D10.1186%2F1471-2407-13-152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeBlanc, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shekhar-Guturja, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krysan, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizarro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, L. E.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of fungal-selective resorcylate aminopyrazole Hsp90 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">2139</span>– <span class="NLM_lpage">2180</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00826</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00826" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslKis7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=2139-2180&author=D.+S.+Huangauthor=E.+V.+LeBlancauthor=T.+Shekhar-Guturjaauthor=N.+Robbinsauthor=D.+J.+Krysanauthor=J.+Pizarroauthor=L.+Whitesellauthor=L.+E.+Cowenauthor=L.+E.+Brown&title=Design+and+synthesis+of+fungal-selective+resorcylate+aminopyrazole+Hsp90+inhibitors&doi=10.1021%2Facs.jmedchem.9b00826"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors</span></div><div class="casAuthors">Huang, David S.; LeBlanc, Emmanuelle V.; Shekhar-Guturja, Tanvi; Robbins, Nicole; Krysan, Damian J.; Pizarro, Juan; Whitesell, Luke; Cowen, Leah E.; Brown, Lauren E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2139-2180</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The mol. chaperone Hsp90, essential in all eukaryotes, plays a multifaceted role in promoting survival, virulence, and drug resistance across diverse pathogenic fungal species.  The chaperone is also critically important, however, to the pathogen's human host, preventing the use of known clin. Hsp90 inhibitors in antifungal applications due to concomitant host toxicity issues.  With the goal of developing Hsp90 inhibitors with acceptable therapeutic indexes for the treatment of invasive fungal infections, we initiated a program to design and synthesize potent inhibitors with selective activity against fungal Hsp90 isoforms over their human counterparts.  Building on our previously reported derivatization of resorcylate natural products to produce fungal-selective compds., we have developed a series of synthetic aminopyrazole-substituted resorcylate amides with broad, potent, and fungal-selective Hsp90 inhibitory activity.  Herein we describe the synthesis of this series, as well as biochem. structure-activity relationships driving selectivity for the Hsp90 isoforms expressed by Cryptococcus neoformans and Candida albicans, two pathogenic fungi of major clin. importance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS8vnKn_iCAbVg90H21EOLACvtfcHk0li3kJFTPFZgJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslKis7nI&md5=7273f759edff9a1bfaecba5929d493a2</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00826%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DD.%2BS.%26aulast%3DLeBlanc%26aufirst%3DE.%2BV.%26aulast%3DShekhar-Guturja%26aufirst%3DT.%26aulast%3DRobbins%26aufirst%3DN.%26aulast%3DKrysan%26aufirst%3DD.%2BJ.%26aulast%3DPizarro%26aufirst%3DJ.%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26aulast%3DBrown%26aufirst%3DL.%2BE.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520fungal-selective%2520resorcylate%2520aminopyrazole%2520Hsp90%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D2139%26epage%3D2180%26doi%3D10.1021%2Facs.jmedchem.9b00826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casadevall, A.</span></span> <span> </span><span class="NLM_article-title">Susceptibility of <i>Cryptococcus neoformans</i> biofilms to antifungal agents in vitro</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1021</span>– <span class="NLM_lpage">1033</span>, <span class="refDoi"> DOI: 10.1128/AAC.50.3.1021-1033.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1128%2FAAC.50.3.1021-1033.2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=16495265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD28XisFamtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2006&pages=1021-1033&author=L.+R.+Martinezauthor=A.+Casadevall&title=Susceptibility+of+Cryptococcus+neoformans+biofilms+to+antifungal+agents+in+vitro&doi=10.1128%2FAAC.50.3.1021-1033.2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro</span></div><div class="casAuthors">Martinez, Luis R.; Casadevall, Arturo</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1021-1033</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Microbial biofilms contribute to virulence and resistance to antibiotics by shielding microbial cells from host defenses and antimicrobial drugs, resp.  Cryptococcus neoformans was demonstrated to form biofilms in polystyrene microtiter plates.  The nos. of CFU of disaggregated biofilms, 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide redn., and light and confocal microscopy were used to measure the fungal mass, the metabolic activity, and the appearance of C. neoformans biofilms, resp.  Biofilm development by C. neoformans followed a std. sequence of events: fungal surface attachment, microcolony formation, and matrix prodn.  The susceptibilities of C. neoformans cells of the biofilm and planktonic phenotypes to four antifungal agents were examd.  The exposure of C. neoformans cells or preformed cryptococcal biofilms to fluconazole or voriconazole did not result in yeast growth inhibition and did not affect the metabolic activities of the biofilms, resp.  In contrast, both C. neoformans cells and preformed biofilms were susceptible to amphotericin B and caspofungin.  However, C. neoformans biofilms were significantly more resistant to amphotericin B and caspofungin than planktonic cells, and their susceptibilities to these drugs were further reduced if cryptococcal cells contained melanin.  A spot ELISA and light and confocal microscopy were used to investigate how antifungal drugs affected C. neoformans biofilm formation.  The mechanism by which amphotericin B and caspofungin interfered with C. neoformans biofilm formation involved capsular polysaccharide release and adherence.  Our results suggest that biofilm formation may diminish the efficacies of some antifungal drugs during cryptococcal infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMH7kllCrH0LVg90H21EOLACvtfcHk0lihxvhJTUSwMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XisFamtLc%253D&md5=1cbd2e8671a5c7adb1353deb1d748efb</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1128%2FAAC.50.3.1021-1033.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.50.3.1021-1033.2006%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez%26aufirst%3DL.%2BR.%26aulast%3DCasadevall%26aufirst%3DA.%26atitle%3DSusceptibility%2520of%2520Cryptococcus%2520neoformans%2520biofilms%2520to%2520antifungal%2520agents%2520in%2520vitro%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2006%26volume%3D50%26spage%3D1021%26epage%3D1033%26doi%3D10.1128%2FAAC.50.3.1021-1033.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casadevall, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosanchuk, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, M. L.</span></span> <span> </span><span class="NLM_article-title">Vesicular transport across the fungal cell wall</span>. <i>Trends Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">158</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1016/j.tim.2008.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1016%2Fj.tim.2008.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=19299133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkt1SktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=158-162&author=A.+Casadevallauthor=J.+D.+Nosanchukauthor=P.+Williamsonauthor=M.+L.+Rodrigues&title=Vesicular+transport+across+the+fungal+cell+wall&doi=10.1016%2Fj.tim.2008.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Vesicular transport across the fungal cell wall</span></div><div class="casAuthors">Casadevall, Arturo; Nosanchuk, Joshua D.; Williamson, Peter; Rodrigues, Marcio L.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Microbiology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">158-162</span>CODEN:
                <span class="NLM_cas:coden">TRMIEA</span>;
        ISSN:<span class="NLM_cas:issn">0966-842X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review and discussion.  Recent findings indicate that fungi use vesicular transport to deliver substances across their cell walls.  Fungal vesicles are similar to mammalian exosomes and could originate from cytoplasmic multivesicular bodies.  Vesicular transport enables the export of large mols. across the cell wall, and vesicles contain lipids, proteins and polysaccharides, many of which are assocd. with virulence.  Concn. of fungal products in vesicles could increase their efficiency in food acquisition and/or delivering potentially noxious substances to other cells, such as amoebae or phagocytes.  The discovery of vesicular transport in fungi opens many new avenues for investigation in basic cell biol. and pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0bnReh_GI77Vg90H21EOLACvtfcHk0lihxvhJTUSwMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkt1SktLg%253D&md5=4059470a49f348bb6dc52793e26a3ea5</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.tim.2008.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tim.2008.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DCasadevall%26aufirst%3DA.%26aulast%3DNosanchuk%26aufirst%3DJ.%2BD.%26aulast%3DWilliamson%26aufirst%3DP.%26aulast%3DRodrigues%26aufirst%3DM.%2BL.%26atitle%3DVesicular%2520transport%2520across%2520the%2520fungal%2520cell%2520wall%26jtitle%3DTrends%2520Microbiol.%26date%3D2009%26volume%3D17%26spage%3D158%26epage%3D162%26doi%3D10.1016%2Fj.tim.2008.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaragoza, O.</span></span> <span> </span><span class="NLM_article-title">Multiple disguises for the same party: The concepts of morphogenesis and phenotypic variations in <i>Cryptococcus neoformans</i></span>. <i>Front. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">181</span>, <span class="refDoi"> DOI: 10.3389/fmicb.2011.00181</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.3389%2Ffmicb.2011.00181" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=21922016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A280%3ADC%252BC3MfktVGqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=181&author=O.+Zaragoza&title=Multiple+disguises+for+the+same+party%3A+The+concepts+of+morphogenesis+and+phenotypic+variations+in+Cryptococcus+neoformans&doi=10.3389%2Ffmicb.2011.00181"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple Disguises for the Same Party: The Concepts of Morphogenesis and Phenotypic Variations in Cryptococcus neoformans</span></div><div class="casAuthors">Zaragoza Oscar</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in microbiology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">181</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although morphological transitions (such as hyphae and pseudohyphae formation) are a common feature among fungi, the encapsulated pathogenic yeast Cryptococcus neoformans is found during infection as blastoconidia.  However, this fungus exhibits striking variations in cellular structure and size, which have important consequences during infection.  This review will summarize the main aspects related with phenotypic and morphological variations in C. neoformans, which can be divided in three classes.  Two of them are related to changes in the capsule, while the third one involves changes in the whole cell.  The three morphological and phenotypic variations in C. neoformans can be classified as: (1) changes in capsule structure, (2) changes in capsule size, and (3) changes in the total size of the cell, which can be achieved by the formation of cryptococcal giant/titan cells or microforms.  These changes have profound consequences on the interaction with the host, involving survival, phagocytosis escape and immune evasion and dissemination.  This article will summarize the main features of these changes, and highlight their importance during the interaction with the host and how they contribute to the development of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThGDlubMUQq75oR8RchjrrfW6udTcc2ebPVRAhoGpLlrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MfktVGqsA%253D%253D&md5=ba89fe719ecae56200960292c0f13bac</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.3389%2Ffmicb.2011.00181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmicb.2011.00181%26sid%3Dliteratum%253Aachs%26aulast%3DZaragoza%26aufirst%3DO.%26atitle%3DMultiple%2520disguises%2520for%2520the%2520same%2520party%253A%2520The%2520concepts%2520of%2520morphogenesis%2520and%2520phenotypic%2520variations%2520in%2520Cryptococcus%2520neoformans%26jtitle%3DFront.%2520Microbiol.%26date%3D2011%26volume%3D2%26spage%3D181%26doi%3D10.3389%2Ffmicb.2011.00181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Meara, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alspaugh, J. A.</span></span> <span> </span><span class="NLM_article-title">The <i>Cryptococcus neoformans</i> capsule: a sword and a shield</span>. <i>Clin. Microbiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">408</span>, <span class="refDoi"> DOI: 10.1128/CMR.00001-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1128%2FCMR.00001-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=22763631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Git7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=387-408&author=T.+R.+O%E2%80%99Mearaauthor=J.+A.+Alspaugh&title=The+Cryptococcus+neoformans+capsule%3A+a+sword+and+a+shield&doi=10.1128%2FCMR.00001-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">The cryptococcus neoformans capsule: a sword and a shield</span></div><div class="casAuthors">O'Meara, Teresa R.; Alspaugh, J. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">387-408</span>CODEN:
                <span class="NLM_cas:coden">CMIREX</span>;
        ISSN:<span class="NLM_cas:issn">0893-8512</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review on the different regulation programs that respond to specific host environmental cues to induce encapsulation.  It examines critically the current information on the regulation of Cryptococcus neoformans capsule synthesis, export, and assembly.  It suggests that fungal cell wall remodeling is an underexplored component of appropriate encapsulation within the host.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTmgImpJA237Vg90H21EOLACvtfcHk0lhdCj1wW5QPRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Git7fN&md5=2d6cca07ad92114721d4c90944de2994</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1128%2FCMR.00001-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FCMR.00001-12%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DT.%2BR.%26aulast%3DAlspaugh%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520Cryptococcus%2520neoformans%2520capsule%253A%2520a%2520sword%2520and%2520a%2520shield%26jtitle%3DClin.%2520Microbiol.%2520Rev.%26date%3D2012%26volume%3D25%26spage%3D387%26epage%3D408%26doi%3D10.1128%2FCMR.00001-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cannon, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamping, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baret, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keniya, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niimi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goffeau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monk, B. C.</span></span> <span> </span><span class="NLM_article-title">Efflux-mediated antifungal drug resistance</span>. <i>Clin. Microbiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">321</span>, <span class="refDoi"> DOI: 10.1128/CMR.00051-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1128%2FCMR.00051-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=19366916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVSqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=291-321&author=R.+D.+Cannonauthor=E.+Lampingauthor=A.+R.+Holmesauthor=K.+Niimiauthor=P.+V.+Baretauthor=M.+V.+Keniyaauthor=K.+Tanabeauthor=M.+Niimiauthor=A.+Goffeauauthor=B.+C.+Monk&title=Efflux-mediated+antifungal+drug+resistance&doi=10.1128%2FCMR.00051-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Efflux-mediated antifungal drug resistance</span></div><div class="casAuthors">Cannon, Richard D.; Lamping, Erwin; Holmes, Ann R.; Niimi, Kyoko; Baret, Philippe V.; Keniya, Mikhail V.; Tanabe, Koichi; Niimi, Masakazu; Goffeau, Andre; Monk, Brian C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">291-321</span>CODEN:
                <span class="NLM_cas:coden">CMIREX</span>;
        ISSN:<span class="NLM_cas:issn">0893-8512</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review.  Fungi cause serious infections in the immunocompromised and debilitated, and the incidence of invasive mycosis has increased significantly over the last 3 decades.  Slow diagnosis and the relatively few classes of antifungal drugs result in high attributable mortality for systemic fungal infections.  Azole antifungals are commonly used for fungal infections, but azole resistance can be a problem for some patient groups.  High-level, clin. significant azole resistance usually involves overexpression of plasma membrane efflux pumps belonging to the ATP-binding cassette (ABC) or the major facilitator superfamily class of transporters.  The heterologous expression of efflux pumps in model systems, such as Saccharomyces cerevisiae, has enabled the functional anal. of efflux pumps from a variety of fungi.  Phylogenetic anal. of the ABC pleiotropic drug resistance family has provided a new view of the evolution of this important class of efflux pumps.  There are several ways in which the clin. significance of efflux-mediated antifungal drug resistance can be mitigated.  Alternative antifungal drugs, such as the echinocandins, that are not efflux pump substrates provide one option.  Potential therapeutic approaches that could overcome azole resistance include targeting efflux pump transcriptional regulators and fungal stress response pathways, blockade of energy supply, and direct inhibition of efflux pumps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRVHHsCpq4zbVg90H21EOLACvtfcHk0liENJGyEy4XtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVSqtL4%253D&md5=a426f60728d0c45c18845346ba1a155d</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1128%2FCMR.00051-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FCMR.00051-08%26sid%3Dliteratum%253Aachs%26aulast%3DCannon%26aufirst%3DR.%2BD.%26aulast%3DLamping%26aufirst%3DE.%26aulast%3DHolmes%26aufirst%3DA.%2BR.%26aulast%3DNiimi%26aufirst%3DK.%26aulast%3DBaret%26aufirst%3DP.%2BV.%26aulast%3DKeniya%26aufirst%3DM.%2BV.%26aulast%3DTanabe%26aufirst%3DK.%26aulast%3DNiimi%26aufirst%3DM.%26aulast%3DGoffeau%26aufirst%3DA.%26aulast%3DMonk%26aufirst%3DB.%2BC.%26atitle%3DEfflux-mediated%2520antifungal%2520drug%2520resistance%26jtitle%3DClin.%2520Microbiol.%2520Rev.%26date%3D2009%26volume%3D22%26spage%3D291%26epage%3D321%26doi%3D10.1128%2FCMR.00051-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, C. W.</span></span> <span> </span><span class="NLM_article-title">Analysis of protein-ligand interactions by fluorescence polarization</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">387</span>, <span class="refDoi"> DOI: 10.1038/nprot.2011.305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1038%2Fnprot.2011.305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=21372817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC3MXislentbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=365-387&author=A.+M.+Rossiauthor=C.+W.+Taylor&title=Analysis+of+protein-ligand+interactions+by+fluorescence+polarization&doi=10.1038%2Fnprot.2011.305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of protein-ligand interactions by fluorescence polarization</span></div><div class="casAuthors">Rossi, Ana M.; Taylor, Colin W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">365-387</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Quantification of the assocns. between biomols. is required both to predict and understand the interactions that underpin all biol. activity.  Fluorescence polarization (FP) provides a nondisruptive means of measuring the assocn. of a fluorescent ligand with a larger mol.  We describe an FP assay in which binding of fluorescein-labeled inositol 1,4,5-trisphosphate (IP3) to N-terminal fragments of IP3 receptors can be characterized at different temps. and in competition with other ligands.  The assay allows the std. Gibbs free energy (ΔG°), enthalpy (ΔH°) and entropy (ΔS°) changes of ligand binding to be detd.  The method is applicable to any purified ligand-binding site for which an appropriate fluorescent ligand is available.  FP can be used to measure low-affinity interactions in real time without the use of radioactive materials, it is nondestructive and, with appropriate care, it can resolve ΔH° and ΔS°.  The first part of the protocol, protein prepn., may take several weeks, whereas the FP measurements, once they have been optimized, would normally take 1-6 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPmq_JwlOSg7Vg90H21EOLACvtfcHk0liENJGyEy4XtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXislentbg%253D&md5=b78e3bcd884a06cdeb8b090227963d33</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2011.305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2011.305%26sid%3Dliteratum%253Aachs%26aulast%3DRossi%26aufirst%3DA.%2BM.%26aulast%3DTaylor%26aufirst%3DC.%2BW.%26atitle%3DAnalysis%2520of%2520protein-ligand%2520interactions%2520by%2520fluorescence%2520polarization%26jtitle%3DNat.%2520Protoc.%26date%3D2011%26volume%3D6%26spage%3D365%26epage%3D387%26doi%3D10.1038%2Fnprot.2011.305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McNaney, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drexler, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hnatyshyn, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvyaga, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knipe, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belcastro, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, M.</span></span> <span> </span><span class="NLM_article-title">An automated liquid chromatography-mass spectrometry process to determine metabolic stability half-life and intrinsic clearance of drug candidates by substrate depletion</span>. <i>Assay Drug Dev. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1089/adt.2007.103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1089%2Fadt.2007.103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=18336089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtFKqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=121-129&author=C.+A.+McNaneyauthor=D.+M.+Drexlerauthor=S.+Y.+Hnatyshynauthor=T.+A.+Zvyagaauthor=J.+O.+Knipeauthor=J.+V.+Belcastroauthor=M.+Sanders&title=An+automated+liquid+chromatography-mass+spectrometry+process+to+determine+metabolic+stability+half-life+and+intrinsic+clearance+of+drug+candidates+by+substrate+depletion&doi=10.1089%2Fadt.2007.103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">An Automated Liquid Chromatography-Mass Spectrometry Process to Determine Metabolic Stability Half-Life and Intrinsic Clearance of Drug Candidates by Substrate Depletion</span></div><div class="casAuthors">McNaney, Colleen A.; Drexler, Dieter M.; Hnatyshyn, Serhiy Y.; Zvyaga, Tatyana A.; Knipe, Jay O.; Belcastro, James V.; Sanders, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Assay and Drug Development Technologies</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">121-129</span>CODEN:
                <span class="NLM_cas:coden">ADDTAR</span>;
        ISSN:<span class="NLM_cas:issn">1540-658X</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">An automated process is described for the detailed assessment of the in vitro metabolic stability properties of drug candidates in support of pharmaceutical property profiling.  Compds. are incubated with liver microsomes using a robotic liq. handler.  Aliquots are taken at various time points, and the resulting samples are quant. analyzed by liq. chromatog.-mass spectrometry utilizing ion trap mass spectrometers to det. the amt. of compd. remaining.  From these data metab. rates can be calcd.  A high degree of automation is achieved through custom software, which is employed for instrument setup, data processing, and results reporting.  The assay setup is highly configurable, allowing for any combination of up to six user-selected time points, variable substrate concn., and microsomes or other biol. active media.  The data, based on relative substrate depletion, affords an est. of metabolic stability through the calcn. of half-life (t1/2) and intrinsic clearance, which are used to differentiate and rank order drug leads.  In general, t1/2 is the time necessary for the metab., following first-order kinetics, of 50 of the initial compd.  Intrinsic clearance is the proportionality const. between rate of metab. of a compd. and its concn. at the enzyme site.  Described here is the setup of the assay, and data from assay test compds. are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEaz4jJWXzM7Vg90H21EOLACvtfcHk0liENJGyEy4XtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtFKqtbs%253D&md5=3833f7d7c4be366bc2d4b3e656ef4ae2</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1089%2Fadt.2007.103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2007.103%26sid%3Dliteratum%253Aachs%26aulast%3DMcNaney%26aufirst%3DC.%2BA.%26aulast%3DDrexler%26aufirst%3DD.%2BM.%26aulast%3DHnatyshyn%26aufirst%3DS.%2BY.%26aulast%3DZvyaga%26aufirst%3DT.%2BA.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DBelcastro%26aufirst%3DJ.%2BV.%26aulast%3DSanders%26aufirst%3DM.%26atitle%3DAn%2520automated%2520liquid%2520chromatography-mass%2520spectrometry%2520process%2520to%2520determine%2520metabolic%2520stability%2520half-life%2520and%2520intrinsic%2520clearance%2520of%2520drug%2520candidates%2520by%2520substrate%2520depletion%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2008%26volume%3D6%26spage%3D121%26epage%3D129%26doi%3D10.1089%2Fadt.2007.103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butts, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koselny, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabrier-Rosello, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellington, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krysan, D. J.</span></span> <span> </span><span class="NLM_article-title">A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis</span>. <i>Eukaryotic Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.1128/EC.00314-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1128%2FEC.00314-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=23243064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitlGjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=278-287&author=A.+Buttsauthor=L.+DiDoneauthor=K.+Koselnyauthor=B.+K.+Baxterauthor=Y.+Chabrier-Roselloauthor=M.+Wellingtonauthor=D.+J.+Krysan&title=A+repurposing+approach+identifies+off-patent+drugs+with+fungicidal+cryptococcal+activity%2C+a+common+structural+chemotype%2C+and+pharmacological+properties+relevant+to+the+treatment+of+cryptococcosis&doi=10.1128%2FEC.00314-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis</span></div><div class="casAuthors">Butts, Arielle; DiDone, Louis; Koselny, Kristy; Baxter, Bonnie K.; Chabrier-Rosello, Yeissa; Wellington, Melanie; Krysan, Damian J.</div><div class="citationInfo"><span class="NLM_cas:title">Eukaryotic Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">278-287</span>CODEN:
                <span class="NLM_cas:coden">ECUEA2</span>;
        ISSN:<span class="NLM_cas:issn">1535-9786</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">New, more accessible therapies for cryptococcosis represent an unmet clin. need of global importance.  We took a repurposing approach to identify previously developed drugs with fungicidal activity toward Cryptococcus neoformans, using a high-throughput screening assay designed to detect drugs that directly kill fungi.  From a set of 1,120 off-patent medications and bioactive mols., we identified 31 drugs/mols. with fungicidal activity, including 15 drugs for which direct antifungal activity had not previously been reported.  A significant portion of the drugs are orally bioavailable and cross the blood-brain barrier, features key to the development of a widely applicable anticryptococcal agent.  Structural anal. of this set revealed a common chemotype consisting of a hydrophobic moiety linked to a basic amine, features that are common to drugs that cross the blood-brain barrier and access the phagolysosome, two important niches of C. neoformans.  Consistent with their fungicidal activity, the set contains eight drugs that are either additive or synergistic in combination with fluconazole.  Importantly, we identified two drugs, amiodarone and thioridazine, with activity against intraphagocytic C. neoformans.  Finally, the set of drugs is also enriched for mols. that inhibit calmodulin, and we have confirmed that seven drugs directly bind C. neoformans calmodulin, providing a mol. target that may contribute to the mechanism of antifungal activity.  Taken together, these studies provide a foundation for the optimization of the antifungal properties of a set of pharmacol. attractive scaffolds for the development of novel anticryptococcal therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRmu1MEpP5JLVg90H21EOLACvtfcHk0li438Sm7JT8RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitlGjtrk%253D&md5=71ae5a50d0c74f0bf7b383e2377212fb</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1128%2FEC.00314-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FEC.00314-12%26sid%3Dliteratum%253Aachs%26aulast%3DButts%26aufirst%3DA.%26aulast%3DDiDone%26aufirst%3DL.%26aulast%3DKoselny%26aufirst%3DK.%26aulast%3DBaxter%26aufirst%3DB.%2BK.%26aulast%3DChabrier-Rosello%26aufirst%3DY.%26aulast%3DWellington%26aufirst%3DM.%26aulast%3DKrysan%26aufirst%3DD.%2BJ.%26atitle%3DA%2520repurposing%2520approach%2520identifies%2520off-patent%2520drugs%2520with%2520fungicidal%2520cryptococcal%2520activity%252C%2520a%2520common%2520structural%2520chemotype%252C%2520and%2520pharmacological%2520properties%2520relevant%2520to%2520the%2520treatment%2520of%2520cryptococcosis%26jtitle%3DEukaryotic%2520Cell%26date%3D2013%26volume%3D12%26spage%3D278%26epage%3D287%26doi%3D10.1128%2FEC.00314-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brough, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aherne, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barril, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgognoni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boxall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cansfield, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, K.-M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, N. G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drysdale, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northfield, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearl, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prodromou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roughley, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surgenor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walmsley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrightt, L.</span></span> <span> </span><span class="NLM_article-title">4,5-diarylisoxazole HSP90 chaperone inhibitors: Potential therapeutic agents for the treatment of cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">196</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1021/jm701018h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701018h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlWqsL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=196-218&author=P.+A.+Broughauthor=W.+Aherneauthor=X.+Barrilauthor=J.+Borgognoniauthor=K.+Boxallauthor=J.+E.+Cansfieldauthor=K.-M.+J.+Cheungauthor=I.+Collinsauthor=N.+G.+M.+Daviesauthor=M.+J.+Drysdaleauthor=B.+Dymockauthor=S.+A.+Ecclesauthor=H.+Finchauthor=A.+Finkauthor=A.+Hayesauthor=R.+Howesauthor=R.+E.+Hubbardauthor=K.+Jamesauthor=A.+M.+Jordanauthor=A.+Lockieauthor=V.+Martinsauthor=A.+Masseyauthor=T.+P.+Matthewsauthor=E.+McDonaldauthor=C.+J.+Northfieldauthor=L.+H.+Pearlauthor=C.+Prodromouauthor=S.+Rayauthor=F.+I.+Raynaudauthor=S.+D.+Roughleyauthor=S.+Y.+Sharpauthor=A.+Surgenorauthor=D.+L.+Walmsleyauthor=P.+Webbauthor=M.+Woodauthor=P.+Workmanauthor=L.+Wrightt&title=4%2C5-diarylisoxazole+HSP90+chaperone+inhibitors%3A+Potential+therapeutic+agents+for+the+treatment+of+cancer&doi=10.1021%2Fjm701018h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer</span></div><div class="casAuthors">Brough, Paul A.; Aherne, Wynne; Barril, Xavier; Borgognoni, Jennifer; Boxall, Kathy; Cansfield, Julie E.; Cheung, Kwai-Ming J.; Collins, Ian; Davies, Nicholas G. M.; Drysdale, Martin J.; Dymock, Brian; Eccles, Suzanne A.; Finch, Harry; Fink, Alexandra; Hayes, Angela; Howes, Robert; Hubbard, Roderick E.; James, Karen; Jordan, Allan M.; Lockie, Andrea; Martins, Vanessa; Massey, Andrew; Matthews, Thomas P.; McDonald, Edward; Northfield, Christopher J.; Pearl, Laurence H.; Prodromou, Chrisostomos; Ray, Stuart; Raynaud, Florence I.; Roughley, Stephen D.; Sharp, Swee Y.; Surgenor, Allan; Walmsley, D. Lee; Webb, Paul; Wood, Mike; Workman, Paul; Wright, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">196-218</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of the Hsp90 [heat shock protein 90] mol. chaperone show considerable promise as potential chemotherapeutic agents for cancer.  The structure-based design, synthesis, structure-activity relationships, and pharmacokinetics of potent small-mol. inhibitors of Hsp90 based on the 4,5-diarylisoxazole scaffold were studied.  Analogs from this series have high affinity for Hsp90, as measured in a fluorescence polarization competitive binding assay, and are active in cancer cell lines where they inhibit proliferation and exhibit a characteristic profile of depletion of oncogenic proteins and concomitant elevation of Hsp72.  The [(morpholinomethyl)phenyl]isoxazolecarboxamide I (VER-52296/NVP-AUY922) is potent in the Hsp90 FP binding assay and inhibits proliferation of various human cancer cell lines in vitro, with GI50 averaging 9 nM.  I is retained in tumors in vivo when administered i.p., as evaluated by cassette dosing in tumor-bearing mice.  In a human colon cancer xenograft model, I inhibits tumor growth by ∼50%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTNA9AoWb8gLVg90H21EOLACvtfcHk0li438Sm7JT8RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlWqsL%252FK&md5=fdb98dec600987e862b9b05555427948</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Fjm701018h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701018h%26sid%3Dliteratum%253Aachs%26aulast%3DBrough%26aufirst%3DP.%2BA.%26aulast%3DAherne%26aufirst%3DW.%26aulast%3DBarril%26aufirst%3DX.%26aulast%3DBorgognoni%26aufirst%3DJ.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DCansfield%26aufirst%3DJ.%2BE.%26aulast%3DCheung%26aufirst%3DK.-M.%2BJ.%26aulast%3DCollins%26aufirst%3DI.%26aulast%3DDavies%26aufirst%3DN.%2BG.%2BM.%26aulast%3DDrysdale%26aufirst%3DM.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DFinch%26aufirst%3DH.%26aulast%3DFink%26aufirst%3DA.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHowes%26aufirst%3DR.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DJordan%26aufirst%3DA.%2BM.%26aulast%3DLockie%26aufirst%3DA.%26aulast%3DMartins%26aufirst%3DV.%26aulast%3DMassey%26aufirst%3DA.%26aulast%3DMatthews%26aufirst%3DT.%2BP.%26aulast%3DMcDonald%26aufirst%3DE.%26aulast%3DNorthfield%26aufirst%3DC.%2BJ.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26aulast%3DProdromou%26aufirst%3DC.%26aulast%3DRay%26aufirst%3DS.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DRoughley%26aufirst%3DS.%2BD.%26aulast%3DSharp%26aufirst%3DS.%2BY.%26aulast%3DSurgenor%26aufirst%3DA.%26aulast%3DWalmsley%26aufirst%3DD.%2BL.%26aulast%3DWebb%26aufirst%3DP.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DWrightt%26aufirst%3DL.%26atitle%3D4%252C5-diarylisoxazole%2520HSP90%2520chaperone%2520inhibitors%253A%2520Potential%2520therapeutic%2520agents%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D196%26epage%3D218%26doi%3D10.1021%2Fjm701018h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taldone, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiosis, G.</span></span> <span> </span><span class="NLM_article-title">Purine-scaffold Hsp90 inhibitors</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1436</span>– <span class="NLM_lpage">1446</span>, <span class="refDoi"> DOI: 10.2174/156802609789895737</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.2174%2F156802609789895737" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=19860732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFakurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=1436-1446&author=T.+Taldoneauthor=G.+Chiosis&title=Purine-scaffold+Hsp90+inhibitors&doi=10.2174%2F156802609789895737"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Purine-scaffold Hsp90 inhibitors</span></div><div class="casAuthors">Taldone, Tony; Chiosis, Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1436-1446</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Hsp90 is a mol. chaperone with important roles in regulating the function of several proteins with potential pathogenic activity.  Because many of these proteins are involved in cancer and neurodegenerative promoting pathways, Hsp90 has emerged as an attractive therapeutic target in these diseases.  Mols. that bind to the N-terminal nucleotide pocket of Hsp90 inhibit its activity, and consequently, disrupt client protein function.  A no. of these inhibitors from several chem. classes are now known, and some are already in clin. trials.  This review focuses on the purine class of Hsp90 inhibitors, their discovery through rational design, and on efforts aimed towards their optimization and development into clin. viable drugs for the treatment of cancer.  Their potential towards neurodegenerative diseases will also be touched upon.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVLlJs6fJ--rVg90H21EOLACvtfcHk0liwQUINzP2LTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFakurg%253D&md5=346a3ef4c1503aee2d918074c1ecb46c</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.2174%2F156802609789895737&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802609789895737%26sid%3Dliteratum%253Aachs%26aulast%3DTaldone%26aufirst%3DT.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DPurine-scaffold%2520Hsp90%2520inhibitors%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D1436%26epage%3D1446%26doi%3D10.2174%2F156802609789895737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartl, F. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavletich, N. P.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of an Hsp90–geldanamycin complex: targeting of a protein chaperone by an antitumor agent</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">250</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)80203-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1016%2FS0092-8674%2800%2980203-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=9108479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADyaK2sXislCitLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1997&pages=239-250&author=C.+E.+Stebbinsauthor=A.+A.+Russoauthor=C.+Schneiderauthor=N.+Rosenauthor=F.+U.+Hartlauthor=N.+P.+Pavletich&title=Crystal+structure+of+an+Hsp90%E2%80%93geldanamycin+complex%3A+targeting+of+a+protein+chaperone+by+an+antitumor+agent&doi=10.1016%2FS0092-8674%2800%2980203-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent</span></div><div class="casAuthors">Stebbins, Charles E.; Russo, Alicia A.; Schneider, Christine; Rosen, Neal; Hartl, F. Ulrich; Pavletich, Nikola P.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">239-250</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Hsp90 chaperone is required for the activation of several families of eukaryotic protein kinases and nuclear hormone receptors, many of which are proto-oncogenic and play a prominent role in cancer.  The geldanamycin antibiotic has antiproliferative and anti-tumor effects, as it binds to Hsp90, inhibits the Hsp90-mediated conformational maturation/refolding reaction, and results in the degrdn. of Hsp90 substrates.  The structure of the geldanamycin-binding domain of Hsp90 (residues 9-232) reveals a pronounced pocket, 15 Å deep. that is highly conserved across species.  Geldanamycin binds inside this pocket, adopting a compact structure similar to that of a polypeptide chain in a turn conformation.  This, and the pocket's similarity to substrate-binding sites, suggest that the pocket binds a portion of the polypeptide substrate and participates in the conformational maturation/refolding reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvnmleAOFITbVg90H21EOLACvtfcHk0liwQUINzP2LTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXislCitLo%253D&md5=54a56450c509727e070f4db20a9d7b1a</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2980203-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252980203-2%26sid%3Dliteratum%253Aachs%26aulast%3DStebbins%26aufirst%3DC.%2BE.%26aulast%3DRusso%26aufirst%3DA.%2BA.%26aulast%3DSchneider%26aufirst%3DC.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DHartl%26aufirst%3DF.%2BU.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26atitle%3DCrystal%2520structure%2520of%2520an%2520Hsp90%25E2%2580%2593geldanamycin%2520complex%253A%2520targeting%2520of%2520a%2520protein%2520chaperone%2520by%2520an%2520antitumor%2520agent%26jtitle%3DCell%26date%3D1997%26volume%3D89%26spage%3D239%26epage%3D250%26doi%3D10.1016%2FS0092-8674%2800%2980203-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keefe, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shortle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lattman, E. E.</span></span> <span> </span><span class="NLM_article-title">The alpha aneurism: a structural motif revealed in an insertion mutant of staphylococcal nuclease</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">3275</span>– <span class="NLM_lpage">3279</span>, <span class="refDoi"> DOI: 10.1073/pnas.90.8.3275</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1073%2Fpnas.90.8.3275" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=8475069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADyaK3sXktVeqtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1993&pages=3275-3279&author=L.+J.+Keefeauthor=J.+Sondekauthor=D.+Shortleauthor=E.+E.+Lattman&title=The+alpha+aneurism%3A+a+structural+motif+revealed+in+an+insertion+mutant+of+staphylococcal+nuclease&doi=10.1073%2Fpnas.90.8.3275"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">The α aneurysm: A structural motif revealed in an insertion mutant of staphylococcal nuclease</span></div><div class="casAuthors">Keefe, Lisa J.; Sondek, John; Shortle, David; Lattman, Eaton E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3275-9</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The x-ray crystal structure of a mutant of staphylococcal nuclease that contains a single glycine residue inserted in the C-terminal α-helix has been solved to 1.67 Å resoln. and refined to a crystallog. R value of 0.170.  This inserted glycine residue is accommodated in the α-helix by formation of a previously uncharacterized bulge, termed the α aneurysm.  A conformational search of known protein structures has identified the α aneurysm in a no. of protein families, including the histocompatibility antigens and Hbs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC-bhIwauF-bVg90H21EOLACvtfcHk0lhSq3lwUEzMhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXktVeqtLo%253D&md5=31be8874ad320f0031f0e8127643b062</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1073%2Fpnas.90.8.3275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.90.8.3275%26sid%3Dliteratum%253Aachs%26aulast%3DKeefe%26aufirst%3DL.%2BJ.%26aulast%3DSondek%26aufirst%3DJ.%26aulast%3DShortle%26aufirst%3DD.%26aulast%3DLattman%26aufirst%3DE.%2BE.%26atitle%3DThe%2520alpha%2520aneurism%253A%2520a%2520structural%2520motif%2520revealed%2520in%2520an%2520insertion%2520mutant%2520of%2520staphylococcal%2520nuclease%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1993%26volume%3D90%26spage%3D3275%26epage%3D3279%26doi%3D10.1073%2Fpnas.90.8.3275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barril, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheridan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surgenor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beswick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drysdale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fromont, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aherne, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boxall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, R. E.</span></span> <span> </span><span class="NLM_article-title">Structure–activity relationships in purine-based inhibitor binding to HSP90 isoforms</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">775</span>– <span class="NLM_lpage">785</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2004.03.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1016%2Fj.chembiol.2004.03.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=15217611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlt1Sjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=775-785&author=L.+Wrightauthor=X.+Barrilauthor=B.+Dymockauthor=L.+Sheridanauthor=A.+Surgenorauthor=M.+Beswickauthor=M.+Drysdaleauthor=A.+Collierauthor=A.+Masseyauthor=N.+Daviesauthor=A.+Finkauthor=C.+Fromontauthor=W.+Aherneauthor=K.+Boxallauthor=S.+Sharpauthor=P.+Workmanauthor=R.+E.+Hubbard&title=Structure%E2%80%93activity+relationships+in+purine-based+inhibitor+binding+to+HSP90+isoforms&doi=10.1016%2Fj.chembiol.2004.03.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships in Purine-Based Inhibitor Binding to HSP90 Isoforms</span></div><div class="casAuthors">Wright, Lisa; Barril, Xavier; Dymock, Brian; Sheridan, Louisa; Surgenor, Allan; Beswick, Mandy; Drysdale, Martin; Collier, Adam; Massey, Andy; Davies, Nick; Fink, Alex; Fromont, Christophe; Aherne, Wynne; Boxall, Kathy; Sharp, Swee; Workman, Paul; Hubbard, Roderick E.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">775-785</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inhibition of the ATPase activity of the chaperone protein HSP90 is a potential strategy for treatment of cancers.  We have detd. structures of the HSP90α N-terminal domain complexed with the purine-based inhibitor, PU3, and analogs with enhanced potency both in enzyme and cell-based assays.  The compds. induce upregulation of HSP70 and downregulation of the known HSP90 client proteins Raf-1, CDK4, and ErbB2, confirming that the mols. inhibit cell growth by a mechanism dependent on HSP90 inhibition.  We have also detd. the first structure of the N-terminal domain of HSP90β, complexed with PU3.  The structures allow a detailed rationale to be developed for the obsd. affinity of the PU3 class of compds. for HSP90 and also provide a structural framework for design of compds. with improved binding affinity and drug-like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2Z11Wd4hiXrVg90H21EOLACvtfcHk0lhSq3lwUEzMhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlt1Sjsrs%253D&md5=dd2146dba0f4b3198d5bc7023e645812</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2004.03.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2004.03.033%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DL.%26aulast%3DBarril%26aufirst%3DX.%26aulast%3DDymock%26aufirst%3DB.%26aulast%3DSheridan%26aufirst%3DL.%26aulast%3DSurgenor%26aufirst%3DA.%26aulast%3DBeswick%26aufirst%3DM.%26aulast%3DDrysdale%26aufirst%3DM.%26aulast%3DCollier%26aufirst%3DA.%26aulast%3DMassey%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DN.%26aulast%3DFink%26aufirst%3DA.%26aulast%3DFromont%26aufirst%3DC.%26aulast%3DAherne%26aufirst%3DW.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DSharp%26aufirst%3DS.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26atitle%3DStructure%25E2%2580%2593activity%2520relationships%2520in%2520purine-based%2520inhibitor%2520binding%2520to%2520HSP90%2520isoforms%26jtitle%3DChem.%2520Biol.%26date%3D2004%26volume%3D11%26spage%3D775%26epage%3D785%26doi%3D10.1016%2Fj.chembiol.2004.03.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halgren, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klicic, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mainz, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repasky, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knoll, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenkin, P. S.</span></span> <span> </span><span class="NLM_article-title">Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1739</span>– <span class="NLM_lpage">1749</span>, <span class="refDoi"> DOI: 10.1021/jm0306430</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0306430" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFyit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1739-1749&author=R.+A.+Friesnerauthor=J.+L.+Banksauthor=R.+B.+Murphyauthor=T.+A.+Halgrenauthor=J.+J.+Klicicauthor=D.+T.+Mainzauthor=M.+P.+Repaskyauthor=E.+H.+Knollauthor=M.+Shelleyauthor=J.+K.+Perryauthor=D.+E.+Shawauthor=P.+Francisauthor=P.+S.+Shenkin&title=Glide%3A+a+new+approach+for+rapid%2C+accurate+docking+and+scoring.+1.+Method+and+assessment+of+docking+accuracy&doi=10.1021%2Fjm0306430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Glide: A new approach for rapid, accurate docking and scoring. 1. method and assessment of docking accuracy</span></div><div class="casAuthors">Friesner, Richard A.; Banks, Jay L.; Murphy, Robert B.; Halgren, Thomas A.; Klicic, Jasna J.; Mainz, Daniel T.; Repasky, Matthew P.; Knoll, Eric H.; Shelley, Mee; Perry, Jason K.; Shaw, David E.; Francis, Perry; Shenkin, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1739-1749</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Unlike other methods for docking ligands to the rigid 3D structure of a known protein receptor, Glide approximates a complete systematic search of the conformational, orientational, and positional space of the docked ligand.  In this search, an initial rough positioning and scoring phase that dramatically narrows the search space is followed by torsionally flexible energy optimization on an OPLS-AA nonbonded potential grid for a few hundred surviving candidate poses.  The very best candidates are further refined via a Monte Carlo sampling of pose conformation; in some cases, this is crucial to obtaining an accurate docked pose.  Selection of the best docked pose uses a model energy function that combines empirical and force-field-based terms.  Docking accuracy is assessed by redocking ligands from 282 cocrystd. PDB complexes starting from conformationally optimized ligand geometries that bear no memory of the correctly docked pose.  Errors in geometry for the top-ranked pose are less than 1 Å in nearly half of the cases and are greater than 2 Å in only about one-third of them.  Comparisons to published data on rms deviations show that Glide is nearly twice as accurate as GOLD and more than twice as accurate as FlexX for ligands having up to 20 rotatable bonds.  Glide is also found to be more accurate than the recently described Surflex method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPuigu31qMMLVg90H21EOLACvtfcHk0lhuUc9hXW1goQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFyit74%253D&md5=8cc2f0022318b12dd972e9c493375bf9</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Fjm0306430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0306430%26sid%3Dliteratum%253Aachs%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DBanks%26aufirst%3DJ.%2BL.%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26aulast%3DKlicic%26aufirst%3DJ.%2BJ.%26aulast%3DMainz%26aufirst%3DD.%2BT.%26aulast%3DRepasky%26aufirst%3DM.%2BP.%26aulast%3DKnoll%26aufirst%3DE.%2BH.%26aulast%3DShelley%26aufirst%3DM.%26aulast%3DPerry%26aufirst%3DJ.%2BK.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DFrancis%26aufirst%3DP.%26aulast%3DShenkin%26aufirst%3DP.%2BS.%26atitle%3DGlide%253A%2520a%2520new%2520approach%2520for%2520rapid%252C%2520accurate%2520docking%2520and%2520scoring.%25201.%2520Method%2520and%2520assessment%2520of%2520docking%2520accuracy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1739%26epage%3D1749%26doi%3D10.1021%2Fjm0306430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halgren, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beard, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, J. L.</span></span> <span> </span><span class="NLM_article-title">Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1750</span>– <span class="NLM_lpage">1759</span>, <span class="refDoi"> DOI: 10.1021/jm030644s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030644s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFyit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1750-1759&author=T.+A.+Halgrenauthor=R.+B.+Murphyauthor=R.+A.+Friesnerauthor=H.+S.+Beardauthor=L.+L.+Fryeauthor=W.+T.+Pollardauthor=J.+L.+Banks&title=Glide%3A+a+new+approach+for+rapid%2C+accurate+docking+and+scoring.+2.+Enrichment+factors+in+database+screening&doi=10.1021%2Fjm030644s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening</span></div><div class="casAuthors">Halgren, Thomas A.; Murphy, Robert B.; Friesner, Richard A.; Beard, Hege S.; Frye, Leah L.; Pollard, W. Thomas; Banks, Jay L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1750-1759</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Glide's ability to identify active compds. in a database screen is characterized by applying Glide to a diverse set of nine protein receptors.  In many cases, two, or even three, protein sites are employed to probe the sensitivity of the results to the site geometry.  To make the database screens as realistic as possible, the screens use sets of "druglike" decoy ligands that have been selected to be representative of what we believe is likely to be found in the compd. collection of a pharmaceutical or biotechnol. company.  Results are presented for releases 1.8, 2.0, and 2.5 of Glide.  The comparisons show that av. measures for both "early" and "global" enrichment for Glide 2.5 are 3 times higher than for Glide 1.8 and more than 2 times higher than for Glide 2.0 because of better results for the least well-handled screens.  This improvement in enrichment stems largely from the better balance of the more widely parametrized GlideScore 2.5 function and the inclusion of terms that penalize ligand-protein interactions that violate established principles of phys. chem., particularly as it concerns the exposure to solvent of charged protein and ligand groups.  Comparisons to results for the thymidine kinase and estrogen receptors published by Rognan and co-workers (J. Med. Chem. 2000, 43, 4759-4767) show that Glide 2.5 performs better than GOLD 1.1, FlexX 1.8, or DOCK 4.01.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT2ptubbKbvLVg90H21EOLACvtfcHk0lhuUc9hXW1goQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFyit78%253D&md5=33d68dd968e65626b449df61e44e37be</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Fjm030644s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030644s%26sid%3Dliteratum%253Aachs%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DBeard%26aufirst%3DH.%2BS.%26aulast%3DFrye%26aufirst%3DL.%2BL.%26aulast%3DPollard%26aufirst%3DW.%2BT.%26aulast%3DBanks%26aufirst%3DJ.%2BL.%26atitle%3DGlide%253A%2520a%2520new%2520approach%2520for%2520rapid%252C%2520accurate%2520docking%2520and%2520scoring.%25202.%2520Enrichment%2520factors%2520in%2520database%2520screening%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1750%26epage%3D1759%26doi%3D10.1021%2Fjm030644s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zurcher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diederich, F.</span></span> <span> </span><span class="NLM_article-title">Structure-based drug design: exploring the proper filling of apolar pockets at enzyme active sites</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">4345</span>– <span class="NLM_lpage">4361</span>, <span class="refDoi"> DOI: 10.1021/jo800527n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo800527n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVOgsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=4345-4361&author=M.+Zurcherauthor=F.+Diederich&title=Structure-based+drug+design%3A+exploring+the+proper+filling+of+apolar+pockets+at+enzyme+active+sites&doi=10.1021%2Fjo800527n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Drug Design: Exploring the Proper Filling of Apolar Pockets at Enzyme Active Sites</span></div><div class="casAuthors">Zurcher, Martina; Diederich, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4345-4361</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The proper filling of apolar pockets at enzyme active sites is central for increasing binding activity and selectivity of hits and leads in medicinal chem.  In our structure-based design approach toward the generation of potent enzyme inhibitors, we encountered a variety of challenges in gaining suitable binding affinity from the occupation of such pockets.  We summarize them here for the first time.  A fluorine scan of tricyclic thrombin inhibitors led to the discovery of favorable orthogonal dipolar C-F···C=O interactions.  Efficient cation-π interactions were established in the S4 pocket of factor Xa, another serine protease from the blood coagulation cascade.  Changing from mono- to bisubstrate inhibitors of catechol O-methyltransferase, a target in the L-DOPA-based treatment of Parkinson's disease, enabled the full exploitation of a previously unexplored hydrophobic pocket.  Conformational preorganization of a pocket at an enzyme active site is crucial for harvesting binding affinity.  This is demonstrated for two enzymes from the nonmevalonate pathway of isoprenoid biosynthesis, IspE and IspF, which are pursued as antimalarial targets.  Disrupting crystallog. defined water networks on the way into a pocket might cost all of the binding free enthalpy gained from its occupation, as revealed in studies with tRNA-guanine transglycosylase, a target against shigellosis.  Investigations of the active site of plasmepsin II, another antimalarial target, showed that principles for proper apolar cavity filling, originally developed for synthetic host-guest systems, are also applicable to enzyme environments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6oxCTxXw8U7Vg90H21EOLACvtfcHk0lj-IlITE66xLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVOgsr0%253D&md5=bda8143b4d43ed274bc61da8b3b37046</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fjo800527n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo800527n%26sid%3Dliteratum%253Aachs%26aulast%3DZurcher%26aufirst%3DM.%26aulast%3DDiederich%26aufirst%3DF.%26atitle%3DStructure-based%2520drug%2520design%253A%2520exploring%2520the%2520proper%2520filling%2520of%2520apolar%2520pockets%2520at%2520enzyme%2520active%2520sites%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2008%26volume%3D73%26spage%3D4345%26epage%3D4361%26doi%3D10.1021%2Fjo800527n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bissantz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, M.</span></span> <span> </span><span class="NLM_article-title">A medicinal chemist’s guide to molecular interactions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">5061</span>– <span class="NLM_lpage">5084</span>, <span class="refDoi"> DOI: 10.1021/jm100112j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100112j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFKjtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5061-5084&author=C.+Bissantzauthor=B.+Kuhnauthor=M.+Stahl&title=A+medicinal+chemist%E2%80%99s+guide+to+molecular+interactions&doi=10.1021%2Fjm100112j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">A Medicinal Chemist's Guide to Molecular Interactions</span></div><div class="casAuthors">Bissantz, Caterina; Kuhn, Bernd; Stahl, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5061-5084</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraV8HPbwsihbVg90H21EOLACvtfcHk0ljyCUXj2tUcSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFKjtbs%253D&md5=f39cf8700267cdc311c73de4d433bab0</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Fjm100112j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100112j%26sid%3Dliteratum%253Aachs%26aulast%3DBissantz%26aufirst%3DC.%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DStahl%26aufirst%3DM.%26atitle%3DA%2520medicinal%2520chemist%25E2%2580%2599s%2520guide%2520to%2520molecular%2520interactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5061%26epage%3D5084%26doi%3D10.1021%2Fjm100112j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Granger, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perfect, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durack, D. T.</span></span> <span> </span><span class="NLM_article-title">Virulence of <i>Cryptococcus neoformans</i>. Regulation of capsule synthesis by carbon dioxide</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">508</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1172/JCI112000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1172%2FJCI112000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=3928681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADyaL2MXltlyhuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1985&pages=508-516&author=D.+L.+Grangerauthor=J.+R.+Perfectauthor=D.+T.+Durack&title=Virulence+of+Cryptococcus+neoformans.+Regulation+of+capsule+synthesis+by+carbon+dioxide&doi=10.1172%2FJCI112000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Virulence of Cryptococcus neoformans.  Regulation of capsule synthesis by carbon dioxide</span></div><div class="casAuthors">Granger, Donald L.; Perfect, John R.; Durack, David T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">508-16</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    </div><div class="casAbstract">C. neoformans Is variably encapsulated in vitro, whereas in tissues it develops a large capsule.  It was obsd. that cells of a strain with thin capsules, when growing in a std. fungal culture medium, became heavily encapsulated when incubated in the serum-free cell culture medium, Dulbecco's modified Eagle's medium (DME).  Capsule size was quantitated phys. by measuring cell vol. and chem. by detg. the content of a capsular monosaccharide, glucuronate.  The CO2/HCO3- couple stimulated capsule development, resulting in visible enlargement by 3 h after exposure to high CO2/HCO3-.  The amt. of capsule per cell was directly proportional to the total millimolar CO2/HCO3- concn. between 24 and 2.4 mM at pH 7.35, but at const. PCO2 (40 torr) and varying [HCO3-], the cells were heavily encapsulated down to pH 6.8.  Concn. of CO2/HCO3- in the physiol. range increased elaboration of polysaccharide into the medium and slowed the cell generation time from 2 to 6 h.  Four other 1st-passage clin. isolates were all heavily encapsulated in DME with CO2/HCO3-, but variably encapsulated in DME without CO2/HCO3-.  Exposure of yeast to increased CO2/HCO3- caused a marked redn. in complement-mediated phagocytosis by mouse macrophages.  A stable clone was isolated which contained capsular polysaccharide, but lacked the CO2-inducible phenotype.  This clone was avirulent for steroid-treated rabbits.  Thus, the prevailing CO2 concn. in mammalian tissues may be one stimulus for capsular polysaccharide synthesis.  This could serve as an adaptive mechanism favoring parasite survival in the host.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoShgYIceZrabVg90H21EOLACvtfcHk0ljyCUXj2tUcSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXltlyhuro%253D&md5=6198ec56309728bd9d81a6fbb5e3045b</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1172%2FJCI112000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI112000%26sid%3Dliteratum%253Aachs%26aulast%3DGranger%26aufirst%3DD.%2BL.%26aulast%3DPerfect%26aufirst%3DJ.%2BR.%26aulast%3DDurack%26aufirst%3DD.%2BT.%26atitle%3DVirulence%2520of%2520Cryptococcus%2520neoformans.%2520Regulation%2520of%2520capsule%2520synthesis%2520by%2520carbon%2520dioxide%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1985%26volume%3D76%26spage%3D508%26epage%3D516%26doi%3D10.1172%2FJCI112000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaFayette, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaas, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schell, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betancourt-Quiroz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunatilaka, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perfect, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span> <span> </span><span class="NLM_article-title">PKC signaling regulates drug resistance of the fungal pathogen <i>Candida albicans</i> via circuitry comprised of Mkc1, calcineurin, and Hsp90</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e1001069</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1001069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1371%2Fjournal.ppat.1001069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=20865172" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&author=S.+L.+LaFayetteauthor=C.+Collinsauthor=A.+K.+Zaasauthor=W.+A.+Schellauthor=M.+Betancourt-Quirozauthor=A.+A.+Gunatilakaauthor=J.+R.+Perfectauthor=L.+E.+Cowen&title=PKC+signaling+regulates+drug+resistance+of+the+fungal+pathogen+Candida+albicans+via+circuitry+comprised+of+Mkc1%2C+calcineurin%2C+and+Hsp90&doi=10.1371%2Fjournal.ppat.1001069"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1001069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1001069%26sid%3Dliteratum%253Aachs%26aulast%3DLaFayette%26aufirst%3DS.%2BL.%26aulast%3DCollins%26aufirst%3DC.%26aulast%3DZaas%26aufirst%3DA.%2BK.%26aulast%3DSchell%26aufirst%3DW.%2BA.%26aulast%3DBetancourt-Quiroz%26aufirst%3DM.%26aulast%3DGunatilaka%26aufirst%3DA.%2BA.%26aulast%3DPerfect%26aufirst%3DJ.%2BR.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26atitle%3DPKC%2520signaling%2520regulates%2520drug%2520resistance%2520of%2520the%2520fungal%2520pathogen%2520Candida%2520albicans%2520via%2520circuitry%2520comprised%2520of%2520Mkc1%252C%2520calcineurin%252C%2520and%2520Hsp90%26jtitle%3DPLoS%2520Pathog.%26date%3D2010%26volume%3D6%26doi%3D10.1371%2Fjournal.ppat.1001069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Houston, J. B.</span></span> <span> </span><span class="NLM_article-title">Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1469</span>– <span class="NLM_lpage">1479</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(94)90520-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1016%2F0006-2952%2894%2990520-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=8185657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADyaK2cXkt1Kju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1994&pages=1469-1479&author=J.+B.+Houston&title=Utility+of+in+vitro+drug+metabolism+data+in+predicting+in+vivo+metabolic+clearance&doi=10.1016%2F0006-2952%2894%2990520-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance</span></div><div class="casAuthors">Houston, J. Brian</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1469-79</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">A review with 54 refs.  The aim of the commentary is to present a strategy to achieve the prediction of in vivo clearance from in vitro data based on the current understanding of metabolite kinetics in vitro and in vivo.  Hepatic microsomes and hepatocyte suspension are the main in vitro system addressed.  The theor. basis of the strategy is outlined and its general applicability evaluated, using a data base of 25 drugs drawn from the literature.  Finally, the prospective value of the approach is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFHqQ8gCJ6lrVg90H21EOLACvtfcHk0lgBgdh4NWAitQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXkt1Kju7c%253D&md5=a6d0abdbd2f0b238a6a01ba63ee67739</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2894%2990520-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252894%252990520-7%26sid%3Dliteratum%253Aachs%26aulast%3DHouston%26aufirst%3DJ.%2BB.%26atitle%3DUtility%2520of%2520in%2520vitro%2520drug%2520metabolism%2520data%2520in%2520predicting%2520in%2520vivo%2520metabolic%2520clearance%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1994%26volume%3D47%26spage%3D1469%26epage%3D1479%26doi%3D10.1016%2F0006-2952%2894%2990520-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, T.</span></span> <span> </span><span class="NLM_article-title">Physiological parameters in laboratory animals and humans</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1093</span>– <span class="NLM_lpage">1095</span>, <span class="refDoi"> DOI: 10.1023/A:1018943613122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1023%2FA%3A1018943613122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=8378254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A280%3ADyaK3szptFaqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1993&pages=1093-1095&author=B.+Daviesauthor=T.+Morris&title=Physiological+parameters+in+laboratory+animals+and+humans&doi=10.1023%2FA%3A1018943613122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Physiological parameters in laboratory animals and humans</span></div><div class="casAuthors">Davies B; Morris T</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical research</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1093-5</span>
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDDwka3A6hEYYPsCkJIw00fW6udTcc2ebjrHL5Xl1qXbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3szptFaqsg%253D%253D&md5=094cdd17306b58cc17c8cf4fd5db9927</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1023%2FA%3A1018943613122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1018943613122%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DB.%26aulast%3DMorris%26aufirst%3DT.%26atitle%3DPhysiological%2520parameters%2520in%2520laboratory%2520animals%2520and%2520humans%26jtitle%3DPharm.%2520Res.%26date%3D1993%26volume%3D10%26spage%3D1093%26epage%3D1095%26doi%3D10.1023%2FA%3A1018943613122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barter, Z. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayliss, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaune, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boobis, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlile, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lake, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipscomb, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelkonen, O. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rostami-Hodjegan, A.</span></span> <span> </span><span class="NLM_article-title">Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.2174/138920007779315053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.2174%2F138920007779315053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=17266522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisVyhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=33-45&author=Z.+E.+Barterauthor=M.+K.+Baylissauthor=P.+H.+Beauneauthor=A.+R.+Boobisauthor=D.+J.+Carlileauthor=R.+J.+Edwardsauthor=J.+B.+Houstonauthor=B.+G.+Lakeauthor=J.+C.+Lipscombauthor=O.+R.+Pelkonenauthor=G.+T.+Tuckerauthor=A.+Rostami-Hodjegan&title=Scaling+factors+for+the+extrapolation+of+in+vivo+metabolic+drug+clearance+from+in+vitro+data%3A+reaching+a+consensus+on+values+of+human+microsomal+protein+and+hepatocellularity+per+gram+of+liver&doi=10.2174%2F138920007779315053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver</span></div><div class="casAuthors">Barter, Zoe E.; Bayliss, Martin K.; Beaune, Philip H.; Boobis, Alan R.; Carlile, David J.; Edwards, Robert J.; Houston, J. Brian; Lake, Brian G.; Lipscomb, John C.; Pelkonen, Olavi R.; Tucker, Geoffrey T.; Rostami-Hodjegan, Amin</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-45</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Reported predictions of human in vivo hepatic clearance from in vitro data have used a variety of values for the scaling factors human microsomal protein (MPPGL) and hepatocellularity (HPGL) per g of liver, generally with no consideration of the extent of their inter-individual variability.  We have collated and analyzed data from a no. of sources, to provide weighted meangeo values of human MPPGL and HPGL of 32 mg g-1 (95% Confidence Interval (CI); 29-34 mg.g-1) and 99×106 cells.g-1 (95% CI; 74-131 mg.g-1), resp.  Although inter-individual variability in values of MPPGL and HPGL was statistically significant, gender, smoking or alc. consumption could not be detected as significant covariates by multiple linear regression.  However, there was a weak but statistically significant inverse relation between age and both MPPGL and HPGL.  These findings indicate the importance of considering differences between study populations when forecasting in vivo pharmacokinetic behavior.  Typical clin. pharmacol. studies, particularly in early drug development, use young, fit, healthy male subjects of around 30 years of age.  In contrast, the av. age of patients for many diseases is about 60 years of age.  The relation between age and MPPGL obsd. in this study ests. values of 40 mg.g-1 for a 30 yr old individual and 31 mg.g-1 for a 60 yr old individual.  Investigators may wish to consider the reported covariates in the selection of scaling factors appropriate for the population in which ests. of clearance are being predicted.  Further studies are required to clarify the influence of age (esp. in pediatric subjects), donor source and ethnicity on values of MPPGL and HPGL.  In the meantime, we recommend that the ests. (and their variances) from the current meta-anal. be used when predicting in vivo kinetic parameters from in vitro data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-oKFsYQqcRbVg90H21EOLACvtfcHk0lhaEqDDfReWsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisVyhsL0%253D&md5=6431a9ed3448601719cd462af751a372</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.2174%2F138920007779315053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920007779315053%26sid%3Dliteratum%253Aachs%26aulast%3DBarter%26aufirst%3DZ.%2BE.%26aulast%3DBayliss%26aufirst%3DM.%2BK.%26aulast%3DBeaune%26aufirst%3DP.%2BH.%26aulast%3DBoobis%26aufirst%3DA.%2BR.%26aulast%3DCarlile%26aufirst%3DD.%2BJ.%26aulast%3DEdwards%26aufirst%3DR.%2BJ.%26aulast%3DHouston%26aufirst%3DJ.%2BB.%26aulast%3DLake%26aufirst%3DB.%2BG.%26aulast%3DLipscomb%26aufirst%3DJ.%2BC.%26aulast%3DPelkonen%26aufirst%3DO.%2BR.%26aulast%3DTucker%26aufirst%3DG.%2BT.%26aulast%3DRostami-Hodjegan%26aufirst%3DA.%26atitle%3DScaling%2520factors%2520for%2520the%2520extrapolation%2520of%2520in%2520vivo%2520metabolic%2520drug%2520clearance%2520from%2520in%2520vitro%2520data%253A%2520reaching%2520a%2520consensus%2520on%2520values%2520of%2520human%2520microsomal%2520protein%2520and%2520hepatocellularity%2520per%2520gram%2520of%2520liver%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2007%26volume%3D8%26spage%3D33%26epage%3D45%26doi%3D10.2174%2F138920007779315053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwatsubo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Prediction of species differences (rats, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data</span>. <i>J. Pharmacol. Exp. Ther. A</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">462</span>– <span class="NLM_lpage">469</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=9353358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADyaK2sXnsV2nu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1997&pages=462-469&author=T.+Iwatsuboauthor=H.+Suzukiauthor=Y.+Sugiyama&title=Prediction+of+species+differences+%28rats%2C+dogs%2C+humans%29+in+the+in+vivo+metabolic+clearance+of+YM796+by+the+liver+from+in+vitro+data"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of species differences (rats, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data</span></div><div class="casAuthors">Iwatsubo, Takafumi; Suzuki, Hiroshi; Sugiyama, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">462-469</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The bioavailability after oral administration of (S)-(-)-2,8-dimethyl-3-methylene-1-oxa-8-azaspiro[4,5]decane-L-tartrate monohydrate (YM796), which is being developed as an antidementia drug, at a dose of 1 mg/kg was very low (3.4%) in rats, but considerably higher (16.1%) in dogs.  The oral clearances (CLoral, Dose/AUCoral) in rats and dogs were, resp., 300 and 18 times more than that already reported in humans.  We have previously reported successful attempts to predict the in vivo hepatic metabolic clearance of YM796 from in vitro data in humans.  In our study, the in vitro metab. of YM796 was detd. using liver microsomes prepd. from both rats and dogs and we also investigated if the species difference obsd. in vivo could be quant. reproduced in vitro.  In rats, total metabolite formation could be described by single component kinetics with a Km of 13.4 μM and a Vmax of 520 nmol/min/g liver.  However, in dogs, total metabolite formation could be described by three components, as also reported for humans.  The Km and Vmax values for the high-affinity, low-capacity component (Km1 and Vmax1) in dogs and humans were, resp., 8.1 and 1.7 μM, and 10.9 and 1.2 nmol/min/g liver.  The overall intrinsic metabolic clearances estd. from the in vitro studies (CLint, in vitro) for rats and dogs were 38.8 and 2.6 mL/min/g liver, resp., being approx. 40 and 3 times more than that previously reported for humans (0.94 mL/min/g liver).  The overall intrinsic hepatic clearances (CLint, in vivo) calcd. from in vivo CLoral were 30.4, 3.4 and 0.73 mL/min/g liver for rats, dogs and humans, resp., indicating that the in vivo hepatic clearance of YM796 can be predicted from in vitro metab. data in each species.  Thus, the pronounced species difference in the metabolic clearance obsd. in vivo can be quant. predicted from in vitro metabolic data using liver microsomes, and was predominantly due to the large difference in the Vmax values.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrugcAGF4l50rVg90H21EOLACvtfcHk0lhaEqDDfReWsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnsV2nu74%253D&md5=8f39d4003d6ccdb945929b0eea3c5439</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIwatsubo%26aufirst%3DT.%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DPrediction%2520of%2520species%2520differences%2520%2528rats%252C%2520dogs%252C%2520humans%2529%2520in%2520the%2520in%2520vivo%2520metabolic%2520clearance%2520of%2520YM796%2520by%2520the%2520liver%2520from%2520in%2520vitro%2520data%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%2520A%26date%3D1997%26volume%3D283%26spage%3D462%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kabsch, W.</span></span> <span> </span><span class="NLM_article-title">XDS</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1107/S0907444909047337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1107%2FS0907444909047337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=20124692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=125-132&author=W.+Kabsch&title=XDS&doi=10.1107%2FS0907444909047337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Software XDS for image rotation, recognition and crystal symmetry assignment</span></div><div class="casAuthors">Kabsch, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The usage and control of recent modifications of the program package XDS for the processing of rotation images are described in the context of previous versions.  New features include automatic detn. of spot size and reflecting range and recognition and assignment of crystal symmetry.  Moreover, the limitations of earlier package versions on the no. of correction/scaling factors and the representation of pixel contents have been removed.  Large program parts have been restructured for parallel processing so that the quality and completeness of collected data can be assessed soon after measurement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv5AyUw00DYbVg90H21EOLACvtfcHk0lhaEqDDfReWsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D&md5=1aa9a38aeb3ce95af4ffb7d8b8a142bd</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1107%2FS0907444909047337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909047337%26sid%3Dliteratum%253Aachs%26aulast%3DKabsch%26aufirst%3DW.%26atitle%3DXDS%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D125%26epage%3D132%26doi%3D10.1107%2FS0907444909047337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krissinel, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNicholas, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannu, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potterton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. S.</span></span> <span> </span><span class="NLM_article-title">Overview of the CCP4 suite and current developments</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1107/S0907444910045749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1107%2FS0907444910045749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=21460441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=235-242&author=M.+D.+Winnauthor=C.+C.+Ballardauthor=K.+D.+Cowtanauthor=E.+J.+Dodsonauthor=P.+Emsleyauthor=P.+R.+Evansauthor=R.+M.+Keeganauthor=E.+B.+Krissinelauthor=A.+G.+Leslieauthor=A.+McCoyauthor=S.+J.+McNicholasauthor=G.+N.+Murshudovauthor=N.+S.+Pannuauthor=E.+A.+Pottertonauthor=H.+R.+Powellauthor=R.+J.+Readauthor=A.+Vaginauthor=K.+S.+Wilson&title=Overview+of+the+CCP4+suite+and+current+developments&doi=10.1107%2FS0907444910045749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of the CCP4 suite and current developments</span></div><div class="casAuthors">Winn, Martyn D.; Ballard, Charles C.; Cowtan, Kevin D.; Dodson, Eleanor J.; Emsley, Paul; Evans, Phil R.; Keegan, Ronan M.; Krissinel, Eugene B.; Leslie, Andrew G. W.; McCoy, Airlie; McNicholas, Stuart J.; Murshudov, Garib N.; Pannu, Navraj S.; Potterton, Elizabeth A.; Powell, Harold R.; Read, Randy J.; Vagin, Alexei; Wilson, Keith S.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  The CCP4 (Collaborative Computational Project, No. 4) software suite is a collection of programs and assocd. data and software libraries which can be used for macromol. structure detn. by X-ray crystallog.  The suite is designed to be flexible, allowing users a no. of methods of achieving their aims.  The programs are from a wide variety of sources but are connected by a common infrastructure provided by std. file formats, data objects and graphical interfaces.  Structure soln. by macromol. crystallog. is becoming increasingly automated and the CCP4 suite includes several automation pipelines.  After giving a brief description of the evolution of CCP4 over the last 30 years, an overview of the current suite is given.  While detailed descriptions are given in the accompanying articles, here it is shown how the individual programs contribute to a complete software package.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_wWMMIol6UrVg90H21EOLACvtfcHk0lga70CQjeKenw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D&md5=c407e4d47bef46864be336d60147c17d</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1107%2FS0907444910045749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910045749%26sid%3Dliteratum%253Aachs%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DBallard%26aufirst%3DC.%2BC.%26aulast%3DCowtan%26aufirst%3DK.%2BD.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DP.%2BR.%26aulast%3DKeegan%26aufirst%3DR.%2BM.%26aulast%3DKrissinel%26aufirst%3DE.%2BB.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%26aulast%3DMcCoy%26aufirst%3DA.%26aulast%3DMcNicholas%26aufirst%3DS.%2BJ.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DPotterton%26aufirst%3DE.%2BA.%26aulast%3DPowell%26aufirst%3DH.%2BR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DK.%2BS.%26atitle%3DOverview%2520of%2520the%2520CCP4%2520suite%2520and%2520current%2520developments%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26spage%3D235%26epage%3D242%26doi%3D10.1107%2FS0907444910045749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohkamp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Features and development of Coot</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1107/S0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+development+of+Coot&doi=10.1107%2FS0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0lhoyaXt0kbt8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2FS0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liebschner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afonine, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunkoczi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croll, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hintze, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeffner, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prisant, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sammito, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobolev, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockwell, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terwilliger, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urzhumtsev, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Videau, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span> <span> </span><span class="NLM_article-title">Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix</span>. <i>Acta Crystallogr., Sect. D: Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">861</span>– <span class="NLM_lpage">877</span>, <span class="refDoi"> DOI: 10.1107/S2059798319011471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1107%2FS2059798319011471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFWkurrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2019&pages=861-877&author=D.+Liebschnerauthor=P.+V.+Afonineauthor=M.+L.+Bakerauthor=G.+Bunkocziauthor=V.+B.+Chenauthor=T.+I.+Crollauthor=B.+Hintzeauthor=L.+W.+Hungauthor=S.+Jainauthor=A.+J.+McCoyauthor=N.+W.+Moriartyauthor=R.+D.+Oeffnerauthor=B.+K.+Poonauthor=M.+G.+Prisantauthor=R.+J.+Readauthor=J.+S.+Richardsonauthor=D.+C.+Richardsonauthor=M.+D.+Sammitoauthor=O.+V.+Sobolevauthor=D.+H.+Stockwellauthor=T.+C.+Terwilligerauthor=A.+G.+Urzhumtsevauthor=L.+L.+Videauauthor=C.+J.+Williamsauthor=P.+D.+Adams&title=Macromolecular+structure+determination+using+X-rays%2C+neutrons+and+electrons%3A+recent+developments+in+Phenix&doi=10.1107%2FS2059798319011471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix</span></div><div class="casAuthors">Liebschner, Dorothee; Afonine, Pavel V.; Baker, Matthew L.; Bunkoczi, Gabor; Chen, Vincent B.; Croll, Tristan I.; Hintze, Bradley; Hung, Li-Wei; Jain, Swati; McCoy, Airlie J.; Moriarty, Nigel W.; Oeffner, Robert D.; Poon, Billy K.; Prisant, Michael G.; Read, Randy J.; Richardson, Jane S.; Richardson, David C.; Sammito, Massimo D.; Sobolev, Oleg V.; Stockwell, Duncan H.; Terwilliger, Thomas C.; Urzhumtsev, Alexandre G.; Videau, Lizbeth L.; Williams, Christopher J.; Adams, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Structural Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">861-877</span>CODEN:
                <span class="NLM_cas:coden">ACSDAD</span>;
        ISSN:<span class="NLM_cas:issn">2059-7983</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Diffraction (X-ray, neutron and electron) and electron cryo-microscopy are powerful methods to det. three-dimensional macromol. structures, which are required to understand biol. processes and to develop new therapeutics against diseases.  The overall structure-soln. workflow is similar for these techniques, but nuances exist because the properties of the reduced exptl. data are different.  Software tools for structure detn. should therefore be tailored for each method.  Phenix is a comprehensive software package for macromol. structure detn. that handles data from any of these techniques.  Tasks performed with Phenix include data-quality assessment, map improvement, model building, the validation/rebuilding/refinement cycle and deposition.  Each tool caters to the type of exptl. data.  The design of Phenix emphasizes the automation of procedures, where possible, to minimize repetitive and time-consuming manual tasks, while default parameters are chosen to encourage best practice.  A graphical user interface provides access to many command-line features of Phenix and streamlines the transition between programs, project tracking and re-running of previous tasks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolHnU8ECe2CrVg90H21EOLACvtfcHk0lhoyaXt0kbt8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFWkurrO&md5=e60be65abece48923abf937a4c2640a6</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1107%2FS2059798319011471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2059798319011471%26sid%3Dliteratum%253Aachs%26aulast%3DLiebschner%26aufirst%3DD.%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DBaker%26aufirst%3DM.%2BL.%26aulast%3DBunkoczi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DCroll%26aufirst%3DT.%2BI.%26aulast%3DHintze%26aufirst%3DB.%26aulast%3DHung%26aufirst%3DL.%2BW.%26aulast%3DJain%26aufirst%3DS.%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DOeffner%26aufirst%3DR.%2BD.%26aulast%3DPoon%26aufirst%3DB.%2BK.%26aulast%3DPrisant%26aufirst%3DM.%2BG.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26aulast%3DSammito%26aufirst%3DM.%2BD.%26aulast%3DSobolev%26aufirst%3DO.%2BV.%26aulast%3DStockwell%26aufirst%3DD.%2BH.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DUrzhumtsev%26aufirst%3DA.%2BG.%26aulast%3DVideau%26aufirst%3DL.%2BL.%26aulast%3DWilliams%26aufirst%3DC.%2BJ.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26atitle%3DMacromolecular%2520structure%2520determination%2520using%2520X-rays%252C%2520neutrons%2520and%2520electrons%253A%2520recent%2520developments%2520in%2520Phenix%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Struct.%2520Biol.%26date%3D2019%26volume%3D75%26spage%3D861%26epage%3D877%26doi%3D10.1107%2FS2059798319011471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenbraun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Key, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanschagrin, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timony, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaviano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliz, P.</span></span> <span> </span><span class="NLM_article-title">Collaboration gets the most out of software</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e01456</span> <span class="refDoi"> DOI: 10.7554/eLife.01456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.7554%2FeLife.01456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=24040512" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&author=A.+Morinauthor=B.+Eisenbraunauthor=J.+Keyauthor=P.+C.+Sanschagrinauthor=M.+A.+Timonyauthor=M.+Ottavianoauthor=P.+Sliz&title=Collaboration+gets+the+most+out+of+software&doi=10.7554%2FeLife.01456"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.7554%2FeLife.01456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.01456%26sid%3Dliteratum%253Aachs%26aulast%3DMorin%26aufirst%3DA.%26aulast%3DEisenbraun%26aufirst%3DB.%26aulast%3DKey%26aufirst%3DJ.%26aulast%3DSanschagrin%26aufirst%3DP.%2BC.%26aulast%3DTimony%26aufirst%3DM.%2BA.%26aulast%3DOttaviano%26aufirst%3DM.%26aulast%3DSliz%26aufirst%3DP.%26atitle%3DCollaboration%2520gets%2520the%2520most%2520out%2520of%2520software%26jtitle%3DeLife%26date%3D2013%26volume%3D2%26doi%3D10.7554%2FeLife.01456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 3 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ellie Rose  Mattoon</span>, <span class="hlFld-ContribAuthor ">Arturo  Casadevall</span>, <span class="hlFld-ContribAuthor ">Radames JB.  Cordero</span>. </span><span class="cited-content_cbyCitation_article-title">Beat the heat: correlates, compounds, and mechanisms involved in fungal thermotolerance. </span><span class="cited-content_cbyCitation_journal-name">Fungal Biology Reviews</span><span> <strong>2021,</strong> <em>36 </em>, 60-75. <a href="https://doi.org/10.1016/j.fbr.2021.03.002" title="DOI URL">https://doi.org/10.1016/j.fbr.2021.03.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.fbr.2021.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.fbr.2021.03.002%26sid%3Dliteratum%253Aachs%26jtitle%3DFungal%2520Biology%2520Reviews%26atitle%3DBeat%252Bthe%252Bheat%25253A%252Bcorrelates%25252C%252Bcompounds%25252C%252Band%252Bmechanisms%252Binvolved%252Bin%252Bfungal%252Bthermotolerance%26aulast%3DMattoon%26aufirst%3DEllie%2BRose%26date%3D2021%26volume%3D36%26spage%3D60%26epage%3D75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rui  Yuan</span>, <span class="hlFld-ContribAuthor ">Jie  Tu</span>, <span class="hlFld-ContribAuthor ">Chunquan  Sheng</span>, <span class="hlFld-ContribAuthor ">Xi  Chen</span>, <span class="hlFld-ContribAuthor ">Na  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Effects of Hsp90 Inhibitor Ganetespib on Inhibition of Azole-Resistant Candida albicans. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Microbiology</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fmicb.2021.680382" title="DOI URL">https://doi.org/10.3389/fmicb.2021.680382</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fmicb.2021.680382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffmicb.2021.680382%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Microbiology%26atitle%3DEffects%252Bof%252BHsp90%252BInhibitor%252BGanetespib%252Bon%252BInhibition%252Bof%252BAzole-Resistant%252BCandida%252Balbicans%26aulast%3DYuan%26aufirst%3DRui%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li  Li</span>, <span class="hlFld-ContribAuthor ">Nannan  Chen</span>, <span class="hlFld-ContribAuthor ">Dandan  Xia</span>, <span class="hlFld-ContribAuthor ">Shicheng  Xu</span>, <span class="hlFld-ContribAuthor ">Wei  Dai</span>, <span class="hlFld-ContribAuthor ">Yuanyuan  Tong</span>, <span class="hlFld-ContribAuthor ">Lei  Wang</span>, <span class="hlFld-ContribAuthor ">Zhengyu  Jiang</span>, <span class="hlFld-ContribAuthor ">Qidong  You</span>, <span class="hlFld-ContribAuthor ">Xiaoli  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a covalent inhibitor of heat shock protein 90 with antitumor activity that blocks the co-chaperone binding via C-terminal modification. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2021,</strong> <em>104 </em><a href="https://doi.org/10.1016/j.chembiol.2021.03.016" title="DOI URL">https://doi.org/10.1016/j.chembiol.2021.03.016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2021.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2021.03.016%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DDiscovery%252Bof%252Ba%252Bcovalent%252Binhibitor%252Bof%252Bheat%252Bshock%252Bprotein%252B90%252Bwith%252Bantitumor%252Bactivity%252Bthat%252Bblocks%252Bthe%252Bco-chaperone%252Bbinding%252Bvia%252BC-terminal%252Bmodification%26aulast%3DLi%26aufirst%3DLi%26date%3D2021%26volume%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01777&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Generic structure of resorcylate aminopyrazoles (RAPs, left) and summary of activity and selectivity profile for previously reported first-generation cryptococcal-selective RAP series of type <b>1</b>, which are <i>N</i>-methylated at R<sup>1</sup> and bear a monosubstituted phenyl ring at R<sup>2</sup> to increase fungal selectivity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01777&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0013.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Building Block Aminopyrazoles <b>4</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01777&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions: (a) MeCN, <i>n-</i>BuLi, tetrahydrofuran (THF), −78 °C to room temperature (rt); (b) R<sup>1</sup>NH-NH<sub>2</sub>, MeOH, 120 °C, microwave or R<sup>1</sup>NH-NH<sub>2</sub>·HCl, NEt<sub>3</sub>, MeOH, 120 °C, microwave.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0014.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Convergent Synthesis of RAPs <b>9a</b>–<b>bi</b> from Resorcylate Amides <b>8a</b>–<b>c</b> and Aminopyrazoles <b>4a</b>–<b>bb</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01777&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions: (a) POCl<sub>3</sub>, DMF, 0 °C to 100 °C; (b) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt; (c) BnBr, K<sub>2</sub>CO<sub>3</sub>, MeCN, reflux; (d) NaOCl<sub>2</sub>, NaH<sub>2</sub>PO<sub>4</sub>·H<sub>2</sub>O, 2-methyl-2-butene, THF/<i>t-</i>BuOH/H<sub>2</sub>O; (e) isoindoline·HCl (for <b>8a</b>), 4-fluoroisoindoline·HCl (for <b>8b</b>), or 5-fluoroisoindoline·HCl (for <b>8c</b>), HATU, Et<sub>3</sub>N, THF/CH<sub>2</sub>Cl<sub>2</sub>; (f) Pd(OAc)<sub>2</sub> (10 mol %), Xantphos (20 mol %), Cs<sub>2</sub>CO<sub>3</sub>, toluene, 130 °C or Pd<sub>2</sub>(dba)<sub>3</sub> (4 mol %), Xantphos (10 mol %), NaOPh, dioxane, 170 °C, microwave; (g) Pd/C (cat.), H<sub>2</sub>, MeOH or Pd(OH)<sub>2</sub>/C (cat.), H<sub>2</sub>, EtOAc.</p></p></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) RAPs with meta-substituted R<sup>2</sup> aryl rings exhibiting high fungal selectivity (FS) for cryptococcal Hsp90 over human isoforms. (B) Among 94 RAPs with fungal target affinity (H99 EC<sub>50</sub>) ≤ 1 μM, only six demonstrate whole-cell antifungal activity (MIC ≤ 25 μM). Values for compounds with either fold-selectivity >5 <b>or</b> MIC<sub>80</sub> ≤ 12.5 μM are highlighted in <b>blue</b>. Values for compounds with both fold-selectivity >5 <b>and</b> MIC<sub>80</sub> ≤ 12.5 μM are highlighted in <b>red</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01777&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Scatter plots of the top 22 most fungal-selective, whole-cell-active RAPs showing that (A) biochemical potency (H99 lysate pEC50, <i>x</i>-axis) and whole-cell antifungal activity (<i>C. neoformans</i> MIC, μM, <i>y</i>-axis) are poorly correlated. Similarly, no correlation is seen between fungal selectivity and therapeutic index (TI, mammalian IC<sub>50</sub> ÷ <i>C. neoformans</i> MIC) in (B) NIH 3T3 cells or (C) HepG2 cells. In (A–C), scatter points are colored based on relative H99 selectivity in cellular lysates. (D) Structures of key highlighted compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01777&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structures of ligands including RAP <b>19</b>;<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> previously reported <i>C. albicans</i>-selective inhibitor CMLD013075;<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> clinical inhibitors NVP-AUY922,<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> AT13387, and SNX-2112; and purine inhibitor PU3.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01777&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Overlay of human, <i>C. albicans</i>, and <i>C. neoformans</i> Hsp90 NBD structures, viewed from the “back” side of the domain. In this view, the ligand-binding pocket and lid helices α4−α6 are behind the protein, away from the viewer, and are deemphasized to accentuate the changes in the β-sheet and α1. (A) Superposition of Cα traces from 21 structures that share a similar core. Traces are colored black, with β-strands in blue with blue labels. The lid is in light gray behind strands β5-β4-β7. Bound ligands in the nucleotide binding pocket are shown in pale orange behind strands β4−β7. The structures include the human protein in the apo state (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YER">1YER</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YES">1YES</a>, 2 chains) and in complex with radicicol (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EGK">4EGK</a>, 1 chain), SNX-2112 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NH7">4NH7</a>, 2 chains), AUY922 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VCI">2VCI</a>, 1 chain), AT13387 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XJX">2XJX</a>, 1 chain), and PU3 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UY6">1UY6</a>, 1 chain); <i>C. albicans</i> apo (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJI">6CJI</a>, 1 chain) and in complex with ADP (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJJ">6CJJ</a>, 1 chain), radicicol (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJL">6CJL</a>, 2 chains), and SNX-2112 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJR">6CJR</a>, 1 chain); and <i>C. neoformans</i> apo (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9R">7K9R</a>, 3 chains) and in complex with AUY922 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9S">7K9S</a>, 6 chains). (B) Same as (A), but with the addition of structures from <i>C. neoformans</i> with compounds <b>10</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9W">7K9W</a>, 2 chains), <b>18</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9V">7K9V</a>, 2 chains), and <b>19</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9U">7K9U</a>, 2 chains), shown in red. This set shows consistent changes in β5, β6, and α1 and a disordering of strand β1 (not modeled in the crystal structures). (C) Same as (A), but with the addition of chains from <i>C. albicans</i> in complex with AUY922 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJS">6CJS</a>, 1 chain) and CMLD013075 (<b>20</b>) (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJP">6CJP</a>, 2 chain), shown in magenta. Changes in the core structure are seen in β6, β1, and α1. (D) Individual structures from the box in (B) showing <i>C. neoformans</i> in complex with AUY922 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9S">7K9S</a>, left) and <b>18</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9V">7K9V</a>, right).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01777&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0007.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Comparison with previously reported complexes. (A) Overlay of the human Hsp90/AT13387 complex (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XJX">2XJX</a>, cyan carbon atoms) with the <i>C. neoformans</i>/<b>10</b> complex (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9W">7K9W</a>, orange carbon atoms). The surface of the fungal protein is shown, and the AT13387 piperazine ring is omitted for clarity. (B) Staggered view of aligned ligands from four complexes: the two chains from the <i>C. neoformans</i>/<b>10</b> crystal structure (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9W">7K9W</a>), human/SNX-2112 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NH7">4NH7</a>), and human/PU3 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UY6">1UY6</a>). The gray oval represents the deep hydrophobic pocket of Hsp90, indicated in the left part of (A).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01777&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0008.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Ligand-driven reorganization of the <i>C. neoformans</i> binding pocket. (A) Overlay of the human (light blue, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VCI">2VCI</a>), <i>C. albicans</i> (red, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJS">6CJS</a>), and <i>C. neoformans</i> (orange, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9S">7K9S</a>) complexes with AUY922. (B) Overlay of the <i>C. neoformans</i> NBD in complex with AUY422 (orange, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9S">7K9S</a>) and RAP compounds <b>10</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9W">7K9W</a>), <b>18</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9V">7K9V</a>), and <b>19</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9U">7K9U</a>) (dark blue). (C–F) Residues L93, F125, and W128 from helices α4, α7, and strand β5, respectively, are in packing contact in the apo (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJI">6CJI</a>, C) and AUY922 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9S">7K9S</a>, D) complexes, but are disrupted by the R<sup>2</sup> aryl ring of the RAPs (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9W">7K9W</a>, E/F). The two chains in the co-crystals of the <i>C. neoformans</i> NBD with <b>10</b> reveal different rotamers of the <i>meta</i>-methoxy aryl ring, shown in (E) and (F).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01777&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0009.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. RAP binding disrupts the β-sheet. (A) Overlay of the <i>C. neoformans</i> and human structures from <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> were divided into two sets. Set A includes all of the eight human structures [<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YER">1YER</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YES">1YES</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EGK">4EGK</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NH7">4NH7</a> (two chains), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VCI">2VCI</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XJX">2XJX</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UY6">1UY6</a>] and the nine <i>C. neoformans</i> apo and AUY922 structures [<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9R">7K9R</a> (three chains) and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9S">7K9S</a> (six chains)] and is shown in black Cα trace. Set B includes the six fungal RAP complexes [<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9U">7K9U</a> (two chains), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9V">7K9V</a> (two chains), and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9W">7K9W</a> (two chains)] and is shown in red Cα trace. Selected side chains from set A are shown in stick representation with van der Waals surface and fungal/human numbering. (B) The same backbone traces are represented, but with the side chains from set B as well as the RAP inhibitor <b>10</b> in space filling representation. Note that strand β1 is present only in the structures from set A.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01777&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0010.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Scatter plots of cryptococcal selectivity, biochemical potency, and whole-cell activity for <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> RAPs, binned by the aminopyrazole substructure class as defined by the R<sup>1</sup> and R<sup>2</sup> substitution patterns. The y-axis depicts cryptococcal fold-selectivity on a logarithmic scale. Points are colored by H99 lysate EC<sub>50</sub> on a logarithmic scale, on a gradient ranging from cyan (10 μM) to red (1 nM). Point symbols indicate whole-cell activity class, with circles corresponding to compounds with little to no whole-cell activity (H99 MIC ≥ 25 μM) and stars indicating whole-cell-active compounds with an H99 MIC < 25 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01777&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0011.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A) Two predominant structural classes among RAPs with optimal combined biochemical potency/fungal selectivity/whole-cell activity profile, each with slightly divergent activity profiles. (B) Representative structures and activities of top inhibitors <b>9ac</b>, <b>9ad</b>, <b>9ba</b>, and <b>9bb</b> from these subclasses.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01777&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/medium/jm0c01777_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0012.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Results of computational modeling using RAP-liganded X-ray crystal structures. (A) X-ray crystal structure (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9V">7K9V</a>) with compound <b>18</b> bound at Chain A. (B, C) Comparative views of two rotamers of compound <b>9an</b> docked into structure 7K9V Chain A. Docking scores are −15.3 and −14.5 kcal/mol, respectively. (D, E) Comparative views of two rotamers of compound <b>9ba</b> docked into structure 7K9V Chain A. Docking scores are −14.7 and −14.5 kcal/mol, respectively. (F, G) Comparative views of two rotamers of compound <b>9bc</b> docked into structure <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9V">7K9V</a> Chain A. Docking scores are −14.2 and −14.4 kcal/mol, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c01777/20210121/images/large/jm0c01777_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01777&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i180">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70240" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70240" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 90 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denning, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gow, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitz, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Netea, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, T. C.</span></span> <span> </span><span class="NLM_article-title">Hidden killers: human fungal infections</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">165rv113</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.3004404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1126%2Fscitranslmed.3004404" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&author=G.+D.+Brownauthor=D.+W.+Denningauthor=N.+A.+Gowauthor=S.+M.+Levitzauthor=M.+G.+Neteaauthor=T.+C.+White&title=Hidden+killers%3A+human+fungal+infections&doi=10.1126%2Fscitranslmed.3004404"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3004404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3004404%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DG.%2BD.%26aulast%3DDenning%26aufirst%3DD.%2BW.%26aulast%3DGow%26aufirst%3DN.%2BA.%26aulast%3DLevitz%26aufirst%3DS.%2BM.%26aulast%3DNetea%26aufirst%3DM.%2BG.%26aulast%3DWhite%26aufirst%3DT.%2BC.%26atitle%3DHidden%2520killers%253A%2520human%2520fungal%2520infections%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2012%26volume%3D4%26doi%3D10.1126%2Fscitranslmed.3004404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanglard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurr, S. J.</span></span> <span> </span><span class="NLM_article-title">Worldwide emergence of resistance to antifungal drugs challenges human health and food security</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">739</span>– <span class="NLM_lpage">742</span>, <span class="refDoi"> DOI: 10.1126/science.aap7999</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1126%2Fscience.aap7999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=29773744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsVCgsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2018&pages=739-742&author=M.+C.+Fisherauthor=N.+J.+Hawkinsauthor=D.+Sanglardauthor=S.+J.+Gurr&title=Worldwide+emergence+of+resistance+to+antifungal+drugs+challenges+human+health+and+food+security&doi=10.1126%2Fscience.aap7999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Worldwide emergence of resistance to antifungal drugs challenges human health and food security</span></div><div class="casAuthors">Fisher, Matthew C.; Hawkins, Nichola J.; Sanglard, Dominique; Gurr, Sarah J.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">6390</span>),
    <span class="NLM_cas:pages">739-742</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The recent rate of emergence of pathogenic fungi that are resistant to the limited no. of commonly used antifungal agents is unprecedented.  The azoles, for example, are used not only for human and animal health care and crop protection but also in antifouling coatings and timber preservation.  The ubiquity and multiple uses of azoles have hastened the independent evolution of resistance in many environments.  One consequence is an increasing risk in human health care from naturally occurring opportunistic fungal pathogens that have acquired resistance to this broad class of chems.  To avoid a global collapse in our ability to control fungal infections and to avoid crit. failures in medicine and food security, we must improve our stewardship of extant chems., promote new antifungal discovery, and leverage emerging technologies for alternative solns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolE2CwqdzBv7Vg90H21EOLACvtfcHk0liH8ltHM0l6kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsVCgsbg%253D&md5=8add9de472138d5aca677fa3585ddd72</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.aap7999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aap7999%26sid%3Dliteratum%253Aachs%26aulast%3DFisher%26aufirst%3DM.%2BC.%26aulast%3DHawkins%26aufirst%3DN.%2BJ.%26aulast%3DSanglard%26aufirst%3DD.%26aulast%3DGurr%26aufirst%3DS.%2BJ.%26atitle%3DWorldwide%2520emergence%2520of%2520resistance%2520to%2520antifungal%2520drugs%2520challenges%2520human%2520health%2520and%2520food%2520security%26jtitle%3DScience%26date%3D2018%26volume%3D360%26spage%3D739%26epage%3D742%26doi%3D10.1126%2Fscience.aap7999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denning, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitz, S. M.</span></span> <span> </span><span class="NLM_article-title">Tackling human fungal infections</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>336</i></span>,  <span class="NLM_fpage">647</span>, <span class="refDoi"> DOI: 10.1126/science.1222236</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1126%2Fscience.1222236" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=22582229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvF2jtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=336&publication_year=2012&pages=647&author=G.+D.+Brownauthor=D.+W.+Denningauthor=S.+M.+Levitz&title=Tackling+human+fungal+infections&doi=10.1126%2Fscience.1222236"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Tackling human fungal infections</span></div><div class="casAuthors">Brown, Gordon D.; Denning, David W.; Levitz, Stuart M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">336</span>
        (<span class="NLM_cas:issue">6082</span>),
    <span class="NLM_cas:pages">647</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEe-AdzM8oD7Vg90H21EOLACvtfcHk0ljbBpvaaaLIwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvF2jtLc%253D&md5=ad0c19c925c3821e35a52717f1cb071e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.1222236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1222236%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DG.%2BD.%26aulast%3DDenning%26aufirst%3DD.%2BW.%26aulast%3DLevitz%26aufirst%3DS.%2BM.%26atitle%3DTackling%2520human%2520fungal%2520infections%26jtitle%3DScience%26date%3D2012%26volume%3D336%26spage%3D647%26doi%3D10.1126%2Fscience.1222236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pfaller, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diekema, D. J.</span></span> <span> </span><span class="NLM_article-title">Epidemiology of invasive mycoses in North America</span>. <i>Crit. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.3109/10408410903241444</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.3109%2F10408410903241444" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=20088682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252FksF2htQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2010&pages=1-53&author=M.+A.+Pfallerauthor=D.+J.+Diekema&title=Epidemiology+of+invasive+mycoses+in+North+America&doi=10.3109%2F10408410903241444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology of invasive mycoses in North America</span></div><div class="casAuthors">Pfaller Michael A; Diekema Daniel J</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in microbiology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-53</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The incidence of invasive mycoses is increasing, especially among patients who are immunocompromised or hospitalized with serious underlying diseases.  Such infections may be broken into two broad categories: opportunistic and endemic.  The most important agents of the opportunistic mycoses are Candida spp., Cryptococcus neoformans, Pneumocystis jirovecii, and Aspergillus spp. (although the list of potential pathogens is ever expanding); while the most commonly encountered endemic mycoses are due to Histoplasma capsulatum, Coccidioides immitis/posadasii, and Blastomyces dermatitidis.  This review discusses the epidemiologic profiles of these invasive mycoses in North America, as well as risk factors for infection, and the pathogens' antifungal susceptibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRHHNyyGVuQmuxsqfvU0ziafW6udTcc2eZJgztAiUxVl7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252FksF2htQ%253D%253D&md5=e68785c3d62889a68a0fcfbceee5fc53</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3109%2F10408410903241444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10408410903241444%26sid%3Dliteratum%253Aachs%26aulast%3DPfaller%26aufirst%3DM.%2BA.%26aulast%3DDiekema%26aufirst%3DD.%2BJ.%26atitle%3DEpidemiology%2520of%2520invasive%2520mycoses%2520in%2520North%2520America%26jtitle%3DCrit.%2520Rev.%2520Microbiol.%26date%3D2010%26volume%3D36%26spage%3D1%26epage%3D53%26doi%3D10.3109%2F10408410903241444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Köhler, J. R.</span>; <span class="NLM_string-name">Hube, B.</span>; <span class="NLM_string-name">Puccia, R.</span>; <span class="NLM_string-name">Casadevall, A.</span>; <span class="NLM_string-name">Perfect, J. R.</span></span> <span> </span><span class="NLM_article-title">Fungi that infect humans</span>.  <i>The Fungal Kingdom</i>; <span class="NLM_publisher-name">Wiley</span>, <span class="NLM_year">2017</span>; Vol.  <span class="NLM_volume">5</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1128%2F9781555819583.ch39" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=J.+R.+K%C3%B6hler&author=B.+Hube&author=R.+Puccia&author=A.+Casadevall&author=J.+R.+Perfect&title=The+Fungal+Kingdom"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1128%2F9781555819583.ch39&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1128%252F9781555819583.ch39%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25B6hler%26aufirst%3DJ.%2BR.%26atitle%3DFungi%2520that%2520infect%2520humans%26btitle%3DThe%2520Fungal%2520Kingdom%26pub%3DWiley%26date%3D2017%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wannemuehler, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marston, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govender, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappas, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiller, T. M.</span></span> <span> </span><span class="NLM_article-title">Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS</span>. <i>AIDS</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">530</span>, <span class="refDoi"> DOI: 10.1097/QAD.0b013e328322ffac</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1097%2FQAD.0b013e328322ffac" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=19182676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A280%3ADC%252BD1M7mvFSmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=525-530&author=B.+J.+Parkauthor=K.+A.+Wannemuehlerauthor=B.+J.+Marstonauthor=N.+Govenderauthor=P.+G.+Pappasauthor=T.+M.+Chiller&title=Estimation+of+the+current+global+burden+of+cryptococcal+meningitis+among+persons+living+with+HIV%2FAIDS&doi=10.1097%2FQAD.0b013e328322ffac"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS</span></div><div class="casAuthors">Park Benjamin J; Wannemuehler Kathleen A; Marston Barbara J; Govender Nelesh; Pappas Peter G; Chiller Tom M</div><div class="citationInfo"><span class="NLM_cas:title">AIDS (London, England)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">525-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Cryptococcal meningitis is one of the most important HIV-related opportunistic infections, especially in the developing world.  In order to help develop global strategies and priorities for prevention and treatment, it is important to estimate the burden of cryptococcal meningitis.  DESIGN:  Global burden of disease estimation using published studies.  METHODS:  We used the median incidence rate of available studies in a geographic region to estimate the region-specific cryptococcal meningitis incidence; this was multiplied by the 2007 United Nations Programme on HIV/AIDS HIV population estimate for each region to estimate cryptococcal meningitis cases.  To estimate deaths, we assumed a 9% 3-month case-fatality rate among high-income regions, a 55% rate among low-income and middle-income regions, and a 70% rate in sub-Saharan Africa, based on studies published in these areas and expert opinion.  RESULTS:  Published incidence ranged from 0.04 to 12% per year among persons with HIV.  Sub-Saharan Africa had the highest yearly burden estimate (median incidence 3.2%, 720 000 cases; range, 144 000-1.3 million).  Median incidence was lowest in Western and Central Europe and Oceania (</=0.1% each).  Globally, approximately 957 900 cases (range, 371 700-1 544 000) of cryptococcal meningitis occur each year, resulting in 624 700 deaths (range, 125 000-1 124 900) by 3 months after infection.  CONCLUSION:  This study, the first attempt to estimate the global burden of cryptococcal meningitis, finds the number of cases and deaths to be very high, with most occurring in sub-Saharan Africa.  Further work is needed to better define the scope of the problem and track the epidemiology of this infection, in order to prioritize prevention, diagnosis, and treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTs2E37kZj4yYkFb3mqPUYDfW6udTcc2eacVVI7zrbZ3rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M7mvFSmuw%253D%253D&md5=22081153f2d332b6f4032023cbecbbeb</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1097%2FQAD.0b013e328322ffac&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FQAD.0b013e328322ffac%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DB.%2BJ.%26aulast%3DWannemuehler%26aufirst%3DK.%2BA.%26aulast%3DMarston%26aufirst%3DB.%2BJ.%26aulast%3DGovender%26aufirst%3DN.%26aulast%3DPappas%26aufirst%3DP.%2BG.%26aulast%3DChiller%26aufirst%3DT.%2BM.%26atitle%3DEstimation%2520of%2520the%2520current%2520global%2520burden%2520of%2520cryptococcal%2520meningitis%2520among%2520persons%2520living%2520with%2520HIV%252FAIDS%26jtitle%3DAIDS%26date%3D2009%26volume%3D23%26spage%3D525%26epage%3D530%26doi%3D10.1097%2FQAD.0b013e328322ffac" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajasingham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarvis, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govender, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiller, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denning, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loyse, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulware, D. R.</span></span> <span> </span><span class="NLM_article-title">Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">873</span>– <span class="NLM_lpage">881</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(17)30243-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1016%2FS1473-3099%2817%2930243-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=28483415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A280%3ADC%252BC1crlt1Sjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=873-881&author=R.+Rajasinghamauthor=R.+M.+Smithauthor=B.+J.+Parkauthor=J.+N.+Jarvisauthor=N.+P.+Govenderauthor=T.+M.+Chillerauthor=D.+W.+Denningauthor=A.+Loyseauthor=D.+R.+Boulware&title=Global+burden+of+disease+of+HIV-associated+cryptococcal+meningitis%3A+an+updated+analysis&doi=10.1016%2FS1473-3099%2817%2930243-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis</span></div><div class="casAuthors">Rajasingham Radha; Smith Rachel M; Park Benjamin J; Chiller Tom M; Jarvis Joseph N; Govender Nelesh P; Denning David W; Loyse Angela; Boulware David R</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Infectious diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">873-881</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Cryptococcus is the most common cause of meningitis in adults living with HIV in sub-Saharan Africa.  Global burden estimates are crucial to guide prevention strategies and to determine treatment needs, and we aimed to provide an updated estimate of global incidence of HIV-associated cryptococcal disease.  METHODS:  We used 2014 Joint UN Programme on HIV and AIDS estimates of adults (aged >15 years) with HIV and antiretroviral therapy (ART) coverage.  Estimates of CD4 less than 100 cells per μL, virological failure incidence, and loss to follow-up were from published multinational cohorts in low-income and middle-income countries.  We calculated those at risk for cryptococcal infection, specifically those with CD4 less than 100 cells/μL not on ART, and those with CD4 less than 100 cells per μL on ART but lost to follow-up or with virological failure.  Cryptococcal antigenaemia prevalence by country was derived from 46 studies globally.  Based on cryptococcal antigenaemia prevalence in each country and region, we estimated the annual numbers of people who are developing and dying from cryptococcal meningitis.  FINDINGS:  We estimated an average global cryptococcal antigenaemia prevalence of 6·0% (95% CI 5·8-6·2) among people with a CD4 cell count of less than 100 cells per μL, with 278 000 (95% CI 195 500-340 600) people positive for cryptococcal antigen globally and 223 100 (95% CI 150 600-282 400) incident cases of cryptococcal meningitis globally in 2014.  Sub-Saharan Africa accounted for 73% of the estimated cryptococcal meningitis cases in 2014 (162 500 cases [95% CI 113 600-193 900]).  Annual global deaths from cryptococcal meningitis were estimated at 181 100 (95% CI 119 400-234 300), with 135 900 (75%; [95% CI 93 900-163 900]) deaths in sub-Saharan Africa.  Globally, cryptococcal meningitis was responsible for 15% of AIDS-related deaths (95% CI 10-19).  INTERPRETATION:  Our analysis highlights the substantial ongoing burden of HIV-associated cryptococcal disease, primarily in sub-Saharan Africa.  Cryptococcal meningitis is a metric of HIV treatment programme failure; timely HIV testing and rapid linkage to care remain an urgent priority.  FUNDING:  None.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR6kthTNuMfLqNc3HjJRoFAfW6udTcc2eY_C6zWYPNHFrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crlt1Sjug%253D%253D&md5=85268904374cb498fc2d92ac35cd4aee</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2817%2930243-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252817%252930243-8%26sid%3Dliteratum%253Aachs%26aulast%3DRajasingham%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DR.%2BM.%26aulast%3DPark%26aufirst%3DB.%2BJ.%26aulast%3DJarvis%26aufirst%3DJ.%2BN.%26aulast%3DGovender%26aufirst%3DN.%2BP.%26aulast%3DChiller%26aufirst%3DT.%2BM.%26aulast%3DDenning%26aufirst%3DD.%2BW.%26aulast%3DLoyse%26aufirst%3DA.%26aulast%3DBoulware%26aufirst%3DD.%2BR.%26atitle%3DGlobal%2520burden%2520of%2520disease%2520of%2520HIV-associated%2520cryptococcal%2520meningitis%253A%2520an%2520updated%2520analysis%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2017%26volume%3D17%26spage%3D873%26epage%3D881%26doi%3D10.1016%2FS1473-3099%2817%2930243-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loyse, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koulla-Shiro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mghamba, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramadhani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyirenda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliyu, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oladele, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesikari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muzoora, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temfack, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mapoure, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimwela, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakhi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngoma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gondwe-Chunda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perfect, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shroufi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrieux-Meyer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosseinipour, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Horst, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klausner, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulware, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyderman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalloo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarvis, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaffar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denning, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lortholary, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dromer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stack, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molloy, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bicanic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Oosterhout, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mwaba, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanyama, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kouanfack, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mfinanga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govender, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, T. S.</span></span> <span> </span><span class="NLM_article-title">Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">e143</span>– <span class="NLM_lpage">e147</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(18)30493-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1016%2FS1473-3099%2818%2930493-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=30344084" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=e143-e147&author=A.+Loyseauthor=J.+Burryauthor=J.+Cohnauthor=N.+Fordauthor=T.+Chillerauthor=I.+Ribeiroauthor=S.+Koulla-Shiroauthor=J.+Mghambaauthor=A.+Ramadhaniauthor=R.+Nyirendaauthor=S.+H.+Aliyuauthor=D.+Wilsonauthor=T.+Leauthor=R.+Oladeleauthor=S.+Lesikariauthor=C.+Muzooraauthor=N.+Kalataauthor=E.+Temfackauthor=Y.+Mapoureauthor=V.+Siniauthor=D.+Chandaauthor=M.+Shimwelaauthor=S.+Lakhiauthor=J.+Ngomaauthor=L.+Gondwe-Chundaauthor=C.+Perfectauthor=A.+Shroufiauthor=I.+Andrieux-Meyerauthor=A.+Chanauthor=C.+Schutzauthor=M.+Hosseinipourauthor=C.+Van+der+Horstauthor=J.+D.+Klausnerauthor=D.+R.+Boulwareauthor=R.+Heydermanauthor=D.+Lallooauthor=J.+Dayauthor=J.+N.+Jarvisauthor=M.+Rodriguesauthor=S.+Jaffarauthor=D.+Denningauthor=C.+Migoneauthor=M.+Dohertyauthor=O.+Lortholaryauthor=F.+Dromerauthor=M.+Stackauthor=S.+F.+Molloyauthor=T.+Bicanicauthor=J.+van+Oosterhoutauthor=P.+Mwabaauthor=C.+Kanyamaauthor=C.+Kouanfackauthor=S.+Mfinangaauthor=N.+Govenderauthor=T.+S.+Harrison&title=Leave+no+one+behind%3A+response+to+new+evidence+and+guidelines+for+the+management+of+cryptococcal+meningitis+in+low-income+and+middle-income+countries&doi=10.1016%2FS1473-3099%2818%2930493-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2818%2930493-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252818%252930493-6%26sid%3Dliteratum%253Aachs%26aulast%3DLoyse%26aufirst%3DA.%26aulast%3DBurry%26aufirst%3DJ.%26aulast%3DCohn%26aufirst%3DJ.%26aulast%3DFord%26aufirst%3DN.%26aulast%3DChiller%26aufirst%3DT.%26aulast%3DRibeiro%26aufirst%3DI.%26aulast%3DKoulla-Shiro%26aufirst%3DS.%26aulast%3DMghamba%26aufirst%3DJ.%26aulast%3DRamadhani%26aufirst%3DA.%26aulast%3DNyirenda%26aufirst%3DR.%26aulast%3DAliyu%26aufirst%3DS.%2BH.%26aulast%3DWilson%26aufirst%3DD.%26aulast%3DLe%26aufirst%3DT.%26aulast%3DOladele%26aufirst%3DR.%26aulast%3DLesikari%26aufirst%3DS.%26aulast%3DMuzoora%26aufirst%3DC.%26aulast%3DKalata%26aufirst%3DN.%26aulast%3DTemfack%26aufirst%3DE.%26aulast%3DMapoure%26aufirst%3DY.%26aulast%3DSini%26aufirst%3DV.%26aulast%3DChanda%26aufirst%3DD.%26aulast%3DShimwela%26aufirst%3DM.%26aulast%3DLakhi%26aufirst%3DS.%26aulast%3DNgoma%26aufirst%3DJ.%26aulast%3DGondwe-Chunda%26aufirst%3DL.%26aulast%3DPerfect%26aufirst%3DC.%26aulast%3DShroufi%26aufirst%3DA.%26aulast%3DAndrieux-Meyer%26aufirst%3DI.%26aulast%3DChan%26aufirst%3DA.%26aulast%3DSchutz%26aufirst%3DC.%26aulast%3DHosseinipour%26aufirst%3DM.%26aulast%3DVan%2Bder%2BHorst%26aufirst%3DC.%26aulast%3DKlausner%26aufirst%3DJ.%2BD.%26aulast%3DBoulware%26aufirst%3DD.%2BR.%26aulast%3DHeyderman%26aufirst%3DR.%26aulast%3DLalloo%26aufirst%3DD.%26aulast%3DDay%26aufirst%3DJ.%26aulast%3DJarvis%26aufirst%3DJ.%2BN.%26aulast%3DRodrigues%26aufirst%3DM.%26aulast%3DJaffar%26aufirst%3DS.%26aulast%3DDenning%26aufirst%3DD.%26aulast%3DMigone%26aufirst%3DC.%26aulast%3DDoherty%26aufirst%3DM.%26aulast%3DLortholary%26aufirst%3DO.%26aulast%3DDromer%26aufirst%3DF.%26aulast%3DStack%26aufirst%3DM.%26aulast%3DMolloy%26aufirst%3DS.%2BF.%26aulast%3DBicanic%26aufirst%3DT.%26aulast%3Dvan%2BOosterhout%26aufirst%3DJ.%26aulast%3DMwaba%26aufirst%3DP.%26aulast%3DKanyama%26aufirst%3DC.%26aulast%3DKouanfack%26aufirst%3DC.%26aulast%3DMfinanga%26aufirst%3DS.%26aulast%3DGovender%26aufirst%3DN.%26aulast%3DHarrison%26aufirst%3DT.%2BS.%26atitle%3DLeave%2520no%2520one%2520behind%253A%2520response%2520to%2520new%2520evidence%2520and%2520guidelines%2520for%2520the%2520management%2520of%2520cryptococcal%2520meningitis%2520in%2520low-income%2520and%2520middle-income%2520countries%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2019%26volume%3D19%26spage%3De143%26epage%3De147%26doi%3D10.1016%2FS1473-3099%2818%2930493-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maertens, J. A.</span></span> <span> </span><span class="NLM_article-title">History of the development of azole derivatives</span>. <i>Clin. Microbiol. Infect.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1111/j.1470-9465.2004.00841.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1111%2Fj.1470-9465.2004.00841.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=14748798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtFymu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=1-10&author=J.+A.+Maertens&title=History+of+the+development+of+azole+derivatives&doi=10.1111%2Fj.1470-9465.2004.00841.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">History of the development of azole derivatives</span></div><div class="casAuthors">Maertens, J. A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology and Infection</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">CMINFM</span>;
        ISSN:<span class="NLM_cas:issn">1198-743X</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Until the 1940s, relatively few agents were available for the treatment of systemic fungal infections.  The development of the polyene antifungals represented a major advance in medical mycol.  Although amphotericin B quickly became the mainstay of therapy for serious infections, its use was assocd. with infusion-related side-effects and dose-limiting nephrotoxicity.  The continued search for new and, less toxic antifungals led to the discovery of the azoles several decades later.  Ketoconazole, the first available compd. for the oral treatment of systemic fungal infections, was released in the early 1980s.  For almost a decade, ketoconazole was regarded as the drug of choice in nonlife-threatening endemic mycoses.  The introduction of the first-generation triazoles represented a second major advance in the treatment of fungal infections.  Both fluconazole and itraconazole displayed a broader spectrum of antifungal activity than the imidazoles and had a markedly improved safety profile compared with amphotericin B and ketoconazole.  Despite widespread use, however, these agents became subject to a no. of clin. important limitations related to their suboptimal spectrum of activity, the development of resistance, the induction of hazardous drug-drug interactions, their less than optimal pharmacokinetic profile (itraconazole capsules), and toxicity.  To overcome these limitations, several analogs have been developed.  These so-called 'second-generation' triazoles, including voriconazole, posaconazole and ravuconazole, have greater potency and possess increased activity against resistant and emerging pathogens, in particular against Aspergillus spp.  If the toxicity profile of these agents is comparable to or better than that of the first-generation triazoles and drug interactions remain manageable, then these compds. represent a true expansion of our antifungal arsenal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmvC1qYnP897Vg90H21EOLACvtfcHk0lgV6HOx1_JKug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtFymu7Y%253D&md5=d57e2d90d93844d58562d357652fd1d7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1111%2Fj.1470-9465.2004.00841.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1470-9465.2004.00841.x%26sid%3Dliteratum%253Aachs%26aulast%3DMaertens%26aufirst%3DJ.%2BA.%26atitle%3DHistory%2520of%2520the%2520development%2520of%2520azole%2520derivatives%26jtitle%3DClin.%2520Microbiol.%2520Infect.%26date%3D2004%26volume%3D10%26spage%3D1%26epage%3D10%26doi%3D10.1111%2Fj.1470-9465.2004.00841.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clay, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cioffi, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hisao, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuttle, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieuwkoop, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comellas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maryum, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uno, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildeman, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rienstra, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, M. D.</span></span> <span> </span><span class="NLM_article-title">Amphotericin forms an extramembranous and fungicidal sterol sponge</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">400</span>– <span class="NLM_lpage">406</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1496</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1038%2Fnchembio.1496" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=24681535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFOnu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=400-406&author=T.+M.+Andersonauthor=M.+C.+Clayauthor=A.+G.+Cioffiauthor=K.+A.+Diazauthor=G.+S.+Hisaoauthor=M.+D.+Tuttleauthor=A.+J.+Nieuwkoopauthor=G.+Comellasauthor=N.+Maryumauthor=S.+Wangauthor=B.+E.+Unoauthor=E.+L.+Wildemanauthor=T.+Gonenauthor=C.+M.+Rienstraauthor=M.+D.+Burke&title=Amphotericin+forms+an+extramembranous+and+fungicidal+sterol+sponge&doi=10.1038%2Fnchembio.1496"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Amphotericin forms an extramembranous and fungicidal sterol sponge</span></div><div class="casAuthors">Anderson, Thomas M.; Clay, Mary C.; Cioffi, Alexander G.; Diaz, Katrina A.; Hisao, Grant S.; Tuttle, Marcus D.; Nieuwkoop, Andrew J.; Comellas, Gemma; Maryum, Nashrah; Wang, Shu; Uno, Brice E.; Wildeman, Erin L.; Gonen, Tamir; Rienstra, Chad M.; Burke, Martin D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">400-406</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">For over 50 years, amphotericin has remained the powerful but highly toxic last line of defense in treating life-threatening fungal infections in humans with minimal development of microbial resistance.  Understanding how this small mol. kills yeast is thus crit. for guiding development of derivs. with an improved therapeutic index and other resistance-refractory antimicrobial agents.  In the widely accepted ion channel model for its mechanism of cytocidal action, amphotericin forms aggregates inside lipid bilayers that permeabilize and kill cells.  In contrast, the authors report that amphotericin exists primarily in the form of large, extramembranous aggregates that kill yeast by extg. ergosterol from lipid bilayers.  These findings reveal that extn. of a polyfunctional lipid underlies the resistance-refractory antimicrobial action of amphotericin and suggests a roadmap for sepg. its cytocidal and membrane-permeabilizing activities.  This new mechanistic understanding is also guiding development of what are to our knowledge the first derivs. of amphotericin that kill yeast but not human cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4oRh3dbpforVg90H21EOLACvtfcHk0lgV6HOx1_JKug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFOnu78%253D&md5=0c093fd6aecb24b98f31a9ee1c0bcecd</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1496%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DT.%2BM.%26aulast%3DClay%26aufirst%3DM.%2BC.%26aulast%3DCioffi%26aufirst%3DA.%2BG.%26aulast%3DDiaz%26aufirst%3DK.%2BA.%26aulast%3DHisao%26aufirst%3DG.%2BS.%26aulast%3DTuttle%26aufirst%3DM.%2BD.%26aulast%3DNieuwkoop%26aufirst%3DA.%2BJ.%26aulast%3DComellas%26aufirst%3DG.%26aulast%3DMaryum%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DUno%26aufirst%3DB.%2BE.%26aulast%3DWildeman%26aufirst%3DE.%2BL.%26aulast%3DGonen%26aufirst%3DT.%26aulast%3DRienstra%26aufirst%3DC.%2BM.%26aulast%3DBurke%26aufirst%3DM.%2BD.%26atitle%3DAmphotericin%2520forms%2520an%2520extramembranous%2520and%2520fungicidal%2520sterol%2520sponge%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26spage%3D400%26epage%3D406%26doi%3D10.1038%2Fnchembio.1496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbach, W. J.</span></span> <span> </span><span class="NLM_article-title">Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance</span>. <i>Eukaryotic Cell</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">747</span>– <span class="NLM_lpage">764</span>, <span class="refDoi"> DOI: 10.1128/EC.00041-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1128%2FEC.00041-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=18375617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmvVSrsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=747-764&author=L.+E.+Cowenauthor=W.+J.+Steinbach&title=Stress%2C+drugs%2C+and+evolution%3A+the+role+of+cellular+signaling+in+fungal+drug+resistance&doi=10.1128%2FEC.00041-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Stress, drugs, and evolution: The role of cellular signaling in fungal drug resistance</span></div><div class="casAuthors">Cowen, Leah E.; Steinbach, William J.</div><div class="citationInfo"><span class="NLM_cas:title">Eukaryotic Cell</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">747-764</span>CODEN:
                <span class="NLM_cas:coden">ECUEA2</span>;
        ISSN:<span class="NLM_cas:issn">1535-9786</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUWyPvwTDrFbVg90H21EOLACvtfcHk0lhON8VzLWYZlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmvVSrsro%253D&md5=a1be495a855797c0781cee6c9a6a0f21</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1128%2FEC.00041-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FEC.00041-08%26sid%3Dliteratum%253Aachs%26aulast%3DCowen%26aufirst%3DL.%2BE.%26aulast%3DSteinbach%26aufirst%3DW.%2BJ.%26atitle%3DStress%252C%2520drugs%252C%2520and%2520evolution%253A%2520the%2520role%2520of%2520cellular%2520signaling%2520in%2520fungal%2520drug%2520resistance%26jtitle%3DEukaryotic%2520Cell%26date%3D2008%26volume%3D7%26spage%3D747%26epage%3D764%26doi%3D10.1128%2FEC.00041-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span> <span> </span><span class="NLM_article-title">Regulatory circuitry governing fungal development, drug resistance, and disease</span>. <i>Microbiol. Mol. Biol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1128/MMBR.00045-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1128%2FMMBR.00045-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=21646428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpslOisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2011&pages=213-267&author=R.+S.+Shapiroauthor=N.+Robbinsauthor=L.+E.+Cowen&title=Regulatory+circuitry+governing+fungal+development%2C+drug+resistance%2C+and+disease&doi=10.1128%2FMMBR.00045-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Regulatory circuitry governing fungal development, drug resistance, and disease</span></div><div class="casAuthors">Shapiro, Rebecca S.; Robbins, Nicole; Cowen, Leah E.</div><div class="citationInfo"><span class="NLM_cas:title">Microbiology and Molecular Biology Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-267</span>CODEN:
                <span class="NLM_cas:coden">MMBRF7</span>;
        ISSN:<span class="NLM_cas:issn">1092-2172</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review.  Pathogenic fungi have become a leading cause of human mortality due to the increasing frequency of fungal infections in immunocompromised populations and the limited armamentarium of clin. useful antifungal drugs.  Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus are the leading causes of opportunistic fungal infections.  In these diverse pathogenic fungi, complex signal transduction cascades are crit. for sensing environmental changes and mediating appropriate cellular responses.  For C. albicans, several environmental cues regulate a morphogenetic switch from yeast to filamentous growth, a reversible transition important for virulence.  Many of the signaling cascades regulating morphogenesis are also required for cells to adapt and survive the cellular stresses imposed by antifungal drugs.  Many of these signaling networks are conserved in C. neoformans and A. fumigatus, which undergo distinct morphogenetic programs during specific phases of their life cycles.  Furthermore, the key mechanisms of fungal drug resistance, including alterations of the drug target, overexpression of drug efflux transporters, and alteration of cellular stress responses, are conserved between these species.  This review focuses on the circuitry regulating fungal morphogenesis and drug resistance and the impact of these pathways on virulence.  Although the three human-pathogenic fungi highlighted in this review are those most frequently encountered in the clinic, they represent a minute fraction of fungal diversity.  Exploration of the conservation and divergence of core signal transduction pathways across C. albicans, C. neoformans, and A. fumigatus provides a foundation for the study of a broader diversity of pathogenic fungi and a platform for the development of new therapeutic strategies for fungal disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDVkw0rexUfrVg90H21EOLACvtfcHk0lhON8VzLWYZlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpslOisbY%253D&md5=3b5e83c509ae56353be4148dd1fb2150</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1128%2FMMBR.00045-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMMBR.00045-10%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DR.%2BS.%26aulast%3DRobbins%26aufirst%3DN.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26atitle%3DRegulatory%2520circuitry%2520governing%2520fungal%2520development%252C%2520drug%2520resistance%252C%2520and%2520disease%26jtitle%3DMicrobiol.%2520Mol.%2520Biol.%2520Rev.%26date%3D2011%26volume%3D75%26spage%3D213%26epage%3D267%26doi%3D10.1128%2FMMBR.00045-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caplan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polvi, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckhalter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span> <span> </span><span class="NLM_article-title">Functional genomic screening reveals core modulators of echinocandin stress responses in <i>Candida albicans</i></span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2292</span>– <span class="NLM_lpage">2298</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2018.04.084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1016%2Fj.celrep.2018.04.084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=29791841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVSgtrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=2292-2298&author=T.+Caplanauthor=E.+J.+Polviauthor=J.+L.+Xieauthor=S.+Buckhalterauthor=M.+D.+Leachauthor=N.+Robbinsauthor=L.+E.+Cowen&title=Functional+genomic+screening+reveals+core+modulators+of+echinocandin+stress+responses+in+Candida+albicans&doi=10.1016%2Fj.celrep.2018.04.084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Functional Genomic Screening Reveals Core Modulators of Echinocandin Stress Responses in Candida albicans</span></div><div class="casAuthors">Caplan, Tavia; Polvi, Elizabeth J.; Xie, Jinglin L.; Buckhalter, Shoshana; Leach, Michelle D.; Robbins, Nicole; Cowen, Leah E.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2292-2298</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Candida albicans is a leading cause of death due to fungal infection.  Treatment of systemic candidiasis often relies on echinocandins, which disrupt cell wall synthesis.  Resistance is readily acquired via mutations in the drug target gene, FKS1.  Both basal tolerance and resistance to echinocandins require cellular stress responses.  We performed a systematic anal. of 3,030 C. albicans mutants to define circuitry governing cellular responses to echinocandins.  We identified 16 genes for which deletion or transcriptional repression enhanced echinocandin susceptibility, including components of the Pkc1-MAPK signaling cascade.  We discovered that the mol. chaperone Hsp90 is required for the stability of Pkc1 and Bck1, establishing key mechanisms through which Hsp90 mediates echinocandin resistance.  We also discovered that perturbation of the CCT chaperonin complex causes enhanced echinocandin sensitivity, altered cell wall architecture, and aberrant septin localization.  Thus, we provide insights into the mechanisms by which cellular chaperones enable crucial responses to echinocandin-induced stress.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9l_0NWj5xVLVg90H21EOLACvtfcHk0lg2sZamQ8OX9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVSgtrjO&md5=09d3c6dc6df400c435862cca5f5f7128</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2018.04.084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2018.04.084%26sid%3Dliteratum%253Aachs%26aulast%3DCaplan%26aufirst%3DT.%26aulast%3DPolvi%26aufirst%3DE.%2BJ.%26aulast%3DXie%26aufirst%3DJ.%2BL.%26aulast%3DBuckhalter%26aufirst%3DS.%26aulast%3DLeach%26aufirst%3DM.%2BD.%26aulast%3DRobbins%26aufirst%3DN.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26atitle%3DFunctional%2520genomic%2520screening%2520reveals%2520core%2520modulators%2520of%2520echinocandin%2520stress%2520responses%2520in%2520Candida%2520albicans%26jtitle%3DCell%2520Rep.%26date%3D2018%26volume%3D23%26spage%3D2292%26epage%3D2298%26doi%3D10.1016%2Fj.celrep.2018.04.084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caplan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span> <span> </span><span class="NLM_article-title">Molecular evolution of antifungal drug resistance</span>. <i>Annu. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">753</span>– <span class="NLM_lpage">775</span>, <span class="refDoi"> DOI: 10.1146/annurev-micro-030117-020345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1146%2Fannurev-micro-030117-020345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=28886681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKlurvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2017&pages=753-775&author=N.+Robbinsauthor=T.+Caplanauthor=L.+E.+Cowen&title=Molecular+evolution+of+antifungal+drug+resistance&doi=10.1146%2Fannurev-micro-030117-020345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Evolution of Antifungal Drug Resistance</span></div><div class="casAuthors">Robbins, Nicole; Caplan, Tavia; Cowen, Leah E.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Microbiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">753-775</span>CODEN:
                <span class="NLM_cas:coden">ARMIAZ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4227</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  The fungal pathogens Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus have transitioned from a rare curiosity to a leading cause of human mortality.  The management of infections caused by these organisms is intimately dependent on the efficacy of antifungal agents; however, fungi that are resistant to these treatments are regularly isolated in the clinic, impeding our ability to control infections.  Given the significant impact fungal pathogens have on human health, it is imperative to understand the mol. mechanisms that govern antifungal drug resistance.  This review describes our current knowledge of the mechanisms by which antifungal drug resistance evolves in exptl. populations and clin. settings.  We explore current antifungal treatment options and discuss promising strategies to impede the evolution of drug resistance.  By tackling antifungal drug resistance as an evolutionary problem, there is potential to improve the utility of current treatments and accelerate the development of novel therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf_rS6B3dA4bVg90H21EOLACvtfcHk0lg2sZamQ8OX9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKlurvE&md5=2eb2fbfc778bce94065a35e0bd9bea3b</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1146%2Fannurev-micro-030117-020345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-micro-030117-020345%26sid%3Dliteratum%253Aachs%26aulast%3DRobbins%26aufirst%3DN.%26aulast%3DCaplan%26aufirst%3DT.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26atitle%3DMolecular%2520evolution%2520of%2520antifungal%2520drug%2520resistance%26jtitle%3DAnnu.%2520Rev.%2520Microbiol.%26date%3D2017%26volume%3D71%26spage%3D753%26epage%3D775%26doi%3D10.1146%2Fannurev-micro-030117-020345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, N.</span>; <span class="NLM_string-name">Wright, G. D.</span>; <span class="NLM_string-name">Cowen, L. E.</span></span>, <span> </span><span class="NLM_article-title">Antifungal Drugs: the Current Armamentarium and Development of New Agents</span>. In  <i>The Fungal Kingdom</i>, <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, J.</span>; <span class="NLM_string-name">Howlett, B.</span>; <span class="NLM_string-name">Crous, P.</span>; <span class="NLM_string-name">Stukenbrock, E.</span>; <span class="NLM_string-name">James, T.</span>; <span class="NLM_string-name">Gow, N.</span></span>, Eds. <span class="NLM_publisher-name">ASM Press</span>: <span class="NLM_publisher-loc">Washington DC</span>., <span class="NLM_year">2017</span>; Vol.  <span class="NLM_volume">4</span>, pp  <span class="NLM_fpage">903</span>– <span class="NLM_lpage">922</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1128%2F9781555819583.ch44" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=903-922&author=N.+Robbins&author=G.+D.+Wright&author=L.+E.+Cowenauthor=J.+Heitman&author=B.+Howlett&author=P.+Crous&author=E.+Stukenbrock&author=T.+James&author=N.+Gow&title=The+Fungal+Kingdom"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1128%2F9781555819583.ch44&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1128%252F9781555819583.ch44%26sid%3Dliteratum%253Aachs%26aulast%3DRobbins%26aufirst%3DN.%26atitle%3DAntifungal%2520Drugs%253A%2520the%2520Current%2520Armamentarium%2520and%2520Development%2520of%2520New%2520Agents%26btitle%3DThe%2520Fungal%2520Kingdom%26aulast%3DHeitman%26aufirst%3DJ.%26pub%3DASM%2520Press%26date%3D2017%26volume%3D4%26spage%3D903%26epage%3D922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Meara, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veri, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polvi, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valaei, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diezmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span> <span> </span><span class="NLM_article-title">Mapping the Hsp90 genetic network reveals ergosterol biosynthesis and phosphatidylinositol-4-kinase signaling as core circuitry governing cellular stress</span>. <i>PLoS Genet.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e1006142</span> <span class="refDoi"> DOI: 10.1371/journal.pgen.1006142</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1371%2Fjournal.pgen.1006142" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=27341673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVyrs77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&author=T.+R.+O%E2%80%99Mearaauthor=A.+O.+Veriauthor=E.+J.+Polviauthor=X.+Liauthor=S.+F.+Valaeiauthor=S.+Diezmannauthor=L.+E.+Cowen&title=Mapping+the+Hsp90+genetic+network+reveals+ergosterol+biosynthesis+and+phosphatidylinositol-4-kinase+signaling+as+core+circuitry+governing+cellular+stress&doi=10.1371%2Fjournal.pgen.1006142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping the Hsp90 genetic network reveals ergosterol biosynthesis and phosphatidylinositol-4-kinase signaling as core circuitry governing cellular stress</span></div><div class="casAuthors">O'Meara, Teresa R.; Veri, Amanda O.; Polvi, Elizabeth J.; Li, Xinliu; Valaei, Seyedeh Fereshteh; Diezmann, Stephanie; Cowen, Leah E.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Genetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e1006142/1-e1006142/21</span>CODEN:
                <span class="NLM_cas:coden">PGLEB5</span>;
        ISSN:<span class="NLM_cas:issn">1553-7404</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Candida albicans is a leading human fungal pathogen that causes life-threatening systemic infections.  A key regulator of C. albicans stress response, drug resistance, morphogenesis, and virulence is the mol. chaperone Hsp90.  Targeting Hsp90 provides a powerful strategy to treat fungal infections; however, the therapeutic utility of current inhibitors is compromised by toxicity due to inhibition of host Hsp90.  To identify components of the Hsp90-dependent circuitry governing virulence and drug resistance that are sufficiently divergent for selective targeting in the pathogen, we pioneered chem. genomic profiling of the Hsp90 genetic network in C. albicans.  Here, we screen mutant collections covering ∼10% of the genome for hypersensitivity to Hsp90 inhibition in multiple environmental conditions.  We identify 158 HSP90 chem. genetic interactors, most of which are important for growth only in specific environments.  We discovered that the sterol C-22 desaturase gene ERG5 and the phosphatidylinositol-4-kinase (PI4K) gene STT4 are HSP90 genetic interactors under multiple conditions, suggesting a function upstream of Hsp90.  By systematic anal. of the ergosterol biosynthetic cascade, we demonstrate that defects in ergosterol biosynthesis induce cellular stress that overwhelms Hsp90's functional capacity.  By anal. of the phosphatidylinositol pathway, we demonstrate that there is a genetic interaction between the PI4K Stt4 and Hsp90.  We also establish that Stt4 is required for normal actin polarization through regulation of Wal1, and suggest a model in which defects in actin remodeling induces stress that creates a cellular demand for Hsp90 that exceeds its functional capacity.  Consistent with this model, actin inhibitors are synergistic with Hsp90 inhibitors.  We highlight new connections between Hsp90 and virulence traits, demonstrating that Erg5 and Stt4 enable activation of macrophage pyroptosis.  This work uncovers novel circuitry regulating Hsp90 functional capacity and new effectors governing drug resistance, morphogenesis, and virulence, revealing new targets for antifungal drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG2e3o6huNAbVg90H21EOLACvtfcHk0ljp0SPtK7jxmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVyrs77I&md5=40afaeaeec33813cc052b32b0b7625ca</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pgen.1006142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pgen.1006142%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DT.%2BR.%26aulast%3DVeri%26aufirst%3DA.%2BO.%26aulast%3DPolvi%26aufirst%3DE.%2BJ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DValaei%26aufirst%3DS.%2BF.%26aulast%3DDiezmann%26aufirst%3DS.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26atitle%3DMapping%2520the%2520Hsp90%2520genetic%2520network%2520reveals%2520ergosterol%2520biosynthesis%2520and%2520phosphatidylinositol-4-kinase%2520signaling%2520as%2520core%2520circuitry%2520governing%2520cellular%2520stress%26jtitle%3DPLoS%2520Genet.%26date%3D2016%26volume%3D12%26doi%3D10.1371%2Fjournal.pgen.1006142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardeshi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuomo, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span> <span> </span><span class="NLM_article-title">Genetic analysis of <i>Candida auris</i> implicates Hsp90 in morphogenesis and azole tolerance and Cdr1 in azole resistance</span>. <i>mBio</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e02529</span>– <span class="NLM_lpage">02518</span>, <span class="refDoi"> DOI: 10.1128/mBio.02529-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1128%2FmBio.02529-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=30696744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht12ht73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=e02529-02518&author=S.+H.+Kimauthor=K.+R.+Iyerauthor=L.+Pardeshiauthor=J.+F.+Munozauthor=N.+Robbinsauthor=C.+A.+Cuomoauthor=K.+H.+Wongauthor=L.+E.+Cowen&title=Genetic+analysis+of+Candida+auris+implicates+Hsp90+in+morphogenesis+and+azole+tolerance+and+Cdr1+in+azole+resistance&doi=10.1128%2FmBio.02529-18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic analysis of Candida auris implicates Hsp90 in morphogenesis and azole tolerance and Cdr1 in azole resistance</span></div><div class="casAuthors">Kim, Sang Hu; Iyer, Kali R.; Pardeshi, Lakhansing; Munoz, Jose F.; Robbins, Nicole; Cuomo, Christina A.; Wong, Koon Ho; Cowen, Leah E.</div><div class="citationInfo"><span class="NLM_cas:title">mBio</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e02529</span>CODEN:
                <span class="NLM_cas:coden">MBIOCL</span>;
        ISSN:<span class="NLM_cas:issn">2150-7511</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Candida auris is an emerging fungal pathogen and a serious global health threat as the majority of clin. isolates display elevated resistance to currently available antifungal drugs.  Despite the increased prevalence of C. auris infections, the mechanisms governing drug resistance remain largely elusive.  However, role of Hsp90 in the pathobiol. of C. auris remains unknown.  In order to study regulatory functions of Hsp90 in C. auris, we placed HSP90 under the control of a doxycycline-repressible promoter to enable transcriptional repression.  We found that Hsp90 is essential for growth in C. auris and that it enables tolerance of clin. isolates with respect to azoles, which inhibit biosynthesis of the membrane sterol ergosterol.  High-level azole resistance was independent of Hsp90 but dependent on the ABC transporter CDR1, deletion of which resulted in abrogated resistance.  Strikingly, we discovered that C. auris undergoes a morphogenetic transition from yeast to filamentous growth in response to HSP90 depletion or cell cycle arrest but not in response to other cues that induce C. albicans filamentation.  Finally, we obsd. that this developmental transition is assocd. with global transcriptional changes, including the induction of cell wall-related genes.  Overall, this report provides a novel insight into mechanisms of drug tolerance and resistance in C. auris and describes a developmental transition in response to perturbation of a core regulator of protein homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL3IYAhv3SN7Vg90H21EOLACvtfcHk0ljp0SPtK7jxmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht12ht73O&md5=673b28df89855de5ff4cd82eab83c550</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1128%2FmBio.02529-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FmBio.02529-18%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DIyer%26aufirst%3DK.%2BR.%26aulast%3DPardeshi%26aufirst%3DL.%26aulast%3DMunoz%26aufirst%3DJ.%2BF.%26aulast%3DRobbins%26aufirst%3DN.%26aulast%3DCuomo%26aufirst%3DC.%2BA.%26aulast%3DWong%26aufirst%3DK.%2BH.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26atitle%3DGenetic%2520analysis%2520of%2520Candida%2520auris%2520implicates%2520Hsp90%2520in%2520morphogenesis%2520and%2520azole%2520tolerance%2520and%2520Cdr1%2520in%2520azole%2520resistance%26jtitle%3DmBio%26date%3D2019%26volume%3D10%26spage%3De02529%26epage%3D02518%26doi%3D10.1128%2FmBio.02529-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veri, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebbji, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Meara, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colazo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vyas, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteway, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span> <span> </span><span class="NLM_article-title">Tuning Hsf1 levels drives distinct fungal morphogenetic programs with depletion impairing Hsp90 function and overexpression expanding the target space</span>. <i>PLoS Genet.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>, <span class="NLM_elocation-id">e1007270</span> <span class="refDoi"> DOI: 10.1371/journal.pgen.1007270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1371%2Fjournal.pgen.1007270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=29590106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslCgtrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&author=A.+O.+Veriauthor=Z.+Miaoauthor=R.+S.+Shapiroauthor=F.+Tebbjiauthor=T.+R.+O%E2%80%99Mearaauthor=S.+H.+Kimauthor=J.+Colazoauthor=K.+Tanauthor=V.+K.+Vyasauthor=M.+Whitewayauthor=N.+Robbinsauthor=K.+H.+Wongauthor=L.+E.+Cowen&title=Tuning+Hsf1+levels+drives+distinct+fungal+morphogenetic+programs+with+depletion+impairing+Hsp90+function+and+overexpression+expanding+the+target+space&doi=10.1371%2Fjournal.pgen.1007270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Tuning Hsf1 levels drives distinct fungal morphogenetic programs with depletion impairing Hsp90 function and overexpression expanding the target space</span></div><div class="casAuthors">Veri, Amanda O.; Miao, Zhengqiang; Shapiro, Rebecca S.; Tebbji, Faiza; O'meara, Teresa R.; Kim, Sang Hu; Colazo, Juan; Tan, Kaeling; Vyas, Valmik K.; Whiteway, Malcolm; Robbins, Nicole; Wong, Koon Ho; Cowen, Leah E.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Genetics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e1007270/1-e1007270/39</span>CODEN:
                <span class="NLM_cas:coden">PGLEB5</span>;
        ISSN:<span class="NLM_cas:issn">1553-7404</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The capacity to respond to temp. fluctuations is crit. for microorganisms to survive within mammalian hosts, and temp. modulates virulence traits of diverse pathogens.  One key temp.-dependent virulence trait of the fungal pathogen Candida albicans is its ability to transition from yeast to filamentous growth, which is induced by environmental cues at host physiol. temp.  A key regulator of temp.-dependent morphogenesis is the mol. chaperone Hsp90, which has complex functional relationships with the transcription factor Hsf1.  Although Hsf1 controls global transcriptional remodeling in response to heat shock, its impact on morphogenesis remains unknown.  Here, we establish an intriguing paradigm whereby overexpression or depletion of C. albicansHSF1 induces morphogenesis in the absence of external cues.  HSF1 depletion compromises Hsp90 function, thereby driving filamentation.  HSF1 overexpression does not impact Hsp90 function, but rather induces a dose-dependent expansion of Hsf1 direct targets that drives overexpression of pos. regulators of filamentation, including Brg1 and Ume6, thereby bypassing the requirement for elevated temp. during morphogenesis.  This work provides new insight into Hsf1-mediated environmentally contingent transcriptional control, implicates Hsf1 in regulation of a key virulence trait, and highlights fascinating biol. whereby either overexpression or depletion of a single cellular regulator induces a profound developmental transition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMfGoaF-w23bVg90H21EOLACvtfcHk0lgtMkEgiY8yqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslCgtrnJ&md5=305df6345b9b590c80a669ae63e4229e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pgen.1007270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pgen.1007270%26sid%3Dliteratum%253Aachs%26aulast%3DVeri%26aufirst%3DA.%2BO.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DShapiro%26aufirst%3DR.%2BS.%26aulast%3DTebbji%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DT.%2BR.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DColazo%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DK.%26aulast%3DVyas%26aufirst%3DV.%2BK.%26aulast%3DWhiteway%26aufirst%3DM.%26aulast%3DRobbins%26aufirst%3DN.%26aulast%3DWong%26aufirst%3DK.%2BH.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26atitle%3DTuning%2520Hsf1%2520levels%2520drives%2520distinct%2520fungal%2520morphogenetic%2520programs%2520with%2520depletion%2520impairing%2520Hsp90%2520function%2520and%2520overexpression%2520expanding%2520the%2520target%2520space%26jtitle%3DPLoS%2520Genet.%26date%3D2018%26volume%3D14%26doi%3D10.1371%2Fjournal.pgen.1007270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Meara, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span> <span> </span><span class="NLM_article-title">The Hsp90 chaperone network modulates <i>Candida</i> virulence traits</span>. <i>Trends Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">809</span>– <span class="NLM_lpage">819</span>, <span class="refDoi"> DOI: 10.1016/j.tim.2017.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1016%2Fj.tim.2017.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=28549824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A280%3ADC%252BC1cnhvVWgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=809-819&author=T.+R.+O%E2%80%99Mearaauthor=N.+Robbinsauthor=L.+E.+Cowen&title=The+Hsp90+chaperone+network+modulates+Candida+virulence+traits&doi=10.1016%2Fj.tim.2017.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The Hsp90 Chaperone Network Modulates Candida Virulence Traits</span></div><div class="casAuthors">O'Meara Teresa R; Robbins Nicole; Cowen Leah E</div><div class="citationInfo"><span class="NLM_cas:title">Trends in microbiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">809-819</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hsp90 is a conserved molecular chaperone that facilitates the folding and function of client proteins.  Hsp90 function is dynamically regulated by interactions with co-chaperones and by post-translational modifications.  In the fungal pathogen Candida albicans, Hsp90 enables drug resistance and virulence by stabilizing diverse signal transducers.  Here, we review studies that have unveiled regulators of Hsp90 function, as well as downstream effectors that govern the key virulence traits of morphogenesis and drug resistance.  We highlight recent work mapping the Hsp90 genetic network in C. albicans under diverse environmental conditions, and how these interactions provide insight into circuitry important for drug resistance, morphogenesis, and virulence.  Ultimately, elucidating the Hsp90 chaperone network will aid in the development of therapeutics to treat fungal disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQIfwZvIeSQw1QKX3ooHxWjfW6udTcc2eZF-2BHIvhYp7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnhvVWgtQ%253D%253D&md5=e4d32d19bc2ed5f682a2048682cb6dd7</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.tim.2017.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tim.2017.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DT.%2BR.%26aulast%3DRobbins%26aufirst%3DN.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26atitle%3DThe%2520Hsp90%2520chaperone%2520network%2520modulates%2520Candida%2520virulence%2520traits%26jtitle%3DTrends%2520Microbiol.%26date%3D2017%26volume%3D25%26spage%3D809%26epage%3D819%26doi%3D10.1016%2Fj.tim.2017.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leach, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klipp, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. J.</span></span> <span> </span><span class="NLM_article-title">Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs</span>. <i>Nat. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">704</span>, <span class="refDoi"> DOI: 10.1038/nrmicro2875</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1038%2Fnrmicro2875" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=22976491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlertbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2012&pages=693-704&author=M.+D.+Leachauthor=E.+Klippauthor=L.+E.+Cowenauthor=A.+J.+Brown&title=Fungal+Hsp90%3A+a+biological+transistor+that+tunes+cellular+outputs+to+thermal+inputs&doi=10.1038%2Fnrmicro2875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs</span></div><div class="casAuthors">Leach, Michelle D.; Klipp, Edda; Cowen, Leah E.; Brown, Alistair J. P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Microbiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">693-704</span>CODEN:
                <span class="NLM_cas:coden">NRMACK</span>;
        ISSN:<span class="NLM_cas:issn">1740-1526</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Heat shock protein 90 (Hsp90) is an essential, abundant and ubiquitous eukaryotic chaperone that has crucial roles in protein folding and modulates the activities of key regulators.  The fungal Hsp90 interactome, which includes numerous client proteins such as receptors, protein kinases and transcription factors, displays a surprisingly high degree of plasticity that depends on environmental conditions.  Furthermore, although fungal Hsp90 levels increase following environmental challenges, Hsp90 activity is tightly controlled via post-translational regulation and an autoregulatory loop involving heat shock transcription factor 1 (Hsf1).  In this Review, we discuss the roles and regulation of fungal Hsp90.  We propose that Hsp90 acts as a biol. transistor that modulates the activity of fungal signaling networks in response to environmental cues via this Hsf1-Hsp90 autoregulatory loop.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxYlx4CLzINrVg90H21EOLACvtfcHk0lgrAgrnZQMaGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlertbnM&md5=26880d38c60d1a9d83c84328240b0e35</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrmicro2875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrmicro2875%26sid%3Dliteratum%253Aachs%26aulast%3DLeach%26aufirst%3DM.%2BD.%26aulast%3DKlipp%26aufirst%3DE.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26aulast%3DBrown%26aufirst%3DA.%2BJ.%26atitle%3DFungal%2520Hsp90%253A%2520a%2520biological%2520transistor%2520that%2520tunes%2520cellular%2520outputs%2520to%2520thermal%2520inputs%26jtitle%3DNat.%2520Rev.%2520Microbiol.%26date%3D2012%26volume%3D10%26spage%3D693%26epage%3D704%26doi%3D10.1038%2Fnrmicro2875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindquist, S.</span></span> <span> </span><span class="NLM_article-title">Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>309</i></span>,  <span class="NLM_fpage">2185</span>– <span class="NLM_lpage">2189</span>, <span class="refDoi"> DOI: 10.1126/science.1118370</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1126%2Fscience.1118370" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=16195452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeksbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2005&pages=2185-2189&author=L.+E.+Cowenauthor=S.+Lindquist&title=Hsp90+potentiates+the+rapid+evolution+of+new+traits%3A+drug+resistance+in+diverse+fungi&doi=10.1126%2Fscience.1118370"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 potentiates the rapid evolution of new traits: Drug resistance in diverse fungi</span></div><div class="casAuthors">Cowen, Leah E.; Lindquist, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">309</span>
        (<span class="NLM_cas:issue">5744</span>),
    <span class="NLM_cas:pages">2185-2189</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Hsp90 is a mol. chaperone for many signal transducers and may influence evolution by releasing previously silent genetic variation in response to environmental change.  In fungi sepd. by ∼800 million years of evolution, Hsp90 potentiated the evolution of drug resistance in a different way, by enabling new mutations to have immediate phenotypic consequences.  Resistance was abrogated by Hsp90 inhibitors and by febrile temps., suggesting new therapeutic strategies and a clin. benefit of fever.  During selection in a human host, drug resistance that was initially Hsp90-dependent evolved toward independence.  Thus, Hsp90 can act in diverse ways to couple environmental contingency to the emergence and fixation of new traits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiYEERY_9yw7Vg90H21EOLACvtfcHk0lgrAgrnZQMaGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeksbbI&md5=153bda853d501270402f5e18ab14b5d8</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1126%2Fscience.1118370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1118370%26sid%3Dliteratum%253Aachs%26aulast%3DCowen%26aufirst%3DL.%2BE.%26aulast%3DLindquist%26aufirst%3DS.%26atitle%3DHsp90%2520potentiates%2520the%2520rapid%2520evolution%2520of%2520new%2520traits%253A%2520drug%2520resistance%2520in%2520diverse%2520fungi%26jtitle%3DScience%26date%3D2005%26volume%3D309%26spage%3D2185%26epage%3D2189%26doi%3D10.1126%2Fscience.1118370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaas, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schell, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perfect, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span> <span> </span><span class="NLM_article-title">Hsp90 governs echinocandin resistance in the pathogenic yeast <i>Candida albicans</i> via calcineurin</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e1000532</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1000532</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1371%2Fjournal.ppat.1000532" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=19649312" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&author=S.+D.+Singhauthor=N.+Robbinsauthor=A.+K.+Zaasauthor=W.+A.+Schellauthor=J.+R.+Perfectauthor=L.+E.+Cowen&title=Hsp90+governs+echinocandin+resistance+in+the+pathogenic+yeast+Candida+albicans+via+calcineurin&doi=10.1371%2Fjournal.ppat.1000532"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1000532&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1000532%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DS.%2BD.%26aulast%3DRobbins%26aufirst%3DN.%26aulast%3DZaas%26aufirst%3DA.%2BK.%26aulast%3DSchell%26aufirst%3DW.%2BA.%26aulast%3DPerfect%26aufirst%3DJ.%2BR.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26atitle%3DHsp90%2520governs%2520echinocandin%2520resistance%2520in%2520the%2520pathogenic%2520yeast%2520Candida%2520albicans%2520via%2520calcineurin%26jtitle%3DPLoS%2520Pathog.%26date%3D2009%26volume%3D5%26doi%3D10.1371%2Fjournal.ppat.1000532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohler, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaas, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schell, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aziz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mylonakis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perfect, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindquist, S.</span></span> <span> </span><span class="NLM_article-title">Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">2818</span>– <span class="NLM_lpage">2823</span>, <span class="refDoi"> DOI: 10.1073/pnas.0813394106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1073%2Fpnas.0813394106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=19196973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD1MXislaht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=2818-2823&author=L.+E.+Cowenauthor=S.+D.+Singhauthor=J.+R.+Kohlerauthor=C.+Collinsauthor=A.+K.+Zaasauthor=W.+A.+Schellauthor=H.+Azizauthor=E.+Mylonakisauthor=J.+R.+Perfectauthor=L.+Whitesellauthor=S.+Lindquist&title=Harnessing+Hsp90+function+as+a+powerful%2C+broadly+effective+therapeutic+strategy+for+fungal+infectious+disease&doi=10.1073%2Fpnas.0813394106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease</span></div><div class="casAuthors">Cowen, Leah E.; Singh, Sheena D.; Kohler, Julia R.; Collins, Cathy; Zaas, Aimee; Schell, Wiley A.; Aziz, Hamza; Mylonakis, Eleftherios; Perfect, John R.; Whitesell, Luke; Lindquist, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2818-2823</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Invasive fungal infections are a leading cause of mortality among immunocompromised individuals.  Treatment is notoriously difficult with the limited armamentarium of antifungal drugs, whose efficacy is compromised by host toxicity, a limited activity spectrum, or the emergence of drug resistance.  We previously established that the mol. chaperone Hsp90 enables the emergence and maintenance of fungal drug resistance.  For the most prevalent fungal pathogen of humans, Candida albicans, Hsp90 mediates resistance to azoles, which inhibit ergosterol biosynthesis and are the most widely deployed antifungals in the clinic.  For the emerging opportunistic pathogen Aspergillus terreus, Hsp90 is required for basal resistance to echinocandins, which inhibit β(1, 3)-glucan synthesis and are the only new class of antifungals to reach the clinic in decades.  Here, we explore the therapeutic potential of Hsp90 inhibitors in fungal disease using a tractable host-model system, larvae of the greater wax moth Galleria mellonella, and a murine model of disseminated disease.  Combination therapy with Hsp90 inhibitors that are well tolerated in humans and an azole rescued larvae from lethal C. albicans infections.  Combination therapy with an Hsp90 inhibitor and an echinocandin rescued larvae from infections with the most lethal mold, Aspergillus fumigatus.  In a murine model of disseminated candidiasis, genetic compromise of C. albicans HSP90 expression enhanced the therapeutic efficacy of an azole.  Thus, harnessing Hsp90 provides a much-needed strategy for improving the treatment of fungal disease because it enhances the efficacy of existing antifungals, blocks the emergence of drug resistance, and exerts broad-spectrum activity against diverse fungal pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtMf02gFiLZLVg90H21EOLACvtfcHk0lip-geqwYP7Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXislaht7s%253D&md5=a0bf89b9285831333d619bb9edc8f4ef</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0813394106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0813394106%26sid%3Dliteratum%253Aachs%26aulast%3DCowen%26aufirst%3DL.%2BE.%26aulast%3DSingh%26aufirst%3DS.%2BD.%26aulast%3DKohler%26aufirst%3DJ.%2BR.%26aulast%3DCollins%26aufirst%3DC.%26aulast%3DZaas%26aufirst%3DA.%2BK.%26aulast%3DSchell%26aufirst%3DW.%2BA.%26aulast%3DAziz%26aufirst%3DH.%26aulast%3DMylonakis%26aufirst%3DE.%26aulast%3DPerfect%26aufirst%3DJ.%2BR.%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DLindquist%26aufirst%3DS.%26atitle%3DHarnessing%2520Hsp90%2520function%2520as%2520a%2520powerful%252C%2520broadly%2520effective%2520therapeutic%2520strategy%2520for%2520fungal%2520infectious%2520disease%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D2818%26epage%3D2823%26doi%3D10.1073%2Fpnas.0813394106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatu, U.</span></span> <span> </span><span class="NLM_article-title">Heat shock protein 90 localizes to the surface and augments virulence factors of <i>Cryptococcus neoformans</i></span>. <i>PLoS Negl. Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">e0005836</span> <span class="refDoi"> DOI: 10.1371/journal.pntd.0005836</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1371%2Fjournal.pntd.0005836" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=28783748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVCltbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&author=S.+Chatterjeeauthor=U.+Tatu&title=Heat+shock+protein+90+localizes+to+the+surface+and+augments+virulence+factors+of+Cryptococcus+neoformans&doi=10.1371%2Fjournal.pntd.0005836"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Heat shock protein 90 localizes to the surface and augments virulence factors of Cryptococcus neoformans</span></div><div class="casAuthors">Chatterjee, Sharanya; Tatu, Utpal</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e0005836/1-e0005836/20</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background Thermotolerance is an essential attribute for pathogenesis of Cryptococcus as exemplified by the fact that only two species in the genus, which can grow at 37°C, are human pathogens.  Species which have other virulence factors including capsule formation and melanisation, but lack the ability to propagate at 37°C are not pathogenic.  In another related fungal pathogen, Candida albicans, heat shock protein 90 has been implicated to be a central player in commanding pathogenicity by governing yeast to hyphal transition and drug resistance.  Exploring Hsp90 biol. in Cryptococcus in context of thermotolerance may thus highlight important regulatory principles of virulence and open new therapeutic avenues.  Methodol./Principal findings Hsp90 is involved in regulating thermotolerance in Cryptococcus as indicated by growth hypersensitivity at 37°C upon mild compromise of Hsp90 function relative to 25°C.  Biochem. studies revealed a more potent inhibition of ATPase activity by pharmacol. inhibitor 17-AAG at 37°C as compared to 25°C.  Catalytic efficiency of the protein at 37°C was found to be 6.39 × 10-5μM-1.  Furthermore, indirect immunofluorescence anal. using a specific antibody revealed cell surface localization of Hsp90 via ER Golgi classical secretory pathway.  Hsp90 was found to be induced under capsule inducing conditions and Hsp90 inhibition led to decrease in capsular vol.  Finally compromising Hsp90 function improved anidulafungin tolerance in Cryptococcus.  Conclusions/Significance Our findings highlight that Hsp90 regulates pathogenicity of the fungus by myriad ways.  Firstly, it is involved in mediating thermotolerance which implies targeting Hsp90 can abrogate thermotolerance and hence growth of the fungus.  Secondly, this study provides the first report of biochem. properties of Hsp90 of a pathogenic fungus.  Finally, since Hsp90 is localised at the cell wall, targeting cell surface Hsp90 can represent a novel strategy to combat this lethal infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox--VK--z5SLVg90H21EOLACvtfcHk0lip-geqwYP7Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVCltbjF&md5=d268755893a680cd9ef4f3e35e88690c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0005836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0005836%26sid%3Dliteratum%253Aachs%26aulast%3DChatterjee%26aufirst%3DS.%26aulast%3DTatu%26aufirst%3DU.%26atitle%3DHeat%2520shock%2520protein%252090%2520localizes%2520to%2520the%2520surface%2520and%2520augments%2520virulence%2520factors%2520of%2520Cryptococcus%2520neoformans%26jtitle%3DPLoS%2520Negl.%2520Trop.%2520Dis.%26date%3D2017%26volume%3D11%26doi%3D10.1371%2Fjournal.pntd.0005836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Aguiar Cordeiro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evangelista, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serpa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marques, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Melo, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Oliveira, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco Jda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Alencar, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandeira Tde, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brilhante, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidrim, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocha, M. F.</span></span> <span> </span><span class="NLM_article-title">, Inhibition of heat-shock protein 90 enhances the susceptibility to antifungals and reduces the virulence of <i>Cryptococcus neoformans</i>/<i>Cryptococcus gattii</i> species complex</span>. <i>Microbiology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1099/mic.0.000222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1099%2Fmic.0.000222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=26645478" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2016&pages=309-317&author=R.+de%0AAguiar+Cordeiroauthor=A.+J.+Evangelistaauthor=R.+Serpaauthor=F.+J.+Marquesauthor=C.+V.+de+Meloauthor=J.+S.+de+Oliveiraauthor=S.+Franco+Jdaauthor=L.+P.+de+Alencarauthor=J.+Bandeira+Tdeauthor=R.+S.+Brilhanteauthor=J.+J.+Sidrimauthor=M.+F.+Rocha&title=%2C+Inhibition+of+heat-shock+protein+90+enhances+the+susceptibility+to+antifungals+and+reduces+the+virulence+of+Cryptococcus+neoformans%2FCryptococcus+gattii+species+complex&doi=10.1099%2Fmic.0.000222"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1099%2Fmic.0.000222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fmic.0.000222%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BAguiar%2BCordeiro%26aufirst%3DR.%26aulast%3DEvangelista%26aufirst%3DA.%2BJ.%26aulast%3DSerpa%26aufirst%3DR.%26aulast%3DMarques%26aufirst%3DF.%2BJ.%26aulast%3Dde%2BMelo%26aufirst%3DC.%2BV.%26aulast%3Dde%2BOliveira%26aufirst%3DJ.%2BS.%26aulast%3DFranco%2BJda%26aufirst%3DS.%26aulast%3Dde%2BAlencar%26aufirst%3DL.%2BP.%26aulast%3DBandeira%2BTde%26aufirst%3DJ.%26aulast%3DBrilhante%26aufirst%3DR.%2BS.%26aulast%3DSidrim%26aufirst%3DJ.%2BJ.%26aulast%3DRocha%26aufirst%3DM.%2BF.%26atitle%3D%252C%2520Inhibition%2520of%2520heat-shock%2520protein%252090%2520enhances%2520the%2520susceptibility%2520to%2520antifungals%2520and%2520reduces%2520the%2520virulence%2520of%2520Cryptococcus%2520neoformans%252FCryptococcus%2520gattii%2520species%2520complex%26jtitle%3DMicrobiology%26date%3D2016%26volume%3D162%26spage%3D309%26epage%3D317%26doi%3D10.1099%2Fmic.0.000222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Q. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. L.</span></span> <span> </span><span class="NLM_article-title">Heat shock protein 90 inhibitors: An update on achievements, challenges, and future directions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1798</span>– <span class="NLM_lpage">1822</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00940</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00940" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVKkurvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1798-1822&author=L.+Liauthor=L.+Wangauthor=Q.+D.+Youauthor=X.+L.+Xu&title=Heat+shock+protein+90+inhibitors%3A+An+update+on+achievements%2C+challenges%2C+and+future+directions&doi=10.1021%2Facs.jmedchem.9b00940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions</span></div><div class="casAuthors">Li, Li; Wang, Lei; You, Qi-Dong; Xu, Xiao-Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1798-1822</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Hsp90 is one of the most important chaperones involved in regulating the maturation of more than 300 client proteins, many of which are closely assocd. with refractory diseases, including cancer, neurodegenerative diseases and viral infections.  Clin. Hsp90 inhibitors bind to the ATP pocket in the N-terminal domain of Hsp90 and subsequently suppress the ATPase activity of Hsp90.  Recently, with the increased understanding of the discrepancies in the isoforms of Hsp90 and the modes of Hsp90-cochaperone-client complex interactions, some new strategies for Hsp90 inhibition have emerged.  Novel Hsp90 inhibitors that offer selective suppression of Hsp90 isoforms or specific disruption of Hsp90-cochaperone protein-protein interactions are expected to breakthrough with satisfactory efficacy and safety profiles.  This review summarizes the recent progress in Hsp90 inhibitors.  Addnl., Hsp90 inhibitory strategies are emphasized in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkbKTcDYjrzrVg90H21EOLACvtfcHk0lgCyl3XSRDlAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVKkurvO&md5=972a35d1b12f5e21a7fa27cbb6bfc0cd</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00940%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYou%26aufirst%3DQ.%2BD.%26aulast%3DXu%26aufirst%3DX.%2BL.%26atitle%3DHeat%2520shock%2520protein%252090%2520inhibitors%253A%2520An%2520update%2520on%2520achievements%252C%2520challenges%252C%2520and%2520future%2520directions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1798%26epage%3D1822%26doi%3D10.1021%2Facs.jmedchem.9b00940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jaeger, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stopfer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaglia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santagata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, N. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trepel, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacks, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindquist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, L.</span></span> <span> </span><span class="NLM_article-title">Rebalancing protein homeostasis enhances tumor antigen presentation</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">6392</span>– <span class="NLM_lpage">6405</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-19-0596</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1158%2F1078-0432.CCR-19-0596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=31213460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVSmsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=6392-6405&author=A.+M.+Jaegerauthor=L.+Stopferauthor=S.+Leeauthor=G.+Gagliaauthor=D.+Sandelauthor=S.+Santagataauthor=N.+U.+Linauthor=J.+B.+Trepelauthor=F.+Whiteauthor=T.+Jacksauthor=S.+Lindquistauthor=L.+Whitesell&title=Rebalancing+protein+homeostasis+enhances+tumor+antigen+presentation&doi=10.1158%2F1078-0432.CCR-19-0596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Rebalancing protein homeostasis enhances tumor antigen presentation</span></div><div class="casAuthors">Jaeger, Alex M.; Stopfer, Lauren; Lee, Sunmin; Gaglia, Giorgio; Sandel, Demi; Santagata, Sandro; Lin, Nancy U.; Trepel, Jane B.; White, Forest; Jacks, Tyler; Lindquis, Susan; Whitesell, Luke</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6392-6405</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Despite the accumulation of extensive genomic alterations, many cancers fail to be recognized as "foreign" and escape destruction by the host immune system.  Immunotherapies designed to address this problem by directly stimulating immune effector cells have led to some remarkable clin. outcomes, but unfortunately, most cancers fail to respond, prompting the need to identify addnl. immunomodulatory treatment options.  Exptl. Design: We elucidated the effect of a novel treatment paradigm using sustained, low-dose HSP90 inhibition in vitro and in syngeneic mouse models using genetic and pharmacol. tools.  Profiling of treatment-assocd. tumor cell antigens was performed using immunopptn. followed by peptide mass spectrometry.  Results: We show that sustained, low-level inhibition of HSP90 both amplifies and diversifies the antigenic repertoire presented by tumor cells on MHC-I mols. through an IFNγ-independent mechanism.  In stark contrast, we find that acute, high-dose exposure to HSP90 inhibitors, the only approach studied in the clinic to date, is broadly immunosuppressive in cell culture and in patients with cancer.  In mice, chronic non-heat shock-inducing HSP90 inhibition slowed progression of colon cancer implants, but only in syngeneic animals with intact immune function.  Addn. of a single dose of nonspecific immune adjuvant to the regimen dramatically increased efficacy, curing a subset of mice receiving combination therapy.  Conclusions: These highly translatable observations support reconsideration of the most effective strategy for targeting HSP90 to treat cancers and suggest a practical approach to repurposing current orally bioavailable HSP90 inhibitors as a new immunotherapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0-I8CkNNE0LVg90H21EOLACvtfcHk0ljdLJFfV0zDpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVSmsrvJ&md5=f35aa9e0e1ba541e3b79461ae2db4b4a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-19-0596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-19-0596%26sid%3Dliteratum%253Aachs%26aulast%3DJaeger%26aufirst%3DA.%2BM.%26aulast%3DStopfer%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DGaglia%26aufirst%3DG.%26aulast%3DSandel%26aufirst%3DD.%26aulast%3DSantagata%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DN.%2BU.%26aulast%3DTrepel%26aufirst%3DJ.%2BB.%26aulast%3DWhite%26aufirst%3DF.%26aulast%3DJacks%26aufirst%3DT.%26aulast%3DLindquist%26aufirst%3DS.%26aulast%3DWhitesell%26aufirst%3DL.%26atitle%3DRebalancing%2520protein%2520homeostasis%2520enhances%2520tumor%2520antigen%2520presentation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D25%26spage%3D6392%26epage%3D6405%26doi%3D10.1158%2F1078-0432.CCR-19-0596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jaeger, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, L.</span></span> <span> </span><span class="NLM_article-title">HSP90: Enabler of cancer adaptation</span>. <i>Annu. Rev. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">297</span>, <span class="refDoi"> DOI: 10.1146/annurev-cancerbio-030518-055533</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1146%2Fannurev-cancerbio-030518-055533" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2019&pages=275-297&author=A.+M.+Jaegerauthor=L.+Whitesell&title=HSP90%3A+Enabler+of+cancer+adaptation&doi=10.1146%2Fannurev-cancerbio-030518-055533"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1146%2Fannurev-cancerbio-030518-055533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-cancerbio-030518-055533%26sid%3Dliteratum%253Aachs%26aulast%3DJaeger%26aufirst%3DA.%2BM.%26aulast%3DWhitesell%26aufirst%3DL.%26atitle%3DHSP90%253A%2520Enabler%2520of%2520cancer%2520adaptation%26jtitle%3DAnnu.%2520Rev.%2520Cancer%2520Biol.%26date%3D2019%26volume%3D3%26spage%3D275%26epage%3D297%26doi%3D10.1146%2Fannurev-cancerbio-030518-055533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gewirth, D. T.</span></span> <span> </span><span class="NLM_article-title">Paralog specific Hsp90 inhibitors - a brief history and a bright future</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2779</span>– <span class="NLM_lpage">2791</span>, <span class="refDoi"> DOI: 10.2174/1568026616666160413141154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.2174%2F1568026616666160413141154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=27072700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOhsrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=2779-2791&author=D.+T.+Gewirth&title=Paralog+specific+Hsp90+inhibitors+-+a+brief+history+and+a+bright+future&doi=10.2174%2F1568026616666160413141154"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Paralog Specific Hsp90 Inhibitors - A Brief History and a Bright Future</span></div><div class="casAuthors">Gewirth, Daniel T.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2779-2791</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background. The high sequence and structural homol. among the hsp90 paralogs - Hsp90α, Hsp90β, Grp94, and Trap-1 - has made the development of paralog-specific inhibitors a challenging proposition.  Objective. This review surveys the state of developments in structural anal., compd. screening, and structure-based design that have been brought to bear on this problem.  Results. First generation compds. that selectively bind to Hsp90, Grp94, or Trap-1 have been identified.  Conclusion. With the proof of principle firmly established, the prospects for further progress are bright.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdyZyrXOyou7Vg90H21EOLACvtfcHk0ljdLJFfV0zDpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOhsrzN&md5=208025ff36aa6e2d92d3ee107b20ab5f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.2174%2F1568026616666160413141154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026616666160413141154%26sid%3Dliteratum%253Aachs%26aulast%3DGewirth%26aufirst%3DD.%2BT.%26atitle%3DParalog%2520specific%2520Hsp90%2520inhibitors%2520-%2520a%2520brief%2520history%2520and%2520a%2520bright%2520future%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2016%26volume%3D16%26spage%3D2779%26epage%3D2791%26doi%3D10.2174%2F1568026616666160413141154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheon, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, B. H.</span></span> <span> </span><span class="NLM_article-title">Development of a mitochondria-targeted Hsp90 inhibitor based on the crystal structures of human TRAP1</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">4358</span>– <span class="NLM_lpage">4367</span>, <span class="refDoi"> DOI: 10.1021/ja511893n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja511893n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksl2htrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=4358-4367&author=C.+Leeauthor=H.+K.+Parkauthor=H.+Jeongauthor=J.+Limauthor=A.+J.+Leeauthor=K.+Y.+Cheonauthor=C.+S.+Kimauthor=A.+P.+Thomasauthor=B.+Baeauthor=N.+D.+Kimauthor=S.+H.+Kimauthor=P.+G.+Suhauthor=J.+H.+Ryuauthor=B.+H.+Kang&title=Development+of+a+mitochondria-targeted+Hsp90+inhibitor+based+on+the+crystal+structures+of+human+TRAP1&doi=10.1021%2Fja511893n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Mitochondria-Targeted Hsp90 Inhibitor Based on the Crystal Structures of Human TRAP1</span></div><div class="casAuthors">Lee, Changwook; Park, Hye-Kyung; Jeong, Hanbin; Lim, Jaehwa; Lee, An-Jung; Cheon, Keun Young; Kim, Chul-Su; Thomas, Ajesh P.; Bae, Boram; Kim, Nam Doo; Kim, Seong Heon; Suh, Pann-Ghill; Ryu, Ja-Hyoung; Kang, Byoung Heon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4358-4367</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The mitochondrial pool of Hsp90 and its mitochondrial paralog, TRAP1, suppresses cell death and reprograms energy metab. in cancer cells; therefore, Hsp90 and TRAP1 have been suggested as target proteins for anticancer drug development.  Here, the authors report that the actual target protein in cancer cell mitochondria is TRAP1, and current Hsp90 inhibitors cannot effectively inactivate TRAP1 because of their insufficient accumulation in the mitochondria.  To develop mitochondrial TRAP1 inhibitors, the authors detd. the crystal structures of human TRAP1 complexed with Hsp90 inhibitors.  The iso-Pr amine of the Hsp90 inhibitor PU-H71 was replaced with the mitochondria-targeting moiety triphenylphosphonium to produce SMTIN-P01.  SMTIN-P01 showed a different mode of action from the nontargeted PU-H71, as well as much improved cytotoxicity to cancer cells.  In addn., the authors detd. the structure of a TRAP1-adenylyl-imidodiphosphate (AMP-PNP) complex.  On the basis of comparative anal. of TRAP1 structures, the authors propose a mol. mechanism of ATP hydrolysis that is crucial for chaperone function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN-VB5CkPi2LVg90H21EOLACvtfcHk0lgX5YZttlY5rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksl2htrs%253D&md5=c1142149eaa5f4157377ce64662fcfc1</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fja511893n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja511893n%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DH.%2BK.%26aulast%3DJeong%26aufirst%3DH.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DA.%2BJ.%26aulast%3DCheon%26aufirst%3DK.%2BY.%26aulast%3DKim%26aufirst%3DC.%2BS.%26aulast%3DThomas%26aufirst%3DA.%2BP.%26aulast%3DBae%26aufirst%3DB.%26aulast%3DKim%26aufirst%3DN.%2BD.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DSuh%26aufirst%3DP.%2BG.%26aulast%3DRyu%26aufirst%3DJ.%2BH.%26aulast%3DKang%26aufirst%3DB.%2BH.%26atitle%3DDevelopment%2520of%2520a%2520mitochondria-targeted%2520Hsp90%2520inhibitor%2520based%2520on%2520the%2520crystal%2520structures%2520of%2520human%2520TRAP1%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D4358%26epage%3D4367%26doi%3D10.1021%2Fja511893n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandelwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stothert, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huard, D. J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duerfeldt, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kizziah, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieberman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickey, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S. J.</span></span> <span> </span><span class="NLM_article-title">Development of glucose regulated protein 94-selective inhibitors based on the BnIm and radamide scaffold</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3471</span>– <span class="NLM_lpage">3488</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00085</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00085" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC28XksFGrs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3471-3488&author=V.+M.+Crowleyauthor=A.+Khandelwalauthor=S.+Mishraauthor=A.+R.+Stothertauthor=D.+J.+E.+Huardauthor=J.+Zhaoauthor=A.+Muthauthor=A.+S.+Duerfeldtauthor=J.+L.+Kizziahauthor=R.+L.+Liebermanauthor=C.+A.+Dickeyauthor=B.+S.+J.+Blagg&title=Development+of+glucose+regulated+protein+94-selective+inhibitors+based+on+the+BnIm+and+radamide+scaffold&doi=10.1021%2Facs.jmedchem.6b00085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Glucose Regulated Protein 94-Selective Inhibitors Based on the BnIm and Radamide Scaffold</span></div><div class="casAuthors">Crowley, Vincent M.; Khandelwal, Anuj; Mishra, Sanket; Stothert, Andrew R.; Huard, Dustin J. E.; Zhao, Jinbo; Muth, Aaron; Duerfeldt, Adam S.; Kizziah, James L.; Lieberman, Raquel L.; Dickey, Chad A.; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3471-3488</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">(Arylmethyl)imidazolylethyl chlorodihydroxybenzoates I (R = Ph, 4-FC6H4, 4-ClC6H4, 4-BrC6H4, 4-IC6H4, 4-MeC6H4, 4-EtC6H4, 4-i-PrC6H4, 4-NCC6H4, 4-HC≡CC6H4, 4-F3CC6H4, 4-PhC6H4, 4-MeOC6H4, 3,4-Cl2C6H3, 1-naphthyl, 2-naphthyl, 5-quinolinyl, 3-FC6H4, 3-ClC6H4, 3-BrC6H4, 3-IC6H4, 3-MeOC6H4, 3-MeC6H4, 3-PhC6H4, 2-FC6H4, 2-ClC6H4, 2-BrC6H4, 2-MeC6H4, 2-H2NC6H4, 2-MeOC6H4, 2-EtC6H4, 2-EtOC6H4, 2-i-PrOC6H4, 2-n-PrOC6H4, 2-F3CC6H4, 2-MeO-4-MeC6H3, 3-furanyl, 2-furanyl, 5-Me-2-furanyl, 5-Cl-2-furanyl, 3,5-dimethyl-2-furanyl, 2-thienyl, 3-thienyl, 5-Me-2-thienyl, 5-Cl-2-thienyl, 4-Cl-2-thienyl, 3-Cl-2-thienyl, 5-isoxazolyl, 2-thiazolyl, 3-vinyl-2-thienyl, 3-vinyl-2-furanyl, 3-Et-2-thienyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 5-pyrimidinyl) were prepd. as selective inhibitors of glucose regulated protein 94 (Grp94), the endoplasmic reticulum-resident isoform of the heat shock protein 90 (Hsp90), for potential use in the treatment of glaucoma and cancer; the effect of the aryl substituents on Grp94 binding and selectivity was detd.  I were prepd. by the cyclocondensation of a bissilylated chloro(oxopropyl)dihydroxybenzoate with glyoxal and arylmethylamines RCH2NH2 (R = Ph, 4-FC6H4, 4-ClC6H4, 4-BrC6H4, 4-IC6H4, 4-MeC6H4, 4-EtC6H4, 4-i-PrC6H4, 4-NCC6H4, 4-HC≡CC6H4, 4-F3CC6H4, 4-PhC6H4, 4-MeOC6H4, 3,4-Cl2C6H3, 1-naphthyl, 2-naphthyl, 5-quinolinyl, 3-FC6H4, 3-ClC6H4, 3-BrC6H4, 3-IC6H4, 3-MeOC6H4, 3-MeC6H4, 3-PhC6H4, 2-FC6H4, 2-ClC6H4, 2-BrC6H4, 2-MeC6H4, 2-H2NC6H4, 2-MeOC6H4, 2-EtC6H4, 2-EtOC6H4, 2-i-PrOC6H4, 2-n-PrOC6H4, 2-F3CC6H4, 2-MeO-4-MeC6H3, 3-furanyl, 2-furanyl, 5-Me-2-furanyl, 5-Cl-2-furanyl, 3,5-dimethyl-2-furanyl, 2-thienyl, 3-thienyl, 5-Me-2-thienyl, 5-Cl-2-thienyl, 4-Cl-2-thienyl, 3-Cl-2-thienyl, 5-isoxazolyl, 2-thiazolyl, 3-vinyl-2-thienyl, 3-vinyl-2-furanyl, 3-Et-2-thienyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 5-pyrimidinyl) followed by desilylation.  I (R = 2-MeO-4-MeC6H3CH2, 5-chloro-2-furanylmethyl) were tested as inhibitors of cell migration in a cancer metastasis model and for their enhancement of the degrdn. of mutants of the protein myocilin in a glaucoma model.  The structures of the lead compd. radamide bound to Hsp82 and Grp94 and of I (R = 5-chloro-2-furanyl) bound to the N-terminal domain of Hsp94 lacking its acidic linker were detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3v_0NEYj1Z7Vg90H21EOLACvtfcHk0lgX5YZttlY5rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksFGrs7k%253D&md5=c73bbf30c243e281aae197689162c9e1</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00085%26sid%3Dliteratum%253Aachs%26aulast%3DCrowley%26aufirst%3DV.%2BM.%26aulast%3DKhandelwal%26aufirst%3DA.%26aulast%3DMishra%26aufirst%3DS.%26aulast%3DStothert%26aufirst%3DA.%2BR.%26aulast%3DHuard%26aufirst%3DD.%2BJ.%2BE.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DMuth%26aufirst%3DA.%26aulast%3DDuerfeldt%26aufirst%3DA.%2BS.%26aulast%3DKizziah%26aufirst%3DJ.%2BL.%26aulast%3DLieberman%26aufirst%3DR.%2BL.%26aulast%3DDickey%26aufirst%3DC.%2BA.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DDevelopment%2520of%2520glucose%2520regulated%2520protein%252094-selective%2520inhibitors%2520based%2520on%2520the%2520BnIm%2520and%2520radamide%2520scaffold%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3471%26epage%3D3488%26doi%3D10.1021%2Facs.jmedchem.6b00085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidler, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Que, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taldone, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finotti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephani, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gewirth, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiosis, G.</span></span> <span> </span><span class="NLM_article-title">Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">677</span>– <span class="NLM_lpage">684</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1038%2Fnchembio.1335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=23995768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlGltb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=677-684&author=P.+D.+Patelauthor=P.+Yanauthor=P.+M.+Seidlerauthor=H.+J.+Patelauthor=W.+Sunauthor=C.+Yangauthor=N.+S.+Queauthor=T.+Taldoneauthor=P.+Finottiauthor=R.+A.+Stephaniauthor=D.+T.+Gewirthauthor=G.+Chiosis&title=Paralog-selective+Hsp90+inhibitors+define+tumor-specific+regulation+of+HER2&doi=10.1038%2Fnchembio.1335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2</span></div><div class="casAuthors">Patel, Pallav D.; Yan, Pengrong; Seidler, Paul M.; Patel, Hardik J.; Sun, Weilin; Yang, Chenghua; Que, Nanette S.; Taldone, Tony; Finotti, Paola; Stephani, Ralph A.; Gewirth, Daniel T.; Chiosis, Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">677-684</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although the Hsp90 chaperone family, comprised in humans of four paralogs, Hsp90α, Hsp90β, Grp94 and Trap-1, has important roles in malignancy, the contribution of each paralog to the cancer phenotype is poorly understood.  This is in large part because reagents to study paralog-specific functions in cancer cells have been unavailable.  Here the authors combine compd. library screening with structural and computational analyses to identify purine-based chem. tools that are specific for Hsp90 paralogs.  The authors show that Grp94 selectivity is due to the insertion of these compds. into a new allosteric pocket.  The authors use these tools to demonstrate that cancer cells use individual Hsp90 paralogs to regulate a client protein in a tumor-specific manner and in response to proteome alterations.  Finally, the authors provide new mechanistic evidence explaining why selective Grp94 inhibition is particularly efficacious in certain breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAIwIoA9btZLVg90H21EOLACvtfcHk0lgX5YZttlY5rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlGltb7J&md5=8bdfb2c60b4171bbdd6046e455e413bb</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1335%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DP.%2BD.%26aulast%3DYan%26aufirst%3DP.%26aulast%3DSeidler%26aufirst%3DP.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BJ.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DQue%26aufirst%3DN.%2BS.%26aulast%3DTaldone%26aufirst%3DT.%26aulast%3DFinotti%26aufirst%3DP.%26aulast%3DStephani%26aufirst%3DR.%2BA.%26aulast%3DGewirth%26aufirst%3DD.%2BT.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DParalog-selective%2520Hsp90%2520inhibitors%2520define%2520tumor-specific%2520regulation%2520of%2520HER2%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D9%26spage%3D677%26epage%3D684%26doi%3D10.1038%2Fnchembio.1335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Que, N. L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duerfeldt, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gewirth, D. T.</span></span> <span> </span><span class="NLM_article-title">Structure based design of a Grp94-selective inhibitor: Exploiting a key residue in Grp94 to optimize paralog-selective binding</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2793</span>– <span class="NLM_lpage">2805</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01608</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01608" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlGhsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2793-2805&author=N.+L.+S.+Queauthor=V.+M.+Crowleyauthor=A.+S.+Duerfeldtauthor=J.+Zhaoauthor=C.+N.+Kentauthor=B.+S.+J.+Blaggauthor=D.+T.+Gewirth&title=Structure+based+design+of+a+Grp94-selective+inhibitor%3A+Exploiting+a+key+residue+in+Grp94+to+optimize+paralog-selective+binding&doi=10.1021%2Facs.jmedchem.7b01608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Design of a Grp94-Selective Inhibitor: Exploiting a Key Residue in Grp94 To Optimize Paralog-Selective Binding</span></div><div class="casAuthors">Que, Nanette L. S.; Crowley, Vincent M.; Duerfeldt, Adam S.; Zhao, Jinbo; Kent, Caitlin N.; Blagg, Brian S. J.; Gewirth, Daniel T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2793-2805</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Grp94 and Hsp90, the ER and cytoplasmic hsp90 paralogs, share a conserved ATP-binding pocket that has been targeted for therapeutics.  Paralog-selective inhibitors may lead to drugs with fewer side effects.  Here, the authors analyzed 1 (BnIm), a benzyl imidazole resorcinylic inhibitor, for its mode of binding.  The structures of 1 bound to Hsp90 and Grp94 reveal large conformational changes in Grp94 but not Hsp90 that expose site 2, a binding pocket adjacent to the central ATP cavity that is ordinarily blocked.  The Grp94:1 structure reveals a flipped pose of the resorcinylic scaffold that inserts into the exposed site 2.  The authors exploited this flipped binding pose to develop a Grp94-selective deriv. of 1.  The authors' structural anal. shows that the ability of the ligand to insert its benzyl imidazole substituent into site 1, a different side pocket off the ATP binding cavity, is the key to exposing site 2 in Grp94.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhACqcGHClIrVg90H21EOLACvtfcHk0lh0v2myjEoeYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlGhsLw%253D&md5=a44f6bf0bd3df65cf20ca570a1ef37b8</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01608%26sid%3Dliteratum%253Aachs%26aulast%3DQue%26aufirst%3DN.%2BL.%2BS.%26aulast%3DCrowley%26aufirst%3DV.%2BM.%26aulast%3DDuerfeldt%26aufirst%3DA.%2BS.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DKent%26aufirst%3DC.%2BN.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26aulast%3DGewirth%26aufirst%3DD.%2BT.%26atitle%3DStructure%2520based%2520design%2520of%2520a%2520Grp94-selective%2520inhibitor%253A%2520Exploiting%2520a%2520key%2520residue%2520in%2520Grp94%2520to%2520optimize%2520paralog-selective%2520binding%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2793%26epage%3D2805%26doi%3D10.1021%2Facs.jmedchem.7b01608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stothert, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suntharalingam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huard, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontaine, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieberman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickey, C. A.</span></span> <span> </span><span class="NLM_article-title">Exploiting the interaction between Grp94 and aggregated myocilin to treat glaucoma</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6470</span>, <span class="refDoi"> DOI: 10.1093/hmg/ddu367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1093%2Fhmg%2Fddu367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=25027323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitl2ntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=6470&author=A.+R.+Stothertauthor=A.+Suntharalingamauthor=D.+J.+Huardauthor=S.+N.+Fontaineauthor=V.+M.+Crowleyauthor=S.+Mishraauthor=B.+S.+Blaggauthor=R.+L.+Liebermanauthor=C.+A.+Dickey&title=Exploiting+the+interaction+between+Grp94+and+aggregated+myocilin+to+treat+glaucoma&doi=10.1093%2Fhmg%2Fddu367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting the interaction between Grp94 and aggregated myocilin to treat glaucoma</span></div><div class="casAuthors">Stothert, Andrew R.; Suntharalingam, Amirthaa; Huard, Dustin J. E.; Fontaine, Sarah N.; Crowley, Vincent M.; Mishra, Sanket; Blagg, Brian S. J.; Lieberman, Raquel L.; Dickey, Chad A.</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6470-6480</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Gain-of-function mutations in the olfactomedin domain of the MYOC gene facilitate the toxic accumulation of amyloid-contg. myocilin aggregates, hastening the onset of the prevalent ocular disorder primary open-angle glaucoma.  Aggregation of wild-type myocilin has been reported in other glaucoma subtypes, suggesting broader relevance of misfolded myocilin across the disease spectrum, but the absence of myocilin does not cause disease.  Thus, strategies aimed at eliminating myocilin could be therapeutically relevant for glaucoma.  Here, a novel and selective Grp94 inhibitor reduced the levels of several mutant myocilin proteins as well as wild-type myocilin when forced to misfold in cells.  This inhibitor rescued mutant myocilin toxicity in primary human trabecular meshwork cells.  Mechanistically, in vitro kinetics studies demonstrate that Grp94 recognizes on-pathway aggregates of the myocilin olfactomedin domain (myoc-OLF), accelerates rates of aggregation and co-ppts. with myoc-OLF.  These results indicate that aberrant myocilin quaternary structure drives Grp94 recognition, rather than peptide motifs exposed by unfolded protein.  Inhibition of Grp94 ameliorates the effects of Grp94-accelerated myoc-OLF aggregation, and Grp94 remains in soln.  In cells, when wild-type myocilin is driven to misfold and aggregate, it becomes a client of Grp94 and sensitive to Grp94 inhibition.  Taken together, the interaction of Grp94 with myocilin aggregates can be manipulated by cellular environment and genetics; this process can be exploited with Grp94 inhibitors to promote the clearance of toxic forms of myocilin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeQYeK777kKLVg90H21EOLACvtfcHk0lh0v2myjEoeYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitl2ntb8%253D&md5=cbabbce383403838a4cbc3ffe24bdce8</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fddu367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fddu367%26sid%3Dliteratum%253Aachs%26aulast%3DStothert%26aufirst%3DA.%2BR.%26aulast%3DSuntharalingam%26aufirst%3DA.%26aulast%3DHuard%26aufirst%3DD.%2BJ.%26aulast%3DFontaine%26aufirst%3DS.%2BN.%26aulast%3DCrowley%26aufirst%3DV.%2BM.%26aulast%3DMishra%26aufirst%3DS.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%26aulast%3DLieberman%26aufirst%3DR.%2BL.%26aulast%3DDickey%26aufirst%3DC.%2BA.%26atitle%3DExploiting%2520the%2520interaction%2520between%2520Grp94%2520and%2520aggregated%2520myocilin%2520to%2520treat%2520glaucoma%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2014%26volume%3D23%26spage%3D6470%26doi%3D10.1093%2Fhmg%2Fddu367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stothert, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suntharalingam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordhues, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huard, D. J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passaglia, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieberman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickey, C. A.</span></span> <span> </span><span class="NLM_article-title">Isoform-selective Hsp90 inhibition rescues model of hereditary open-angle glaucoma</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">17951</span> <span class="refDoi"> DOI: 10.1038/s41598-017-18344-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1038%2Fs41598-017-18344-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=29263415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A280%3ADC%252BC1MzjslWisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&author=A.+R.+Stothertauthor=A.+Suntharalingamauthor=X.+Tangauthor=V.+M.+Crowleyauthor=S.+J.+Mishraauthor=J.+M.+Websterauthor=B.+A.+Nordhuesauthor=D.+J.+E.+Huardauthor=C.+L.+Passagliaauthor=R.+L.+Liebermanauthor=B.+S.+J.+Blaggauthor=L.+J.+Blairauthor=J.+Korenauthor=C.+A.+Dickey&title=Isoform-selective+Hsp90+inhibition+rescues+model+of+hereditary+open-angle+glaucoma&doi=10.1038%2Fs41598-017-18344-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Isoform-selective Hsp90 inhibition rescues model of hereditary open-angle glaucoma</span></div><div class="casAuthors">Stothert Andrew R; Suntharalingam Amirthaa; Tang Xiaolan; Webster Jack M; Nordhues Bryce A; Blair Laura J; Koren John 3rd; Dickey Chad A; Tang Xiaolan; Passaglia Christopher L; Crowley Vincent M; Mishra Sanket J; Blagg Brian S J; Huard Dustin J E; Lieberman Raquel L</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17951</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The heat shock protein 90 (Hsp90) family of molecular chaperones regulates protein homeostasis, folding, and degradation.  The ER-resident Hsp90 isoform, glucose-regulated protein 94 (Grp94), promotes the aggregation of mutant forms of myocilin, a protein associated with primary open-angle glaucoma.  While inhibition of Grp94 promotes the degradation of mutant myocilin in vitro, to date no Grp94-selective inhibitors have been investigated in vivo.  Here, a Grp94-selective inhibitor facilitated mutant myocilin degradation and rescued phenotypes in a transgenic mouse model of hereditary primary open-angle glaucoma.  Ocular toxicities previously associated with pan-Hsp90 inhibitors were not evident with our Grp94-selective inhibitor, 4-Br-BnIm.  Our study suggests that selective inhibition of a distinct Hsp90 family member holds translational promise for ocular and other diseases associated with cell stress and protein misfolding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREMjSSm_naSNhSDZx9hyjKfW6udTcc2ebTd9Fv0YT7O7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MzjslWisQ%253D%253D&md5=2d2b50528853d6b6d6a5704655da3c56</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-18344-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-18344-4%26sid%3Dliteratum%253Aachs%26aulast%3DStothert%26aufirst%3DA.%2BR.%26aulast%3DSuntharalingam%26aufirst%3DA.%26aulast%3DTang%26aufirst%3DX.%26aulast%3DCrowley%26aufirst%3DV.%2BM.%26aulast%3DMishra%26aufirst%3DS.%2BJ.%26aulast%3DWebster%26aufirst%3DJ.%2BM.%26aulast%3DNordhues%26aufirst%3DB.%2BA.%26aulast%3DHuard%26aufirst%3DD.%2BJ.%2BE.%26aulast%3DPassaglia%26aufirst%3DC.%2BL.%26aulast%3DLieberman%26aufirst%3DR.%2BL.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26aulast%3DBlair%26aufirst%3DL.%2BJ.%26aulast%3DKoren%26aufirst%3DJ.%26aulast%3DDickey%26aufirst%3DC.%2BA.%26atitle%3DIsoform-selective%2520Hsp90%2520inhibition%2520rescues%2520model%2520of%2520hereditary%2520open-angle%2520glaucoma%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26doi%3D10.1038%2Fs41598-017-18344-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandelwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S. J.</span></span> <span> </span><span class="NLM_article-title">Development of radamide analogs as Grp94 inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4083</span>– <span class="NLM_lpage">4098</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.05.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1016%2Fj.bmc.2014.05.075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=25027801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFGru7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=4083-4098&author=A.+Muthauthor=V.+Crowleyauthor=A.+Khandelwalauthor=S.+Mishraauthor=J.+Zhaoauthor=J.+Hallauthor=B.+S.+J.+Blagg&title=Development+of+radamide+analogs+as+Grp94+inhibitors&doi=10.1016%2Fj.bmc.2014.05.075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Development of radamide analogs as Grp94 inhibitors</span></div><div class="casAuthors">Muth, Aaron; Crowley, Vincent; Khandelwal, Anuj; Mishra, Sanket; Zhao, Jinbo; Hall, Jessica; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4083-4098</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Hsp90 isoform-selective inhibition is highly desired as it can potentially avoid the toxic side-effects of pan-inhibition.  The current study developed selective inhibitors of one such isoform, Grp94, predicated on the chimeric and pan-Hsp90 inhibitor, radamide (RDA).  Replacement of the quinone moiety of RDA with a Ph ring (2) was found to be better suited for Grp94 inhibition as it can fully interact with a unique hydrophobic pocket present in Grp94.  An extensive SAR for this scaffold showed that substitutions at the 2- and 4-positions (8 and 27, resp.) manifested excellent Grp94 affinity and selectivity.  Introduction of heteroatoms into the ring also proved beneficial, with a 2-pyridine deriv. (38) exhibiting the highest Grp94 affinity (Kd = 820 nM).  Subsequent cell-based assays showed that these Grp94 inhibitors inhibit migration of the metastatic breast cancer cell line, MDA-MB-231, as well as exhibit an anti-proliferative affect against the multiple myeloma cell line, RPMI 8226.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxdbHibsHh3rVg90H21EOLACvtfcHk0lgsKgIhDDFiMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFGru7bK&md5=6025c533f1c107eb5c54a559c679c8d2</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.05.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.05.075%26sid%3Dliteratum%253Aachs%26aulast%3DMuth%26aufirst%3DA.%26aulast%3DCrowley%26aufirst%3DV.%26aulast%3DKhandelwal%26aufirst%3DA.%26aulast%3DMishra%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DHall%26aufirst%3DJ.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DDevelopment%2520of%2520radamide%2520analogs%2520as%2520Grp94%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D4083%26epage%3D4098%26doi%3D10.1016%2Fj.bmc.2014.05.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khandelwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S. J.</span></span> <span> </span><span class="NLM_article-title">Resorcinol-based Grp94-selective inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1013</span>– <span class="NLM_lpage">1018</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00193</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00193" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVejs73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1013-1018&author=A.+Khandelwalauthor=V.+M.+Crowleyauthor=B.+S.+J.+Blagg&title=Resorcinol-based+Grp94-selective+inhibitors&doi=10.1021%2Facsmedchemlett.7b00193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Resorcinol-Based Grp94-Selective Inhibitors</span></div><div class="casAuthors">Khandelwal, Anuj; Crowley, Vincent M.; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1013-1018</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glucose regulated protein 94 (Grp94) is the endoplasmic reticulum resident of the 90 kDa heat shock protein (Hsp90) family and represents a promising therapeutic target for the treatment of several diseases.  Grp94 is the most unique member of the 90 kDa heat shock protein family due to a five amino acid insertion into its primary sequence, which creates hydrophobic subpockets exclusive to Grp94 that can be utilized for selective inhibition.  The first resorcinol-based Grp94-selective inhibitor I to take advantage of the hydrophobic S2 subpocket has been developed and shown to manifest low nanomolar affinity and ∼10-fold selectivity for Grp94.  Furthermore, these Grp94-selective inhibitors manifest low micromolar GI50 values against multiple myeloma cells, supporting Grp94 as an emerging target for the treatment of this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok_wSMzlEsHLVg90H21EOLACvtfcHk0lhV0FHqBZjvIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVejs73K&md5=a398cf6e5adaacc4892aed8b2340b901</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00193%26sid%3Dliteratum%253Aachs%26aulast%3DKhandelwal%26aufirst%3DA.%26aulast%3DCrowley%26aufirst%3DV.%2BM.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DResorcinol-based%2520Grp94-selective%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D1013%26epage%3D1018%26doi%3D10.1021%2Facsmedchemlett.7b00193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khandelwal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzbeierlein, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matts, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, B. S. J.</span></span> <span> </span><span class="NLM_article-title">Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">425</span> <span class="refDoi"> DOI: 10.1038/s41467-017-02013-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1038%2Fs41467-017-02013-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=29382832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A280%3ADC%252BC1MvlsFyksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&author=A.+Khandelwalauthor=C.+N.+Kentauthor=M.+Balchauthor=S.+Pengauthor=S.+J.+Mishraauthor=J.+Dengauthor=V.+W.+Dayauthor=W.+Liuauthor=C.+Subramanianauthor=M.+Cohenauthor=J.+M.+Holzbeierleinauthor=R.+Mattsauthor=B.+S.+J.+Blagg&title=Structure-guided+design+of+an+Hsp90%CE%B2+N-terminal+isoform-selective+inhibitor&doi=10.1038%2Fs41467-017-02013-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor</span></div><div class="casAuthors">Khandelwal Anuj; Mishra Sanket J; Kent Caitlin N; Blagg Brian S J; Balch Maurie; Peng Shuxia; Deng Junpeng; Matts Robert; Day Victor W; Liu Weiya; Holzbeierlein Jeffery M; Subramanian Chitra; Cohen Mark</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">425</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The 90 kDa heat shock protein (Hsp90) is a molecular chaperone responsible for folding proteins that are directly associated with cancer progression.  Consequently, inhibition of the Hsp90 protein folding machinery results in a combinatorial attack on numerous oncogenic pathways.  Seventeen small-molecule inhibitors of Hsp90 have entered clinical trials, all of which bind the Hsp90 N-terminus and exhibit pan-inhibitory activity against all four Hsp90 isoforms. pan-Inhibition of Hsp90 appears to be detrimental as toxicities have been reported alongside induction of the pro-survival heat shock response.  The development of Hsp90 isoform-selective inhibitors represents an alternative approach towards the treatment of cancer that may limit some of the detriments.  Described herein is a structure-based approach to design isoform-selective inhibitors of Hsp90β, which induces the degradation of select Hsp90 clients without concomitant induction of Hsp90 levels.  Together, these initial studies support the development of Hsp90β-selective inhibitors as a method to overcome the detriments associated with pan-inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmyRre9-yoQBpyrDyM_m9cfW6udTcc2eZnFSic-mUr37ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvlsFyksA%253D%253D&md5=cfa47e314c9bdbc1c38802108330cba7</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-02013-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-02013-1%26sid%3Dliteratum%253Aachs%26aulast%3DKhandelwal%26aufirst%3DA.%26aulast%3DKent%26aufirst%3DC.%2BN.%26aulast%3DBalch%26aufirst%3DM.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DMishra%26aufirst%3DS.%2BJ.%26aulast%3DDeng%26aufirst%3DJ.%26aulast%3DDay%26aufirst%3DV.%2BW.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DSubramanian%26aufirst%3DC.%26aulast%3DCohen%26aufirst%3DM.%26aulast%3DHolzbeierlein%26aufirst%3DJ.%2BM.%26aulast%3DMatts%26aufirst%3DR.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DStructure-guided%2520design%2520of%2520an%2520Hsp90%25CE%25B2%2520N-terminal%2520isoform-selective%2520inhibitor%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26doi%3D10.1038%2Fs41467-017-02013-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohkubo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muraoka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitotsumachi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitade, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanoh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonekura, K.</span></span> <span> </span><span class="NLM_article-title">TAS-116, a highly selective inhibitor of heat shock protein 90α and β, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1158%2F1535-7163.MCT-14-0219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=25416789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslWgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=14-22&author=S.+Ohkuboauthor=Y.+Kodamaauthor=H.+Muraokaauthor=H.+Hitotsumachiauthor=C.+Yoshimuraauthor=M.+Kitadeauthor=A.+Hashimotoauthor=K.+Itoauthor=A.+Gomoriauthor=K.+Takahashiauthor=Y.+Shibataauthor=A.+Kanohauthor=K.+Yonekura&title=TAS-116%2C+a+highly+selective+inhibitor+of+heat+shock+protein+90%CE%B1+and+%CE%B2%2C+demonstrates+potent+antitumor+activity+and+minimal+ocular+toxicity+in+preclinical+models&doi=10.1158%2F1535-7163.MCT-14-0219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models</span></div><div class="casAuthors">Ohkubo, Shuichi; Kodama, Yasuo; Muraoka, Hiromi; Hitotsumachi, Hiroko; Yoshimura, Chihoko; Kitade, Makoto; Hashimoto, Akihiro; Ito, Kenjiro; Gomori, Akira; Takahashi, Koichi; Shibata, Yoshihiro; Kanoh, Akira; Yonekura, Kazuhiko</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-22</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The mol. chaperone HSP90 plays a crucial role in cancer cell growth and survival by stabilizing cancer-related proteins.  A no. of HSP90 inhibitors have been developed clin. for cancer therapy; however, potential off-target and/or HSP90-related toxicities have proved problematic.  The 4-(1H-pyrazolo[3,4-b]pyridine-1-yl)benzamide TAS-116 is a selective inhibitor of cytosolic HSP90α and β that does not inhibit HSP90 paralogs such as endoplasmic reticulum GRP94 or mitochondrial TRAP1.  Oral administration of TAS-116 led to tumor shrinkage in human tumor xenograft mouse models accompanied by depletion of multiple HSP90 clients, demonstrating that the inhibition of HSP90α and β alone was sufficient to exert antitumor activity in certain tumor models.  One of the most notable HSP90-related adverse events universally obsd. to differing degrees in the clin. setting is visual disturbance.  A two-week administration of the isoxazole resorcinol NVP-AUY922, an HSP90 inhibitor, caused marked degeneration and disarrangement of the outer nuclear layer of the retina and induced photoreceptor cell death in rats.  In contrast, TAS-116 did not produce detectable photoreceptor injury in rats, probably due to its lower distribution in retinal tissue.  Importantly, in a rat model, the antitumor activity of TAS-116 was accompanied by a higher distribution of the compd. in s.c. xenografted NCI-H1975 non-small cell lung carcinoma tumors than in retina.  Moreover, TAS-116 showed activity against orthotopically transplanted NCI-H1975 lung tumors.  Together, these data suggest that TAS-116 has a potential to maximize antitumor activity while minimizing adverse effects such as visual disturbances that are obsd. with other compds. of this class.  Mol Cancer Ther; 14(1); 14-22. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB25Txc_IcKbVg90H21EOLACvtfcHk0lgSbD_tuENAMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslWgug%253D%253D&md5=3ffdc26a7f0178d4e44413e22c003f77</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0219%26sid%3Dliteratum%253Aachs%26aulast%3DOhkubo%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DY.%26aulast%3DMuraoka%26aufirst%3DH.%26aulast%3DHitotsumachi%26aufirst%3DH.%26aulast%3DYoshimura%26aufirst%3DC.%26aulast%3DKitade%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DA.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DGomori%26aufirst%3DA.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DShibata%26aufirst%3DY.%26aulast%3DKanoh%26aufirst%3DA.%26aulast%3DYonekura%26aufirst%3DK.%26atitle%3DTAS-116%252C%2520a%2520highly%2520selective%2520inhibitor%2520of%2520heat%2520shock%2520protein%252090%25CE%25B1%2520and%2520%25CE%25B2%252C%2520demonstrates%2520potent%2520antitumor%2520activity%2520and%2520minimal%2520ocular%2520toxicity%2520in%2520preclinical%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D14%26epage%3D22%26doi%3D10.1158%2F1535-7163.MCT-14-0219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccola, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turnbull, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kargo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woody, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcacio, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nezami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamos, D.</span></span> <span> </span><span class="NLM_article-title">Identification of novel HSP90α/β isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington’s Disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3382</span>– <span class="NLM_lpage">3400</span>, <span class="refDoi"> DOI: 10.1021/jm500042s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500042s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFGlsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3382-3400&author=J.+T.+Ernstauthor=T.+Neubertauthor=M.+Liuauthor=S.+Sperryauthor=H.+Zuccolaauthor=A.+Turnbullauthor=B.+Fleckauthor=W.+Kargoauthor=L.+Woodyauthor=P.+Chiangauthor=D.+Tranauthor=W.+Chenauthor=P.+Snyderauthor=T.+Alcacioauthor=A.+Nezamiauthor=J.+Reynoldsauthor=K.+Alviauthor=L.+Gouletauthor=D.+Stamos&title=Identification+of+novel+HSP90%CE%B1%2F%CE%B2+isoform+selective+inhibitors+using+structure-based+drug+design.+Demonstration+of+potential+utility+in+treating+CNS+disorders+such+as+Huntington%E2%80%99s+Disease&doi=10.1021%2Fjm500042s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel HSP90α/β isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease</span></div><div class="casAuthors">Ernst, Justin T.; Neubert, Timothy; Liu, Michael; Sperry, Samuel; Zuccola, Harmon; Turnbull, Amy; Fleck, Beth; Kargo, William; Woody, Lisa; Chiang, Peggy; Tran, Dao; Chen, Weichao; Snyder, Phillip; Alcacio, Timothy; Nezami, Azin; Reynolds, James; Alvi, Khisal; Goulet, Lance; Stamos, Dean</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3382-3400</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A structure-based drug design strategy was used to optimize a novel benzolactam series of HSP90α/β inhibitors to achieve >1000-fold selectivity vs. the HSP90 endoplasmic reticulum and mitochondrial isoforms (GRP94 and TRAP1, resp.).  Selective HSP90α/β inhibitors were found to be equipotent to pan-HSP90 inhibitors in promoting the clearance of mutant huntington protein (mHtt) in vitro, however with less cellular toxicity.  Improved tolerability profiles may enable the use of HSP90α/β selective inhibitors in treating chronic neurodegenerative indications such as Huntington's disease (HD).  A potent, selective, orally available HSP90α/β inhibitor, 8-Cyclopentyl-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)-3,4-dihydroisoquinolin-1(2H)-one, was identified that crosses the blood-brain barrier and demonstrated proof of concept by successfully reducing brain Htt levels following oral dosing in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKpHcuphxPXbVg90H21EOLACvtfcHk0lgSbD_tuENAMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFGlsLY%253D&md5=0d55fb738fc0f0615b5336b8dc17056a</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm500042s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500042s%26sid%3Dliteratum%253Aachs%26aulast%3DErnst%26aufirst%3DJ.%2BT.%26aulast%3DNeubert%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DSperry%26aufirst%3DS.%26aulast%3DZuccola%26aufirst%3DH.%26aulast%3DTurnbull%26aufirst%3DA.%26aulast%3DFleck%26aufirst%3DB.%26aulast%3DKargo%26aufirst%3DW.%26aulast%3DWoody%26aufirst%3DL.%26aulast%3DChiang%26aufirst%3DP.%26aulast%3DTran%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DSnyder%26aufirst%3DP.%26aulast%3DAlcacio%26aufirst%3DT.%26aulast%3DNezami%26aufirst%3DA.%26aulast%3DReynolds%26aufirst%3DJ.%26aulast%3DAlvi%26aufirst%3DK.%26aulast%3DGoulet%26aufirst%3DL.%26aulast%3DStamos%26aufirst%3DD.%26atitle%3DIdentification%2520of%2520novel%2520HSP90%25CE%25B1%252F%25CE%25B2%2520isoform%2520selective%2520inhibitors%2520using%2520structure-based%2520drug%2520design.%2520Demonstration%2520of%2520potential%2520utility%2520in%2520treating%2520CNS%2520disorders%2520such%2520as%2520Huntington%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3382%26epage%3D3400%26doi%3D10.1021%2Fjm500042s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccola, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neubert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turnbull, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vought, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamos, D.</span></span> <span> </span><span class="NLM_article-title">Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity—Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">204</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.11.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1016%2Fj.bmcl.2013.11.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=24332488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOlt7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=204-208&author=J.+T.+Ernstauthor=M.+Liuauthor=H.+Zuccolaauthor=T.+Neubertauthor=K.+Beaumontauthor=A.+Turnbullauthor=A.+Kallelauthor=B.+Voughtauthor=D.+Stamos&title=Correlation+between+chemotype-dependent+binding+conformations+of+HSP90%CE%B1%2F%CE%B2+and+isoform+selectivity%E2%80%94Implications+for+the+structure-based+design+of+HSP90%CE%B1%2F%CE%B2+selective+inhibitors+for+treating+neurodegenerative+diseases&doi=10.1016%2Fj.bmcl.2013.11.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases</span></div><div class="casAuthors">Ernst, Justin T.; Liu, Michael; Zuccola, Harmon; Neubert, Timothy; Beaumont, Kevin; Turnbull, Amy; Kallel, Adam; Vought, Bryan; Stamos, Dean</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">204-208</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">HSP90 continues to be a target of interest for neurodegeneration indications.  Selective knockdown of the HSP90 cytosolic isoforms α and β is sufficient to reduce mutant huntingtin protein levels in vitro.  Chemotype-dependent binding conformations of HSP90α/β appear to strongly influence isoform selectivity.  The rational design of HSP90α/β inhibitors selective vs. the mitochondrial (TRAP1) and endoplasmic reticulum (GRP94) isoforms offers a potential mitigating strategy for mechanism-based toxicities.  Better tolerated HSP90 inhibitors would be attractive for targeting chronic neurodegenerative diseases such as Huntington's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq64ZOr5JsRerVg90H21EOLACvtfcHk0ljmY5z28dtH2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOlt7jO&md5=6799a46090ee297d70700f7c42b79f80</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.11.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.11.036%26sid%3Dliteratum%253Aachs%26aulast%3DErnst%26aufirst%3DJ.%2BT.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DZuccola%26aufirst%3DH.%26aulast%3DNeubert%26aufirst%3DT.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DTurnbull%26aufirst%3DA.%26aulast%3DKallel%26aufirst%3DA.%26aulast%3DVought%26aufirst%3DB.%26aulast%3DStamos%26aufirst%3DD.%26atitle%3DCorrelation%2520between%2520chemotype-dependent%2520binding%2520conformations%2520of%2520HSP90%25CE%25B1%252F%25CE%25B2%2520and%2520isoform%2520selectivity%25E2%2580%2594Implications%2520for%2520the%2520structure-based%2520design%2520of%2520HSP90%25CE%25B1%252F%25CE%25B2%2520selective%2520inhibitors%2520for%2520treating%2520neurodegenerative%2520diseases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D204%26epage%3D208%26doi%3D10.1016%2Fj.bmcl.2013.11.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shekhar-Guturja, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeBlanc, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nation, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trilles, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krysan, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindquist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatu, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizarro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span> <span> </span><span class="NLM_article-title">Structural basis for species-selective targeting of Hsp90 in a pathogenic fungus</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">402</span> <span class="refDoi"> DOI: 10.1038/s41467-018-08248-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1038%2Fs41467-018-08248-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=30679438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntFersrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&author=L.+Whitesellauthor=N.+Robbinsauthor=D.+S.+Huangauthor=C.+A.+McLellanauthor=T.+Shekhar-Guturjaauthor=E.+V.+LeBlancauthor=C.+S.+Nationauthor=R.+Huiauthor=A.+Hutchinsonauthor=C.+Collinsauthor=S.+Chatterjeeauthor=R.+Trillesauthor=J.+L.+Xieauthor=D.+J.+Krysanauthor=S.+Lindquistauthor=J.+A.+Porcoauthor=U.+Tatuauthor=L.+E.+Brownauthor=J.+Pizarroauthor=L.+E.+Cowen&title=Structural+basis+for+species-selective+targeting+of+Hsp90+in+a+pathogenic+fungus&doi=10.1038%2Fs41467-018-08248-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for species-selective targeting of Hsp90 in a pathogenic fungus</span></div><div class="casAuthors">Whitesell, Luke; Robbins, Nicole; Huang, David S.; McLellan, Catherine A.; Shekhar-Guturja, Tanvi; LeBlanc, Emmanuelle V.; Nation, Catherine S.; Hui, Raymond; Hutchinson, Ashley; Collins, Cathy; Chatterjee, Sharanya; Trilles, Richard; Xie, Jinglin L.; Krysan, Damian J.; Lindquist, Susan; Porco, John A., Jr.; Tatu, Utpal; Brown, Lauren E.; Pizarro, Juan; Cowen, Leah E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">402</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">New strategies are needed to counter the escalating threat posed by drug-resistant fungi.  The mol. chaperone Hsp90 affords a promising target because it supports survival, virulence and drug-resistance across diverse pathogens.  Inhibitors of human Hsp90 under development as anticancer therapeutics, however, exert host toxicities that preclude their use as antifungals.  Seeking a route to species-selectivity, we investigate the nucleotide-binding domain (NBD) of Hsp90 from the most common human fungal pathogen, Candida albicans.  Here we report structures for this NBD alone, in complex with ADP or in complex with known Hsp90 inhibitors.  Encouraged by the conformational flexibility revealed by these structures, we synthesize an inhibitor with >25-fold binding-selectivity for fungal Hsp90 NBD.  Comparing co-crystals occupied by this probe vs. anticancer Hsp90 inhibitors revealed major, previously unreported conformational rearrangements.  These insights and our probe's species-selectivity in culture support the feasibility of targeting Hsp90 as a promising antifungal strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc0j6rgX3IDrVg90H21EOLACvtfcHk0lhb8Ua_V7FJ0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntFersrg%253D&md5=ee973dc62c7912479f26d2ad26f024bc</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-08248-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-08248-w%26sid%3Dliteratum%253Aachs%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DRobbins%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DD.%2BS.%26aulast%3DMcLellan%26aufirst%3DC.%2BA.%26aulast%3DShekhar-Guturja%26aufirst%3DT.%26aulast%3DLeBlanc%26aufirst%3DE.%2BV.%26aulast%3DNation%26aufirst%3DC.%2BS.%26aulast%3DHui%26aufirst%3DR.%26aulast%3DHutchinson%26aufirst%3DA.%26aulast%3DCollins%26aufirst%3DC.%26aulast%3DChatterjee%26aufirst%3DS.%26aulast%3DTrilles%26aufirst%3DR.%26aulast%3DXie%26aufirst%3DJ.%2BL.%26aulast%3DKrysan%26aufirst%3DD.%2BJ.%26aulast%3DLindquist%26aufirst%3DS.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26aulast%3DTatu%26aufirst%3DU.%26aulast%3DBrown%26aufirst%3DL.%2BE.%26aulast%3DPizarro%26aufirst%3DJ.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26atitle%3DStructural%2520basis%2520for%2520species-selective%2520targeting%2520of%2520Hsp90%2520in%2520a%2520pathogenic%2520fungus%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26doi%3D10.1038%2Fs41467-018-08248-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woodhead, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angove, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chessari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyle, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosme, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazal, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueroa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederickson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMenamin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parra, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trewartha, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinkovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolford, A. J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of (2,4-Dihydroxy-5-isopropylphenyl)- 5-(4-methylpiperazin-1-ylmethyl)-1,3- dihydroisoindol-2-yl methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">5956</span>– <span class="NLM_lpage">5969</span>, <span class="refDoi"> DOI: 10.1021/jm100060b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100060b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCitrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5956-5969&author=A.+J.+Woodheadauthor=H.+Angoveauthor=M.+G.+Carrauthor=G.+Chessariauthor=M.+Congreveauthor=J.+E.+Coyleauthor=J.+Cosmeauthor=B.+Grahamauthor=P.+J.+Dayauthor=R.+Downhamauthor=L.+Fazalauthor=R.+Feltellauthor=E.+Figueroaauthor=M.+Fredericksonauthor=J.+Lewisauthor=R.+McMenaminauthor=C.+W.+Murrayauthor=M.+A.+O%E2%80%99Brienauthor=L.+Parraauthor=S.+Patelauthor=T.+Phillipsauthor=D.+C.+Reesauthor=S.+Richauthor=D.+M.+Smithauthor=G.+Trewarthaauthor=M.+Vinkovicauthor=B.+Williamsauthor=A.+J.+A.+Woolford&title=Discovery+of+%282%2C4-Dihydroxy-5-isopropylphenyl%29-+5-%284-methylpiperazin-1-ylmethyl%29-1%2C3-+dihydroisoindol-2-yl+methanone+%28AT13387%29%2C+a+novel+inhibitor+of+the+molecular+chaperone+Hsp90+by+fragment+based+drug+design&doi=10.1021%2Fjm100060b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design</span></div><div class="casAuthors">Woodhead, Andrew J.; Angove, Hayley; Carr, Maria G.; Chessari, Gianni; Congreve, Miles; Coyle, Joseph E.; Cosme, Jose; Graham, Brent; Day, Philip J.; Downham, Robert; Fazal, Lynsey; Feltell, Ruth; Figueroa, Eva; Frederickson, Martyn; Lewis, Jonathan; McMenamin, Rachel; Murray, Christopher W.; O'Brien, M. Alistair; Parra, Lina; Patel, Sahil; Phillips, Theresa; Rees, David C.; Rich, Sharna; Smith, Donna-Michelle; Trewartha, Gary; Vinkovic, Mladen; Williams, Brian; Woolford, Alison J.-A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5956-5969</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of the mol. chaperone heat shock protein 90 (Hsp90) are currently generating significant interest in clin. development as potential treatments for cancer.  In a preceding publication (DOI: 10.1021/jm100059d) we describe Astex's approach to screening fragments against Hsp90 and the subsequent optimization of two hits into leads with inhibitory activities in the low nanomolar range.  This paper describes the structure guided optimization of the 2,4-dihydroxybenzamide lead mol. 1 and details some of the drug discovery strategies employed in the identification of AT13387 (35), which has progressed through preclin. development and is currently being tested in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEEtcgAmkVk7Vg90H21EOLACvtfcHk0lgvdhHra2gdFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCitrg%253D&md5=a2d2ac6dd9e9ba4cb89f83c32727a1d8</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm100060b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100060b%26sid%3Dliteratum%253Aachs%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26aulast%3DAngove%26aufirst%3DH.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DChessari%26aufirst%3DG.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DCoyle%26aufirst%3DJ.%2BE.%26aulast%3DCosme%26aufirst%3DJ.%26aulast%3DGraham%26aufirst%3DB.%26aulast%3DDay%26aufirst%3DP.%2BJ.%26aulast%3DDownham%26aufirst%3DR.%26aulast%3DFazal%26aufirst%3DL.%26aulast%3DFeltell%26aufirst%3DR.%26aulast%3DFigueroa%26aufirst%3DE.%26aulast%3DFrederickson%26aufirst%3DM.%26aulast%3DLewis%26aufirst%3DJ.%26aulast%3DMcMenamin%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%2BA.%26aulast%3DParra%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DT.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DRich%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DD.%2BM.%26aulast%3DTrewartha%26aufirst%3DG.%26aulast%3DVinkovic%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DB.%26aulast%3DWoolford%26aufirst%3DA.%2BJ.%2BA.%26atitle%3DDiscovery%2520of%2520%25282%252C4-Dihydroxy-5-isopropylphenyl%2529-%25205-%25284-methylpiperazin-1-ylmethyl%2529-1%252C3-%2520dihydroisoindol-2-yl%2520methanone%2520%2528AT13387%2529%252C%2520a%2520novel%2520inhibitor%2520of%2520the%2520molecular%2520chaperone%2520Hsp90%2520by%2520fragment%2520based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5956%26epage%3D5969%26doi%3D10.1021%2Fjm100060b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Do, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speranza, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polley, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trepel, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinders, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antony, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neckers, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doroshow, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummar, S.</span></span> <span> </span><span class="NLM_article-title">Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors</span>. <i>Invest. New Drug.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">921</span>– <span class="NLM_lpage">930</span>, <span class="refDoi"> DOI: 10.1007/s10637-015-0255-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1007%2Fs10637-015-0255-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=26082332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVektLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=921-930&author=K.+Doauthor=G.+Speranzaauthor=L.-C.+Changauthor=E.+C.+Polleyauthor=R.+Bishopauthor=W.+Zhuauthor=J.+B.+Trepelauthor=S.+Leeauthor=M.-J.+Leeauthor=R.+J.+Kindersauthor=L.+Phillipsauthor=J.+Collinsauthor=J.+Lyonsauthor=W.+Jeongauthor=R.+Antonyauthor=A.+P.+Chenauthor=L.+Neckersauthor=J.+H.+Doroshowauthor=S.+Kummar&title=Phase+I+study+of+the+heat+shock+protein+90+%28Hsp90%29+inhibitor+onalespib+%28AT13387%29+administered+on+a+daily+for+2+consecutive+days+per+week+dosing+schedule+in+patients+with+advanced+solid+tumors&doi=10.1007%2Fs10637-015-0255-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors</span></div><div class="casAuthors">Do, Khanh; Speranza, Giovanna; Chang, Lun-Ching; Polley, Eric C.; Bishop, Rachel; Zhu, Weimin; Trepel, Jane B.; Lee, Sunmin; Lee, Min-Jung; Kinders, Robert J.; Phillips, Larry; Collins, Jerry; Lyons, John; Jeong, Woondong; Antony, Ramya; Chen, Alice P.; Neckers, Len; Doroshow, James H.; Kummar, Shivaani</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">921-930</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Inhibition of heat shock 90 (Hsp90) mol. chaperones allows targeting of multiple proteins involved in tumorigenesis.  We investigated the safety, recommended phase 2 dose (RP2D), and pharmacokinetic and pharmacodynamic profile of onalespib (AT13387), a potent synthetic Hsp90 inhibitor, administered on days 1, 2, 8, 9, 15, and 16 of 28 day cycles (QDx2/wk) in a phase I trial.  This study followed an accelerated titrn. design with a starting dose of 20 mg/m2/dose and a std. 3 + 3 dose escalation design for dose level 4 (120 mg/m2/dose) and above.  Addnl. patients were enrolled at the RP2D with mandatory paired tumor biopsies to assess modulation of 210 client proteins using reverse phase protein array anal.  Thirty-one patients were treated; RP2D was established at 160 mg/m2/dose on the QDx2/wk schedule.  Common toxicities were gastrointestinal, hepatic, and hematol.  Pharmacokinetic profile was linear and plasma levels increased proportionally with dose (T1/2 ∼8 h).  No responses were obsd.; eight patients had stable disease for > 2 cycles with one patient remaining on study for 6 cycles.  Target engagement was demonstrated by transcriptional upregulation of Hsp70 and Hsp27 in PBMCs.  Statistically significant modulation of client proteins was not achieved in the 9 paired tumor biopsies evaluated; however, hierarchical clustering revealed two subgroups of patients with differential patterns of protein expression.  Further combination studies are needed in order to target prospective driver oncoproteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCXt8s5_XMBLVg90H21EOLACvtfcHk0lj0K32A1YchnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVektLfJ&md5=624adbaad8dad65d69ea9318a96e984e</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs10637-015-0255-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-015-0255-1%26sid%3Dliteratum%253Aachs%26aulast%3DDo%26aufirst%3DK.%26aulast%3DSperanza%26aufirst%3DG.%26aulast%3DChang%26aufirst%3DL.-C.%26aulast%3DPolley%26aufirst%3DE.%2BC.%26aulast%3DBishop%26aufirst%3DR.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DTrepel%26aufirst%3DJ.%2BB.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DM.-J.%26aulast%3DKinders%26aufirst%3DR.%2BJ.%26aulast%3DPhillips%26aufirst%3DL.%26aulast%3DCollins%26aufirst%3DJ.%26aulast%3DLyons%26aufirst%3DJ.%26aulast%3DJeong%26aufirst%3DW.%26aulast%3DAntony%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DA.%2BP.%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26aulast%3DKummar%26aufirst%3DS.%26atitle%3DPhase%2520I%2520study%2520of%2520the%2520heat%2520shock%2520protein%252090%2520%2528Hsp90%2529%2520inhibitor%2520onalespib%2520%2528AT13387%2529%2520administered%2520on%2520a%2520daily%2520for%25202%2520consecutive%2520days%2520per%2520week%2520dosing%2520schedule%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drug.%26date%3D2015%26volume%3D33%26spage%3D921%26epage%3D930%26doi%3D10.1007%2Fs10637-015-0255-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agulnik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahadevan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedel, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Mehren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trent, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yule, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oganesian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keer, H.</span></span> <span> </span><span class="NLM_article-title">Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2016.03.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1016%2Fj.ejca.2016.03.076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=27156227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslKqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2016&pages=94-101&author=A.+J.+Wagnerauthor=M.+Agulnikauthor=M.+C.+Heinrichauthor=D.+Mahadevanauthor=R.+F.+Riedelauthor=M.+von+Mehrenauthor=J.+Trentauthor=G.+D.+Demetriauthor=C.+L.+Corlessauthor=M.+Yuleauthor=J.+F.+Lyonsauthor=A.+Oganesianauthor=H.+Keer&title=Dose-escalation+study+of+a+second-generation+non-ansamycin+HSP90+inhibitor%2C+onalespib+%28AT13387%29%2C+in+combination+with+imatinib+in+patients+with+metastatic+gastrointestinal+stromal+tumour&doi=10.1016%2Fj.ejca.2016.03.076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour</span></div><div class="casAuthors">Wagner, Andrew J.; Agulnik, Mark; Heinrich, Michael C.; Mahadevan, Daruka; Riedel, Richard F.; von Mehren, Margaret; Trent, Jonathan; Demetri, George D.; Corless, Christopher L.; Yule, Murray; Lyons, John F.; Oganesian, Aram; Keer, Harold</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">94-101</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Gastrointestinal stromal tumors (GIST) treated with the tyrosine kinase inhibitor (TKI) imatinib can become resistant when addnl. mutations in the receptor tyrosine kinases KIT or PDGFRA block imatinib activity.  Mutated KIT requires the mol. chaperone heat-shock protein 90 (HSP90) to maintain stability and activity.  Onalespib (AT13387) is a potent non-ansamycin HSP90 inhibitor.  We hypothesised that the combination of onalespib and imatinib may be safe and effective in managing TKI-resistant GIST.In this dose-escalation study, we evaluated the safety and efficacy of combination once-weekly i.v. onalespib for 3 wk and daily oral imatinib in 28-d cycles.  Twenty-six patients with TKI-resistant GIST were enrolled into four sequential dose cohorts of onalespib (dose range, 150-220 mg/m2) and imatinib 400 mg.  The relationship between tumor mutational status (KIT/PDGFRA) and efficacy of treatment was explored.Common onalespib-related adverse events were diarrhea (58%), nausea (50%), injection site events (46%), vomiting (39%), fatigue (27%), and muscle spasms (23%).  Overall, 81% of patients reported more than one onalespib-related gastrointestinal disorder.  Nine patients (35%) had a best response of stable disease, including two patients who had KIT mutations known to be assocd. with resistance to imatinib and sunitinib.  Disease control at 4 mo was achieved in five patients (19%), and median progression-free survival was 112 d (95% confidence interval 43-165).  One patient with PDGFRA-mutant GIST had a partial response for more than 376 d.The combination of onalespib plus imatinib was well tolerated but exhibited limited antitumor activity as dosed in this TKI-resistant GIST patient population.Trial registration ID: clinicaltrials.gov: NCT01294202.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0EPUydR0h8bVg90H21EOLACvtfcHk0lhF37KQ37Oa0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslKqs7s%253D&md5=53b38c85eb3a83c174f28347d985ecf9</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2016.03.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2016.03.076%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26aulast%3DAgulnik%26aufirst%3DM.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DMahadevan%26aufirst%3DD.%26aulast%3DRiedel%26aufirst%3DR.%2BF.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DTrent%26aufirst%3DJ.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DYule%26aufirst%3DM.%26aulast%3DLyons%26aufirst%3DJ.%2BF.%26aulast%3DOganesian%26aufirst%3DA.%26aulast%3DKeer%26aufirst%3DH.%26atitle%3DDose-escalation%2520study%2520of%2520a%2520second-generation%2520non-ansamycin%2520HSP90%2520inhibitor%252C%2520onalespib%2520%2528AT13387%2529%252C%2520in%2520combination%2520with%2520imatinib%2520in%2520patients%2520with%2520metastatic%2520gastrointestinal%2520stromal%2520tumour%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2016%26volume%3D61%26spage%3D94%26epage%3D101%26doi%3D10.1016%2Fj.ejca.2016.03.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Canella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welker, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abas, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesanakurti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarajan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beattie, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulman, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gumin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurcan, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puduvalli, V. K.</span></span> <span> </span><span class="NLM_article-title">Efficacy of onalespib, a long-acting second-generation HSP90 inhibitor, as a single agent and in combination with temozolomide against malignant gliomas</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6215</span>– <span class="NLM_lpage">6226</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-3151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1158%2F1078-0432.CCR-16-3151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=28679777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1CgtrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=6215-6226&author=A.+Canellaauthor=A.+M.+Welkerauthor=J.+Y.+Yooauthor=J.+Xuauthor=F.+S.+Abasauthor=D.+Kesanakurtiauthor=P.+Nagarajanauthor=C.+E.+Beattieauthor=E.+P.+Sulmanauthor=J.+Liuauthor=J.+Guminauthor=F.+F.+Langauthor=M.+N.+Gurcanauthor=B.+Kaurauthor=D.+Sampathauthor=V.+K.+Puduvalli&title=Efficacy+of+onalespib%2C+a+long-acting+second-generation+HSP90+inhibitor%2C+as+a+single+agent+and+in+combination+with+temozolomide+against+malignant+gliomas&doi=10.1158%2F1078-0432.CCR-16-3151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas</span></div><div class="casAuthors">Canella, Alessandro; Welker, Alessandra M.; Yoo, Ji Young; Xu, Jihong; Abas, Fazly S.; Kesanakurti, Divya; Nagarajan, Prabakaran; Beattie, Christine E.; Sulman, Erik P.; Liu, Joseph; Gumin, Joy; Lang, Frederick F.; Gurcan, Metin N.; Kaur, Balveen; Sampath, Deepa; Puduvalli, Vinay K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6215-6226</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: HSP90, a highly conserved mol. chaperone that regulates the function of several oncogenic client proteins, is altered in glioblastoma.  However, HSP90 inhibitors currently in clin. trials are short-acting, have unacceptable toxicities, or are unable to cross the blood-brain barrier (BBB).  We examd. the efficacy of onalespib, a potent, long-acting novel HSP90 inhibitor as a single agent and in combination with temozolomide (TMZ) against gliomas in vitro and in vivo.  Exptl. Design: The effect of onalespib on HSP90, its client proteins, and on the biol. of glioma cell lines and patient-derived glioma-initiating cells (GSC) was detd.  Brain and plasma pharmacokinetics of onalespib and its ability to inhibit HSP90 in vivo were assessed in non-tumor-bearing mice.  Its efficacy as a single agent or in combination with TMZ was assessed in vitro and in vivo using zebrafish and patient-derived GSC xenograft mouse glioma models.  Results: Onalespib-mediated HSP90 inhibition depleted several survival-promoting client proteins such as EGFR, EGFRvIII, and AKT, disrupted their downstream signaling, and decreased the proliferation, migration, angiogenesis, and survival of glioma cell lines and GSCs.  Onalespib effectively crossed the BBB to inhibit HSP90 in vivo and extended survival as a single agent in zebrafish xenografts and in combination with TMZ in both zebrafish and GSC mouse xenografts.  Conclusions: Our results demonstrate the long-acting effects of onalespib against gliomas in vitro and in vivo, which combined with its ability to cross the BBB support its development as a potential therapeutic agent in combination with TMZ against gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqiyFYlY0U3bVg90H21EOLACvtfcHk0ljMK0wCbM-D6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1CgtrfO&md5=ad3c936d44737c257889bbd4602c4dc3</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-3151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-3151%26sid%3Dliteratum%253Aachs%26aulast%3DCanella%26aufirst%3DA.%26aulast%3DWelker%26aufirst%3DA.%2BM.%26aulast%3DYoo%26aufirst%3DJ.%2BY.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DAbas%26aufirst%3DF.%2BS.%26aulast%3DKesanakurti%26aufirst%3DD.%26aulast%3DNagarajan%26aufirst%3DP.%26aulast%3DBeattie%26aufirst%3DC.%2BE.%26aulast%3DSulman%26aufirst%3DE.%2BP.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGumin%26aufirst%3DJ.%26aulast%3DLang%26aufirst%3DF.%2BF.%26aulast%3DGurcan%26aufirst%3DM.%2BN.%26aulast%3DKaur%26aufirst%3DB.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DPuduvalli%26aufirst%3DV.%2BK.%26atitle%3DEfficacy%2520of%2520onalespib%252C%2520a%2520long-acting%2520second-generation%2520HSP90%2520inhibitor%252C%2520as%2520a%2520single%2520agent%2520and%2520in%2520combination%2520with%2520temozolomide%2520against%2520malignant%2520gliomas%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D6215%26epage%3D6226%26doi%3D10.1158%2F1078-0432.CCR-16-3151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stühmer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zöllinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegmund, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grella, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knop, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortüm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unzicker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quadt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chène, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoepfer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Echeverría, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einsele, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wajant, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargou, R. C.</span></span> <span> </span><span class="NLM_article-title">Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1604</span>– <span class="NLM_lpage">1612</span>, <span class="refDoi"> DOI: 10.1038/leu.2008.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1038%2Fleu.2008.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=18480838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpslSntL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=1604-1612&author=T.+St%C3%BChmerauthor=A.+Z%C3%B6llingerauthor=D.+Siegmundauthor=M.+Chatterjeeauthor=E.+Grellaauthor=S.+Knopauthor=M.+Kort%C3%BCmauthor=C.+Unzickerauthor=M.+R.+Jensenauthor=C.+Quadtauthor=P.+Ch%C3%A8neauthor=J.+Schoepferauthor=C.+Garc%C3%ADa-Echeverr%C3%ADaauthor=H.+Einseleauthor=H.+Wajantauthor=R.+C.+Bargou&title=Signalling+profile+and+antitumour+activity+of+the+novel+Hsp90+inhibitor+NVP-AUY922+in+multiple+myeloma&doi=10.1038%2Fleu.2008.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma</span></div><div class="casAuthors">Stuehmer, T.; Zoellinger, A.; Siegmund, D.; Chatterjee, M.; Grella, E.; Knop, S.; Kortuem, M.; Unzicker, C.; Jensen, M. R.; Quadt, C.; Chene, P.; Schoepfer, J.; Garcia-Echeverria, C.; Einsele, H.; Wajant, H.; Bargou, R. C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1604-1612</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We as well as others have recently shown that Hsp90 is overexpressed in multiple myeloma (MM) and critically contributes to tumor cell survival.  Pharmacol. blockade of Hsp90 has consistently been found to induce MM cell death.  However, most data have been obtained with MM cell lines whereas knowledge about the mol. effects of pharmacol. Hsp90 blockade in primary tumor cells is limited.  Furthermore, these investigations have so far focused on geldanamycin derivs.  We analyzed the biochem. effects of a novel diarylisoxazole-based Hsp90 inhibitor (NVP-AUY922) on signalling pathways and cell death in a large set of primary MM tumor samples and in MM cell lines.  Treated cells displayed the mol. signature and pharmacodynamic properties for abrogation of Hsp90 function, such as downregulation of multiple survival pathways and strong upregulation of Hsp70.  NVP-AUY922 treatment efficiently induced MM cell apoptosis and revealed both sensitive and resistant subgroups.  Sensitivity was not correlated with TP53 mutation or Hsp70 induction levels and stromal cells from the bone marrow microenvironment were unable to abrogate NVP-AUY922-induced apoptosis of MM cells.  Thus, NVP-AUY922 may be a promising drug for treatment of MM and clin. studies are warranted.  Leukemia (2008) 22, 1604-1612; doi:10.1038/leu.2008.111; published online 15 May 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY5_BOjQZtgLVg90H21EOLACvtfcHk0ljMK0wCbM-D6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpslSntL8%253D&md5=5a83e6c4e8d05b3ad9fddd3b0d55a63f</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fleu.2008.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2008.111%26sid%3Dliteratum%253Aachs%26aulast%3DSt%25C3%25BChmer%26aufirst%3DT.%26aulast%3DZ%25C3%25B6llinger%26aufirst%3DA.%26aulast%3DSiegmund%26aufirst%3DD.%26aulast%3DChatterjee%26aufirst%3DM.%26aulast%3DGrella%26aufirst%3DE.%26aulast%3DKnop%26aufirst%3DS.%26aulast%3DKort%25C3%25BCm%26aufirst%3DM.%26aulast%3DUnzicker%26aufirst%3DC.%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DQuadt%26aufirst%3DC.%26aulast%3DCh%25C3%25A8ne%26aufirst%3DP.%26aulast%3DSchoepfer%26aufirst%3DJ.%26aulast%3DGarc%25C3%25ADa-Echeverr%25C3%25ADa%26aufirst%3DC.%26aulast%3DEinsele%26aufirst%3DH.%26aulast%3DWajant%26aufirst%3DH.%26aulast%3DBargou%26aufirst%3DR.%2BC.%26atitle%3DSignalling%2520profile%2520and%2520antitumour%2520activity%2520of%2520the%2520novel%2520Hsp90%2520inhibitor%2520NVP-AUY922%2520in%2520multiple%2520myeloma%26jtitle%3DLeukemia%26date%3D2008%26volume%3D22%26spage%3D1604%26epage%3D1612%26doi%3D10.1038%2Fleu.2008.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoepfer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radimerski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guy, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brueggen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quadt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drysdale, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Echeverria, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chène, P.</span></span> <span> </span><span class="NLM_article-title">NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">R33</span> <span class="refDoi"> DOI: 10.1186/bcr1996</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1186%2Fbcr1996" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=18430202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A280%3ADC%252BD1czktlKhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&author=M.+R.+Jensenauthor=J.+Schoepferauthor=T.+Radimerskiauthor=A.+Masseyauthor=C.+T.+Guyauthor=J.+Brueggenauthor=C.+Quadtauthor=A.+Bucklerauthor=R.+Cozensauthor=M.+J.+Drysdaleauthor=C.+Garcia-Echeverriaauthor=P.+Ch%C3%A8ne&title=NVP-AUY922%3A+a+small+molecule+HSP90+inhibitor+with+potent+antitumor+activity+in+preclinical+breast+cancer+models&doi=10.1186%2Fbcr1996"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models</span></div><div class="casAuthors">Jensen Michael Rugaard; Schoepfer Joseph; Radimerski Thomas; Massey Andrew; Guy Chantale T; Brueggen Josef; Quadt Cornelia; Buckler Alan; Cozens Robert; Drysdale Martin J; Garcia-Echeverria Carlos; Chene Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer research : BCR</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">R33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Heat shock protein 90 (HSP90) is a key component of a multichaperone complex involved in the post-translational folding of a large number of client proteins, many of which play essential roles in tumorigenesis.  HSP90 has emerged in recent years as a promising new target for anticancer therapies.  METHODS:  The concentrations of the HSP90 inhibitor NVP-AUY922 required to reduce cell numbers by 50% (GI50 values) were established in a panel of breast cancer cell lines and patient-derived human breast tumors.  To investigate the properties of the compound in vivo, the pharmacokinetic profile, antitumor effect, and dose regimen were established in a BT-474 breast cancer xenograft model.  The effect on HSP90-p23 complexes, client protein degradation, and heat shock response was investigated in cell culture and breast cancer xenografts by immunohistochemistry, Western blot analysis, and immunoprecipitation.  RESULTS:  We show that the novel small molecule HSP90 inhibitor NVP-AUY922 potently inhibits the proliferation of human breast cancer cell lines with GI50 values in the range of 3 to 126 nM.  NVP-AUY922 induced proliferative inhibition concurrent with HSP70 upregulation and client protein depletion--hallmarks of HSP90 inhibition.  Intravenous acute administration of NVP-AUY922 to athymic mice (30 mg/kg) bearing subcutaneous BT-474 breast tumors resulted in drug levels in excess of 1,000 times the cellular GI50 value for about 2 days.  Significant growth inhibition and good tolerability were observed when the compound was administered once per week.  Therapeutic effects were concordant with changes in pharmacodynamic markers, including HSP90-p23 dissociation, decreases in ERBB2 and P-AKT, and increased HSP70 protein levels.  CONCLUSION:  NVP-AUY922 is a potent small molecule HSP90 inhibitor showing significant activity against breast cancer cells in cellular and in vivo settings.  On the basis of its mechanism of action, preclinical activity profile, tolerability, and pharmaceutical properties, the compound recently has entered clinical phase I breast cancer trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQRY3cZ5prrYd1QT_1O5WBYfW6udTcc2eYivd397sVWxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czktlKhuw%253D%253D&md5=2779e042ee1da49407fc813cca82305e</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1186%2Fbcr1996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fbcr1996%26sid%3Dliteratum%253Aachs%26aulast%3DJensen%26aufirst%3DM.%2BR.%26aulast%3DSchoepfer%26aufirst%3DJ.%26aulast%3DRadimerski%26aufirst%3DT.%26aulast%3DMassey%26aufirst%3DA.%26aulast%3DGuy%26aufirst%3DC.%2BT.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DQuadt%26aufirst%3DC.%26aulast%3DBuckler%26aufirst%3DA.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DDrysdale%26aufirst%3DM.%2BJ.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DCh%25C3%25A8ne%26aufirst%3DP.%26atitle%3DNVP-AUY922%253A%2520a%2520small%2520molecule%2520HSP90%2520inhibitor%2520with%2520potent%2520antitumor%2520activity%2520in%2520preclinical%2520breast%2520cancer%2520models%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2008%26volume%3D10%26doi%3D10.1186%2Fbcr1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onozawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuse, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akimov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boku, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtsu, A.</span></span> <span> </span><span class="NLM_article-title">Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">629</span>– <span class="NLM_lpage">636</span>, <span class="refDoi"> DOI: 10.1007/s00280-014-2521-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1007%2Fs00280-014-2521-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=25059319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1egu7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=629-636&author=T.+Doiauthor=Y.+Onozawaauthor=N.+Fuseauthor=T.+Yoshinoauthor=K.+Yamazakiauthor=J.+Watanabeauthor=M.+Akimovauthor=M.+Robsonauthor=N.+Bokuauthor=A.+Ohtsu&title=Phase+I+dose-escalation+study+of+the+HSP90+inhibitor+AUY922+in+Japanese+patients+with+advanced+solid+tumors&doi=10.1007%2Fs00280-014-2521-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors</span></div><div class="casAuthors">Doi, Toshihiko; Onozawa, Yusuke; Fuse, Nozomu; Yoshino, Takayuki; Yamazaki, Kentaro; Watanabe, Junichiro; Akimov, Mikhail; Robson, Matthew; Boku, Narikazu; Ohtsu, Atsushi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">629-636</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: AUY922 is a potent non-geldanamycin inhibitor of heat-shock protein 90.  This study was carried out in Japanese patients to det. the max. tolerated dose (MTD), and to characterize safety, tolerability and pharmacokinetics of single-agent AUY922.  Methods: Japanese patients with advanced solid tumors whose disease had progressed on at least one line of std. therapy, or for whom no std. therapy existed, were treated with AUY922 (i.v., once-weekly, 28-day cycle, starting dose 8 mg/m2).  Results: Thirty-one patients were treated.  Two DLTs were reported in one patient of the 54 mg/m2 cohort; fatigue and decreased appetite (both Grade 3, resolving to Grade 1 within 8 days).  No MTD was detd., and the dose recommended for Phase II studies was detd. to be 70 mg/m2 once-weekly.  Most common drug-related toxicities were diarrhea, night blindness and nausea.  Grade 1 and 2 visual toxicities at high AUY922 doses ≥22 mg/m2 were obsd.  Ten patients (32 %) achieved a best overall response of stable disease, and one patient (3 %) achieved a confirmed partial response.  Conclusion: Overall, AUY922 exhibited acceptable toxicities and demonstrated potential clin. activity in Japanese patients, with similar safety and pharmacokinetic profiles to those reported in a preceding global Phase I study in Western patients (CAUY922A2101).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHpBWf7yeQ6rVg90H21EOLACvtfcHk0li99rjpp9VOag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1egu7bI&md5=b45329cadb86c932a68ced6951b796db</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1007%2Fs00280-014-2521-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-014-2521-x%26sid%3Dliteratum%253Aachs%26aulast%3DDoi%26aufirst%3DT.%26aulast%3DOnozawa%26aufirst%3DY.%26aulast%3DFuse%26aufirst%3DN.%26aulast%3DYoshino%26aufirst%3DT.%26aulast%3DYamazaki%26aufirst%3DK.%26aulast%3DWatanabe%26aufirst%3DJ.%26aulast%3DAkimov%26aufirst%3DM.%26aulast%3DRobson%26aufirst%3DM.%26aulast%3DBoku%26aufirst%3DN.%26aulast%3DOhtsu%26aufirst%3DA.%26atitle%3DPhase%2520I%2520dose-escalation%2520study%2520of%2520the%2520HSP90%2520inhibitor%2520AUY922%2520in%2520Japanese%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2014%26volume%3D74%26spage%3D629%26epage%3D636%26doi%3D10.1007%2Fs00280-014-2521-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seggewiss-Bernhardt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargou, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alegre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bladé, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottmann, O. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Ibarra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akimov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, S. P.</span></span> <span> </span><span class="NLM_article-title">Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">2185</span>– <span class="NLM_lpage">2192</span>, <span class="refDoi"> DOI: 10.1002/cncr.29339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1002%2Fcncr.29339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=25809731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVKntL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2015&pages=2185-2192&author=R.+Seggewiss-Bernhardtauthor=R.+C.+Bargouauthor=Y.+T.+Gohauthor=A.+K.+Stewartauthor=A.+Spencerauthor=A.+Alegreauthor=J.+Blad%C3%A9author=O.+G.+Ottmannauthor=C.+Fernandez-Ibarraauthor=H.+Luauthor=S.+Painauthor=M.+Akimovauthor=S.+P.+Iyer&title=Phase+1%2F1B+trial+of+the+heat+shock+protein+90+inhibitor+NVP-AUY922+as+monotherapy+or+in+combination+with+bortezomib+in+patients+with+relapsed+or+refractory+multiple+myeloma&doi=10.1002%2Fcncr.29339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma</span></div><div class="casAuthors">Seggewiss-Bernhardt, Ruth; Bargou, Ralf C.; Goh, Yeow Tee; Stewart, A. Keith; Spencer, Andrew; Alegre, Adrian; Blade, Joan; Ottmann, Oliver G.; Fernandez-Ibarra, Cristina; Lu, Hong; Pain, Scott; Akimov, Mikhail; Iyer, Swaminathan Padmanabhan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2185-2192</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BACKGROUND : NVP-AUY922 (AUY; Luminespib) with or without bortezomib showed preclin. activity against multiple myeloma (MM) cells.  This phase 1/1B study assessed NVP-AUY922 alone and with bortezomib in patients with relapsed or refractory MM.  METHODS : Dose escalation was guided by an adaptive Bayesian logistic regression model.  In phase 1, patients who progressed after 2 to 4 prior therapies received NVP-AUY922 i.v. once weekly.  In phase 1B, patients who progressed after 2 or fewer prior therapies received NVP-AUY922 plus bortezomib.  The primary objective was to det. the max. tolerated dose (MTD) of NVP-AUY922.  RESULTS : Twenty-four patients received NVP-AUY922 monotherapy at doses of 8 to 70 mg/m2.  One dose-limiting toxicity (DLT) was obsd. (grade 3 blurred vision at 70 mg/m2); no MTD was reached.  The recommended phase 2 dose was 70 mg/m2.  The most frequent drug-related adverse events (AEs) were diarrhea, nausea, and ocular toxicities.  Grade 3/4 AEs were uncommon (<10%).  Eight patients discontinued treatment because of AEs; 5 had ocular toxicities (≥45 mg/m2).  The best response was stable disease in 66.7% of the patients.  There were no partial or complete responses.  Five patients received NVP-AUY922 (which was started at 50 mg/m2) plus bortezomib (1.3 mg/m2).  Three of these patients experienced DLT.  No further dose escalation was performed; the MTD for NVP-AUY922 plus bortezomib was not established.  CONCLUSIONS : This study showed disease stabilization with NVP-AUY922 in patients with relapsed or refractory MM.  The MTD for NVP-AUY922 was not reached, but reversible ocular toxicity has been reported at high dose levels.  Bortezomib at the std. recommended dose plus NVP-AUY922 was not tolerated.  Cancer 2015;121:2185-2192. © 2015 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV8J1qkTHQbbVg90H21EOLACvtfcHk0li99rjpp9VOag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVKntL3L&md5=5ecc6c0563033e7449a8bda4490354ce</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1002%2Fcncr.29339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.29339%26sid%3Dliteratum%253Aachs%26aulast%3DSeggewiss-Bernhardt%26aufirst%3DR.%26aulast%3DBargou%26aufirst%3DR.%2BC.%26aulast%3DGoh%26aufirst%3DY.%2BT.%26aulast%3DStewart%26aufirst%3DA.%2BK.%26aulast%3DSpencer%26aufirst%3DA.%26aulast%3DAlegre%26aufirst%3DA.%26aulast%3DBlad%25C3%25A9%26aufirst%3DJ.%26aulast%3DOttmann%26aufirst%3DO.%2BG.%26aulast%3DFernandez-Ibarra%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DPain%26aufirst%3DS.%26aulast%3DAkimov%26aufirst%3DM.%26aulast%3DIyer%26aufirst%3DS.%2BP.%26atitle%3DPhase%25201%252F1B%2520trial%2520of%2520the%2520heat%2520shock%2520protein%252090%2520inhibitor%2520NVP-AUY922%2520as%2520monotherapy%2520or%2520in%2520combination%2520with%2520bortezomib%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520multiple%2520myeloma%26jtitle%3DCancer%26date%3D2015%26volume%3D121%26spage%3D2185%26epage%3D2192%26doi%3D10.1002%2Fcncr.29339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renouf, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krzyzanowska, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmuck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, M. J.</span></span> <span> </span><span class="NLM_article-title">A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">541</span>– <span class="NLM_lpage">545</span>, <span class="refDoi"> DOI: 10.1007/s00280-016-3102-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1007%2Fs00280-016-3102-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=27422303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ejtLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2016&pages=541-545&author=D.+J.+Renoufauthor=D.+Hedleyauthor=M.+K.+Krzyzanowskaauthor=M.+Schmuckauthor=L.+Wangauthor=M.+J.+Moore&title=A+phase+II+study+of+the+HSP90+inhibitor+AUY922+in+chemotherapy+refractory+advanced+pancreatic+cancer&doi=10.1007%2Fs00280-016-3102-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer</span></div><div class="casAuthors">Renouf, D. J.; Hedley, D.; Krzyzanowska, M. K.; Schmuck, M.; Wang, L.; Moore, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">541-545</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Objectives: AUY922 is a novel heat shock protein inhibitor with preclin. activity in pancreatic cancer.  This phase II study evaluated the efficacy of AUY922 in patients with advanced pancreatic cancer previously treated with chemotherapy.  Methods: In this single-arm, Simon two-stage phase II trial, patients with metastatic or locally advanced pancreatic ductal adenocarcinoma who had progressed on at least one line of chemotherapy and were of good performances status (ECOG 0 or 1) were treated with AUY922 at a dose of 70 mg/m2 IV weekly.  The primary endpoint was disease control rate (objective response and stable disease ≥16 wk).  Results: Twelve patients were accrued, all of whom received treatment.  At least possibly related ≥grade 3 adverse events included fatigue (8 %) and AST elevation (8 %).  Ten patients were evaluable for response with 1 (10 %) having stable disease and 9 (90 %) progressive disease.  The median progression-free survival was 1.6 mo, and the median overall survival was 2.9 mo.  Conclusions: AUY922 was not assocd. with significant efficacy in previously treated patients with advanced pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCYdfJvebVGLVg90H21EOLACvtfcHk0ljx_THmFUHykw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ejtLrJ&md5=e34132dfb40cc97ab41c169c59612e8a</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1007%2Fs00280-016-3102-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-016-3102-y%26sid%3Dliteratum%253Aachs%26aulast%3DRenouf%26aufirst%3DD.%2BJ.%26aulast%3DHedley%26aufirst%3DD.%26aulast%3DKrzyzanowska%26aufirst%3DM.%2BK.%26aulast%3DSchmuck%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMoore%26aufirst%3DM.%2BJ.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520the%2520HSP90%2520inhibitor%2520AUY922%2520in%2520chemotherapy%2520refractory%2520advanced%2520pancreatic%2520cancer%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2016%26volume%3D78%26spage%3D541%26epage%3D545%26doi%3D10.1007%2Fs00280-016-3102-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bendell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penley, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigel, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earwood, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span> <span> </span><span class="NLM_article-title">A phase 2 study of the Hsp90 inhibitor AUY922 as treatment for patients with refractory gastrointestinal stromal tumors</span>. <i>Cancer Invest.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">270</span>, <span class="refDoi"> DOI: 10.1080/07357907.2016.1193746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1080%2F07357907.2016.1193746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=27379708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFCrsr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=265-270&author=J.+C.+Bendellauthor=T.+M.+Bauerauthor=R.+Lamarauthor=M.+Josephauthor=W.+Penleyauthor=D.+S.+Thompsonauthor=D.+R.+Spigelauthor=R.+Oweraauthor=C.+M.+Laneauthor=C.+Earwoodauthor=H.+A.+Burris&title=A+phase+2+study+of+the+Hsp90+inhibitor+AUY922+as+treatment+for+patients+with+refractory+gastrointestinal+stromal+tumors&doi=10.1080%2F07357907.2016.1193746"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors</span></div><div class="casAuthors">Bendell, Johanna C.; Bauer, Todd M.; Lamar, Ruth; Joseph, Mathew; Penley, William; Thompson, Dana S.; Spigel, David R.; Owera, Rami; Lane, Cassie M.; Earwood, Chris; Burris, Howard A., III</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Investigation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">265-270</span>CODEN:
                <span class="NLM_cas:coden">CINVD7</span>;
        ISSN:<span class="NLM_cas:issn">0735-7907</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Background: AUY922 is an inhibitor of heat shock protein 90 (Hsp90).  Hsp90 inhibitors induce kit degrdn. in preclin. gastrointestinal stromal tumor (GIST) models.  This trial was designed to det. the progression-free survival (PFS) of patients with GIST refractory to or intolerant of imatinib and sunitinib.  Methods: Eligible patients received AUY922 70 mg/mg2 by i.v. (IV) infusion on days 1, 8, and 15 of 21-day cycles.  Treatment continued until progression or unacceptable toxicity.  Results: Between Dec. 2011 and Jan. 2015, 25 patients were enrolled (median age, 63 years; 56% male) and received a median of 2 cycles (range: 1-12) of AUY922 treatment.  Thirty-four patients were planned, but enrollment was stopped early due to slow accrual.  Median PFS was 3.9 mo (95% CI: 2.5, 5.3) and median OS was 8.5 mo (95% CI: 5.2, 16.7).  Radiog. response was evaluated in 21 patients; one patient achieved PR (4%) with another 15 having best response of stable disease (60%).  The most common treatment-related adverse event was diarrhea (60% all grades).  Reversible ocular toxicities that resulted in drug hold (24%) or redn. (8%) were also obsd.  Conclusion: AUY922 produced a median PFS which compares favorably to historical controls of placebo (6 wk) for patients refractory to treatment with imatinib.  While diarrhea and ocular toxicities were common, the majority of patients received treatment until disease progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmYmW82WPEprVg90H21EOLACvtfcHk0ljx_THmFUHykw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFCrsr%252FE&md5=5dfc57d92a51bc78c5765387cac0393c</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1080%2F07357907.2016.1193746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07357907.2016.1193746%26sid%3Dliteratum%253Aachs%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DLamar%26aufirst%3DR.%26aulast%3DJoseph%26aufirst%3DM.%26aulast%3DPenley%26aufirst%3DW.%26aulast%3DThompson%26aufirst%3DD.%2BS.%26aulast%3DSpigel%26aufirst%3DD.%2BR.%26aulast%3DOwera%26aufirst%3DR.%26aulast%3DLane%26aufirst%3DC.%2BM.%26aulast%3DEarwood%26aufirst%3DC.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26atitle%3DA%2520phase%25202%2520study%2520of%2520the%2520Hsp90%2520inhibitor%2520AUY922%2520as%2520treatment%2520for%2520patients%2520with%2520refractory%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DCancer%2520Invest.%26date%3D2016%26volume%3D34%26spage%3D265%26epage%3D270%26doi%3D10.1080%2F07357907.2016.1193746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bear, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ying, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsoum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">London, C.</span></span> <span> </span><span class="NLM_article-title">The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors</span>. <i>Exp. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1266</span>– <span class="NLM_lpage">1277</span>, <span class="refDoi"> DOI: 10.1016/j.exphem.2008.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1016%2Fj.exphem.2008.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=18657349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFylsLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=1266-1277&author=T.-Y.+Linauthor=M.+Bearauthor=Z.+Duauthor=K.+P.+Foleyauthor=W.+Yingauthor=J.+Barsoumauthor=C.+London&title=The+novel+HSP90+inhibitor+STA-9090+exhibits+activity+against+Kit-dependent+and+-independent+malignant+mast+cell+tumors&doi=10.1016%2Fj.exphem.2008.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors</span></div><div class="casAuthors">Lin, Tzu-Yin; Bear, Misty; Du, Zhenjian; Foley, Kevin P.; Ying, Weiwen; Barsoum, James; London, Cheryl</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Hematology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1266-1277</span>CODEN:
                <span class="NLM_cas:coden">EXHMA6</span>;
        ISSN:<span class="NLM_cas:issn">0301-472X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Mutations of the receptor tyrosine kinase Kit occur in several human and canine cancers.  While Kit inhibitors have activity in the clin. setting, they possess variable efficacy against particular forms of mutant Kit and drug resistance often develops over time.  Inhibitors of heat shock protein 90 (HSP90), a chaperone for which Kit is a client protein, have demonstrated activity against human cancers and evidence suggests they downregulate several mutated and imatinib-resistant forms of Kit.  The purpose of this study was to evaluate a novel HSP90 inhibitor, STA-9090, against wild-type (WT) and mutant Kit in canine bone marrow-derived cultured mast cells (BMCMCs), malignant mast cell lines, and fresh malignant mast cells.  BMCMCs, cell lines, and fresh malignant mast cells were treated with STA-9090, 17-AAG, and SU11654 and evaluated for loss in cell viability, cell death, alterations in HSP90 and Kit expression/signaling, and Kit mutation.  STA-9090 activity was tested in a canine mastocytoma xenograft model.  Treatment of BMCMCs, cell lines, and fresh malignant cells with STA-9090 induced growth inhibition, apoptosis that was caspase-3/7-dependent, and downregulation of phospho/total Kit and Akt, but not extracellular signal-regulated kinase (ERK) or phosphoinositide-3 kinase (PI-3K).  Loss of Kit cell-surface expression was also obsd.  Furthermore, STA-9090 exhibited superior activity to 17-AAG and SU11654, and was effective against malignant mast cells expressing either WT or mutant Kit.  Lastly, STA-9090 inhibited tumor growth in a canine mastocytoma mouse xenograft model.  STA-9090 exhibits broad activity against mast cells expressing WT or mutant Kit, suggesting it may be an effective agent in the clin. setting against mast cell malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzWCSaAah6lrVg90H21EOLACvtfcHk0lhT323sG1GRCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFylsLvK&md5=0ded2a0f878a699b895088651fc47913</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.exphem.2008.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exphem.2008.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DT.-Y.%26aulast%3DBear%26aufirst%3DM.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DFoley%26aufirst%3DK.%2BP.%26aulast%3DYing%26aufirst%3DW.%26aulast%3DBarsoum%26aufirst%3DJ.%26aulast%3DLondon%26aufirst%3DC.%26atitle%3DThe%2520novel%2520HSP90%2520inhibitor%2520STA-9090%2520exhibits%2520activity%2520against%2520Kit-dependent%2520and%2520-independent%2520malignant%2520mast%2520cell%2520tumors%26jtitle%3DExp.%2520Hematol.%26date%3D2008%26volume%3D36%26spage%3D1266%26epage%3D1277%26doi%3D10.1016%2Fj.exphem.2008.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ying, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proia, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackman, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatsuta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acquaviva, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsoum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koya, K.</span></span> <span> </span><span class="NLM_article-title">Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">484</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0755</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1158%2F1535-7163.MCT-11-0755" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=22144665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=475-484&author=W.+W.+Yingauthor=Z.+J.+Duauthor=L.+J.+Sunauthor=K.+P.+Foleyauthor=D.+A.+Proiaauthor=R.+K.+Blackmanauthor=D.+Zhouauthor=T.+Inoueauthor=N.+Tatsutaauthor=J.+Sangauthor=S.+X.+Yeauthor=J.+Acquavivaauthor=L.+S.+Ogawaauthor=Y.+Wadaauthor=J.+Barsoumauthor=K.+Koya&title=Ganetespib%2C+a+unique+triazolone-containing+Hsp90+inhibitor%2C+exhibits+potent+antitumor+activity+and+a+superior+safety+profile+for+cancer+therapy&doi=10.1158%2F1535-7163.MCT-11-0755"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy</span></div><div class="casAuthors">Ying, Weiwen; Du, Zhenjian; Sun, Lijun; Foley, Kevin P.; Proia, David A.; Blackman, Ronald K.; Zhou, Dan; Inoue, Takayo; Tatsuta, Noriaki; Sang, Jim; Ye, Shuxia; Acquaviva, Jamie; Ogawa, Luisa Shin; Wada, Yumiko; Barsoum, James; Koya, Keizo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">475-484</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Targeted inhibition of the mol. chaperone Hsp90 results in the simultaneous blockade of multiple oncogenic signaling pathways and has, thus, emerged as an attractive strategy for the development of novel cancer therapeutics.  Ganetespib (formerly known as STA-9090) is a unique resorcinolic triazolone inhibitor of Hsp90 that is currently in clin. trials for a no. of human cancers.  In the present study, we showed that ganetespib exhibits potent in vitro cytotoxicity in a range of solid and hematol. tumor cell lines, including those that express mutated kinases that confer resistance to small-mol. tyrosine kinase inhibitors.  Ganetespib treatment rapidly induced the degrdn. of known Hsp90 client proteins, displayed superior potency to the ansamycin inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG), and exhibited sustained activity even with short exposure times.  In vivo, ganetespib showed potent antitumor efficacy in solid and hematol. xenograft models of oncogene addiction, as evidenced by significant growth inhibition and/or regressions.  Notably, evaluation of the microregional activity of ganetespib in tumor xenografts showed that ganetespib was efficiently distributed throughout tumor tissue, including hypoxic regions >150 μm from the microvasculature, to inhibit proliferation and induce apoptosis.  Importantly, ganetespib showed no evidence of cardiac or liver toxicity.  Taken together, this preclin. activity profile indicates that ganetespib may have broad application for a variety of human malignancies, and with select mechanistic and safety advantages over other first- and second-generation Hsp90 inhibitors.  Mol Cancer Ther; 11(2); 475-84.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFhzG1TPr4lbVg90H21EOLACvtfcHk0liu2Inz5c7W1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWksrY%253D&md5=269d41b30e5add9b9503cb43a98b0157</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0755%26sid%3Dliteratum%253Aachs%26aulast%3DYing%26aufirst%3DW.%2BW.%26aulast%3DDu%26aufirst%3DZ.%2BJ.%26aulast%3DSun%26aufirst%3DL.%2BJ.%26aulast%3DFoley%26aufirst%3DK.%2BP.%26aulast%3DProia%26aufirst%3DD.%2BA.%26aulast%3DBlackman%26aufirst%3DR.%2BK.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DTatsuta%26aufirst%3DN.%26aulast%3DSang%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DS.%2BX.%26aulast%3DAcquaviva%26aufirst%3DJ.%26aulast%3DOgawa%26aufirst%3DL.%2BS.%26aulast%3DWada%26aufirst%3DY.%26aulast%3DBarsoum%26aufirst%3DJ.%26aulast%3DKoya%26aufirst%3DK.%26atitle%3DGanetespib%252C%2520a%2520unique%2520triazolone-containing%2520Hsp90%2520inhibitor%252C%2520exhibits%2520potent%2520antitumor%2520activity%2520and%2520a%2520superior%2520safety%2520profile%2520for%2520cancer%2520therapy%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D475%26epage%3D484%26doi%3D10.1158%2F1535-7163.MCT-11-0755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lock, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carol, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maris, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorlick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keir, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billups, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurmasheva, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houghton, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. A.</span></span> <span> </span><span class="NLM_article-title">Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program</span>. <i>Pediatr. Blood Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">E42</span>– <span class="NLM_lpage">E45</span>, <span class="refDoi"> DOI: 10.1002/pbc.24451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1002%2Fpbc.24451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=23303741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslWhu7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2013&pages=E42-E45&author=R.+B.+Lockauthor=H.+Carolauthor=J.+M.+Marisauthor=M.+H.+Kangauthor=C.+P.+Reynoldsauthor=E.+A.+Kolbauthor=R.+Gorlickauthor=S.+T.+Keirauthor=C.+A.+Billupsauthor=R.+T.+Kurmashevaauthor=P.+J.+Houghtonauthor=M.+A.+Smith&title=Initial+testing+%28stage+1%29+of+ganetespib%2C+an+Hsp90+inhibitor%2C+by+the+pediatric+preclinical+testing+program&doi=10.1002%2Fpbc.24451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program</span></div><div class="casAuthors">Lock, Richard B.; Carol, Hernan; Maris, John M.; Kang, Min H.; Reynolds, C. Patrick; Kolb, E. Anders; Gorlick, Richard; Keir, Stephen T.; Billups, Catherine A.; Kurmasheva, Raushan T.; Houghton, Peter J.; Smith, Malcolm A.</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric Blood & Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">E42-E45, 4</span>CODEN:
                <span class="NLM_cas:coden">PBCEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1545-5017</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Ganetespib, an Hsp90 inhibitor, was tested against the PPTP in vitro cell line panel and selected xenografts in vivo, including JAK2- and BRAF-mutated models.  Ganetespib demonstrated potent in vitro cytotoxic activity (median rIC50 8.8 nM, range 4.4- 27.1 nM).  In vivo, ganetespib induced significant differences in EFS distribution for 4 of 11 xenografts.  Intermediate activity (EFS T/C > 2) was noted only for the MV4;11 xenograft, and there were no objective responses.  Administered as single agents, Hsp90 inhibitors examd. by the PPTP have shown limited evidence for a therapeutic window against both solid tumor and leukemia pediatric preclin. models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxyDM0rHGFS7Vg90H21EOLACvtfcHk0liu2Inz5c7W1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslWhu7bJ&md5=20c807fb3c0f989ef4825d486764032f</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1002%2Fpbc.24451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpbc.24451%26sid%3Dliteratum%253Aachs%26aulast%3DLock%26aufirst%3DR.%2BB.%26aulast%3DCarol%26aufirst%3DH.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26aulast%3DKang%26aufirst%3DM.%2BH.%26aulast%3DReynolds%26aufirst%3DC.%2BP.%26aulast%3DKolb%26aufirst%3DE.%2BA.%26aulast%3DGorlick%26aufirst%3DR.%26aulast%3DKeir%26aufirst%3DS.%2BT.%26aulast%3DBillups%26aufirst%3DC.%2BA.%26aulast%3DKurmasheva%26aufirst%3DR.%2BT.%26aulast%3DHoughton%26aufirst%3DP.%2BJ.%26aulast%3DSmith%26aufirst%3DM.%2BA.%26atitle%3DInitial%2520testing%2520%2528stage%25201%2529%2520of%2520ganetespib%252C%2520an%2520Hsp90%2520inhibitor%252C%2520by%2520the%2520pediatric%2520preclinical%2520testing%2520program%26jtitle%3DPediatr.%2520Blood%2520Cancer%26date%3D2013%26volume%3D60%26spage%3DE42%26epage%3DE45%26doi%3D10.1002%2Fpbc.24451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jhaveri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lake, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilewski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldfarb, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drullinsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugarman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasserheit-Leiblich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moynahan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddington, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haque, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vukovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Hariry, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, S.</span></span> <span> </span><span class="NLM_article-title">A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer</span>. <i>Clin. Breast Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">160</span>, <span class="refDoi"> DOI: 10.1016/j.clbc.2013.12.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1016%2Fj.clbc.2013.12.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=24512858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFegsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=154-160&author=K.+Jhaveriauthor=S.+Chandarlapatyauthor=D.+Lakeauthor=T.+Gilewskiauthor=M.+Robsonauthor=S.+Goldfarbauthor=P.+Drullinskyauthor=S.+Sugarmanauthor=C.+Wasserheit-Leiblichauthor=J.+Fasanoauthor=M.+E.+Moynahanauthor=G.+D%E2%80%99Andreaauthor=K.+Limauthor=L.+Reddingtonauthor=S.+Haqueauthor=S.+Patilauthor=L.+Baumanauthor=V.+Vukovicauthor=I.+El-Hariryauthor=C.+Hudisauthor=S.+Modi&title=A+phase+II+open-label+study+of+ganetespib%2C+a+novel+heat+shock+protein+90+inhibitor+for+patients+with+metastatic+breast+cancer&doi=10.1016%2Fj.clbc.2013.12.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer</span></div><div class="casAuthors">Jhaveri, Komal; Chandarlapaty, Sarat; Lake, Diana; Gilewski, Teresa; Robson, Mark; Goldfarb, Shari; Drullinsky, Pamela; Sugarman, Steven; Wasserheit-Leiblich, Carolyn; Fasano, Julie; Moynahan, Mary Ellen; D'Andrea, Gabriella; Lim, Kristina; Reddington, Laura; Haque, Sofia; Patil, Sujata; Bauman, Lynne; Vukovic, Vojo; El-Hariry, Iman; Hudis, Clifford; Modi, Shanu</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Breast Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">154-160</span>CODEN:
                <span class="NLM_cas:coden">CBCLB7</span>;
        ISSN:<span class="NLM_cas:issn">1526-8209</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background:Ganetespib is a small mol., nongeldanamycin HSP90 inhibitor with potent inhibitory effects on HSP90-dependent oncoproteins of relevance to breast cancer pathogenesis.  We therefore tested ganetespib in an unselected cohort of patients with MBC.  Patients and Methods: Patients were treated with single agent ganetespib at 200 mg/m2 once weekly for 3 wk, on a 28-day cycle.  Therapy was continued until disease progression.  The primary end point was ORR using Reponse Evaluation Criteria in Solid Tumors version 1.1.  Results: Twenty-two patients were enrolled with a median age of 51(range, 38-70) years and a median Eastern Cooperative Oncol. Group performance status of 0 (range, 0-1).  Most patients had at least 2 previous lines of chemotherapy in the metastatic setting.  Most common toxicities, largely grade 1/2, were diarrhea, fatigue, nausea, and hypersensitivity reaction.  The ORR in this unselected population was 9%, with all responses coming from the subset of patients with HER2-pos. MBC (2/13; 15%).  One patient with TNBC had objective tumor regression in the lung metastases.  The clin. benefit rate (complete response + partial response + stable disease > 6 mo) was 9%, median progression-free survival was 7 wk (95% confidence interval [CI], 7-19), and median overall survival was 46 wk (95% CI, 27-not applicable).  Conclusion: The study did not meet the prespecified criteria for ORR in the first stage of the Simon 2-stage model in this heavily pretreated unselected population of MBC.  However, activity was obsd. in trastuzumab-refractory HER2-pos. and TNBC.  Ganetespib was well tolerated and responses in more targeted populations harboring specific HSP90-dependent oncoproteins justifies its further study, particularly as part of rational combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKRWFzPxBRzbVg90H21EOLACvtfcHk0lhAzD9W_zEw2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFegsLc%253D&md5=15edad6cf71a9559eb42997563c57f53</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.clbc.2013.12.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clbc.2013.12.012%26sid%3Dliteratum%253Aachs%26aulast%3DJhaveri%26aufirst%3DK.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DLake%26aufirst%3DD.%26aulast%3DGilewski%26aufirst%3DT.%26aulast%3DRobson%26aufirst%3DM.%26aulast%3DGoldfarb%26aufirst%3DS.%26aulast%3DDrullinsky%26aufirst%3DP.%26aulast%3DSugarman%26aufirst%3DS.%26aulast%3DWasserheit-Leiblich%26aufirst%3DC.%26aulast%3DFasano%26aufirst%3DJ.%26aulast%3DMoynahan%26aufirst%3DM.%2BE.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DG.%26aulast%3DLim%26aufirst%3DK.%26aulast%3DReddington%26aufirst%3DL.%26aulast%3DHaque%26aufirst%3DS.%26aulast%3DPatil%26aufirst%3DS.%26aulast%3DBauman%26aufirst%3DL.%26aulast%3DVukovic%26aufirst%3DV.%26aulast%3DEl-Hariry%26aufirst%3DI.%26aulast%3DHudis%26aufirst%3DC.%26aulast%3DModi%26aufirst%3DS.%26atitle%3DA%2520phase%2520II%2520open-label%2520study%2520of%2520ganetespib%252C%2520a%2520novel%2520heat%2520shock%2520protein%252090%2520inhibitor%2520for%2520patients%2520with%2520metastatic%2520breast%2520cancer%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D154%26epage%3D160%26doi%3D10.1016%2Fj.clbc.2013.12.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jhaveri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teplinsky, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadoo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speyer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haque, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteva, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, S.</span></span> <span> </span><span class="NLM_article-title">A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>, <span class="NLM_elocation-id">89</span> <span class="refDoi"> DOI: 10.1186/s13058-017-0879-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1186%2Fs13058-017-0879-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=28764748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVGju7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&author=K.+Jhaveriauthor=R.+Wangauthor=E.+Teplinskyauthor=S.+Chandarlapatyauthor=D.+Solitauthor=K.+Cadooauthor=J.+Speyerauthor=G.+D%E2%80%99Andreaauthor=S.+Adamsauthor=S.+Patilauthor=S.+Haqueauthor=T.+O%E2%80%99Neillauthor=K.+Friedmanauthor=F.+J.+Estevaauthor=C.+Hudisauthor=S.+Modi&title=A+phase+I+trial+of+ganetespib+in+combination+with+paclitaxel+and+trastuzumab+in+patients+with+human+epidermal+growth+factor+receptor-2+%28HER2%29-positive+metastatic+breast+cancer&doi=10.1186%2Fs13058-017-0879-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer</span></div><div class="casAuthors">Jhaveri, Komal; Wang, Rui; Teplinsky, Eleonora; Chandarlapaty, Sarat; Solit, David; Cadoo, Karen; Speyer, James; D'Andrea, Gabriella; Adams, Sylvia; Patil, Sujata; Haque, Sofia; O'Neill, Tara; Friedman, Kent; Esteva, Francisco J.; Hudis, Clifford; Modi, Shanu</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89/1-89/8</span>CODEN:
                <span class="NLM_cas:coden">BRCRFS</span>;
        ISSN:<span class="NLM_cas:issn">1465-542X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Targeted therapies in HER2-pos. metastatic breast cancer significantly improve outcomes but efficacy is limited by therapeutic resistance.  HER2 is an acutely sensitive Heat Shock Protein 90 (HSP90) client and HSP90 inhibition can overcome trastuzumab resistance.  Preclin. data suggest that HSP90 inhibition is synergistic with taxanes with the potential for significant clin. activity.  We therefore tested ganetespib, a HSP90 inhibitor, in combination with paclitaxel and trastuzumab in patients with trastuzumab-refractory HER2-pos. metastatic breast cancer.  Methods: In this phase I dose-escalation study, patients with trastuzumab-resistant HER2-pos. metastatic breast cancer received weekly trastuzumab (2 mg/kg) and paclitaxel (80 mg/m2) on days 1, 8, 15, and 22 of a 28-day cycle with escalating doses of ganetespib (100 mg/m2, 150 mg/m2, and a third cohort of 125 mg/m2 if needed) on days 1, 8, and 15.  Therapy was continued until disease progression or toxicity.  The primary objective was to establish the safety and max. tolerated dose and/or recommended phase II dose (RP2D) of this therapy.  The secondary objectives included evaluation of the effects of ganetespib on the pharmacokinetics of paclitaxel, and to make a preliminary assessment of the efficacy of the combination therapy.  Results: Dose escalation was completed for the two main cohorts without any obsd. dose-limiting toxicities.  Nine patients received treatment.  The median prior lines of anti-HER2 therapy numbered three (range 2-4), including prior pertuzumab in 9/9 patients and ado-trastuzumab emtansine (T-DM1) in 8/9 patients.  The most common grade 1/2 adverse events (AEs) were diarrhea, fatigue, anemia, and rash.  There were no grade 4 AEs related to ganetespib.  The overall response rate was 22% (2/9 patients had partial response) and stable disease was seen in 56% (5/9 patients).  The clin. benefit rate was 44% (4/9 patients).  The median progression-free survival was 20 wk (range 8-55).  Conclusion: The RP2D of ganetespib is 150 mg/m2 in combination with weekly paclitaxel plus trastuzumab.  The combination was safe and well tolerated.  Despite prior taxanes, pertuzumab, and T-DM1, clin. activity of this triplet regimen in this heavily pretreated cohort is promising and warrants further study in HER2-pos. metastatic breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUSvrm6d3_trVg90H21EOLACvtfcHk0lgaA3xsVZe7xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVGju7zO&md5=7e725dae322c9d5b8cf3967665da5c82</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1186%2Fs13058-017-0879-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-017-0879-5%26sid%3Dliteratum%253Aachs%26aulast%3DJhaveri%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DTeplinsky%26aufirst%3DE.%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DSolit%26aufirst%3DD.%26aulast%3DCadoo%26aufirst%3DK.%26aulast%3DSpeyer%26aufirst%3DJ.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DG.%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DPatil%26aufirst%3DS.%26aulast%3DHaque%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DT.%26aulast%3DFriedman%26aufirst%3DK.%26aulast%3DEsteva%26aufirst%3DF.%2BJ.%26aulast%3DHudis%26aufirst%3DC.%26aulast%3DModi%26aufirst%3DS.%26atitle%3DA%2520phase%2520I%2520trial%2520of%2520ganetespib%2520in%2520combination%2520with%2520paclitaxel%2520and%2520trastuzumab%2520in%2520patients%2520with%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520%2528HER2%2529-positive%2520metastatic%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2017%26volume%3D19%26doi%3D10.1186%2Fs13058-017-0879-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heilbrun, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonarakis, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaishampayan, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzinic, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heath, E. I.</span></span> <span> </span><span class="NLM_article-title">A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study</span>. <i>Invest. New Drug.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1007/s10637-015-0307-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1007%2Fs10637-015-0307-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=26581400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWlsLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=112-118&author=M.+K.+Thakurauthor=L.+K.+Heilbrunauthor=S.+Shengauthor=M.+Steinauthor=G.+Liuauthor=E.+S.+Antonarakisauthor=U.+Vaishampayanauthor=S.+H.+Dzinicauthor=X.+Liauthor=S.+Freemanauthor=D.+Smithauthor=E.+I.+Heath&title=A+phase+II+trial+of+ganetespib%2C+a+heat+shock+protein+90+Hsp90%29+inhibitor%2C+in+patients+with+docetaxel-pretreated+metastatic+castrate-resistant+prostate+cancer+%28CRPC%29-a+prostate+cancer+clinical+trials+consortium+%28PCCTC%29+study&doi=10.1007%2Fs10637-015-0307-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study</span></div><div class="casAuthors">Thakur, Manish K.; Heilbrun, Lance K.; Sheng, Shijie; Stein, Mark; Liu, Glenn; Antonarakis, Emmanuel S.; Vaishampayan, Ulka; Dzinic, Sijana H.; Li, Xiaohua; Freeman, Stacy; Smith, Daryn; Heath, Elisabeth I.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">112-118</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Introduction Heat shock protein 90 (Hsp90) has been studied as a therapeutic target in many cancers.  In preclin. trials, the Hsp90 ATPase inhibitor ganetespib demonstrated potent inhibition of solid tumor growth, with superior potency than prior Hsp90 inhibitors.  Given the promising preclin. outcome and favorable pharmacol. properties of ganetespib, we conducted a phase II trial of single-agent ganetespib in patients with metastatic, castrate-resistant prostate cancer (mCRPC).  The primary objective of the study was to det. the 6-mo progression-free survival (PFS) rate.  Methods Patients with mCRPC who had been previously treated with docetaxel were enrolled after meeting eligibility criteria.  All patients received ganetespib at 200 mg/m2 on days 1, 8, and 15 of every 28 days (one cycle).  Subjects who tolerated therapy were continued on ganetespib until disease progression.  Considering that Hsp90 acetylation may confer insensitivity to Hsp90 inhibitors and maspin inhibits protein deacetylation, maspin-assocd. mol. markers were evaluated.  Results Eighteen patients were recruited into the trial; most were Caucasian, had performance status 1, had received prior docetaxel, and were heavily pretreated.  Of the 17 patients who were treated, none attained 6-mo PFS.  Only 2 patients achieved PFS > 4 mo.  The median PFS was 1.9 mo.  As per the study design, the trial was terminated after the interim anal.  The most frequent types of Grade 3 toxicity were dehydration, diarrhea, and fatigue.  Mol. markers provided little addnl. insight regarding drug activity.  Conclusions Ganetespib demonstrated minimal clin. activity in men with mCRPC.  The true 6-mo PFS rate was, at most, 0.20.  Possible reasons for this include selection of a heavily pretreated patient population and lack of agent potency in patients with mCRPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEc_FjjTbGprVg90H21EOLACvtfcHk0likUyqbZfpA0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWlsLjN&md5=08f9e46b0d9880d2caa2395be001ce8e</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1007%2Fs10637-015-0307-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-015-0307-6%26sid%3Dliteratum%253Aachs%26aulast%3DThakur%26aufirst%3DM.%2BK.%26aulast%3DHeilbrun%26aufirst%3DL.%2BK.%26aulast%3DSheng%26aufirst%3DS.%26aulast%3DStein%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DAntonarakis%26aufirst%3DE.%2BS.%26aulast%3DVaishampayan%26aufirst%3DU.%26aulast%3DDzinic%26aufirst%3DS.%2BH.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DFreeman%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DHeath%26aufirst%3DE.%2BI.%26atitle%3DA%2520phase%2520II%2520trial%2520of%2520ganetespib%252C%2520a%2520heat%2520shock%2520protein%252090%2520Hsp90%2529%2520inhibitor%252C%2520in%2520patients%2520with%2520docetaxel-pretreated%2520metastatic%2520castrate-resistant%2520prostate%2520cancer%2520%2528CRPC%2529-a%2520prostate%2520cancer%2520clinical%2520trials%2520consortium%2520%2528PCCTC%2529%2520study%26jtitle%3DInvest.%2520New%2520Drug.%26date%3D2016%26volume%3D34%26spage%3D112%26epage%3D118%26doi%3D10.1007%2Fs10637-015-0307-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadlow, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaszkowsky, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolpin, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCleary, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheehan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundaram, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karol, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, A. X.</span></span> <span> </span><span class="NLM_article-title">A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma</span>. <i>Invest. New Drug.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">128</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1007/s10637-014-0164-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1007%2Fs10637-014-0164-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=25248753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVSru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=128-137&author=L.+Goyalauthor=R.+C.+Wadlowauthor=L.+S.+Blaszkowskyauthor=B.+M.+Wolpinauthor=T.+A.+Abramsauthor=N.+J.+McClearyauthor=S.+Sheehanauthor=E.+Sundaramauthor=M.+D.+Karolauthor=J.+Chenauthor=A.+X.+Zhu&title=A+phase+I+and+pharmacokinetic+study+of+ganetespib+%28STA-9090%29+in+advanced+hepatocellular+carcinoma&doi=10.1007%2Fs10637-014-0164-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma</span></div><div class="casAuthors">Goyal, Lipika; Wadlow, Raymond C.; Blaszkowsky, Lawrence S.; Wolpin, Brian M.; Abrams, Thomas A.; McCleary, Nadine Jackson; Sheehan, Susan; Sundaram, Eamala; Karol, Michael D.; Chen, John; Zhu, Andrew X.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">128-137</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Background: Ganetespib (STA-9090) is an Hsp90 inhibitor that downregulates VEGFR, c-MET, HER2, IGF-IR, EGFR, and other Hsp90 client proteins involved in hepatocarcinogenesis, thereby making it an attractive therapy for HCC.  This Phase I study was performed to establish the safety, tolerability, recommended Phase 2 dose (RP2D), and preliminary clin. activity of ganetespib in previously treated patients with advanced HCC.  Methods: Patients with advanced HCC, Child-Pugh A cirrhosis, progression on or intolerance to sorafenib, and ECOG PS ≤ 1 were enrolled in a std. 3x3 dose escalation study at doses of 100 mg/m2, 150 mg/m2, and 200 mg/m2 IV given on days 1, 8, and 15 of each 28-day cycle.  Objective response by RECIST version 1.1 criteria was evaluated by CT/MRI every 8 wk.  Results: Fourteen patients were enrolled in this trial and received at least one dose of the study drug.  Of the 14 patients: median age, 57 years old; male 71 %; Asian 36 %; HCC etiol. (HBV 36 %, HCV 43 %, Hemachromatosis 7 %, unknown 21 %); Child Pugh Class (A 93 %, B 7 %); median no. of prior treatments 2; median baseline AFP 70.1 ng/mL.  The RP2D was detd. to be 200 mg/m2.  The most commonly seen AEs were diarrhea (93 %), fatigue (71 %), AST elevation (64 %), and hyperglycemia (64 %).  The most common Gr 3/4 AEs were hyperglycemia (21 %) and lipasemia (21 %).  One (7 %) patient had a fatal AE, septic shock, within 30 days of receiving the study drug.  One dose-limiting toxicity, grade 3 lipasemia, was obsd. at the 100 mg/m2 dose.  Pharmacokinetics studies showed a t1/2, CL, Tmax, and Vss of 6.45 h, 48.28 L/h (25.56 L/h/m2), 0.76 h, and 191 L (100.4 L/m2), resp.  No objective responses were seen; one patient (7 %) had stable disease at 16 wk.  Median time to progression was 1.8 mo, and median overall survival was 7.2 mo.  Conclusion: Ganetespib had a manageable safety profile in patients with advanced HCC who had progressed on at least one line of systemic therapy.  The pharmacokinetic profile showed that ganetespib exposure in patients with mild hepatic dysfunction is similar to that seen in patients with normal liver function.  Ganetespib showed limited clin. benefit in patients with advanced HCC in this phase I trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr57teDffjuSrVg90H21EOLACvtfcHk0likUyqbZfpA0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVSru7c%253D&md5=c55ec15b28353dea4e1aca73525f7e9b</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1007%2Fs10637-014-0164-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-014-0164-8%26sid%3Dliteratum%253Aachs%26aulast%3DGoyal%26aufirst%3DL.%26aulast%3DWadlow%26aufirst%3DR.%2BC.%26aulast%3DBlaszkowsky%26aufirst%3DL.%2BS.%26aulast%3DWolpin%26aufirst%3DB.%2BM.%26aulast%3DAbrams%26aufirst%3DT.%2BA.%26aulast%3DMcCleary%26aufirst%3DN.%2BJ.%26aulast%3DSheehan%26aufirst%3DS.%26aulast%3DSundaram%26aufirst%3DE.%26aulast%3DKarol%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DA.%2BX.%26atitle%3DA%2520phase%2520I%2520and%2520pharmacokinetic%2520study%2520of%2520ganetespib%2520%2528STA-9090%2529%2520in%2520advanced%2520hepatocellular%2520carcinoma%26jtitle%3DInvest.%2520New%2520Drug.%26date%3D2015%26volume%3D33%26spage%3D128%26epage%3D137%26doi%3D10.1007%2Fs10637-014-0164-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Socinski, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Hariry, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koczywas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vukovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paschold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonomi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahmer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belani, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huberman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teofilovici, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span> <span> </span><span class="NLM_article-title">A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non–small cell lung cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">3068</span>– <span class="NLM_lpage">3077</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-3381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1158%2F1078-0432.CCR-12-3381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=23553849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC3sXos12isLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=3068-3077&author=M.+A.+Socinskiauthor=J.+Goldmanauthor=I.+El-Hariryauthor=M.+Koczywasauthor=V.+Vukovicauthor=L.+Hornauthor=E.+Pascholdauthor=R.+Salgiaauthor=H.+Westauthor=L.+V.+Sequistauthor=P.+Bonomiauthor=J.+Brahmerauthor=L.-C.+Chenauthor=A.+Sandlerauthor=C.+P.+Belaniauthor=T.+Webbauthor=H.+Harperauthor=M.+Hubermanauthor=S.+Ramalingamauthor=K.-K.+Wongauthor=F.+Teofiloviciauthor=W.+Guoauthor=G.+I.+Shapiro&title=A+multicenter+phase+II+study+of+ganetespib+monotherapy+in+patients+with+genotypically+defined+advanced+non%E2%80%93small+cell+lung+cancer&doi=10.1158%2F1078-0432.CCR-12-3381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Socinski, Mark A.; Goldman, Jonathan; El-Hariry, Iman; Koczywas, Marianna; Vukovic, Vojo; Horn, Leora; Paschold, Eugene; Salgia, Ravi; West, Howard; Sequist, Lecia V.; Bonomi, Philip; Brahmer, Julie; Chen, Lin-Chi; Sandler, Alan; Belani, Chandra P.; Webb, Timothy; Harper, Harry; Huberman, Mark; Ramalingam, Suresh; Wong, Kwok-Kin; Teofilovici, Florentina; Guo, Wei; Shapiro, Geoffrey I.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3068-3077</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Ganetespib is a novel inhibitor of the heat shock protein 90 (Hsp90), a chaperone protein crit. to tumor growth and proliferation.  In this phase II study, we evaluated the activity and tolerability of ganetespib in previously treated patients with non-small cell lung cancer (NSCLC).  Exptl. Design: Patients were enrolled into cohort A (mutant EGFR), B (mutant KRAS), or C (no EGFR or KRAS mutations).  Patients were treated with 200 mg/m2 ganetespib by i.v. infusion once weekly for 3 wk followed by 1 wk of rest, until disease progression.  The primary endpoint was progression-free survival (PFS) at 16 wk.  Secondary endpoints included objective response (ORR), duration of treatment, tolerability, median PFS, overall survival (OS), and correlative studies.  Results: Ninety-nine patients with a median of 2 prior systemic therapies were enrolled; 98 were assigned to cohort A (n = 15), B (n = 17), or C (n = 66), with PFS rates at 16 wk of 13.3%, 5.9%, and 19.7%, resp.  Four patients (4%) achieved partial response (PR); all had disease that harbored anaplastic lymphoma kinase (ALK) gene rearrangement, retrospectively detected by FISH (n = 1) or PCR-based assays (n = 3), in crizotinib-naive patients enrolled to cohort C. Eight patients (8.1%) experienced treatment-related serious adverse events (AE); 2 of these (cardiac arrest and renal failure) resulted in death.  The most common AEs were diarrhea, fatigue, nausea, and anorexia.  Conclusions: Ganetespib monotherapy showed a manageable side effect profile as well as clin. activity in heavily pretreated patients with advanced NSCLCs, particularly in patients with tumors harboring ALK gene rearrangement.  Clin Cancer Res; 19(11); 3068-77. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFukeZlyNCmbVg90H21EOLACvtfcHk0lg274jl2dSggA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXos12isLw%253D&md5=7fe5177633a6f003a7412431e6fb492d</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-3381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-3381%26sid%3Dliteratum%253Aachs%26aulast%3DSocinski%26aufirst%3DM.%2BA.%26aulast%3DGoldman%26aufirst%3DJ.%26aulast%3DEl-Hariry%26aufirst%3DI.%26aulast%3DKoczywas%26aufirst%3DM.%26aulast%3DVukovic%26aufirst%3DV.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DPaschold%26aufirst%3DE.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DWest%26aufirst%3DH.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DBonomi%26aufirst%3DP.%26aulast%3DBrahmer%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DL.-C.%26aulast%3DSandler%26aufirst%3DA.%26aulast%3DBelani%26aufirst%3DC.%2BP.%26aulast%3DWebb%26aufirst%3DT.%26aulast%3DHarper%26aufirst%3DH.%26aulast%3DHuberman%26aufirst%3DM.%26aulast%3DRamalingam%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DTeofilovici%26aufirst%3DF.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26atitle%3DA%2520multicenter%2520phase%2520II%2520study%2520of%2520ganetespib%2520monotherapy%2520in%2520patients%2520with%2520genotypically%2520defined%2520advanced%2520non%25E2%2580%2593small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D3068%26epage%3D3077%26doi%3D10.1158%2F1078-0432.CCR-12-3381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raju, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Hariry, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teofilivici, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vukovic, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karol, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, L. S.</span></span> <span> </span><span class="NLM_article-title">A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">152</span> <span class="refDoi"> DOI: 10.1186/1471-2407-13-152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1186%2F1471-2407-13-152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=23530663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotVKisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&author=J.+W.+Goldmanauthor=R.+N.+Rajuauthor=G.+A.+Gordonauthor=I.+El-Hariryauthor=F.+Teofiliviciauthor=V.+M.+Vukovicauthor=R.+Bradleyauthor=M.+D.+Karolauthor=Y.+Chenauthor=W.+Guoauthor=T.+Inoueauthor=L.+S.+Rosen&title=A+first+in+human%2C+safety%2C+pharmacokinetics%2C+and+clinical+activity+phase+I+study+of+once+weekly+administration+of+the+Hsp90+inhibitor+ganetespib+%28STA-9090%29+in+patients+with+solid+malignancies&doi=10.1186%2F1471-2407-13-152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies</span></div><div class="casAuthors">Goldman, Jonathan W.; Raju, Robert N.; Gordon, Gregory A.; El-Hariry, Iman; Teofilivici, Florentina; Vukovic, Vojo M.; Bradley, Robert; Karol, Michael D.; Chen, Yu; Guo, Wei; Inoue, Takayo; Rosen, Lee S.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">152</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: This phase I study investigated the max. tolerated dose (MTD), safety, pharmacokinetics and antitumor activity of ganetespib in patients with solid malignancies.  Methods: Patients were enrolled in cohorts of escalating ganetespib doses, given as 1 h IV infusion, once weekly for 3 wk, followed by a 1-wk rest until disease progression or unacceptable toxicity.  Endpoints included safety, pharmacokinetic and pharmacodynamic parameters and preliminary clin. activity.  Results: Fifty-three patients were treated at doses escalating from 7 to 259 mg/m2.  The most common adverse events were Grade 1 and 2 diarrhea, fatigue, nausea or vomiting.  Dose-limiting toxicities (DLT) obsd. were: one Grade 3 amylase elevation (150 mg/m2), one Grade 3 diarrhea and one Grade 3 and one Grade 4 asthenia (259 mg/m2).  The MTD was 216 mg/m2 and the recommended phase 2 dose was established at 200 mg/m2 given IV at Days 1, 8, and 15 every 4 wk.  There was a linear relationship between dose and exposure.  Plasma HSP70 protein levels remained elevated for over a week post treatment.  Disease control rate (objective response and stable disease at ≥16 wk) was 24.4%.  Conclusions: Ganetespib is well tolerated as a weekly infusion for 3 of every 4 wk cycle.  The recommended phase II dose is 200 mg/m2, and is assocd. with an acceptable tolerability profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_c-SmyNHbmbVg90H21EOLACvtfcHk0liRS6rJA9vD9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotVKisbc%253D&md5=55823d1bccdb38864b2528a787e3d16b</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-13-152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-13-152%26sid%3Dliteratum%253Aachs%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DRaju%26aufirst%3DR.%2BN.%26aulast%3DGordon%26aufirst%3DG.%2BA.%26aulast%3DEl-Hariry%26aufirst%3DI.%26aulast%3DTeofilivici%26aufirst%3DF.%26aulast%3DVukovic%26aufirst%3DV.%2BM.%26aulast%3DBradley%26aufirst%3DR.%26aulast%3DKarol%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DRosen%26aufirst%3DL.%2BS.%26atitle%3DA%2520first%2520in%2520human%252C%2520safety%252C%2520pharmacokinetics%252C%2520and%2520clinical%2520activity%2520phase%2520I%2520study%2520of%2520once%2520weekly%2520administration%2520of%2520the%2520Hsp90%2520inhibitor%2520ganetespib%2520%2528STA-9090%2529%2520in%2520patients%2520with%2520solid%2520malignancies%26jtitle%3DBMC%2520Cancer%26date%3D2013%26volume%3D13%26doi%3D10.1186%2F1471-2407-13-152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeBlanc, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shekhar-Guturja, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krysan, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pizarro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, L. E.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of fungal-selective resorcylate aminopyrazole Hsp90 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">2139</span>– <span class="NLM_lpage">2180</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00826</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00826" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslKis7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=2139-2180&author=D.+S.+Huangauthor=E.+V.+LeBlancauthor=T.+Shekhar-Guturjaauthor=N.+Robbinsauthor=D.+J.+Krysanauthor=J.+Pizarroauthor=L.+Whitesellauthor=L.+E.+Cowenauthor=L.+E.+Brown&title=Design+and+synthesis+of+fungal-selective+resorcylate+aminopyrazole+Hsp90+inhibitors&doi=10.1021%2Facs.jmedchem.9b00826"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors</span></div><div class="casAuthors">Huang, David S.; LeBlanc, Emmanuelle V.; Shekhar-Guturja, Tanvi; Robbins, Nicole; Krysan, Damian J.; Pizarro, Juan; Whitesell, Luke; Cowen, Leah E.; Brown, Lauren E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2139-2180</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The mol. chaperone Hsp90, essential in all eukaryotes, plays a multifaceted role in promoting survival, virulence, and drug resistance across diverse pathogenic fungal species.  The chaperone is also critically important, however, to the pathogen's human host, preventing the use of known clin. Hsp90 inhibitors in antifungal applications due to concomitant host toxicity issues.  With the goal of developing Hsp90 inhibitors with acceptable therapeutic indexes for the treatment of invasive fungal infections, we initiated a program to design and synthesize potent inhibitors with selective activity against fungal Hsp90 isoforms over their human counterparts.  Building on our previously reported derivatization of resorcylate natural products to produce fungal-selective compds., we have developed a series of synthetic aminopyrazole-substituted resorcylate amides with broad, potent, and fungal-selective Hsp90 inhibitory activity.  Herein we describe the synthesis of this series, as well as biochem. structure-activity relationships driving selectivity for the Hsp90 isoforms expressed by Cryptococcus neoformans and Candida albicans, two pathogenic fungi of major clin. importance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS8vnKn_iCAbVg90H21EOLACvtfcHk0liRS6rJA9vD9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslKis7nI&md5=7273f759edff9a1bfaecba5929d493a2</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00826&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00826%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DD.%2BS.%26aulast%3DLeBlanc%26aufirst%3DE.%2BV.%26aulast%3DShekhar-Guturja%26aufirst%3DT.%26aulast%3DRobbins%26aufirst%3DN.%26aulast%3DKrysan%26aufirst%3DD.%2BJ.%26aulast%3DPizarro%26aufirst%3DJ.%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26aulast%3DBrown%26aufirst%3DL.%2BE.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520fungal-selective%2520resorcylate%2520aminopyrazole%2520Hsp90%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D2139%26epage%3D2180%26doi%3D10.1021%2Facs.jmedchem.9b00826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casadevall, A.</span></span> <span> </span><span class="NLM_article-title">Susceptibility of <i>Cryptococcus neoformans</i> biofilms to antifungal agents in vitro</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1021</span>– <span class="NLM_lpage">1033</span>, <span class="refDoi"> DOI: 10.1128/AAC.50.3.1021-1033.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1128%2FAAC.50.3.1021-1033.2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=16495265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD28XisFamtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2006&pages=1021-1033&author=L.+R.+Martinezauthor=A.+Casadevall&title=Susceptibility+of+Cryptococcus+neoformans+biofilms+to+antifungal+agents+in+vitro&doi=10.1128%2FAAC.50.3.1021-1033.2006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro</span></div><div class="casAuthors">Martinez, Luis R.; Casadevall, Arturo</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1021-1033</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Microbial biofilms contribute to virulence and resistance to antibiotics by shielding microbial cells from host defenses and antimicrobial drugs, resp.  Cryptococcus neoformans was demonstrated to form biofilms in polystyrene microtiter plates.  The nos. of CFU of disaggregated biofilms, 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide redn., and light and confocal microscopy were used to measure the fungal mass, the metabolic activity, and the appearance of C. neoformans biofilms, resp.  Biofilm development by C. neoformans followed a std. sequence of events: fungal surface attachment, microcolony formation, and matrix prodn.  The susceptibilities of C. neoformans cells of the biofilm and planktonic phenotypes to four antifungal agents were examd.  The exposure of C. neoformans cells or preformed cryptococcal biofilms to fluconazole or voriconazole did not result in yeast growth inhibition and did not affect the metabolic activities of the biofilms, resp.  In contrast, both C. neoformans cells and preformed biofilms were susceptible to amphotericin B and caspofungin.  However, C. neoformans biofilms were significantly more resistant to amphotericin B and caspofungin than planktonic cells, and their susceptibilities to these drugs were further reduced if cryptococcal cells contained melanin.  A spot ELISA and light and confocal microscopy were used to investigate how antifungal drugs affected C. neoformans biofilm formation.  The mechanism by which amphotericin B and caspofungin interfered with C. neoformans biofilm formation involved capsular polysaccharide release and adherence.  Our results suggest that biofilm formation may diminish the efficacies of some antifungal drugs during cryptococcal infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMH7kllCrH0LVg90H21EOLACvtfcHk0ljaIEkCZLpYcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XisFamtLc%253D&md5=1cbd2e8671a5c7adb1353deb1d748efb</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1128%2FAAC.50.3.1021-1033.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.50.3.1021-1033.2006%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez%26aufirst%3DL.%2BR.%26aulast%3DCasadevall%26aufirst%3DA.%26atitle%3DSusceptibility%2520of%2520Cryptococcus%2520neoformans%2520biofilms%2520to%2520antifungal%2520agents%2520in%2520vitro%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2006%26volume%3D50%26spage%3D1021%26epage%3D1033%26doi%3D10.1128%2FAAC.50.3.1021-1033.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casadevall, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosanchuk, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, M. L.</span></span> <span> </span><span class="NLM_article-title">Vesicular transport across the fungal cell wall</span>. <i>Trends Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">158</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1016/j.tim.2008.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1016%2Fj.tim.2008.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=19299133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkt1SktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=158-162&author=A.+Casadevallauthor=J.+D.+Nosanchukauthor=P.+Williamsonauthor=M.+L.+Rodrigues&title=Vesicular+transport+across+the+fungal+cell+wall&doi=10.1016%2Fj.tim.2008.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Vesicular transport across the fungal cell wall</span></div><div class="casAuthors">Casadevall, Arturo; Nosanchuk, Joshua D.; Williamson, Peter; Rodrigues, Marcio L.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Microbiology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">158-162</span>CODEN:
                <span class="NLM_cas:coden">TRMIEA</span>;
        ISSN:<span class="NLM_cas:issn">0966-842X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review and discussion.  Recent findings indicate that fungi use vesicular transport to deliver substances across their cell walls.  Fungal vesicles are similar to mammalian exosomes and could originate from cytoplasmic multivesicular bodies.  Vesicular transport enables the export of large mols. across the cell wall, and vesicles contain lipids, proteins and polysaccharides, many of which are assocd. with virulence.  Concn. of fungal products in vesicles could increase their efficiency in food acquisition and/or delivering potentially noxious substances to other cells, such as amoebae or phagocytes.  The discovery of vesicular transport in fungi opens many new avenues for investigation in basic cell biol. and pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0bnReh_GI77Vg90H21EOLACvtfcHk0ljaIEkCZLpYcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkt1SktLg%253D&md5=4059470a49f348bb6dc52793e26a3ea5</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.tim.2008.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tim.2008.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DCasadevall%26aufirst%3DA.%26aulast%3DNosanchuk%26aufirst%3DJ.%2BD.%26aulast%3DWilliamson%26aufirst%3DP.%26aulast%3DRodrigues%26aufirst%3DM.%2BL.%26atitle%3DVesicular%2520transport%2520across%2520the%2520fungal%2520cell%2520wall%26jtitle%3DTrends%2520Microbiol.%26date%3D2009%26volume%3D17%26spage%3D158%26epage%3D162%26doi%3D10.1016%2Fj.tim.2008.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaragoza, O.</span></span> <span> </span><span class="NLM_article-title">Multiple disguises for the same party: The concepts of morphogenesis and phenotypic variations in <i>Cryptococcus neoformans</i></span>. <i>Front. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">181</span>, <span class="refDoi"> DOI: 10.3389/fmicb.2011.00181</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.3389%2Ffmicb.2011.00181" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=21922016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A280%3ADC%252BC3MfktVGqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=181&author=O.+Zaragoza&title=Multiple+disguises+for+the+same+party%3A+The+concepts+of+morphogenesis+and+phenotypic+variations+in+Cryptococcus+neoformans&doi=10.3389%2Ffmicb.2011.00181"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple Disguises for the Same Party: The Concepts of Morphogenesis and Phenotypic Variations in Cryptococcus neoformans</span></div><div class="casAuthors">Zaragoza Oscar</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in microbiology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">181</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although morphological transitions (such as hyphae and pseudohyphae formation) are a common feature among fungi, the encapsulated pathogenic yeast Cryptococcus neoformans is found during infection as blastoconidia.  However, this fungus exhibits striking variations in cellular structure and size, which have important consequences during infection.  This review will summarize the main aspects related with phenotypic and morphological variations in C. neoformans, which can be divided in three classes.  Two of them are related to changes in the capsule, while the third one involves changes in the whole cell.  The three morphological and phenotypic variations in C. neoformans can be classified as: (1) changes in capsule structure, (2) changes in capsule size, and (3) changes in the total size of the cell, which can be achieved by the formation of cryptococcal giant/titan cells or microforms.  These changes have profound consequences on the interaction with the host, involving survival, phagocytosis escape and immune evasion and dissemination.  This article will summarize the main features of these changes, and highlight their importance during the interaction with the host and how they contribute to the development of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThGDlubMUQq75oR8RchjrrfW6udTcc2eZWBW3XhZWR6bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MfktVGqsA%253D%253D&md5=ba89fe719ecae56200960292c0f13bac</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.3389%2Ffmicb.2011.00181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmicb.2011.00181%26sid%3Dliteratum%253Aachs%26aulast%3DZaragoza%26aufirst%3DO.%26atitle%3DMultiple%2520disguises%2520for%2520the%2520same%2520party%253A%2520The%2520concepts%2520of%2520morphogenesis%2520and%2520phenotypic%2520variations%2520in%2520Cryptococcus%2520neoformans%26jtitle%3DFront.%2520Microbiol.%26date%3D2011%26volume%3D2%26spage%3D181%26doi%3D10.3389%2Ffmicb.2011.00181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Meara, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alspaugh, J. A.</span></span> <span> </span><span class="NLM_article-title">The <i>Cryptococcus neoformans</i> capsule: a sword and a shield</span>. <i>Clin. Microbiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">408</span>, <span class="refDoi"> DOI: 10.1128/CMR.00001-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1128%2FCMR.00001-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=22763631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Git7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=387-408&author=T.+R.+O%E2%80%99Mearaauthor=J.+A.+Alspaugh&title=The+Cryptococcus+neoformans+capsule%3A+a+sword+and+a+shield&doi=10.1128%2FCMR.00001-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">The cryptococcus neoformans capsule: a sword and a shield</span></div><div class="casAuthors">O'Meara, Teresa R.; Alspaugh, J. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">387-408</span>CODEN:
                <span class="NLM_cas:coden">CMIREX</span>;
        ISSN:<span class="NLM_cas:issn">0893-8512</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review on the different regulation programs that respond to specific host environmental cues to induce encapsulation.  It examines critically the current information on the regulation of Cryptococcus neoformans capsule synthesis, export, and assembly.  It suggests that fungal cell wall remodeling is an underexplored component of appropriate encapsulation within the host.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTmgImpJA237Vg90H21EOLACvtfcHk0lib7WBx6B4kFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Git7fN&md5=2d6cca07ad92114721d4c90944de2994</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1128%2FCMR.00001-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FCMR.00001-12%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DT.%2BR.%26aulast%3DAlspaugh%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520Cryptococcus%2520neoformans%2520capsule%253A%2520a%2520sword%2520and%2520a%2520shield%26jtitle%3DClin.%2520Microbiol.%2520Rev.%26date%3D2012%26volume%3D25%26spage%3D387%26epage%3D408%26doi%3D10.1128%2FCMR.00001-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cannon, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamping, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baret, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keniya, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanabe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niimi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goffeau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monk, B. C.</span></span> <span> </span><span class="NLM_article-title">Efflux-mediated antifungal drug resistance</span>. <i>Clin. Microbiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">321</span>, <span class="refDoi"> DOI: 10.1128/CMR.00051-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1128%2FCMR.00051-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=19366916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVSqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=291-321&author=R.+D.+Cannonauthor=E.+Lampingauthor=A.+R.+Holmesauthor=K.+Niimiauthor=P.+V.+Baretauthor=M.+V.+Keniyaauthor=K.+Tanabeauthor=M.+Niimiauthor=A.+Goffeauauthor=B.+C.+Monk&title=Efflux-mediated+antifungal+drug+resistance&doi=10.1128%2FCMR.00051-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Efflux-mediated antifungal drug resistance</span></div><div class="casAuthors">Cannon, Richard D.; Lamping, Erwin; Holmes, Ann R.; Niimi, Kyoko; Baret, Philippe V.; Keniya, Mikhail V.; Tanabe, Koichi; Niimi, Masakazu; Goffeau, Andre; Monk, Brian C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Microbiology Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">291-321</span>CODEN:
                <span class="NLM_cas:coden">CMIREX</span>;
        ISSN:<span class="NLM_cas:issn">0893-8512</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review.  Fungi cause serious infections in the immunocompromised and debilitated, and the incidence of invasive mycosis has increased significantly over the last 3 decades.  Slow diagnosis and the relatively few classes of antifungal drugs result in high attributable mortality for systemic fungal infections.  Azole antifungals are commonly used for fungal infections, but azole resistance can be a problem for some patient groups.  High-level, clin. significant azole resistance usually involves overexpression of plasma membrane efflux pumps belonging to the ATP-binding cassette (ABC) or the major facilitator superfamily class of transporters.  The heterologous expression of efflux pumps in model systems, such as Saccharomyces cerevisiae, has enabled the functional anal. of efflux pumps from a variety of fungi.  Phylogenetic anal. of the ABC pleiotropic drug resistance family has provided a new view of the evolution of this important class of efflux pumps.  There are several ways in which the clin. significance of efflux-mediated antifungal drug resistance can be mitigated.  Alternative antifungal drugs, such as the echinocandins, that are not efflux pump substrates provide one option.  Potential therapeutic approaches that could overcome azole resistance include targeting efflux pump transcriptional regulators and fungal stress response pathways, blockade of energy supply, and direct inhibition of efflux pumps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRVHHsCpq4zbVg90H21EOLACvtfcHk0lhxoUz9vvSqWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVSqtL4%253D&md5=a426f60728d0c45c18845346ba1a155d</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1128%2FCMR.00051-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FCMR.00051-08%26sid%3Dliteratum%253Aachs%26aulast%3DCannon%26aufirst%3DR.%2BD.%26aulast%3DLamping%26aufirst%3DE.%26aulast%3DHolmes%26aufirst%3DA.%2BR.%26aulast%3DNiimi%26aufirst%3DK.%26aulast%3DBaret%26aufirst%3DP.%2BV.%26aulast%3DKeniya%26aufirst%3DM.%2BV.%26aulast%3DTanabe%26aufirst%3DK.%26aulast%3DNiimi%26aufirst%3DM.%26aulast%3DGoffeau%26aufirst%3DA.%26aulast%3DMonk%26aufirst%3DB.%2BC.%26atitle%3DEfflux-mediated%2520antifungal%2520drug%2520resistance%26jtitle%3DClin.%2520Microbiol.%2520Rev.%26date%3D2009%26volume%3D22%26spage%3D291%26epage%3D321%26doi%3D10.1128%2FCMR.00051-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, C. W.</span></span> <span> </span><span class="NLM_article-title">Analysis of protein-ligand interactions by fluorescence polarization</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">387</span>, <span class="refDoi"> DOI: 10.1038/nprot.2011.305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1038%2Fnprot.2011.305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=21372817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC3MXislentbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=365-387&author=A.+M.+Rossiauthor=C.+W.+Taylor&title=Analysis+of+protein-ligand+interactions+by+fluorescence+polarization&doi=10.1038%2Fnprot.2011.305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of protein-ligand interactions by fluorescence polarization</span></div><div class="casAuthors">Rossi, Ana M.; Taylor, Colin W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">365-387</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Quantification of the assocns. between biomols. is required both to predict and understand the interactions that underpin all biol. activity.  Fluorescence polarization (FP) provides a nondisruptive means of measuring the assocn. of a fluorescent ligand with a larger mol.  We describe an FP assay in which binding of fluorescein-labeled inositol 1,4,5-trisphosphate (IP3) to N-terminal fragments of IP3 receptors can be characterized at different temps. and in competition with other ligands.  The assay allows the std. Gibbs free energy (ΔG°), enthalpy (ΔH°) and entropy (ΔS°) changes of ligand binding to be detd.  The method is applicable to any purified ligand-binding site for which an appropriate fluorescent ligand is available.  FP can be used to measure low-affinity interactions in real time without the use of radioactive materials, it is nondestructive and, with appropriate care, it can resolve ΔH° and ΔS°.  The first part of the protocol, protein prepn., may take several weeks, whereas the FP measurements, once they have been optimized, would normally take 1-6 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPmq_JwlOSg7Vg90H21EOLACvtfcHk0lhNEeVSvDTCrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXislentbg%253D&md5=b78e3bcd884a06cdeb8b090227963d33</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2011.305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2011.305%26sid%3Dliteratum%253Aachs%26aulast%3DRossi%26aufirst%3DA.%2BM.%26aulast%3DTaylor%26aufirst%3DC.%2BW.%26atitle%3DAnalysis%2520of%2520protein-ligand%2520interactions%2520by%2520fluorescence%2520polarization%26jtitle%3DNat.%2520Protoc.%26date%3D2011%26volume%3D6%26spage%3D365%26epage%3D387%26doi%3D10.1038%2Fnprot.2011.305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McNaney, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drexler, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hnatyshyn, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvyaga, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knipe, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belcastro, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, M.</span></span> <span> </span><span class="NLM_article-title">An automated liquid chromatography-mass spectrometry process to determine metabolic stability half-life and intrinsic clearance of drug candidates by substrate depletion</span>. <i>Assay Drug Dev. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1089/adt.2007.103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1089%2Fadt.2007.103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=18336089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtFKqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=121-129&author=C.+A.+McNaneyauthor=D.+M.+Drexlerauthor=S.+Y.+Hnatyshynauthor=T.+A.+Zvyagaauthor=J.+O.+Knipeauthor=J.+V.+Belcastroauthor=M.+Sanders&title=An+automated+liquid+chromatography-mass+spectrometry+process+to+determine+metabolic+stability+half-life+and+intrinsic+clearance+of+drug+candidates+by+substrate+depletion&doi=10.1089%2Fadt.2007.103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">An Automated Liquid Chromatography-Mass Spectrometry Process to Determine Metabolic Stability Half-Life and Intrinsic Clearance of Drug Candidates by Substrate Depletion</span></div><div class="casAuthors">McNaney, Colleen A.; Drexler, Dieter M.; Hnatyshyn, Serhiy Y.; Zvyaga, Tatyana A.; Knipe, Jay O.; Belcastro, James V.; Sanders, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Assay and Drug Development Technologies</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">121-129</span>CODEN:
                <span class="NLM_cas:coden">ADDTAR</span>;
        ISSN:<span class="NLM_cas:issn">1540-658X</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">An automated process is described for the detailed assessment of the in vitro metabolic stability properties of drug candidates in support of pharmaceutical property profiling.  Compds. are incubated with liver microsomes using a robotic liq. handler.  Aliquots are taken at various time points, and the resulting samples are quant. analyzed by liq. chromatog.-mass spectrometry utilizing ion trap mass spectrometers to det. the amt. of compd. remaining.  From these data metab. rates can be calcd.  A high degree of automation is achieved through custom software, which is employed for instrument setup, data processing, and results reporting.  The assay setup is highly configurable, allowing for any combination of up to six user-selected time points, variable substrate concn., and microsomes or other biol. active media.  The data, based on relative substrate depletion, affords an est. of metabolic stability through the calcn. of half-life (t1/2) and intrinsic clearance, which are used to differentiate and rank order drug leads.  In general, t1/2 is the time necessary for the metab., following first-order kinetics, of 50 of the initial compd.  Intrinsic clearance is the proportionality const. between rate of metab. of a compd. and its concn. at the enzyme site.  Described here is the setup of the assay, and data from assay test compds. are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEaz4jJWXzM7Vg90H21EOLACvtfcHk0lhNEeVSvDTCrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtFKqtbs%253D&md5=3833f7d7c4be366bc2d4b3e656ef4ae2</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1089%2Fadt.2007.103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2007.103%26sid%3Dliteratum%253Aachs%26aulast%3DMcNaney%26aufirst%3DC.%2BA.%26aulast%3DDrexler%26aufirst%3DD.%2BM.%26aulast%3DHnatyshyn%26aufirst%3DS.%2BY.%26aulast%3DZvyaga%26aufirst%3DT.%2BA.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DBelcastro%26aufirst%3DJ.%2BV.%26aulast%3DSanders%26aufirst%3DM.%26atitle%3DAn%2520automated%2520liquid%2520chromatography-mass%2520spectrometry%2520process%2520to%2520determine%2520metabolic%2520stability%2520half-life%2520and%2520intrinsic%2520clearance%2520of%2520drug%2520candidates%2520by%2520substrate%2520depletion%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2008%26volume%3D6%26spage%3D121%26epage%3D129%26doi%3D10.1089%2Fadt.2007.103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butts, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koselny, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabrier-Rosello, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellington, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krysan, D. J.</span></span> <span> </span><span class="NLM_article-title">A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis</span>. <i>Eukaryotic Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.1128/EC.00314-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1128%2FEC.00314-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=23243064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitlGjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=278-287&author=A.+Buttsauthor=L.+DiDoneauthor=K.+Koselnyauthor=B.+K.+Baxterauthor=Y.+Chabrier-Roselloauthor=M.+Wellingtonauthor=D.+J.+Krysan&title=A+repurposing+approach+identifies+off-patent+drugs+with+fungicidal+cryptococcal+activity%2C+a+common+structural+chemotype%2C+and+pharmacological+properties+relevant+to+the+treatment+of+cryptococcosis&doi=10.1128%2FEC.00314-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis</span></div><div class="casAuthors">Butts, Arielle; DiDone, Louis; Koselny, Kristy; Baxter, Bonnie K.; Chabrier-Rosello, Yeissa; Wellington, Melanie; Krysan, Damian J.</div><div class="citationInfo"><span class="NLM_cas:title">Eukaryotic Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">278-287</span>CODEN:
                <span class="NLM_cas:coden">ECUEA2</span>;
        ISSN:<span class="NLM_cas:issn">1535-9786</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">New, more accessible therapies for cryptococcosis represent an unmet clin. need of global importance.  We took a repurposing approach to identify previously developed drugs with fungicidal activity toward Cryptococcus neoformans, using a high-throughput screening assay designed to detect drugs that directly kill fungi.  From a set of 1,120 off-patent medications and bioactive mols., we identified 31 drugs/mols. with fungicidal activity, including 15 drugs for which direct antifungal activity had not previously been reported.  A significant portion of the drugs are orally bioavailable and cross the blood-brain barrier, features key to the development of a widely applicable anticryptococcal agent.  Structural anal. of this set revealed a common chemotype consisting of a hydrophobic moiety linked to a basic amine, features that are common to drugs that cross the blood-brain barrier and access the phagolysosome, two important niches of C. neoformans.  Consistent with their fungicidal activity, the set contains eight drugs that are either additive or synergistic in combination with fluconazole.  Importantly, we identified two drugs, amiodarone and thioridazine, with activity against intraphagocytic C. neoformans.  Finally, the set of drugs is also enriched for mols. that inhibit calmodulin, and we have confirmed that seven drugs directly bind C. neoformans calmodulin, providing a mol. target that may contribute to the mechanism of antifungal activity.  Taken together, these studies provide a foundation for the optimization of the antifungal properties of a set of pharmacol. attractive scaffolds for the development of novel anticryptococcal therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRmu1MEpP5JLVg90H21EOLACvtfcHk0ljCDbZXlpnyRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitlGjtrk%253D&md5=71ae5a50d0c74f0bf7b383e2377212fb</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1128%2FEC.00314-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FEC.00314-12%26sid%3Dliteratum%253Aachs%26aulast%3DButts%26aufirst%3DA.%26aulast%3DDiDone%26aufirst%3DL.%26aulast%3DKoselny%26aufirst%3DK.%26aulast%3DBaxter%26aufirst%3DB.%2BK.%26aulast%3DChabrier-Rosello%26aufirst%3DY.%26aulast%3DWellington%26aufirst%3DM.%26aulast%3DKrysan%26aufirst%3DD.%2BJ.%26atitle%3DA%2520repurposing%2520approach%2520identifies%2520off-patent%2520drugs%2520with%2520fungicidal%2520cryptococcal%2520activity%252C%2520a%2520common%2520structural%2520chemotype%252C%2520and%2520pharmacological%2520properties%2520relevant%2520to%2520the%2520treatment%2520of%2520cryptococcosis%26jtitle%3DEukaryotic%2520Cell%26date%3D2013%26volume%3D12%26spage%3D278%26epage%3D287%26doi%3D10.1128%2FEC.00314-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brough, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aherne, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barril, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgognoni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boxall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cansfield, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, K.-M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, N. G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drysdale, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northfield, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearl, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prodromou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roughley, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surgenor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walmsley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrightt, L.</span></span> <span> </span><span class="NLM_article-title">4,5-diarylisoxazole HSP90 chaperone inhibitors: Potential therapeutic agents for the treatment of cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">196</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1021/jm701018h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701018h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlWqsL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=196-218&author=P.+A.+Broughauthor=W.+Aherneauthor=X.+Barrilauthor=J.+Borgognoniauthor=K.+Boxallauthor=J.+E.+Cansfieldauthor=K.-M.+J.+Cheungauthor=I.+Collinsauthor=N.+G.+M.+Daviesauthor=M.+J.+Drysdaleauthor=B.+Dymockauthor=S.+A.+Ecclesauthor=H.+Finchauthor=A.+Finkauthor=A.+Hayesauthor=R.+Howesauthor=R.+E.+Hubbardauthor=K.+Jamesauthor=A.+M.+Jordanauthor=A.+Lockieauthor=V.+Martinsauthor=A.+Masseyauthor=T.+P.+Matthewsauthor=E.+McDonaldauthor=C.+J.+Northfieldauthor=L.+H.+Pearlauthor=C.+Prodromouauthor=S.+Rayauthor=F.+I.+Raynaudauthor=S.+D.+Roughleyauthor=S.+Y.+Sharpauthor=A.+Surgenorauthor=D.+L.+Walmsleyauthor=P.+Webbauthor=M.+Woodauthor=P.+Workmanauthor=L.+Wrightt&title=4%2C5-diarylisoxazole+HSP90+chaperone+inhibitors%3A+Potential+therapeutic+agents+for+the+treatment+of+cancer&doi=10.1021%2Fjm701018h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer</span></div><div class="casAuthors">Brough, Paul A.; Aherne, Wynne; Barril, Xavier; Borgognoni, Jennifer; Boxall, Kathy; Cansfield, Julie E.; Cheung, Kwai-Ming J.; Collins, Ian; Davies, Nicholas G. M.; Drysdale, Martin J.; Dymock, Brian; Eccles, Suzanne A.; Finch, Harry; Fink, Alexandra; Hayes, Angela; Howes, Robert; Hubbard, Roderick E.; James, Karen; Jordan, Allan M.; Lockie, Andrea; Martins, Vanessa; Massey, Andrew; Matthews, Thomas P.; McDonald, Edward; Northfield, Christopher J.; Pearl, Laurence H.; Prodromou, Chrisostomos; Ray, Stuart; Raynaud, Florence I.; Roughley, Stephen D.; Sharp, Swee Y.; Surgenor, Allan; Walmsley, D. Lee; Webb, Paul; Wood, Mike; Workman, Paul; Wright, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">196-218</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors of the Hsp90 [heat shock protein 90] mol. chaperone show considerable promise as potential chemotherapeutic agents for cancer.  The structure-based design, synthesis, structure-activity relationships, and pharmacokinetics of potent small-mol. inhibitors of Hsp90 based on the 4,5-diarylisoxazole scaffold were studied.  Analogs from this series have high affinity for Hsp90, as measured in a fluorescence polarization competitive binding assay, and are active in cancer cell lines where they inhibit proliferation and exhibit a characteristic profile of depletion of oncogenic proteins and concomitant elevation of Hsp72.  The [(morpholinomethyl)phenyl]isoxazolecarboxamide I (VER-52296/NVP-AUY922) is potent in the Hsp90 FP binding assay and inhibits proliferation of various human cancer cell lines in vitro, with GI50 averaging 9 nM.  I is retained in tumors in vivo when administered i.p., as evaluated by cassette dosing in tumor-bearing mice.  In a human colon cancer xenograft model, I inhibits tumor growth by ∼50%.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTNA9AoWb8gLVg90H21EOLACvtfcHk0lgR0dV_QiopcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlWqsL%252FK&md5=fdb98dec600987e862b9b05555427948</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Fjm701018h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701018h%26sid%3Dliteratum%253Aachs%26aulast%3DBrough%26aufirst%3DP.%2BA.%26aulast%3DAherne%26aufirst%3DW.%26aulast%3DBarril%26aufirst%3DX.%26aulast%3DBorgognoni%26aufirst%3DJ.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DCansfield%26aufirst%3DJ.%2BE.%26aulast%3DCheung%26aufirst%3DK.-M.%2BJ.%26aulast%3DCollins%26aufirst%3DI.%26aulast%3DDavies%26aufirst%3DN.%2BG.%2BM.%26aulast%3DDrysdale%26aufirst%3DM.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DFinch%26aufirst%3DH.%26aulast%3DFink%26aufirst%3DA.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHowes%26aufirst%3DR.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DJordan%26aufirst%3DA.%2BM.%26aulast%3DLockie%26aufirst%3DA.%26aulast%3DMartins%26aufirst%3DV.%26aulast%3DMassey%26aufirst%3DA.%26aulast%3DMatthews%26aufirst%3DT.%2BP.%26aulast%3DMcDonald%26aufirst%3DE.%26aulast%3DNorthfield%26aufirst%3DC.%2BJ.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26aulast%3DProdromou%26aufirst%3DC.%26aulast%3DRay%26aufirst%3DS.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DRoughley%26aufirst%3DS.%2BD.%26aulast%3DSharp%26aufirst%3DS.%2BY.%26aulast%3DSurgenor%26aufirst%3DA.%26aulast%3DWalmsley%26aufirst%3DD.%2BL.%26aulast%3DWebb%26aufirst%3DP.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DWrightt%26aufirst%3DL.%26atitle%3D4%252C5-diarylisoxazole%2520HSP90%2520chaperone%2520inhibitors%253A%2520Potential%2520therapeutic%2520agents%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D196%26epage%3D218%26doi%3D10.1021%2Fjm701018h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taldone, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiosis, G.</span></span> <span> </span><span class="NLM_article-title">Purine-scaffold Hsp90 inhibitors</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1436</span>– <span class="NLM_lpage">1446</span>, <span class="refDoi"> DOI: 10.2174/156802609789895737</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.2174%2F156802609789895737" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=19860732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFakurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=1436-1446&author=T.+Taldoneauthor=G.+Chiosis&title=Purine-scaffold+Hsp90+inhibitors&doi=10.2174%2F156802609789895737"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Purine-scaffold Hsp90 inhibitors</span></div><div class="casAuthors">Taldone, Tony; Chiosis, Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1436-1446</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Hsp90 is a mol. chaperone with important roles in regulating the function of several proteins with potential pathogenic activity.  Because many of these proteins are involved in cancer and neurodegenerative promoting pathways, Hsp90 has emerged as an attractive therapeutic target in these diseases.  Mols. that bind to the N-terminal nucleotide pocket of Hsp90 inhibit its activity, and consequently, disrupt client protein function.  A no. of these inhibitors from several chem. classes are now known, and some are already in clin. trials.  This review focuses on the purine class of Hsp90 inhibitors, their discovery through rational design, and on efforts aimed towards their optimization and development into clin. viable drugs for the treatment of cancer.  Their potential towards neurodegenerative diseases will also be touched upon.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVLlJs6fJ--rVg90H21EOLACvtfcHk0lgc1ADlB5maUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFakurg%253D&md5=346a3ef4c1503aee2d918074c1ecb46c</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.2174%2F156802609789895737&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802609789895737%26sid%3Dliteratum%253Aachs%26aulast%3DTaldone%26aufirst%3DT.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DPurine-scaffold%2520Hsp90%2520inhibitors%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D1436%26epage%3D1446%26doi%3D10.2174%2F156802609789895737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartl, F. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavletich, N. P.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of an Hsp90–geldanamycin complex: targeting of a protein chaperone by an antitumor agent</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">250</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)80203-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1016%2FS0092-8674%2800%2980203-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=9108479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADyaK2sXislCitLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1997&pages=239-250&author=C.+E.+Stebbinsauthor=A.+A.+Russoauthor=C.+Schneiderauthor=N.+Rosenauthor=F.+U.+Hartlauthor=N.+P.+Pavletich&title=Crystal+structure+of+an+Hsp90%E2%80%93geldanamycin+complex%3A+targeting+of+a+protein+chaperone+by+an+antitumor+agent&doi=10.1016%2FS0092-8674%2800%2980203-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent</span></div><div class="casAuthors">Stebbins, Charles E.; Russo, Alicia A.; Schneider, Christine; Rosen, Neal; Hartl, F. Ulrich; Pavletich, Nikola P.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">239-250</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Hsp90 chaperone is required for the activation of several families of eukaryotic protein kinases and nuclear hormone receptors, many of which are proto-oncogenic and play a prominent role in cancer.  The geldanamycin antibiotic has antiproliferative and anti-tumor effects, as it binds to Hsp90, inhibits the Hsp90-mediated conformational maturation/refolding reaction, and results in the degrdn. of Hsp90 substrates.  The structure of the geldanamycin-binding domain of Hsp90 (residues 9-232) reveals a pronounced pocket, 15 Å deep. that is highly conserved across species.  Geldanamycin binds inside this pocket, adopting a compact structure similar to that of a polypeptide chain in a turn conformation.  This, and the pocket's similarity to substrate-binding sites, suggest that the pocket binds a portion of the polypeptide substrate and participates in the conformational maturation/refolding reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvnmleAOFITbVg90H21EOLACvtfcHk0lgVuYdxRZlXRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXislCitLo%253D&md5=54a56450c509727e070f4db20a9d7b1a</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2980203-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252980203-2%26sid%3Dliteratum%253Aachs%26aulast%3DStebbins%26aufirst%3DC.%2BE.%26aulast%3DRusso%26aufirst%3DA.%2BA.%26aulast%3DSchneider%26aufirst%3DC.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DHartl%26aufirst%3DF.%2BU.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26atitle%3DCrystal%2520structure%2520of%2520an%2520Hsp90%25E2%2580%2593geldanamycin%2520complex%253A%2520targeting%2520of%2520a%2520protein%2520chaperone%2520by%2520an%2520antitumor%2520agent%26jtitle%3DCell%26date%3D1997%26volume%3D89%26spage%3D239%26epage%3D250%26doi%3D10.1016%2FS0092-8674%2800%2980203-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keefe, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shortle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lattman, E. E.</span></span> <span> </span><span class="NLM_article-title">The alpha aneurism: a structural motif revealed in an insertion mutant of staphylococcal nuclease</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">3275</span>– <span class="NLM_lpage">3279</span>, <span class="refDoi"> DOI: 10.1073/pnas.90.8.3275</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1073%2Fpnas.90.8.3275" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=8475069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADyaK3sXktVeqtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1993&pages=3275-3279&author=L.+J.+Keefeauthor=J.+Sondekauthor=D.+Shortleauthor=E.+E.+Lattman&title=The+alpha+aneurism%3A+a+structural+motif+revealed+in+an+insertion+mutant+of+staphylococcal+nuclease&doi=10.1073%2Fpnas.90.8.3275"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">The α aneurysm: A structural motif revealed in an insertion mutant of staphylococcal nuclease</span></div><div class="casAuthors">Keefe, Lisa J.; Sondek, John; Shortle, David; Lattman, Eaton E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3275-9</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The x-ray crystal structure of a mutant of staphylococcal nuclease that contains a single glycine residue inserted in the C-terminal α-helix has been solved to 1.67 Å resoln. and refined to a crystallog. R value of 0.170.  This inserted glycine residue is accommodated in the α-helix by formation of a previously uncharacterized bulge, termed the α aneurysm.  A conformational search of known protein structures has identified the α aneurysm in a no. of protein families, including the histocompatibility antigens and Hbs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC-bhIwauF-bVg90H21EOLACvtfcHk0lgVuYdxRZlXRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXktVeqtLo%253D&md5=31be8874ad320f0031f0e8127643b062</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1073%2Fpnas.90.8.3275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.90.8.3275%26sid%3Dliteratum%253Aachs%26aulast%3DKeefe%26aufirst%3DL.%2BJ.%26aulast%3DSondek%26aufirst%3DJ.%26aulast%3DShortle%26aufirst%3DD.%26aulast%3DLattman%26aufirst%3DE.%2BE.%26atitle%3DThe%2520alpha%2520aneurism%253A%2520a%2520structural%2520motif%2520revealed%2520in%2520an%2520insertion%2520mutant%2520of%2520staphylococcal%2520nuclease%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1993%26volume%3D90%26spage%3D3275%26epage%3D3279%26doi%3D10.1073%2Fpnas.90.8.3275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barril, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheridan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surgenor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beswick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drysdale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fromont, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aherne, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boxall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, R. E.</span></span> <span> </span><span class="NLM_article-title">Structure–activity relationships in purine-based inhibitor binding to HSP90 isoforms</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">775</span>– <span class="NLM_lpage">785</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2004.03.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1016%2Fj.chembiol.2004.03.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=15217611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlt1Sjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=775-785&author=L.+Wrightauthor=X.+Barrilauthor=B.+Dymockauthor=L.+Sheridanauthor=A.+Surgenorauthor=M.+Beswickauthor=M.+Drysdaleauthor=A.+Collierauthor=A.+Masseyauthor=N.+Daviesauthor=A.+Finkauthor=C.+Fromontauthor=W.+Aherneauthor=K.+Boxallauthor=S.+Sharpauthor=P.+Workmanauthor=R.+E.+Hubbard&title=Structure%E2%80%93activity+relationships+in+purine-based+inhibitor+binding+to+HSP90+isoforms&doi=10.1016%2Fj.chembiol.2004.03.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships in Purine-Based Inhibitor Binding to HSP90 Isoforms</span></div><div class="casAuthors">Wright, Lisa; Barril, Xavier; Dymock, Brian; Sheridan, Louisa; Surgenor, Allan; Beswick, Mandy; Drysdale, Martin; Collier, Adam; Massey, Andy; Davies, Nick; Fink, Alex; Fromont, Christophe; Aherne, Wynne; Boxall, Kathy; Sharp, Swee; Workman, Paul; Hubbard, Roderick E.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">775-785</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inhibition of the ATPase activity of the chaperone protein HSP90 is a potential strategy for treatment of cancers.  We have detd. structures of the HSP90α N-terminal domain complexed with the purine-based inhibitor, PU3, and analogs with enhanced potency both in enzyme and cell-based assays.  The compds. induce upregulation of HSP70 and downregulation of the known HSP90 client proteins Raf-1, CDK4, and ErbB2, confirming that the mols. inhibit cell growth by a mechanism dependent on HSP90 inhibition.  We have also detd. the first structure of the N-terminal domain of HSP90β, complexed with PU3.  The structures allow a detailed rationale to be developed for the obsd. affinity of the PU3 class of compds. for HSP90 and also provide a structural framework for design of compds. with improved binding affinity and drug-like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2Z11Wd4hiXrVg90H21EOLACvtfcHk0liDjWRvfuFf7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlt1Sjsrs%253D&md5=dd2146dba0f4b3198d5bc7023e645812</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2004.03.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2004.03.033%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DL.%26aulast%3DBarril%26aufirst%3DX.%26aulast%3DDymock%26aufirst%3DB.%26aulast%3DSheridan%26aufirst%3DL.%26aulast%3DSurgenor%26aufirst%3DA.%26aulast%3DBeswick%26aufirst%3DM.%26aulast%3DDrysdale%26aufirst%3DM.%26aulast%3DCollier%26aufirst%3DA.%26aulast%3DMassey%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DN.%26aulast%3DFink%26aufirst%3DA.%26aulast%3DFromont%26aufirst%3DC.%26aulast%3DAherne%26aufirst%3DW.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DSharp%26aufirst%3DS.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26atitle%3DStructure%25E2%2580%2593activity%2520relationships%2520in%2520purine-based%2520inhibitor%2520binding%2520to%2520HSP90%2520isoforms%26jtitle%3DChem.%2520Biol.%26date%3D2004%26volume%3D11%26spage%3D775%26epage%3D785%26doi%3D10.1016%2Fj.chembiol.2004.03.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halgren, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klicic, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mainz, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repasky, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knoll, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenkin, P. S.</span></span> <span> </span><span class="NLM_article-title">Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1739</span>– <span class="NLM_lpage">1749</span>, <span class="refDoi"> DOI: 10.1021/jm0306430</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0306430" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFyit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1739-1749&author=R.+A.+Friesnerauthor=J.+L.+Banksauthor=R.+B.+Murphyauthor=T.+A.+Halgrenauthor=J.+J.+Klicicauthor=D.+T.+Mainzauthor=M.+P.+Repaskyauthor=E.+H.+Knollauthor=M.+Shelleyauthor=J.+K.+Perryauthor=D.+E.+Shawauthor=P.+Francisauthor=P.+S.+Shenkin&title=Glide%3A+a+new+approach+for+rapid%2C+accurate+docking+and+scoring.+1.+Method+and+assessment+of+docking+accuracy&doi=10.1021%2Fjm0306430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Glide: A new approach for rapid, accurate docking and scoring. 1. method and assessment of docking accuracy</span></div><div class="casAuthors">Friesner, Richard A.; Banks, Jay L.; Murphy, Robert B.; Halgren, Thomas A.; Klicic, Jasna J.; Mainz, Daniel T.; Repasky, Matthew P.; Knoll, Eric H.; Shelley, Mee; Perry, Jason K.; Shaw, David E.; Francis, Perry; Shenkin, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1739-1749</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Unlike other methods for docking ligands to the rigid 3D structure of a known protein receptor, Glide approximates a complete systematic search of the conformational, orientational, and positional space of the docked ligand.  In this search, an initial rough positioning and scoring phase that dramatically narrows the search space is followed by torsionally flexible energy optimization on an OPLS-AA nonbonded potential grid for a few hundred surviving candidate poses.  The very best candidates are further refined via a Monte Carlo sampling of pose conformation; in some cases, this is crucial to obtaining an accurate docked pose.  Selection of the best docked pose uses a model energy function that combines empirical and force-field-based terms.  Docking accuracy is assessed by redocking ligands from 282 cocrystd. PDB complexes starting from conformationally optimized ligand geometries that bear no memory of the correctly docked pose.  Errors in geometry for the top-ranked pose are less than 1 Å in nearly half of the cases and are greater than 2 Å in only about one-third of them.  Comparisons to published data on rms deviations show that Glide is nearly twice as accurate as GOLD and more than twice as accurate as FlexX for ligands having up to 20 rotatable bonds.  Glide is also found to be more accurate than the recently described Surflex method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPuigu31qMMLVg90H21EOLACvtfcHk0lhIa80Y5m7z2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFyit74%253D&md5=8cc2f0022318b12dd972e9c493375bf9</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Fjm0306430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0306430%26sid%3Dliteratum%253Aachs%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DBanks%26aufirst%3DJ.%2BL.%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26aulast%3DKlicic%26aufirst%3DJ.%2BJ.%26aulast%3DMainz%26aufirst%3DD.%2BT.%26aulast%3DRepasky%26aufirst%3DM.%2BP.%26aulast%3DKnoll%26aufirst%3DE.%2BH.%26aulast%3DShelley%26aufirst%3DM.%26aulast%3DPerry%26aufirst%3DJ.%2BK.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DFrancis%26aufirst%3DP.%26aulast%3DShenkin%26aufirst%3DP.%2BS.%26atitle%3DGlide%253A%2520a%2520new%2520approach%2520for%2520rapid%252C%2520accurate%2520docking%2520and%2520scoring.%25201.%2520Method%2520and%2520assessment%2520of%2520docking%2520accuracy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1739%26epage%3D1749%26doi%3D10.1021%2Fjm0306430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halgren, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beard, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banks, J. L.</span></span> <span> </span><span class="NLM_article-title">Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1750</span>– <span class="NLM_lpage">1759</span>, <span class="refDoi"> DOI: 10.1021/jm030644s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030644s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFyit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1750-1759&author=T.+A.+Halgrenauthor=R.+B.+Murphyauthor=R.+A.+Friesnerauthor=H.+S.+Beardauthor=L.+L.+Fryeauthor=W.+T.+Pollardauthor=J.+L.+Banks&title=Glide%3A+a+new+approach+for+rapid%2C+accurate+docking+and+scoring.+2.+Enrichment+factors+in+database+screening&doi=10.1021%2Fjm030644s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening</span></div><div class="casAuthors">Halgren, Thomas A.; Murphy, Robert B.; Friesner, Richard A.; Beard, Hege S.; Frye, Leah L.; Pollard, W. Thomas; Banks, Jay L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1750-1759</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Glide's ability to identify active compds. in a database screen is characterized by applying Glide to a diverse set of nine protein receptors.  In many cases, two, or even three, protein sites are employed to probe the sensitivity of the results to the site geometry.  To make the database screens as realistic as possible, the screens use sets of "druglike" decoy ligands that have been selected to be representative of what we believe is likely to be found in the compd. collection of a pharmaceutical or biotechnol. company.  Results are presented for releases 1.8, 2.0, and 2.5 of Glide.  The comparisons show that av. measures for both "early" and "global" enrichment for Glide 2.5 are 3 times higher than for Glide 1.8 and more than 2 times higher than for Glide 2.0 because of better results for the least well-handled screens.  This improvement in enrichment stems largely from the better balance of the more widely parametrized GlideScore 2.5 function and the inclusion of terms that penalize ligand-protein interactions that violate established principles of phys. chem., particularly as it concerns the exposure to solvent of charged protein and ligand groups.  Comparisons to results for the thymidine kinase and estrogen receptors published by Rognan and co-workers (J. Med. Chem. 2000, 43, 4759-4767) show that Glide 2.5 performs better than GOLD 1.1, FlexX 1.8, or DOCK 4.01.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT2ptubbKbvLVg90H21EOLACvtfcHk0lhIa80Y5m7z2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFyit78%253D&md5=33d68dd968e65626b449df61e44e37be</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Fjm030644s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030644s%26sid%3Dliteratum%253Aachs%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DBeard%26aufirst%3DH.%2BS.%26aulast%3DFrye%26aufirst%3DL.%2BL.%26aulast%3DPollard%26aufirst%3DW.%2BT.%26aulast%3DBanks%26aufirst%3DJ.%2BL.%26atitle%3DGlide%253A%2520a%2520new%2520approach%2520for%2520rapid%252C%2520accurate%2520docking%2520and%2520scoring.%25202.%2520Enrichment%2520factors%2520in%2520database%2520screening%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1750%26epage%3D1759%26doi%3D10.1021%2Fjm030644s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zurcher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diederich, F.</span></span> <span> </span><span class="NLM_article-title">Structure-based drug design: exploring the proper filling of apolar pockets at enzyme active sites</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">4345</span>– <span class="NLM_lpage">4361</span>, <span class="refDoi"> DOI: 10.1021/jo800527n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo800527n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVOgsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=4345-4361&author=M.+Zurcherauthor=F.+Diederich&title=Structure-based+drug+design%3A+exploring+the+proper+filling+of+apolar+pockets+at+enzyme+active+sites&doi=10.1021%2Fjo800527n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Drug Design: Exploring the Proper Filling of Apolar Pockets at Enzyme Active Sites</span></div><div class="casAuthors">Zurcher, Martina; Diederich, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4345-4361</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The proper filling of apolar pockets at enzyme active sites is central for increasing binding activity and selectivity of hits and leads in medicinal chem.  In our structure-based design approach toward the generation of potent enzyme inhibitors, we encountered a variety of challenges in gaining suitable binding affinity from the occupation of such pockets.  We summarize them here for the first time.  A fluorine scan of tricyclic thrombin inhibitors led to the discovery of favorable orthogonal dipolar C-F···C=O interactions.  Efficient cation-π interactions were established in the S4 pocket of factor Xa, another serine protease from the blood coagulation cascade.  Changing from mono- to bisubstrate inhibitors of catechol O-methyltransferase, a target in the L-DOPA-based treatment of Parkinson's disease, enabled the full exploitation of a previously unexplored hydrophobic pocket.  Conformational preorganization of a pocket at an enzyme active site is crucial for harvesting binding affinity.  This is demonstrated for two enzymes from the nonmevalonate pathway of isoprenoid biosynthesis, IspE and IspF, which are pursued as antimalarial targets.  Disrupting crystallog. defined water networks on the way into a pocket might cost all of the binding free enthalpy gained from its occupation, as revealed in studies with tRNA-guanine transglycosylase, a target against shigellosis.  Investigations of the active site of plasmepsin II, another antimalarial target, showed that principles for proper apolar cavity filling, originally developed for synthetic host-guest systems, are also applicable to enzyme environments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6oxCTxXw8U7Vg90H21EOLACvtfcHk0lj2K_ShcR2ivg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVOgsr0%253D&md5=bda8143b4d43ed274bc61da8b3b37046</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fjo800527n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo800527n%26sid%3Dliteratum%253Aachs%26aulast%3DZurcher%26aufirst%3DM.%26aulast%3DDiederich%26aufirst%3DF.%26atitle%3DStructure-based%2520drug%2520design%253A%2520exploring%2520the%2520proper%2520filling%2520of%2520apolar%2520pockets%2520at%2520enzyme%2520active%2520sites%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2008%26volume%3D73%26spage%3D4345%26epage%3D4361%26doi%3D10.1021%2Fjo800527n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bissantz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, M.</span></span> <span> </span><span class="NLM_article-title">A medicinal chemist’s guide to molecular interactions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">5061</span>– <span class="NLM_lpage">5084</span>, <span class="refDoi"> DOI: 10.1021/jm100112j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100112j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFKjtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5061-5084&author=C.+Bissantzauthor=B.+Kuhnauthor=M.+Stahl&title=A+medicinal+chemist%E2%80%99s+guide+to+molecular+interactions&doi=10.1021%2Fjm100112j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">A Medicinal Chemist's Guide to Molecular Interactions</span></div><div class="casAuthors">Bissantz, Caterina; Kuhn, Bernd; Stahl, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5061-5084</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraV8HPbwsihbVg90H21EOLACvtfcHk0lhNugB8TnU10g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFKjtbs%253D&md5=f39cf8700267cdc311c73de4d433bab0</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Fjm100112j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100112j%26sid%3Dliteratum%253Aachs%26aulast%3DBissantz%26aufirst%3DC.%26aulast%3DKuhn%26aufirst%3DB.%26aulast%3DStahl%26aufirst%3DM.%26atitle%3DA%2520medicinal%2520chemist%25E2%2580%2599s%2520guide%2520to%2520molecular%2520interactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5061%26epage%3D5084%26doi%3D10.1021%2Fjm100112j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Granger, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perfect, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durack, D. T.</span></span> <span> </span><span class="NLM_article-title">Virulence of <i>Cryptococcus neoformans</i>. Regulation of capsule synthesis by carbon dioxide</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">508</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1172/JCI112000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1172%2FJCI112000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=3928681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADyaL2MXltlyhuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1985&pages=508-516&author=D.+L.+Grangerauthor=J.+R.+Perfectauthor=D.+T.+Durack&title=Virulence+of+Cryptococcus+neoformans.+Regulation+of+capsule+synthesis+by+carbon+dioxide&doi=10.1172%2FJCI112000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Virulence of Cryptococcus neoformans.  Regulation of capsule synthesis by carbon dioxide</span></div><div class="casAuthors">Granger, Donald L.; Perfect, John R.; Durack, David T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">508-16</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    </div><div class="casAbstract">C. neoformans Is variably encapsulated in vitro, whereas in tissues it develops a large capsule.  It was obsd. that cells of a strain with thin capsules, when growing in a std. fungal culture medium, became heavily encapsulated when incubated in the serum-free cell culture medium, Dulbecco's modified Eagle's medium (DME).  Capsule size was quantitated phys. by measuring cell vol. and chem. by detg. the content of a capsular monosaccharide, glucuronate.  The CO2/HCO3- couple stimulated capsule development, resulting in visible enlargement by 3 h after exposure to high CO2/HCO3-.  The amt. of capsule per cell was directly proportional to the total millimolar CO2/HCO3- concn. between 24 and 2.4 mM at pH 7.35, but at const. PCO2 (40 torr) and varying [HCO3-], the cells were heavily encapsulated down to pH 6.8.  Concn. of CO2/HCO3- in the physiol. range increased elaboration of polysaccharide into the medium and slowed the cell generation time from 2 to 6 h.  Four other 1st-passage clin. isolates were all heavily encapsulated in DME with CO2/HCO3-, but variably encapsulated in DME without CO2/HCO3-.  Exposure of yeast to increased CO2/HCO3- caused a marked redn. in complement-mediated phagocytosis by mouse macrophages.  A stable clone was isolated which contained capsular polysaccharide, but lacked the CO2-inducible phenotype.  This clone was avirulent for steroid-treated rabbits.  Thus, the prevailing CO2 concn. in mammalian tissues may be one stimulus for capsular polysaccharide synthesis.  This could serve as an adaptive mechanism favoring parasite survival in the host.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoShgYIceZrabVg90H21EOLACvtfcHk0ljsebi5GXhvPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXltlyhuro%253D&md5=6198ec56309728bd9d81a6fbb5e3045b</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1172%2FJCI112000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI112000%26sid%3Dliteratum%253Aachs%26aulast%3DGranger%26aufirst%3DD.%2BL.%26aulast%3DPerfect%26aufirst%3DJ.%2BR.%26aulast%3DDurack%26aufirst%3DD.%2BT.%26atitle%3DVirulence%2520of%2520Cryptococcus%2520neoformans.%2520Regulation%2520of%2520capsule%2520synthesis%2520by%2520carbon%2520dioxide%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1985%26volume%3D76%26spage%3D508%26epage%3D516%26doi%3D10.1172%2FJCI112000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaFayette, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaas, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schell, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betancourt-Quiroz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunatilaka, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perfect, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowen, L. E.</span></span> <span> </span><span class="NLM_article-title">PKC signaling regulates drug resistance of the fungal pathogen <i>Candida albicans</i> via circuitry comprised of Mkc1, calcineurin, and Hsp90</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e1001069</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1001069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1371%2Fjournal.ppat.1001069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=20865172" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&author=S.+L.+LaFayetteauthor=C.+Collinsauthor=A.+K.+Zaasauthor=W.+A.+Schellauthor=M.+Betancourt-Quirozauthor=A.+A.+Gunatilakaauthor=J.+R.+Perfectauthor=L.+E.+Cowen&title=PKC+signaling+regulates+drug+resistance+of+the+fungal+pathogen+Candida+albicans+via+circuitry+comprised+of+Mkc1%2C+calcineurin%2C+and+Hsp90&doi=10.1371%2Fjournal.ppat.1001069"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1001069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1001069%26sid%3Dliteratum%253Aachs%26aulast%3DLaFayette%26aufirst%3DS.%2BL.%26aulast%3DCollins%26aufirst%3DC.%26aulast%3DZaas%26aufirst%3DA.%2BK.%26aulast%3DSchell%26aufirst%3DW.%2BA.%26aulast%3DBetancourt-Quiroz%26aufirst%3DM.%26aulast%3DGunatilaka%26aufirst%3DA.%2BA.%26aulast%3DPerfect%26aufirst%3DJ.%2BR.%26aulast%3DCowen%26aufirst%3DL.%2BE.%26atitle%3DPKC%2520signaling%2520regulates%2520drug%2520resistance%2520of%2520the%2520fungal%2520pathogen%2520Candida%2520albicans%2520via%2520circuitry%2520comprised%2520of%2520Mkc1%252C%2520calcineurin%252C%2520and%2520Hsp90%26jtitle%3DPLoS%2520Pathog.%26date%3D2010%26volume%3D6%26doi%3D10.1371%2Fjournal.ppat.1001069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Houston, J. B.</span></span> <span> </span><span class="NLM_article-title">Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1469</span>– <span class="NLM_lpage">1479</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(94)90520-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1016%2F0006-2952%2894%2990520-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=8185657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADyaK2cXkt1Kju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1994&pages=1469-1479&author=J.+B.+Houston&title=Utility+of+in+vitro+drug+metabolism+data+in+predicting+in+vivo+metabolic+clearance&doi=10.1016%2F0006-2952%2894%2990520-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance</span></div><div class="casAuthors">Houston, J. Brian</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1469-79</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">A review with 54 refs.  The aim of the commentary is to present a strategy to achieve the prediction of in vivo clearance from in vitro data based on the current understanding of metabolite kinetics in vitro and in vivo.  Hepatic microsomes and hepatocyte suspension are the main in vitro system addressed.  The theor. basis of the strategy is outlined and its general applicability evaluated, using a data base of 25 drugs drawn from the literature.  Finally, the prospective value of the approach is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFHqQ8gCJ6lrVg90H21EOLACvtfcHk0lgWEQcEYTWU5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXkt1Kju7c%253D&md5=a6d0abdbd2f0b238a6a01ba63ee67739</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2894%2990520-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252894%252990520-7%26sid%3Dliteratum%253Aachs%26aulast%3DHouston%26aufirst%3DJ.%2BB.%26atitle%3DUtility%2520of%2520in%2520vitro%2520drug%2520metabolism%2520data%2520in%2520predicting%2520in%2520vivo%2520metabolic%2520clearance%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1994%26volume%3D47%26spage%3D1469%26epage%3D1479%26doi%3D10.1016%2F0006-2952%2894%2990520-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, T.</span></span> <span> </span><span class="NLM_article-title">Physiological parameters in laboratory animals and humans</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1093</span>– <span class="NLM_lpage">1095</span>, <span class="refDoi"> DOI: 10.1023/A:1018943613122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1023%2FA%3A1018943613122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=8378254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A280%3ADyaK3szptFaqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1993&pages=1093-1095&author=B.+Daviesauthor=T.+Morris&title=Physiological+parameters+in+laboratory+animals+and+humans&doi=10.1023%2FA%3A1018943613122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Physiological parameters in laboratory animals and humans</span></div><div class="casAuthors">Davies B; Morris T</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical research</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1093-5</span>
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDDwka3A6hEYYPsCkJIw00fW6udTcc2eahMK9M8hNGxrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3szptFaqsg%253D%253D&md5=094cdd17306b58cc17c8cf4fd5db9927</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1023%2FA%3A1018943613122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1018943613122%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DB.%26aulast%3DMorris%26aufirst%3DT.%26atitle%3DPhysiological%2520parameters%2520in%2520laboratory%2520animals%2520and%2520humans%26jtitle%3DPharm.%2520Res.%26date%3D1993%26volume%3D10%26spage%3D1093%26epage%3D1095%26doi%3D10.1023%2FA%3A1018943613122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barter, Z. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayliss, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaune, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boobis, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlile, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lake, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipscomb, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelkonen, O. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rostami-Hodjegan, A.</span></span> <span> </span><span class="NLM_article-title">Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.2174/138920007779315053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.2174%2F138920007779315053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=17266522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisVyhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=33-45&author=Z.+E.+Barterauthor=M.+K.+Baylissauthor=P.+H.+Beauneauthor=A.+R.+Boobisauthor=D.+J.+Carlileauthor=R.+J.+Edwardsauthor=J.+B.+Houstonauthor=B.+G.+Lakeauthor=J.+C.+Lipscombauthor=O.+R.+Pelkonenauthor=G.+T.+Tuckerauthor=A.+Rostami-Hodjegan&title=Scaling+factors+for+the+extrapolation+of+in+vivo+metabolic+drug+clearance+from+in+vitro+data%3A+reaching+a+consensus+on+values+of+human+microsomal+protein+and+hepatocellularity+per+gram+of+liver&doi=10.2174%2F138920007779315053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver</span></div><div class="casAuthors">Barter, Zoe E.; Bayliss, Martin K.; Beaune, Philip H.; Boobis, Alan R.; Carlile, David J.; Edwards, Robert J.; Houston, J. Brian; Lake, Brian G.; Lipscomb, John C.; Pelkonen, Olavi R.; Tucker, Geoffrey T.; Rostami-Hodjegan, Amin</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-45</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Reported predictions of human in vivo hepatic clearance from in vitro data have used a variety of values for the scaling factors human microsomal protein (MPPGL) and hepatocellularity (HPGL) per g of liver, generally with no consideration of the extent of their inter-individual variability.  We have collated and analyzed data from a no. of sources, to provide weighted meangeo values of human MPPGL and HPGL of 32 mg g-1 (95% Confidence Interval (CI); 29-34 mg.g-1) and 99×106 cells.g-1 (95% CI; 74-131 mg.g-1), resp.  Although inter-individual variability in values of MPPGL and HPGL was statistically significant, gender, smoking or alc. consumption could not be detected as significant covariates by multiple linear regression.  However, there was a weak but statistically significant inverse relation between age and both MPPGL and HPGL.  These findings indicate the importance of considering differences between study populations when forecasting in vivo pharmacokinetic behavior.  Typical clin. pharmacol. studies, particularly in early drug development, use young, fit, healthy male subjects of around 30 years of age.  In contrast, the av. age of patients for many diseases is about 60 years of age.  The relation between age and MPPGL obsd. in this study ests. values of 40 mg.g-1 for a 30 yr old individual and 31 mg.g-1 for a 60 yr old individual.  Investigators may wish to consider the reported covariates in the selection of scaling factors appropriate for the population in which ests. of clearance are being predicted.  Further studies are required to clarify the influence of age (esp. in pediatric subjects), donor source and ethnicity on values of MPPGL and HPGL.  In the meantime, we recommend that the ests. (and their variances) from the current meta-anal. be used when predicting in vivo kinetic parameters from in vitro data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-oKFsYQqcRbVg90H21EOLACvtfcHk0lgHsCAr_OxS1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisVyhsL0%253D&md5=6431a9ed3448601719cd462af751a372</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.2174%2F138920007779315053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920007779315053%26sid%3Dliteratum%253Aachs%26aulast%3DBarter%26aufirst%3DZ.%2BE.%26aulast%3DBayliss%26aufirst%3DM.%2BK.%26aulast%3DBeaune%26aufirst%3DP.%2BH.%26aulast%3DBoobis%26aufirst%3DA.%2BR.%26aulast%3DCarlile%26aufirst%3DD.%2BJ.%26aulast%3DEdwards%26aufirst%3DR.%2BJ.%26aulast%3DHouston%26aufirst%3DJ.%2BB.%26aulast%3DLake%26aufirst%3DB.%2BG.%26aulast%3DLipscomb%26aufirst%3DJ.%2BC.%26aulast%3DPelkonen%26aufirst%3DO.%2BR.%26aulast%3DTucker%26aufirst%3DG.%2BT.%26aulast%3DRostami-Hodjegan%26aufirst%3DA.%26atitle%3DScaling%2520factors%2520for%2520the%2520extrapolation%2520of%2520in%2520vivo%2520metabolic%2520drug%2520clearance%2520from%2520in%2520vitro%2520data%253A%2520reaching%2520a%2520consensus%2520on%2520values%2520of%2520human%2520microsomal%2520protein%2520and%2520hepatocellularity%2520per%2520gram%2520of%2520liver%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2007%26volume%3D8%26spage%3D33%26epage%3D45%26doi%3D10.2174%2F138920007779315053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwatsubo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span> <span> </span><span class="NLM_article-title">Prediction of species differences (rats, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data</span>. <i>J. Pharmacol. Exp. Ther. A</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">462</span>– <span class="NLM_lpage">469</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=9353358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADyaK2sXnsV2nu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1997&pages=462-469&author=T.+Iwatsuboauthor=H.+Suzukiauthor=Y.+Sugiyama&title=Prediction+of+species+differences+%28rats%2C+dogs%2C+humans%29+in+the+in+vivo+metabolic+clearance+of+YM796+by+the+liver+from+in+vitro+data"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of species differences (rats, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data</span></div><div class="casAuthors">Iwatsubo, Takafumi; Suzuki, Hiroshi; Sugiyama, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">462-469</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The bioavailability after oral administration of (S)-(-)-2,8-dimethyl-3-methylene-1-oxa-8-azaspiro[4,5]decane-L-tartrate monohydrate (YM796), which is being developed as an antidementia drug, at a dose of 1 mg/kg was very low (3.4%) in rats, but considerably higher (16.1%) in dogs.  The oral clearances (CLoral, Dose/AUCoral) in rats and dogs were, resp., 300 and 18 times more than that already reported in humans.  We have previously reported successful attempts to predict the in vivo hepatic metabolic clearance of YM796 from in vitro data in humans.  In our study, the in vitro metab. of YM796 was detd. using liver microsomes prepd. from both rats and dogs and we also investigated if the species difference obsd. in vivo could be quant. reproduced in vitro.  In rats, total metabolite formation could be described by single component kinetics with a Km of 13.4 μM and a Vmax of 520 nmol/min/g liver.  However, in dogs, total metabolite formation could be described by three components, as also reported for humans.  The Km and Vmax values for the high-affinity, low-capacity component (Km1 and Vmax1) in dogs and humans were, resp., 8.1 and 1.7 μM, and 10.9 and 1.2 nmol/min/g liver.  The overall intrinsic metabolic clearances estd. from the in vitro studies (CLint, in vitro) for rats and dogs were 38.8 and 2.6 mL/min/g liver, resp., being approx. 40 and 3 times more than that previously reported for humans (0.94 mL/min/g liver).  The overall intrinsic hepatic clearances (CLint, in vivo) calcd. from in vivo CLoral were 30.4, 3.4 and 0.73 mL/min/g liver for rats, dogs and humans, resp., indicating that the in vivo hepatic clearance of YM796 can be predicted from in vitro metab. data in each species.  Thus, the pronounced species difference in the metabolic clearance obsd. in vivo can be quant. predicted from in vitro metabolic data using liver microsomes, and was predominantly due to the large difference in the Vmax values.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrugcAGF4l50rVg90H21EOLACvtfcHk0li2lmXctyNRMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnsV2nu74%253D&md5=8f39d4003d6ccdb945929b0eea3c5439</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIwatsubo%26aufirst%3DT.%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DSugiyama%26aufirst%3DY.%26atitle%3DPrediction%2520of%2520species%2520differences%2520%2528rats%252C%2520dogs%252C%2520humans%2529%2520in%2520the%2520in%2520vivo%2520metabolic%2520clearance%2520of%2520YM796%2520by%2520the%2520liver%2520from%2520in%2520vitro%2520data%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%2520A%26date%3D1997%26volume%3D283%26spage%3D462%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kabsch, W.</span></span> <span> </span><span class="NLM_article-title">XDS</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1107/S0907444909047337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1107%2FS0907444909047337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=20124692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=125-132&author=W.+Kabsch&title=XDS&doi=10.1107%2FS0907444909047337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Software XDS for image rotation, recognition and crystal symmetry assignment</span></div><div class="casAuthors">Kabsch, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The usage and control of recent modifications of the program package XDS for the processing of rotation images are described in the context of previous versions.  New features include automatic detn. of spot size and reflecting range and recognition and assignment of crystal symmetry.  Moreover, the limitations of earlier package versions on the no. of correction/scaling factors and the representation of pixel contents have been removed.  Large program parts have been restructured for parallel processing so that the quality and completeness of collected data can be assessed soon after measurement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv5AyUw00DYbVg90H21EOLACvtfcHk0ljOePiuUGk7zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D&md5=1aa9a38aeb3ce95af4ffb7d8b8a142bd</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1107%2FS0907444909047337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909047337%26sid%3Dliteratum%253Aachs%26aulast%3DKabsch%26aufirst%3DW.%26atitle%3DXDS%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D125%26epage%3D132%26doi%3D10.1107%2FS0907444909047337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krissinel, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNicholas, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannu, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potterton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. S.</span></span> <span> </span><span class="NLM_article-title">Overview of the CCP4 suite and current developments</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1107/S0907444910045749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1107%2FS0907444910045749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=21460441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=235-242&author=M.+D.+Winnauthor=C.+C.+Ballardauthor=K.+D.+Cowtanauthor=E.+J.+Dodsonauthor=P.+Emsleyauthor=P.+R.+Evansauthor=R.+M.+Keeganauthor=E.+B.+Krissinelauthor=A.+G.+Leslieauthor=A.+McCoyauthor=S.+J.+McNicholasauthor=G.+N.+Murshudovauthor=N.+S.+Pannuauthor=E.+A.+Pottertonauthor=H.+R.+Powellauthor=R.+J.+Readauthor=A.+Vaginauthor=K.+S.+Wilson&title=Overview+of+the+CCP4+suite+and+current+developments&doi=10.1107%2FS0907444910045749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of the CCP4 suite and current developments</span></div><div class="casAuthors">Winn, Martyn D.; Ballard, Charles C.; Cowtan, Kevin D.; Dodson, Eleanor J.; Emsley, Paul; Evans, Phil R.; Keegan, Ronan M.; Krissinel, Eugene B.; Leslie, Andrew G. W.; McCoy, Airlie; McNicholas, Stuart J.; Murshudov, Garib N.; Pannu, Navraj S.; Potterton, Elizabeth A.; Powell, Harold R.; Read, Randy J.; Vagin, Alexei; Wilson, Keith S.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  The CCP4 (Collaborative Computational Project, No. 4) software suite is a collection of programs and assocd. data and software libraries which can be used for macromol. structure detn. by X-ray crystallog.  The suite is designed to be flexible, allowing users a no. of methods of achieving their aims.  The programs are from a wide variety of sources but are connected by a common infrastructure provided by std. file formats, data objects and graphical interfaces.  Structure soln. by macromol. crystallog. is becoming increasingly automated and the CCP4 suite includes several automation pipelines.  After giving a brief description of the evolution of CCP4 over the last 30 years, an overview of the current suite is given.  While detailed descriptions are given in the accompanying articles, here it is shown how the individual programs contribute to a complete software package.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_wWMMIol6UrVg90H21EOLACvtfcHk0lhdcG9akNfypQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D&md5=c407e4d47bef46864be336d60147c17d</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1107%2FS0907444910045749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910045749%26sid%3Dliteratum%253Aachs%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DBallard%26aufirst%3DC.%2BC.%26aulast%3DCowtan%26aufirst%3DK.%2BD.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DP.%2BR.%26aulast%3DKeegan%26aufirst%3DR.%2BM.%26aulast%3DKrissinel%26aufirst%3DE.%2BB.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%26aulast%3DMcCoy%26aufirst%3DA.%26aulast%3DMcNicholas%26aufirst%3DS.%2BJ.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DPotterton%26aufirst%3DE.%2BA.%26aulast%3DPowell%26aufirst%3DH.%2BR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DK.%2BS.%26atitle%3DOverview%2520of%2520the%2520CCP4%2520suite%2520and%2520current%2520developments%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26spage%3D235%26epage%3D242%26doi%3D10.1107%2FS0907444910045749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohkamp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title">Features and development of Coot</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1107/S0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+development+of+Coot&doi=10.1107%2FS0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0lhdcG9akNfypQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2FS0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liebschner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afonine, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunkoczi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croll, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hintze, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeffner, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prisant, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sammito, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobolev, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockwell, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terwilliger, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urzhumtsev, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Videau, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span> <span> </span><span class="NLM_article-title">Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix</span>. <i>Acta Crystallogr., Sect. D: Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">861</span>– <span class="NLM_lpage">877</span>, <span class="refDoi"> DOI: 10.1107/S2059798319011471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.1107%2FS2059798319011471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFWkurrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2019&pages=861-877&author=D.+Liebschnerauthor=P.+V.+Afonineauthor=M.+L.+Bakerauthor=G.+Bunkocziauthor=V.+B.+Chenauthor=T.+I.+Crollauthor=B.+Hintzeauthor=L.+W.+Hungauthor=S.+Jainauthor=A.+J.+McCoyauthor=N.+W.+Moriartyauthor=R.+D.+Oeffnerauthor=B.+K.+Poonauthor=M.+G.+Prisantauthor=R.+J.+Readauthor=J.+S.+Richardsonauthor=D.+C.+Richardsonauthor=M.+D.+Sammitoauthor=O.+V.+Sobolevauthor=D.+H.+Stockwellauthor=T.+C.+Terwilligerauthor=A.+G.+Urzhumtsevauthor=L.+L.+Videauauthor=C.+J.+Williamsauthor=P.+D.+Adams&title=Macromolecular+structure+determination+using+X-rays%2C+neutrons+and+electrons%3A+recent+developments+in+Phenix&doi=10.1107%2FS2059798319011471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix</span></div><div class="casAuthors">Liebschner, Dorothee; Afonine, Pavel V.; Baker, Matthew L.; Bunkoczi, Gabor; Chen, Vincent B.; Croll, Tristan I.; Hintze, Bradley; Hung, Li-Wei; Jain, Swati; McCoy, Airlie J.; Moriarty, Nigel W.; Oeffner, Robert D.; Poon, Billy K.; Prisant, Michael G.; Read, Randy J.; Richardson, Jane S.; Richardson, David C.; Sammito, Massimo D.; Sobolev, Oleg V.; Stockwell, Duncan H.; Terwilliger, Thomas C.; Urzhumtsev, Alexandre G.; Videau, Lizbeth L.; Williams, Christopher J.; Adams, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Structural Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">861-877</span>CODEN:
                <span class="NLM_cas:coden">ACSDAD</span>;
        ISSN:<span class="NLM_cas:issn">2059-7983</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Diffraction (X-ray, neutron and electron) and electron cryo-microscopy are powerful methods to det. three-dimensional macromol. structures, which are required to understand biol. processes and to develop new therapeutics against diseases.  The overall structure-soln. workflow is similar for these techniques, but nuances exist because the properties of the reduced exptl. data are different.  Software tools for structure detn. should therefore be tailored for each method.  Phenix is a comprehensive software package for macromol. structure detn. that handles data from any of these techniques.  Tasks performed with Phenix include data-quality assessment, map improvement, model building, the validation/rebuilding/refinement cycle and deposition.  Each tool caters to the type of exptl. data.  The design of Phenix emphasizes the automation of procedures, where possible, to minimize repetitive and time-consuming manual tasks, while default parameters are chosen to encourage best practice.  A graphical user interface provides access to many command-line features of Phenix and streamlines the transition between programs, project tracking and re-running of previous tasks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolHnU8ECe2CrVg90H21EOLACvtfcHk0lgaWaMYxotxeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFWkurrO&md5=e60be65abece48923abf937a4c2640a6</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1107%2FS2059798319011471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2059798319011471%26sid%3Dliteratum%253Aachs%26aulast%3DLiebschner%26aufirst%3DD.%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DBaker%26aufirst%3DM.%2BL.%26aulast%3DBunkoczi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DCroll%26aufirst%3DT.%2BI.%26aulast%3DHintze%26aufirst%3DB.%26aulast%3DHung%26aufirst%3DL.%2BW.%26aulast%3DJain%26aufirst%3DS.%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DOeffner%26aufirst%3DR.%2BD.%26aulast%3DPoon%26aufirst%3DB.%2BK.%26aulast%3DPrisant%26aufirst%3DM.%2BG.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26aulast%3DSammito%26aufirst%3DM.%2BD.%26aulast%3DSobolev%26aufirst%3DO.%2BV.%26aulast%3DStockwell%26aufirst%3DD.%2BH.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DUrzhumtsev%26aufirst%3DA.%2BG.%26aulast%3DVideau%26aufirst%3DL.%2BL.%26aulast%3DWilliams%26aufirst%3DC.%2BJ.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26atitle%3DMacromolecular%2520structure%2520determination%2520using%2520X-rays%252C%2520neutrons%2520and%2520electrons%253A%2520recent%2520developments%2520in%2520Phenix%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Struct.%2520Biol.%26date%3D2019%26volume%3D75%26spage%3D861%26epage%3D877%26doi%3D10.1107%2FS2059798319011471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenbraun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Key, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanschagrin, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timony, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaviano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliz, P.</span></span> <span> </span><span class="NLM_article-title">Collaboration gets the most out of software</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e01456</span> <span class="refDoi"> DOI: 10.7554/eLife.01456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=10.7554%2FeLife.01456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;key=24040512" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&author=A.+Morinauthor=B.+Eisenbraunauthor=J.+Keyauthor=P.+C.+Sanschagrinauthor=M.+A.+Timonyauthor=M.+Ottavianoauthor=P.+Sliz&title=Collaboration+gets+the+most+out+of+software&doi=10.7554%2FeLife.01456"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.7554%2FeLife.01456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.01456%26sid%3Dliteratum%253Aachs%26aulast%3DMorin%26aufirst%3DA.%26aulast%3DEisenbraun%26aufirst%3DB.%26aulast%3DKey%26aufirst%3DJ.%26aulast%3DSanschagrin%26aufirst%3DP.%2BC.%26aulast%3DTimony%26aufirst%3DM.%2BA.%26aulast%3DOttaviano%26aufirst%3DM.%26aulast%3DSliz%26aufirst%3DP.%26atitle%3DCollaboration%2520gets%2520the%2520most%2520out%2520of%2520software%26jtitle%3DeLife%26date%3D2013%26volume%3D2%26doi%3D10.7554%2FeLife.01456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YER" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YER','PDB','1YER'); return false;">PDB: 1YER</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YES" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YES','PDB','1YES'); return false;">PDB: 1YES</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EGK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EGK','PDB','4EGK'); return false;">PDB: 4EGK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NH7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NH7','PDB','4NH7'); return false;">PDB: 4NH7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VCI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VCI','PDB','2VCI'); return false;">PDB: 2VCI</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XJX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XJX','PDB','2XJX'); return false;">PDB: 2XJX</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UY6" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UY6','PDB','1UY6'); return false;">PDB: 1UY6</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJI','PDB','6CJI'); return false;">PDB: 6CJI</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJJ','PDB','6CJJ'); return false;">PDB: 6CJJ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJL" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJL','PDB','6CJL'); return false;">PDB: 6CJL</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJR','PDB','6CJR'); return false;">PDB: 6CJR</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9R" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9R','PDB','7K9R'); return false;">PDB: 7K9R</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9S" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9S','PDB','7K9S'); return false;">PDB: 7K9S</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9W" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9W','PDB','7K9W'); return false;">PDB: 7K9W</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9V" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9V','PDB','7K9V'); return false;">PDB: 7K9V</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9U" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9U','PDB','7K9U'); return false;">PDB: 7K9U</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJS" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJS','PDB','6CJS'); return false;">PDB: 6CJS</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CJP','PDB','6CJP'); return false;">PDB: 6CJP</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i173"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01777">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_76305"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01777?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01777</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Supporting Tables 1–8, Supporting Figures S1–S7 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Confirmation of lysate EC<sub>50s</sub> (Table 1); confirmation of fungal selectivity using purified NBDs (Table 2); HepG2 cytotoxicity dose–response data and statistics (Table 3); NIH 3T3 cytotoxicity dose–response data and statistics (Table 4); crystallographic data for apoprotein and NVP-AUY922-liganded structures (Table 5); crystallographic data for RAP-liganded structures (Table 6); features of selected Hsp90 NBD structures (Table 7); summary of computational docking results for the compounds in Table 4 (Table 8); correlation between lysate and purified NBD potencies in <i>C. neoformans</i> (Figure S1); correlation between lysate and purified NBD potencies in human (Figure S2); correlation between fold-selectivities calculated using lysates and purified NBDs (Figure S3); HepG2 cytotoxicity dose–response curves (Figure S4); NIH 3T3 cytotoxicity dose–response curves (Figure S5); ligand variability in the <i>C. neoformans</i> RAP complexes (Figure S6); and contact sites between ligands and structural elements of HSP90 (Figure S7) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_002.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and associated biological data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_003.csv">CSV</a>)</p></li><li><p class="inline">Coordinate files used to generate <a id="rightTab-" class=" internalNav" href="#fig11">Figure <a id="rightTab-" class=" internalNav" href="#fig11">11</a></a>B (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_004.pdb">PDB</a>)</p></li><li><p class="inline">Coordinate files used to generate <a id="rightTab-" class=" internalNav" href="#fig11">Figure <a id="rightTab-" class=" internalNav" href="#fig11">11</a></a>C (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_005.pdb">PDB</a>)</p></li><li><p class="inline">Coordinate files used to generate <a id="rightTab-" class=" internalNav" href="#fig11">Figure <a id="rightTab-" class=" internalNav" href="#fig11">11</a></a>D (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_006.pdb">PDB</a>)</p></li><li><p class="inline">Coordinate files used to generate <a id="rightTab-" class=" internalNav" href="#fig11">Figure <a id="rightTab-" class=" internalNav" href="#fig11">11</a></a>E (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_007.pdb">PDB</a>)</p></li><li><p class="inline">Coordinate files used to generate <a id="rightTab-" class=" internalNav" href="#fig11">Figure <a id="rightTab-" class=" internalNav" href="#fig11">11</a></a>F (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_008.pdb">PDB</a>)</p></li><li><p class="inline">Coordinate files used to generate <a id="rightTab-" class=" internalNav" href="#fig11">Figure <a id="rightTab-" class=" internalNav" href="#fig11">11</a></a>G (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_009.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_001.pdf">jm0c01777_si_001.pdf (1.61 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_002.pdf">jm0c01777_si_002.pdf (710.27 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_003.csv">jm0c01777_si_003.csv (9.13 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_004.pdb">jm0c01777_si_004.pdb (857.16 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_005.pdb">jm0c01777_si_005.pdb (857.16 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_006.pdb">jm0c01777_si_006.pdb (858.06 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_007.pdb">jm0c01777_si_007.pdb (858.06 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_008.pdb">jm0c01777_si_008.pdb (858.48 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01777/suppl_file/jm0c01777_si_009.pdb">jm0c01777_si_009.pdb (858.48 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Coordinates have been deposited in the PDB with the following accession numbers: apo (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9R">7K9R</a>), NVP-AUY922 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9S">7K9S</a>), compound <b>19</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9U">7K9U</a>), compound <b>18</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9V">7K9V</a>), and compound <b>10</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K9W">7K9W</a>). The authors will release coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01777&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-2%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01777" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01777" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799df1bde982390","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
